Transection of the oesophagus for bleeding oesophagea

British Journal of Surgery 60, 646-649

DOI: 10.1002/bjs.1800600817

Citation Report

#	Article	IF	CITATIONS
1	Hepatobiliary Disease., 0,, 132-138.		0
2	Editorial: Massive upper gastrointestinal bleeding BMJ: British Medical Journal, 1974, 1, 403-404.	2.4	2
3	Interposition "H" Grafting for Portal Hypertension. Archives of Surgery, 1974, 108, 502.	2.3	8
4	Emergency and Elective Operations for Bleeding Esophageal Varices. Surgical Clinics of North America, 1974, 54, 561-571.	0.5	6
5	Modified oesophagoscope for injecting oesophageal varices BMJ: British Medical Journal, 1975, 2, 540-541.	2.4	29
6	Editorial: New measures for bleeding oesophageal varices BMJ: British Medical Journal, 1975, 3, 450-450.	2.4	0
7	Interposition grafting for portal hypertension. American Journal of Surgery, 1975, 130, 733-738.	0.9	16
8	CLINICAL PHARMACOKINETIC STUDIES. InPharma, 1976, 31, 20-20.	0.0	1
9	Fibreoptic endoscopy and the use of the Sengstaken tube in acute gastrointestinal haemorrhage in patients with portal hypertension and varices Gut, 1976, 17, 258-263.	6.1	116
10	Results of Interposition "H―Grafts for Portal Hypertension. Annals of Surgery, 1978, 187, 515-522.	2.1	18
11	Use of anaesthesia. Preoperative assessment of patients BMJ: British Medical Journal, 1980, 280, 1507-1508.	2.4	1
12	Prospective comparison of two Sengstaken tubes in the management of patients with variceal haemorrhage Gut, 1980, 21, 570-573.	6.1	31
13	PROSPECTIVE CONTROLLED TRIAL OF INJECTION SCLEROTHERAPY IN PATIENTS WITH CIRRHOSIS AND RECENT VARICEAL HÆMORRHAGE. Lancet, The, 1980, 316, 552-554.	6.3	141
14	Endoscopic sclerotherapy in acute variceal hemorrhage. American Journal of Surgery, 1981, 141, 164-168.	0.9	46
15	Transhepatic embolization in patients with acute variceal hemorrhage. American Journal of Surgery, 1981, 142, 731-734.	0.9	9
16	Variceal hemorrhage. Gastroenterology, 1981, 81, 635.	0.6	4
17	Does multiple injection sclerotherapy have a role in the long-term management of oesophageal varices?. Postgraduate Medical Journal, 1982, 58, 399-402.	0.9	6
18	Strategies in the Management of Bleeding Varices. Australian and New Zealand Journal of Medicine, 1982, 12, 320-324.	0.5	0

#	Article	IF	Citations
19	INCREASED LONG-TERM SURVIVAL IN VARICEAL HAEMORRHAGE USING INJECTION SCLEROTHERAPY. Lancet, The, 1982, 319, 124-127.	6.3	264
20	CONTROLLED TRIAL OF TERLIPRESSIN ('GLYPRESSIN') VERSUS VASOPRESSIN IN THE EARLY TREATMENT OF OESOPHAGEAL VARICES. Lancet, The, 1982, 320, 66-68.	6.3	149
21	The liver and anaesthesia. Canadian Anaesthetists' Society Journal, 1983, 30, 208-217.	0.5	15
22	Emergency endoscopic sclerotherapy for bleeding esophageal varices: a prospective study in patients not responding to balloon tamponade. Gastrointestinal Endoscopy, 1983, 29, 8-14.	0.5	68
23	The history of injection sclerotherapy for esophageal varices. Gastrointestinal Endoscopy, 1983, 29, 303-307.	0.5	11
24	POSTER COMMUNICATIONS. British Journal of Pharmacology, 1983, 80, 494P.	2.7	1
25	Controlled Trial of Propranolol for the Prevention of Recurrent Variceal Hemorrhage in Patients with Cirrhosis. New England Journal of Medicine, 1983, 309, 1539-1542.	13.9	313
26	Factors affecting successful endoscopic sclerotherapy for oesophageal varices Gut, 1983, 24, 946-949.	6.1	65
27	THE MANAGEMENT OF ACUTE VARICEAL HAEMORRHAGE. ANZ Journal of Surgery, 1983, 53, 197-202.	0.3	9
28	Esophageal Procedures to Control Bleeding from Varices. Surgical Clinics of North America, 1983, 63, 905-914.	0.5	10
29	Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension Gut, 1984, 25, 121-124.	6.1	92
30	Injection sclerotherapy for oesophageal varices: a prospective randomised trial of different treatment schedules Gut, 1984, 25, 129-132.	6.1	120
31	Perivenous sclerotherapy of oesophageal varices. Indian Journal of Thoracic and Cardiovascular Surgery, 1984, 3, 17-21.	0.2	0
32	Sclerotherapy of Esophageal Varices: An Endoscopic and Portographic Study. Hepatology, 1984, 4, 877-884.	3.6	24
33	Monitoring the liver. Canadian Anaesthetists' Society Journal, 1984, 31, 401-402.	0.5	0
34	Reductions in portal pressure by selective beta 2â€adrenoceptor blockade in patients with cirrhosis and portal hypertension British Journal of Clinical Pharmacology, 1984, 17, 753-757.	1.1	31
35	Prospective study of nasogastric feeding via east Grinstead \hat{A}^{\otimes} or Viomedex \hat{A}^{\otimes} tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition, 1984, 3, 63-66.	2.3	14
36	Body protein metabolism and plasma amino acids in cirrhosis of the liver. The effect of varying the branched chain amino acid content of intravenous amino acid solutions. Clinical Nutrition, 1984, 3, 153-162.	2.3	12

#	Article	IF	CITATIONS
37	Clarification of Risk Factors for Abdominal Operations in Patients with Hepatic Cirrhosis. Annals of Surgery, 1984, 199, 648-655.	2.1	464
38	Management of Complications of Portal Hypertension. Surgical Clinics of North America, 1985, 65, 231-262.	0.5	9
39	Long-Term Sclerotherapy of Bleeding Esophageal Varices in Patients with Liver Cirrhosis. Scandinavian Journal of Gastroenterology, 1985, 20, 51-58.	0.6	37
41	A prospective, randomized controlled trial of chronic esophageal variceal sclerotherapy. Hepatology, 1985, 5, 584-589.	3.6	248
42	Improved survival following injection sclerotherapy for esophageal varices: Final analysis of a controlled trial. Hepatology, 1985, 5, 827-830.	3.6	309
43	The Prevention of Recurrent Variceal Haemorrhage by Chronic Injection Sclerotherapy. Scottish Medical Journal, 1985, 30, 148-151.	0.7	2
44	Morbidity and mortality after peritoneovenous shunt surgery for refractory ascites Gut, 1985, 26, 1070-1073.	6.1	36
45	Clinical course of cirrhosis in young adults and therapeutic potential of liver transplantation Gut, 1985, 26, 1359-1363.	6.1	18
46	Pharmacology of propranolol in patients with cirrhosis and portal hypertension Gut, 1985, 26, 14-19.	6.1	33
47	Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy?. Gut, 1985, 26, 1226-1232.	6.1	482
48	B1 selective adrenoreceptor blockade for the long term management of variceal bleeding. A prospective randomised trial to compare oral metoprolol with injection sclerotherapy in cirrhosis Gut, 1985, 26, 421-425.	6.1	28
49	Total and renal sympathetic nervous system activity in alcoholic cirrhosis. Journal of Hepatology, 1985, 1, 639-648.	1.8	77
50	Endoscopic Nd:YAG laser therapy for active esophageal variceal bleeding. Gastrointestinal Endoscopy, 1985, 31, 4-9.	0.5	38
51	Sedation for gastroscopy: a comparative study of midazolam and Diazemuls in patients with and without cirrhosis British Journal of Clinical Pharmacology, 1986, 22, 643-647.	1.1	17
52	Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity British Journal of Clinical Pharmacology, 1986, 21, 191-196.	1.1	74
53	Repeated endoscopic sclerotherapy of oesophageal varices due to non-cirrhotic portal fibrosis using intravariceal polidocanol. Journal of Gastroenterology and Hepatology (Australia), 1986, 1, 443-448.	1.4	5
54	Preponderance of serum and intra-hepatic $5\hat{l}_{\pm}$ -dihydrotestosterone in males with hepatocellular carcinoma despite low circulating androgen levels. Journal of Hepatology, 1986, 3, 304-309.	1.8	7
55	Effect of somatostatin on oesophageal variceal pressure assessed by direct measurement. Journal of Hepatology, 1986, 2, 262-266.	1.8	29

#	Article	IF	CITATIONS
56	EVIDENCE FOR DOWN-REGULATION OF BETA-2-ADRENOCEPTORS IN CIRRHOTIC PATIENTS WITH SEVERE ASCITES. Lancet, The, 1986, 327, 1409-1411.	6.3	136
57	Effects of repeated injection sclerotherapy on acid gastroesophageal reflux. Gastrointestinal Endoscopy, 1986, 32, 81-83.	0.5	21
58	SYMPATHETIC TONE MODULATES PORTAL VENOUS PRESSURE IN ALCOHOLIC CIRRHOSIS. Lancet, The, 1986, 328, 939-943.	6.3	85
59	Results of a randomized trial of end-to-side portacaval shunt and distal splenorenal shunt in alcoholic liver disease and variceal bleeding. Gastroenterology, 1986, 91, 802-809.	0.6	112
60	Prognostic significance of serum bile acids in cirrhosis. Hepatology, 1986, 6, 50-53.	3.6	77
61	Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology, 1986, 6, 79-86.	3.6	177
62	A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology, 1986, 6, 410-413.	3.6	209
63	Vasopressin and nitroglycerin in the treatment of bleeding varices: The bottom line. Hepatology, 1986, 6, 523-525.	3.6	50
64	Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. Hepatology, 1986, 6, 673-675.	3.6	91
65	Prognostic value of the aminopyrine breath test in cirrhotic patients. Hepatology, 1986, 6, 928-931.	3.6	96
66	Propranolol for the prevention of recurrent variceal hemorrhage: A controlled trial. Hepatology, 1986, 6, 1239-1243.	3.6	149
67	Endoscopic sclerotherapy for esophageal varices. Digestive Diseases and Sciences, 1986, 31, 108-121.	1.1	37
68	Effect of branched chain amino acid infusions on body protein metabolism in cirrhosis of liver Gut, 1986, 27, 96-102.	6.1	16
69	Somatostatin in Portal Hypertension. Scandinavian Journal of Gastroenterology, 1986, 21, 256-258.	0.6	2
70	Denver Peritoneovenous Shunting for Malignant or Cirrhotic Ascites: A Prospective Consecutive Series. Scandinavian Journal of Gastroenterology, 1986, 21, 1161-1172.	0.6	15
71	Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis Gut, 1986, 27, 1204-1209.	6.1	191
72	Acute Esophageal Variceal Sclerotherapy. JAMA - Journal of the American Medical Association, 1986, 255, 497.	3.8	150
73	Variceal bleeding: does variable delay in trial entry invalidate comparison between trials?. Gut, 1987, 28, 653-656.	6.1	7

#	Article	IF	CITATIONS
74	Propranolol in the Prevention of First Upper Gastrointestinal Tract Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal Varices. New England Journal of Medicine, 1987, 317, 856-861.	13.9	292
75	Surgery in the Patient with Liver Disease. Medical Clinics of North America, 1987, 71, 453-476.	1.1	50
76	Systemic and hepatic hemodynamics after variceal hemorrhage: Effects of propranolol and placebo. Gastroenterology, 1987, 93, 1218-1224.	0.6	44
77	Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity British Journal of Clinical Pharmacology, 1987, 23, 753-757.	1.1	48
78	Increased Susceptibility to Liver Disease in Relation to Alcohol Consumption in Women. Scandinavian Journal of Gastroenterology, 1987, 22, 1251-1256.	0.6	79
80	Sonographic evaluation of the portal venous system after elective endoscopic sclerotherapy of esophageal varices. Surgical Endoscopy and Other Interventional Techniques, 1987, 1, 165-167.	1.3	4
81	Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology, 1987, 7, 149-154.	3.6	97
82	Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: Prospective, randomized comparison of propranolol and sclerotherapy. Hepatology, 1987, 7, 355-361.	3.6	101
83	Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleeding. Hepatology, 1987, 7, 447-451.	3.6	97
84	Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: Possible role of serotonergic mechanisms in portal hypertension. Hepatology, 1987, 7, 644-647.	3.6	66
85	Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology, 1987, 7, 660-664.	3.6	303
86	Prevention of recurrence of esophageal varices after endoscopic injection sclerotherapy with ethanolamine oleate. Hepatology, 1987, 7, 810-815.	3.6	114
87	Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double-blind, randomized trial. Hepatology, 1987, 7, 1278-1284.	3.6	117
88	Alterations in the carbohydrate moiety of alpha-1-acid glycoprotein purified from human cirrhotic ascitic fluid. BBA - Proteins and Proteomics, 1987, 913, 308-312.	2.1	39
89	Preoperative evaluation. Journal of General Internal Medicine, 1987, 2, 257-269.	1.3	15
90	Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer, 1988, 62, 760-762.	2.0	35
91	Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: A multicenter, randomized clinical trial. Hepatology, 1988, 8, 1-5.	3.6	78
92	Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: A prospective, randomized study. Hepatology, 1988, 8, 6-9.	3.6	160

#	Article	IF	CITATIONS
93	Prophylactic propranolol: The first big step. Hepatology, 1988, 8, 167-170.	3.6	17
94	Renal sodium retention in cirrhosis: Tubular site and relation to hepatic dysfunction. Hepatology, 1988, 8, 831-836.	3.6	65
95	A prospective evaluation of bacteremic patients with chronic liver disease. Hepatology, 1988, 8, 1099-1103.	3.6	70
96	Prophylactic sclerotherapy of high-risk esophageal varices: Results of a multicentric prospective controlled trial. Hepatology, 1988, 8, 1495-1500.	3.6	95
97	Glucagon selectively increases splanchnic blood flow in patients with well-compensated cirrhosis. Hepatology, 1988, 8, 1501-1505.	3.6	42
98	Prognostic value of indocyanine green and lidocaine kinetics for survival and chronic hepatic encephalopathy in cirrhotic patients following elective end-to-side portacaval shunt. Hepatology, 1988, 8, 1506-1510.	3.6	22
99	Altered platelet function in cirrhosis of the liver: Impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology, 1988, 8, 1620-1626.	3.6	84
100	Immediate endoscopic sclerosis of bleeding esophageal varices. Surgical Endoscopy and Other Interventional Techniques, 1988, 2, 18-23.	1.3	30
101	Frequency of upper gastrointestinal lesions in patients with liver cirrhosis. Digestive Diseases and Sciences, 1988, 33, 1218-1222.	1.1	47
102	Bisoprolol. Drugs, 1988, 36, 256-285.	4.9	49
103	Initial control of bleeding from esophageal varices with the Sengstaken-Blakemore tube. American Journal of Surgery, 1988, 155, 509-511.	0.9	23
104	Endoscopic ligation of esophageal varices. American Journal of Surgery, 1988, 156, 9B-12B.	0.9	51
105	Modifications of Concanavalin A patterns of $\hat{l}\pm 1$ -acid glycoprotein and $\hat{l}\pm 2$ -HS glycoprotein in alcoholic liver disease. Clinica Chimica Acta, 1988, 176, 49-57.	0.5	34
106	Atrial natriuretic peptide in alcoholic cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1988, 3, 601-609.	1.4	2
107	Urinary Tract Candidosis. Lancet, The, 1988, 332, 1000-1002.	6.3	1
108	Abnormal tissue oxygenation in patients with cirrhosis and liver failure. Journal of Hepatology, 1988, 7, 98-105.	1.8	110
109	Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. Journal of Hepatology, 1988, 7, 118-125.	1.8	138
111	Reduction in Early Recurrence of Variceal Bleeding by Propranolol. Scandinavian Journal of Gastroenterology, 1988, 23, 369-374.	0.6	34

#	Article	IF	CITATIONS
112	Auxiliary Partial Liver Transplantation for End-Stage Chronic Liver Disease. New England Journal of Medicine, 1988, 319, 1507-1511.	13.9	130
113	Prediction of the First Variceal Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal Varices. New England Journal of Medicine, 1988, 319, 983-989.	13.9	1,278
114	Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension Gut, 1988, 29, 372-377.	6.1	58
115	Relationship among Beta-Adrenergic Blockade, Propranolol Concentration, and Liver Function in Patients with Cirrhosis. Scandinavian Journal of Gastroenterology, 1988, 23, 925-930.	0.6	15
116	Prophylactic Sclerotherapy before the First Episode of Variceal Hemorrhage in Patients with Cirrhosis. New England Journal of Medicine, 1988, 319, 8-15.	13.9	158
117	Should Portosystemic Shunt Be Reconsidered in the Treatment of Intractable Ascites in Cirrhosis?. Archives of Surgery, 1988, 123, 987.	2.3	72
118	Somatostatin does not reduce oesophageal variceal pressure in liver cirrhotics Gut, 1988, 29, 153-156.	6.1	68
119	Comparative Haemodynamic Effects of Betaxolol and Propranolol in Patients with Cirrhosis. Scandinavian Journal of Gastroenterology, 1988, 23, 691-695.	0.6	21
120	Protease Inhibitors in Liver Disease. Scandinavian Journal of Gastroenterology, 1988, 23, 620-624.	0.6	13
121	Steady-State Extrarenal Sorbitol Clearance as a Measure of Hepatic Plasma Flow. Gastroenterology, 1988, 95, 749-759.	0.6	100
122	Neutrophil and eosinophil involvement of the small bowel affected by chronic alcoholism Gut, 1988, 29, 1656-1660.	6.1	10
123	Prophylactic sclerotherapy for varices BMJ: British Medical Journal, 1988, 297, 370-371.	2.4	2
124	Pressure of intraoesophageal varices assessed by fine needle puncture: its relation to endoscopic signs and severity of liver disease in patients with cirrhosis Gut, 1989, 30, 228-232.	6.1	54
125	Prophylactic endoscopic sclerotherapy of oesophageal varices in liver cirrhosis. A multicentre prospective controlled randomised trial in Vienna Gut, 1989, 30, 873-879.	6.1	50
126	Propranolol in the Primary Prevention of Upper Gastrointestinal Tract Haemorrhage in Patients with Cirrhosis of the Liver and Oesophageal Varices1. Drugs, 1989, 37, 52-61.	4.9	3
127	Plasma leucine enkephalin is increased in liver disease Gut, 1989, 30, 1392-1395.	6.1	38
128	Anesthesia and Pain Control. Veterinary Clinics of North America - Small Animal Practice, 1989, 19, 1223-1238.	0.5	7
129	Propranolol in Prevention of Rebleeding from Oesophageal Varices during the Course of Endoscopic Sclerotherapy. Scandinavian Journal of Gastroenterology, 1989, 24, 339-345.	0.6	7 5

#	Article	IF	CITATIONS
130	Glucose metabolism in cirrhosis: A review with some perspectives for the future. Diabetes/metabolism Reviews, 1989, 5, 691-709.	0.2	122
132	Frequent endoscopic variceal sclerotherapy increases risk of complications. Digestive Diseases and Sciences, 1989, 34, 1068-1074.	1.1	32
133	Midazolam versus diazepam for combined esophogastroduodenoscopy and colonoscopy. Digestive Diseases and Sciences, 1989, 34, 1265-1271.	1.1	21
134	Esophageal tamponade in the management of acute variceal hemorrhage. Digestive Diseases and Sciences, 1989, 34, 913-918.	1.1	49
135	Suivi endoscopique aprÃ"s sclérothérapie élective de varices Å"sophagiennes. Acta Endoscopica, 1989, 19, 239-249.	0.0	0
136	Correlation of caffeine elimination and child's classification in liver cirrhosis. Klinische Wochenschrift, 1989, 67, 6-15.	0.6	40
137	Long-term prognosis of esophageal variceal cases treated with injection sclerotherapy. Gastroenterologia Japonica, 1989, 24, 469-475.	0.4	4
138	Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver. Gastroenterologia Japonica, 1989, 24, 159-163.	0.4	4
139	Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. British Journal of Haematology, 1989, 71, 65-70.	1.2	94
140	Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: Search for an additive effect. Hepatology, 1989, 9, 83-87.	3.6	53
141	Controlled clinical trial of injection sclerotherapy for active variceal bleeding. Hepatology, 1989, 9, 274-277.	3.6	211
142	Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology, 1989, 9, 417-422.	3.6	74
143	Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology, 1989, 9, 423-426.	3.6	74
144	Propranolol does not alter cerebral blood flow and functions in cirrhotic patients without previous hepatic encephalopathy. Hepatology, 1989, 9, 439-442.	3.6	16
145	Cirrhotics with variceal hemorrhage: The importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology, 1989, 9, 801-807.	3.6	144
146	Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: Evidence for an impaired cardiopulmonary baroreflex function. Hepatology, 1989, 10, 93-97.	3.6	33
147	Blunted natriuretic response and low blood pressure after atrial natriuretic factor in early cirrhosis. Hepatology, 1989, 10, 148-153.	3.6	32
148	Sucralfate for the prevention of early rebleeding following injection sclerotherapy for esophageal varices. Hepatology, 1989, 10, 279-282.	3.6	53

#	Article	IF	CITATIONS
149	Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis. Hepatology, 1989, 10, 283-287.	3.6	51
150	Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. Hepatology, 1989, 10, 346-348.	3.6	21
151	Successful endoscopic obturation of gastric varices with butyl cyanoacrylate. Hepatology, 1989, 10, 488-493.	3.6	165
152	Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial. Hepatology, 1989, 10, 962-968.	3.6	121
153	A method to evaluate changes in prognostic status during follow-up, illustrated by an assessment of the effect of a rebleed in patients with oesophageal variceal bleeding. Computers in Biology and Medicine, 1989, 19, 181-188.	3.9	9
154	Endoscopic removal of impacted Sengstaken-Blakemore tube. Surgical Endoscopy and Other Interventional Techniques, 1989, 3, 54-55.	1.3	4
155	Penetration of cefoperazone into ascites. European Journal of Clinical Pharmacology, 1989, 37, 577-580.	0.8	6
156	INHIBITION OF PLATELET AGGREGATION BY ABNORMAL HIGH DENSITY LIPOPROTEIN PARTICLES IN PLASMA FROM PATIENTS WITH HEPATIC CIRRHOSIS. Lancet, The, 1989, 333, 693-695.	6.3	69
157	Renal function and effective \hat{l}^2 -blockade in cirrhosis with ascites. Journal of Hepatology, 1989, 8, 279-286.	1.8	16
158	Prescribing for patients with liver disease. Bailliere's Clinical Gastroenterology, 1989, 3, 109-130.	0.9	5
159	Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. Journal of Hepatology, 1989, 9, 16-22.	1.8	58
160	Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. Journal of Hepatology, 1989, 9, 319-325.	1.8	74
161	Superiority of the Child-Pugh Classification to Quantitative Liver Function Tests for Assessing Prognosis of Liver Cirrhosis. Scandinavian Journal of Gastroenterology, 1989, 24, 269-276.	0.6	241
162	A Comparison of Sclerotherapy with Staple Transection of the Esophagus for the Emergency Control of Bleeding from Esophageal Varices. New England Journal of Medicine, 1989, 321, 857-862.	13.9	166
163	Drug metabolism in liver disease. , 1989, 40, 439-474.		83
164	Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension British Journal of Clinical Pharmacology, 1989, 27, 763-770.	1.1	22
165	The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease British Journal of Clinical Pharmacology, 1989, 27, 205-213.	1.1	36
166	Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. Journal of Hepatology, 1989, 9, 246-251.	1.8	32

#	Article	IF	CITATIONS
167	Endoscopic findings in alcoholic liver disease: Does gender make a difference?. Alcohol, 1989, 6, 465-468.	0.8	16
168	Prevention of stricture formation after endoscopic sclerotherapy of esophageal varices. Gastrointestinal Endoscopy, 1989, 35, 377-380.	0.5	23
169	Population Pharmacokinetic Analysis of Bisoprolol. Clinical Pharmacokinetics, 1989, 17, 53-63.	1.6	21
170	Prognosis after the First Episode of Gastrointestinal Bleeding or Coma in Cirrhosis: Survival and Prognostic Factors. Scandinavian Journal of Gastroenterology, 1989, 24, 999-1006.	0.6	7 5
171	Improved Results with Selective Distal Splenorenal Shunt in a Highly Selected Patient Population. Annals of Surgery, 1989, 210, 184-189.	2.1	24
172	A Randomised Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis. Drugs, 1989, 37, 30-34.	4.9	6
173	Portal Hypertension. Medical Clinics of North America, 1989, 73, 931-953.	1.1	80
174	Combined Upper and Lower Gastrointestinal Endoscopy: A Prospective Study in Alcoholic and Nonalcoholic Cirrhosis. Alcoholism: Clinical and Experimental Research, 1989, 13, 790-794.	1.4	13
175	Spontaneous Ruptured Hepatocellular Carcinoma; An Appraisal of Surgical Treatment. Annals of Surgery, 1989, 210, 24-28.	2.1	81
176	Steatorrhoea in Cirrhosis: Effect of Ursodeoxycholic Acid Administration. Journal of International Medical Research, 1990, 18, 289-297.	0.4	9
177	Distal Splenorenal Shunt Versus Endoscopic Sclerotherapy in the Prevention of Variceal Rebleeding First Stage of a Randomized, Controlled Trial. Annals of Surgery, 1990, 211, 178-186.	2.1	68
178	Splenomegaly—an insensitive sign of portal hypertension. Australian and New Zealand Journal of Medicine, 1990, 20, 771-774.	0.5	40
179	Influence of the Degree of Liver Failure on Portal Blood Flow in Patients with Liver Cirrhosis. Scandinavian Journal of Gastroenterology, 1990, 25, 395-400.	0.6	28
180	Taking the Tension out of the Portal System: An Approach to the Management of Portal Hypertension in the 1990s. Scandinavian Journal of Gastroenterology, 1990, 25, 131-145.	0.6	14
182	Flash Visual Evoked Responses in the Early Encephalopathy of Chronic Liver Disease. Scandinavian Journal of Gastroenterology, 1990, 25, 1205-1214.	0.6	16
183	Propranolol May Prevent Recurrence of Oesophageal Varices after Obliteration by Endoscopic Sclerotherapy. Scandinavian Journal of Gastroenterology, 1990, 25, 352-356.	0.6	26
184	Gastroesophageal endoscopic features in cirrhosis. Gastroenterology, 1990, 98, 156-162.	0.6	190
185	Nonshunting Operations for Variceal Hemorrhage. Surgical Clinics of North America, 1990, 70, 425-448.	0.5	20

#	Article	IF	CITATIONS
186	Resection of hepatocellular carcinomas. Gastroenterology, 1990, 98, 733-738.	0.6	314
187	Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. Gastroenterology, 1990, 98, 185-190.	0.6	104
188	Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. Gastroenterology, 1990, 98, 715-720.	0.6	328
189	Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology, 1990, 98, 1594-1602.	0.6	128
190	Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Gastroenterology, 1990, 99, 1388-1395.	0.6	251
191	Colonic disease in cirrhosis. Gastroenterology, 1990, 99, 195-199.	0.6	112
192	Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clinical Pharmacology and Therapeutics, 1990, 47, 731-739.	2.3	68
193	Anesthesia for liver transplantation in patients with arterial hypoxemia. Transplant International, 1990, 3, 103-107.	0.8	2
194	A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin–antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. British Journal of Haematology, 1990, 74, 471-479.	1.2	64
195	Cirrhosis of the liver. Digestive Diseases and Sciences, 1990, 35, 1403-1408.	1.1	46
196	Serum-ascites albumin gradients in nonalcoholic liver disease. Digestive Diseases and Sciences, 1990, 35, 33-37.	1.1	15
197	Prevalence of duodenal ulcer in cirrhotic males referred for liver transplantation. Digestive Diseases and Sciences, 1990, 35, 321-326.	1.1	44
198	Diarrhea as a presenting symptom of hepatocellular carcinoma. Digestive Diseases and Sciences, 1990, 35, 681-685.	1.1	18
199	Prevalence of endoscopic findings in 510 consecutive individuals with cirrhosis evaluated prospectively. Digestive Diseases and Sciences, 1990, 35, 705-710.	1.1	62
200	Drug metabolism in liver disease. Current Anaesthesia and Critical Care, 1990, 1, 204-212.	0.3	2
201	Gastric red spots in patients with cirrhosis: Subclinical condition of gastric mucosal hemorrhage?. Gastroenterologia Japonica, 1990, 25, 685-692.	0.4	23
202	Comparison between ultrasonographic signs and the degree of portal hypertension in patients with cirrhosis. Gastrointestinal Radiology, 1990, 15, 218-222.	0.4	81
203	Effects of a small bolus dose of ANF in healthy volunteers and in patients with volume retaining disorders. Klinische Wochenschrift, 1990, 68, 709-717.	0.6	14

#	Article	IF	CITATIONS
204	Can hepatic failure after surgery for hepatocellular carcinoma in cirrhotic patients be prevented?. World Journal of Surgery, 1990, 14, 123-127.	0.8	83
205	Anesthesia for liver transplantation in patients with arterial hypoxemia. Transplant International, 1990, 3, 103-107.	0.8	3
206	Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the abssence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology, 1990, 11, 7-11.	3.6	118
207	A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term magnagement of variceal bleeding. Hepatology, 1990, 11, 353-359.	3.6	78
208	Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: A prospective study of twenty-seven cases in cirrhotic patients. Hepatology, 1990, 11, 360-364.	3.6	80
209	Spontaneous bacterial empyema in cirrhotic patients: Analysis of eleven cases. Hepatology, 1990, 11, 365-370.	3.6	100
210	Energy metabolism in patients with acute and chronic liver disease. Hepatology, 1990, 11, 387-393.	3.6	147
211	A randomized trial of terlipressin plus nitroglycerin vs. balloon tamponade in the control of acute variceal hemorrhage. Hepatology, 1990, 11, 678-681.	3.6	88
212	Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology, 1990, 11, 874-878.	3.6	148
213	Abnormal pressor response to vasopressin in patients with cirrhosis: Evidence for impaired buffering mechanisms. Hepatology, 1990, 12, 7-12.	3.6	38
214	Predictive value of whole blood chemiluminescence in patients with alcoholic hepatitis. Hepatology, 1990, 12, 264-272.	3.6	11
215	The auditory P300 event—related potential: An objective marker of the encephalopathy of chronic liver disease. Hepatology, 1990, 12, 688-694.	3.6	68
216	Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: Results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology, 1990, 12, 1413-1419.	3.6	115
217	Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer, 1990, 65, 926-930.	2.0	56
218	Terlipressin (Triglycyl-Lysine Vasopressin) Controls Acute Bleeding Oesophageal Varices: A Double-Blind, Randomized, Placebo-Controlled Trial. Scandinavian Journal of Gastroenterology, 1990, 25, 622-630.	0.6	131
219	Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding Gut, 1990, 31, 1298-1302.	6.1	189
220	Prognostic Scores in Oesophageal or Gastric Variceal Bleeding. Scandinavian Journal of Gastroenterology, 1990, 25, 501-512.	0.6	8
221	Factors of Prognostic Importance in Primary Biliary Cirrhosis. Scandinavian Journal of Gastroenterology, 1990, 25, 119-126.	0.6	75

#	Article	IF	CITATIONS
222	Relation between zinc status and hepatic functional reserve in patients with liver disease Gut, 1990, 31, 694-697.	6.1	46
223	Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites Gut, 1990, 31, 204-207.	6.1	89
224	Alterations of glucose metabolism in chronic liver disease. Diabetes Research and Clinical Practice, 1990, 8, 29-36.	1.1	56
225	Use of prognostic models for assessment of value of liver transplantation in primary biliary cirrhosis. Lancet, The, 1990, 335, 493-497.	6.3	69
226	A comparative evaluation of sclerosants for esophageal varices: a prospective randomized controlled study. Gastrointestinal Endoscopy, 1990, 36, 127-130.	0.5	31
227	Assessment of hepatic function. Journal of Hepatology, 1990, 10, 129-137.	1.8	50
228	Submaximal oxygen consumption in liver cirrhosis. Journal of Hepatology, 1990, 10, 163-167.	1.8	82
229	Systemic and portal haemodynamic changes following triglycyllysine vasopressin plus nitroglycerin administration in patients with hepatitis B-related cirrhosis. Journal of Hepatology, 1990, 10, 370-374.	1.8	33
230	The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis. Journal of Hepatology, 1990, 11, 221-225.	1.8	56
231	Endoscopic and histologic appearance of the gastric mucosa in patients with portal hypertension. Gastrointestinal Endoscopy, 1990, 36, 575-579.	0.5	60
232	Patient characteristics in support: Disease specific clinical data. Journal of Clinical Epidemiology, 1990, 43, S41-S45.	2.4	6
233	Study population in SUPPORT: Patients (as defined by disease categories and mortality projections), surrogates, and physicians. Journal of Clinical Epidemiology, 1990, 43, S11-S28.	2.4	60
234	Endoscopic classification of gastric varices. Gastrointestinal Endoscopy, 1990, 36, 276-280.	0.5	168
235	Natural history of hepatocellular carcinoma in Spain. Journal of Hepatology, 1990, 10, 311-317.	1.8	122
236	Endoscopic variceal ligation in patients who have failed endoscopic sclerotherapy. Gastrointestinal Endoscopy, 1990, 36, 572-574.	0.5	47
237	Surgical procedures for bleeding esophagogastric varices when sclerotherapy fails: A prospective study. American Journal of Surgery, 1990, 160, 43-47.	0.9	25
238	Hormonal and metabolic changes during exercise in cirrhotic patients. Metabolism: Clinical and Experimental, 1990, 39, 18-24.	1.5	34
239	Comparative efficacy of emergency endoscopic sclerotherapy for active variceal bleeding due to cirrhosis of the liver, non-cirrhotic portal fibrosis and extrahepatic portal venous obstruction. Journal of Gastroenterology and Hepatology (Australia), 1990, 5, 432-437.	1.4	14

#	Article	IF	CITATIONS
240	Assessment of liver function: Principles and practice. Journal of Gastroenterology and Hepatology (Australia), 1990, 5, 468-482.	1.4	43
241	Hepatic function and liver resection. Journal of Gastroenterology and Hepatology (Australia), 1990, 5, 296-309.	1.4	86
242	Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure British Journal of Clinical Pharmacology, 1990, 29, 9-18.	1.1	19
243	Haemodynamic and pharmacokinetic study of intravenous fenoldopam in patients with hepatic cirrhosis British Journal of Clinical Pharmacology, 1990, 29, 19-25.	1.1	8
244	The metabolism and bioavailability of morphine in patients with severe liver cirrhosis British Journal of Clinical Pharmacology, 1990, 29, 289-297.	1.1	167
245	Survival after transhepatic embolization of gastro-oesophageal varices. Clinical Radiology, 1991, 44, 178-180.	0.5	3
246	Decrease in plasma tryptophan after a tryptophan-free amino acid solution. A comparison between cirrhotic and control subjects. Life Sciences, 1991, 48, 409-418.	2.0	14
247	Efficacy of endoscopic sclerotherapy on longâ€term management of oesophageal varices: A comparative study of results in patients with cirrhosis of the liver, nonâ€cirrhotic portal fibrosis (NCPF) and extrahepatic portal venous obstruction (EHO)*. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 471-475.	1.4	27
248	Comparative effects of 5% ethanolamine oleate versus 5% sodium morrhuate for sclerotherapy of oesphageal varices. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 476-480.	1.4	9
249	A randomized controlled study of low-dose and high-dose terlipressin in the control of acute oesophageal variceal haemorrhage. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 481-484.	1.4	10
250	Duplex Doppler ultrasound of the ligamentum teres and portal vein: A clinically useful adjunct in the evaluation of patients with known or suspected chronic liver disease or portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 61-65.	1.4	10
251	Snake skin pattern gastropathy in cirrhotic patients. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 145-149.	1.4	32
252	Reduction of transmural oesophageal variceal pressure by metoclopramide. Journal of Hepatology, 1991, 12, 362-366.	1.8	29
253	Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. Journal of Hepatology, 1991, 12, 283-289.	1.8	69
254	Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet, The, 1991, 337, 1431-1434.	6.3	264
255	Clearance of atrial natriuretic peptide in patients with cirrhosis. Journal of Hepatology, 1991, 13, 351-357.	1.8	10
256	Outcome of injection sclerotherapy using absolute alcohol in patients with cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction. Gastrointestinal Endoscopy, 1991, 37, 460-464.	0.5	17
257	Endoscopic sclerotherapy in the management of gastric variceal haemorrhage. Journal of Hepatology, 1991, 13, 274-278.	1.8	85

#	Article	IF	CITATIONS
258	Regional sympathetic activity, severity of liver disease and hemodynamics in patients with cirrhosis. Journal of Hepatology, 1991, 13, 161-168.	1.8	39
259	A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. Journal of Hepatology, 1991, 12, 236-240.	1.8	59
260	Chronic viral hepatitis. Journal of Hepatology, 1991, 13, S27-S30.	1.8	0
261	Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet, The, 1991, 337, 1250-1253.	6.3	135
262	Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. Journal of Endocrinological Investigation, 1991, 14, 317-321.	1.8	61
263	Development of Gastroesophageal Varices and Risk of Variceal Bleeding in Patients With Cirrhosis. Digestive Endoscopy, 1991, 3, 485-490.	1.3	8
264	PERIâ€OPERATIVE MORTALITY IN HEPATIC RESECTION. ANZ Journal of Surgery, 1991, 61, 201-206.	0.3	34
265	Correlations between plasma levels of fibrin(ogen) derivatives as quantified by different assays based on monoclonal antibodies. Thrombosis Research, 1991, 61, 441-452.	0.8	3
266	Jejunal immunoglobulin secretion in alcoholic patients with and without cirrhosis. Journal of Hepatology, 1991, 12, 145-149.	1.8	13
267	Endoscopic injection sclerotherapy versus conservative treatment for patients with unresectable hepatocellular carcinoma and bleeding esophageal varices. Gastrointestinal Endoscopy, 1991, 37, 161-164.	0.5	30
268	Caffeine Metabolism., 1991,, 513-539.		3
269	Endoscopic Tissue Adhesive for Gastric Varices. HPB Surgery, 1991, 3, 214-216.	2.2	0
270	Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis. Annals of Surgery, 1991, 214, 114-117.	2.1	523
271	Portasystemic Shunting Versus Liver Transplantation for the Budd-Chiari Syndrome. Annals of Surgery, 1991, 214, 581-589.	2.1	102
272	Interrelation between Esophageal Varices, and Systemic and Hepatic Hemodynamics in Male Patients with Compensated Cirrhosis Japanese Journal of Medicine, 1991, 30, 318-325.	0.1	9
273	Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology, 1991, 100, 1737-1742.	0.6	283
274	Medical and Surgical Treatment of Acute Bleeding from Esophageal Varices in Patients with Cirrhosis. Scandinavian Journal of Gastroenterology, 1991, 26, 897-908.	0.6	2
275	Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics. Gastroenterology, 1991, 100, 520-528.	0.6	474

#	Article	IF	CITATIONS
276	Assessment of the Risk of Bleeding From Esophageal Varices by Continuous Monitoring of Portal Pressure. Gastroenterology, 1991, 100, 1403-1410.	0.6	93
277	Prophylactic sclerotherapy in high-risk cirrhotics selected by endoscopic criteria. Gastroenterology, 1991, 101, 1087-1093.	0.6	58
278	A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology, 1991, 101, 1382-1390.	0.6	116
279	A prospective controlled study of the risk of bacteremia in emergency sclerotherapy of esophageal varices. Gastroenterology, 1991, 101, 1642-1648.	0.6	79
280	Spontaneous bacterial peritonitis in patients with hepatitis B-related cirrhosis and hepatocellular carcinoma. Gastroenterology, 1991, 101, 1656-1662.	0.6	23
281	Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Gastroenterology, 1991, 100, 160-167.	0.6	193
282	Value of Preoperative Physiologic Assessment in Outcome of Patients Undergoing Major Surgical Procedures. Surgical Clinics of North America, 1991, 71, 1141-1150.	0.5	12
283	Prediction of Variceal Hemorrhage in Cirrhosis: A Prospective Follow-up Study. Gastroenterology, 1991, 100, 1332-1337.	0.6	140
284	Sclérothérapie prophylactique des varices œsophagiennes à haut risque de saignement etude prospective et randomisée, avec longue période de surveillance. Acta Endoscopica, 1991, 21, 463-472.	0.0	2
285	Portal hypertensive colopathy. Digestive Diseases and Sciences, 1991, 36, 1774-1781.	1.1	101
286	Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Digestive Diseases and Sciences, 1991, 36, 1197-1203.	1.1	86
287	Low serum levels of ?-interferon, ?-interferon, and interleukin-2 in alcoholic cirrhosis. Digestive Diseases and Sciences, 1991, 36, 1209-1212.	1.1	28
288	Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage. Digestive Diseases and Sciences, 1991, 36, 299-302.	1.1	27
289	Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer. Clinical Biochemistry, 1991, 24, 491-496.	0.8	27
290	Plasma noradrenaline in cirrhosis: a study of kinetics and temporal relationship to ascites formation. European Journal of Clinical Investigation, 1991, 21, 238-243.	1.7	21
291	Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: A systemic, splanchnic and renal hemodynamic study. Hepatology, 1991, 13, 111-116.	3.6	26
292	Prophylactic sclerotherapy for esophageal varices: Long-term results of a single-center trial. Hepatology, 1991, 13, 117-123.	3.6	63
293	Hemodynamic study during transdermal application of nitroglycerin tape in patients with cirrhosis. Hepatology, 1991, 13, 124-128.	3.6	26

#	Article	IF	Citations
294	Hyposensitivity to vasopressin in patients with hepatitis B–related cirrhosis during acute variceal hemorrhage. Hepatology, 1991, 13, 407-412.	3.6	28
295	Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a western comparative study in 60 patients. Hepatology, 1991, 13, 427-433.	3.6	135
296	Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: A simplified method. Hepatology, 1991, 13, 460-466.	3.6	34
297	Plasma catecholamines in patients with presinusoidal portal hypertension: Comparison with cirrhotic patients and nonportal hypertensive subjects. Hepatology, 1991, 13, 913-916.	3.6	18
298	Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology, 1991, 13, 1044-1051.	3.6	88
299	Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. Hepatology, 1991, 14, 91-98.	3.6	63
300	Effect of insulin and plasma amino acid concentration on leucine metabolism in cirrhosis. Hepatology, 1991, 14, 432-441.	3.6	46
301	Are patients with primary biliary cirrhosis hypermetabolic? a comparison between patients before and after liver transplantation and controls. Hepatology, 1991, 14, 464-472.	3.6	29
302	Sexual function and testosterone levels in men with nonalcoholic liver disease. Hepatology, 1991, 14, 479-482.	3.6	35
303	Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. Hepatology, 1991, 14, 483-487.	3.6	35
304	Bone loss after liver transplantation. Hepatology, 1991, 14, 613-619.	3.6	182
305	Effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Hepatology, 1991, 14, 824-829.	3.6	42
306	Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology, 1991, 14, 1013-1015.	3.6	25
307	Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology, 1991, 14, 1029-1034.	3.6	117
308	Relationships between plasma atrial natriuretic peptide concentrations and hemodynamics and hematocrit in patients with cirrhosis. Hepatology, 1991, 14, 1035-1039.	3.6	8
309	Surgical treatment of severe postshunt hepatic encephalopathy. World Journal of Surgery, 1991, 15, 109-113.	0.8	12
310	Results of endoscopic variceal sclerotherapy: Influence of etiology of portal hypertension and hepatic functional status. Gastroenterologia Japonica, 1991, 26, 32-35.	0.4	3
311	Functional hepatic imaging with receptor-binding radiopharmaceutical: Clinical potential as a measure of functioning hepatocyte mass. Gastroenterologia Japonica, 1991, 26, 734-741.	0.4	48

#	ARTICLE	IF	CITATIONS
312	Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy subjects and in disease states. European Journal of Clinical Pharmacology, 1991, 40, 101-106.	0.8	6
313	Portal hypertension25 years of progress Gut, 1991, 32, S18-S24.	6.1	6
314	Congestive gastropathy and Helicobacter pylori: an endoscopic and morphometric study Gut, 1991, 32, 351-354.	6.1	65
315	Paracentesis with Intravenous Infusion of Albumin as Compared with Peritoneovenous Shunting in Cirrhosis with Refractory Ascites. New England Journal of Medicine, 1991, 325, 829-835.	13.9	294
316	Hepatocellular Carcinoma in Italian Patients with Cirrhosis. New England Journal of Medicine, 1991, 325, 675-680.	13.9	773
317	Plasma beta endorphin in cirrhosis and renal failure Gut, 1991, 32, 306-308.	6.1	13
318	Amenorrhoea in women with non-alcoholic chronic liver disease Gut, 1991, 32, 202-206.	6.1	61
319	Hepatic Parenchymal Dysfunction in Schistosoma japonicum Infection. Journal of Infectious Diseases, 1991, 164, 1186-1192.	1.9	12
320	Decreased Serum Growth Hormone-Binding Protein in Patients with Liver Cirrhosis. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 777-780.	1.8	52
321	Non-invasive diagnosis of portal vein occlusion by radionuclide angiography Gut, 1992, 33, 1671-1674.	6.1	5
322	Bleeding varices in the elderly Gut, 1992, 33, 1009-1010.	6.1	6
323	Pugh's grading in the classification of liver decompensation Gut, 1992, 33, 1583-1583.	6.1	15
324	Metabolic Clearance of a Fat Emulsion Containing Mediumâ€Chain Triglycerides in Cirrhotic Patients. Journal of Parenteral and Enteral Nutrition, 1992, 16, 279-283.	1.3	21
325	Plasma concentrations of endogenous heparinoids in portal hypertension Gut, 1992, 33, 1549-1552.	6.1	40
326	A prospective trial of endoscopic sclerotherapy v oesophageal transection and gastric devascularisation in the long term management of bleeding oesophageal varices Gut, 1992, 33, 1553-1558.	6.1	22
327	Resource Utilization and Outcome of Liver Transplantation for Alcoholic Cirrhosis. Archives of Surgery, 1992, 127, 772.	2.3	40
328	Factors related to early mortality in cirrhotic patients bleeding from varices and treated by urgent sclerotherapy Gut, 1992, 33, 1381-1385.	6.1	43
329	Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis Gut, 1992, 33, 836-842.	6.1	85

#	Article	IF	CITATIONS
330	Activation of the classical complement pathway in spontaneous bacterial peritonitis Gut, 1992, 33, 307-311.	6.1	6
331	Endoscopic Sclerotherapy as Compared with Endoscopic Ligation for Bleeding Esophageal Varices. New England Journal of Medicine, 1992, 326, 1527-1532.	13.9	684
332	The Treatment of Esophageal Varices. Annual Review of Medicine, 1992, 43, 69-82.	5.0	14
333	Chronic Hepatitis and Cirrhosis., 1992,, 281-415.		O
334	Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology, 1992, 102, 2033-2041.	0.6	117
335	Portal hypertensive gastropathy in patients with cirrhosis. Gastroenterology, 1992, 102, 2060-2065.	0.6	98
336	Hemodynamic, neurohumoral, and metabolic responses to amino acid infusion in patients with cirrhosis. Gastroenterology, 1992, 103, 601-608.	0.6	9
337	Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology, 1992, 103, 229-234.	0.6	79
338	Serum levels of cytokines in chronic liver diseases. Gastroenterology, 1992, 103, 264-274.	0.6	711
339	Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology, 1992, 102, 973-979.	0.6	177
340	Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. Gastroenterology, 1992, 102, 1309-1318.	0.6	42
341	Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology, 1992, 103, 641-646.	0.6	105
342	Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology, 1992, 103, 1875-1882.	0.6	112
343	Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology, 1992, 102, 1736-1741.	0.6	164
344	Oral administration of clonidine in patients with alcoholic cirrhosis. Gastroenterology, 1992, 102, 248-254.	0.6	57
345	Breast Cancer-Associated Antigen Ca 15.3 In Liver Cirrhosis. Acta Oncológica, 1992, 31, 741-744.	0.8	7
346	The disposition of dapsone in cirrhosis. Clinical Pharmacology and Therapeutics, 1992, 51, 689-700.	2.3	40
347	Local Deterioration of the Cutaneous Venoarterial Reflex of the Hand in Cirrhosis. Scandinavian Journal of Gastroenterology, 1992, 27, 326-332.	0.6	8

#	Article	IF	CITATIONS
348	Decreased in vitro Production of Tumor Necrosis Factor in Primary Biliary Cirrhosis Patients. Scandinavian Journal of Gastroenterology, 1992, 27, 124-128.	0.6	25
349	Relationship of Insulin Resistance to Protein-Energy Malnutrition in Patients with Alcoholic Liver Cirrhosis: Effect of Short-Term Nutritional Support. Alcoholism: Clinical and Experimental Research, 1992, 16, 971-978.	1.4	4
350	Relationship of portal pressure, anorectal varices and hemorrhoids in cirrhotic patients. Journal of Hepatology, 1992, 15, 170-173.	1.8	51
351	Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients. Journal of Hepatology, 1992, 15, 299-303.	1.8	47
352	Hemodynamic and sympathetic responses to human atrial natriuretic peptide infusion in patients with cirrhosis. Journal of Hepatology, 1992, 14, 347-356.	1.8	19
353	Alteration of erythrocyte glutathione, cysteine and glutathione synthetase in alcoholic and non-alcoholic cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation, 1992, 52, 207-213.	0.6	27
354	Mechanisms and Consequences of Portal Hypertension. Drugs, 1992, 44, 1-13.	4.9	15
355	Effects of vaso-active agents on hepatic function and blood gases in patients with cirrhosis: A study of vasopressin and nitroglycerin. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 148-153.	1.4	8
356	Hypercholesterolaemia in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 491-496.	1.4	22
357	Surgical resection and survival in western patients with hepatocellular carcinoma. Journal of Hepatology, 1992, 15, 350-355.	1.8	28
358	Bacterial peritonitis and sclerotherapy for variceal hemorrhage. Gastrointestinal Endoscopy, 1992, 38, 200.	0.5	3
359	Selenium in chronic liver disease. Journal of Hepatology, 1992, 14, 176-182.	1.8	89
360	Ascites dynamics in cirrhosis. Journal of Hepatology, 1992, 16, 369-375.	1.8	15
361	Value of measurement of mean portal flow velocity by Doppler flowmetry in the diagnosis of portal hypertension. Journal of Hepatology, 1992, 16, 298-303.	1.8	164
362	Metabolic responses to lipid infusions in patients with liver cirrhosis. Clinical Nutrition, 1992, 11, 193-206.	2.3	37
363	Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clinical Nutrition, 1992, 11, 303-308.	2.3	14
364	Hepatocellular carcinoma. Journal of Hepatology, 1992, 16, 66-72.	1.8	22
365	Bacteriuria in patients with cirrhosis. Journal of Hepatology, 1992, 16, 73-76.	1.8	29

#	Article	IF	Citations
366	Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis B-related cirrhosis. Journal of Hepatology, 1992, 15, 54-58.	1.8	17
367	Natural history of autonomic neuropathy in chronic liver disease. Lancet, The, 1992, 339, 1462-1464.	6.3	164
368	Thermogenic response to intravenous nutrition in patients with cirrhosis. Journal of Hepatology, 1992, 16, 145-152.	1.8	9
369	Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. Journal of Hepatology, 1992, 15, 35-39.	1.8	8
370	Peripheral and cardiovascular autonomic impairment in chronic liver disease: prevalence and relation to hepatic function. Journal of Hepatology, 1992, 16, 177-183.	1.8	82
371	Injection sclerotherapy preceded by esophageal tamponade versus immediate sclerotherapy in arresting active variceal bleeding: a prospective randomized trial. Gastrointestinal Endoscopy, 1992, 38, 421-424.	0.5	47
372	Disseminated intravascular coagulation in liver cirrhosis. Journal of Hepatology, 1992, 15, 330-335.	1.8	46
373	A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. Journal of Hepatology, 1992, 16, 320-325.	1.8	110
374	The validity of bioelectrical impedance analysis in estimating total body water in patients with cirrhosis. Journal of Hepatology, 1992, 16, 59-65.	1.8	38
375	Increased procoagulant activity in peripheral blood mononuclear cells from patients with liver cirrhosis. Thrombosis Research, 1992, 68, 103-108.	0.8	10
376	Bed-rest-induced hypernatriuresis in cirrhotic patients without ascites: does it contribute to maintain â€~compensation'?. Journal of Hepatology, 1992, 16, 190-196.	1.8	56
377	The thermogenic and metabolic effects of food in liver cirrhosis: Consequences on the storage of nutrients and the hormonal counterregulatory response. Metabolism: Clinical and Experimental, 1992, 41, 476-482.	1.5	28
378	Pharmacokinetics of glafenine and glafenic acid in patients with cirrhosis, compared to healthy volunteers. Fundamental and Clinical Pharmacology, 1992, 6, 197-203.	1.0	5
379	Pharmacokinetics of lomefloxacin in patients with cirrhosis. American Journal of Medicine, 1992, 92, S41-S44.	0.6	11
380	Spontaneous Dialytic Ultrafiltration with Intraperitoneal Reinfusion of the Concentrate versus Large Paracentesis in Cirrhotic Patients with Intractable Ascites: A Randomized Study. International Journal of Artificial Organs, 1992, 15, 432-435.	0.7	15
381	Spontaneous Dialytic Ultrafiltration with Intraperitoneal Reinfusion of the Concentrate in 15 Cirrhotic Patients with Intractable Ascites. International Journal of Artificial Organs, 1992, 15, 168-171.	0.7	1
382	Evaluation of the Behavior of Carcinoembryonic Antigen in Cirrhotic Patients. International Journal of Biological Markers, 1992, 7, 244-248.	0.7	8
383	A Pugh score of 8 adequately selects patients with parenchymal cirrhosis for liver transplantation. Transplant International, 1992, 5, S175-S178.	0.8	2

#	Article	IF	CITATIONS
384	A Comparison of Sms 201-995 and Oesophageal Tamponade in the Control of Acute Variceal Haemorrhage. HPB Surgery, 1992, 6, 7-17.	2.2	12
385	Fibronectin as a Prognostic Indicator in Portal Hypertension. HPB Surgery, 1992, 5, 229-234.	2.2	1
386	Increased Sympathetic Nervous Activity and the Effects of Its Inhibition with Clonidine in Alcoholic Cirrhosis. Annals of Internal Medicine, 1992, 116, 446-456.	2.0	112
387	Surgical Measures for Active Variceal Bleeding. Gastrointestinal Endoscopy Clinics of North America, 1992, 2, 77-93.	0.6	1
388	Endoscopic Diagnosis and Classification of Varices. Gastrointestinal Endoscopy Clinics of North America, 1992, 2, 17-30.	0.6	5
389	Pattern and concentration of free and acetylated polyamines in urine of cirrhotic patients. International Journal of Biological Markers, 1992, 7, 52-58.	0.7	7
390	Protein-calorie malnutrition in liver cirrhosis. The Clinical Investigator, 1992, 70, 478-86.	0.6	239
391	Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions. Cancer Chemotherapy and Pharmacology, 1992, 31, S38-S44.	1.1	13
392	Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors. Cancer Chemotherapy and Pharmacology, 1992, 31, S82-S85.	1.1	39
393	Esophageal strictures following endoscopic variceal sclerotherapy. Digestive Diseases and Sciences, 1992, 37, 347-352.	1.1	25
394	Balloon tamponade and vasoactive drugs in the control of acute variceal haemorrhage. Bailliere's Clinical Gastroenterology, 1992, 6, 451-463.	0.9	5
395	The role of portosystemic shunting in the management of portal hypertension. Bailliere's Clinical Gastroenterology, 1992, 6, 497-515.	0.9	10
396	Pharmacokinetics of famotidine in patients with cirrhosis and ascites. European Journal of Clinical Pharmacology, 1992, 43, 559-562.	0.8	7
397	Upper gastro-intestinal tract bleeding in cirrhotic children candidates for liver transplantation. European Journal of Pediatrics, 1992, 151, 326-328.	1.3	52
398	Pre- and post-transplant assessment of liver function in paediatric liver transplantation. European Journal of Pediatrics, 1992, 151, S39-S43.	1.3	16
399	Portal Hypertension and Bleeding Esophageal Varices. Annals of Vascular Surgery, 1992, 6, 553-561.	0.4	6
400	Glucagon-independent renal hyperaemia and hyperfiltration after an oral protein load in Child A liver cirrhosis. European Journal of Clinical Investigation, 1992, 22, 31-37.	1.7	9
401	Preoperative assessment of hepatic function. Bailliere's Clinical Anaesthesiology, 1992, 6, 781-793.	0.2	1

#	Article	IF	CITATIONS
402	Anaesthetic management of patients with alcoholic liver disease. Bailliere's Clinical Anaesthesiology, 1992, 6, 847-861.	0.2	1
403	Sclerotherapy vs. esophageal transection vs. distal splenorenal shunt for the clinical management of esophageal varices in patients with child class A and B liver function: A prospective randomized trial. Hepatology, 1992, 15, 63-68.	3.6	35
404	Endoscopic injection sclerotherapy for 1,000 patients with esophageal varices: A nine-year prospective study. Hepatology, 1992, 15, 69-75.	3.6	84
405	Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: A preliminary report. Hepatology, 1992, 15, 252-257.	3.6	21
406	Esophageal staple transection as a salvage procedure after failure of acute injection sclerotherapy. Hepatology, 1992, 15, 403-406.	3.6	26
407	Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology, 1992, 15, 672-676.	3.6	88
408	Energy expenditure and substrate oxidation in patients with cirrhosis: The impact of cause, clinical staging and nutritional state. Hepatology, 1992, 15, 782-794.	3.6	281
409	Total effective vascular compliance in patients with cirrhosis: A study of the response to acute blood volume expansion. Hepatology, 1992, 15, 809-815.	3.6	56
410	Polymorphism of alcohol dehydrogenase, alcohol and aldehyde dehydrogenase activities: Implication in alcoholic cirrhosis in white patients. Hepatology, 1992, 15, 1017-1022.	3.6	63
411	Bleeding from staple line erosion after esophageal transection: Effect of omeprazole. Hepatology, 1992, 15, 1031-1035.	3.6	7
412	Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology, 1992, 15, 1054-1059.	3.6	71
413	A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (child class B and C) cirrhotic patients. Hepatology, 1992, 16, 89-94.	3.6	50
414	Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology, 1992, 16, 132-137.	3.6	410
415	Defective methionine metabolism in cirrhosis: Relation to severity of liver disease. Hepatology, 1992, 16, 149-155.	3.6	59
416	Hormonal status of postmenopausal women with alcohol-induced cirrhosis: Further findings and a review of the literature. Hepatology, 1992, 16, 312-319.	3.6	44
417	The hemodynamic status of preascitic cirrhosis: An evaluation under steady-state conditions and after postural change. Hepatology, 1992, 16, 341-346.	3.6	87
418	Increased tissue-type plasminogen activator activity in orthotopic but not heterotopic liver transplantation: The role of the anhepatic period. Hepatology, 1992, 16, 404-408.	3.6	28
419	Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial. Hepatology, 1992, 16, 912-919.	3.6	43

#	Article	IF	CITATIONS
420	Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma. Hepatology, 1992, 16, 1150-1155.	3.6	41
421	Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: Clinical correlations. Hepatology, 1992, 16, 1382-1388.	3.6	146
422	Antipyrine metabolism in patients with liver metastases from colorectal cancer. Cancer, 1992, 70, 1477-1482.	2.0	5
423	Gross pathologic types of hepatocellular carcinoma in Italian patients: Relationship with demographic, environmental, and clinical factors. Cancer, 1993, 72, 1557-1563.	2.0	94
424	Hyperfibrinolysis Resulting from Clotting Activation in Patients with Different Degrees of Cirrhosis. Hepatology, 1993, 17, 78-83.	3.6	88
425	Quantitative assessment of hepatocellular function throughin vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. Hepatology, 1993, 17, 814-819.	3.6	72
426	Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology, 1993, 17, 828-832.	3.6	112
427	Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: Dependence on liver cell failure. Hepatology, 1993, 18, 28-35.	3.6	18
428	Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy. Hepatology, 1993, 18, 36-40.	3.6	77
429	Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: A multicenter randomized trial. Hepatology, 1993, 18, 61-65.	3.6	88
430	Prior esophageal variceal bleeding does not adversely affect survival after orthotopic liver transplantation. Hepatology, 1993, 18, 66-72.	3.6	8
431	Albumin synthesis rates in cirrhosis: Correlation with child-turcotte classification. Hepatology, 1993, 18, 292-297.	3.6	72
432	Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: Long-term hemodynamic and renal effects. Hepatology, 1993, 18, 477-484.	3.6	61
433	Changes of serum 7S fragment of type IV collagen and N-terminal propertide of type III procollagen after transcatheter arterial embolization as a model of acute liver injury. Hepatology, 1993, 18, 809-815.	3.6	10
434	Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis. Hepatology, 1993, 18, 847-852.	3.6	8
435	Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. Hepatology, 1993, 18, 1061-1068.	3.6	111
436	Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double-blind study. Hepatology, 1993, 18, 1102-1107.	3.6	81
437	Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology, 1993, 18, 1121-1126.	3.6	305

#	Article	IF	CITATIONS
438	Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease. Hepatology, 1993, 18, 1132-1138.	3.6	71
439	Preoperative evaluation of a patient for hepatic surgery. Journal of Surgical Oncology, 1993, 53, 49-51.	0.8	18
440	Surgical risk in alcoholic cirrhotic postmenopausal women: Prognostic value of levels of hormones. Journal of Surgical Oncology, 1993, 53, 52-54.	0.8	4
441	Prognostic indicators in patients with cirrhosis and hepatocellular carcinoma undergoing surgical resection. Journal of Surgical Oncology, 1993, 53, 67-69.	0.8	6
442	Renal sodium handling and neurohumoral systems in patients with cirrhosis in sitting posture: effects of spironolactone and water immersion. The Clinical Investigator, 1993, 71, 894-7.	0.6	0
443	Study of serum procollagen type III peptide in patients with hepatic cirrhosis from a clinical point of view. The Clinical Investigator, 1993, 71, 416-8.	0.6	2
444	Influence of insulin on glucose metabolism and lipolysis in adipose tissue in situ in patients with liver cirrhosis. European Journal of Clinical Investigation, 1993, 23, 837-844.	1.7	9
445	Effect of transferrin concentration on bacterial growth in human ascitic fluid from cirrhotic and neoplastic patients. European Journal of Clinical Investigation, 1993, 23, 699-705.	1.7	14
446	Reduced portosystemic hemodynamic responsiveness after orthostasis in patients with cirrhosis. Digestive Diseases and Sciences, 1993, 38, 1251-1258.	1.1	13
447	Hepatic [14C]aminopyrine demethylation capacity after portocaval shunting. Digestive Diseases and Sciences, 1993, 38, 2177-2182.	1.1	17
448	Surgical treatment of complications of portal hypertension. Acta Chirurgica Austriaca, 1993, 25, 163-165.	0.2	0
450	Orthotopic liver transplantation in the presence of partial or total portal vein thrombosis: Problems in diagnosis and management. World Journal of Surgery, 1993, 17, 669-674.	0.8	71
451	Critical appraisal of the angiographic portacaval shunt (TIPS). American Journal of Surgery, 1993, 165, 566-571.	0.9	131
452	Endoscopic evaluation of the therapeutic effect of sclerotherapy for esophageal varices. Gastrointestinal Endoscopy, 1993, 39, 37-42.	0.5	13
453	Endoscopic ligation of esophageal varices compared with injection sclerotherapy: a prospective randomized trial. Gastrointestinal Endoscopy, 1993, 39, 123-126.	0.5	95
454	The effects of indomethacin and naproxen on zidovudine pharmacokinetics British Journal of Clinical Pharmacology, 1993, 36, 82-85.	1.1	17
455	Changes of sex hormone levels in patients with hepatitis B virus-related postnecrotic cirrhosis: Relationship to the severity of portal hypertension. Journal of Hepatology, 1993, 18, 101-105.	1.8	11
456	Diurnal pattern of variceal bleeding in cirrhotic patients. Journal of Hepatology, 1993, 19, 15-22.	1.8	39

#	Article	IF	CITATIONS
457	Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. Journal of Hepatology, 1993, 19, 43-50.	1.8	5
458	Hepatic hemodynamic features in patients with esophageal or gastric varices. Journal of Hepatology, 1993, 19, 85-89.	1.8	47
459	Measuring lidocaine metabolite â€" monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. Journal of Hepatology, 1993, 19, 140-147.	1.8	72
460	Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. Journal of Hepatology, 1993, 17, 308-314.	1.8	121
461	Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. Journal of Hepatology, 1993, 18, 185-195.	1.8	144
462	Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. Journal of Hepatology, 1993, 18, 290-294.	1.8	75
463	A prospective study of bacterial infections in patients with cirrhosis. Journal of Hepatology, 1993, 18, 353-358.	1.8	455
464	Effects of vasopressin and nicardipine on hemodynamics and liver function in patients with cirrhosis: comparison with vasopressin alone. Journal of Hepatology, 1993, 19, 345-352.	1.8	5
465	Autonomic and peripheral neuropathy in primary biliary cirrhosis. Journal of Hepatology, 1993, 19, 401-407.	1.8	32
466	Energy expenditure and substrate metabolism after oral fructose in patients with cirrhosis. Journal of Hepatology, 1993, 19, 241-251.	1.8	12
467	A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy. Journal of Hepatology, 1993, 19, 291-300.	1.8	32
468	Changes of hepatic and systemic haemodynamics following somatostatin administration in patients with hepatitis B-related cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 15-20.	1.4	10
469	Hypothalamicâ€pituitary adrenal function in endâ€stage nonâ€alcoholic liver disease. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 247-253.	1.4	61
470	Does propranolol maintain post-sclerotherapy variceal obliteration? A prospective randomized study. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 358-362.	1.4	15
471	Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. Antimicrobial Agents and Chemotherapy, 1993, 37, 1587-1592.	1.4	83
472	Clinical Pharmacokinetics of Newer Antibacterial Agents in Liver Disease. Clinical Pharmacokinetics, 1993, 24, 46-58.	1.6	37
473	Disposition of Ibuprofen in Patients with Liver Cirrhosis. Clinical Pharmacokinetics, 1993, 25, 154-163.	1.6	27
474	Assessment of atrial natriuretic peptide resistance in cirrhosis with head-out water immersion and atrial natriuretic peptide infusion. Canadian Journal of Physiology and Pharmacology, 1993, 71, 157-164.	0.7	9

#	ARTICLE	IF	CITATIONS
475	To treat or not to treat?. Journal of Hepatology, 1993, 17, S42-S46.	1.8	37
476	Metabolic effects of \hat{l}^2 -adrenergic receptor blockade in advanced alcoholic cirrhosis. Journal of Hepatology, 1993, 17, 74-80.	1.8	7
477	The lowly nasogastric tube: Still appropriate after all these years (at times). American Journal of Emergency Medicine, 1993, 11, 84-89.	0.7	23
478	Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. Journal of Hepatology, 1993, 17, 56-61.	1.8	90
479	The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. Journal of Hepatology, 1993, 17, 227-235.	1.8	37
480	The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites. Biomedicine and Pharmacotherapy, 1993, 47, 345-352.	2.5	21
481	Pulmonary Complications of Orthotopic Liver Transplantation. Mayo Clinic Proceedings, 1993, 68, 427-434.	1.4	69
482	Excretion of caffeine and its primary degradation products into bile. Journal of Hepatology, 1993, 17, 67-73.	1.8	33
483	Prevalence of hyperfibrinolysis in patients with liver cirrhosis. Fibrinolysis, 1993, 7, 59-62.	0.5	19
484	Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet, The, 1993, 342, 895-898.	6.3	107
485	Incidence of altered glucose tolerance in liver cirrhosis. Diabetes Research and Clinical Practice, 1993, 22, 37-44.	1.1	52
486	The Influence of Endoscopic Injection Sclerotherapy on Organs Surrounding the Esophagus. Digestive Endoscopy, 1993, 5, 23-32.	1.3	1
487	Effect of Endoscopic Injection Sclerotherapy on Acute Bleeding from Esophageal Varices in Cirrhotic Patients with Advanced Hepatocellular Carcinoma. Digestive Endoscopy, 1993, 5, 151-155.	1.3	0
488	Efficacy of Prophylactic Endoscopic Variceal Sclerotherapy in Patients with Hepatocellular Carcinoma. Digestive Endoscopy, 1993, 5, 350-358.	1.3	1
489	Serum concentrations of laminin in cirrhosis of the liver Gut, 1993, 34, 974-976.	6.1	16
490	Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1263-1268.	1.8	53
491	Ethanol challenge in non-alcoholic patients with schistosomiasis Journal of Clinical Pathology, 1993, 46, 250-253.	1.0	32
492	The History of the Surgical Treatment of Portal Hypertension. Archives of Surgery, 1993, 128, 925.	2.3	8

#	Article	IF	Citations
493	High Levels of Tumor Necrosis Factor-Â and Interleukin-6 in the Ascitic Fluid of Cirrhotic Patients with Spontaneous Bacterial Peritonitis. Clinical Infectious Diseases, 1993, 17, 218-223.	2.9	58
494	Congestive jejunopathy in portal hypertension Gut, 1993, 34, 694-697.	6.1	7 5
495	Successful use of a transjugular intrahepatic portosystemic stent shunt to control severe refractory oesophageal variceal haemorrhage in a poor risk patient Postgraduate Medical Journal, 1993, 69, 945-947.	0.9	0
496	Early detection of protein depletion in alcoholic cirrhosis: Role of body composition analysis. Gastroenterology, 1993, 105, 1839-1845.	0.6	134
497	Tumor necrosis factor \hat{l}_{\pm} and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology, 1993, 104, 1492-1497.	0.6	205
498	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology, 1993, 105, 229-236.	0.6	820
499	Manometry of esophageal varices: Comparison of an endoscopic balloon technique with needle puncture. Gastroenterology, 1993, 105, 1159-1166.	0.6	57
500	Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology, 1993, 105, 188-193.	0.6	95
501	Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology, 1993, 105, 1167-1172.	0.6	77
502	Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology, 1993, 104, 1133-1138.	0.6	256
503	Complications and Risk Factors After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis Associated with Primary Sclerosing Cholangitis. Annals of Surgery, 1993, 217, 314-320.	2.1	57
504	Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology, 1993, 105, 148-156.	0.6	62
505	Hepatocellular Carcinoma in Liver Cirrhosis: A Prospective Study. Scandinavian Journal of Gastroenterology, 1993, 28, 540-544.	0.6	37
506	Sclerotherapy versus \hat{l}^2 blockade: Unanticipated anomalies of experimental design. Gastroenterology, 1993, 105, 1575-1577.	0.6	5
507	Malignant lymphoproliferative disorders in liver cirrhosis. Annals of Oncology, 1993, 4, 245-250.	0.6	16
508	Diagnostic utility of laboratory tests in alcoholic liver disease. Clinical Chemistry, 1994, 40, 1641-1651.	1.5	65
509	Glycocalicin: a new assay-the normal plasma levels and its potential usefulness in selected diseases. Blood, 1994, 83, 691-702.	0.6	93
510	Limitations of Serum Creatinine Level and Creatinine Clearance as Filtration Markers in Cirrhosis. Archives of Internal Medicine, 1994, 154, 201.	4.3	246

#	Article	IF	CITATIONS
511	Liver Transplantation Without the Use of Blood Products. Archives of Surgery, 1994, 129, 528.	2.3	59
512	Comparison of Transjugular and Surgical Portosystemic Shunts on the Outcome of Liver Transplantation. Archives of Surgery, 1994, 129, 1018.	2.3	65
513	Combined (short-term plus longterm) sclerotherapy ν short-term only sclerotherapy: a randomised prospective trial. Gut, 1994, 35, 687-691.	6.1	8
514	Resistance of erythrocytes to lipid peroxidation in alcoholic patients Gut, 1994, 35, 1753-1756.	6.1	9
515	Oral Isosorbide-5-Mononitrate Reduces the Rebleeding Rate during the Course of Injection Sclerotherapy for Esophageal Varices. Scandinavian Journal of Gastroenterology, 1994, 29, 363-370.	0.6	12
516	Glucose Intolerance in Liver Cirrhosis: Role of Hepatic and Non-Hepatic Influences. Clinical Chemistry and Laboratory Medicine, 1994, 32, 749-58.	1.4	27
517	Changes in Debrisoquine Hydroxylation Capacity Following Liver Surgery. Human and Experimental Toxicology, 1994, 13, 537-541.	1.1	3
518	Pharmacological, Toxicologic, and Microbiological Considerations in the Choice of Initial Antibiotic Therapy for Serious Infections in Patients with Cirrhosis of the Liver. Clinical Infectious Diseases, 1994, 18, 324-335.	2.9	35
519	Abnormalities of Doppler waveform of the hepatic veins in patients with chronic liver disease: correlation with histologic findings American Journal of Roentgenology, 1994, 162, 833-837.	1.0	110
520	Portal Venous Flow and Follow-up in Patients with Liver Disease and Healthy Subjects: Assessment with Duplex Doppler. Scandinavian Journal of Gastroenterology, 1994, 29, 172-177.	0.6	22
521	Gram-negative bacillary cellulitis in patients with hepatic cirrhosis. European Journal of Clinical Microbiology and Infectious Diseases, 1994, 13, 19-24.	1.3	57
522	Hyperintense lesions of the globus pallidus on MRI in children with chronic liver disease. European Journal of Pediatrics, 1994, 153, 802-806.	1.3	5
523	Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma. Journal of Gastroenterology, 1994, 29, 745-750.	2.3	7
524	Impaired gastric mucosal energy metabolism in congestive gastropathy in cirrhotic patients. Journal of Gastroenterology, 1994, 29, 245-249.	2.3	5
525	Endoscopic injection sclerotherapy for esophageal varices in the elderly. World Journal of Surgery, 1994, 18, 764-768.	0.8	1
526	Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis Emergency control and prevention of early rebleeding. The Clinical Investigator, 1994, 72, 653-659.	0.6	40
527	Markers of potential esophageal variceal rebleeding in cirrhotic patients undergoing endoscopic injection sclerotherapy. Journal of Hepato-Biliary-Pancreatic Surgery, 1994, 1, 168-171.	2.0	0
528	Lipiodolization for unresectable hepatocellular carcinoma: An analysis of 205 patients using univariate and multivariate analysis. Journal of Surgical Oncology, 1994, 56, 54-58.	0.8	24

#	Article	IF	CITATIONS
529	Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year Study of 127 French Patients. Cancer, 1994, 74, 16-24.	2.0	177
530	Prospective flow cytometric DNA analysis of hepatocellular carcinoma specimens collected by ultrasound-guided fine needle aspiration. Cancer, 1994, 74, 599-605.	2.0	25
531	Early and late changes in fasting and absorptive plasma amino acids and ammonia after distal splenorenal shunt in cirrhosis. Hepatology, 1994, 19, 329-338.	3.6	2
532	Diuretics vs. paracentesis followed by diuretics in cirrhosis: Effect on ascites opsonic activity and immunoglobulin and complement concentrations. Hepatology, 1994, 19, 346-353.	3.6	8
533	Polymorphism of alcohol and aldehyde dehydrogenase genes and alcoholic cirrhosis in chinese patients. Hepatology, 1994, 19, 360-366.	3.6	157
534	Influence of paraesophageal venous collaterals on efficacy of endoscopic sclerotherapy for esophageal varices. Hepatology, 1994, 19, 602-608.	3. 6	47
535	Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology, 1994, 19, 628-634.	3.6	79
536	Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors. Hepatology, 1994, 19, 1115-1123.	3. 6	168
537	Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology, 1994, 19, 1418-1423.	3.6	59
538	Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology, 1994, 19, 1513-1520.	3 . 6	2,456
539	Prognostic significance of diabetes in patients with cirrhosis. Hepatology, 1994, 20, 119-125.	3.6	161
540	Skeletal muscle glycogen content in patients with cirrhosis. Hepatology, 1994, 20, 135-141.	3 . 6	21
541	Monoethylglicinexylidide test: A prognostic indicator of survival in cirrhosis. Hepatology, 1994, 20, 383-387.	3.6	58
542	Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials. Hepatology, 1994, 20, 643-650.	3.6	83
543	Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis. Hepatology, 1994, 20, 800-803.	3.6	36
544	Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology, 1994, 20, 804-812.	3.6	37
545	Evaluation of hepatocellular function by way of receptor-mediated uptake of a technetium-99m—labeled asialoglycoprotein analog. Hepatology, 1994, 20, 917-923.	3.6	38
546	Cerebral Phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. Hepatology, 1994, 20, 1173-1178.	3.6	55

#	Article	IF	CITATIONS
547	Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter italian study. Hepatology, 1994, 20, 1225-1230.	3.6	119
548	Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy. Hepatology, 1994, 20, 1432-1436.	3.6	79
549	Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: Long-term hemodynamic and renal effects. Hepatology, 1994, 20, 1502-1508.	3.6	67
550	Multi-variate stepwise discriminant analysis research affecting portal hypertension's grade factors of liver function. Journal of Tongji Medical University, 1994, 14, 56-60.	0.1	0
551	Delayed gastric emptying in patients with liver cirrhosis. Digestive Diseases and Sciences, 1994, 39, 983-987.	1.1	64
552	Effects of propranolol on gastric mucosal perfusion and serum gastrin level in cirrhotic patients with portal hypertensive gastropathy. Digestive Diseases and Sciences, 1994, 39, 2433-2438.	1.1	22
553	Wedged hepatic venous pressure reflects portal venous pressure during vasoactive drug administration in nonalcoholic cirrhosis. Digestive Diseases and Sciences, 1994, 39, 2439-2444.	1.1	16
554	Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy. Metabolic Brain Disease, 1994, 9, 347-359.	1.4	95
555	Serum IgE levels in liver cirrhosis Contrasting results in alcoholic and non-alcoholic patients. Clinical and Experimental Allergy, 1994, 24, 540-548.	1.4	32
556	Zinc and magnesium in liver cirrhosis. European Journal of Clinical Investigation, 1994, 24, 149-155.	1.7	36
557	EVALUATION OF INDOCYANINE GREEN RETENTION AND AMINOPYRINE BREATH TESTS IN PATIENTS WITH MALIGNANT BILIARY OBSTRUCTION. ANZ Journal of Surgery, 1994, 64, 759-762.	0.3	11
558	Life quality of patients undergoing liver transplantation. Transplant International, 1994, 7, 675-678.	0.8	3
559	An improved assay for urinary LTE4. Prostaglandins, 1994, 47, 281-292.	1.2	12
560	Resting energy expenditure and nutritional state in patients with liver cirrhosis before and after liver transplantation. Clinical Nutrition, 1994, 13, 145-152.	2.3	61
561	The Transjugular Intrahepatic Portosystemic Stent-Shunt Procedure for Variceal Bleeding. New England Journal of Medicine, 1994, 330, 165-171.	13.9	715
562	Pharmacokinetics of Famciclovir in Subjects with Chronic Hepatic Disease. Journal of Clinical Pharmacology, 1994, 34, 1199-1207.	1.0	30
563	Effect of cigarette smoking on caffeine and trimethadione N-demethylation catalyzed by different cytochrome P450 isozymes in patients with cirrhosis. International Hepatology Communications, 1994, 2, 341-346.	0.7	6
564	Orthotopic Liver Transplantation for Preoperative Early-Stage Hepatocellular Carcinoma. Mayo Clinic Proceedings, 1994, 69, 509-514.	1.4	19

#	Article	IF	CITATIONS
565	Morbidity and mortality in cirrhotic patients undergoing major cardiac, thoracic or vascular surgery. Journal of Cardiothoracic and Vascular Anesthesia, 1994, 8, 72.	0.6	0
566	The role of transjugular intrahepatic portosystemic shunts in the management of patients with end-stage liver disease. American Journal of Surgery, 1994, 168, 592-597.	0.9	22
567	Dynamics of cognitive brain dysfunction in patients with cirrhotic liver disease: an event-related P300 potential perspective. Electroencephalography and Clinical Neurophysiology, 1994, 91, 33-41.	0.3	24
568	Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis. Clinica Chimica Acta, 1994, 224, 125-129.	0.5	14
569	Lipid metabolism and substrate oxidation during intravenous fructose administration in cirrhosis. Metabolism: Clinical and Experimental, 1994, 43, 1171-1181.	1.5	4
570	Failure of glucagon to stimulate hepatic glycogenolysis in well-nourished patients with mild cirrhosis. Metabolism: Clinical and Experimental, 1994, 43, 85-89.	1.5	35
571	Intravascular clotting activation and systemic hyperfibrinolysis in patients with severe liver cirrhosis: The role of ascites. Fibrinolysis, 1994, 8, 353-358.	0.5	3
572	Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. Journal of Hepatology, 1994, 20, 206-212.	1.8	72
573	Ascites apheresis, concentration and reinfusion for the treatment of massive or refractory ascites in cirrhosis. Journal of Hepatology, 1994, 20, 289-295.	1.8	15
574	Splanchnic and peripheral glucose metabolism in cirrhosis. Journal of Hepatology, 1994, 20, 760-767.	1.8	13
575	Lipid metabolism and insulin resistance in cirrhosis. Journal of Hepatology, 1994, 20, 782-791.	1.8	8
576	Incidence of gallstones in a population of patients with cirrhosis. Journal of Hepatology, 1994, 20, 797-801.	1.8	57
577	Indirect evidence to suggest that prolactin induces salt retention in cirrhosis. Journal of Hepatology, 1994, 21, 347-352.	1.8	4
578	Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis. Journal of Hepatology, 1994, 21, 424-429.	1.8	22
579	Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. Journal of Hepatology, 1994, 20, 531-536.	1.8	80
580	Hand skin temperature changes in patients with chronic liver disease. Journal of Hepatology, 1994, 21, 927-933.	1.8	7
581	Blunted postprandial reaction of portal venous flow in chronic liver disease, assessed with duplex Doppler: significance for prognosis. Journal of Hepatology, 1994, 21, 966-973.	1.8	19
582	Endoscopic injection sclerotherapy vs. endoscopic variceal ligation in arresting acute variceal bleeding for patients with advanced hepatocellular carcinoma. Journal of Hepatology, 1994, 21, 1048-1052.	1.8	24

#	Article	IF	CITATIONS
583	Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels. Journal of Hepatology, 1994, 21, 1086-1091.	1.8	31
584	Renal sodium handling in cirrhosis with ascites: mechanisms of impaired natriuretic response to reclining. Journal of Hepatology, 1994, 21, 1116-1122.	1.8	8
585	Portal pressure after prophylactic sclerotherapy in patients with high-risk varices. Journal of Hepatology, 1994, 21, 515-520.	1.8	22
586	Ventilation-perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. Journal of Hepatology, 1994, 21, 52-57.	1.8	41
587	Prevention of rebleeding from oesophageal varices: two-year follow up of a prospective controlled trial of propranolol in addition to sclerotherapy. Journal of Hepatology, 1994, 21, 81-87.	1.8	30
588	A comparison of skinfold anthropometry and bioelectrical impedance analysis for measuring percentage body fat in patients with cirrhosis. Journal of Hepatology, 1994, 21, 878-883.	1.8	27
589	Relationships between the severity of cirrhosis and haemodynamic values in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 148-153.	1.4	34
590	Long-term prognosis and prognostic factors of liver cirrhosis in the 1980s. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 154-161.	1.4	21
591	Effects of an infusion of branched-chain amino acids on neurophysiological and psychometric testings in cirrhotic patients with mild hepatic encephalopathy. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 366-372.	1.4	21
592	Analyses of proliferating cell nuclear antigen-positive cells in hepatocellular carcinoma: Comparisons with clinical findings. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 425-432.	1.4	6
593	Prolonged bleeding time in cirrhotic patients: Relationship to peripheral vasodilation and severity of cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 437-441.	1.4	4
594	Total paracentesis in non-alcoholic cirrhotics with massive ascites: Mid-term effects on systemic and hepatic haemodynamics and renal function. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 592-596.	1.4	11
595	Pathomorphological study of HCV antibodyâ€positive liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 624-630.	1.4	33
596	Oesophageal perforation following endoscopic variceal ligation and balloon tamponade. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 659-662.	1.4	8
597	Decreased variation of electrocardiographic R–R interval in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 232-235.	1.4	7
598	Cruveilhier-Baumgarten syndrome: An efficient spontaneous portosystemic collateral preventing oesophageal varices bleeding. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 236-241.	1.4	13
599	Zidovudine pharmacokinetics in zidovudineâ€induced bone marrow toxicity British Journal of Clinical Pharmacology, 1994, 37, 7-12.	1.1	20
600	The effect of liver disease and food on plasma MEGX concentrations British Journal of Clinical Pharmacology, 1994, 37, 298-301.	1.1	10

#	Article	IF	Citations
601	Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis British Journal of Clinical Pharmacology, 1994, 37, 375-381.	1.1	11
602	Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome British Journal of Clinical Pharmacology, 1994, 37, 421-426.	1.1	28
603	Arterial oxygen desaturation during non-sedated diagnostic upper gastrointestinal endoscopy in patients with cirrhosis. Gastrointestinal Endoscopy, 1994, 40, 281-284.	0.5	15
604	McCormack's endoscopic signs for diagnosing portal hypertension: Comparison with gastroesophageal varices. Gastrointestinal Endoscopy, 1994, 40, 470-473.	0.5	10
605	Design of the abdominal aortic Aneurysm Detection and Management Study. Journal of Vascular Surgery, 1994, 20, 296-303.	0.6	97
606	Insulin Action on Glucose Transport in Isolated Skeletal Muscle from Patients with Liver Cirrhosis. Scandinavian Journal of Gastroenterology, 1994, 29, 71-76.	0.6	4
607	One-month regular oral nutrition in alcoholic cirrhotic patients. Changes of nutritional status, hepatic function and serum lipid pattern. British Journal of Nutrition, 1994, 72, 937-946.	1.2	35
608	Body composition in nonalcoholic cirrhosis: The effect of disease etiology and severity on nutritional compartments. Gastroenterology, 1994, 106, 1611-1617.	0.6	99
609	Plasma arginine vasopressin response to oral, gastric, and intravenous water load in patients with cirrhosis. Gastroenterology, 1994, 106, 678-685.	0.6	4
610	nm23-H1 Expression and disease recurrence after surgical resection of small hepatocellular carcinoma. Gastroenterology, 1994, 107, 486-491.	0.6	27
611	Evaluation of nutritional status by using anthropometry in adults with alcoholic and nonalcoholic liver disease. American Journal of Clinical Nutrition, 1994, 60, 269-273.	2.2	60
612	A Study of Endotoxaemia in Patients with Primary Biliary Cirrhosis. Journal of International Medical Research, 1994, 22, 95-99.	0.4	19
613	Definition and Classification of Negative Outcomes in Solid Organ Transplantation Application in Liver Transplantation. Annals of Surgery, 1994, 220, 109-120.	2.1	303
614	EARLY DEATH OR RETRANSPLANTATION IN ADULTS AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1994, 57, 1028-1036.	0.5	85
615	Long-term oral refeeding of patients with cirrhosis of the liver. British Journal of Nutrition, 1995, 74, 557-567.	1.2	95
616	Altered endogenous growth hormone secretory kinetics and diurnal GHâ€binding protein profiles in adults with chronic liver disease. Clinical Endocrinology, 1995, 43, 265-275.	1.2	66
617	Hypothalamicâ€pituitaryâ€testicular function in endâ€stage nonâ€alcoholic liver disease before and after liver transplantation. Clinical Endocrinology, 1995, 43, 331-337.	1.2	82
618	Liposoluble vitamins and naturally occurring carotenoids in porphyria cutanea tarda. European Journal of Clinical Investigation, 1995, 25, 510-514.	1.7	17

#	Article	IF	CITATIONS
619	Anesthesia for the patient with liver disease. Seminars in Anesthesia, 1995, 14, 193-203.	0.3	1
620	Lack of Plasma Complement Activation in Severe Acute Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 1995, 19, 1537-1540.	1.4	8
621	Utility of Carbohydrate-Deficient Transferrin as a Marker of Relapse in Alcoholic Patients. Alcoholism: Clinical and Experimental Research, 1995, 19, 611-616.	1.4	50
622	A non-invasive method for evaluating cirrhotic portal hypertension by administration of 99mTc-MIBI per rectum. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 169-173.	1.4	4
623	Carbohydrate-deficient transferrin in alcoholics with liver disease. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 174-178.	1.4	16
624	Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 198-204.	1.4	56
625	Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 256-260.	1.4	16
626	Haemodynamic effects of a combination of propranolol and clonidine in patients with post-hepatitic cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 281-286.	1.4	7
627	Epirubicin-lipiodol chemotherapy versus131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer, 1995, 76, 2202-2210.	2.0	66
628	Relationship between portal blood flow measured by image-directed doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. Journal of Clinical Ultrasound, 1995, 23, 297-303.	0.4	18
629	The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transplantation, 1995, 1, 249-255.	1.9	86
630	Research Articles: Pharmacokinetics of Promazine in Patients with Hepatic Cirrhosis-Correlation with a Novel Galactose Single Point Method. Journal of Pharmaceutical Sciences, 1995, 84, 111-114.	1.6	9
631	Glycine conjugation of para-aminobenzoic acid (PABA): A quantitative test of liver function. Clinical Biochemistry, 1995, 28, 531-540.	0.8	34
632	Serum hepatocyte growth factor levels in liver diseases: Clinical implications. Hepatology, 1995, 21, 106-112.	3.6	203
633	Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology, 1995, 21, 120-128.	3.6	192
634	Spontaneous bacterial peritonitis in cirrhotic patients treated using paracentesis or diuretics: Results of a randomized study. Hepatology, 1995, 21, 340-344.	3.6	22
635	Effect of functional grade and etiology onin vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: Biochemical basis of spectral appearances. Hepatology, 1995, 21, 417-427.	3.6	86
636	Interobserver and interquipment variability of echo-doppler examination of the portal vein: Effect of a cooperative training program. Hepatology, 1995, 21, 428-433.	3.6	152

#	Article	IF	CITATIONS
637	31P magnetic resonance spectroscopy of the liver: Correlation with standardized serum, clinical, and histological changes in diffuse liver disease. Hepatology, 1995, 21, 443-449.	3.6	31
638	Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology, 1995, 21, 680-688.	3.6	119
639	Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 [7-36 amide] after oral glucose in cirrhosis. Hepatology, 1995, 21, 933-941.	3.6	19
640	Neopterin and soluble tumor necrosis factor receptor type I in alcohol-induced cirrhosis. Hepatology, 1995, 21, 976-978.	3.6	39
641	Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: A prospective randomized trial. Hepatology, 1995, 21, 1517-1522.	3.6	183
642	Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. Hepatology, 1995, 22, 96-100.	3.6	24
643	Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis. Hepatology, 1995, 22, 124-131.	3.6	62
644	High plasma levels of atrial natriuretic peptide in preascitic cirrhosis: Indirect evidence of reduced natriuretic effectiveness of the peptide. Hepatology, 1995, 22, 132-137.	3.6	18
645	A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. Hepatology, 1995, 22, 466-471.	3.6	218
646	Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology, 1995, 22, 1132-1135.	3.6	29
647	An investigation of whether polymorphisms of cytochrome P4502E1 are genetic markers of susceptibility to alcoholic end-stage organ damage in a chinese population. Hepatology, 1995, 22, 1409-1414.	3.6	38
648	Randomized control trial of lipo-prostaglandin E1 in patients with acute liver injury induced by Lipiodol-targeted chemotherapy*. Clinical Pharmacology and Therapeutics, 1995, 57, 582-589.	2.3	5
649	Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clinical Pharmacology and Therapeutics, 1995, 58, 390-398.	2.3	24
650	Peripheral blood CD3 and CD4 T-lymphocyte reduction correlates with severity of liver cirrhosis. International Journal of Clinical and Laboratory Research, 1995, 25, 153-156.	1.0	47
651	Clinical significance of the trimethadione tolerance test in chronic hepatitis: A useful indicator of hepatic drug metabolizing capacity. Journal of Gastroenterology, 1995, 30, 478-484.	2.3	16
652	Patent ductus venosus associated with a hyperintense globus pallidum on T1-weighted magnetic resonance imaging and pulmonary hypertension. European Journal of Pediatrics, 1995, 154, 526-529.	1.3	29
653	Evaluation of portal circulation through the superior mesenteric vein with an enteric capsule of [1231]iodoamphetamine. Journal of Gastroenterology, 1995, 30, 55-60.	2.3	1
654	Increased serum IgE in alcohol abusers. Clinical and Experimental Allergy, 1995, 25, 756-764.	1.4	48

#	Article	IF	CITATIONS
655	Transjugular intrahepatic porto-systemic shunt (TIPS): Indications and follow up. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 1995, 2, 29-36.	1.4	1
656	MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status. Metabolic Brain Disease, 1995, 10, 175-188.	1.4	91
657	Prognosis and life expectancy in chronic liver disease. Digestive Diseases and Sciences, 1995, 40, 1805-1815.	1.1	114
658	Regional distribution of transforming growth factor-alpha and epidermal growth factor in normal and portal hypertensive gastric mucosa in humans. Digestive Diseases and Sciences, 1995, 40, 263-267.	1.1	16
659	Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis. Digestive Diseases and Sciences, 1995, 40, 428-434.	1.1	25
660	Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation. Metabolic Brain Disease, 1995, 10, 219-231.	1.4	116
661	1 Clinical evaluation of liver disease. Bailliere's Clinical Gastroenterology, 1995, 9, 639-659.	0.9	11
662	2 Liver function tests. Bailliere's Clinical Gastroenterology, 1995, 9, 661-677.	0.9	9
663	Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Digestive Diseases and Sciences, 1995, 40, 1252-1256.	1.1	137
664	Interferon alfa for chronic active hepatitis B. Medical Journal of Australia, 1995, 162, 8-11.	0.8	22
665	Complications of Chronic Liver Disease. Critical Care Clinics, 1995, 11, 431-463.	1.0	18
666	New Approaches to Endoscopic Therapy for Hemostasis of Upper GI Bleed. Scandinavian Journal of Gastroenterology, 1995, 30, 90-95.	0.6	4
667	Hospital Mortality of Major Hepatectomy for Hepatocellular Carcinoma Associated With Cirrhosis. Archives of Surgery, 1995, 130, 198.	2.3	260
668	Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Antimicrobial Agents and Chemotherapy, 1995, 39, 2732-2737.	1.4	39
669	Sclerotherapy with or without Octreotide for Acute Variceal Bleeding. New England Journal of Medicine, 1995, 333, 555-560.	13.9	267
670	The Transjugular Intrahepatic Portosystemic Stent–Shunt Procedure for Refractory Ascites. New England Journal of Medicine, 1995, 332, 1192-1197.	13.9	423
671	Sonographic assessment of the distal end of the thoracic duct in healthy volunteers and in patients with portal hypertension American Journal of Roentgenology, 1995, 165, 863-866.	1.0	19
672	Assessment of Relative Contributions of Fibrinolysis and Fibrinogenolysis to the Abnormalities of Plasma Fibrinogen/Fibrin-Retated D and E Antigens and Their Ratio in Liver Cirrhosis. Clinical and Applied Thrombosis/Hemostasis, 1995, 1, 183-187.	0.7	0

#	Article	IF	CITATIONS
673	Aeromonas Bacteremia: Review of 59 Episodes. Clinical Infectious Diseases, 1995, 20, 1298-1304.	2.9	160
674	Cirrhosis of the human liver: an in vitro 31P nuclear magnetic resonance study. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1995, 1272, 113-118.	1.8	32
675	Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 41-45.	1.0	26
676	Brain magnetic resonance imaging in non-alcoholic cirrhosis. European Journal of Radiology, 1995, 21, 84-88.	1.2	13
677	Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Biomedicine and Pharmacotherapy, 1995, 49, 364-368.	2.5	5
678	Short-term changes in energy metabolism after 1 month of a regular oral diet in severely malnourished cirrhotic patients. Metabolism: Clinical and Experimental, 1995, 44, 765-770.	1.5	34
679	Effects of beta-blockade on hepatic conversion of amino acid nitrogen and on urea synthesis in cirrhosis. Metabolism: Clinical and Experimental, 1995, 44, 899-905.	1.5	2
680	Cleavage of high molecular weight kininogen in ascites and plasma of patients with cirrhosis. Thrombosis Research, 1995, 78, 277-282.	0.8	8
681	Measuring plasma fibrinogen levels in patients with liver cirrhosis. The occurrence of proteolytic fibrin(ogen) degradation products and their influence on several fibrinogen assays. Thrombosis Research, 1995, 78, 353-362.	0.8	28
682	Hemostasis activation in patients with liver cirrhosis. Thrombosis Research, 1995, 77, 271-278.	0.8	40
683	Clinical evaluation of a monoclonal antibody to serum KM01 for the diagnosis of hepatocellular carcinoma. Clinica Chimica Acta, 1995, 236, 71-79.	0.5	2
684	Abnormalities of the Bereitschaftspotential and MRI pallidal signal in non-encephalopathic cirrhotic patients. Electroencephalography and Clinical Neurophysiology, 1995, 94, 425-431.	0.3	6
685	Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochemical Pharmacology, 1995, 49, 873-881.	2.0	94
686	Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. American Journal of Surgery, 1995, 169, 28-35.	0.9	314
687	A critical appraisal of the small-diameter portacaval H-graft. American Journal of Surgery, 1995, 170, 10-14.	0.9	8
688	Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology, 1995, 108, 138-144.	0.6	238
689	Prognostic significance of bacterial infection in bleeding cirrhotic patients: A prospective study. Gastroenterology, 1995, 108, 1828-1834.	0.6	300
690	Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: Results in 90 patients. Gastroenterology, 1995, 108, 1143-1151.	0.6	315

#	Article	IF	CITATIONS
691	Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: Relationships with portal hemodynamics. Gastroenterology, 1995, 108, 1152-1158.	0.6	141
692	Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology, 1995, 109, 531-539.	0.6	129
693	Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients. Gastroenterology, 1995, 109, 917-922.	0.6	191
694	In vivo hepatic 31P magnetic resonance spectroscopy in chronic alcohol abusers. Gastroenterology, 1995, 108, 776-788.	0.6	35
695	The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis British Journal of Clinical Pharmacology, 1995, 39, 445-448.	1.1	11
696	Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. Journal of Hepatology, 1995, 23, 681-688.	1.8	58
697	Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil. Journal of Hepatology, 1995, 23, 689-696.	1.8	28
698	Elevated levels of serum carbohydrate deficient transferrin are not specific for alcohol abuse in patients with liver disease. Journal of Hepatology, 1995, 23, 706-711.	1.8	27
699	Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. Journal of Hepatology, 1995, 22, 410-415.	1.8	95
700	Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. Journal of Hepatology, 1995, 22, 616-622.	1.8	35
701	Hemodynamic and renal effects of ascites apheresis, concentration and reinfusion in advanced cirrhosis. Journal of Hepatology, 1995, 22, 10-16.	1.8	23
702	Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. Journal of Hepatology, 1995, 22, 309-318.	1.8	89
703	Characterization of mechanisms causing hypoalbuminemia in rats with long-term bile duct ligation. Journal of Hepatology, 1995, 23, 79-86.	1.8	21
704	Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. Journal of Hepatology, 1995, 23, 129-134.	1.8	60
705	Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophaegeal varices, and hyperdynamic circulation Journal of Hepatology, 1995, 22, 165-172.	1.8	341
706	Aminopyrine breath test improves long-term prognostic evaluation in patients with alcoholic cirrhosis in Child classes A and B. Journal of Hepatology, 1995, 22, 179-183.	1.8	22
707	Sulphoxidation and sulphation capacity in patients with primary biliary cirrhosis. Journal of Hepatology, 1995, 22, 551-560.	1.8	40
708	The Effects of Chronic Administration of Indomethacin and Misoprostol on Renal Function in Cirrhotic Patients with and without Ascites. Scandinavian Journal of Gastroenterology, 1995, 30, 1194-1199.	0.6	18

#	Article	IF	CITATIONS
709	Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver Disease. Clinical Pharmacokinetics, 1995, 29, 370-391.	1.6	181
710	Endoscopic variceal ligation versus conservative treatment for patients with hepatocellular carcinoma and bleeding esophageal varices. Gastrointestinal Endoscopy, 1995, 42, 535-539.	0.5	12
711	Changes in portal hypertensive gastropathy after endoscopic variceal sclerotherapy or ligation: An endoscopic observation. Gastrointestinal Endoscopy, 1995, 42, 139-144.	0.5	44
712	Randomised trial of effects of interferon- \hat{l} \pm on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, The, 1995, 346, 1051-1055.	6.3	911
713	Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet, The, 1995, 346, 865-868.	6.3	343
714	Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 47-50.	1.4	66
715	CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients British Journal of Clinical Pharmacology, 1995, 39, 71-76.	1.1	59
716	Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients*1. Hepatology, 1995, 22, 96-100.	3.6	11
717	31P magnetic resonance spectroscopy of the liver: Correlation with standardized serum, clinical, and histological changes in diffuse liver disease. Hepatology, 1995, 21, 443-449.	3.6	9
718	Comparison of Surgical Treatment of Ulcerative Colitis Associated With Primary Sclerosing Cholangitis: Ileal Pouch-Anal Anastomosis Versus Brooke Ileostomy. Mayo Clinic Proceedings, 1996, 71, 748-756.	1.4	59
719	Frequency and Clinical Implications of Increased Pulmonary Artery Pressures in Liver Transplant Patients. Mayo Clinic Proceedings, 1996, 71, 543-551.	1.4	246
720	MANAGEMENT OF PORTAL HYPERTENSION AND ITS COMPLICATIONS. Medical Clinics of North America, 1996, 80, 1021-1034.	1.1	11
721	Is the role of transjugular intrahepatic portosystemic shunts limited in the management of patients with end-stage liver disease?. American Journal of Surgery, 1996, 172, 536-540.	0.9	18
722	Medium aperture meso-caval shunts reliably prevent recurrent variceal hemorrhages. American Journal of Surgery, 1996, 171, 490-494.	0.9	5
723	Effect of verapamil on portal and splanchnic hemodynamics in patients with advanced posthepatitic cirrhosis using duplex Doppler ultrasound. European Journal of Radiology, 1996, 23, 97-101.	1.2	8
724	Nutritional assessment in chronic liver disease patients: A comparison between skeletal muscle function and standard nutritional parameters. Nutrition Research, 1996, 16, 545-553.	1.3	2
725	Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial. Electroencephalography and Clinical Neurophysiology, 1996, 98, 29-34.	0.3	23
726	Carnitine metabolism in chronic liver disease. Life Sciences, 1996, 59, 1579-1599.	2.0	27

#	Article	IF	CITATIONS
727	Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet, The, 1996, 348, 1677-1681.	6.3	131
728	Comparison of resection, liver transplantation and transcatheter oily chemoembolization in treatment of hepatocellular carcinoma. Journal of Hepatology, 1996, 24, 293-300.	1.8	99
729	Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. Journal of Hepatology, 1996, 24, 161-168.	1.8	63
730	In vivo hepatic magnetic resonance spectroscopy: clinical or research tool?. Journal of Hepatology, 1996, 25, 414-424.	1.8	11
731	Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study. Journal of Hepatology, 1996, 24, 570-573.	1.8	21
732	Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis. Journal of Hepatology, 1996, 24, 574-580.	1.8	35
733	Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. Journal of Hepatology, 1996, 24, 377-384.	1.8	116
734	Effect of octreotide on total effective vascular compliance in patients with posthepatitic cirrhosis. Journal of Hepatology, 1996, 24, 81-87.	1.8	15
735	Transamination of methionine after loading in patients with cirrhosis. Journal of Hepatology, 1996, 24, 95-100.	1.8	9
736	Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. Journal of Hepatology, 1996, 25, 474-480.	1.8	49
737	Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow. Journal of Hepatology, 1996, 25, 491-497.	1.8	26
738	Transdermal nitroglycerin in cirrhosis. A 24-hour echo-Doppler study of splanchnic hemodynamics. Journal of Hepatology, 1996, 25, 498-503.	1.8	10
739	Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. Journal of Hepatology, 1996, 25, 684-688.	1.8	84
740	Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis. Journal of Hepatology, 1996, 24, 692-698.	1.8	18
741	Systemic haemodynamic changes in patients with cystic fibrosis with and without chronic liver disease. Journal of Hepatology, 1996, 25, 900-908.	1.8	3
742	Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. Metabolism: Clinical and Experimental, 1996, 45, 652-657.	1.5	29
743	Primary liver transplantation without transfusion of red blood cells. Surgery, 1996, 120, 698-705.	1.0	45
744	Comparison of a modified Sugiura procedure with portal systemic shunt for prevention of recurrent variceal bleeding in cirrhosis. Surgery, 1996, 119, 214-221.	1.0	17

#	ARTICLE	IF	CITATIONS
745	Combined endoscopic clipping and injection sclerotherapy for esophageal varices. Gastrointestinal Endoscopy, 1996, 43, 140-143.	0.5	12
746	Hypoxemia during diagnostic laparoscopy: a prospective study. Gastrointestinal Endoscopy, 1996, 44, 124-128.	0.5	17
747	Effect of alcohol abuse and glutathione administration on the circulating levels of glutathione and on antipyrine metabolism in patients with alcoholic liver cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation, 1996, 56, 441-447.	0.6	25
748	Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer American Journal of Roentgenology, 1996, 167, 759-768.	1.0	728
749	The assessment of body composition in patients with cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 213-225.	2.2	29
750	Pharmacokinetics of Meloxicam in Patients with Hepatic Cirrhosis in Comparison with Healthy Volunteers. Clinical Drug Investigation, 1996, 11, 97-107.	1.1	6
751	A Reassessment of the Optimal Sampling Time for the MEGX Liver Function Test. Clinical Drug Investigation, 1996, 12, 181-187.	1.1	4
752	Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. Journal of Antimicrobial Chemotherapy, 1996, 37, 27-39.	1.3	60
753	Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency. Journal of Clinical Pharmacology, 1996, 36, 206-215.	1.0	42
7 54	Complications of Endoscopic Biliary Sphincterotomy. New England Journal of Medicine, 1996, 335, 909-919.	13.9	2,367
755	Long-Term Management of Esophageal Varices by Endoscopic Sclerotherapy (EST): A Review of 12 Years' Experience. Diagnostic and Therapeutic Endoscopy, 1996, 2, 211-217.	1.5	1
756	Pharmacokinetics of Trapidil in Patients with Chronic Liver Disease. Journal of Clinical Pharmacology, 1996, 36, 897-902.	1.0	3
757	Repeated Doses of Rocuronium Bromide Administered to Cirrhotic and Control Patients Receiving Isoflurane. Anesthesiology, 1996, 84, 1092-1100.	1.3	39
758	Pharmacokinetics of Dichloroacetate in Patients Undergoing Liver Transplantation. Anesthesiology, 1996, 84, 851-858	1.3	17
759	Chapter 3 Cancer cells and metastasis. New Comprehensive Biochemistry, 1996, 30, 183.	0.1	4
760	Chapter 3b Cancer cells and metastasis. New Comprehensive Biochemistry, 1996, , 197-210.	0.1	0
761	Evaluation of Interferon Treatment in Cirrhotic Patients with Hepatitis C. Journal of the Japanese Association for Infectious Diseases, 1996, 70, 597-604.	0.0	2
762	Malnutrition in alcoholic and virus-related cirrhosis. American Journal of Clinical Nutrition, 1996, 63, 602-609.	2.2	242

#	Article	IF	CITATIONS
763	Helicobacter pylori Infection in Congestive Gastropathy. Helicobacter, 1996, 1, 168-171.	1.6	14
764	Unresectable hepatocellular carcinoma in cirrhosis. Digestive Diseases and Sciences, 1996, 41, 2332-2339.	1.1	71
765	MR imaging and spectroscopy of the basal ganglia in chronic liver disease: Correlation of T1-weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra. Metabolic Brain Disease, 1996, 11, 249-268.	1.4	49
766	Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Digestive Diseases and Sciences, 1996, 41, 552-556.	1.1	187
767	Effect of liver cirrhosis and age on the glutathione concentration in the plasma, erythrocytes, and gastric mucosa of man. Free Radical Biology and Medicine, 1996, 20, 483-488.	1.3	59
768	Metabolic, endocrine, haemodynamic and pulmonary responses to different types of exercise in individuals with normal or reduced liver function. European Journal of Applied Physiology and Occupational Physiology, 1996, 74, 246-257.	1.2	14
769	Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselectivel²-blocker. Digestive Diseases and Sciences, 1996, 41, 1722-1726.	1.1	23
770	Gastric mucus generation in cirrhotic patients with portal hypertension. Digestive Diseases and Sciences, 1996, 41, 1727-1732.	1.1	18
771	Outcome prediction for patients with cirrhosis of the liver in a medical ICU: A comparison of the APACHE scores and liver-specific scoringsystems. Intensive Care Medicine, 1996, 22, 559-563.	3.9	85
772	MR imaging enhancement with superparamagnetic iron oxidein chronic liver disease: influence of liver dysfunction andparenchymal pathology. Abdominal Imaging, 1996, 21, 318-323.	2.0	36
773	Effect of moderate or severe liver dysfunction on the pharmacokinetics of Î ³ -hydroxybutyric acid. European Journal of Clinical Pharmacology, 1996, 50, 305-310.	0.8	47
774	Portal Hypertension and Bleeding Esophagogastric Varices. Annals of Vascular Surgery, 1996, 10, 415-426.	0.4	2
775	Influence of clinicopathological variables on CYP protein expression in human liver. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 33-39.	1.4	28
776	Echo-Doppler measurements of portal vein and superior mesenteric artery blood flow in humans: Inter- and intra-observer short-term reproducibility. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 40-46.	1.4	52
777	Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 59-64.	1.4	63
778	Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 208-215.	1.4	25
779	Vasopressin plus oxygen vs vasopressin alone in cirrhotic patients with portal-hypertensive gastropathy: Effects on gastric mucosal haemodynamics and oxygenation. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 216-222.	1.4	16
780	Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis?. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 417-421.	1.4	123

#	Article	IF	Citations
781	Hyperglucagonaemia in cirrhotic patients and its relationship to the severity of cirrhosis and haemodynamic values. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 422-428.	1.4	12
782	Complications of percutaneous transhepatic catheterization of the portal venous system in patients with portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 630-634.	1.4	28
783	Plasma interleukinâ€8 levels in patients with postâ€hepatitic cirrhosis: Relationship to severity of liver disease, portal hypertension and hyperdynamic circulation. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 635-640.	1.4	11
784	Circadian occurrence of variceal bleeding in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 1115-1120.	1.4	17
785	Interferon- \hat{l} ±2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. Journal of Viral Hepatitis, 1996, 3, 333-340.	1.0	10
786	The relationship between cytokine concentrations and hemostatic abnormalities in patients with liver cirrhosis of postviral or cryptogenic origin. Fibrinolysis, 1996, 10, 249-254.	0.5	2
787	Serum and Ascitic Levels of Soluble Intercellular Adhesion Molecule-1 in Patients with Alcoholic Liver Cirrhosis: Relation to Biochemical Markers of Disease Activity and Alcohol Intake. Alcoholism: Clinical and Experimental Research, 1996, 20, 929-933.	1.4	6
788	Protein-energy status and 15N-glycine kinetic study of child a cirrhotic patients fed low- to high-protein energy diets. Nutrition, 1996, 12, 519-523.	1.1	12
789	Energy metabolism in portal hypertension in children. Nutrition, 1996, 12, 469-474.	1.1	21
790	Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease. Hepatology, 1996, 23, 471-475.	3.6	72
791	High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia. Hepatology, 1996, 23, 1377-1383.	3.6	140
792	Albumin but not fibrinogen synthesis correlates with galactose elimination capacity in patients with cirrhosis of the liver. Hepatology, 1996, 24, 53-59.	3.6	73
793	The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology, 1996, 24, 556-560.	3.6	178
794	Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology, 1996, 24, 1116-1120.	3.6	278
795	Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: Studies under flow conditions. Hepatology, 1996, 24, 1137-1142.	3.6	49
796	The lidocaine monoethylglycinexylidide test of liver function. Liver Transplantation, 1996, 2, 242-245.	1.9	5
797	Glucose and potassium metabolic responses to insulin during liver transplantation. Liver Transplantation, 1996, 2, 443-454.	1.9	22
798	Clinical and pathologic features of hepatocellular carcinoma in young and older italian patients., 1996, 77, 2223-2232.		51

#	Article	IF	Citations
799	Efficacy of a surveillance program for early detection of hepatocellular carcinoma., 1996, 78, 977-985.		179
800	Advances in hepatic resection and results for hepatocellular carcinoma., 1996, 12, 183-188.		9
801	T-cell activation, expression of adhesion molecules and response to ethanol in alcoholic cirrhosis. Immunology Letters, 1996, 50, 179-183.	1.1	35
802	Ultrasound-guided percutaneous ethanol injection: first choice for treatment of hepatocellular carcinoma in the elderly. Archives of Gerontology and Geriatrics, 1996, 22, 295-303.	1.4	1
803	The effect of liver disease on urine caffeine metabolite ratios*. Clinical Pharmacology and Therapeutics, 1996, 59, 624-635.	2.3	24
804	Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study Gut, 1996, 39, 319-324.	6.1	82
805	Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models Gut, 1996, 39, 141-146.	6.1	38
806	Portal Hypertensive Colopathy in Patients with Cirrhosis. Scandinavian Journal of Gastroenterology, 1996, 31, 490-494.	0.6	53
807	New Approaches to Endoscopic Therapy for a Haemostasis Upper GI Bleed. Scandinavian Journal of Gastroenterology, 1996, 31, 116-123.	0.6	7
808	Cathepsin D Serum Mass Concentrations in Patients with Hepatocellular Carcinoma and/or Liver Cirrhosis. Clinical Chemistry and Laboratory Medicine, 1996, 34, 555-60.	1.4	12
809	Hyperfibrinolysis in hepatosplenic schistosomiasis Journal of Clinical Pathology, 1996, 49, 990-993.	1.0	13
810	Portal Duplex Sonography in Liver Cirrhosis: A Useful Supplement to Endoscopic Evaluation of Bleeding Risk of Esophageal Varices?. Scandinavian Journal of Gastroenterology, 1996, 31, 495-499.	0.6	9
811	Neuropsychological Characterization and Detection of Subclinical Hepatic Encephalopathy. Archives of Neurology, 1996, 53, 758-763.	4.9	152
812	Effect of transjugular intrahepatic portosystemic shunt on quality of life American Journal of Roentgenology, 1996, 167, 963-969.	1.0	43
813	Plasma Interleukin-6 Levels in Patients with Cirrhosis Relationship to Endotoxemia, Tumor Necrosis Factor-α, and Hyperdynamic Circulation. Scandinavian Journal of Gastroenterology, 1996, 31, 500-505.	0.6	96
814	Compensated cirrhosis due to viral hepatitis: using MR imaging to predict clinical progression American Journal of Roentgenology, 1997, 169, 801-805.	1.0	32
815	Gallstones in Cirrhotics Revisited by a Laparoscopic View. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 1997, 7, 213-220.	0.5	40
816	Percutaneous management of hepatocellular carcinoma: Patient selection for percutaneous alcohol injection alone or combined with arterial chemoembolization. Minimally Invasive Therapy and Allied Technologies, 1997, 6, 65-70.	0.6	1

#	Article	IF	CITATIONS
817	Oxygen Metabolism During Liver Transplantation. Anesthesia and Analgesia, 1997, 85, 746-752.	1.1	6
818	Is Cryosurgical Ablation Appropriate for Treating Hepatocellular Cancer?. Archives of Surgery, 1997, 132, 599.	2.3	26
819	Morbid Prognostic Features in Patients With Chronic Liver Failure Undergoing Nonhepatic Surgery. Archives of Surgery, 1997, 132, 880.	2.3	85
820	Relationship between Portal Pressure, Esophageal Varices, and Variceal Bleeding on the Basis of the Stage and Cause of Cirrhosis. Scandinavian Journal of Gastroenterology, 1997, 32, 731-735.	0.6	31
821	Increased Serum Concentration of IgA2 Subclass and IgA2/IgA1 Ratio: Specific Markers of Chronic Alcoholic Abuse?. Clinical Chemistry and Laboratory Medicine, 1997, 35, 275-9.	1.4	4
822	The Liver: New Functional, Prognostic and Diagnostic Tests. Annals of Clinical Biochemistry, 1997, 34, 121-141.	0.8	14
823	Percutaneous Ethanol Injection in the Treatment of Hepatocellular Carcinoma: A Multicenter Survey of Evaluation Practices and Complication Rates. Scandinavian Journal of Gastroenterology, 1997, 32, 1168-1173.	0.6	184
824	Effect of long-term refeeding on protein metabolism in patients with cirrhosis of the liver. British Journal of Nutrition, 1997, 77, 197-212.	1.2	61
825	Oxygen Metabolism During Liver Transplantation. Anesthesia and Analgesia, 1997, 85, 746-752.	1.1	6
826	Respiratory mechanics in patients with tense cirrhotic ascites. European Respiratory Journal, 1997, 10, 1622-1630.	3.1	27
827	Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. British Journal of Cancer, 1997, 76, 968-974.	2.9	125
828	Elevated urinary transforming growth factor- \hat{l}^21 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. British Journal of Cancer, 1997, 76, 244-250.	2.9	51
829	Endogenous Nitric Oxide in Exhaled Air from Patients with Liver Cirrhosis. Scandinavian Journal of Gastroenterology, 1997, 32, 591-597.	0.6	25
830	The clinical pharmacokinetics of zolmitriptan. Cephalalgia, 1997, 17, 15-20.	1.8	66
831	Reporting Standards for Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology, 1997, 8, 289-297.	0.2	40
832	Clutathione kinetics in normal man and in patients with liver cirrhosis. Journal of Hepatology, 1997, 26, 606-613.	1.8	48
833	IV Cefuroxime Plus Oral Clarithromycin or IV Erythromycin for the Treatment of Community-Acquired Pneumonia in Hospitalised Patients. Clinical Drug Investigation, 1997, 14, 23-34.	1.1	2
834	L-[1-13C] phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. American Journal of Surgery, 1997, 173, 270-273.	0.9	49

#	ARTICLE	IF	Citations
835	Preoperative predictors of blood transfusion in liver resection for tumor. American Journal of Surgery, 1997, 173, 275-279.	0.9	48
836	Arterial oxygen desaturation during emergent nonsedated upper gastrointestinal endoscopy in the emergency department. American Journal of Emergency Medicine, 1997, 15, 644-647.	0.7	29
837	Cortico-spinal pathways and inhibitory mechanisms in hepatic encephalopathy. Electroencephalography and Clinical Neurophysiology - Electromyography and Motor Control, 1997, 105, 72-78.	1.4	29
838	Liver transplantation in Ohio. Surgery, 1997, 122, 842-849.	1.0	10
839	Value of the measurement of portal flow velocity in the differential diagnosis of asymptomatic splenomegaly. Clinical Radiology, 1997, 52, 220-223.	0.5	4
840	Effect of ondansetron hydrochloride on nausea and vomiting after transcatheter arterial embolization in patients with hepatocellular carcinoma. Current Therapeutic Research, 1997, 58, 10-15.	0.5	0
841	Impaired nonoxidative glucose metabolism in patients with liver cirrhosis: Effects of two insulin doses. Metabolism: Clinical and Experimental, 1997, 46, 840-843.	1.5	14
842	Carnitine metabolism in patients with chronic liver disease. Hepatology, 1997, 25, 148-153.	3.6	36
843	Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet, The, 1997, 349, 1043-1049.	6.3	257
844	Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. Journal of Hepatology, 1997, 26, 305-311.	1.8	30
845	Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Journal of Hepatology, 1997, 26, 312-324.	1.8	93
846	The pharmacokinetics of octreotide in cirrhosis and in healthy man. Journal of Hepatology, 1997, 26, 1018-1025.	1.8	28
847	Significance of tumor vascularity as a predictor of long-term prognosis in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection therapy. Journal of Hepatology, 1997, 26, 1055-1062.	1.8	35
848	Urinary assays for desmosine and hydroxylysylpyridinoline in the detection of cirrhosis. Journal of Hepatology, 1997, 27, 993-1002.	1.8	21
849	CYP2E1 activity in patients with alcoholic liver disease. Journal of Hepatology, 1997, 27, 1009-1014.	1.8	53
850	Daily profile of plasma endothelial-1 and -3 in pre-ascitic cirrhosis: relationships with the arterial pressure and renal functin. Journal of Hepatology, 1997, 26, 808-815.	1.8	22
851	Cerebral autoregulation in patients with cirrhosis and ascites. Journal of Hepatology, 1997, 27, 114-120.	1.8	38
852	Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. Journal of Hepatology, 1997, 27, 796-802.	1.8	61

#	Article	IF	CITATIONS
853	Splanchnic and extrasplanchic arterial hemodynamics in patients with cirrhosis. Journal of Hepatology, 1997, 27, 817-823.	1.8	53
854	Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. Journal of Hepatology, 1997, 27, 862-870.	1.8	89
855	Increased peripheral mononuclear cells expression of adhesion molecules in alcoholic cirrhosis: its relation to immune activation. Journal of Hepatology, 1997, 27, 477-483.	1.8	25
856	Effect of posture-induced blood volume expansion on systemic and regional hemodynamics in patients with cirrhosis. Journal of Hepatology, 1997, 27, 484-491.	1.8	28
857	Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alterations. Journal of Hepatology, 1997, 27, 492-495.	1.8	80
858	Effect of liver cirrhosis on the systemic availability of naltrexone in humans. Journal of Hepatology, 1997, 27, 505-511.	1.8	40
859	Prognostic evaluation of patients with parenchymal cirrhosis. Journal of Hepatology, 1997, 26, 642-649.	1.8	45
860	Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices. Journal of Hepatology, 1997, 26, 1235-1241.	1.8	46
861	Autonomic dysfunction in patients with non-alcoholic chronic liver disease. Journal of Hepatology, 1997, 26, 1242-1248.	1.8	64
862	Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis. Journal of Hepatology, 1997, 26, 1249-1254.	1.8	42
863	Diversity of antinucelar antibody responses in hepatocellular carcinoma. Journal of Hepatology, 1997, 26, 1255-1265.	1.8	39
864	Prognostic models in chronic liver disease: validity, usefulness and future role. Journal of Hepatology, 1997, 26, 1414-1424.	1.8	39
865	Drug elimination in chronic liver diseases. Journal of Hepatology, 1997, 26, 63-72.	1.8	20
866	Gastrointestinal bleeding in cirrhotic patients with hepatocellular carcinoma undergoing intrahepatic artery chemotherapy. Gastrointestinal Endoscopy, 1997, 46, 430-434.	0.5	7
867	Efficacy of prophylactic sclerotherapy in patients with hepatocellular carcinoma and varices negative for the red color sign. Gastrointestinal Endoscopy, 1997, 45, 498-502.	0.5	11
868	Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment. Antimicrobial Agents and Chemotherapy, 1997, 41, 2793-2796.	1.4	18
869	Fibronectin in the ascitic fluid of cirrhotic patients: correlation with biochemical risk factors for the development of spontaneous bacterial peritonitis. Brazilian Journal of Medical and Biological Research, 1997, 30, 843-847.	0.7	5
870	Effects of Endoscopic Variceal Ligation on Systemic and Splanchnic Hemodynamics in Patients with Cirrhosis Kurume Medical Journal, 1997, 44, 191-199.	0.0	4

#	Article	IF	CITATIONS
871	Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis. Clinical Chemistry, 1997, 43, 1952-1957.	1.5	14
872	Plasma concentrations of cyclic 3',5'-guanosine monophosphate in patients with cirrhosis: Relationship with atrial natriuretic peptide and haemodynamics. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 233-236.	1.4	17
873	Gall-bladder wall thickening in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 445-449.	1.4	27
874	Prolonged bleeding time: A new clinical manifestation of hepatocellular carcinoma?. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 563-568.	1.4	2
875	Abnormality in fatty acid composition of gastric mucosal phospholipids in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid-enriched soft oil capsule. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 644-652.	1.4	8
876	Pharmacokinetics and Safety of Tiagabine in Subjects with Various Degrees of Hepatic Function. Epilepsia, 1997, 38, 445-451.	2.6	62
877	Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. British Journal of Cancer, 1997, 75, 1460-1466.	2.9	42
878	Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition, 1997, 13, v-190.	1.1	59
879	Influence of liver failure, ascites, and energy expenditure on the response to oral nutrition in alcoholic liver cirrhosis. Nutrition, 1997, 13, 613-621.	1.1	68
880	Increased cytokine production is associated with acute inflammation in cirrhotic alcoholic patients. International Hepatology Communications, 1997, 6, 166-174.	0.7	4
881	Prognostic value of free-water peritoneal clearance in decompensated cirrhosis: a 3 year prospective follow-up. International Hepatology Communications, 1997, 6, 279-287.	0.7	0
882	3 Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Bailliere's Clinical Gastroenterology, 1997, 11, 243-256.	0.9	202
883	Microbial colonization of closed-system suction catheters used in liver transplant patients. Intensive and Critical Care Nursing, 1997, 13, 72-76.	1.4	29
884	Plasma iPGE2 and i6-keto PGF1α in the course of liver cirrhosis. Prostaglandins, 1997, 53, 11-20.	1.2	15
885	Helicobacter pylori Infection Among Patients with Alcoholic and Nonalcoholic Cirrhosis. Helicobacter, 1997, 2, 149-151.	1.6	16
886	Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. Digestive Diseases and Sciences, 1997, 42, 536-541.	1.1	109
887	Plasma concentration of endothelin-1 does not reflect renal vasoconstriction as estimated by duplex ultrasonography in cirrhosis. Digestive Diseases and Sciences, 1997, 42, 542-545.	1.1	9
888	Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences, 1997, 42, 1708-1714.	1.1	35

#	Article	IF	Citations
889	Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. Digestive Diseases and Sciences, 1997, 42, 529-535.	1.1	15
890	Lactate blood levels in the perioperative period of orthotopic liver transplantation. International Journal of Clinical and Laboratory Research, 1997, 27, 123-128.	1.0	50
891	Endoscopic follow-up study of development of gastric antral vascular ectasia associated with liver cirrhosis. Journal of Gastroenterology, 1997, 32, 587-592.	2.3	13
892	Red cell survival in patients with nonalcoholic liver cirrhosis before and after distal splenorenal shunt. Journal of Gastroenterology, 1997, 32, 318-323.	2.3	0
893	Influence of extravariceal collateral channel pattern on recurrence of esophageal varices after sclerotherapy. Journal of Gastroenterology, 1997, 32, 715-719.	2.3	21
894	Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose. Journal of Gastroenterology, 1997, 32, 777-782.	2.3	47
895	Measurement of the expiratory ammonia concentration and its clinical significance. Metabolic Brain Disease, 1997, 12, 161-169.	1.4	22
896	Quantification and genotyping of serum HCV-RNA in patients with chronic hepatitis C undergoing interferon treatment. Archives of Virology, 1997, 142, 459-464.	0.9	11
897	Transjugular intrahepatic portosystemic shunting (TIPS) with balloon-expandable and self-expanding stents: Technical and clinical aspects after 3 1/2 years' experience. CardioVascular and Interventional Radiology, 1997, 20, 29-37.	0.9	24
898	Osteoporosis and Bone Mineral Metabolism Disorders in Cirrhotic Patients Referred for Orthotopic Liver Transplantation. Calcified Tissue International, 1997, 60, 148-154.	1.5	195
899	Splenomegaly and hypersplenism in cirrhotic patients before and after orthotopic liver transplantation. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 1997, 6, 43-47.	1.4	1
901	Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis. Ultrasound in Medicine and Biology, 1997, 23, 675-682.	0.7	54
902	Clinical application of hepatic venous hemodynamics by Doppler ultrasonography in chronic liver disease. Ultrasound in Medicine and Biology, 1997, 23, 829-835.	0.7	13
903	Phase shift of the hepatic vein flow velocity waveform in chronic liver disease: Experimental and clinical studies. Ultrasound in Medicine and Biology, 1997, 23, 821-828.	0.7	7
904	The pharmacokinetics of a single dose of artemisinin in subjects with liver cirrhosis. Tropical Medicine and International Health, 1997, 2, 957-962.	1.0	9
905	Carnitine metabolism in patients with chronic liver disease. Hepatology, 1997, 25, 148-153.	3.6	26
906	Hepatic venous pressure measurement: An old test as a new prognostic marker in cirrhosis?. Hepatology, 1997, 25, 245-248.	3.6	165
907	Risk factors for hemorrhage from gastric fundal varices. Hepatology, 1997, 25, 307-312.	3.6	329

#	Article	IF	CITATIONS
908	Identification of high- and low-risk patients before liver transplantation: A prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology, 1997, 25, 652-657.	3.6	341
909	Hepatic lobar differences in progression of chronic liver disease: Correlation of asialoglycoprotein scintigraphy and hepatic functional reserve. Hepatology, 1997, 25, 828-832.	3.6	57
910	The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology, 1997, 25, 1049-1053.	3.6	122
911	Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology, 1997, 25, 1346-1350.	3.6	180
912	Liver transplantation for alcoholic liver disease: Evaluation of a selection protocol. Hepatology, 1997, 25, 1478-1484.	3.6	74
913	Cerebral benzodiazepine receptor bindingin vivo in patients with recurrent hepatic encephalopathy. Hepatology, 1997, 26, 277-282.	3.6	26
914	Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology, 1997, 26, 1131-1137.	3.6	257
915	Liver transplantation for cryptogenic cirrhosis. Liver Transplantation, 1997, 3, 359-364.	1.9	64
916	Orthotopic liver transplantation with preservation of portocaval flow compared with venovenous bypass. Liver Transplantation, 1997, 3, 518-525.	1.9	29
917	MR imaging of the liver: Effect of portal hypertension on hepatic parenchymal enhancement using a gadolinium chelate. Journal of Magnetic Resonance Imaging, 1997, 7, 142-146.	1.9	11
918	Prognostic significance of surgical margin in hepatocellular carcinoma resection: An analysis of 165 Childs' A patients. , 1997, 66, 122-126.		81
919	Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection., 1997, 79, 1501-1508.		64
920	Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in france., 1997, 74, 614-619.		31
921	Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology and Therapeutics, 1997, 62, 272-278.	2.3	87
922	Effects of liver disease on the disposition of the opioid antagonist nalmefene*. Clinical Pharmacology and Therapeutics, 1997, 61, 15-23.	2.3	18
923	Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6*. Clinical Pharmacology and Therapeutics, 1998, 64, 8-17.	2.3	92
924	Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation*. Clinical Pharmacology and Therapeutics, 1998, 63, 296-302.	2.3	22
925	Portal hemodynamics by duplex Doppler sonography in different grades of cirrhosis. Digestive Diseases and Sciences, 1998, 43, 354-357.	1.1	49

#	Article	IF	Citations
926	Prognostic value of generation of growth hormone-stimulated insulin-like growth factor-I (IGF-I) and its binding protein-3 in patients with compensated and decompensated liver cirrhosis. Digestive Diseases and Sciences, 1998, 43, 1317-1321.	1.1	19
927	Analysis of impaired exercise capacity in patients with cirrhosis. Digestive Diseases and Sciences, 1998, 43, 1701-1707.	1.1	68
928	Effects of octreotide on lower esophageal sphincter in patients with cirrhosis and portal hypertension. Digestive Diseases and Sciences, 1998, 43, 1566-1571.	1.1	9
929	Effect of hepatic insufficiency on pharmacokinetics and drug dosing., 1998, 20, 183-192.		63
930	Helicobacter pylori infection and peptic ulcer disease in cirrhosis. Digestive Diseases and Sciences, 1998, 43, 1219-1225.	1.1	48
931	The basal ganglia and portal-systemic encephalopathy. Metabolic Brain Disease, 1998, 13, 261-272.	1.4	44
932	Cerebral magnetic resonance imaging in patients with chronic liver disease. Metabolic Brain Disease, 1998, 13, 273-290.	1.4	44
933	The carbohydrate-deficient transferrin test in hospital practice. Drug and Alcohol Review, 1998, 17, 105-109.	1.1	2
934	Transjugular intrahepatic portosystemic shunt (TIPS) for variceal bleeding in portal hypertension: comparison of emergency and elective interventions. Digestive Diseases and Sciences, 1998, 43, 2463-2469.	1.1	45
935	Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices: A Feasibility Study. CardioVascular and Interventional Radiology, 1998, 21, 27-30.	0.9	78
936	Complement System Is Not Activated in Primary Biliary Cirrhosis. Clinical Immunology and Immunopathology, 1998, 87, 297-303.	2.1	10
937	Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of refractory ascites. Australian and New Zealand Journal of Medicine, 1998, 28, 620-626.	0.5	21
938	Antipyrine clearance in chronic and neoplastic liver diseases: A study of 518 patients. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 460-466.	1.4	17
939	Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 907-913.	1.4	57
940	Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?. British Journal of Cancer, 1998, 77, 1145-1148.	2.9	11
942	Effects of Systemic Prostaglandin E1 on Splanchnic and Peripheral Haemodynamics in Control Subjects and in Patients with Cirrhosis. Prostaglandins and Other Lipid Mediators, 1998, 55, 209-218.	1.0	5
943	Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology, 1998, 27, 28-34.	3.6	356
944	Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology, 1998, 27, 67-72.	3.6	214

#	Article	IF	CITATIONS
945	Daily energy and substrate metabolism in patients with cirrhosis. Hepatology, 1998, 27, 346-350.	3.6	98
946	Somatosensory evoked potentials in subclinical portosystemic encephalopathy: A comparison with psychometric tests. Hepatology, 1998, 27, 357-361.	3.6	46
947	Cerebral blood flow and metabolism in patients with chronic liver disease undergoing orthotopic liver transplantation. Hepatology, 1998, 27, 369-376.	3.6	55
948	Splenic impedance indices: A useful method to monitor patients after liver transplantation?. Hepatology, 1998, 27, 674-678.	3.6	19
949	Plasma selenium in patients with cirrhosis. Hepatology, 1998, 27, 794-798.	3.6	97
950	Effects of systemic prostaglandin e on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. Hepatology, 1998, 27, 815-821.	3.6	10
951	Decreased muscle strength in patients with alcoholic liver cirrhosis in relation to nutritional status, alcohol abstinence, liver function, and neuropathy. Hepatology, 1998, 27, 1200-1206.	3.6	92
952	Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power. Hepatology, 1998, 27, 1572-1577.	3.6	357
953	Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology, 1998, 27, 1578-1583.	3.6	482
954	Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology, 1998, 28, 39-44.	3.6	138
955	Subclinical hepatic encephalopathy impairs daily functioning. Hepatology, 1998, 28, 45-49.	3.6	470
956	The additive effect of sclerotherapy to patients receiving repeated endoscopic variceal ligation: A prospective, randomized trial. Hepatology, 1998, 28, 391-395.	3.6	82
957	Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: Comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology, 1998, 28, 683-688.	3.6	73
958	Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology, 1998, 28, 695-699.	3.6	209
959	A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology, 1998, 28, 751-755.	3.6	1,271
960	Doppler study of mesenteric, hepatic, and portal circulation in alcoholic cirrhosis: Relationship between quantitative doppler measurements and the severity of portal hypertension and hepatic failure. Hepatology, 1998, 28, 932-936.	3.6	124
961	Hepatic artery resistance in alcoholic liver disease. Hepatology, 1998, 28, 1182-1186.	3.6	54
962	Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology, 1998, 28, 1187-1190.	3.6	259

#	Article	IF	Citations
963	Lipoprotein-X in patients with cirrhosis: Its relationship to cholestasis and hypercholesterolemia. Hepatology, 1998, 28, 1199-1205.	3.6	34
964	Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology, 1998, 28, 1206-1214.	3.6	73
965	Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology, 1998, 28, 1215-1225.	3.6	138
966	Reduction of renal cortical blood flow assessed by doppler in cirrhotic patients with refractory ascites. Hepatology, 1998, 28, 1235-1240.	3.6	59
967	Cryosurgery as a treatment for advanced stage hepatocellular carcinoma., 1998, 82, 1268-1278.		61
968	Hepatocellular carcinoma in Asian Americans. Cancer, 1998, 83, 1723-1729.	2.0	2
969	The fucosylation index of ?-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer, 1998, 83, 2076-2082.	2.0	86
970	Serum ?-L-fucosidase activity and early detection of hepatocellular carcinoma., 1998, 83, 2468-2474.		7 5
971	Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injectionâ€"a single-center analysis including 132 patients. , 1998, 79, 601-605.		109
972	Hemodynamic changes in hepatic artery after glucose ingestion in healthy subjects and patients with cirrhosis., 1998, 26, 137-142.		9
973	Health-related quality of life after liver transplantation. Liver Transplantation, 1998, 4, 215-221.	1.9	67
974	Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transplantation, 1998, 4, 416-423.	1.9	71
975	Outcome of patients with cirrhosis requiring intensive care unit support: Prospective assessment of predictors of mortality. Journal of Gastroenterology, 1998, 33, 73-79.	2.3	88
976	Role of extravariceal collateral channels in the development of portal-hypertensive gastropathy before and after sclerotherapy. Journal of Gastroenterology, 1998, 33, 142-146.	2.3	7
977	Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency. European Journal of Clinical Pharmacology, 1998, 54, 567-571.	0.8	39
978	Pharmacokinetics of milnacipran in liver impairment. European Journal of Drug Metabolism and Pharmacokinetics, 1998, 23, 273-279.	0.6	29
979	Pharmacokinetics of milnacipran in renal impairment. European Journal of Drug Metabolism and Pharmacokinetics, 1998, 23, 280-286.	0.6	39
980	Protein-bound and unbound bile acids in serum of patients with liver cirrhosis. Hepatology Research, 1998, 10, 217-224.	1.8	2

#	Article	IF	CITATIONS
981	Risk factors for loss of lean body mass after liver transplantation. Applied Radiation and Isotopes, 1998, 49, 663-664.	0.7	15
982	Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. Journal of Viral Hepatitis, 1998, 5, 255-264.	1.0	30
983	The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. Alimentary Pharmacology and Therapeutics, 1998, 12, 657-665.	1.9	11
984	A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10â€fmg/kg or 20â€fmg/kg. Alimentary Pharmacology and Therapeutics, 1998, 12, 965-971.	1.9	33
985	Endogenous dopaminergic activity in Child–Pugh A cirrhosis: potential role in renal sodium handling and in the maintenance of clinical compensation. European Journal of Clinical Investigation, 1998, 28, 131-137.	1.7	9
986	Diabetes mellitus after liver transplantation: a possible relation with the nutritional status. Diabetes Research and Clinical Practice, 1998, 41, 203-205.	1.1	0
988	Conference. Journal of Clinical Anesthesia, 1998, 10, 253-261.	0.7	21
989	Hepatocellular carcinoma in children: Clinical review and comparison with adult cases. Journal of Pediatric Surgery, 1998, 33, 1350-1354.	0.8	88
990	Psychological distress in patients with chronic, nonalcoholic, uncomplicated liver disease. Journal of Psychosomatic Research, 1998, 44, 547-554.	1.2	18
991	Delayed hepatic resection for ruptured hepatocellular carcinoma. Surgery, 1998, 124, 33-37.	1.0	30
992	Staged hepatectomy after emergency transcatheter arterial embolization for ruptured hepatocellular carcinoma. Surgery, 1998, 124, 526-535.	1.0	51
993	Erythrocyte membrane lipids and serum selenium in post-viral and alcoholic cirrhosis. Clinica Chimica Acta, 1998, 270, 139-150.	0.5	26
994	Renal dysfunction in liver cirrhosis: Renal duplex doppler US vs. Scintigraphy for early identification. Clinical Radiology, 1998, 53, 44-48.	0.5	14
995	Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology, 1998, 115, 110-115.	0.6	95
996	Transjugular intrahepatic portosystemic shunt for bleeding angiodysplasia-like lesions in portal-hypertensive colopathy. Gastroenterology, 1998, 115, 167-172.	0.6	25
997	Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: A new approach. Gastroenterology, 1998, 114, 305-310.	0.6	239
998	Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. Journal of Hepatology, 1998, 29, 250-256.	1.8	54
999	Characteristics of hepatocellular carcinoma in Italy. Journal of Hepatology, 1998, 29, 944-952.	1.8	146

#	Article	IF	CITATIONS
1000	Spontaneous pulsatility and pharmacokinectics of growth hormone in liver cirrhotic patients. Journal of Hepatology, 1998, 29, 559-564.	1.8	20
1001	Regional cerebral blood flow changes in patients with cirrhosis assessed with 99mTc-HM-PAO single-photon emission computed tomography: effect of liver transplantation. Journal of Hepatology, 1998, 29, 78-84.	1.8	40
1002	Nutritional and prognostic significance of serum hypothyroxinemia in hospitalized patients with liver cirrhosis. Journal of Hepatology, 1998, 28, 115-121.	1.8	29
1003	Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. Journal of Hepatology, 1998, 29, 736-742.	1.8	85
1004	Sequential variceal pressure measurement by endoscopic needle puncture during maintenance sclerotherapy: the correlation between variceal pressure and variceal rebleeding. Journal of Hepatology, 1998, 29, 772-778.	1.8	20
1005	Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. Journal of Hepatology, 1998, 28, 615-621.	1.8	289
1006	The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis. Journal of Hepatology, 1998, 28, 631-638.	1.8	51
1007	Upright posture decreases esophageal varices flow velocity in patients with cirrhosis. Journal of Hepatology, 1998, 28, 447-453.	1.8	11
1008	Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. Journal of Hepatology, 1998, 28, 847-855.	1.8	23
1009	Liver Transplantation for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: Predicting Outcomes With Natural History Models. Mayo Clinic Proceedings, 1998, 73, 575-588.	1.4	51
1010	TREATMENT OF ALCOHOLIC HEPATITIS. Clinics in Liver Disease, 1998, 2, 799-819.	1.0	9
1011	Predictive Factors Influencing the Therapeutic Response to Diuretic Treatment of Ascites in Nonazotemic Cirrhotic Patients. Scandinavian Journal of Gastroenterology, 1998, 33, 441-447.	0.6	10
1012	Effects of Branched-Chain-Enriched Amino Acid Solution on Insulin and Glucagon Secretion and Blood Glucose Level in Liver Cirrhosis. Scandinavian Journal of Gastroenterology, 1998, 33, 853-859.	0.6	16
1013	Electrogastrographic Study of the Effect of Transcatheter Arterial Chemoembolization on Gastric Myoelectric Activity. Scandinavian Journal of Gastroenterology, 1998, 33, 1164-1169.	0.6	4
1014	AST/ALT Ratio Predicts Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. American Journal of Gastroenterology, 1998, 93, 44-48.	0.2	435
1015	Prognostic Value of Progressive Decrease in Serum Cholesterol in Predicting Survival in Child-Pugh C Viral Cirrhosis. Scandinavian Journal of Gastroenterology, 1998, 33, 1213-1218.	0.6	50
1016	Increased nitric oxide production in the liver in the perioperative period of partial hepatectomy with Pringle's maneuver. Journal of Hepatology, 1998, 28, 212-220.	1.8	34
1017	Effects of Aging and Liver Disease upon the Pharmacokinetics of Nipradilol. Clinical Drug Investigation, 1998, 16, 251-257.	1.1	2

#	Article	IF	Citations
1018	Thickened gastric mucosal capillary wall: A histological marker for portal hypertension. Pathology, 1998, 30, 10-13.	0.3	21
1019	Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. Gut, 1998, 42, 861-867.	6.1	46
1020	Infections Due to Nonâ€O1 <i>Vibrio cholerae</i> in Southern Taiwan: Predominance in Cirrhotic Patients. Clinical Infectious Diseases, 1998, 27, 774-780.	2.9	108
1021	Biliary Complications After Hepatic Resection. Archives of Surgery, 1998, 133, 156-61.	2.3	170
1022	Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. American Journal of Gastroenterology, 1998, 93, 2022-2036.	0.2	230
1023	Effect of Hepatic Impairment on the Pharmacokinetics of Zolmitriptan. Journal of Clinical Pharmacology, 1998, 38, 694-701.	1.0	9
1024	Value of echo-enhanced Doppler sonography in evaluation of transjugular intrahepatic portosystemic shunts American Journal of Roentgenology, 1998, 170, 1041-1046.	1.0	30
1025	Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. American Journal of Gastroenterology, 1998, 93, 2148-2153.	0.2	19
1026	Prediction and Limitation of Hepatic Tumor Resection Without Blood Transfusion in Cirrhotic Patients. Archives of Surgery, 1998, 133, 1007.	2.3	37
1027	Dark adaptation in early primary biliary cirrhosis. Eye, 1998, 12, 419-426.	1.1	7
1028	Increased Plasma Levels of Substance P and Disturbed Water Excretion in Patients with Liver Cirrhosis. Scandinavian Journal of Gastroenterology, 1998, 33, 860-866.	0.6	13
1029	Beneficial Hemodynamic Effects of Dipyridamole on Portal Circulation in Cirrhosis. American Journal of Gastroenterology, 1998, 93, 429-433.	0.2	6
1030	Epidemiology of peptic ulcer disease in cirrhotic patients: role of helicobacter pylori infection. American Journal of Gastroenterology, 1998, 93, 2501-2507.	0.2	43
1031	Urgent Transjugular Intrahepatic Portosystemic Shunt for Control of Acute Variceal Bleeding. American Journal of Gastroenterology, 1998, 93, 75-79.	0.2	83
1032	Small bowel motility in primary biliary cirrhosis. American Journal of Gastroenterology, 1998, 93, 2436-2440.	0.2	16
1033	The Effect of Ciprofloxacin in the Prevention of Bacterial Infection in Patients With Cirrhosis After Upper Gastrointestinal Bleeding. American Journal of Gastroenterology, 1998, 93, 962-966.	0.2	125
1034	Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. American Journal of Gastroenterology, 1998, 93, 1925-1930.	0.2	32
1035	Effect of meal induced splanchnic arterial vasodilatation on renal arterial haemodynamics in normal subjects and patients with cirrhosis. Gut, 1998, 43, 843-848.	6.1	24

#	Article	IF	Citations
1036	Intrasplenic venous flow patterns demonstrated by Doppler ultrasound in patients with portal hypertension British Journal of Radiology, 1998, 71, 384-387.	1.0	5
1037	Exhaled Nitric Oxide and Impaired Oxygenation in Cirrhotic Patients before and after Liver Transplantation. Annals of Internal Medicine, 1998, 129, 375.	2.0	160
1038	Pharmacokinetics of Rifapentine in Patients with Varying Degrees of Hepatic Dysfunction. Journal of Clinical Pharmacology, 1998, 38, 517-524.	1.0	15
1039	Response to Symptom-Limited Exercise in Patients With the Hepatopulmonary Syndrome. Chest, 1998, 114, 736-741.	0.4	27
1040	Urinary Excretion of Free and Acetylated Polyamines in Hepatocellular Carcinoma. International Journal of Biological Markers, 1998, 13, 92-97.	0.7	6
1041	Risks of Intra-Abdominal Nonshunt Surgery in Cirrhotics. Digestive Diseases, 1998, 16, 225-231.	0.8	12
1042	DETERMINATION OF PLASMA Â-GLUTATHIONE-S-TRANSFERASES IN CHRONIC ALCOHOL ABUSERS: RELATIONSHIP WITH ALCOHOL INTAKE AND LIVER INVOLVEMENT. Alcohol and Alcoholism, 1998, 33, 366-372.	0.9	17
1043	Nitric oxide synthase activity is increased in relation to the severity of liver dysfunction. Clinical Science, 1998, 95, 355-359.	1.8	19
1044	Chylothorax in Cirrhosis of the Liver. Chest, 1998, 114, 154-159.	0.4	100
1045	Population Pharmacokinetics of Ceftizoxime Administered by Continuous Infusion in Clinically Ill Adult Patients. Antimicrobial Agents and Chemotherapy, 1998, 42, 1783-1787.	1.4	22
1046	Immunohistochemical Detection of 4â€Hydroxyâ€2â€nonenalâ€Modifiedâ€Protein Adducts in Human Alcoholic Liver Diseases. Alcoholism: Clinical and Experimental Research, 1998, 22, 145S-149S.	1.4	31
1047	Increased Thromboxane Metabolites Excretion in Liver Cirrhosis. Thrombosis and Haemostasis, 1998, 79, 747-751.	1.8	29
1048	Hepatic pyruvate dehydrogenase activity in humans: effect of cirrhosis, transplantation, and dichloroacetate. American Journal of Physiology - Renal Physiology, 1998, 274, G569-G577.	1.6	11
1049	Pituitary glycoprotein hormone a -subunit secretion by cirrhotic patients. Brazilian Journal of Medical and Biological Research, 1999, 32, 73-77.	0.7	1
1050	Alcohol-induced generation of lipid peroxidation products in humans. Journal of Clinical Investigation, 1999, 104, 805-813.	3.9	216
1051	Pharmacokinetics of Dirithromycin in Patients with Mild or Moderate Cirrhosis. Antimicrobial Agents and Chemotherapy, 1999, 43, 1556-1559.	1.4	8
1052	Effect of liver disease and transplantation on urea synthesis in humans: relationship to acid-base status. American Journal of Physiology - Renal Physiology, 1999, 276, G1145-G1152.	1.6	26
1053	Understanding oesophageal varices. Nursing Standard (Royal College of Nursing (Great Britain): 1987), 1999, 14, 46-52.	0.1	4

#	Article	IF	CITATIONS
1054	Doppler ultrasonographic evaluation of the early changes in renal resistive index in cirrhotic patients undergoing liver transplantation Journal of Ultrasound in Medicine, 1999, 18, 497-502.	0.8	13
1055	The Timing and Role of Nontransplant Surgery in Management of Variceal Bleeding. Gastrointestinal Endoscopy Clinics of North America, 1999, 9, 331-345.	0.6	1
1056	Cirrhotic liver enhancement on dual-phase helical CT: comparison with noncirrhotic livers in 146 patients American Journal of Roentgenology, 1999, 173, 1193-1197.	1.0	43
1057	Precaval draining vein from paraesophageal varices: radiologic-anatomic correlation American Journal of Roentgenology, 1999, 172, 651-654.	1.0	10
1058	Relation between severity of liver disease and renal oxygen consumption in patients with cirrhosis. Gut, 1999, 45, 117-121.	6.1	21
1059	Viral-induced cirrhosis: grading of severity using MR imaging American Journal of Roentgenology, 1999, 173, 591-596.	1.0	49
1060	Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut, 1999, 44, 264-269.	6.1	91
1061	Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene < SUBTITLE > Results From a 3-Year Randomized Clinical Trial < /SUBTITLE > . JAMA - Journal of the American Medical Association, 1999, 282, 637.	3.8	2,938
1062	Hepatectomy for Hepatocellular Carcinoma. Archives of Surgery, 1999, 134, 1124.	2.3	168
1063	Recommendations for Vitamin C Intake. JAMA - Journal of the American Medical Association, 1999, 282, 2118.	3.8	6
1064	Close Relation Between Cirrhosis and Gallstones. Archives of Internal Medicine, 1999, 159, 49.	4.3	89
1065	Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut, 1999, 44, 270-273.	6.1	99
1066	Renal distal tubular handling of sodium in central fluid volume homoeostasis in preascitic cirrhosis. Gut, 1999, 45, 750-755.	6.1	28
1067	Cefotaxime, Desacetylâ€Cefotaxime, and Bactericidal Activity in Spontaneous Bacterial Peritonitis. Journal of Infectious Diseases, 1999, 180, 1597-1602.	1.9	9
1068	Indications for referral and assessment in adultliver transplantation: a clinical guideline. Gut, 1999, 45, vi1-vi22.	6.1	76
1069	Balloon-Occluded Retrograde Transvenous Obliteration of High Risk Gastric Fundal Varices. American Journal of Gastroenterology, 1999, 94, 643-649.	0.2	113
1070	Effects of Octreotide on Central Hemodynamics and Systemic Oxygen Use in Patients With Viral Cirrhosis. American Journal of Gastroenterology, 1999, 94, 1012-1017.	0.2	3
1071	Prognostic Usefulness of Ultrasonographic Signs of Portal Hypertension in Patients With Child–Pugh Stage A Liver Cirrhosis. American Journal of Gastroenterology, 1999, 94, 3595-3600.	0.2	6

#	Article	IF	CITATIONS
1072	Effects of A New Orally Active Dopamine Prodrug, Docarpamine, on Refractory Ascites: A Pilot Study. American Journal of Gastroenterology, 1999, 94, 2475-2481.	0.2	4
1073	Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease. American Journal of Gastroenterology, 1999, 94, 1601-1604.	0.2	91
1074	Autonomic Nervous System Tone Measured by Baroreflex Sensitivity Is Depressed in Patients With End-Stage Liver Disease. American Journal of Gastroenterology, 1999, 94, 986-989.	0.2	26
1075	Helicobacter Pylori Infection, Plasma Ammonia Levels, and Psychometric Testing in Cirrhotic Patients. American Journal of Gastroenterology, 1999, 94, 2214-2218.	0.2	18
1076	Role of Substance P in The Pathogenesis of Spider Angiomas in Patients With Nonalcoholic Liver Cirrhosis. American Journal of Gastroenterology, 1999, 94, 502-507.	0.2	19
1077	Predictors of Clinical Response to Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Cirrhotic Patients With Refractory Ascites. American Journal of Gastroenterology, 1999, 94, 1361-1365.	0.2	31
1078	Risk Factors for The Development of Bacterial Infections in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 1999, 94, 2193-2197.	0.2	93
1079	Hyperammonia and Cerebral Herniation: Is an Abnormality of Ammonia Metabolism Responsible?. American Journal of Gastroenterology, 1999, 94, 3646.	0.2	3
1080	The size of central vascular space in cirrhosis; position-induced redistribution of central blood volume. Hepatology Research, 1999, 14, 49-61.	1.8	0
1081	Characteristic changes of peripheral lymphocyte subset in cirrhotic patients with hepatitis C virus—correlation with cirrhosis severity. Hepatology Research, 1999, 15, 43-51.	1.8	4
1082	Clinical significance and correlates of whole body potassium status in patients with liver cirrhosis. Hepatology Research, 1999, 16, 36-48.	1.8	15
1083	État nutritionnel des patients avec maladies du foie : épidémiologie et pronostic. Nutrition Clinique Et Metabolisme, 1999, 13, 232-240.	0.2	1
1084	Pain and health related quality of life after heart, kidney, and liver transplantation. Clinical Transplantation, 1999, 13, 453-460.	0.8	54
1085	The monoethylglycinexylidide test for grading of liver cirrhosis. Alimentary Pharmacology and Therapeutics, 1999, 13, 67-75.	1.9	18
1086	Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. Alimentary Pharmacology and Therapeutics, 1999, 13, 1451-1458.	1.9	12
1087	[13C]-Galactose breath test: correlation with liver fibrosis in chronic hepatitis C. European Journal of Clinical Investigation, 1999, 29, 624-629.	1.7	30
1088	Prediction of oesophagogastric varices in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 785-790.	1.4	76
1089	Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 811-816.	1.4	23

#	ARTICLE	IF	Citations
1090	Mixed cryoglobulinaemia associated with hepatitis C virus infection: A predictor factor for treatment with interferon?. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1108-1111.	1.4	12
1091	Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a caseâ€control study. Australian and New Zealand Journal of Medicine, 1999, 29, 300-307.	0.5	23
1092	Effect of mesocaval interposition shunting and repeated sclerotherapy on blood levels of gastrointestinal regulatory peptides, amino acids, and lysosomal enzymes - a prospective randomised trial. Liver International, 1999, 19, 3-11.	1.9	3
1093	Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver International, 1999, 19, 381-388.	1.9	27
1094	Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy. Liver International, 1999, 19, 389-398.	1.9	55
1095	Ethanol Consumption, Amino Acid and Glutathione Blood Levels in Patients With and Without Chronic Liver Disease. Alcoholism: Clinical and Experimental Research, 1999, 23, 1780-1784.	1.4	35
1096	Increase of Serum Des-gamma-Carboxy Prothrombin in Alcoholic Liver Disease Without Hepatocellular Carcinoma. Alcoholism: Clinical and Experimental Research, 1999, 23, 67S-70S.	1.4	25
1097	Effects of Continuous Hepatitis with Persistent Hepatitis C Viremia on Outcome after Resection of Hepatocellular Carcinoma. Japanese Journal of Cancer Research, 1999, 90, 162-170.	1.7	41
1098	Gastroduodenal Vascular Ectasia in Patients with Liver Cirrhosis. Digestive Endoscopy, 1999, 11, 241-245.	1.3	9
1099	Assessment of liver function by the MEGX test in patients with schistosomiasis and cirrhosis. Clinical Biochemistry, 1999, 32, 207-212.	0.8	2
1100	Effect of eating on plasma radical-trapping antioxidant activity (TRAP) in patients with cirrhosis. Clinical Biochemistry, 1999, 32, 447-453.	0.8	2
1101	Colonic wall thickening in cirrhotic patients: CT features and its clinical significance. Abdominal Imaging, 1999, 24, 125-128.	2.0	9
1102	Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. Metabolic Brain Disease, 1999, 14, 239-251.	1.4	28
1103	Locoregional treatments for hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 1999, 13, 611-622.	1.0	20
1104	Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis*1. Clinical Pharmacology and Therapeutics, 1999, 66, 380-390.	2.3	8
1105	Rapid estimation of creatinine clearances in patients with liver dysfunction. Digestive Diseases and Sciences, 1999, 44, 1222-1227.	1.1	6
1106	Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Digestive Diseases and Sciences, 1999, 44, 1249-1253.	1.1	192
1107	Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Digestive Diseases and Sciences, 1999, 44, 372-376.	1.1	47

#	Article	IF	CITATIONS
1108	Diagnosis of hepatopulmonary syndrome with contrast transesophageal echocardiography: advantages over contrast transthoracic echocardiography. Digestive Diseases and Sciences, 1999, 44, 1243-1248.	1.1	68
1109	Serum pancreatic enzyme concentrations in chronic viral liver diseases. Digestive Diseases and Sciences, 1999, 44, 350-355.	1.1	28
1110	Relationship of portal pressure and colorectal vasculopathy in patients with cirrhosis. Digestive Diseases and Sciences, 1999, 44, 149-154.	1.1	14
1111	Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis. Digestive Diseases and Sciences, 1999, 44, 377-384.	1.1	8
1112	Essential fatty acid deficiencies in patients with chronic liver disease are not reversed by short-term intravenous lipid supplementation. Digestive Diseases and Sciences, 1999, 44, 1342-1348.	1.1	20
1113	TIPS allowing for an endoscopic mucosal resection of early gastric cancer in a cirrhotic patient with severe hypertensive gastropathy: Report of a case. Surgery Today, 1999, 29, 902-905.	0.7	12
1114	Influence of histological inflammatory activity on regenerative capacity of liver after percutaneous transhepatic portal vein embolization. Journal of Gastroenterology, 1999, 34, 100-104.	2.3	25
1115	Portal venous blood flow while breath-holding after inspiration or expiration and during normal respiration in controls and cirrhotics. Journal of Gastroenterology, 1999, 34, 613-618.	2.3	25
1116	Pulse analysis of patients with severe liver problems. Studying pulse spectrums to determine the effects on other organs. IEEE Engineering in Medicine and Biology Magazine, 1999, 18, 73-75.	1.1	60
1117	Low plasma levels of docosahexaenoic acid in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid–enriched soft oil capsule. Nutrition, 1999, 15, 284-288.	1.1	17
1118	Mesohepatectomy for centrally located hepatocellular carcinoma: an appraisal of a rare procedure. Journal of the American College of Surgeons, 1999, 188, 508-515.	0.2	68
1119	Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology, 1999, 29, 62-67.	3.6	1,044
1120	Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology, 1999, 29, 334-339.	3.6	205
1121	Transjugular intrahepatic portosystemic shunt: Short-term and long-term effects on hepatic and systemic hemodynamics in patients with Cirrhosis. Hepatology, 1999, 29, 632-639.	3.6	106
1122	Infection and hemostasis in decompensated cirrhosis: A prospective study using thrombelastography. Hepatology, 1999, 29, 1085-1090.	3.6	83
1123	Macronutrient preference, dietary intake, and substrate oxidation among stable cirrhotic patients. Hepatology, 1999, 29, 1380-1386.	3.6	40
1124	The relative role of the child-pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology, 1999, 29, 1643-1648.	3.6	124
1125	Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis. Hepatology, 1999, 29, 1655-1661.	3.6	713

#	Article	IF	CITATIONS
1126	Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: A clinical and electrophysiologic study. Hepatology, 1999, 29, 1698-1703.	3.6	89
1127	The risk of surgery in patients with liver disease. Hepatology, 1999, 29, 1617-1623.	3.6	255
1128	Outcome of Budd-Chiari syndrome: A multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology, 1999, 30, 84-89.	3.6	226
1129	Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology, 1999, 30, 265-270.	3.6	45
1130	Resting energy expenditure should be measured in patients with cirrhosis, not predicted. Hepatology, 1999, 30, 655-664.	3.6	83
1131	Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology, 1999, 30, 1387-1392.	3 . 6	79
1132	Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology, 1999, 30, 1434-1440.	3.6	1,869
1133	Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis., 1999, 85, 2132-2137.		216
1134	Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma., 1999, 86, 793-798.		44
1135	Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan., 1999, 86, 799-804.		47
1136	Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection., 1999, 86, 1682-1690.		73
1137	Hepatic arterial resistance after mixed-meal ingestion in healthy subjects and patients with chronic liver disease., 1999, 27, 239-248.		12
1138	Evaluating response to nutritional therapy using the branched-chain amino acid/tyrosine ratio in patients with chronic liver disease. Journal of Clinical Laboratory Analysis, 1999, 13, 31-34.	0.9	38
1139	Surgery in the Patient With Liver Disease. Mayo Clinic Proceedings, 1999, 74, 593-599.	1.4	89
1140	Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut, 1999, 45, 295-300.	6.1	529
1141	Nitrite and Nitrate Levels in Patients with Cirrhosis of the Liver: Influence of Kidney Function and Fasting State. Scandinavian Journal of Gastroenterology, 1999, 34, 297-302.	0.6	29
1142	The Rebleeding Course and Long-Term Outcome of Esophageal Variceal Hemorrhage after Ligation: Comparison with Sclerotherapy. Scandinavian Journal of Gastroenterology, 1999, 34, 1071-1076.	0.6	40
1143	Spider Angiomas in Patients with Liver Cirrhosis: Role of Alcoholism and Impaired Liver Function. Scandinavian Journal of Gastroenterology, 1999, 34, 520-523.	0.6	37

#	Article	IF	CITATIONS
1144	Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule. Medical Hypotheses, 1999, 52, 515-519.	0.8	39
1145	Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet, The, 1999, 353, 1579-1583.	6.3	242
1146	Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. Journal of Hepatology, 1999, 30, 125-130.	1.8	136
1147	Prophylactic banding ligation of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized trial. Journal of Hepatology, 1999, 31, 451-456.	1.8	81
1148	Prevalence and risk factors of bacteriuria in cirrhotic patients: a prospective case-control multicenter study in 244 patients. Journal of Hepatology, 1999, 31, 464-468.	1.8	26
1149	Hepatocyte proliferative activity in human liver cirrhosis. Journal of Hepatology, 1999, 30, 461-471.	1.8	41
1150	Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. Journal of Hepatology, 1999, 30, 472-478.	1.8	237
1151	Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. Journal of Hepatology, 1999, 30, 479-484.	1.8	66
1152	Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. Journal of Hepatology, 1999, 30, 876-881.	1.8	75
1153	Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Journal of Hepatology, 1999, 30, 890-895.	1.8	500
1154	Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. Journal of Hepatology, 1999, 31, 84-90.	1.8	51
1155	A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Journal of Hepatology, 1999, 31, 133-141.	1.8	464
1156	Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. Journal of Hepatology, 1999, 30, 632-638.	1.8	42
1157	Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. Journal of Hepatology, 1999, 30, 660-668.	1.8	56
1158	Effect of transcatheter arterial chemoembolization on kidney hemodynamics and function in patients with cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 1999, 31, 340-346.	1.8	3
1159	S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology, 1999, 30, 1081-1089.	1.8	428
1160	Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of Aleuria aurantia lectin-reactive serum cholinesterase to immunoreactive protein. Clinica Chimica Acta, 1999, 281, 37-46.	0.5	19
1161	A Psychometric Normative Database for Pre-Liver Transplantation Evaluations. Psychosomatics, 1999, 40, 479-485.	2.5	50

#	Article	IF	CITATIONS
1162	The role of portosystemic shunting in children in the transplant era. Journal of Pediatric Surgery, 1999, 34, 117-123.	0.8	23
1163	Hepatic arterial flow volume and reserve in patients with cirrhosis: Use of intra-arterial Doppler and adenosine infusion. Gastroenterology, 1999, 116, 906-914.	0.6	83
1164	Prevalence of paraesophageal varices and gastric varices in patients achieving variceal obliteration by banding ligation and by injection sclerotherapy. Gastrointestinal Endoscopy, 1999, 49, 428-436.	0.5	90
1165	Left gastric vein hemodynamics and variceal recurrence in patients undergoing prophylactic endoscopic ligation of high-risk esophageal varices. Gastrointestinal Endoscopy, 1999, 50, 768-774.	0.5	19
1166	Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. Gastrointestinal Endoscopy, 1999, 49, 690-694.	0.5	83
1167	Sclerotherapy plus ligation versus ligation for the treatment of esophageal varices: a prospective randomized study. Gastrointestinal Endoscopy, 1999, 50, 7-12.	0.5	63
1168	Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing lower intestinal endoscopy. Gastrointestinal Endoscopy, 1999, 49, 214-217.	0.5	44
1169	Endosonographic, endoscopic, and histologic evaluation of alterations in the rectal venous system in patients with portal hypertension. Gastrointestinal Endoscopy, 1999, 49, 218-227.	0.5	51
1170	Development and application of endoloops for the treatment of bleeding esophageal varices. Gastrointestinal Endoscopy, 1999, 50, 677-684.	0.5	16
1171	Effects of Liver Disease on Pharmacokinetics. Clinical Pharmacokinetics, 1999, 37, 399-431.	1.6	205
1172	Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. American Journal of Gastroenterology, 1999, 94, 1361-1365.	0.2	43
1173	Does quantitative serologic testing for Helicobacter pylori predict peptic ulcer disease in cirrhosis?. Gastrointestinal Endoscopy, 1999, 50, 381-386.	0.5	6
1174	The critically ill patient after hepatobiliary surgery. Critical Care, 1999, 3, 139.	2.5	6
1175	Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites22Part of this work was performed while holding a Fellowship in Hepatology from Schering Canada American Journal of Medicine, 1999, 106, 315-322.	0.6	63
1177	Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. Clinical Science, 1999, 96, 467-474.	1.8	6
1178	Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension. Clinical Science, 1999, 96, 475-481.	1.8	12
1179	Up-regulation of nitric oxide production by interferon- \hat{l}^3 in cultured peritoneal macrophages from patients with cirrhosis. Clinical Science, 1999, 97, 399-406.	1.8	5
1180	Hypermetabolism in clinically stable patients with liver cirrhosis. American Journal of Clinical Nutrition, 1999, 69, 1194-1201.	2.2	226

#	Article	IF	CITATIONS
1181	Nutritional Support in Alcoholic Cirrhotic Patients Improves Host Defenses. Journal of the American College of Nutrition, 1999, 18, 434-441.	1.1	51
1182	Patterns of energy intake in patients with cirrhosis and healthy volunteers. British Journal of Nutrition, 1999, 82, 41-48.	1.2	9
1183	Pharmacokinetics and Pharmacodynamics of Rapacuronium in Patients with CirrhosisÂ. Anesthesiology, 1999, 91, 1305-1305.	1.3	26
1184	Morbidity and Mortality in Cirrhotic Patients Undergoing Anesthesia and SurgeryÂ. Anesthesiology, 1999, 90, 42-53.	1.3	347
1185	Hepatitis C: A Challenge for the Generalist. Hospital Practice (1995), 2000, 35, 97-118.	0.5	2
1186	Sequential changes in plasma cytokine and endotoxin levels in cirrhotic patients with bacterial infection. Clinical Science, 2000, 98, 419-425.	1.8	24
1187	Laparoscopic Cholecystectomy in Cirrhosis: Contraindication or Privileged Indication?. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2000, 10, 360-363.	0.4	26
1188	A Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 2000, 75, 688-694.	1.4	285
1189	Anterior Approach for Major Right Hepatic Resection for Large Hepatocellular Carcinoma. Annals of Surgery, 2000, 232, 25-31.	2.1	181
1190	Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients. Blood Coagulation and Fibrinolysis, 2000, 11, S87-S93.	0.5	66
1191	Assessment of hepatic blood flow by PET with 15O water: Correlation between per-rectal portal scintigraphy with 99Tcm-pertechnetate and scintigraphy with 99Tcm-GSA. Nuclear Medicine Communications, 2000, 21, 533-538.	0.5	7
1192	PROGNOSTIC FACTORS FOR LONG-TERM ACTUAL PATIENT SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATION IN CHILDREN. Transplantation, 2000, 70, 1448-1453.	0.5	23
1193	A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization., 2000, 88, 50-57.		157
1194	Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma., 2000, 88, 1016-1024.		108
1195	How should patients with hepatocellular carcinoma be staged? Cancer, 2000, 89, 2266-2273.	2.0	153
1196	Pseudothrombosis in the portal venous system: A potential pitfall with gadolinium-enhanced dynamic gradient-recalled echo imaging of the liver. Journal of Magnetic Resonance Imaging, 2000, 12, 763-768.	1.9	8
1197	Primary liver tumors. Journal of Surgical Oncology, 2000, 19, 135-144.	1.4	59
1198	Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology, 2000, 31, 7-11.	3.6	328

#	Article	IF	CITATIONS
1199	Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology, 2000, 31, 54-58.	3.6	242
1200	Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000, 31, 207-210.	3.6	435
1201	Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology, 2000, 31, 230-234.	3.6	139
1202	Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology, 2000, 31, 324-329.	3.6	127
1203	Liver transplantation. Liver Transplantation, 2000, 6, 122-135.	1.3	97
1204	Endoscopic Evaluation of Rectal Mucosal Reddening in Patients with Liver Cirrhosis. Digestive Endoscopy, 2000, 12, 229-232.	1.3	0
1205	The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. British Journal of Clinical Pharmacology, 2000, 49, 21-26.	1.1	33
1206	The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. British Journal of Clinical Pharmacology, 2000, 49, 417-421.	1.1	38
1207	Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. British Journal of Clinical Pharmacology, 2000, 50, 108-115.	1.1	56
1208	Dysphagia after prophylactic endoscopic injection sclerotherapy for oesophageal varices: Not fatal but a distressing complication. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 320-323.	1.4	7
1209	Renovascular resistance assessed by color Doppler ultrasonography in patients with chronic liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 1424-1429.	1.4	23
1210	Evaluation of balloon-occluded hepatic venography with carbon dioxide for portography and correlation between retrograde portogram and liver function in patients with liver cirrhosis. Hepatology Research, 2000, 18, 239-251.	1.8	2
1211	The natural history and prognostic factors in patients with cirrhosis and gastric fundal varices without prior bleeding. Hepatology Research, 2000, 17, 145-155.	1.8	16
1212	Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis. Hepatology Research, 2000, 18, 184-189.	1.8	7 3
1213	Effect of cisapride on portal haemodynamics in patients with liver cirrhosis using duplex Doppler ultrasonography. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 2000, 12, 95-101.	1.4	0
1214	Serum gastrin and gastrin-immunoreactive cells in the antral mucosa of patients with alcoholic liver diseaseNote. Apmis, 2000, 108, 51-56.	0.9	1
1215	Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol, 2000, 22, 147-157.	0.8	86
1216	Spin-echo echo-planar MR imaging of hepatocellular carcinoma arising from chronic liver damage: comparison with turbo spin-echo imaging. Computerized Medical Imaging and Graphics, 2000, 24, 43-48.	3.5	2

#	Article	IF	CITATIONS
1217	Factors affecting survival after living-related liver transplantation. Transplant International, 2000, 13, S136-S139.	0.8	6
1218	Diastolic Function Impairment in Alcoholics. Alcoholism: Clinical and Experimental Research, 2000, 24, 1830-1835.	1.4	57
1219	Perioperative safety and prognosis in hepatocellular carcinoma patients with impaired liver function 11 No competing interests declared. Journal of the American College of Surgeons, 2000, 190, 574-579.	0.2	34
1220	Effectiveness of gastric devascularization and splenectomy for patients with gastric varices 11 No competing interests declared Journal of the American College of Surgeons, 2000, 191, 498-503.	0.2	59
1221	Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis 11 No competing interests declared Journal of the American College of Surgeons, 2000, 191, 657-660.	0.2	82
1222	The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal Dysfunction. Pharmacotherapy, 2000, 20, 318-329.	1.2	347
1223	Safety and Pharmacokinetics of a Single Oral Dose of Gatifloxacin in Patients with Moderate to Severe Hepatic Impairment. Pharmacotherapy, 2000, 20, 87S-94S.	1.2	22
1224	Delayed hemoperitoneum following large-volume paracentesis in a patient with cirrhosis and ascites. Digestive Diseases and Sciences, 2000, 45, 357-358.	1.1	17
1225	Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis. Digestive Diseases and Sciences, 2000, 45, 581-586.	1.1	10
1226	Evaluation of gallbladder motility in patients with liver cirrhosis: relationship to gallstone formation. Digestive Diseases and Sciences, 2000, 45, 1109-1114.	1.1	29
1227	Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Digestive Diseases and Sciences, 2000, 45, 1392-1399.	1.1	47
1229	The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma. Surgery Today, 2000, 30, 892-895.	0.7	67
1230	Plasma endothelin-1 levels in liver cirrhosis. International Journal of Clinical and Laboratory Research, 2000, 30, 169-172.	1.0	13
1231	Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology, 2000, 31, 840-845.	3.6	546
1232	A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology, 2000, 31, 864-871.	3.6	2,466
1233	Endoscopic Variceal Ligation Plus Nadolol and Sucralfate Compared With Ligation Alone for the Prevention of Variceal Rebleeding: A Prospective, Randomized Trial. Hepatology, 2000, 32, 461-465.	3.6	258
1234	Increased hepatic iron and cirrhosis: No evidence for an adverse effect on patient outcome following liver transplantation. Hepatology, 2000, 32, 1200-1207.	3.6	46
1235	Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology, 2000, 32, 1208-1215.	3.6	174

#	Article	IF	CITATIONS
1236	Impact of liver transplantation on health-related quality of life. Liver Transplantation, 2000, 6, 779-783.	1.3	92
1237	Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transplantation, 2000, 6, 715-720.	1.3	32
1238	Adaptation of the Mayo Primary Biliary Cirrhosis Natural History Model for Application in Liver Transplant Candidates. Liver Transplantation, 2000, 6, 489-494.	1.3	50
1239	Confirmation of the role of the mayo risk score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis. Liver Transplantation, 2000, 6, 749-752.	1.3	11
1240	Correlation of high levels of hyaluronan and cytokines (IL-1beta, IL-6, and TGF-beta) in ascitic fluid of cirrhotic patients. Digestive Diseases and Sciences, 2000, 45, 2229-2232.	1.1	7
1241	Current views on hepatitis C virus infection. Current Infectious Disease Reports, 2000, 2, 55-60.	1.3	2
1242	Factors affecting survival after living-related liver transplantation. Transplant International, 2000, 13, S136-S139.	0.8	7
1243	Measurement of Serum Hyaluronate as a Predictor of Human Liver Failure after Major Hepatectomy. World Journal of Surgery, 2000, 24, 359-364.	0.8	37
1244	Intracellular pH measurements of the whole head and the basal ganglia in chronic liver disease: A phosphorus-31 MR spectroscopy study. Metabolic Brain Disease, 2000, 15, 223-240.	1.4	25
1246	Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Annals of Nuclear Medicine, 2000, 14, 121-126.	1.2	102
1247	Determining resectability for hepatocellular carcinoma: the role of laparoscopy and laparoscopic ultrasonography. Journal of Hepato-Biliary-Pancreatic Surgery, 2000, 7, 260-264.	2.0	29
1248	Correlation of Serum Concentrations of Cystatin C and Creatinine to Inulin Clearance in Liver Cirrhosis. Clinical Chemistry, 2000, 46, 712-715.	1.5	124
1249	An Appraisal of Liver and Portal Vein Resection for Hepatocellular Carcinoma With Tumor Thrombi Extending to Portal Bifurcation. Archives of Surgery, 2000, 135, 1273-1279.	2.3	83
1251	Cholestasis is the Main Determinant of Abnormal CA 19–9 Levels in Patients with Liver Cirrhosis. International Journal of Biological Markers, 2000, 15, 226-230.	0.7	26
1252	Hepatectomy Using an Ultrasonically Activated Scalpel for Hepatocellular Carcinoma. Digestive Surgery, 2000, 17, 138-142.	0.6	9
1253	Validation of the Modified Tnm-Izumi Classification for Hepatocellular Carcinoma. Tumori, 2000, 86, 8-11.	0.6	15
1254	Lipolysis and lipid oxidation in cirrhosis and after liver transplantation. American Journal of Physiology - Renal Physiology, 2000, 278, G967-G973.	1.6	11
1255	Color Doppler sonography for evaluating response to transcatheter arterial embolization and percutaneous ethanol injection therapy and for detecting recurrence of hepatocellular carcinoma Journal of Ultrasound in Medicine, 2000, 19, 807-814.	0.8	4

#	Article	IF	CITATIONS
1256	Pulmonary Hypertension Associated with Liver Cirrhosis: An Echocardiographic Study. Angiology, 2000, 51, 1013-1020.	0.8	32
1257	The prognostic significance of subclinical hepatic encephalopathy. American Journal of Gastroenterology, 2000, 95, 2029-2034.	0.2	213
1258	Prognostic Indicators of Risk for First Variceal Bleeding in Cirrhosis: A Multicenter Study in 711 Patients To Validate and Improve The North Italian Endoscopic Club (Niec) Index. American Journal of Gastroenterology, 2000, 95, 2915-2920.	0.2	109
1259	Cholestatic Liver Diseases and Health-Related Quality of Life. American Journal of Gastroenterology, 2000, 95, 497-502.	0.2	137
1260	An Open-Label Study of Lamivudine for Chronic Hepatitis B in Six Patients With Chronic Renal Failure Before and After Kidney Transplantation. American Journal of Gastroenterology, 2000, 95, 3579-3583.	0.2	31
1261	Natural History of Cirrhotic Patients With Small Esophageal Varices: A Prospective Study. American Journal of Gastroenterology, 2000, 95, 503-508.	0.2	99
1262	Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. American Journal of Gastroenterology, 2000, 95, 199-203.	0.2	58
1263	Delayed liquid gastric emptying in patients with hepatocellular carcinoma. American Journal of Gastroenterology, 2000, 95, 3230-3237.	0.2	11
1264	Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. American Journal of Gastroenterology, 2000, 95, 2015-2022.	0.2	94
1265	Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. American Journal of Gastroenterology, 2000, 95, 2328-2332.	0.2	100
1266	Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. American Journal of Gastroenterology, 2000, 95, 1051-1055.	0.2	18
1267	Upper Gastrointestinal Bleeding in Patients With Hepatic Cirrhosis: Clinical Course and Mortality Prediction. American Journal of Gastroenterology, 2000, 95, 484-489.	0.2	88
1268	Treatment of Small Hepatocellular Carcinoma With Percutaneous Ethanol Injection: A Validated Prognostic Model. American Journal of Gastroenterology, 2000, 95, 2921-2927.	0.2	31
1269	Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. American Journal of Gastroenterology, 2000, 95, 218-222.	0.2	98
1270	Renal Clearance of N ¹ -Methylnicotinamide: A Sensitive Marker of the Severity of Liver Dysfunction in Cirrhosis. Nephron, 2000, 84, 32-39.	0.9	8
1271	Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma British Journal of Radiology, 2000, 73, 1091-1097.	1.0	58
1272	Pharmacokinetics of Diclofenac Sodium in Chronic Active Hepatitis and Alcoholic Cirrhosis. Journal of Clinical Pharmacology, 2000, 40, 250-257.	1.0	12
1273	The Liver and Vascular Surgery. Seminars in Cardiothoracic and Vascular Anesthesia, 2000, 4, 275-288.	0.4	1

#	ARTICLE	IF	CITATIONS
1274	Percutaneous Radio-frequency Thermal Ablation of Nonresectable Hepatocellular Carcinoma after Occlusion of Tumor Blood Supply. Radiology, 2000, 217, 119-126.	3.6	490
1275	UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut, 2000, 46, 1iii-15.	6.1	116
1276	Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma in Patients with Cirrhosis: Evaluation of Damage to Nontumorous Liver Tissueâ€"Long-term Prospective Study. Radiology, 2000, 215, 123-128.	3.6	89
1277	Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function. Antimicrobial Agents and Chemotherapy, 2000, 44, 821-826.	1.4	75
1278	Transforming Growth Factor- \hat{l}^21 as a Surrogate Marker of Hepatic Dysfunction in Chronic Liver Diseases. Clinical Chemistry and Laboratory Medicine, 2000, 38, 1129-31.	1.4	12
1279	Antiphospholipid antibodies in alcoholic liver disease are influenced by histological damage but not by alcohol consumption. Lupus, 2000, 9, 451-455.	0.8	6
1280	Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut, 2000, 46, 546-552.	6.1	48
1281	Elevated Soluble Tumour Necrosis Factor Receptor Serum Concentrations and Short-Term Mortality in Liver Cirrhosis without Acute Infections. Digestion, 2000, 62, 44-51.	1.2	7
1282	CIRCULATING TRANSFORMING GROWTH FACTOR \hat{l}^2 1AS AN INDICATOR OF HEPATIC FUNCTION IMPAIRMENT IN LIVER CIRRHOSIS. Cytokine, 2000, 12, 677-681.	1.4	59
1283	Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal bleeding in cirrhotic patients: a randomized, prospective and controlled trial. Gastrointestinal Endoscopy, 2000, 51, 157-163.	0.5	37
1284	Nutritional assessment in alcoholic patients. Its relationship with alcoholic intake, feeding habits, organic complications and social problems. Drug and Alcohol Dependence, 2000, 59, 295-304.	1.6	54
1285	Nutritional effects of oral zinc supplementation in cirrhosis. Nutrition Research, 2000, 20, 1079-1089.	1.3	33
1286	Factors affecting survival and long-term outcome in the cirrhotic patient undergoing hepatic resection for hepatocellular carcinoma. European Journal of Surgical Oncology, 2000, 26, 387-392.	0.5	28
1287	Synthesis of glutathione in response to methionine load in control subjects and in patients with cirrhosis. Metabolism: Clinical and Experimental, 2000, 49, 1434-1439.	1.5	28
1288	Plasma granulocyte elastase levels and its relation to D-dimer in liver cirrhosis. Fibrinolysis and Proteolysis, 2000, 14, 300-304.	1.1	0
1289	The lidocaine (MEGX) test as an index of hepatic function: Its clinical usefulness in liver surgery⯆⯆⯆. Surgery, 2000, 127, 464-471.	1.0	91
1290	Liver function and encephalopathy after partial vs direct side-to-side portacaval shunt: A prospective randomized clinical trial. Surgery, 2000, 127, 614-621.	1.0	18
1291	A6. $\hat{a} \in f$ Appetite and nutritional intake in patients with chronic liver disease. Journal of Human Nutrition and Dietetics, 2000, 13, 363-371.	1.3	1

#	Article	IF	CITATIONS
1292	A Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 2000, 75, 688-694.	1.4	280
1293	Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. New England Journal of Medicine, 2000, 342, 1301-1308.	13.9	14,454
1294	Risk Factors for Recurrence after Resection of Hepatitis C Virus-related Hepatocellular Carcinoma. World Journal of Surgery, 2000, 24, 1559-1565.	0.8	70
1295	Bacterial Infection in Cirrhotic Patients and Its Relationship With Alcohol. American Journal of Gastroenterology, 2000, 95, 1290-1293.	0.2	99
1296	Modification of cardiac function in cirrhotic patients with and without ascites. American Journal of Gastroenterology, 2000, 95, 3200-3205.	0.2	133
1297	Is the Increase in Serum Cystathionine Levels in Patients with Liver Cirrhosis a Consequence of Impaired Homocysteine Transsulfuration at the Level of ?-Cystathionase?. Scandinavian Journal of Gastroenterology, 2000, 35, 866-872.	0.6	53
1298	Chinese Alcoholic Patients With Esophageal Cancer Are Genetically Different From Alcoholics With Acute Pancreatitis and Liver Cirrhosis. American Journal of Gastroenterology, 2000, 95, 2958-2964.	0.2	89
1299	The Natural History of Portal Hypertensive Gastropathy: Influence of Variceal Eradication. American Journal of Gastroenterology, 2000, 95, 2888-2893.	0.2	102
1300	Cirrosis hepática. Medicine, 2000, 8, 485-492.	0.0	0
1301	LIVER TRANSPLANTATION. Clinics in Liver Disease, 2000, 4, 513-532.	1.0	12
1302	THE CURRENT STATUS OF LIVER TRANSPLANTATION FOR PRIMARY HEPATIC MALIGNANCY. Clinics in Liver Disease, 2000, 4, 591-605.	1.0	28
1304	Regulation of hepatic blood flow in patients with liver cirrhosis and after liver transplantation. Pathophysiology, 2000, 6, 251-260.	1.0	6
1305	Left ventricular volumes in liver cirrhosis. Digestive and Liver Disease, 2000, 32, 392-397.	0.4	13
1306	Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Digestive and Liver Disease, 2000, 32, 605-610.	0.4	143
1307	Can dietary intake influence plasma levels of amino acids in liver cirrhosis?. Digestive and Liver Disease, 2000, 32, 611-616.	0.4	7
1308	Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: long-term efficacy and safety. Gastrointestinal Endoscopy, 2000, 52, 160-167.	0.5	321
1309	Mucosal abnormalities of the colon in patients with portal hypertension: An endoscopic study. Gastrointestinal Endoscopy, 2000, 52, 511-516.	0.5	60
1310	Pharmacokinetics of Reboxetine in Volunteers with Hepatic Impairment. Clinical Drug Investigation, 2000, 19, 473-477.	1.1	9

#	Article	IF	CITATIONS
1311	Recurrence of esophageal varices following endoscopic treatment and its impact on rebleeding: comparison of sclerotherapy and ligation. Journal of Hepatology, 2000, 32, 202-208.	1.8	79
1312	Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 2000, 33, 907-914.	1.8	315
1313	Serum leptin levels in post-hepatitis liver cirrhosis. Journal of Hepatology, 2000, 33, 38-42.	1.8	43
1314	Gene expression of TNF-receptors in peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Journal of Hepatology, 2000, 32, 51-57.	1.8	34
1315	Screening of subclinical hepatic encephalopathy. Journal of Hepatology, 2000, 32, 748-753.	1.8	177
1316	Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. Journal of Hepatology, 2000, 33, 301-307.	1.8	190
1317	Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when?. Journal of Hepatology, 2000, 33, 329-332.	1.8	22
1318	High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis. Journal of Hepatology, 2000, 32, 426-433.	1.8	15
1319	Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. Journal of Hepatology, 2000, 32, 447-452.	1.8	93
1320	The liver: a large endocrine gland. Journal of Hepatology, 2000, 32, 505-507.	1.8	17
1321	Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. Journal of Hepatology, 2000, 32, 19-24.	1.8	972
1322	Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. American Journal of Gastroenterology, 2000, 95, 2015-2022.	0.2	76
1323	Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology, 2001, 120, 170-178.	0.6	431
1324	Liver transplantation: Current status and novel approaches to liver replacement. Gastroenterology, 2001, 120, 749-762.	0.6	201
1325	Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis. Gastroenterology, 2001, 121, 131-139.	0.6	264
1326	Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology, 2001, 121, 389-395.	0.6	137
1327	A new "sandwich―method of combined endoscopic variceal ligation and sclerotherapy versus ligation alone in the treatment of esophageal variceal bleeding: A randomized trial. Gastrointestinal Endoscopy, 2001, 53, 572-578.	0.5	42
1328	Adjuvant sclerotherapy after ligation for the treatment of esophageal varices: A prospective, randomized long-term study. Gastrointestinal Endoscopy, 2001, 53, 566-571.	0.5	34

#	Article	IF	CITATIONS
1329	The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: A prospective, controlled trial. Gastrointestinal Endoscopy, 2001, 53, 579-584.	0.5	68
1330	Feasibility and potential benefit of maintenance endoscopic variceal ligation in patients with unresectable hepatocellular carcinoma and acute esophageal variceal hemorrhage: a controlled trial. Gastrointestinal Endoscopy, 2001, 54, 18-23.	0.5	28
1331	Helicobacter pylori is not a risk factor for hepatic encephalopathy. Digestive and Liver Disease, 2001, 33, 414-419.	0.4	20
1332	Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients. A placebo, controlled evaluation. Journal of Hepatology, 2001, 34, 373-377.	1.8	15
1333	Serum \hat{l}_{\pm} -fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. Journal of Hepatology, 2001, 34, 570-575.	1.8	677
1334	Daily variation of azygos and portal blood flow and the effect of propranolol administration once an evening in cirrhotics. Journal of Hepatology, 2001, 34, 26-31.	1.8	14
1335	Hepatopulmonary syndrome in candidates for liver transplantation. Journal of Hepatology, 2001, 34, 651-657.	1.8	195
1336	Amino acid challenge in patients with cirrhosis: a model for the assessment of treatments for hepatic encephalopathy. Journal of Hepatology, 2001, 34, 658-664.	1.8	42
1337	Increase of serum estradiol in cirrhotic men treated by transjugular intrahepatic portosystemic stent shunt. Journal of Hepatology, 2001, 34, 818-824.	1.8	20
1338	Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. Journal of Hepatology, 2001, 34, 903-910.	1.8	217
1339	Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. Journal of Hepatology, 2001, 35, 421-430.	1.8	3,959
1340	The prognostic value of histology in the assessment of patients with Budd–Chiari syndrome. Journal of Hepatology, 2001, 35, 338-343.	1.8	92
1341	Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. Journal of Hepatology, 2001, 35, 733-738.	1.8	62
1342	Excitatory and inhibitory mechanisms in Wilson's disease: investigation with magnetic motor cortex stimulation. Journal of the Neurological Sciences, 2001, 192, 35-40.	0.3	12
1343	Hepatic Perfusion Parameters in Chronic Liver Disease. American Journal of Roentgenology, 2001, 176, 667-673.	1.0	294
1344	Malignant Portal Venous Obstructions Treated by Stent Placement: Significant Factors Affecting Patency. Journal of Vascular and Interventional Radiology, 2001, 12, 1407-1415.	0.2	71
1345	Management of medically refractory ascites. American Journal of Surgery, 2001, 181, 256-264.	0.9	19
1346	Plasma endothelin-1 level as a marker reflecting the severity of portal hypertension in biliary atresia. Journal of Pediatric Surgery, 2001, 36, 1609-1612.	0.8	18

#	Article	IF	CITATIONS
1347	Hepatocellular carcinoma: Multimodality management. Surgery, 2001, 130, 554-560.	1.0	20
1348	Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointestinal Endoscopy, 2001, 53, 308-312.	0.5	211
1349	Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clinical Therapeutics, 2001, 23, 1180-1192.	1.1	31
1350	Effect of liver disease on dose optimization. International Congress Series, 2001, 1220, 247-258.	0.2	2
1351	Serum and ascitic fluid nitrate levels in patients with cirrhosis. Clinica Chimica Acta, 2001, 306, 127-132.	0.5	22
1352	A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine. Transplantation Proceedings, 2001, 33, 2557-2562.	0.3	2
1354	The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong. Pharmacoeconomics, 2001, 19, 947-953.	1.7	25
1355	Gastroesophageal Variceal Hemorrhage. New England Journal of Medicine, 2001, 345, 669-681.	13.9	369
1356	Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis. New England Journal of Medicine, 2001, 344, 23-28.	13.9	218
1357	The effect of liver transplantation on circulating levels of estradiol and progesterone in male patients: Parallelism with hepatopulmonary syndrome and systemic hyperdynamic circulation improvement. Journal of Endocrinological Investigation, 2001, 24, 503-509.	1.8	27
1360	ELEVATION OF CA-125 LEVEL IS DUE TO ABDOMINAL DISTENSION IN LIVER TRANSPLANTATION CANDIDATES. Transplantation, 2001, 72, 1519-1522.	0.5	14
1361	Primary prophylaxis of variceal bleeding in cirrhosis. European Journal of Gastroenterology and Hepatology, 2001, 13, 349-358.	0.8	16
1362	Anesthetic Concerns for the Patient with Renal or Hepatic Disease. Refresher Courses in Anesthesiology, 2001, 29, 213-228.	0.1	4
1363	Cirrhosis and Laparoscopic Cholecystectomy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2001, 11, 165-169.	0.4	19
1364	Sequential Changes in the Metabolic Response to Orthotopic Liver Transplantation During the First Year After Surgery. Annals of Surgery, 2001, 234, 245-255.	2.1	100
1365	Correlations Between Colonic Wall Thickening in Patients with Virally Induced Cirrhosis on CT and Clinical Status. Journal of Computer Assisted Tomography, 2001, 25, 786-791.	0.5	6
1366	Fatal Bleeding from a Residual Vein at the Esophageal Ulcer Base After Successful Endoscopic Variceal Ligation. Journal of Clinical Gastroenterology, 2001, 32, 158-160.	1.1	15
1367	Reactivation of Viral Replication After Liver Resection in Patients Infected With Hepatitis B Virus. Annals of Surgery, 2001, 233, 139-145.	2.1	50

#	Article	IF	CITATIONS
1368	Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis? European Journal of Gastroenterology and Hepatology, 2001, 13, 1217-1224.	0.8	11
1369	Models predicting the natural history of cirrhosis and need for liver transplantation. Current Opinion in Organ Transplantation, 2001, 6, 107-113.	0.8	3
1370	Comparative Tacrolimus Pharmacokinetics: Normal versus Mildly Hepatically Impaired Subjects. Journal of Clinical Pharmacology, 2001, 41, 628-635.	1.0	42
1371	Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiology and Infection, 2001, 127, 443-450.	1.0	92
1372	Perioperative Care for the Patient with Renal or Hepatic Disease. Anesthesia and Analgesia, 2001, , 99-103.	1,1	1
1373	Predictors of Mortality and Resource Utilization in Cirrhotic Patients Admitted to the Medical ICU. Chest, 2001, 119, 1489-1497.	0.4	157
1374	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. Clinical Science, 2001, 101, 621-628.	1.8	68
1375	Effects of Long-Term Postoperative Interferon-α Therapy on Intrahepatic Recurrence after Resection of Hepatitis C Virus–Related Hepatocellular Carcinoma. Annals of Internal Medicine, 2001, 134, 963.	2.0	244
1377	Basal and Post-Methionine Serum Homocysteine and Lipoprotein Abnormalities in Patients With Chronic Liver Disease. Journal of Investigative Medicine, 2001, 49, 325-329.	0.7	12
1378	Improved Results of Liver Resection for Hepatocellular Carcinoma on Cirrhosis Give the Procedure Added Value. Annals of Surgery, 2001, 234, 71-78.	2.1	309
1379	REDUCED TRANSFUSION REQUIREMENTS BY RECOMBINANT FACTOR VIIa IN ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 2001, 71, 402-405.	0.5	232
1380	No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. European Journal of Gastroenterology and Hepatology, 2001, 13, 171-175.	0.8	36
1381	Bone Disease After Liver Transplantation: A Long-Term Prospective Study of Bone Mass Changes, Hormonal Status and Histomorphometric Characteristics. Osteoporosis International, 2001, 12, 484-492.	1.3	160
1382	Prophylaxis of rebleeding from isolated gastric fundal varices by balloon-occluded retrograde transvenous obliteration. Abdominal Imaging, 2001, 26, 578-580.	2.0	5
1383	Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis. Journal of Gastroenterology, 2001, 36, 368-374.	2.3	9
1384	Role ofHelicobacter pylori in cirrhotic patients with dyspepsia: A13C-urea breath test study. Advances in Therapy, 2001, 18, 140-150.	1.3	12
1385	Binding rate constant of Tc-99m DTPA galactosyl human serum albumin measured by quantitative dynamic SPECT â€"Clinical evaluation as a total and regional liver function testâ€". Annals of Nuclear Medicine, 2001, 15, 191-198.	1.2	6
1386	Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcified Tissue International, 2001, 68, 83-86.	1.5	119

#	Article	IF	CITATIONS
1387	Le carcinome hépato-cellulaire, prévention et diagnostic précoce: où en sommes-nous?. Acta Endoscopica, 2001, 31, 515-520.	0.0	1
1388	Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. Ultrasound in Medicine and Biology, 2001, 27, 901-907.	0.7	63
1389	Current endoscopic therapeutic options in the management of variceal bleeding. Alimentary Pharmacology and Therapeutics, 2001, 15, 575-594.	1.9	65
1390	Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NO-independent mechanism in chronic liver disease. Alimentary Pharmacology and Therapeutics, 2001, 15, 857-864.	1.9	17
1391	Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2001, 15, 1967-1973.	1.9	11
1392	Hepatic phenylalanine metabolism measured by the [13 C]phenylalanine breath test. European Journal of Clinical Investigation, 2001, 31, 356-361.	1.7	26
1393	Cerebral vascular resistance assessed by transcranial color Doppler ultrasonography in patients with chronic liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 890-897.	1.4	16
1394	Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 660-665.	1.4	97
1395	High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 1274-1281.	1.4	39
1396	Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 1409-1414.	1.4	21
1397	Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein1. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 1378-1383.	1.4	127
1398	The clinical importance of the trimethadione tolerance test as a method for quantitative assessment of hepatic functional reserve in patients with biliary atresia. Journal of Clinical Pharmacy and Therapeutics, 2001, 26, 417-424.	0.7	5
1399	Circulating levels of insulin-like growth factors and their binding proteins in patients with chronic liver disease: lack of correlation with bone mineral density. Liver, 2001, 21, 123-128.	0.1	24
1400	Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. Liver, 2001, 21, 26-30.	0.1	36
1401	The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. Liver, 2001, 21, 350-356.	0.1	9
1402	Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer, 2001, 91, 957-963.	2.0	53
1403	Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer, 2001, 91, 1342-1348.	2.0	89
1404	Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer, 2001, 92, 126-135.	2.0	76

#	Article	IF	CITATIONS
1405	Characteristics and course of small hepatocellular carcinomas in patients with hepatitis C virus types 1 and 2. Journal of Medical Virology, 2001, 63, 120-127.	2.5	6
1406	Association between duplex Doppler sonographic flow pattern in right hepatic vein and various liver diseases. Journal of Clinical Ultrasound, 2001, 29, 25-30.	0.4	56
1407	Leukocyte arylsulfatase A activity in patients with alcohol-related cirrhosis. American Journal of Human Biology, 2001, 13, 297-300.	0.8	7
1408	Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clinical Pharmacology and Therapeutics, 2001, 70, 425-430.	2.3	80
1409	Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Digestive Diseases and Sciences, 2001, 46, 1313-1320.	1.1	18
1410	Congestion of superior mesenteric veins and small bowel mucosal injury after endoscopic treatment of esophageal varices in patients with portal hypertension. Digestive Diseases and Sciences, 2001, 46, 2353-2359.	1.1	2
1411	Relationship of Blood Trace Elements to Liver Damage, Nutritional Status, and Oxidative Stress in Chronic Nonalcoholic Liver Disease. Biological Trace Element Research, 2001, 81, 245-254.	1.9	47
1412	Influence of cirrhosis on lamotrigine pharmacokinetics. British Journal of Clinical Pharmacology, 2001, 51, 410-414.	1.1	43
1413	A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33, 464-470.	3.6	4,112
1414	Predicting the prognosis of chronic liver disease: An evolution from child to MELD. Hepatology, 2001, 33, 473-475.	3.6	177
1415	A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology, 2001, 33, 1060-1064.	3.6	408
1416	Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology, 2001, 33, 1124-1129.	3.6	698
1417	Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001, 33, 1394-1403.	3.6	1,931
1418	Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology, 2001, 34, 19-27.	3. 6	81
1419	Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology, 2001, 34, 411-416.	3.6	243
1420	Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology, 2001, 34, 255-261.	3.6	221
1421	Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology, 2001, 34, 707-713.	3.6	195
1422	Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: Evidence for a receptor-specific mechanism. Hepatology, 2001, 34, 884-888.	3.6	39

#	Article	IF	CITATIONS
1423	Impact of gastroenterology consultation on the outcomes of patients admitted to the hospital with decompensated cirrhosis. Hepatology, 2001, 34, 1089-1095.	3.6	61
1424	Prevalence of Liver Disease in Patients with Streptococcus bovis Bacteraemia. Journal of Infection, 2001, 42, 116-119.	1.7	63
1425	Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transplantation, 2001, 7, 631-636.	1.3	184
1426	MELD and PELD: Application of survival models to liver allocation. Liver Transplantation, 2001, 7, 567-580.	1.3	753
1427	Editorial: Improvement in cerebral perfusion after MARS therapy: Further clues about the pathogenesis of hepatic encephalopathy?. Liver Transplantation, 2001, 7, 713-715.	1.3	17
1428	Critical graft size in adult-to-adult living donor liver transplantation: Impact of the recipient's disease. Liver Transplantation, 2001, 7, 948-953.	1.3	263
1429	Decreased splanchnic oxygen uptake and increased systemic oxygen uptake in cirrhosis are normalized after liver transplantation. Liver Transplantation, 2001, 7, 1015-1022.	1.3	12
1430	Hemostatic profiles in 39 dogs with congenital portosystemic shunts. Veterinary Surgery, 2001, 30, 97-104.	0.5	46
1431	Increased Circulating Leptin Levels in Chronic Alcoholism. Alcoholism: Clinical and Experimental Research, 2001, 25, 83-88.	1.4	122
1432	A Variant of Des-gamma-Carboxy Prothrombin Was Increased in Alcoholic Liver Disease Without Hepatocellular Carcinoma. Alcoholism: Clinical and Experimental Research, 2001, 25, 46S-50S.	1.4	9
1433	Influence of Previous Interferon Therapy on Recurrence after Resection of Hepatitis C Virus-related Hepatocellular Carcinoma. Japanese Journal of Cancer Research, 2001, 92, 59-66.	1.7	24
1434	Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Research, 2001, 52, 199-207.	1.9	47
1435	Hepatocellular carcinoma: Current surgical management. Seminars in Oncology, 2001, 28, 474-486.	0.8	31
1436	Nutrition and survival in patients with liver cirrhosis. Nutrition, 2001, 17, 445-450.	1.1	454
1437	Feature subset selection by genetic algorithms and estimation of distribution algorithms. Artificial Intelligence in Medicine, 2001, 23, 187-205.	3.8	45
1438	Ziprasidone, a New Atypical Antipsychotic Drug. Pharmacotherapy, 2001, 21, 717-730.	1.2	47
1439	Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut, 2001, 48, 110-115.	6.1	80
1440	Improving prognosis following a first variceal haemorrhage over four decades. Gut, 2001, 49, 682-685.	6.1	189

#	Article	IF	CITATIONS
1441	PHYSICAL PERFORMANCE AND HEALTH-RELATED QUALITY OF LIFE IN MEN ON A LIVER TRANSPLANTATION WAITING LIST. Journal of Rehabilitation Medicine, 2001, 33, 260-265.	0.8	46
1442	Novel approach to bleeding in patients undergoing cardiac surgery with liver dysfunction. European Journal of Cardio-thoracic Surgery, 2001, 19, 219-220.	0.6	26
1443	Hyperhomocysteinemia in Liver Cirrhosis. Hypertension, 2001, 38, 1217-1221.	1.3	97
1444	Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut, 2001, 48, 390-396.	6.1	134
1445	Serum 90K/MAC-2BP Glycoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: a Comparison with α-Fetoprotein. Clinical Chemistry and Laboratory Medicine, 2001, 39, 961-5.	1.4	39
1446	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut, 2001, 48, 251-259.	6.1	567
1447	Health-related quality of life in chronic liver disease: the impact of type and severity of disease. American Journal of Gastroenterology, 2001, 96, 2199-2205.	0.2	281
1448	Small Intestinal Bacterial Overgrowth versus Antimicrobial Capacity in Patients with Spontaneous Bacterial Peritonitis. Scandinavian Journal of Gastroenterology, 2001, 36, 92-96.	0.6	27
1449	Serum Xanthine Oxidase in Human Liver Disease. American Journal of Gastroenterology, 2001, 96, 1194-1199.	0.2	49
1450	Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. American Journal of Gastroenterology, 2001, 96, 2442-2447.	0.2	90
1451	Hepatocyte Proliferation and Risk of Hepatocellular Carcinoma in Cirrhotic Patients. American Journal of Gastroenterology, 2001, 96, 1575-1580.	0.2	38
1452	Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. American Journal of Gastroenterology, 2001, 96, 1877-1880.	0.2	125
1453	Focal Neurological Signs in Hepatic Encephalopathy in Cirrhotic Patients: An Underestimated Entity?. American Journal of Gastroenterology, 2001, 96, 515-518.	0.2	83
1454	Prognostic value of hepatocyte proliferative activity after transjugular intrahepatic portosystemic shunt. American Journal of Gastroenterology, 2001, 96, 1866-1871.	0.2	4
1455	Hemodynamic Effects of A Combination of Prazosin and Terlipressin in Patients With Viral Cirrhosis. American Journal of Gastroenterology, 2001, 96, 1210-1216.	0.2	11
1456	Assessment of Utilities and Health-Related Quality of Life in Patients With Chronic Liver Disease. American Journal of Gastroenterology, 2001, 96, 579-583.	0.2	133
1457	Influence of Esophageal Varices and Spontaneous Portal-Systemic Shunts on Postprandial Splanchnic Hemodynamics. American Journal of Gastroenterology, 2001, 96, 550-556.	0.2	17
1458	Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut, 2001, 49, 106-111.	6.1	23

#	Article	IF	CITATIONS
1459	Evidence for altered hepatic gluconeogenesis in patients with cirrhosis using in vivo 31-phosphorus magnetic resonance spectroscopy. Gut, 2001, 49, 557-564.	6.1	66
1460	Small Intestinal Bacterial Overgrowth versus Antimicrobial Capacity in Patients with Spontaneous Bacterial Peritonitis. Scandinavian Journal of Gastroenterology, 2001, 36, 92-96.	0.6	35
1461	Expression of a Novel Protein by Regenerating Hepatocytes and Peripheral Blood Lymphocytes. Vaccine Journal, 2001, 8, 1292-1294.	2.6	3
1462	Renovascular Impedance and Esophageal Varices in Patients with Child-Pugh Class A Cirrhosis. Radiology, 2001, 219, 712-715.	3.6	20
1464	Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism. European Journal of Clinical Nutrition, 2001, 55, 980-988.	1.3	40
1465	Dendroaspis natriuretic peptide in hepatic cirrhosis. American Journal of Gastroenterology, 2001, 96, 2724-2729.	0.2	6
1466	Pilot Study of Local Radiotherapy for Portal Vein Tumor Thrombus in Patients with Unresectable Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology, 2001, 31, 147-152.	0.6	28
1467	Portal Venous Stent Placement in Patients with Pancreatic and Biliary Neoplasms Invading Portal Veins and Causing Portal Hypertension: Initial Experience. Radiology, 2001, 220, 150-156.	3.6	61
1468	Lack of prognostic usefulness of hepatic venous pressures and hemodynamic values in a select group of patients with severe alcoholic cirrhosis. American Journal of Gastroenterology, 2002, 97, 1187-1190.	0.2	19
1469	Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. American Journal of Gastroenterology, 2002, 97, 2063-2070.	0.2	58
1470	Spontaneous Listeria monocytogenes peritonitis: a population-based study of 13 cases collected in Spain. American Journal of Gastroenterology, 2002, 97, 1507-1511.	0.2	43
1471	Prospective validation of the Rockall risk scoring system for upper GI hemorrhage in subgroups of patients with varices and peptic ulcers. American Journal of Gastroenterology, 2002, 97, 630-635.	0.2	87
1472	Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). American Journal of Gastroenterology, 2002, 97, 734-744.	0.2	282
1473	Xanthine oxidoreductase activity in human liver disease. American Journal of Gastroenterology, 2002, 97, 2079-2085.	0.2	62
1474	Video-Assisted Thoracoscopic Surgery With Talc Pleurodesis in the Management of Symptomatic Hepatic Hydrothorax. American Journal of Gastroenterology, 2002, 97, 3172-3175.	0.2	68
1475	Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal. American Journal of Gastroenterology, 2002, 97, 2383-2390.	0.2	9
1476	Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). American Journal of Gastroenterology, 2002, 97, 142-148.	0.2	98
1477	Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. American Journal of Gastroenterology, 2002, 97, 978-981.	0.2	48

#	Article	IF	CITATIONS
1478	Impairment of Psychomotor Responses After Conscious Sedation in Cirrhotic Patients Undergoing Therapeutic Upper Gi Endoscopy. American Journal of Gastroenterology, 2002, 97, 1717-1721.	0.2	46
1479	Under pressure to prognosticate. American Journal of Gastroenterology, 2002, 97, 1088-1090.	0.2	0
1480	Renal tubular events following passage from the supine to the standing position in patients with compensated liver cirrhosis: loss of tubuloglomerular feedback. Gut, 2002, 51, 736-741.	6.1	11
1481	Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. Age and Ageing, 2002, 31, 457-462.	0.7	11
1482	Cirrhosis: Modified Caudate–Right Lobe Ratio. Radiology, 2002, 224, 769-774.	3.6	179
1483	Portal vein pulsatility and spectral width changes in patients with portal hypertension: relation to the severity of liver disease. British Journal of Radiology, 2002, 75, 417-421.	1.0	27
1484	GH Treatment in Adults with Chronic Liver Disease: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2751-2759.	1.8	31
1485	Gadolinium-enhanced MR Imaging of the Liver: Optimizing Imaging Delay for Hepatic Arterial and Portal Venous Phasesâ€"A Prospective Randomized Study in Patients with Chronic Liver Damage. Radiology, 2002, 225, 407-415.	3.6	62
1486	Impairment of albumin and whole body postprandial protein synthesis in compensated liver cirrhosis. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E304-E311.	1.8	36
1487	Prognostic Factors in Patients with Hepatocellular Carcinoma Treated by Transcatheter Arterial Embolization. Japanese Journal of Clinical Oncology, 2002, 32, 455-460.	0.6	23
1488	Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation, 2002, 62, 39-47.	0.6	4
1489	HCC: What's the score. Gut, 2002, 50, 749-750.	6.1	5
1490	Rocuronium plasma concentrations during three phases of liver transplantation: relationship with early postoperative graft liver function $\hat{a} \in \hat{a} \in \hat{b}$. British Journal of Anaesthesia, 2002, 88, 764-770.	1.5	22
1491	Nosocomial Spontaneous Bacterial Peritonitis and Bacteremia in Cirrhotic Patients: Impact of Isolate Type on Prognosis and Characteristics of Infection. Clinical Infectious Diseases, 2002, 35, 1-10.	2.9	185
1492	Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut, 2002, 51, 853-859.	6.1	283
1493	Therapeutic Efficacy of Transcatheter Arterial Chemoembolization as Compared With Hepatic Resection in Hepatocellular Carcinoma Patients With Compensated Liver Function in a Hepatitis B Virus–Endemic Area: A Prospective Cohort Study. Journal of Clinical Oncology, 2002, 20, 4459-4465.	0.8	106
1494	Indication and assessment for liver transplantation. Clinical Medicine, 2002, 2, 313-316.	0.8	4
1495	The Effect of Controlled Drinking in Alcoholic Cardiomyopathy. Annals of Internal Medicine, 2002, 136, 192.	2.0	114

#	Article	IF	CITATIONS
1496	Angiotensin-Converting Enzyme Gene Polymorphism Is Associated with Vulnerability to Alcoholic Cardiomyopathy. Annals of Internal Medicine, 2002, 137, 321.	2.0	71
1497	Remission and Survival Following Monthly Intraarterial Cisplatinum in Nonresectable Hepatoma. Cancer Investigation, 2002, 20, 613-625.	0.6	42
1498	Enhanced monocyte tissue factor expression in hepatosplenic Schistosomiasis. Blood Coagulation and Fibrinolysis, 2002, 13, 43-47.	0.5	5
1499	Detection of Hypervascular Hepatocellular Carcinoma: Comparison of SPIO-enhanced MRI With Dynamic Helical CT. Journal of Computer Assisted Tomography, 2002, 26, 701-710.	0.5	25
1500	Helicobacter pylori, Gastric Juice, and Arterial Ammonia Levels in Patients with Cirrhosis. Journal of Clinical Gastroenterology, 2002, 34, 578-581.	1.1	21
1501	Increased rate of bone loss at the femoral neck in patients with chronic liver disease. European Journal of Gastroenterology and Hepatology, 2002, 14, 43-48.	0.8	26
1502	Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology, 2002, 14, 159-165.	0.8	123
1503	Surgery and Ablative Therapy for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2002, 35, S130-S137.	1.1	61
1504	Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology and Hepatology, 2002, 14, 377-381.	0.8	27
1505	Pharmacokinetic study of esomeprazole in patients with hepatic impairment. European Journal of Gastroenterology and Hepatology, 2002, 14, 491-496.	0.8	28
1506	Prediction of Esophageal Varices in Patients With Cirrhosis. Journal of Clinical Gastroenterology, 2002, 34, 81-85.	1.1	194
1507	Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy. Transplantation, 2002, 73, 1936-1943.	0.5	23
1508	Prothrombin index is an indirect marker of severe liver fibrosis. European Journal of Gastroenterology and Hepatology, 2002, 14, 1133-1141.	0.8	75
1509	Hepatic Iron Deposition on Magnetic Resonance Imaging: Correlation with Inflammatory Activity. Journal of Computer Assisted Tomography, 2002, 26, 988-993.	0.5	18
1510	Preoperative Predictors of Survival After Resection of Small Hepatocellular Carcinomas. Annals of Surgery, 2002, 235, 722-731.	2.1	170
1511	Extended Hepatic Resection for Hepatocellular Carcinoma in Patients with Cirrhosis: Is It Justified?. Annals of Surgery, 2002, 236, 602-611.	2.1	166
1512	Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Critical Care Medicine, 2002, 30, 1-6.	0.4	375
1513	Pharmacokinetics and Safety of Gadobenate Dimeglumine (Multihance) in Subjects With Impaired Liver Function. Investigative Radiology, 2002, 37, 299-308.	3.5	30

#	Article	IF	Citations
1514	Serum Biotinidase Activity in Children With Chronic Liver Disease and Its Clinical Significance. Journal of Pediatric Gastroenterology and Nutrition, 2002, 34, 59-62.	0.9	14
1515	Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers. Journal of Clinical Pharmacology, 2002, 42, 428-436.	1.0	17
1516	Occlusion of Hepatic Blood Inflow for Complex Central Liver Resections in Cirrhotic Patients. Archives of Surgery, 2002, 137, 1369-76.	2.3	43
1517	Cimetidine administration and tubular creatinine secretion in patients with compensated cirrhosis. Clinical Science, 2002, 102, 91-98.	1.8	21
1518	Impaired sympathetic regulation of cerebral blood flow in patients with cirrhosis of the liver. Clinical Science, 2002, 103, 43-51.	1.8	13
1519	Interferon for hepatocellular carcinoma. The Cochrane Library, 2002, , .	1.5	1
1520	Small Hepatocellular Carcinoma. Journal of Ultrasound in Medicine, 2002, 21, 67-76.	0.8	10
1521	Extrahepatic Conditions and Hepatic Encephalopathy in Elderly Patients. American Journal of the Medical Sciences, 2002, 324, 1-4.	0.4	15
1522	Emotional Stress, Psychosocial Variables and Coping Associated with Hepatitis C Virus and Human Immunodeficiency Virus Infections in Intravenous Drug Users. Psychotherapy and Psychosomatics, 2002, 71, 342-349.	4.0	36
1523	Reversibility of Cirrhosis in Patients Cured of Thalassemia by Bone Marrow Transplantation. Annals of Internal Medicine, 2002, 136, 667.	2.0	89
1524	Progress in Surgical Treatment of Hepatocellular Carcinoma. Oncology, 2002, 62, 74-81.	0.9	74
1525	Recovery Rate and Prognosis in Older Persons Who Develop Acute Lung Injury and the Acute Respiratory Distress Syndrome. Annals of Internal Medicine, 2002, 136, 25.	2.0	213
1526	Prognostic Assessment and Evaluation of the Benefits of Treatment. Journal of Clinical Gastroenterology, 2002, 35, S138-S142.	1.1	28
1527	The use of quantitative Doppler ultrasonography to predict posthepatectomy complications on the basis of hepatic hemodynamic parameters. Surgery, 2002, 132, 431-440.	1.0	8
1528	Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial. Critical Care Medicine, 2002, 30, 2205-2211.	0.4	603
1529	Chronic Hepatic Disease: Usefulness of Serial CT Examinations. Journal of Computer Assisted Tomography, 2002, 26, 418-421.	0.5	5
1530	Implications of estradiol and progesterone in pulmonary vasodilatation in cirrhotic patients. Journal of Endocrinological Investigation, 2002, 25, 4-10.	1.8	15
1531	The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. American Journal of Gastroenterology, 2002, 97, 2855-2860.	0.2	59

#	Article	IF	CITATIONS
1532	Extent of resection for hepatocellular carcinoma 2 cm or less in greatest diameter. American Journal of Surgery, 2002, 184, 437-440.	0.9	5
1533	Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis – amelioration by liver transplantation. Journal of Hepatology, 2002, 36, 66-71.	1.8	109
1534	Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. Journal of Hepatology, 2002, 36, 356-361.	1.8	39
1535	MELD score is better than Child–Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. Journal of Hepatology, 2002, 36, 494-500.	1.8	248
1536	Surgical versus medical treatment of refractory ascites. The Cochrane Library, 2002, , .	1.5	0
1537	Vascular reserve in the lower limbs of cirrhotic patients: a duplex Doppler ultrasound study. Digestive and Liver Disease, 2002, 34, 717-722.	0.4	1
1538	Hepatitis C virus RNA quantitation in hepatic veins and peripheral blood in patients with liver cirrhosis: evidence for low level intrahepatic hepatitis C virus replication in advanced liver disease. Digestive and Liver Disease, 2002, 34, 802-807.	0.4	4
1539	Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: A randomized, controlled trial. Gastroenterology, 2002, 122, 916-922.	0.6	36
1540	Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 2002, 123, 134-140.	0.6	1,332
1541	Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology, 2002, 123, 728-734.	0.6	161
1542	Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology, 2002, 123, 719-727.	0.6	266
1543	Pharmacokinetics of Omeprazole Given by Continuous Intravenous Infusion to Patients with Varying Degrees of Hepatic Dysfunction. Clinical Pharmacokinetics, 2002, 41, 999-1004.	1.6	24
1544	Cancer Antigen 125 in Patients With Chronic Liver Disease. Mayo Clinic Proceedings, 2002, 77, 538-541.	1.4	37
1545	Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut, 2002, 50, 881-885.	6.1	214
1546	Hepatofugal portal flow in advanced liver cirrhosis with spontaneous portosystemic shunts: effects on parenchymal hepatic enhancement at dual-phase helical CT. Abdominal Imaging, 2002, 27, 536-540.	2.0	13
1547	Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. American Journal of Gastroenterology, 2002, 97, 1223-1227.	0.2	68
1548	Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. Gut, 2002, 50, 707-712.	6.1	40
1549	Hemodynamic Effects of a Combination of Octreotide and Terlipressin Patients with Viral Hepatitis Related Cirrhosis. Scandinavian Journal of Gastroenterology, 2002, 37, 482-487.	0.6	22

#	Article	IF	CITATIONS
1550	Liver Fibrosis: What's the Beginning of Autonomic Deficit?. Scandinavian Journal of Gastroenterology, 2002, 37, 1235-1236.	0.6	1
1551	Plasma cystatin C as a marker of renal function in patients with liver cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation, 2002, 62, 129-134.	0.6	36
1552	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, The, 2002, 359, 1734-1739.	6.3	3,172
1553	TIPS: a therapy to prevent variceal rebleeding in patients listed for liver transplantation. Transplantation Proceedings, 2002, 34, 635-637.	0.3	8
1554	Liver transplantation: who and when?. Transplantation Proceedings, 2002, 34, 2465-2467.	0.3	2
1555	Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. Journal of Hepatology, 2002, 36, 793-798.	1.8	105
1556	Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. Journal of Hepatology, 2002, 36, 751-758.	1.8	53
1557	Effects of long-term oral misoprostol administration on hepatic amino acid–nitrogen metabolism in patients with cirrhosis. Journal of Hepatology, 2002, 37, 15-21.	1.8	1
1558	Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. Journal of Hepatology, 2002, 37, 548-555.	1.8	104
1559	Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. Journal of Hepatology, 2002, 37, 767-772.	1.8	91
1560	Hepatic Venous Pressure Gradients Measured by Duplex Ultrasound. Clinical Radiology, 2002, 57, 746-752.	0.5	24
1561	Computed tomographic features of hepatocellular carcinoma predict long-term survival after hepatic resection. European Journal of Surgical Oncology, 2002, 28, 235-242.	0.5	8
1562	Portal venous velocity in the follow-up of patients with biliary atresia after Kasai portoenterostomy. Journal of Pediatric Surgery, 2002, 37, 873-876.	0.8	7
1563	Abnormal brain energy metabolism shown by in vivo phosphorus magnetic resonance spectroscopy in patients with chronic liver disease. Brain Research Bulletin, 2002, 59, 75-82.	1.4	20
1564	Segmental Transcatheter Arterial Chemoembolization Treatment in Patients with Cirrhosis and Inoperable Hepatocellular Carcinomas. Journal of Vascular and Interventional Radiology, 2002, 13, 995-999.	0.2	31
1565	Application of preoperative portal vein embolization before major hepatic resection in patients with normal or abnormal liver parenchyma. Surgery, 2002, 131, 26-33.	1.0	90
1566	Chemoembolization of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2002, 13, S211-S221.	0.2	208
1567	Diagnostic Value of Plasma Cystatin C as a Glomerular Filtration Marker in Decompensated Liver Cirrhosis. Clinical Chemistry, 2002, 48, 850-858.	1.5	139

#	ARTICLE	IF	CITATIONS
1569	Hepatocellular Carcinoma. Journal of Ultrasound in Medicine, 2002, 21, 1015-1022.	0.8	4
1570	Outcome of peritoneal dialysis in cirrhotic patients with chronic renal failure. American Journal of Kidney Diseases, 2002, 40, 161-168.	2.1	51
1571	Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter 1 1No competing interests declared Journal of the American College of Surgeons, 2002, 194, 592-602.	0.2	389
1572	Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition, 2002, 18, 229-234.	1.1	205
1573	Malnutrition is a risk factor in cirrhotic patients undergoing surgery. Nutrition, 2002, 18, 978-986.	1.1	127
1574	Texture analysis of human liver. Journal of Magnetic Resonance Imaging, 2002, 15, 68-74.	1.9	104
1575	Quantitative Doppler evaluation of the splenoportal venous system in various stages of cirrhosis: Differences between right and left portal veins. Journal of Clinical Ultrasound, 2002, 30, 537-543.	0.4	16
1576	Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. Journal of Surgical Oncology, 2002, 80, 143-148.	0.8	62
1577	Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Cancer, 2002, 95, 2353-2360.	2.0	147
1578	Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Cancer, 2002, 95, 2539-2545.	2.0	97
1579	Quantitative lung perfusion scintigraphy and detection of intrapulmonary shunt in liver cirrhosis. Annals of Nuclear Medicine, 2002, 16, 577-581.	1.2	13
1580	Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World Journal of Surgery, 2002, 26, 555-560.	0.8	28
1581	Predictors of successful hepatic resection: Prognostic usefulness of hepatic asialoglycoprotein receptor analysis. World Journal of Surgery, 2002, 26, 1342-1347.	0.8	76
1582	One Hundred Citation Classics in General Surgical Journals. World Journal of Surgery, 2002, 26, 1099-1105.	0.8	356
1583	Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis. European Journal of Applied Physiology, 2002, 86, 509-516.	1.2	363
1584	Elevated serum chromogranin A in patients with hepatocellular carcinoma. Clinical and Experimental Medicine, 2002, 2, 119-123.	1.9	15
1585	Propranolol ameliorates thrombocytopenia in patients with cirrhosis. Journal of Gastroenterology, 2002, 37, 112-118.	2.3	11
1586	Severe catabolic state after prolonged fasting in cirrhotic patients: effect of oral branched-chain amino-acid-enriched nutrient mixture. Journal of Gastroenterology, 2002, 37, 531-536.	2.3	59

#	Article	IF	CITATIONS
1587	Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. Journal of Gastroenterology, 2002, 37, 1028-1034.	2.3	35
1588	Plasma amino acids in cirrhosis and after liver transplantation: influence of liver function, hepatic hemodynamics and circulating hormones. Clinical Transplantation, 2002, 16, 9-17.	0.8	27
1589	The pathophysiological basis of acute-on-chronic liver failure. Liver, 2002, 22, 5-13.	0.1	162
1590	Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. British Journal of Surgery, 2002, 89, 418-422.	0.1	158
1591	Effects of esophageal varices obliteration by endoscopic variceal sclerotherapy on asialoscintigraphy and liver function test. Hepatology Research, 2002, 22, 45-51.	1.8	5
1592	Thrombopoietin receptor (c-Mpl) is constitutively expressed on platelets of patients with liver cirrhosis, and correlates with its disease progression. Hepatology Research, 2002, 23, 115-121.	1.8	11
1593	Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatology Research, 2002, 24, 395-403.	1.8	121
1594	Diagnostic des hépatopathies et de leur sévérité. IRBM News, 2002, 23, 41-48.	0.1	2
1595	Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well-preserved liver function. Journal of Internal Medicine, 2002, 252, 537-541.	2.7	8
1596	Liver transplant recipients' ability to cope during the first 12â€∫ months after transplantation - a prospective study. Scandinavian Journal of Caring Sciences, 2002, 16, 345-352.	1.0	20
1597	Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Alimentary Pharmacology and Therapeutics, 2002, 16, 361-372.	1.9	97
1598	13 C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Alimentary Pharmacology and Therapeutics, 2002, 16, 717-725.	1.9	48
1599	Evaluation of Helicobacter pylori diagnostic methods in patients with liver cirrhosis. Alimentary Pharmacology and Therapeutics, 2002, 16, 1283-1289.	1.9	22
1600	Breath testing for human liver function assessment. Alimentary Pharmacology and Therapeutics, 2002, 16, 1977-1996.	1.9	94
1601	Intestinal first pass metabolism of midazolam in liver cirrhosis - effect of grapefruit juice. British Journal of Clinical Pharmacology, 2002, 54, 120-124.	1.1	49
1602	Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. British Journal of Surgery, 2002, 87, 1182-1187.	0.1	100
1603	Improving operative safety for cirrhotic liver resection. British Journal of Surgery, 2002, 88, 210-215.	0.1	53
1604	Increased serum leptin concentrations correlate with soluble tumour necrosis factor receptor levels in patients with cirrhosis. Clinical Endocrinology, 2002, 57, 805-811.	1.2	30

#	Article	IF	CITATIONS
1605	131 I lipiodol therapy for unresectable hepatocellular carcinoma. ANZ Journal of Surgery, 2002, 72, 210-214.	0.3	12
1606	Hepatocellular carcinoma: current approaches to diagnosis and management. Internal Medicine Journal, 2002, 32, 394-400.	0.5	19
1607	Liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S294-S297.	1.4	1
1608	Scoring severity of chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S298-S299.	1.4	3
1609	Pathophysiology of portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S482-S487.	1.4	9
1610	Effect of anaemia on haemodynamics in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2002, 14, 370-375.	1.4	12
1611	Effects of splenectomy on liver volume and prognosis of cirrhosis in patients with esophageal varices1. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 77-80.	1.4	37
1612	Mediation of transcatheter arterial chemoembolization induced gastric slow-wave dysrhythmia by endogenous prostaglandin1. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 46-51.	1.4	2
1613	Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: A controlled study. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 973-979.	1.4	88
1614	Hepatorenal syndrome in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 739-747.	1.4	55
1615	Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 1205-1210.	1.4	14
1616	Delayed gastrointestinal transit in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 1254-1259.	1.4	8
1617	Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transplant International, 2002, 15, 34-38.	0.8	21
1618	Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. Transplant International, 2002, 15, 188-195.	0.8	29
1619	Coagulation profiles and intraoperative substitution requirements during elective piggyback liver transplantation with prophylactic antifibrinolytic therapy. Transplant International, 2002, 15, 310-316.	0.8	3
1620	Alterations in serum leptin in chronic liver disease. Digestive Diseases and Sciences, 2002, 47, 183-189.	1.1	19
1621	Dopaminergic control of renal tubular function in patients with compensated cirrhosis. Digestive Diseases and Sciences, 2002, 47, 392-400.	1.1	4
1622	Quantification of the electroencephalographic theta/alpha ratio for the assessment of portal-systemic encephalopathy following implantation of transjugular intrahepatic portosystemic stent shunt (TIPSS). Metabolic Brain Disease, 2002, 17, 19-28.	1.4	13

#	Article	IF	CITATIONS
1623	Clinical predictors of large esophagogastric varices in patients with hepatocellular carcinoma. Digestive Diseases and Sciences, 2002, 47, 723-729.	1.1	7
1624	Child comes of age. Hepatology, 2002, 35, 244-245.	3.6	24
1625	Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology, 2002, 35, 616-621.	3.6	68
1626	Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology, 2002, 35, 1282-1284.	3.6	103
1627	Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology, 2002, 35, 1441-1448.	3.6	21
1628	Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity?. Hepatology, 2002, 36, 403-409.	3.6	295
1629	Racial differences in effectiveness of \hat{l}_{\pm} -fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology, 2002, 36, 410-417.	3.6	145
1630	Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology, 2002, 36, 949-958.	3.6	368
1631	Influence of endothelin-1 on hemodynamics during liver transplantation with and without temporary portocaval shunt: Results of a clinical randomized study. Liver Transplantation, 2002, 8, 27-33.	1.3	3
1632	Rapid improvement of autonomic and peripheral neuropathy after liver transplantation: A single case report. Liver Transplantation, 2002, 8, 164-166.	1.3	7
1633	Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transplantation, 2002, 8, 278-284.	1.3	189
1634	Is MELD really the definitive score for liver allocation?. Liver Transplantation, 2002, 8, 795-798.	1.3	37
1635	Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transplantation, 2002, 8, 765-774.	1.3	367
1636	Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transplantation, 2002, 8, 873-883.	1.3	355
1637	An examination of factors predicting prioritization for liver transplantation. Liver Transplantation, 2002, 8, 957-961.	1.3	4
1638	Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: A safe and effective bridge to liver transplantation. Liver Transplantation, 2002, 8, 1165-1174.	1.3	151
1639	The Impact of Liver Metastasis on Mortality in Patients Initially Diagnosed With Locally Advanced or Resectable Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2003, 33, 155-164.	0.4	11
1640	Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Digestive Diseases and Sciences, 2003, 48, 877-881.	1.1	17

#	Article	IF	Citations
1641	Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology, 2003, 38, 230-237.	3.6	124
1642	Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology, 2003, 38, 599-612.	3.6	732
1643	Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology, 2003, 38, 1210-1218.	3.6	430
1644	Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology, 2003, 38, 1227-1236.	3.6	53
1645	Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transplantation, 2003, 9, 12-18.	1.3	189
1646	Predictive models of short- and long-term survival in patients with nonbiliary cirrhosis. Liver Transplantation, 2003, 9, 260-267.	1.3	21
1647	Psychological outcome and quality of life following liver transplantation: A prospective, national, single-center study. Liver Transplantation, 2003, 9, 712-720.	1.3	111
1648	A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transplantation, 2003, 9, 684-692.	1.3	238
1649	Impact of right-lobe live donor liver transplantation on patients waiting for liver transplantation. Liver Transplantation, 2003, 9, 863-869.	1.3	47
1650	Liver transplantation for primary sclerosing cholangitis in the Nordic countries: Outcome after acceptance to the waiting list. Liver Transplantation, 2003, 9, 961-969.	1.3	61
1651	Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Digestive Diseases and Sciences, 2003, 48, 179-186.	1.1	40
1652	Oral amino acid load mimicking hemoglobin results in reduced regional cerebral perfusion and deterioration in memory tests in patients with cirrhosis of the liver. Metabolic Brain Disease, 2003, 18, 37-49.	1.4	36
1653	TIPS for management of refractory ascites: response and survival are both unpredictable. Digestive Diseases and Sciences, 2003, 48, 542-550.	1.1	39
1654	Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients. Digestive Diseases and Sciences, 2003, 48, 556-560.	1.1	70
1655	Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. Digestive Diseases and Sciences, 2003, 48, 802-808.	1.1	18
1656	Partial splenic embolization: long-term outcome. Langenbeck's Archives of Surgery, 2003, 387, 421-426.	0.8	65
1657	IHPBA concordant classification of primary liver cancer: working group report. Journal of Hepato-Biliary-Pancreatic Surgery, 2003, 10, 26-30.	2.0	66
1658	Appropriate Surgical Management of Small Hepatocellular Carcinomas in Patients Infected with Hepatitis C Virus. World Journal of Surgery, 2003, 27, 437-442.	0.8	12

#	Article	IF	CITATIONS
1659	Risk Factors for Nonhepatic Surgery in Patients with Cirrhosis. World Journal of Surgery, 2003, 27, 647-652.	0.8	130
1660	Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. European Journal of Clinical Pharmacology, 2003, 58, 669-675.	0.8	56
1661	Radiation therapy for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. International Journal of Clinical Oncology, 2003, 8, 151-155.	1.0	2
1662	Patients with severe liver cirrhosis followed up by L-[1-13 C] phenylalanine breath test. Journal of Gastroenterology, 2003, 38, 1086-1090.	2.3	14
1663	Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). Journal of Gastroenterology, 2003, 38, 207-215.	2.3	644
1664	Evaluation of nutritional practice in hospitalized cirrhotic patients. Nutrition, 2003, 19, 515-521.	1.1	161
1666	Thoracoabdominal approach for right-sided hepatic resection for hepatocellular carcinoma. Journal of the American College of Surgeons, 2003, 196, 418-427.	0.2	33
1667	Colorectal adenocarcinoma in cirrhotic patients. Journal of the American College of Surgeons, 2003, 196, 874-879.	0.2	7 5
1668	Prediction of GFR in liver transplant candidates. American Journal of Kidney Diseases, 2003, 42, 1169-1176.	2.1	111
1669	Management of variceal hemorrhage. Current Problems in Surgery, 2003, 40, 255-343.	0.6	11
1670	Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis. Clinical Nutrition, 2003, 22, 553-559.	2.3	57
1671	Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer, 2003, 97, 1253-1262.	2.0	306
1672	The des-?-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer, 2003, 98, 2671-2677.	2.0	43
1673	Autonomic deficit in early cirrhosis. Hepatology, 2003, 33, 482-483.	3.6	0
1674	Magnetic resonance imaging of the liver with ultrashort TE (UTE) pulse sequences. Journal of Magnetic Resonance Imaging, 2003, 18, 709-713.	1.9	47
1675	Autonomic and peripheral neuropathy in endstage liver disease and following liver transplantation. Muscle and Nerve, 2003, 28, 595-600.	1.0	23
1676	Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial. Liver Transplantation, 2000, 6, 277-286.	1.3	227
1677	Around the world with the model for end-stage liver disease. Liver Transplantation, 2003, 9, 1118-1119.	1.3	6

#	Article	IF	CITATIONS
1678	Autologous blood storage before hepatectomy for hepatocellular carcinoma with underlying liver disease. British Journal of Surgery, 2003, 90, 23-28.	0.1	35
1679	Separate analysis of asialoglycoprotein receptors in the right and left hepatic lobes using Tc-GSA SPECT. Hepatology, 2003, 38, 1401-1409.	3.6	28
1680	Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatology Research, 2003, 27, 309-314.	1.8	48
1681	Effect of Levovist® on splanchnic hemodynamics in cirrhotic patients. Ultrasound in Medicine and Biology, 2003, 29, 643-648.	0.7	4
1682	Non pulsatile hepatic and portal vein waveforms in patients with liver cirrhosis: concordant and disconcordant relationships. Ultrasound in Medicine and Biology, 2003, 29, S60.	0.7	1
1683	Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature. Critical Reviews in Oncology/Hematology, 2003, 46, 285-295.	2.0	6
1684	Hepatocellular carcinoma: surgical indications and results. Critical Reviews in Oncology/Hematology, 2003, 47, 13-27.	2.0	70
1685	Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver International, 2003, 23, 243-248.	1.9	145
1686	Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver International, 2003, 23, 45-53.	1.9	215
1687	Hypoglycaemia in patients with liver diseases administered levothyroxine. Journal of Clinical Pharmacy and Therapeutics, 2003, 28, 355-361.	0.7	0
1688	Reduced urinary $6\hat{l}^2$ -hydroxycortisol to cortisol ratios in patients with liver cirrhosis. Hepatology Research, 2003, 26, 28-33.	1.8	11
1689	Endoscopic color Doppler ultrasonographic evaluation of recurrent esophagogastric varices following endoscopic injection sclerotherapy. Hepatology Research, 2003, 26, 174-180.	1.8	4
1690	Natural course of changes in hepatic functional reserve in patients with chronic liver diseases evaluated by scintigraphy with GSA. Hepatology Research, 2003, 27, 129-135.	1.8	16
1691	Oxidative breakdown of octanoic acid is maintained in patients with cirrhosis despite advanced disease. Neurogastroenterology and Motility, 2003, 15, 113-120.	1.6	36
1692	Emergency embolization of spontaneous ruptured hepatocellular carcinoma: Correlation between survival and Childâ [°] Pugh classification. Journal of Medical Imaging and Radiation Oncology, 2003, 47, 231-235.	0.6	18
1693	Evaluation of the albumin-gamma-glutamyltransferase isoenzyme as a diagnostic marker of hepatocellular carcinoma-complicating liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 288-295.	1.4	9
1694	Peripheral neuropathy in liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 922-926.	1.4	24
1695	Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 934-942.	1.4	104

#	Article	IF	CITATIONS
1696	Pleuropulmonary complications of esophageal variceal sclerotherapy with absolute alcohol. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 910-914.	1.4	5
1697	Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1156-1161.	1.4	12
1698	Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial [ISRCTN03215899]. BMC Gastroenterology, 2003, 3, 22.	0.8	30
1699	Results of resections for hepatocellular carcinoma in a new hepatobiliary unit. ANZ Journal of Surgery, 2003, 73, 8-13.	0.3	13
1700	Natural history and prognostic prediction of patients with hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2003, 17, 98-102.	1.9	21
1701	Stool antigen for the diagnosis of Helicobacter pylori infection in cirrhosis: comparative usefulness of three different methods. Alimentary Pharmacology and Therapeutics, 2003, 17, 727-731.	1.9	16
1702	The utility of the 13 C-galactose breath test as a measure of liver function. Alimentary Pharmacology and Therapeutics, 2003, 18, 995-1002.	1.9	22
1703	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. British Journal of Clinical Pharmacology, 2003, 55, 86-93.	1.1	46
1704	Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile. British Journal of Clinical Pharmacology, 2003, 57, 344-348.	1.1	7
1705	Hepatocellular carcinoma. British Journal of Surgery, 2003, 85, 1319-1331.	0.1	130
1706	Cytolysis following chemoembolization for hepatocellular carcinoma. British Journal of Surgery, 2003, 86, 176-180.	0.1	41
1707	Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. Clinical Endocrinology, 2003, 58, 207-212.	1.2	24
1708	Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries. European Journal of Clinical Investigation, 2003, 33, 249-255.	1.7	16
1709	Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. International Journal of Radiation Oncology Biology Physics, 2003, 57, 113-119.	0.4	176
1710	Hepatic amino-acid metabolism in liver cirrhosis and in the long-term course after liver transplantation. Transplant International, 2003, 16, 1-8.	0.8	22
1711	A survival-based scoring-system for initial graft function following orthotopic liver transplantation. Transplant International, 2003, 16, 794-800.	0.8	31
1712	Organ allocation: model for end-stage liver disease, Child-Turcotte-Pugh, Mayo risk score, or something else. Clinics in Liver Disease, 2003, 7, 715-727.	1.0	22
1713	Effect of Minimal Listing Criteria on Waiting List Registration for Liver Transplantation: A Process-Outcome Analysis. Mayo Clinic Proceedings, 2003, 78, 431-435.	1.4	5

#	Article	IF	CITATIONS
1715	Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surgical Oncology Clinics of North America, 2003, 12, 51-63.	0.6	52
1716	Surgery in the patient with liver disease. Medical Clinics of North America, 2003, 87, 211-227.	1.1	38
1717	Albumin and other plasma expanders for paracentesis treatment of ascites in cirrhotic patients. The Cochrane Library, 2003 , , .	1.5	1
1718	Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a cochrane meta-analysis. Gastroenterology, 2003, 124, 1277-1291.	0.6	208
1719	Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology, 2003, 124, 1792-1801.	0.6	554
1720	Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology, 2003, 125, 1042-1052.	0.6	344
1721	Helicobacter pylori diagnosis in patients with liver cirrhosis. Digestive and Liver Disease, 2003, 35, 566-570.	0.4	7
1722	MELD: The answer or just more questions?. Gastroenterology, 2003, 124, 251-254.	0.6	34
1723	The North American Study for the Treatment of Refractory Ascites. Gastroenterology, 2003, 124, 634-641.	0.6	424
1724	Primary Prophylaxis of Variceal Bleeding. Gastrointestinal Endoscopy, 2003, 58, 558-567.	0.5	21
1725	Reduced quality of life of patients with hepatocellular carcinoma. Digestive and Liver Disease, 2003, 35, 46-54.	0.4	48
1726	Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. International Journal of Antimicrobial Agents, 2003, 22, 112-121.	1.1	31
1727	Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. American Journal of Gastroenterology, 2003, 98, 1844-1848.	0.2	67
1728	Histopathological changes after microwave coagulation therapy for patients with hepatocellular carcinoma: review of 15 explanted livers. American Journal of Gastroenterology, 2003, 98, 2052-2059.	0.2	40
1729	Diabetes Mellitus Is A Risk Factor for Hepatic Decompensation in Patients With Hepatocellular Carcinoma Undergoing Resection: A Longitudinal Study. American Journal of Gastroenterology, 2003, 98, 2293-2298.	0.2	63
1730	Evolution of liver transplantation for hepatocellular carcinoma. Journal of Hepatology, 2003, 39, 888-895.	1.8	31
1731	Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. European Journal of Surgical Oncology, 2003, 29, 735-742.	0.5	23
1732	Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology, 2003, 37, 1154-1164.	3.6	147

#	Article	IF	CITATIONS
1733	Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. Journal of Hepatology, 2003, 38, 24-31.	1.8	165
1734	Incidence and natural history of small esophageal varices in cirrhotic patients. Journal of Hepatology, 2003, 38, 266-272.	1.8	466
1735	Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation. Journal of Hepatology, 2003, 38, 273-280.	1.8	61
1736	Budd–Chiari syndrome: a review by an expert panel. Journal of Hepatology, 2003, 38, 364-371.	1.8	446
1737	Rating fibrosis progression in chronic liver diseases. Journal of Hepatology, 2003, 38, 357-360.	1.8	40
1738	QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. Journal of Hepatology, 2003, 38, 461-467.	1.8	88
1739	Recurrent pleural effusion complicating liver cirrhosis. Annals of Thoracic Surgery, 2003, 75, 986-989.	0.7	33
1740	Ultrasound Detection of Abdominal Lymph Nodes in Chronic Liver Diseases. A Retrospective Analysis. Clinical Radiology, 2003, 58, 372-377.	0.5	32
1741	Spiral computed tomography versus ultrasound in the follow-up of cirrhotic patients previously treated for hepatocellular carcinoma: a prospective study. Journal of Hepatology, 2003, 39, 93-98.	1.8	13
1742	Memory function in early hepatic encephalopathy. Journal of Hepatology, 2003, 39, 320-325.	1.8	107
1743	Quantitative liver-spleen scan using single photon emission computerized tomography (SPECT) for assessment of hepatic function in cirrhotic patients. Journal of Hepatology, 2003, 39, 326-332.	1.8	31
1744	Cirrhosis and bleeding: the need for very early management. Journal of Hepatology, 2003, 39, 509-514.	1.8	55
1745	Systemic and regional hemodynamics in pre-ascitic cirrhosis: effects of posture. Journal of Hepatology, 2003, 39, 502-508.	1.8	20
1746	Improvement of prognostic power of the Child–Pugh classification of liver cirrhosis by hyaluronan. Journal of Hepatology, 2003, 39, 947-953.	1.8	28
1747	A review of rivastigmine: A reversible cholinesterase inhibitor. Clinical Therapeutics, 2003, 25, 1634-1653.	1.1	105
1748	Treatment of hepatocellular carcinoma: is there an optimal strategy?. Cancer Treatment Reviews, 2003, 29, 99-104.	3.4	61
1749	Whole Blood Manganese Correlates with High Signal Intensities on T1-Weighted MRI in Patients with Liver Cirrhosis. NeuroToxicology, 2003, 24, 909-915.	1.4	62
1750	MR Imaging Features of Primary Sclerosing Cholangitis: Patterns of Cirrhosis in Relationship to Clinical Severity of Disease. Radiology, 2003, 226, 675-685.	3.6	91

#	Article	IF	CITATIONS
1751	Rocuronium infusion requirements and plasma concentrations at constant levels of neuromuscular paralysis during three phases of liver transplantation. Journal of Clinical Anesthesia, 2003, 15, 257-266.	0.7	17
1752	EBAG9/RCAS1 expression in hepatocellular carcinoma. European Journal of Cancer, 2003, 39, 1552-1561.	1.3	30
1753	Clinical application of TcGSA. Nuclear Medicine and Biology, 2003, 30, 845-849.	0.3	78
1754	Reporting Standards for Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology, 2003, 14, S419-S426.	0.2	64
1755	Influence of Mild Liver Impairment on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist. Journal of Clinical Pharmacology, 2003, 43, 15-22.	1.0	33
1756	No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor. Clinical Pharmacokinetics, 2003, 42, 755-764.	1.6	37
1757	Comparison of Percutaneous Acetic Acid Injection and Percutaneous Ethanol Injection for Hepatocellular Carcinoma in Cirrhotic Patients: A Prospective Study. Scandinavian Journal of Gastroenterology, 2003, 38, 770-778.	0.6	78
1758	Mini-asterixis in hepatic encephalopathy induced by pathologic thalamo-motor-cortical coupling. Neurology, 2003, 61, 689-692.	1.5	88
1759	MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut, 2003, 52, 134-139.	6.1	269
1760	Chronic Parkinsonism Associated With Cirrhosis. Archives of Neurology, 2003, 60, 521.	4.9	233
1761	Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut, 2003, 52, 879-885.	6.1	244
1762	Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut, 2003, 52, 1200-1205.	6.1	380
1763	Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut, 2003, 52, 1194-1199.	6.1	60
1764	Surgical Management of Synchronous Hepatocellular Carcinoma and Gastric Cancer. Digestive Surgery, 2003, 20, 133-140.	0.6	5
1765	Serum Concentration of Type IV Collagen 7S Domain as a Marker for Increased Risk of Recurrence after Liver Resection for Hepatocellular Carcinoma. Digestive Surgery, 2003, 20, 201-208.	0.6	5
1766	Leptin in Relation to Hepatocellular Carcinoma in Patients with Liver Cirrhosis. Hormone Research in Paediatrics, 2003, 60, 185-190.	0.8	29
1767	Severe Liver Fibrosis or Cirrhosis: Accuracy of US for Detection—Analysis of 300 Cases. Radiology, 2003, 227, 89-94.	3.6	293
1768	Prognostic Impact of Renal Impairment and Sodium Imbalance in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunting for the Prevention of Variceal Rebleeding. Digestion, 2003, 67, 146-153.	1.2	16

#	Article	IF	CITATIONS
1769	Validity and Clinical Utility of the Aspartate Aminotransferase–Alanine Aminotransferase Ratio in Assessing Disease Severity and Prognosis in Patients With Hepatitis C Virus–Related Chronic Liver Disease. Archives of Internal Medicine, 2003, 163, 218.	4.3	295
1770	Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment. Journal of Clinical Pharmacology, 2003, 43, 1136-1148.	1.0	22
1771	N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis. American Journal of Gastroenterology, 2003, 98, 1982-1988.	0.2	87
1772	Improved Patient Survival After Acute Variceal Bleeding: A Multicenter, Cohort Study. American Journal of Gastroenterology, 2003, 98, 653-659.	0.2	352
1773	Grading portal gastropathy: validation of a gastropathy scoring system. American Journal of Gastroenterology, 2003, 98, 1758-1765.	0.2	52
1774	Relationship of The Model for End-Stage Liver Disease (Meld) Scale To Hepatic Encephalopathy, As Defined by Electroencephalography and Neuropsychometric Testing, and Ascites. American Journal of Gastroenterology, 2003, 98, 1395-1399.	0.2	81
1775	Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. American Journal of Gastroenterology, 2003, 98, 2516-2520.	0.2	79
1776	Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut, 2003, 52, 1355-1362.	6.1	163
1777	Estrogen Receptor Classification for Hepatocellular Carcinoma: Comparison With Clinical Staging Systems. Journal of Clinical Oncology, 2003, 21, 441-446.	0.8	61
1778	Postoperative Pain Relief After Hepatic Resection in Cirrhotic Patients: The Efficacy of a Single Small Dose of Ketamine Plus Morphine Epidurally. Anesthesia and Analgesia, 2003, 96, 475-480.	1.1	14
1779	Immunogenicity and Safety of Hepatitis A Vaccine in Children With Chronic Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2003, 37, 258-261.	0.9	44
1780	INVESTIGATION OF ALCOHOL METABOLIZING ENZYME GENES IN CHINESE ALCOHOLICS WITH AVASCULAR NECROSIS OF HIP JOINT, PANCREATITIS AND CIRRHOSIS OF THE LIVER. Alcohol and Alcoholism, 2003, 38, 431-436.	0.9	78
1781	Nitrous Oxide Attenuates Pressor but Augments Norepinephrine Response to Laryngoscopy and Endotracheal Intubation. Anesthesia and Analgesia, 2003, 96, 1516-1521.	1.1	5
1782	Postoperative Pain Relief After Hepatic Resection in Cirrhotic Patients: The Efficacy of a Single Small Dose of Ketamine Plus Morphine Epidurally. Anesthesia and Analgesia, 2003, 96, 475-480.	1.1	39
1783	Current Status of Surgery in the Management of Hepatocellular Carcinoma. Cancer Reviews: Asia-Pacific, 2003, 01, 211-226.	0.1	0
1784	Cognitive Deficits in Patients With Hepatic Cirrhosis and in Liver Transplant Recipients. Journal of Neuropsychiatry and Clinical Neurosciences, 2003, 15, 84-89.	0.9	53
1785	Laparoscopic Liver Resection for Subcapsular Hepatocellular Carcinoma Complicating Chronic Liver Disease. Archives of Surgery, 2003, 138, 763.	2.3	269
1786	Hepatic Flow Parameters Measured with MR Imaging and Doppler US: Correlations with Degree of Cirrhosis and Portal Hypertension. Radiology, 2003, 229, 409-414.	3.6	276

#	Article	IF	CITATIONS
1787	Comparison of Meld, Child-Pugh, and Emory Model for The Prediction of Survival in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunting. American Journal of Gastroenterology, 2003, 98, 1167-1174.	0.2	156
1788	Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function. Journal of Clinical Pharmacology, 2003, 43, 1361-1369.	1.0	10
1789	Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrology Dialysis Transplantation, 2003, 18, 750-758.	0.4	17
1790	Predicting Outcome of Critically Ill Patients With Cirrhosis Admitted to the Intensive Care Unit: Who's Keeping Score?. Journal of Clinical Gastroenterology, 2003, 37, 203-205.	1.1	3
1791	Changing perspectives in the nutritional management of disease. Proceedings of the Nutrition Society, 2003, 62, 765-772.	0.4	5
1792	Effect of Hepatitis C Virus Infection and Abstinence From Alcohol on Survival in Patients With Alcoholic Cirrhosis. Journal of Clinical Gastroenterology, 2003, 36, 170-174.	1.1	43
1793	Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child???Pugh classification in male patients with alcoholic and virus-related cirrhosis. European Journal of Gastroenterology and Hepatology, 2003, 15, 495-501.	0.8	16
1794	Differential expression of toll-like receptors 2 and 4 in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2003, 15, 275-282.	0.8	42
1795	Gastroduodenal and intestinal permeability in primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2003, 15, 967-973.	0.8	39
1796	Habitual Betel Quid Chewing as a Risk Factor for Cirrhosis. Medicine (United States), 2003, 82, 365-372.	0.4	45
1797	Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. European Journal of Gastroenterology and Hepatology, 2003, 15, 495-501.	0.8	113
1798	Altered alanine plasma levels despite normalized hepatic alanine extraction in the long-term course after liver transplantation. Transplantation, 2003, 75, 804-810.	0.5	6
1799	The Impact of Hepatitis C Status on Postoperative Outcome. Anesthesia and Analgesia, 2003, 97, 550-554.	1.1	7
1800	Liver Resection for Hepatocellular Carcinoma on Cirrhosis. Annals of Surgery, 2003, 237, 536-543.	2.1	312
1801	Prognosis After Hepatic Resection for Stage IVA Hepatocellular Carcinoma. Annals of Surgery, 2003, 237, 376-383.	2.1	92
1802	Hepatic venous pressure gradient determination in patients with hepatitis C virus-related and alcoholic cirrhosis. European Journal of Gastroenterology and Hepatology, 2003, 15, 1085-1089.	0.8	17
1803	Survival gain after liver transplantation for patients with alcoholic liver disease: a comparison across models and centers. Transplantation, 2003, 76, 1479-1486.	0.5	6
1804	Ascites Fluid and Plasma Calprotectin Concentrations in Liver Disease. Scandinavian Journal of Gastroenterology, 2003, 38, 415-420.	0.6	21

#	Article	IF	CITATIONS
1805	Value of Live Donor Liver Transplantation Experience in Major Hepatectomy for Hepatocellular Carcinoma. Archives of Surgery, 2003, 138, 265.	2.3	17
1806	Using a General Internal Medicine Consult Service to Teach Residents and Care for Patients. American Journal of the Medical Sciences, 2003, 326, 73-78.	0.4	3
1807	Hepatic Resection for Bilobar Hepatocellular Carcinoma. Archives of Surgery, 2003, 138, 100.	2.3	41
1808	A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood, 2003, 102, 78-82.	0.6	119
1809	Serum Insulin-Like Growth Factor-II and α-Fetoprotein as Tumor Markers of Hepatocellular Carcinoma. Tumor Biology, 2003, 24, 291-298.	0.8	36
1810	Bacterial infections associated with hepatic encephalopathy: Prevalence and outcome. Annals of Hepatology, 2003, 2, 41-45.	0.6	36
1811	Renal Impairment after Spontaneous Bacterial Peritonitis: Incidence and Prognosis. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 187-190.	1.8	36
1812	Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. American Journal of Clinical Nutrition, 2003, 77, 1269-1277.	2.2	49
1813	Pharmacokinetic Analysis of Rapacuronium and Its Metabolite During Liver Transplantation: An Assessment of Its Potential as a Pharmacodynamic Probe. Baylor University Medical Center Proceedings, 2003, 16, 275-279.	0.2	1
1814	Avaliação do eixo hipotálamo-hipófise-gônada e prevalência de hipogonadismo central em homens e mulheres com cirrose hepática. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 593-600.	1.3	2
1815	Hip arthroplasty in patients with cirrhosis of the liver. Journal of Bone and Joint Surgery: British Volume, 2003, 85-B, 818-821.	3.4	44
1816	Spider angiomas in patients with liver cirrhosis: Role of vascular endothelial growth factor and basic fibroblast growth factor. World Journal of Gastroenterology, 2003, 9, 2832.	1.4	53
1817	Low bone mineral density in noncholestatic liver cirrhosis: prevalence, severity and prediction. Arquivos De Gastroenterologia, 2003, 40, 152-158.	0.3	7
1818	Influence of nutritional status on alcoholic myopathy. American Journal of Clinical Nutrition, 2003, 78, 326-333.	2.2	30
1819	The Prognosis of Liver Cirrhosis in Recent Years in Korea. Journal of Korean Medical Science, 2003, 18, 833.	1.1	45
1821	Thrombocytosis: A paraneoplastic syndrome in patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2004, 10, 2472.	1.4	88
1822	Non-pulsatile hepatic and portal vein waveforms in patients with liver cirrhosis: concordant and discordant relationships. British Journal of Radiology, 2004, 77, 547-550.	1.0	16
1824	The role of vasoactive drugs in the treatment of oesophageal varices. Expert Opinion on Pharmacotherapy, 2004, 5, 349-360.	0.9	13

#	Article	IF	CITATIONS
1825	Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arquivos De Gastroenterologia, 2004, 41, 180-184.	0.3	36
1827	Survival and Prognostic Factors in Patients with Hepatocellular Carcinoma Treated by Percutaneous Ethanol Injection: A 10-Year Experience. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 611-618.	1.8	15
1828	Comparison of Superparamagnetic Iron Oxide–Enhanced and Gadobenate Dimeglumine–Enhanced Dynamic MRI for Detection of Small Hepatocellular Carcinomas. American Journal of Roentgenology, 2004, 182, 1217-1223.	1.0	43
1829	Bilateral diploic arteriovenous fistula causing scalp hematoma. Journal of Neurosurgery, 2004, 100, 950-955.	0.9	12
1830	Impact of Preoperative Fine-needle Aspiration Cytologic Examination on Clinical Outcome in Patients With Hepatocellular Carcinoma in a Tertiary Referral Center. Archives of Surgery, 2004, 139, 193.	2.3	31
1831	The Natural History of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis and Mild Portal Hypertension. American Journal of Gastroenterology, 2004, 99, 1959-1965.	0.2	98
1832	Impact of Chronic Hepatitis B Virus (HBV) Infection on Outcomes of Patients Infected with HIV in an Area Where HBV Infection Is Hyperendemic. Clinical Infectious Diseases, 2004, 38, 1471-1477.	2.9	78
1833	Prevalence of Î ² 2-Glycoprotein I Antibody in Patients with Liver Cirrhosis: Relationship with Î ² 2-Glycoprotein I Plasma Levels and Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 183-186.	0.7	3
1834	Serum Metabolite/Caffeine Ratios as a Test for Liver Function. Journal of Clinical Pharmacology, 2004, 44, 338-347.	1.0	31
1835	Extrahepatic Spread from Hepatocellular Carcinoma: Who are Candidates for Aggressive Anti-cancer Treatment?. Japanese Journal of Clinical Oncology, 2004, 34, 733-739.	0.6	31
1836	Outcome Prediction for Critically III Cirrhotic Patients: A Comparison of APACHE II and Child-Pugh Scoring Systems. Journal of Intensive Care Medicine, 2004, 19, 105-110.	1.3	58
1837	Psychomotor Slowing in Hepatitis C and HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 131-137.	0.9	59
1838	Osteoporosis, Mineral Metabolism, and Serum Soluble Tumor Necrosis Factor Receptor p55 in Viral Cirrhosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4325-4330.	1.8	87
1839	Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliative Medicine, 2004, 18, 93-99.	1.3	36
1840	Surveillance for Hepatocellular Carcinoma in Elderly Italian Patients With Cirrhosis: Effects on Cancer Staging and Patient Survival. American Journal of Gastroenterology, 2004, 99, 1470-1476.	0.2	116
1841	Clinical Course of Lamivudine Monotherapy in Patients with Decompensated Cirrhosis due to HBeAg negative chronic HBV infection. American Journal of Gastroenterology, 2004, 99, 57-63.	0.2	71
1842	Differential Mechanism and Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma Undergoing Surgical and Nonsurgical Treatment. American Journal of Gastroenterology, 2004, 99, 1479-1487.	0.2	58
1843	Surgical Management of Hepatic Malignancy. Cancer Investigation, 2004, 22, 283-303.	0.6	18

#	Article	IF	Citations
1844	Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. Annals of Oncology, 2004, 15, 775-780.	0.6	22
1845	Optimal timing for living-related liver transplantation in children. Clinical Transplantation, 2004, 18, 497-501.	0.8	12
1846	The value of the PRISM scores in comparing pediatric liver transplant outcomes. Pediatric Transplantation, 2004, 8, 208-209.	0.5	1
1847	Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transplant International, 2004, 17, 31-38.	0.8	22
1848	Renal resistive indexes and some renal functions in liver cirrhotic children. Pediatrics International, 2004, 46, 67-71.	0.2	7
1849	Intraoperative blood transfusion requirement is the main determinant of early surgical re-intervention after orthotopic liver transplantation. Transplant International, 2004, 17, 673-679.	0.8	4
1850	Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 327-332.	1.4	18
1851	Role of zinc in subclinical hepatic encephalopathy: Comparison with somatosensory-evoked potentials. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 375-379.	1.4	16
1852	Propranolol alone may not be acceptable to prevent first esophageal variceal bleeding in Japanese cirrhotic patients: Randomized controlled trial. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 576-581.	1.4	5
1853	Correlation between plasma levels of matrix metalloproteinase (MMP)-9 /MMP-2 ratio and alpha-fetoproteins in chronic hepatitis carrying hepatitis B virus. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 565-571.	1.4	26
1854	Clinical significance of variceal hemorrhage in recent years in patients with liver cirrhosis and esophageal varices. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1042-1051.	1.4	23
1855	Many staging systems for hepatocellular carcinoma: Evolution from Child-Pugh, Okuda to SLiDe. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1227-1232.	1.4	20
1856	Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1423-1426.	1.4	13
1857	Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. British Journal of Clinical Pharmacology, 2004, 58, 9-17.	1.1	17
1858	The safety and tolerability of donepezil in patients with Alzheimer's disease. British Journal of Clinical Pharmacology, 2004, 58, 1-8.	1.1	89
1859	Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Alimentary Pharmacology and Therapeutics, 2004, 19, 999-1007.	1.9	43
1860	An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. Journal of Internal Medicine, 2004, 256, 63-69.	2.7	52
1861	Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver International, 2004, 24, 21-28.	1.9	79

#	Article	IF	CITATIONS
1862	Liver transplantation in the era of model for end-stage liver disease. Liver International, 2004, 24, 1-8.	1.9	34
1863	Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver International, 2004, 24, 210-215.	1.9	60
1864	Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver International, 2004, 24, 477-483.	1.9	73
1865	Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?*. Liver International, 2004, 24, 465-470.	1.9	30
1866	Circulating concentrations of interleukin-18, interleukin-18 binding protein, and gamma interferon in patients with alcoholic hepatitis. Liver International, 2004, 24, 582-587.	1.9	18
1867	Clinical Characteristics of Portal Hemodynamics in Alcoholic Liver Cirrhosis. Alcoholism: Clinical and Experimental Research, 2004, 28, 148S-152S.	1.4	7
1868	Serum Ceruloplasmin and Ferroxidase Activity Are Not Decreased in Hepatic Failure Related to Alcoholic Cirrhosis: Clinical and Pathophysiological Implications. Alcoholism: Clinical and Experimental Research, 2004, 28, 775-779.	1.4	20
1869	Improving liver allocation: MELD and PELD. American Journal of Transplantation, 2004, 4, 114-131.	2.6	227
1870	Comparative Analysis of Outcome Following Liver Transplantation in US Veterans. American Journal of Transplantation, 2004, 4, 788-795.	2.6	19
1871	Competing Risks Analysis of Predictors of Delisting Owing to Tumor Progression in Liver Transplant Candidates with Hepatocellular Carcinoma. American Journal of Transplantation, 2004, 4, 774-781.	2.6	29
1872	Selective use of diagnostic laparoscopy prior to planned hepatectomy for patients with hepatocellular carcinoma. Surgery, 2004, 135, 273-281.	1.0	34
1873	Neoplasms of the liver and the bile ducts. Seminars in Roentgenology, 2004, 39, 412-427.	0.2	11
1874	Effects of prolonged oral nutritional support in malnourished cirrhotic patients: results of a pilot study. Gastroenterologie Clinique Et Biologique, 2004, 28, 36-39.	0.9	21
1875	Increased oro-cecal transit time in grade I or II hepatic encephalopathy. Gastroenterologie Clinique Et Biologique, 2004, 28, 1240-1244.	0.9	9
1878	Follow-up of Adverse Drug Reactions from Peginterferon alfa-2b–Ribavirin Therapy. Pharmacotherapy, 2004, 24, 1546-1553.	1.2	30
1879	Anesthesia for liver transplant surgery. Anesthesiology Clinics, 2004, 22, 687-711.	1.4	87
1880	Radiofrequency thermal ablation with expandable needle of focal liver malignancies: complication report. European Radiology, 2004, 14, 31-37.	2.3	82
1881	Laparoscopic liver resections for hepatocellular carcinoma (HCC) in cirrhotic patients. Hpb, 2004, 6, 236-246.	0.1	46

#	Article	IF	CITATIONS
1882	Plasma Trace Elements, Vitamin B12, Folate, and Homocysteine Levels in Cirrhotic Patients Compared to Healthy Controls. Biochemistry (Moscow), 2004, 69, 693-696.	0.7	18
1883	Helicobacter pylori density and cagA status in cirrhotic patients: A case-control study. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1174-1178.	1.4	8
1884	CASE REPORT: Successful Balloon-Occluded Retrograde Transvenous Obliteration for Ruptured Gastric Fundal Varices in a Patient with Child–Pugh C Cirrhosis: Case Report and Literature Review. Digestive Diseases and Sciences, 2004, 49, 270-274.	1.1	1
1885	High Ascitic Fluid Leptin Levels in Patients with Decompensated Liver Cirrhosis and Sterile Ascites: Relationship with TNF-Â Levels. Digestive Diseases and Sciences, 2004, 49, 275-280.	1.1	7
1886	Prognostic Index of Cirrhotic Patients with Hepatic Encephalopathy with and Without Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2004, 49, 1174-1180.	1.1	15
1887	Changes in Brain Size in Hepatic Encephalopathy: A Coregistered MRI Study. Metabolic Brain Disease, 2004, 19, 431-445.	1.4	22
1888	Health status versus utilities of patients with end-stage liver disease. Quality of Life Research, 2004, 13, 773-782.	1.5	29
1889	Severe chronic pancreatitis and severe liver cirrhosis have different frequencies and are independent risk factors in male Japanese alcoholics. Journal of Gastroenterology, 2004, 39, 879-887.	2.3	41
1890	Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis. Journal of Gastroenterology, 2004, 39, 1078-1084.	2.3	10
1891	Serum hyaluronan as a marker reflecting the severity of cirrhosis and portal hypertension in postoperative biliary atresia. Pediatric Surgery International, 2004, 20, 773-777.	0.6	9
1892	Opsonophagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factor-α and lipopolysaccharide in patients' blood. Journal of Infection and Chemotherapy, 2004, 10, 200-207.	0.8	52
1893	Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1468-1476.	0.4	173
1894	Alterations in thyroid Doppler arterial resistance indices, volume and hormones in cirrhosis: relationships with splanchnic haemodynamics. Ultrasound in Medicine and Biology, 2004, 30, 19-25.	0.7	8
1895	Simulating the Allocation of Organs for Transplantation. Health Care Management Science, 2004, 7, 331-338.	1.5	71
1897	Deterioration of Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma after Resection: Incidence, Risk Factors, and Association with Intrahepatic Tumor Recurrence. World Journal of Surgery, 2004, 28, 258-262.	0.8	28
1898	Risk Factors for Postoperative Delirium after Liver Resection for Hepatocellular Carcinoma. World Journal of Surgery, 2004, 28, 982-986.	0.8	84
1899	Serum Hyaluronate Level for Predicting Subclinical Liver Dysfunction after Hepatectomy. World Journal of Surgery, 2004, 28, 971-976.	0.8	31
1900	The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemotherapy and Pharmacology, 2004, 53, 475-481.	1.1	23

#	ARTICLE	IF	CITATIONS
1901	Key research issues in the management of hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S87-90.	1.1	3
1902	Does intubation really equal death in cirrhotic patients? Factors influencing outcome in patients with liver cirrhosis requiring mechanical ventilation. Intensive Care Medicine, 2004, 30, 1564-71.	3.9	73
1903	Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transplant International, 2004, 17, 31-38.	0.8	24
1904	Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study. BMC Gastroenterology, 2004, 4, 23.	0.8	26
1905	Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology, 2004, 39, 230-238.	3.6	99
1906	Increased duodenal expression of divalent metal transporter 1 and iron-regulated gene 1 in cirrhosis. Hepatology, 2004, 39, 492-499.	3.6	16
1907	Minimal hepatic encephalopathy impairs fitness to drive. Hepatology, 2004, 39, 739-745.	3.6	262
1908	Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials. Hepatology, 2004, 39, 592-598.	3.6	60
1909	Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial. Hepatology, 2004, 39, 746-753.	3.6	390
1910	Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology, 2004, 39, 1441-1449.	3.6	578
1911	Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology, 2004, 40, 65-72.	3.6	196
1912	Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis. Hepatology, 2004, 40, 73-79.	3.6	107
1913	Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology, 2004, 40, 652-659.	3.6	681
1914	Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology, 2004, 40, 667-676.	3.6	822
1915	Low-grade steatosis and major changes in portal flow as new prognostic factors in steroid-treated alcoholic hepatitis. Hepatology, 2004, 40, 1370-1378.	3.6	37
1916	Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology, 2004, 40, 1396-1405.	3.6	342
1917	Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000. Cancer, 2004, 100, 2415-2421.	2.0	42
1918	Clinical application of Nd:YAG laser for the treatment of small hepatocellular carcinoma with new shaped laser probe. Lasers in Surgery and Medicine, 2004, 35, 135-139.	1.1	6

#	Article	IF	CITATIONS
1919	Randomized trial comparing pulmonary alterations after conventional with venovenous bypass versus piggyback liver transplantation. Liver Transplantation, 2004, 10, 425-433.	1.3	24
1920	Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transplantation, 2004, 10, 418-424.	1.3	115
1921	Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transplantation, 2004, 10, 1109-1119.	1.3	272
1922	Binding of bilirubin and bromosulphthalein to albumin: Implications for understanding the pathophysiology of liver failure and its management. Liver Transplantation, 2004, 10, 1531-1538.	1.3	38
1923	Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: Results of a multicenter study. Journal of Surgical Oncology, 2004, 85, 36-41.	0.8	119
1924	Effect of Mild and Moderate Hepatic Impairment on Azimilide Pharmacokinetics Following Single Dose Oral Administration. Journal of Pharmaceutical Sciences, 2004, 93, 1279-1286.	1.6	2
1925	Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clinical Pharmacology and Therapeutics, 2004, 75, 80-88.	2.3	95
1926	Longâ€term prognosis of patients with alcoholic liver cirrhosis: a 15â€year followâ€up study of 100 Norwegian patients admitted to one unit. Scandinavian Journal of Gastroenterology, 2004, 39, 858-863.	0.6	89
1927	Prognostic index of liver cirrhosis with ascites with and without hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2004, 39, 1272-1279.	0.6	12
1928	Clinical value of increased serum creatinine concentration as predictor of short-term outcome in decompensated cirrhosis. Scandinavian Journal of Gastroenterology, 2004, 39, 1149-1153.	0.6	13
1929	Persistent retention of acetic acid is associated with complete tumour necrosis in patients with hepatocellular carcinoma undergoing percutaneous acetic acid injection. Scandinavian Journal of Gastroenterology, 2004, 39, 168-173.	0.6	7
1930	Recently published papers: clunk-click every trip, smile, but don't stop for a drink on the way. Critical Care, 2004, 8, 408.	2.5	0
1931	Acute Administration of Carvedilol is More Effective than Propranolol Plus Isosorbide-5-Mononitrate in the Reduction of Portal Pressure in Patients with Viral Cirrhosis. American Journal of Gastroenterology, 2004, 99, 1953-1958.	0.2	48
1932	Polytetrafluoroethylene-Covered Stent Grafts for TIPS Procedure: 1-Year Patency and Clinical Results. American Journal of Gastroenterology, 2004, 99, 280-285.	0.2	73
1933	Plasma Ghrelin Concentrations, Food Intake, and Anorexia in Liver Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2136-2141.	1.8	65
1934	Frequency, Clinical Characteristics, and Respiratory Parameters of Hepatopulmonary Syndrome. Mayo Clinic Proceedings, 2004, 79, 42-48.	1.4	109
1936	Predicting outcome after cardiac surgery in patients with cirrhosis: A comparison of Child-Pugh and MELD scores. Clinical Gastroenterology and Hepatology, 2004, 2, 719-723.	2.4	239
1938	Determinants of health-related quality of life in patients with chronic liver diseases. Clinical Gastroenterology and Hepatology, 2004, 2, 157-163.	2.4	95

#	Article	IF	CITATIONS
1939	Preoperative assessment of liver function. Surgical Clinics of North America, 2004, 84, 355-373.	0.5	212
1940	Use of Yttrium-90 Glass Microspheres (TheraSphere) for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology, 2004, 15, 335-345.	0.2	201
1941	Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clinical Gastroenterology and Hepatology, 2004, 2, 820-824.	2.4	73
1943	Current role of portal vein embolization/hepatic artery chemoembolization. Surgical Clinics of North America, 2004, 84, 643-657.	0.5	54
1944	Hepatic Arterial Infusion Chemotherapy with Use of an Implanted Port System in Patients with Advanced Hepatocellular Carcinoma: Prognostic Factors. Journal of Vascular and Interventional Radiology, 2004, 15, 835-841.	0.2	24
1945	chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical) Tj ETQq1	1 0.78431	4 rgBT /Ove

#	Article	IF	CITATIONS
1958	Determination of plasma prothrombin levels by a novel Ca2+-dependent prothrombin activator (CA-1) in patients with chronic liver diseases. Clinica Chimica Acta, 2004, 341, 123-126.	0.5	0
1959	Role of cytokine gene polymorphism and hepatic transforming growth factor \hat{l}^21 expression in recurrent hepatitis C after liver transplantation. Cytokine, 2004, 27, 7-14.	1.4	47
1960	The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. European Journal of Surgical Oncology, 2004, 30, 765-770.	0.5	39
1961	Increased serum soluble tumor necrosis factor receptor levels are associated with insulin resistance in liver cirrhosis. Metabolism: Clinical and Experimental, 2004, 53, 922-926.	1.5	12
1962	Mechanism of dichloroacetate-induced hypolactatemia in humans with or without cirrhosis. Metabolism: Clinical and Experimental, 2004, 53, 1087-1094.	1.5	11
1963	Evaluation of liver function for hepatic resection for hepatocellular carcinoma in the liver with damaged parenchyma. Journal of Surgical Research, 2004, 116, 248-252.	0.8	38
1964	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. Journal of Hepatology, 2004, 40, 124-131.	1.8	161
1965	Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism. Journal of Hepatology, 2004, 40, 228-233.	1.8	114
1966	Inappropriately low angiotensin II generation: a factor determining reduced kidney function and survival in patients with decompensated cirrhosis. Journal of Hepatology, 2004, 40, 417-423.	1.8	13
1967	Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. Journal of Hepatology, 2004, 40, 736-741.	1.8	512
1968	Deficient phospholipase C activity in blood polimorphonuclear neutrophils from patients with liver cirrhosis. Journal of Hepatology, 2004, 40, 749-756.	1.8	25
1969	Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. Journal of Hepatology, 2004, 41, 55-59.	1.8	95
1970	Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. Journal of Hepatology, 2004, 41, 421-426.	1.8	122
1971	Prognostic models including the Child–Pugh, MELD and Mayo risk scores—where are we and where should we go?. Journal of Hepatology, 2004, 41, 344-350.	1.8	132
1972	Clinical outcome after cardiac operations in patients with cirrhosis. Annals of Thoracic Surgery, 2004, 77, 500-505.	0.7	165
1973	Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study. Current Therapeutic Research, 2004, 65, 1-12.	0.5	18
1974	The Budd–Chiari Syndrome. New England Journal of Medicine, 2004, 350, 578-585.	13.9	472
1975	Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointestinal Endoscopy, 2004, 59, 333-338.	0.5	140

#	Article	IF	CITATIONS
1976	A pilot study of 2-octyl cyanoacrylate injection for treatment of gastric fundal varices in humans. Gastrointestinal Endoscopy, 2004, 59, 553-558.	0.5	118
1977	Ileal varices and portal hypertensive ileopathy in patients with cirrhosis and portal hypertension. Gastrointestinal Endoscopy, 2004, 60, 778-783.	0.5	62
1978	The characteristics and the prognosis for patients presenting with actively bleeding esophageal varices at endoscopy. Gastrointestinal Endoscopy, 2004, 60, 714-720.	0.5	27
1979	Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. Journal of Hepatology, 2004, 40, 247-254.	1.8	469
1980	Cirrosis hep?tica. Medicine, 2004, 9, 489-493.	0.0	0
1982	Factor VIII expression in liver disease. Thrombosis and Haemostasis, 2004, 91, 267-275.	1.8	171
1983	New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. European Journal of Gastroenterology and Hepatology, 2004, 16, 743-751.	0.8	62
1984	Surgical Resection Versus Percutaneous Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma on Cirrhotic Liver. Annals of Surgery, 2004, 240, 102-107.	2.1	237
1985	Partial Necrosis on Hepatocellular Carcinoma Nodules Facilitates Tumor Recurrence after Liver Transplantation. Transplantation, 2004, 78, 1780-1786.	0.5	105
1986	Biopsychosocial Predictors of Health-Related Quality of Life in Patients With Chronic Hepatitis C. Psychosomatic Medicine, 2004, 66, 954-958.	1.3	7 3
1987	Moderate Liver Impairment Has No Influence on Daptomycin Pharmacokinetics. Journal of Clinical Pharmacology, 2004, 44, 715-722.	1.0	28
1988	Validation of the German version of the Chronic Liver Disease Questionnaire. European Journal of Gastroenterology and Hepatology, 2004, 16, 599-606.	0.8	55
1989	Preoperative preparation of patients with advanced liver disease. Critical Care Medicine, 2004, 32, S106-S115.	0.4	108
1990	Two-dose Daclizumab Induction Therapy in 209 Liver Transplants: A Single-Center Analysis. Transplantation, 2004, 78, 1212-1217.	0.5	28
1991	TIPS versus paracentesis for cirrhotic patients with refractory ascites., 2004,, CD004889.		29
1992	Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation. Annals of Surgery, 2004, 240, 900-909.	2.1	452
1993	Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study. Anti-Cancer Drugs, 2004, 15, 719-724.	0.7	14
1994	CLIP score as a prognostic indicator for hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2004, 16, 675-680.	0.8	9

#	ARTICLE	IF	CITATIONS
1995	Habitual Betel Quid Chewing and Risk for Hepatocellular Carcinoma Complicating Cirrhosis. Medicine (United States), 2004, 83, 176-187.	0.4	61
1996	Postprandial splanchnic haemodynamic changes in patients with liver cirrhosis and patent paraumbilical vein. European Journal of Gastroenterology and Hepatology, 2004, 16, 1339-1345.	0.8	6
1997	Cerebral Oxygen Extraction and Autoregulation during Extracorporeal Whole Body Hyperthermia in Humans. Anesthesiology, 2004, 100, 1101-1107.	1.3	18
1998	Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts. Journal of Clinical Gastroenterology, 2004, 38, 590-594.	1.1	31
2000	Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. Clinical Science, 2004, 106, 27-34.	1.8	23
2001	Minimal Hepatic Encephalopathy. Archives of Neurology, 2004, 61, 242.	4.9	68
2002	Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E82-E89.	1.8	138
2003	Longitudinal Modifications of the MELD Score Have Prognostic Meaning in Patients With Liver Cirrhosis. Journal of Clinical Gastroenterology, 2005, 39, 912-914.	1.1	11
2004	In VivoMetabolic Activity of CYP2C19 and CYP3A in Relation to CYP2C19 Genetic Polymorphism in Chronic Liver Disease. Journal of Clinical Pharmacology, 2005, 45, 1221-1229.	1.0	40
2005	Beta Blocker Prophylaxis for Patients With Variceal Hemorrhage. Journal of Clinical Gastroenterology, 2005, 39, 435-440.	1.1	26
2006	Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases. Journal of Clinical Gastroenterology, 2005, 39, 540-543.	1.1	406
2007	Diagnostic Usefulness of Carbohydrate Antigen-125 in Cancerous and Noncancerous Peritoneal Effusions. Tohoku Journal of Experimental Medicine, 2005, 205, 11-18.	0.5	6
2008	Value of Doppler Sonography in Assessing the Progression of Chronic Viral Hepatitis and in the Diagnosis and Grading of Cirrhosis. Journal of Ultrasound in Medicine, 2005, 24, 311-321.	0.8	43
2009	Transjugular intrahepatic portosystemic stent shunt: 11 years?? experience at a regional referral centre. European Journal of Gastroenterology and Hepatology, 2005, 17, 1165-1171.	0.8	18
2010	Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood, 2005, 105, 4527-4531.	0.6	138
2011	Portopulmonary Hypertension. Circulation Journal, 2005, 69, 1386-1393.	0.7	5
2012	Current Management of Portal Hypertension. Journal of Gastrointestinal Surgery, 2005, 9, 992-1005.	0.9	62
2013	Hepatic Resection of Hepatocellular Carcinoma in Patients With Cirrhosis: Model of End-Stage Liver Disease (MELD) Score Predicts Perioperative Mortality. Journal of Gastrointestinal Surgery, 2005, 9, 1207-1215.	0.9	216

#	Article	IF	CITATIONS
2014	Clinical comparison of branched-chain amino acid (-Leucine, -Isoleucine, -Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV–EN study). Hepatology Research, 2005, 31, 232-240.	1.8	47
2015	Apoptosis of blood mononuclear cells in alcoholic liver cirrhosis. Toxicology, 2005, 212, 124-134.	2.0	18
2016	Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh) Tj ETQq0 0 0 rg Therapeutics, 2005, 77, 529-541.	BT /Overlo 2.3	ock 10 Tf 50 56
2017	Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database. Annals of Surgical Oncology, 2005, 12, 364-373.	0.7	226
2018	Surgical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinical Reviews in Allergy and Immunology, 2005, 28, 167-174.	2.9	2
2019	Surgical treatment of hepatocellular carcinoma. Hpb, 2005, 7, 42-49.	0.1	126
2020	Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: Longâ€ŧerm outcomes. Hpb, 2005, 7, 214-221.	0.1	59
2021	A Randomized Control Trial of Bi-Monthly Versus Bi-Weekly Endoscopic Variceal Ligation of Esophageal Varices. American Journal of Gastroenterology, 2005, 100, 2005-2009.	0.2	7 5
2022	Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver International, 2005, 25, 331-336.	1.9	49
2023	Equilibrium of acidifying and alkalinizing metabolic acid-base disorders in cirrhosis Liver International, 2005, 25, 505-512.	1.9	29
2024	Hyperhomocysteinaemia in chronic liver diseases: role of disease stage, vitamin status and methylenetetrahydrofolate reductase genetics. Liver International, 2005, 25, 49-56.	1.9	55
2025	Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis Liver International, 2005, 25, 787-795.	1.9	20
2026	Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver International, 2005, 25, 305-310.	1.9	42
2027	Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver International, 2005, 25, 848-853.	1.9	63
2028	Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver International, 2005, 25, 954-961.	1.9	33
2029	Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabetic Medicine, 2005, 22, 1530-1535.	1.2	43
2030	MELD score versus conventional UNOS status in predicting short-term mortality after liver transplantation*. Transplant International, 2005, 18, 65-72.	0.8	21
2031	Endoscopic variceal ligation of patients with liver cirrhosis and cirrhosis accompanied by hepatocellular carcinoma. Digestive Endoscopy, 2005, 17, 143-147.	1.3	0

#	Article	IF	CITATIONS
2032	Therapeutic efficacy of isosorbide dinitrate for dysphagia after endoscopic injection sclerotherapy for varices in cirrhotic patients. Digestive Endoscopy, 2005, 17, 148-152.	1.3	0
2033	Predictors of death on the waiting list for liver transplantation characterized by a long waiting time. Transplant International, 2005, 18, 572-576.	0.8	22
2034	The optimal timing of liver transplantation in patients with chronic cholestatic liver disease. Transplant International, 2005, 18, 937-940.	0.8	3
2035	Effect of liver cirrhosis on body composition: Evidence of significant depletion even in mild disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 209-216.	1.4	68
2036	IMPACT OF TUMOR FACTORS ON THE PROGNOSIS OF PATIENTS WITH ADVANCED CIRRHOSIS (CHILD–PUGH) 2005, 20, 963-965.	Tj ETQq0 (1.4	O 0 rgBT /O\ 4
2037	Budd-Chiari syndrome: Long-term effect on outcome with transjugular intrahepatic portosystemic shunt. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1494-1502.	1.4	47
2038	Brain natriuretic peptide and severity of disease in nonâ€alcoholic cirrhotic patients. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1115-1120.	1.4	60
2039	Prognostic potential of hepatocyte volume and cytokine expression in cirrhotic portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1519-1526.	1.4	1
2040	Evidence of a dynamic aldosteroneâ€independent distal tubular control of renal sodium excretion in compensated liver cirrhosis*. Journal of Internal Medicine, 2005, 257, 358-366.	2.7	7
2041	The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. British Journal of Clinical Pharmacology, 2005, 59, 160-166.	1.1	16
2042	Validity of 13C-phenylalanine breath test to evaluate functional capacity of hepatocyte in patients with liver cirrhosis and acute hepatitis. Alimentary Pharmacology and Therapeutics, 2005, 21, 851-859.	1.9	15
2043	Factors predisposing to peptic ulcer disease in asymptomatic cirrhotic patients. Alimentary Pharmacology and Therapeutics, 2005, 21, 1459-1465.	1.9	26
2044	The 13C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Alimentary Pharmacology and Therapeutics, 2005, 22, 395-403.	1.9	23
2045	Systematic review: the model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?. Alimentary Pharmacology and Therapeutics, 2005, 22, 1079-1089.	1.9	351
2046	Assessment of sexual functions in patients with chronic liver disease. International Journal of Impotence Research, 2005, 17, 343-345.	1.0	36
2047	Decreased Activity of Plasma ADAMTS13 May Contribute to the Development of Liver Disturbance and Multiorgan Failure in Patients with Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 2005, 29, 264S-71S.	1.4	31
2048	Prospective cohort study comparing sequential organ failure assessment and acute physiology, age, chronic health evaluation III scoring systems for hospital mortality prediction in critically ill cirrhotic patients. International Journal of Clinical Practice, 2005, 60, 160-166.	0.8	46
2049	Feature selection in Bayesian classifiers for the prognosis of survival of cirrhotic patients treated with TIPS. Journal of Biomedical Informatics, 2005, 38, 376-388.	2.5	69

#	Article	IF	CITATIONS
2050	Necrotising fasciitis: clinical features in patients with liver cirrhosis. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2005, 58, 702-707.	1.1	52
2051	The Impact of Pre-Operative Loco-Regional Therapy on Outcome After Liver Transplantation for Hepatocellular Carcinoma. American Journal of Transplantation, 2005, 5, 795-804.	2.6	169
2052	Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. Translational Research, 2005, 146, 238-243.	2.4	53
2053	Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. Translational Research, 2005, 146, 347-351.	2.4	103
2054	The current status of living donor liver transplantation. Current Problems in Surgery, 2005, 42, 144-183.	0.6	14
2055	Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology, 2005, 41, 32-39.	3.6	360
2056	Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology, 2005, 41, 553-558.	3.6	617
2057	AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology, 2005, 41, 1407-1432.	3.6	735
2058	Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. Hepatology, 2005, 42, 27-34.	3.6	410
2059	Disruption of smooth pursuit eye movements in cirrhosis: Relationship to hepatic encephalopathy and its treatment. Hepatology, 2005, 42, 772-781.	3.6	26
2060	Management of hepatocellular carcinoma. Hepatology, 2005, 42, 1208-1236.	3.6	5,426
2061	A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer, 2005, 103, 756-762.	2.0	71
2062	Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer, 2005, 104, 794-801.	2.0	99
2063	Early experience with the Boerema button for bleeding oesophageal varices. British Journal of Surgery, 2005, 63, 117-121.	0.1	15
2064	Clinical experience with silicone rubber grafts as shunts in portal hypertension. British Journal of Surgery, 2005, 65, 585-587.	0.1	0
2065	Long term follow-up of interposition mesocaval shunting in portal hypertension. British Journal of Surgery, 2005, 68, 485-487.	0.1	26
2066	â€~Currents and clots'—an approach to the problem of acute variceal bleeding. British Journal of Surgery, 2005, 68, 692-696.	0.1	6
2067	The acute treatment of haemorrhage from oesophageal varices: A comparison of oesophageal transection and staple gun anastomosis with mesocaval shunt. British Journal of Surgery, 2005, 68, 734-737.	0.1	38

#	ARTICLE	IF	Citations
2068	Tamponade and injection sclerotherapy in the management of bleeding oesophageal varices. British Journal of Surgery, 2005, 69, 76-78.	0.1	166
2069	A new posterior exposure of the splenic vein for an H-graft splenorenal shunt. British Journal of Surgery, 2005, 69, 376-379.	0.1	7
2070	Randomized controlled trial of injection sclerotherapy for bleeding oesophageal varices—an interim report. British Journal of Surgery, 2005, 70, 20-22.	0.1	52
2071	Prediction of outcome following acute variceal haemorrhage. British Journal of Surgery, 2005, 72, 91-95.	0.1	74
2072	Injection sclerotherapy of oesophageal varices with the freehand technique: Experience in Hong Kong. British Journal of Surgery, 2005, 73, 193-195.	0.1	7
2073	Distal splenorenal (Warren) shunt in the management of actively bleeding oesophageal varices. British Journal of Surgery, 2005, 73, 618-620.	0.1	9
2074	Prospective randomized trial comparing two injection techniques for sclerosing oesophageal varices: Over-tube and free-hand. British Journal of Surgery, 2005, 74, 603-606.	0.1	19
2075	Trial of sclerosing agents in patients with oesophageal varices. British Journal of Surgery, 2005, 75, 751-753.	0.1	40
2076	Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices: A prospective randomized trial. British Journal of Surgery, 2005, 76, 715-718.	0.1	45
2077	Platelet aggregability after endoscopic intravariceal injection of 5 per cent ethanolamine oleate into oesophageal varices. British Journal of Surgery, 2005, 76, 939-942.	0.1	0
2078	Eradication of oesophageal varices recurring after portal non-decompressive surgery by injection sclerotherapy. British Journal of Surgery, 2005, 77, 940-943.	0.1	9
2079	Injection sclerotherapy for bleeding varices: Risk factors and complications. British Journal of Surgery, 2005, 78, 1098-1101.	0.1	6
2080	Staple-line erosion: A common source of recurrent bleeding following stapled oesophageal transection. British Journal of Surgery, 2005, 78, 1355-1357.	0.1	7
2081	Emergency liver resection for spontaneous rupture of hepatocellular carcinoma complicating cirrhosis. British Journal of Surgery, 2005, 80, 747-749.	0.1	65
2082	Results of major hepatectomy for large primary liver cancer in patients with cirrhosis. British Journal of Surgery, 2005, 81, 427-431.	0.1	59
2083	Emergency oesophageal transection for uncontrolled variceal haemorrhage. British Journal of Surgery, 2005, 81, 992-995.	0.1	15
2084	Emergency transjugular intrahepatic portasystemic stent shunting as salvage treatment for uncontrolled variceal bleeding. British Journal of Surgery, 2005, 81, 1324-1327.	0.1	108
2085	Hepatectomy with an ultrasonic dissector for hepatocellular carcinoma. British Journal of Surgery, 2005, 83, 117-120.	0.1	115

#	ARTICLE	IF	CITATIONS
2086	Liver resection for hepatocellular carcinoma in patients with cirrhosis. British Journal of Surgery, 2005, 92, 348-355.	0.1	101
2087	MELD fails to measure quality of life in liver transplant candidates. Liver Transplantation, 2005, 11, 218-223.	1.3	113
2088	Intraoperative direct measurement of hepatic arterial buffer response in patients with or without cirrhosis. Liver Transplantation, 2005, 11 , $684-691$.	1.3	49
2089	Ablation therapy in containing extension of hepatocellular carcinoma: A simulative analysis of dropout from the waiting list for liver transplantation. Liver Transplantation, 2005, 11, 508-514.	1.3	20
2090	Evaluation for liver transplantation: Adherence to AASLD referral guidelines in a large veterans affairs center. Liver Transplantation, 2005, 11, 1370-1378.	1.3	93
2091	Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplantation, 2005, 11, 895-900.	1.3	224
2092	Variceal hemorrhage and cystic fibrosis: Outcomes and implications for liver transplantation. Liver Transplantation, 2005, 11, 1522-1526.	1.3	59
2093	Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transplantation, 2005, 11, 1117-1126.	1.3	204
2094	Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplantation, 2005, 11, 973-979.	1.3	251
2095	A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transplantation, 2005, 11, 1505-1514.	1.3	272
2096	Indication of Hepatectomy for Cirrhotic Patients with Hepatocellular Carcinoma Classified as Child-Pugh Class B. World Journal of Surgery, 2005, 29, 734-738.	0.8	16
2097	Hepatectomy as Treatment of Choice for Hepatocellular Carcinoma in Elderly Cirrhotic Patients. World Journal of Surgery, 2005, 29, 1101-1105.	0.8	84
2098	Intraoperative blood transfusion requirement is the main determinant of early surgical re-intervention after orthotopic liver transplantation. Transplant International, 2005, 17, 673-679.	0.8	120
2099	Epidemiology and natural history of hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 3-23.	1.0	303
2100	Assessment of hepatic reserve for indication of hepatic resection: how I do it. Journal of Hepato-Biliary-Pancreatic Surgery, 2005, 12, 31-37.	2.0	67
2101	Assessment of hepatic reserve for the indication of hepatic resection: how I do it. Journal of Hepato-Biliary-Pancreatic Surgery, 2005, 12, 27-30.	2.0	13
2102	Assessment of hepatic reserve prior to hepatic resection. Journal of Hepato-Biliary-Pancreatic Surgery, 2005, 12, 10-15.	2.0	22
2103	Risk factors for early death after liver resection in patients with solitary hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery, 2005, 12, 399-404.	2.0	46

#	Article	IF	CITATIONS
2104	Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. Journal of Gastroenterology, 2005, 40, 70-78.	2.3	61
2105	Percutaneous radiofrequency ablation with cooled electrodes combined with hepatic arterial balloon occlusion in hepatocellular carcinoma. Journal of Gastroenterology, 2005, 40, 171-178.	2.3	29
2106	Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. Journal of Gastroenterology, 2005, 40, 274-282.	2.3	22
2107	Emergency balloon-occluded retrograde transvenous obliteration for gastric varices. Journal of Gastroenterology, 2005, 40, 964-971.	2.3	58
2108	Use of the Six-Shooter Ligation Device in the Management of Bleeding Esophageal Varices: A Developing-Country Experience. Digestive Diseases and Sciences, 2005, 50, 394-398.	1.1	7
2109	Loss of Tubuloglomerular Feedback in Decompensated Liver Cirrhosis: Physiopathological Implications. Digestive Diseases and Sciences, 2005, 50, 955-963.	1.1	15
2110	Evaluation of Endoscopic Variceal Ligation (EVL) Versus Propanolol Plus Isosorbide Mononitrate/Nadolol (ISMN) in the Prevention of Variceal Rebleeding: Comparison of Cirrhotic and Noncirrhotic Patients. Digestive Diseases and Sciences, 2005, 50, 1538-1547.	1,1	45
2111	Whole Blood and Red Blood Cell Manganese Reflected Signal Intensities of T1â€Weighted Magnetic Resonance Images better than Plasma Manganese in Liver Cirrhotics. Journal of Occupational Health, 2005, 47, 68-73.	1.0	32
2112	Antimicrobial Therapy in Patients with Acute Variceal Hemorrhage. Canadian Journal of Gastroenterology & Hepatology, 2005, 19, 607-611.	1.8	8
2113	Pharmacokinetics of Adefovir after Oral Administration of Adefovir Dipivoxil 10 mg in Healthy Japanese Males and Japanese Patients with Chronic Hepatitis B. Japanese Journal of Clinical Pharmacology and Therapeutics, 2005, 36, 289-296.	0.1	0
2114	A new insight into the differences among non-cirrhotic and cirrhotic patients using the liver disease quality of life instrument (LDQOL). Annals of Hepatology, 2005, 4, 264-271.	0.6	21
2115	MELD <i>vs</i> Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. World Journal of Gastroenterology, 2005, 11, 3099.	1.4	81
2116	Primary sclerosing cholangitis: Updates in diagnosis and therapy. World Journal of Gastroenterology, 2005, 11, 7.	1.4	30
2117	Etiology and functional status of liver cirrhosis by ³¹ P MR spectroscopy. World Journal of Gastroenterology, 2005, 11, 6926.	1.4	46
2118	Usefulness of serum des- \hat{l}^3 -carboxy prothrombin in detection of hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 6115.	1.4	83
2119	Dynamic Contrast-Enhanced MRI in the Liver. , 2005, , 239-261.		0
2120	Current Indications, Contraindications, Delisting Criteria, and Timing for Liver Transplantation., 2005, , 95-114.		5
2121	Effects of L-carnitine in patients with hepatic encephalopathy. World Journal of Gastroenterology, 2005, 11, 7197.	1.4	85

#	ARTICLE	IF	CITATIONS
2122	Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: Comparison with Child-Pugh score and serum bile acid levels. World Journal of Gastroenterology, 2005, 11, 142.	1.4	51
2123	Critical Appraisal of the Clinical and Pathologic Predictors of Survival After Resection of Large Hepatocellular Carcinoma. Archives of Surgery, 2005, 140, 450.	2.3	203
2124	ERYTHROCYTE THIAMINE (Th) ESTERS: A MAJOR FACTOR OF THE ALCOHOL WITHDRAWAL SYNDROME OR A CANDIDATE MARKER FOR ALCOHOLISM ITSELF?. Alcohol and Alcoholism, 2005, 40, 283-290.	0.9	7
2125	Comparison of the Usefulness of Three Staging Systems for Hepatocellular Carcinoma (CLIP, BCLC, and) Tj ETQq1	1.0.78431 0.2	14 rgBT /0\ 78
2126	Delivering Care to Injection Drug Users Coinfected with HIV and Hepatitis C Virus. Clinical Infectious Diseases, 2005, 40, S355-S361.	2.9	39
2127	Staging classifications for hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2005, 5, 377-383.	1.5	13
2128	Risk Factors for Invasive Aspergillosis in Solid-Organ Transplant Recipients: A Case-Control Study. Clinical Infectious Diseases, 2005, 41, 52-59.	2.9	286
2129	Proton Beam Therapy for Hepatocellular Carcinoma: A Retrospective Review of 162 Patients. Clinical Cancer Research, 2005, 11, 3799-3805.	3.2	220
2130	Transjugular Intrahepatic Portosystemic Shunts: Adjunctive Embolotherapy of Gastroesophageal Collateral Vessels in the Prevention of Variceal Rebleeding. Radiology, 2005, 236, 360-367.	3.6	115
2131	Esophageal Varices: Evaluation with Esophagography with Barium versus Endoscopic Gastroduodenoscopy in Patients with Compensated Cirrhosis—Blinded Prospective Study. Radiology, 2005, 237, 535-540.	3.6	16
2132	The Evaluation of the Patient Undergoing an Elective Transjugular Intrahepatic Portosystemic Shunt Procedure. Seminars in Interventional Radiology, 2005, 22, 266-270.	0.3	7
2133	Effect of Thalidomide in Hepatocellular Carcinoma: Assessment with Power Doppler US and Analysis of Circulating Angiogenic Factors. Radiology, 2005, 235, 509-516.	3.6	26
2134	Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction. Journal of Clinical Pharmacology, 2005, 45, 1145-1152.	1.0	158
2135	Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected Subjects. Antimicrobial Agents and Chemotherapy, 2005, 49, 643-649.	1.4	50
2136	Endoscopic Variceal Ligation plus Propranolol versus Endoscopic Variceal Ligation Alone in Primary Prophylaxis of Variceal Bleeding. American Journal of Gastroenterology, 2005, 100, 797-804.	0.2	132
2137	Preoperative Assessment of the Patient with Liver Disease. American Journal of Gastroenterology, 2005, 100, 2116-2127.	0.2	42
2138	Cardiac, Neuroadrenergic, and Portal Hemodynamic Effects of Prolonged Aldosterone Blockade in Postviral Child A Cirrhosis. American Journal of Gastroenterology, 2005, 100, 1110-1116.	0.2	62
2139	Long-Term Results of Partial Splenic Artery Embolization as Supplemental Treatment for Portal-Systemic Encephalopathy. American Journal of Gastroenterology, 2005, 100, 43-47.	0.2	67

#	Article	IF	CITATIONS
2140	Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut, 2005, 54, 419-425.	6.1	237
2141	Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2005, 23, 4338-4346.	0.8	127
2142	Is it safe to perform esophagectomy in esophageal cancer patients combined with liver cirrhosis?. Interactive Cardiovascular and Thoracic Surgery, 2005, 4, 423-425.	0.5	35
2143	Prone position reduces lung stress and strain in severe acute respiratory distress syndrome. European Respiratory Journal, 2005, 25, 534-544.	3.1	129
2144	A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2005, 97, 1532-1538.	3.0	567
2145	Infected and Noninfected Ascites in Pediatric Patients. Journal of Pediatric Gastroenterology and Nutrition, 2005, 40, 289-294.	0.9	42
2146	Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension: a capsule endoscopy study. Gastrointestinal Endoscopy, 2005, 62, 529-534.	0.5	168
2147	The effects of eradication of Helicobacter pylori on the recurrence of duodenal ulcers in patients with cirrhosis. Gastrointestinal Endoscopy, 2005, 62, 350-356.	0.5	43
2148	Liver enzyme alteration: a guide for clinicians. Cmaj, 2005, 172, 367-379.	0.9	1,300
2149	Treatment of Alcoholic Hepatitis. Clinics in Liver Disease, 2005, 9, 103-134.	1.0	38
2150	Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival. Journal of Vascular and Interventional Radiology, 2005, 16, 1627-1639.	0.2	392
2151	Transcatheter Arterial Chemoembolization Therapy for Patients With Hepatocellular Carcinoma: A Case-Controlled Study. Clinical Gastroenterology and Hepatology, 2005, 3, 918-925.	2.4	32
2152	Selection Criteria for Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Procedures: Current Status. Journal of Vascular and Interventional Radiology, 2005, 16, 449-455.	0.2	51
2153	Hemostatic Defects in End Stage Liver Disease. Critical Care Clinics, 2005, 21, 563-587.	1.0	90
2154	Effects of Oral Branched-Chain Amino Acid Granules on Event-Free Survival in Patients With Liver Cirrhosis. Clinical Gastroenterology and Hepatology, 2005, 3, 705-713.	2.4	467
2155	Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: Factors Associated with Liver Toxicities. Journal of Vascular and Interventional Radiology, 2005, 16, 205-213.	0.2	175
2156	A randomized controlled trial of acarbose in hepatic encephalopathy. Clinical Gastroenterology and Hepatology, 2005, 3, 184-191.	2.4	116
2157	Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: A Risk-Stratification Analysis. Journal of Vascular and Interventional Radiology, 2005, 16, 195-203.	0.2	114

#	Article	IF	CITATIONS
2158	Characteristics, prognosis and outcome of patients with oesophageal varices in a university hospital in Sweden 1994–1999. Scandinavian Journal of Gastroenterology, 2005, 40, 1462-1468.	0.6	14
2159	Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut, 2005, 54, 411-418.	6.1	215
2160	Effect of Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ranolazine Sustained-Release Tablets. Journal of Clinical Pharmacology, 2005, 45, 802-809.	1.0	43
2161	Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. Journal of Hepatology, 2005, 42, S100-S107.	1.8	481
2162	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. Journal of Hepatology, 2005, 42, 535-540.	1.8	101
2163	Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. Journal of Hepatology, 2005, 43, 142-148.	1.8	106
2164	Developing concepts on MELD: delta and cutoffs. Journal of Hepatology, 2005, 42, 790-792.	1.8	13
2165	Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. Journal of Hepatology, 2005, 43, 310-316.	1.8	44
2166	Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observation. Journal of Hepatology, 2005, 43, 458-464.	1.8	189
2167	The RANKL/OPG system and bone mineral density in patients with chronic liver disease. Journal of Hepatology, 2005, 43, 973-983.	1.8	100
2168	Electroencephalographic staging ofÂhepatic encephalopathy byÂanÂartificial neural network andÂanÂexpert system. Neurophysiologie Clinique, 2005, 35, 162-167.	1.0	6
2169	Heat shock protein 27 expression in patients with chronic liver damage. Immunobiology, 2005, 209, 729-735.	0.8	17
2170	Biopsychosocial predictors of fatigue in chronic hepatitis C. Journal of Psychosomatic Research, 2005, 58, 173-178.	1.2	37
2171	Detecting AFP mRNA in peripheral blood of the patients with hepatocellular carcinoma, liver cirrhosis and hepatitis. Clinica Chimica Acta, 2005, 361, 119-127.	0.5	17
2172	Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis. European Journal of Surgical Oncology, 2005, 31, 882-890.	0.5	24
2173	Role of endoscopy for primary prophylaxis of variceal bleeding. Techniques in Gastrointestinal Endoscopy, 2005, 7, 32-36.	0.3	0
2174	Recurrence Rate and Transplantability After Liver Resection in Patients With Hepatocellular Carcinoma Who Initially Met Transplantation Criteria. Transplantation Proceedings, 2005, 37, 1254-1256.	0.3	27
2175	Operative Risk of Total Hip and Knee Arthroplasty in Cirrhotic Patients. Journal of Arthroplasty, 2005, 20, 460-466.	1.5	76

#	Article	IF	CITATIONS
2176	Cardiac Surgery in Patients With Liver Cirrhosis. Annals of Thoracic Surgery, 2005, 79, 1551-1554.	0.7	57
2177	Indications of partial hepatectomy for transplantable hepatocellular carcinoma with compensated cirrhosis. American Journal of Surgery, 2005, 189, 167-172.	0.9	31
2179	Dose Adjustment in Patients with Liver Disease. Drug Safety, 2005, 28, 529-545.	1.4	198
2180	Population Pharmacokinetics of Olmesartan Following Oral Administration of its Prodrug, Olmesartan Medoxomil. Clinical Pharmacokinetics, 2005, 44, 1329-1342.	1.6	28
2181	Colchicine treatment of alcoholic cirrhosis: A randomized, placebo-controlled clinical trial of patient survival. Gastroenterology, 2005, 128, 882-890.	0.6	57
2182	Uncovered Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-Analysis. Gastroenterology, 2005, 129, 1282-1293.	0.6	209
2183	Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinomaâ [*] †A pilot study. Digestive and Liver Disease, 2005, 37, 254-259.	0.4	7
2184	Psychological status and depression in patients with liver cirrhosis. Digestive and Liver Disease, 2005, 37, 593-600.	0.4	154
2185	Nutritional state and energy balance in cirrhotic patients with or without hypermetabolisma~†Multicentre prospective study by the â€~Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease, 2005, 37, 681-688.	0.4	76
2186	The Effects of Liver and Renal Dysfunction on the Pharmacokinetics of Sedatives and Analgesics in the Critically III Patient. Critical Care Nursing Clinics of North America, 2005, 17, 245-250.	0.4	13
2187	Effect of Long-Term Postoperative Interferon Therapy on Intrahepatic Recurrence and Survival Rate after Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma. Intervirology, 2005, 48, 71-75.	1.2	59
2188	Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2005, 40, 68-75.	0.6	47
2189	Prevalence and Prognostic Significance of the Presence of Esophageal Varices in Patients With Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2006, 4, 1378-1384.	2.4	69
2190	Quantitative EEG Analysis before and after Liver Transplantation. Clinical EEG and Neuroscience, 2006, 37, 34-40.	0.9	8
2191	Current management of the complications of portal hypertension: variceal bleeding and ascites. Cmaj, 2006, 174, 1433-1443.	0.9	55
2192	Effect of the Etiology of Viral Cirrhosis on the Survival of Patients with Hepatocellular Carcinoma. American Journal of Gastroenterology, 2006, 101, 91-98.	0.2	81
2193	Oral Glucose Tolerance Test Predicts Prognosis of Patients with Liver Cirrhosis. American Journal of Gastroenterology, 2006, 101, 70-75.	0.2	140
2194	Neurologic and Non-neurologic Predictors of Mortality in Ischemic Stroke Patients Admitted to the Intensive Care Unit. Journal of the Formosan Medical Association, 2006, 105, 653-658.	0.8	15

#	Article	IF	CITATIONS
2195	Comparison of Endoscopic Variceal Ligation and Nadolol Plus Isosorbide-5-mononitrate in the Prevention of First Variceal Bleeding in Cirrhotic Patients. Journal of the Chinese Medical Association, 2006, 69, 453-460.	0.6	14
2196	The EEG assessment of low-grade hepatic encephalopathy: Comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. Clinical Neurophysiology, 2006, 117, 2243-2251.	0.7	51
2197	Analysis of EEG tracings in frequency and time domain in hepatic encephalopathy. Computer Methods and Programs in Biomedicine, 2006, 81, 203-212.	2.6	11
2198	Alcoholic Hepatitis. Clinics in Liver Disease, 2006, 10, 219-237.	1.0	22
2199	Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers. Clinical Gastroenterology and Hepatology, 2006, 4, 1528-1536.	2.4	97
2200	Impact of Surveillance on Survival of Patients With Initial Hepatocellular Carcinoma: A Study From Japan. Clinical Gastroenterology and Hepatology, 2006, 4, 1170-1176.	2.4	57
2201	Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. Clinical Gastroenterology and Hepatology, 2006, 4, 1395-1402.	2.4	10
2202	Palliative Care for Patients with End-Stage Liver Disease Ineligible for Liver Transplantation. Gastroenterology Clinics of North America, 2006, 35, 201-219.	1.0	50
2203	Usefulness of Artificial Neural Network for Differential Diagnosis of Hepatic Masses on CT Images. Academic Radiology, 2006, 13, 951-962.	1.3	22
2204	Distal Splenorenal Shunt Versus Transjugular Intrahepatic Portal Systematic Shunt for Variceal Bleeding: A Randomized Trial. Gastroenterology, 2006, 130, 1643-1651.	0.6	233
2205	Genomic Decoding of Hepatocellular Carcinoma. Gastroenterology, 2006, 131, 1344-1346.	0.6	14
2206	Clinical Pharmacokinetics of Ranolazine. Clinical Pharmacokinetics, 2006, 45, 469-491.	1.6	134
2207	The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase. Journal of Clinical Pharmacology, 2006, 46, 88-102.	1.0	68
2208	TIPS versus paracentesis for cirrhotic patients with refractory ascites. The Cochrane Library, 2006, , CD004889.	1.5	99
2209	Risk of Recurrence in a Long-term Follow-up After Surgery in 417 Patients With Hepatitis B- or Hepatitis C-Related Hepatocellular Carcinoma. Annals of Surgery, 2006, 244, 771-780.	2.1	142
2210	Ischaemic jejunal vasculitis during treatment with pegylated interferon-alpha 2b and ribavirin for hepatitis C virus related cirrhosis. Digestive and Liver Disease, 2006, 38, 352-354.	0.4	8
2211	The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointestinal Endoscopy, 2006, 64, 855-864.	0.5	94
2212	Causes of death and determinants of outcome in critically ill patients. Critical Care, 2006, 10, R154.	2.5	178

#	Article	IF	Citations
2213	Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Critical Care, 2006, 10, R169.	2.5	121
2214	Lung Cancer Surgery in Patients With Liver Cirrhosis. Annals of Thoracic Surgery, 2006, 82, 1027-1032.	0.7	22
2215	Dental Management of Patients with End-Stage Liver Disease. Dental Clinics of North America, 2006, 50, 563-590.	0.8	20
2216	The incidence of hepatic pseudolesions caused by focal rib compression as seen on multidetector row CT in patients of different hepatic function. European Journal of Radiology, 2006, 57, 108-114.	1.2	2
2217	Evaluation of pathological features of hepatocellular carcinoma by contrast-enhanced ultrasonography: Comparison with pathology on resected specimen. European Journal of Radiology, 2006, 59, 74-81.	1.2	25
2218	Prediction of the risk of hepatic failure in patients with portal vein invasion hepatoma after hepatic resection. European Journal of Surgical Oncology, 2006, 32, 72-76.	0.5	32
2219	Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. Journal of Hepatology, 2006, 44, 310-316.	1.8	19
2220	Cardiac electrophysiological abnormalities in patients with cirrhosis. Journal of Hepatology, 2006, 44, 994-1002.	1.8	141
2221	Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology, 2006, 44, 723-731.	1.8	378
2222	Molecular prognostication of liver cancer: End of the beginning. Journal of Hepatology, 2006, 44, 798-805.	1.8	69
2223	Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. Journal of Hepatology, 2006, 44, 1089-1097.	1.8	47
2224	Antiepileptic drugs and liver disease. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 156-164.	0.9	99
2225	Two-Stage Transjugular Intrahepatic Porta-Systemic Shunt for Patients With Cirrhosis and a High Risk of Portal-Systemic Encephalopathy Patients as a Bridge to Orthotopic Liver Transplantation: A Preliminary Report. Transplantation Proceedings, 2006, 38, 204-208.	0.3	10
2226	Urinary tract infection in non-hospitalized patients with cirrhosis and no symptoms of urinary tract infection: a case series study. Brazilian Journal of Infectious Diseases, 2006, 10, 380-3.	0.3	6
2227	Vitamin A metabolic aspects and alcoholic liver disease. Revista De Nutricao, 2006, 19, 601-610.	0.4	0
2228	Disease-specific health-related quality of life and its determinants in liver cirrhosis patients in Lithuania. World Journal of Gastroenterology, 2006, 12, 7792.	1.4	35
2229	Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. Thrombosis and Haemostasis, 2006, 95, 221-223.	1.8	22
2230	Two-component models are of limited value for the assessment of body composition in patients with cirrhosis. American Journal of Clinical Nutrition, 2006, 84, 1151-1162.	2.2	43

#	Article	IF	CITATIONS
2231	Evaluation of nutritional status of nonhospitalized patients with liver cirrhosis. Arquivos De Gastroenterologia, 2006, 43, 269-274.	0.3	115
2232	Antibiotic Prophylaxis Using Third Generation Cephalosporins Can Reduce the Risk of Early Rebleeding in the First Acute Gastroesophageal Variceal Hemorrhage: A Prospective Randomized Study. Journal of Korean Medical Science, 2006, 21, 883.	1.1	59
2233	Continuous Ambulatory Peritoneal Dialysis in Patients with Hepatitis B Liver Disease. Peritoneal Dialysis International, 2006, 26, 213-217.	1.1	18
2234	Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects With Hepatic Impairment. Journal of Pharmacological Sciences, 2006, 102, 405-412.	1.1	26
2235	Development of Dosage Design of Hepatic Metabolizing Drugs Using Serum Albumin Level in Chronic Hepatic Failure. Biological and Pharmaceutical Bulletin, 2006, 29, 1692-1699.	0.6	7
2236	Accumulation of Symmetric Dimethylarginine in Hepatorenal Syndrome. Experimental Biology and Medicine, 2006, 231, 70-75.	1.1	54
2237	Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania. Epidemiology and Infection, 2006, 134, 95-101.	1.0	23
2238	Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study. European Journal of Gastroenterology and Hepatology, 2006, 18, 713-720.	0.8	18
2239	Predictive Indices of Morbidity and Mortality After Liver Resection. Annals of Surgery, 2006, 243, 373-379.	2.1	299
2240	Liver Transplantation and Recurrent Hepatocellular Carcinoma: Predictive Value of Nodule Size in a Retrospective and Explant Study. Transplantation, 2006, 81, 1532-1541.	0.5	70
2241	Anterior Approach Versus Conventional Approach Right Hepatic Resection for Large Hepatocellular Carcinoma. Annals of Surgery, 2006, 244, 194-203.	2.1	218
2242	Predictive Indices of Morbidity and Mortality After Liver Resection. Annals of Surgery, 2006, 244, 635-637.	2.1	6
2243	Liver Allocation for Hepatocellular Carcinoma: A European Center Policy in the Pre-MELD Era. Transplantation, 2006, 81, 525-530.	0.5	20
2245	Hepatopulmonary syndrome in patients with chronic liver disease: role of pulse oximetry. BMC Gastroenterology, 2006, 6, 15.	0.8	35
2246	The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis. BMC Gastroenterology, 2006, 6, 39.	0.8	13
2247	Nitrogen isotopic composition in hair protein is different in liver cirrhotic patients. Rapid Communications in Mass Spectrometry, 2006, 20, 2973-2978.	0.7	69
2248	Biologie et cirrhose. Revue Francophone Des Laboratoires, 2006, 2006, 65-71.	0.0	3
2249	Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival?. Transplant International, 2006, 19, 275-281.	0.8	49

#	Article	IF	CITATIONS
2250	Analysis of differences in outcome of two European liver transplant centers. Transplant International, 2006, 19, 372-380.	0.8	23
2251	Conventional versus piggyback technique of caval implantation; without extra-corporeal veno-venous bypass. A comparative study. Transplant International, 2006, 19, 795-801.	0.8	37
2252	Is there ileopathy in portal hypertension?. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 392-397.	1.4	16
2253	Relationship between levels of DNA damage in lymphocytes and histopathological severity of chronic hepatitis C and various clinical forms of hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 610-616.	1.4	23
2254	Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 413-419.	1.4	72
2255	Measurement of parenchymal function and bile duct flow in primary sclerosing cholangitis using dynamic 99mTc-HIDA SPECT. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 674-681.	1.4	10
2256	Factors predicting success of endoscopic variceal ligation for secondary prophylaxis of esophageal variceal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 237-241.	1.4	26
2257	Hemorheology in patients with liver cirrhosis: Special emphasis on its relation to severity of esophageal variceal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 908-913.	1.4	16
2258	Clinicopathological study of scirrhous hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 060606032707065-???.	1.4	71
2259	Increased serum and hepatic tissue levels of interleukin-18 in patients with fulminant hepatic failure. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1731-1736.	1.4	15
2260	Factors influencing the prevalence of gallstones in liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 060616025538010-???.	1.4	10
2261	Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. Liver International, 2006, 26, 271-278.	1.9	95
2262	Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver International, 2006, 26, 543-551.	1.9	46
2263	Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver International, 2006, 26, 673-679.	1.9	25
2264	Quality of life in hepatitis C. Liver International, 2006, 26, 755-765.	1.9	65
2265	Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. Journal of Thrombosis and Haemostasis, 2006, 4, 717-720.	1.9	42
2266	Hemostasis in chronic liver disease. Journal of Thrombosis and Haemostasis, 2006, 4, 2064-2065.	1.9	8
2267	Secondary Aeromonas peritonitis is associated with polymicrobial ascites culture and absence of liver cirrhosis compared to primary Aeromonas peritonitis. Apmis, 2006, 114, 772-778.	0.9	15

#	Article	IF	CITATIONS
2268	Risk factors, Sequential Organ Failure Assessment and Model for End-stage Liver Disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Alimentary Pharmacology and Therapeutics, 2006, 23, 883-893.	1.9	232
2269	Review article: scoring systems for assessing prognosis in critically ill adult cirrhotics. Alimentary Pharmacology and Therapeutics, 2006, 24, 453-464.	1.9	143
2270	Nutritional status and prognosis in cirrhotic patients. Alimentary Pharmacology and Therapeutics, 2006, 24, 563-572.	1.9	161
2271	Comparative and integrative functional genomics of HCC. Oncogene, 2006, 25, 3801-3809.	2.6	109
2272	Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine. Clinical Pharmacology and Therapeutics, 2006, 79, 489-499.	2.3	30
2273	Repeated proton beam therapy for hepatocellular carcinoma. International Journal of Radiation Oncology Biology Physics, 2006, 65, 196-202.	0.4	92
2274	Fasting plasma ghrelin levels reflect malnutrition state in patients with liver cirrhosis. Hepatology Research, 2006, 34, 117-123.	1.8	20
2275	Comparison of the grade evaluated by "Liver damage―of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma. Hepatology Research, 2006, 34, 266-272.	1.8	24
2276	A proposal of the modified liver damage classification for hepatocellular carcinoma. Hepatology Research, 2006, 34, 124-129.	1.8	6
2277	Management and outcomes of hepatic cirrhosis: Findings from the RING study. Hepatology Research, 2006, 36, 176-181.	1.8	4
2278	Microbubble disappearance-time is the appropriate timing for liver-specific imaging after injection of Levovist. Ultrasound in Medicine and Biology, 2006, 32, 1809-1815.	0.7	10
2279	Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). European Radiology, 2006, 16, 661-669.	2.3	212
2280	Liver failure following partial hepatectomy. Hpb, 2006, 8, 165-174.	0.1	68
2281	The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS Journal, 2006, 8, E14-E19.	2.2	23
2282	A New Mutation of Wilson's Disease P-Type ATPase Gene in a Patient with Cirrhosis and Coombs-Positive Hemolytic Anemia. Digestive Diseases and Sciences, 2006, 51, 34-38.	1.1	8
2283	The Effectiveness of Lamivudine Treatment in Cirrhotic Patients with HBV Precore Mutations: A Prospective, Open-Label Study. Digestive Diseases and Sciences, 2006, 51, 1196-1202.	1.1	5
2284	The Relationship of Heart Rate Variability with Severity and Prognosis of Cirrhosis. Digestive Diseases and Sciences, 2006, 51, 1614-1618.	1.1	68
2285	Amino Acid Challenge in Patients with Cirrhosis and Control Subjects: Ammonia, Plasma Amino Acid and EEG Changes. Metabolic Brain Disease, 2006, 21, 1-10.	1.4	17

#	ARTICLE	IF	Citations
2286	Early detection of liver failure after hepatectomy by indocyanine green elimination rate measured by pulse dye-densitometry. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 543-548.	2.0	36
2287	High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. Journal of Gastroenterology, 2006, 41, 240-249.	2.3	5
2288	Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. Journal of Gastroenterology, 2006, 41, 250-256.	2.3	44
2289	Comparison of three methods of nutritional assessment in liver cirrhosis: subjective global assessment, traditional nutritional parameters, and body composition analysis. Journal of Gastroenterology, 2006, 41, 476-482.	2.3	77
2290	Bone mineral density in children with cirrhosis. Journal of Gastroenterology, 2006, 41, 873-877.	2.3	5
2291	Model for end-stage liver disease (MELD) score and cost-effectiveness on living donor liver transplantation. Journal of Gastroenterology, 2006, 41, 1023-1024.	2.3	1
2292	Exclusion of trisialo-transferrin from carbohydrate-deficient transferrin measurement: advantage in patients with chronic liver disease?. Wiener Medizinische Wochenschrift, 2006, 156, 216-222.	0.5	4
2293	Liver transplantation organ allocation between Child and MELD. Wiener Medizinische Wochenschrift, 2006, 156, 410-415.	0.5	7
2294	Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132, 547-555.	1.2	60
2295	Autonomic dysfunction and impaired cerebral autoregulation in cirrhosis. Clinical Autonomic Research, 2006, 16, 208-216.	1.4	33
2296	Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 810-816.	3.3	31
2297	188Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 344-352.	3.3	25
2298	Portal Hypertension: Contraindication to Liver Surgery?. World Journal of Surgery, 2006, 30, 992-999.	0.8	136
2299	Factors Associated with Disease Survival after Surgical Resection in Chinese Patients with Hepatocellular Carcinoma. World Journal of Surgery, 2006, 30, 439-445.	0.8	29
2300	Percutaneous Treatment of Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. CardioVascular and Interventional Radiology, 2006, 29, 778-784.	0.9	27
2301	Proton Beam Therapy for Hepatocellular Carcinoma Patients with Severe Cirrhosis. Strahlentherapie Und Onkologie, 2006, 182, 713-720.	1.0	63
2302	Elevation of $N\hat{l}\mu$ -(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clinical Biochemistry, 2006, 39, 39-45.	0.8	71
2303	Comparison of multilayer perceptron training algorithms for portal venous doppler signals in the cirrhosis disease. Expert Systems With Applications, 2006, 31, 406-413.	4.4	33

#	ARTICLE	IF	Citations
2304	Safety Profile of Concomitant Use of Caspofungin and Cyclosporine or Tacrolimus in Liver Transplant Patients. Infection, 2006, 34, 328-332.	2.3	38
2305	Liver Transplantation with the Meld System: A Prospective Study from a Single European Center American Journal of Transplantation, 2006, 6, 1572-1577.	2.6	64
2306	Symptom experience, psychological distress, and quality of life in Korean patients with liver cirrhosis: A cross-sectional survey. International Journal of Nursing Studies, 2006, 43, 1047-1056.	2.5	42
2307	Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2006, 202, 155-168.	0.2	77
2308	Recovery from Liver Failure after Hepatectomy for Hepatocellular Carcinoma in Cirrhosis: Meaning of the Model for End-Stage Liver Disease. Journal of the American College of Surgeons, 2006, 203, 670-676.	0.2	51
2309	Impact of Cirrhosis on Outcomes in Trauma. Journal of the American College of Surgeons, 2006, 203, 908-913.	0.2	39
2310	Hepatocellular Carcinoma: Molecular Biology and Therapy. Seminars in Oncology, 2006, 33, 79-83.	0.8	41
2311	Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. European Journal of Haematology, 2006, 77, 513-517.	1.1	48
2312	Symptom Experience in Korean Patients with Liver Cirrhosis. Journal of Pain and Symptom Management, 2006, 31, 326-334.	0.6	28
2313	Nutritional indices in cirrhotic patients. Nutrition, 2006, 22, 216-217.	1.1	20
2314	Hepatocellular carcinoma with silent and cirrhotic nonâ€alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Pathology International, 2006, 56, 40-45.	0.6	21
2315	Efficacy and safety of radiofrequency ablation for perivascular hepatocellular carcinoma without hepatic inflow occlusion. British Journal of Surgery, 2006, 93, 440-447.	0.1	39
2316	Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer, 2006, 107, 591-598.	2.0	74
2317	Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology, 2006, 43, 27-33.	3 . 6	39
2318	Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology, 2006, 43, 42-50.	3.6	111
2319	Hepatology over the years. Hepatology, 2006, 43, S6-S12.	3.6	2
2320	Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology, 2006, 43, 682-689.	3.6	458
2321	Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology, 2006, 43, 698-706.	3.6	186

#	Article	IF	CITATIONS
2322	A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-Butyl-2-Cyanoacrylate injection versus band ligation. Hepatology, 2006, 43, 690-697.	3.6	290
2323	The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology, 2006, 43, 1303-1310.	3.6	527
2324	Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology, 2006, 44, 53-61.	3.6	534
2325	Thrombin generation in patients with cirrhosis: The role of platelets. Hepatology, 2006, 44, 440-445.	3.6	347
2326	Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. Hepatology, 2006, 44, 823-835.	3.6	140
2327	Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transplantation, 2006, 12, 95-104.	1.3	89
2328	Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transplantation, 2006, 12, 966-971.	1.3	264
2329	A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transplantation, 2006, 12, 1049-1061.	1.3	279
2330	Impact of UCSF criteria according to pre- and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time. Liver Transplantation, 2006, 12, 1761-1769.	1.3	405
2331	Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation. Journal of Surgical Oncology, 2006, 93, 273-278.	0.8	6
2332	Gradient- and spin-echo T2-weighted imaging for SPIO-enhanced detection and characterization of focal liver lesions. Journal of Magnetic Resonance Imaging, 2006, 23, 712-719.	1.9	16
2333	Natural history of compensated cirrhosis in the Child-Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections. Journal of Medical Virology, 2006, 78, 459-465.	2.5	54
2334	Comparison of Gadobenate Dimeglumine-Enhanced Dynamic MRI and 16-MDCT for the Detection of Hepatocellular Carcinoma. American Journal of Roentgenology, 2006, 186, 149-157.	1.0	92
2335	Renovascular Impedance Correlates with Portal Pressure in Patients with Liver Cirrhosis. Radiology, 2006, 240, 581-586.	3.6	42
2336	Influence of Homozygosity for Methionine at Codon 129 of the Human Prion Gene on the Onset of Neurological and Hepatic Symptoms in Wilson Disease. Archives of Neurology, 2006, 63, 982.	4.9	40
2337	Portosystemic myelopathy: Spastic paraparesis after portosystemic shunting. Scandinavian Journal of Gastroenterology, 2006, 41, 619-625.	0.6	37
2338	Ursodeoxycholic acid in primary biliary cirrhosis improves glutathione status but fails to reduce lipid peroxidation. Redox Report, 2006, 11, 117-123.	1.4	12
2339	Laboratory Testing for Liver Disease. , 2006, , 235-250.		0

#	Article	IF	CITATIONS
2340	Hepatocellular Carcinoma in Patients with Chronic Liver Disease: Comparison of SPIO-enhanced MR Imaging and 16–Detector Row CT. Radiology, 2006, 238, 531-541.	3.6	109
2341	The Adaptive Response of the Reticuloendothelial System to Major Liver Resection in Humans. Annals of Surgery, 2006, 243, 507-514.	2.1	53
2342	Olfactory Deficits in Patients Affected by Minimal Hepatic Encephalopathy: A Pilot Study. Chemical Senses, 2006, 31, 273-278.	1.1	22
2343	Liver Failure Is Uncommon in Adults Receiving Longâ€Term Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2006, 30, 202-208.	1.3	74
2344	Integrating Palliative Care for Liver Transplant Candidates. JAMA - Journal of the American Medical Association, 2006, 295, 2168.	3.8	108
2345	In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy. Gut, 2006, 55, 547-553.	6.1	88
2346	Antiretroviral Medication Considerations for Individuals Coinfected with HIV and Hepatitis C Virus. AIDS Patient Care and STDs, 2006, 20, 678-692.	1.1	8
2347	Fingolimod (FTY720) in Severe Hepatic Impairment: Pharmacokinetics and Relationship to Markers of Liver Function. Journal of Clinical Pharmacology, 2006, 46, 149-156.	1.0	23
2348	Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients. American Journal of Gastroenterology, 2006, 101, 2044-2050.	0.2	143
2349	Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size. American Journal of Gastroenterology, 2006, 101, 2038-2043.	0.2	148
2350	Platelet Count/Spleen Diameter Ratio for the Noninvasive Diagnosis of Esophageal Varices: Results of a Multicenter, Prospective, Validation Study. American Journal of Gastroenterology, 2006, 101, 2511-2519.	0.2	215
2351	A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C. Clinical Chemistry, 2006, 52, 1887-1896.	1.5	210
2352	Cirrhosis., 2007,, 1-5.		0
2353	Clinical Prediction Tool To Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multidrug Resistance. Antimicrobial Agents and Chemotherapy, 2007, 51, 417-422.	1.4	51
2354	Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101. Journal of Clinical Oncology, 2007, 25, 3055-3060.	0.8	65
2355	Surveillance for Early Diagnosis of Hepatocellular Carcinoma: Is It Effective in Intermediate/Advanced Cirrhosis?. American Journal of Gastroenterology, 2007, 102, 2448-2457.	0.2	110
2356	Impact of Etiology of Cirrhosis on the Survival of Patients Diagnosed With Hepatocellular Carcinoma During Surveillance. CME. American Journal of Gastroenterology, 2007, 102, 1022-1031.	0.2	54
2357	Octreotide Enhances Portal Pressure Reduction Induced by Propranolol in Cirrhosis: A Randomized, Controlled Trial. American Journal of Gastroenterology, 2007, 102, 2206-2213.	0.2	11

#	Article	IF	CITATIONS
2358	Impact of Hepatitis D Virus Infection on the Long-Term Outcomes of Patients with Hepatitis B Virus and HIV Coinfection in the Era of Highly Active Antiretroviral Therapy: A Matched Cohort Study. Clinical Infectious Diseases, 2007, 44, 988-995.	2.9	79
2359	Different drinking patterns for women and men with alcohol dependence with and without alcoholic cirrhosis. Alcohol and Alcoholism, 2007, 43, 39-45.	0.9	39
2360	Incidence rates and causes of cirrhosis in a Norwegian population. Scandinavian Journal of Gastroenterology, 2007, 42, 1501-1508.	0.6	27
2361	Effectiveness of Hepatic Resection for Early-stage Hepatocellular Carcinoma in Cirrhotic Patients: Subgroup Analysis according to Milan Criteria. Japanese Journal of Clinical Oncology, 2007, 37, 287-295.	0.6	46
2362	Synbiotic-associated improvement in liver function in cirrhotic patients: Relation to changes in circulating cytokine messenger RNA and protein levels. Microbial Ecology in Health and Disease, 2007, 19, 7-16.	3.8	22
2363	Temporary Indwelling Catheter System via the Left Brachial Artery: Evaluation in 83 Patients with Hepatic Tumors. American Journal of Roentgenology, 2007, 188, 652-658.	1.0	2
2364	Liver resections: complications and survival outcome. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 269-279.	0.7	1
2365	Tumor Size and Operative Risks of Extended Right-Sided Hepatic Resection for Hepatocellular Carcinoma—Invited Critique. Archives of Surgery, 2007, 142, 69.	2.3	0
2366	The Impact of Cirrhosis on CD4+ T Cell Counts in HIV-Seronegative Patients. Clinical Infectious Diseases, 2007, 44, 431-437.	2.9	109
2367	Liver failure during pregnancy. Gut, 2007, 57, 83-83.	6.1	6
2368	Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study. Clinical Cancer Research, 2007, 13, 3660-3666.	3.2	48
2369	Preoperative evaluation of patients with liver disease. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 266-276.	1.7	78
2370	Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clinical Medicine, 2007, 7, 119-124.	0.8	107
2371	MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut, 2007, 56, 1283-1290.	6.1	180
2372	Correlations between magnetic resonance spectroscopy alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy. Gut, 2007, 56, 1736-1742.	6.1	72
2373	Partial liver transplantation-living donor liver transplantation and split liver transplantation. Nephrology Dialysis Transplantation, 2007, 22, viii13-viii22.	0.4	20
2374	Open-Heart Surgery in Patients with Liver Cirrhosis: Indications, Risk Factors, and Clinical Outcomes. European Surgical Research, 2007, 39, 67-74.	0.6	47
2375	Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy, 2007, 51, 3264-3272.	1.4	21

#	Article	IF	CITATIONS
2376	Hemodynamic Features of Doppler Ultrasonography in Patients With Portal Hypertension. Journal of Ultrasound in Medicine, 2007, 26, 1689-1696.	0.8	15
2377	Tumor Size and Operative Risks of Extended Right-Sided Hepatic Resection for Hepatocellular Carcinoma. Archives of Surgery, 2007, 142, 63.	2.3	12
2378	Heart Transplantation in Patients With End-Stage Heart Failure and Cardiac Ascites. Circulation Journal, 2007, 71, 1744-1748.	0.7	14
2379	Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood, 2007, 109, 2430-2437.	0.6	61
2380	A Simple Score for Predicting Alcohol Relapse After Liver Transplantation. Archives of Internal Medicine, 2007, 167, 1183.	4.3	186
2381	Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. American Journal of Clinical Nutrition, 2007, 85, 1257-1266.	2.2	244
2382	Mayo Clinic Model for End Stage Liver Disease (MELD) for Predicting Outcome in Patients With Hepatic Encephalopathy. Journal of Clinical Gastroenterology, 2007, 41, 223-224.	1.1	0
2383	Modification of Acid-Base Balance in Cirrhotic Patients Undergoing Liver Resection for Hepatocellular Carcinoma. Annals of Surgery, 2007, 245, 902-908.	2.1	16
2384	Increase in expression of monocytic tissue factor (CD142) with monocytes and blood platelet activation in liver cirrhosis. Blood Coagulation and Fibrinolysis, 2007, 18, 739-744.	0.5	16
2385	Removal of Bile Acids by Two Different Extracorporeal Liver Support Systems in Acute-on-Chronic Liver Failure. ASAIO Journal, 2007, 53, 187-193.	0.9	50
2386	Predictors of Mortality in Hepatic Encephalopathy in Acute and Chronic Liver Disease. Journal of Clinical Gastroenterology, 2007, 41, 922-926.	1.1	20
2387	Acute Traumatic Coagulopathy: Initiated by Hypoperfusion. Annals of Surgery, 2007, 245, 812-818.	2.1	646
2388	Usefulness of Combining Sequentially Acquired Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Resovist-Enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma. Journal of Computer Assisted Tomography, 2007, 31, 702-711.	0.5	27
2390	Percutaneous Closure after Inadvertent Carotid Artery Cannulation. Puncture Repair with Angio-Seal Deployment. Neuroradiology Journal, 2007, 20, 355-358.	0.6	1
2391	Laboratory Test Variability and Model for End-Stage Liver Disease Score Calculation: Effect on Liver Allocation and Proposal for Adjustment. Transplantation, 2007, 83, 919-924.	0.5	18
2392	Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 257-263.	0.8	60
2393	Familial Mediterranean Fever and Cryptogenic Cirrhosis. Medicine (United States), 2007, 86, 355-362.	0.4	25
2394	Characteristics of Waitlisted Patients for Liver Transplantation at a Liver Transplantation Unit in the City of Ribeirão Preto, São Paulo, Brazil, Especially Considering Child and Model for End Stage Liver Disease (MELD) Scores. Transplantation Proceedings, 2007, 39, 387-389.	0.3	2

#	Article	IF	CITATIONS
2395	Comparison of Child-Turcotte-Pugh and Pediatric End-Stage Liver Disease Scoring Systems to Predict Morbidity and Mortality of Children Awaiting Liver Transplantation. Transplantation Proceedings, 2007, 39, 3175-3177.	0.3	16
2396	Modified Child-Pugh score as a marker for postoperative bleeding from invasive dental procedures. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2007, 104, 56-60.	1.6	12
2397	Long-Term Outcome of Surgical Treatment for Non-Small Cell Lung Cancer With Comorbid Liver Cirrhosis. Annals of Thoracic Surgery, 2007, 84, 1810-1817.	0.7	21
2398	Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. European Journal of Surgical Oncology, 2007, 33, 746-751.	0.5	69
2399	Factors predicting survival in advanced T-staged hepatocellular carcinoma patients treated with reduction hepatectomy followed by transcatheter arterial chemoembolization. European Journal of Surgical Oncology, 2007, 33, 1019-1024.	0.5	4
2400	The use of conjugated hyperbilirubinemia greater than 100 $\hat{l}\frac{1}{4}$ mol/L as an indicator of irreversible liver disease in infants with short bowel syndrome. Journal of Pediatric Surgery, 2007, 42, 359-362.	0.8	25
2401	Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. Journal of Hepatology, 2007, 46, 387-394.	1.8	258
2402	Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis. Journal of Hepatology, 2007, 46, 447-458.	1.8	69
2403	Endotoxemia contributes to the immune paralysis in patients with cirrhosis. Journal of Hepatology, 2007, 46, 816-826.	1.8	132
2404	Bradykinesia in cirrhotic patients with early hepatic encephalopathy is related to a decreased glucose uptake of frontomesial cortical areas relevant for movement initiation. Journal of Hepatology, 2007, 46, 1034-1039.	1.8	28
2405	[215] SIX MINUTE WALK TEST TO ASSESS FUNCTIONAL CAPACITY IN CHRONIC LIVER DISEASE PATIENTS. Journal of Hepatology, 2007, 46, S89.	1.8	0
2406	Serum biotinidase is a sensitive and specific biochemical marker of hepatic dysfunction: A preliminary report. Hepatology Research, 2007, 37, 13-17.	1.8	2
2407	Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatology Research, 2007, 37, 94-100.	1.8	87
2408	The prevalence of atherosclerosis in cirrhotic patients: assessment of two aspects of atherosis and sclerosis. Hepatology Research, 2007, 37, 152-157.	1.8	10
2409	Tumor Necrosis Factor-α 308.2 Polymorphism Is Associated with Advanced Hepatic Fibrosis and Higher Risk for Hepatocellular Carcinoma. Neoplasia, 2007, 9, 987-992.	2.3	76
2410	Portal Hypertensive Duodenopathy: Clinical, Endoscopic, and Histopathologic Profiles. American Journal of Gastroenterology, 2007, 102, 2793-2802.	0.2	43
2411	Strategies for Safer Liver Surgery and Partial Liver Transplantation. New England Journal of Medicine, 2007, 356, 1545-1559.	13.9	892
2413	Anidulafungin Does Not Require Dosage Adjustment in Subjects With Varying Degrees of Hepatic or Renal Impairment. Journal of Clinical Pharmacology, 2007, 47, 461-470.	1.0	98

#	Article	IF	CITATIONS
2414	Sensitivity and specificity of bispectral index for classification of overt hepatic encephalopathy: a multicentre, observer blinded, validation study. Gut, 2007, 57, 77-83.	6.1	32
2415	The Rationale for Developing Scoring Systems for Clinical Practice. Thoracic Surgery Clinics, 2007, 17, 343-351.	0.4	7
2416	Liver transplantation. Journal of Ultrasound, 2007, 10, 28-45.	0.7	8
2417	Serum Albumin as a Significant Prognostic Factor for Patients with Gastric Carcinoma. Annals of Surgical Oncology, 2007, 14, 381-389.	0.7	185
2419	Steady-State Pharmacokinetics of Roflumilast and Roflumilast N-Oxide in Patients with Mild and Moderate Liver Cirrhosis. Clinical Pharmacokinetics, 2007, 46, 403-416.	1.6	35
2420	Antiarrhythmics. Clinical Pharmacokinetics, 2007, 46, 985-996.	1.6	50
2421	Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Digestive and Liver Disease, 2007, 39, 52-59.	0.4	14
2422	Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Digestive and Liver Disease, 2007, 39, 1011-1017.	0.4	13
2423	Right liver lobe/albumin ratio: Contribution to non-invasive assessment of portal hypertension. World Journal of Gastroenterology, 2007, 13, 5331.	1.4	42
2424	Management and Treatment of Hepatitis C Virus in Patients with HIV and Hepatitis C Virus Coinfection: A Practical Guide for Health Care Professionals. Canadian Journal of Infectious Diseases and Medical Microbiology, 2007, 18, 293-303.	0.7	9
2425	Effect of Liver Disease on Pharmacokinetics. , 2007, , 73-87.		4
2426	Gastroesophageal reflux in cirrhotic patients with esophageal varices without endoscopic treatment. Arquivos De Gastroenterologia, 2007, 44, 145-150.	0.3	17
2429	Assessment of hepatic functional reserve by cirrhosis grading and liver volume measurement using CT. World Journal of Gastroenterology, 2007, 13, 3956.	1.4	43
2430	Perioperative Risk of Hip Arthroplasty in Patients with Cirrhotic Liver Disease. Journal of Korean Medical Science, 2007, 22, 223.	1.1	32
2431	Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma. World Journal of Gastroenterology, 2007, 13, 3221.	1.4	30
2433	Kentucky Hepatoma. Archives of Surgery, 2007, 142, 431.	2.3	7
2434	Leptin levels in the differential diagnosis between benign and malignant ascites. World Journal of Gastroenterology, 2007, 13, 398.	1.4	6
2435	Six Minute Walk Test to assess functional capacity in chronic liver disease patients. World Journal of Gastroenterology, 2007, 13, 3996.	1.4	80

#	Article	IF	CITATIONS
2436	Paclitaxel coated-stent for early-onset thrombosis after liver transplantation. Annals of Hepatology, 2007, 6, 272-275.	0.6	7
2437	Involvement of serum apolipoprotein Al and B100 and lecithin cholesterol acyl transferase in alcoholic cirrhotics. Annals of Hepatology, 2007, 6, 227-232.	0.6	5
2438	Peripheral blood monocytes from patients with HBV related decompensated liver cirrhosis can differentiate into functional hepatocytes. American Journal of Hematology, 2007, 82, 949-954.	2.0	41
2439	A Prospective Randomized Study of Two Sclerotherapy Techniques for Esophageal Varices. Hepatology, 1983, 3, 681-684.	3.6	87
2440	Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology, 2007, 46, 831-840.	3.6	287
2441	Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology, 2007, 46, 1872-1882.	3.6	249
2442	Conduction and excitability properties of peripheral nerves in end-stage liver disease. Muscle and Nerve, 2007, 35, 730-738.	1.0	30
2443	Effect of side and size of graft on surgical outcomes of adult-to-adult live donor liver transplantation. Liver Transplantation, 2007, 13, 91-98.	1.3	39
2444	In a MELD-based economy, how can we fight off inflation?. Liver Transplantation, 2007, 13, 2-4.	1.3	19
2445	Bacterial translocation during liver transplantation: A randomized trial comparing conventional with venovenous bypass vs. piggyback methods. Liver Transplantation, 2007, 13, 488-496.	1.3	38
2446	Psychological strain in urgent indications for living donor liver transplantation. Liver Transplantation, 2007, 13, 886-895.	1.3	62
2447	Clinicopathological characteristics of patients with hepatocellular carcinoma after hepatectomy: Relationship with status of viral hepatitis. Journal of Surgical Oncology, 2007, 96, 487-492.	0.8	18
2448	Spectral analysing of portal vein Doppler signals in the cirrhosis patients. Computers in Biology and Medicine, 2007, 37, 1303-1307.	3.9	7
2449	Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clinical Biochemistry, 2007, 40, 651-655.	0.8	51
2450	CD117 (c-kit) Expression in Human Hepatocellular Carcinoma. Clinical Oncology, 2007, 19, 204-208.	0.6	37
2451	Proton Beam Therapy for Aged Patients With Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 805-812.	0.4	56
2452	EXERCISE PERFORMANCE AND VENTILATORY EFFICIENCY IN PATIENTS WITH MILD AND MODERATE LIVER CIRRHOSIS. Clinical and Experimental Pharmacology and Physiology, 2007, 35, 070908085607001-???.	0.9	20
2453	Risk factors for liver transplantation waiting list mortality. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 119-124.	1.4	47

#	Article	IF	Citations
2454	Role of meal carbohydrate content for the imbalance of plasma amino acids in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1241-1248.	1.4	8
2455	Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: What is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 95-101.	1.4	70
2456	Predicting pleural effusion and ascites following extended hepatectomy in the non-cirrhotic liver. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 837-840.	1.4	13
2457	Factors influencing change in health-related quality of life after liver transplantation. Clinical Transplantation, 2007, 21, 481-499.	0.8	42
2458	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. Journal of Viral Hepatitis, 2007, 14, 64-69.	1.0	22
2459	ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. British Journal of Haematology, 2007, 138, 534-540.	1.2	135
2460	Hypomagnesaemia, cardiac arrhythmias and orthotopic liver transplantation. Anaesthesia, 1994, 49, 403-405.	1.8	25
2461	The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension. Alimentary Pharmacology and Therapeutics, 1988, 2, 143-151.	1.9	11
2462	Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man. Alimentary Pharmacology and Therapeutics, 1988, 2, 361-367.	1.9	12
2463	The antiâ€secretory effect and pharmacokinetics of omeprazole in chronic liver disease. Alimentary Pharmacology and Therapeutics, 1988, 2, 429-437.	1.9	16
2464	Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics, 1990, 4, 83-96.	1.9	6
2465	Enbucrilate for gastric varices: extended experience in 92 patients. Alimentary Pharmacology and Therapeutics, 2007, 26, 49-59.	1.9	49
2466	Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 141-148.	1.9	181
2467	Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with endâ€stage cirrhosis. Alimentary Pharmacology and Therapeutics, 2007, 26, 717-726.	1.9	17
2468	Longâ€term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Alimentary Pharmacology and Therapeutics, 2007, 26, 839-846.	1.9	16
2469	Increased von Willebrand Factor Over Decreased ADAMTS13 Activity May Contribute to the Development of Liver Disturbance and Multiorgan Failure in Patients With Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 2007, 31, S27-S35.	1.4	41
2470	Evaluation of Quantitative Portal Venous, Hepatic Arterial, and Total Hepatic Tissue Blood Flow Using Xenon CT in Alcoholic Liver Cirrhosis: Comparison With Liver Cirrhosis C. Alcoholism: Clinical and Experimental Research, 2007, 31, S43-S48.	1.4	16
2471	Improving outcome in patients undergoing liver surgery. Liver International, 2007, 27, 26-39.	1.9	27

#	Article	IF	CITATIONS
2472	Prognostic models in cirrhosis: an aid but not a replacement for clinical judgement. Liver International, 2007, 27, 595-597.	1.9	2
2473	Manganese superoxide dismutase activity and incidence of hepatocellular carcinoma in patients with Child?Pugh class A liver cirrhosis: a 7-year follow-up study. Liver International, 2007, 27, 791-797.	1.9	16
2474	Acid?base disturbances in critically ill patients with cirrhosis. Liver International, 2007, 27, 901-909.	1.9	65
2475	Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver International, 2007, 27, 1232-1239.	1.9	24
2476	Serum nitric oxide levels in children with Wilson's disease. International Journal of Clinical Practice, 2007, 61, 1530-1534.	0.8	2
2477	Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. International Journal of Clinical Practice, 2007, 62, 1056-1062.	0.8	62
2478	QT Interval Correction in Patients with Cirrhosis. Journal of Cardiovascular Electrophysiology, 2007, 18, 77-82.	0.8	67
2479	Budd?Chiari syndrome from an advanced practice nurse perspective. Journal of the American Academy of Nurse Practitioners, 2007, 19, 486-495.	1.4	0
2480	Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients. European Journal of Pharmacology, 2007, 569, 222-227.	1.7	35
2482	Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Hepatology Research, 2007, 37, S267-74.	1.8	21
2483	Short Waitlist Time Does Not Adversely Impact Outcome Following Liver Transplantation for Hepatocellular Carcinoma. American Journal of Transplantation, 2007, 7, 1594-1600.	2.6	28
2484	Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSFâ€Expanded Criteria Based on Preoperative Imaging. American Journal of Transplantation, 2007, 7, 2587-2596.	2.6	490
2485	Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes. Surgery, 2007, 141, 330-339.	1.0	350
2486	A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery, 2007, 141, 598-609.	1.0	100
2487	Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery, 2007, 141, 589-597.	1.0	136
2488	Management practices for gastrointestinal hemorrhage related to portal hypertention in cirrhotic patients: evaluation of the impact of the Paris consensus workshop. Gastroenterologie Clinique Et Biologique, 2007, 31, 970-974.	0.9	7
2489	Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: Analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters. Scandinavian Journal of Gastroenterology, 2007, 42, 256-262.	0.6	29
2490	Clinical Characteristics and Surgical Outcome in Hepatocellular Carcinoma without Hepatitis B Virus Surface Antigen or Hepatitis C Virus Antibody. Annals of Surgical Oncology, 2007, 14, 1170-1181.	0.7	13

#	Article	IF	CITATIONS
2491	An Analysis of Resection vs Transplantation for Early Hepatocellular Carcinoma: Defining the Optimal Therapy at a Single Institution. Annals of Surgical Oncology, 2007, 14, 2608-2614.	0.7	88
2492	The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. European Journal of Clinical Pharmacology, 2007, 63, 677-686.	0.8	60
2493	RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients. Intensive Care Medicine, 2007, 33, 1921-1930.	3.9	123
2494	Proton Irradiation in a Single Fraction for Hepatocellular Carcinoma Patients with Uncontrollable Ascites. Strahlentherapie Und Onkologie, 2007, 183, 411-416.	1.0	19
2495	Liver Resection for Hepatocellular Carcinoma in a Hepatitis B Endemic Area. World Journal of Surgery, 2007, 31, 1775-1781.	0.8	243
2496	Local Therapeutic Results of Computed Tomography-Guided Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Results of 265 Tumors in 79 Patients. CardioVascular and Interventional Radiology, 2007, 30, 1144-1155.	0.9	20
2497	P300 cognitive evoked potentials before and after liver transplantation. Metabolic Brain Disease, 2007, 22, 139-144.	1.4	6
2498	Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Quality of Life Research, 2007, 16, 389-397.	1.5	70
2499	Prognostic Index for Survival in Patients After Treatment for Primary Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2007, 52, 2444-2451.	1.1	6
2500	Bifidobacterium longum with Fructo-Oligosaccharide (FOS) Treatment in Minimal Hepatic Encephalopathy: A Randomized, Double-Blind, Placebo-Controlled Study. Digestive Diseases and Sciences, 2007, 52, 3259-3265.	1.1	162
2501	Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection. Digestive Diseases and Sciences, 2007, 52, 2531-2539.	1.1	139
2502	Correlation Between Findings on MRCP and Gadolinium-Enhanced MR of the Liver and a Survival Model for Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2007, 52, 3499-3506.	1.1	34
2503	Factors Prognostic of Survival in Patients Awaiting Liver Transplantation for End-Stage Liver Disease. Digestive Diseases and Sciences, 2007, 52, 3217-3223.	1.1	19
2504	Estimation of the binding ability of main transport proteins of blood plasma with liver cirrhosis by the fluorescent probe method. Journal of Applied Spectroscopy, 2007, 74, 561-566.	0.3	1
2505	Impact of intraoperative ultrasonography in laparoscopic liver surgery. Surgical Endoscopy and Other Interventional Techniques, 2007, 21, 181-188.	1.3	78
2506	Predictors of hepatic venous trunk invasion and prognostic factors in patients with hepatocellular carcinomas that had come into contact with the trunk of major hepatic veins. Journal of Hepato-Biliary-Pancreatic Surgery, 2007, 14, 289-296.	2.0	12
2507	The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. Journal of Gastroenterology, 2007, 42, 101-119.	2.3	372
2508	Color Doppler endoscopic ultrasonography in identifying groups at a high-risk of recurrence of esophageal varices after endoscopic treatment. Journal of Gastroenterology, 2007, 42, 219-224.	2.3	37

#	Article	IF	CITATIONS
2509	Hypersplenism is related to age of onset of liver disease. Irish Journal of Medical Science, 2007, 176, 293-296.	0.8	11
2510	Conventional Predictors of Survival Poorly Predict and Significantly Underpredict Survival after H-graft Portacaval Shunts. Journal of Gastrointestinal Surgery, 2007, 11, 89-94.	0.9	4
2511	Referrals for Surgical Therapy in Patients with Hepatocellular Carcinoma: A Community Experience. Journal of Gastrointestinal Surgery, 2007, 11, 76-81.	0.9	5
2512	Radio Frequency Ablation for Hepatocellular Carcinoma in Cirrhotic Patients: Prognostic Factors for Survival. Journal of Gastrointestinal Surgery, 2007, 11, 143-149.	0.9	34
2513	Prognosis and Results After Resection of Very Large (≥10Âcm) Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2007, 11, 589-595.	0.9	80
2514	Usefulness of prognostic indices in upper gastrointestinal bleeding. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 233-242.	1.0	35
2515	A Modified Percutaneous Transhepatic Variceal Embolization with 2-Octyl Cyanoacrylate Versus Endoscopic Ligation in Esophageal Variceal Bleeding Management: Randomized Controlled Trial. Digestive Diseases and Sciences, 2008, 53, 2258-2267.	1.1	30
2516	Effect of Portal Hypertension in the Small Bowel: An Endoscopic Approach. Digestive Diseases and Sciences, 2008, 53, 2144-2150.	1.1	51
2517	Long-term Outcomes of Acute Gastric Variceal Bleeding in 48 Patients Following Treatment with Cyanoacrylate. Digestive Diseases and Sciences, 2008, 53, 544-550.	1.1	42
2518	Acetyl-l-Carnitine Treatment in Minimal Hepatic Encephalopathy. Digestive Diseases and Sciences, 2008, 53, 3018-3025.	1.1	86
2519	Hyperreninemic hypoaldosteronism syndrome, plasma concentrations of interleukin-6 and outcome in critically ill patients with liver cirrhosis. Intensive Care Medicine, 2008, 34, 116-124.	3.9	28
2520	Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. European Journal of Clinical Pharmacology, 2008, 64, 1147-1161.	0.8	518
2521	Hepatic Resection is Justified for Elderly Patients with Hepatocellular Carcinoma. World Journal of Surgery, 2008, 32, 2223-2229.	0.8	69
2522	HA/GSAâ€Rmax Ratio as a Predictor of Postoperative Liver Failure. World Journal of Surgery, 2008, 32, 2410-2418.	0.8	26
2524	Analysis of Recurrence Pattern and Its Influence on Survival Outcome After Radiofrequency Ablation of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2008, 12, 183-191.	0.9	146
2525	The impact of new data in the treatment of advanced hepatocellular carcinoma. Current Oncology Reports, 2008, 10, 199-205.	1.8	25
2526	The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis. Advances in Therapy, 2008, 25, 190-200.	1.3	6
2527	Perioperative Neurological Complications After Liver Transplantation are Best Predicted by Pre-transplant Hepatic Encephalopathy. Neurocritical Care, 2008, 8, 253-258.	1.2	93

#	Article	IF	CITATIONS
2528	Models for prediction of mortality from cirrhosis with special reference to artificial neural network: a critical review. Hepatology International, 2008, 2, 31-38.	1.9	16
2529	Long-term results of elective hepatectomy for the treatment of ruptured hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery, 2008, 15, 178-182.	2.0	36
2530	Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. Journal of Gastroenterology, 2008, 43, 159-170.	2.3	65
2531	Does gastroesophageal reflux have an influence on bleeding from esophageal varices?. Journal of Gastroenterology, 2008, 43, 803-808.	2.3	15
2532	Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. Journal of Gastroenterology, 2008, 43, 967-974.	2.3	54
2533	Voxelâ€based diffusion tensor magnetic resonance imaging evaluation of lowâ€grade hepatic encephalopathy. Journal of Magnetic Resonance Imaging, 2008, 27, 1061-1068.	1.9	52
2534	Treatment and prognosis of hepatocellular carcinoma: A population based study in France. Journal of Surgical Oncology, 2008, 98, 505-509.	0.8	68
2535	Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transplantation, 2008, 14, 526-533.	1.3	42
2536	Dichloroacetate stabilizes the intraoperative acid-base balance during liver transplantation. Liver Transplantation, 2008, 14, 989-998.	1.3	6
2537	Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transplantation, 2008, 14, 1725-1731.	1.3	82
2538	Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transplantation, 2008, 14, 1449-1460.	1.3	101
2539	Microvascular head and neck reconstruction in patients with liver cirrhosis. Head and Neck, 2008, 30, 829-835.	0.9	11
2540	Comorbidity and survival of Danish cirrhosis patients: A nationwide population-based cohort study. Hepatology, 2008, 48, 214-220.	3.6	103
2541	Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis. Hepatology, 2008, 48, 819-827.	3.6	508
2542	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseaseâ€modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheumatism, 2008, 59, 762-784.	6.7	1,311
2543	Impact of postoperative complications on long-term outcome of curative resection for hepatocellular carcinoma. British Journal of Surgery, 2008, 96, 81-87.	0.1	153
2544	Endoscopic haemostasis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 899-927.	1.0	3
2545	Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 1093-1108.	1.0	25

#	Article	IF	CITATIONS
2546	Tenofovir plus lamivudine as rescue therapy for adefovirâ€resistant chronic hepatitis B in hepatitis B e antigenâ€positive patients with liver cirrhosis. Liver International, 2008, 28, 814-820.	1.9	32
2547	Bridging Locoregional Therapy for Hepatocellular Carcinoma Prior to Liver Transplantation. Annals of Surgical Oncology, 2008, 15, 3169-3177.	0.7	127
2548	Microvascular Invasion in Patients with Hepatocellular Carcinoma and Its Predictable Clinicopathological Factors. Annals of Surgical Oncology, 2008, 15, 1375-1382.	0.7	347
2549	Surgical Treatment of Hepatocellular Carcinoma beyond Milan Criteria. Results of Liver Resection, Salvage Transplantation, and Primary Liver Transplantation. Annals of Surgical Oncology, 2008, 15, 1383-1391.	0.7	316
2550	Cardiovascular status after postural change in compensated cirrhosis: an argument for vasodilatory concept. Liver, 1997, 17, 1-6.	0.1	4
2551	<i>In vivo</i> and <i>in vitro</i> hepatic ³¹ P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver. Liver, 1997, 17, 198-209.	0.1	59
2552	Determination of plasma alphaâ€glutathione Sâ€transferases in patients with HCVâ€related chronic infection: its significance and possible clinical relevance. Liver, 1998, 18, 166-172.	0.1	13
2553	Effects of orthotopic liver transplantation on body composition. Liver, 1998, 18, 173-179.	0.1	43
2554	Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. Liver, 1998, 18, 420-426.	0.1	15
2555	Management of combined hepatocellular and cholangiocarcinoma. International Journal of Clinical Practice, 2008, 62, 1271-1278.	0.8	130
2556	Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. British Journal of Cancer, 2008, 98, 1161-1165.	2.9	50
2557	Longâ€ŧerm outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd–Chiari syndrome. Liver International, 2008, 28, 249-256.	1.9	44
2558	The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. Journal of Thrombosis and Haemostasis, 2008, 6, 243-248.	1.9	35
2559	Development and psychometric evaluation of a chronic liver diseaseâ€specific quality of life questionnaire. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 231-238.	1.4	10
2560	Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 459-466.	1.4	11
2561	Abnormality of the hepatic vein waveforms in cirrhotic patients with portal hypertension and its prognostic implications. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e129-36.	1.4	15
2562	Malnutrition and hypermetabolism are not risk factors for the presence of hepatic encephalopathy: A cross-sectional study. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 606-610.	1.4	19
2563	A prospective and comparative cohort study on efficacy and drug resistance during longâ€term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 794-803.	1.4	27

#	Article	IF	CITATIONS
2564	Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a $10 \hat{a} \in \mathbf{y}$ ear period in a retrospective study. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 482-490.	1.4	24
2565	Preoperative evaluation of hepatic functional reserve by converted ICGR15 calculated from ^{99m} Tcâ€GSA scintigraphy. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1235-1241.	1.4	38
2566	Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1267-1275.	1.4	11
2567	Clinical features and survival in Chinese patients with hepatitis B e antigenâ€negative hepatitis B virusâ€related cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1250-1258.	1.4	9
2568	Model for the endâ€stage liver disease and death prediction in a cohort of Brazilian patients on the waiting list for liver transplantation. Clinical Transplantation, 2008, 22, 651-656.	0.8	15
2569	Severity scoring in the ICU: a review. Acta Anaesthesiologica Scandinavica, 2008, 52, 467-478.	0.7	142
2570	Impairment of healthâ€related quality of life in functional dyspepsia and chronic liver disease: the influence of depression and anxiety. Alimentary Pharmacology and Therapeutics, 2008, 27, 561-571.	1.9	44
2571	Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Alimentary Pharmacology and Therapeutics, 2008, 28, 62-75.	1.9	69
2572	Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes. Clinical and Experimental Immunology, 2008, 95, 83-90.	1.1	55
2573	Components of the reninâ€angiotensinâ€aldosterone system in plasma and ascites in hepatic cirrhosis. European Journal of Clinical Investigation, 2008, 38, 939-944.	1.7	18
2574	Decreased contact factor mediated fibrinolysis in cirrhosis. British Journal of Haematology, 1993, 85, 542-545.	1.2	13
2575	Inter-relationships between platelet count, platelet IgG, serum IgG, immune complexes and severity of liver disease. International Journal of Laboratory Hematology, 2008, 13, 127-135.	0.2	35
2577	Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis. Clinical Imaging, 2008, 32, 453-459.	0.8	12
2578	Assessment of Transcutaneous Bilirubinometry in Hospitalized Adults. Journal of the American College of Surgeons, 2008, 206, 1129-1136.	0.2	8
2579	Randomised, controlled study of transhepatic obliteration of varices and oesophageal stapling transection in uncontrolled variceal haemorrhage. Liver, 1983, 3, 122-128.	0.1	17
2580	Treatment of acute hepatic encephalopathy in cirrhotics with a branchedâ€chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver, 1985, 5, 282-289.	0.1	76
2581	Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. Liver, 1989, 9, 1-5.	0.1	50
2582	Bacteremia in patients with cirrhosis of the liver. Liver, 1991, 11, 334-339.	0.1	94

#	Article	IF	Citations
2583	Arterial and mixed venous acidâ€base status in patients with cirrhosis. Influence of liver failure. Liver, 1993, 13, 20-24.	0.1	27
2584	Effect of dobutamine on the arterial ketone body ratio and portal blood flow velocity in cirrhosis. Liver, 1993, 13, 209-216.	0.1	2
2585	Changes in laminin content in livers of patients with alcoholic liver disease. Liver, 1995, 15, 324-331.	0.1	5
2586	Biochemical and clinical study of muscle atrophy at thenar and hypothenar eminences in patients with cirrhosis. Liver, 2008, 16, 19-22.	0.1	3
2587	Does the measurement of portal flow velocity have any value in the identification of patients with cirrhosis at risk of digestive bleeding?. Liver, 1996, 16, 84-87.	0.1	16
2588	Short―and longâ€term hemodynamic response to octreotide in portal hypertensive patients: a doubleâ€blind, controlled study. Liver, 1996, 16, 225-234.	0.1	25
2589	THE TREATMENT OF OESOPHAGEAL VARICES AND PORTAL HYPERTENSION. Journal of Clinical Pharmacy and Therapeutics, 2008, 10, 1-14.	0.7	2
2590	Liver Transplantation for Recurrent Hepatocellular Carcinoma on Cirrhosis After Liver Resection: University of Bologna Experience. American Journal of Transplantation, 2008, 8, 1177-1185.	2.6	153
2591	Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery, 2008, 143, 607-615.	1.0	135
2592	Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 378-390.	13.9	12,004
2593	Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene-Covered Stent Grafts. American Journal of Gastroenterology, 2008, 103, 2738-2746.	0.2	239
2594	Pharmacokinetics and Pharmacodynamics of Cinacalcet inÂHepatic Impairment. Clinical Drug Investigation, 2008, 28, 635-643.	1.1	19
2595	Correlation of liver-spleen scan findings with modified Child-Pugh classification. Revista Española De Medicina Nuclear, 2008, 27, 99-102.	0.3	2
2597	LONG TERM FOLLOWâ€UP OF PATIENTS FOLLOWING SUCCESSFUL SELECTIVE AND NONâ€SELECTIVE PORTASYSTEMIC SHUNT SURGERY. Australian and New Zealand Journal of Surgery, 1985, 55, 355-358.	0.2	6
2598	Hemodynamic Features of Gastrorenal Shunt. Academic Radiology, 2008, 15, 1148-1154.	1.3	24
2599	Neither Multiple Tumors Nor Portal Hypertension Are Surgical Contraindications for Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1908-1916.	0.6	645
2600	TIPS for Budd-Chiari Syndrome: Long-Term Results and Prognostics Factors in 124 Patients. Gastroenterology, 2008, 135, 808-815.	0.6	319
2601	Computerized Psychometric Testing in Minimal Encephalopathy and Modulation by Nitrogen Challenge and Liver Transplant. Gastroenterology, 2008, 135, 1582-1590.	0.6	69

#	Article	IF	CITATIONS
2602	Treatment of acute variceal bleeding. Digestive and Liver Disease, 2008, 40, 328-336.	0.4	50
2603	Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: A prospective study. Digestive and Liver Disease, 2008, 40, 684-689.	0.4	29
2604	Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy. American Journal of Gastroenterology, 2008, 103, 1707-1715.	0.2	235
2605	Management of Chronic Liver Failure Until Liver Transplantation. Medical Clinics of North America, 2008, 92, 839-860.	1.1	7
2606	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood, 2008, 111, 4922-4929.	0.6	319
2607	Type II Gall Bladder Perforation with Abdominal Wall Abscess in a Cirrhotic Patient: Case Report and Review of the Literature. Journal of Surgical Education, 2008, 65, 367-371.	1.2	19
2608	Effect of chronic \hat{I}^2 -blockade on QT interval in patients with liver cirrhosis. Journal of Hepatology, 2008, 48, 415-421.	1.8	83
2609	Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. Journal of Hepatology, 2008, 48, 559-566.	1.8	10
2610	Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. Journal of Hepatology, 2008, 49, 34-42.	1.8	61
2611	Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. Journal of Hepatology, 2008, 48, 945-951.	1.8	257
2612	Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. Journal of Hepatology, 2008, 49, 223-232.	1.8	90
2613	Factors That Predict Survival in Patients With Cirrhosis Considered for Liver Transplantation. Transplantation Proceedings, 2008, 40, 2965-2967.	0.3	16
2614	Hepatopulmonary Syndrome: Morbidity and Survival After Liver Transplantation. Transplantation Proceedings, 2008, 40, 3512-3516.	0.3	44
2615	Increased circulating urotensin II in cirrhosis: Potential implications in liver disease. Peptides, 2008, 29, 868-872.	1.2	13
2616	TAFI deficiency in liver cirrhosis: Relation with plasma fibrinolysis and survival. Thrombosis Research, 2008, 121, 763-768.	0.8	23
2617	Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thrombosis and Haemostasis, 2008, 99, 1019-1029.	1.8	141
2618	Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération) Tj ETQq0 0 (0 ng:B T/Ov	e slo ck 10 Tf
2619	Radiofrequency ablation of hepatocellular carcinoma: Long-term outcome and prognostic factors. European Journal of Radiology, 2008, 67, 336-347.	1.2	107

#	Article	IF	CITATIONS
2620	Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?. European Journal of Surgical Oncology, 2008, 34, 256-262.	0.5	51
2621	Oxidative damage of albumin in advanced liver disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 469-473.	1.8	127
2622	Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: Possible association with hepatic function impairment. Cytokine, 2008, 44, 14-17.	1.4	29
2623	Soluble interleukin-2 receptor and soluble CD8 in liver cirrhosis and obstructive jaundice. Clinical and Experimental Immunology, 2008, 82, 344-349.	1.1	12
2624	Impaired cerebral oscillatory processing in hepatic encephalopathy. Clinical Neurophysiology, 2008, 119, 265-272.	0.7	26
2625	Cirrosis hep?tica. Medicine, 2008, 10, 685-690.	0.0	0
2627	Liver cirrhosis. Lancet, The, 2008, 371, 838-851.	6.3	1,745
2628	288 COMORBIDITY AND SURVIVAL OF DANISH CIRRHOSIS PATIENTS - A NATIONWIDE POPULATION-BASED COHORT STUDY. Journal of Hepatology, 2008, 48, S115.	1.8	0
2629	Development of evidenceâ€based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatology Research, 2008, 38, 37-51.	1.8	279
2630	Measurement of serum branchedâ€chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease. Hepatology Research, 2008, 38, 267-272.	1.8	45
2631	Supplement improves nutrition and stresses caused by examinationâ€associated fasting in patients with liver cirrhosis. Hepatology Research, 2008, 38, 1178-1185.	1.8	6
2632	Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncology, The, 2008, 9, 1181-1190.	5.1	71
2633	lodized Oil Accumulation in Hypervascular Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization: Comparison of Imaging Findings with CT during Hepatic Arteriography. Journal of Vascular and Interventional Radiology, 2008, 19, 333-341.	0.2	21
2634	Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte–colony-stimulating factor mobilization therapy. Cytotherapy, 2008, 10, 390-396.	0.3	52
2635	Spleen Enlargement on Follow-Up Evaluation: A Noninvasive Predictor of Complications of Portal Hypertension in Cirrhosis. Clinical Gastroenterology and Hepatology, 2008, 6, 1129-1134.	2.4	58
2636	Efficacy of a haemostatic matrix for the management of bleeding in patients undergoing liver resection: results from 237 cases. Current Medical Research and Opinion, 2008, 24, 1011-1015.	0.9	30
2637	The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A Current Medical Research and Opinion, 2008, 24, 1943-1950.	0.9	5
2638	Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment. Journal of Clinical Pharmacology, 2008, 48, 1411-1419.	1.0	152

#	ARTICLE	IF	CITATIONS
2639	Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. American Journal of Gastroenterology, 2008, 103, 914-921.	0.2	429
2640	Chemoembolization Combined With Radiofrequency Ablation for Patients With Hepatocellular Carcinoma Larger Than 3 cm. JAMA - Journal of the American Medical Association, 2008, 299, 1669.	3.8	172
2641	Predictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology, 2008, 38, 675-682.	0.6	17
2642	Relevance of clotting tests in liver disease. Postgraduate Medical Journal, 2008, 84, 177-181.	0.9	38
2643	Diagnostic Accuracy of Imaging for Liver Cirrhosis Compared to Histologically Proven Liver Cirrhosis. Intervirology, 2008, 51, 17-26.	1.2	128
2644	A New Prognostic Staging System for Hepatocellular Carcinoma: Value of the Biomarker Combined Japan Integrated Staging Score. Intervirology, 2008, 51, 86-94.	1.2	41
2645	Heat Shock Protein A1B 1267 Polymorphism Is Highly Associated With Risk and Prognosis of Hepatocellular Carcinoma. Medicine (United States), 2008, 87, 87-98.	0.4	20
2646	Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 493-501.	0.2	57
2647	Serum prohepcidin reflects the degree of liver function impairment in liver cirrhosis. Biomarkers, 2008, 13, 478-485.	0.9	22
2648	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 1995-2004.	13.9	1,148
2649	Symptom Management in Hepatocellular Carcinoma. Clinical Journal of Oncology Nursing, 2008, 12, 759-766.	0.3	69
2650	Regulatory mechanisms underlying agmatine homeostasis in humans. American Journal of Physiology - Renal Physiology, 2008, 295, G1104-G1110.	1.6	33
2651	Human Herpesvirus Type 8 in Patients With Cirrhosis. American Journal of Clinical Pathology, 2008, 130, 231-237.	0.4	13
2652	Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. New England Journal of Medicine, 2008, 359, 2429-2441.	13.9	445
2653	Bacterial Infections, Sepsis, and Multiorgan Failure in Cirrhosis. Seminars in Liver Disease, 2008, 28, 026-042.	1.8	460
2654	Phenylalanine and tyrosine kinetics in compensated liver cirrhosis: effects of meal ingestion. American Journal of Physiology - Renal Physiology, 2008, 295, G598-G604.	1.6	24
2655	Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. Radiology, 2008, 248, 132-139.	3.6	29
2656	ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scandinavian Journal of Gastroenterology, 2008, 43, 1241-1248.	0.6	28

#	Article	IF	CITATIONS
2657	Laparoscopic US-Guided Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Liver Cirrhosis: Feasibility and Clinical Outcome. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2008, 18, 797-801.	0.5	20
2658	Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic Impairment. Journal of Clinical Pharmacology, 2008, 48, 445-454.	1.0	27
2659	Survival Analysis of Patients With Transplantable Recurrent Hepatocellular Carcinoma. Archives of Surgery, 2008, 143, 68.	2.3	60
2660	Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World Journal of Gastroenterology, 2008, 14, 2757.	1.4	82
2661	Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy. World Journal of Gastroenterology, 2008, 14, 4370.	1.4	16
2662	Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients. The Cochrane Library, 2010, 2010, CD005443.	1.5	6
2663	Impact of neutrophil apoptosis on haemostatic activation in chronic liver disease patients. Blood Coagulation and Fibrinolysis, 2008, 19, 535-542.	0.5	2
2664	Therapeutic Strategy of Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy. Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 220-226.	0.8	19
2665	Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. European Journal of Gastroenterology and Hepatology, 2008, 20, 865-873.	0.8	19
2666	Pilot Study of Combination Therapy With Transcatheter Arterial Infusion Chemotherapy Using Iodized Oil and Percutaneous Radiofrequency Ablation During Occlusion of Hepatic Blood Flow for Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 311-316.	0.6	10
2667	Serum and Ascitic Fluid Superoxide Dismutase and Malondialdehyde Levels in Patients with Cirrhosis. Biomarker Insights, 2008, 3, BMI.S639.	1.0	2
2669	Complications of Cirrhosis., 0,, 215-234.		1
2670	Surgical Management (Resection)., 2008, , 121-134.		0
2671	Intestinal metaplasia in portal hypertensive gastropathy: a frequent pathology. European Journal of Gastroenterology and Hepatology, 2008, 20, 874-880.	0.8	13
2673	Outcome of patients with cirrhosis admitted to intensive care. Current Opinion in Critical Care, 2008, 14, 202-207.	1.6	24
2674	Clinical and Laboratory Predictors of Esophageal Varices in Children and Adolescents With Portal Hypertension Syndrome. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 178-183.	0.9	58
2675	Low Serum Level of Cholinesterase at Recurrence of Pancreatic Cancer Is a Poor Prognostic Factor and Relates to Systemic Disorder and Nerve Plexus Invasion. Pancreas, 2008, 36, 241-248.	0.5	31
2676	Endoscopic Band Ligation of Esophageal Varices in Patients on Anticoagulation. Journal of Clinical Gastroenterology, 2008, 42, 782-785.	1.1	10

#	Article	IF	Citations
2677	Cardiac Output Measurement in Patients Undergoing Liver Transplantation: Pulmonary Artery Catheter Versus Uncalibrated Arterial Pressure Waveform Analysis. Anesthesia and Analgesia, 2008, 106, 1480-1486.	1.1	176
2678	In-hospital mortality in spontaneous bacterial peritonitis: a new predictive model. European Journal of Gastroenterology and Hepatology, 2008, 20, 1176-1181.	0.8	80
2679	Model for end-stage liver disease-sodium predicts prognosis in patients with chronic severe hepatitis B. Chinese Medical Journal, 2008, 121, 2065-2069.	0.9	10
2680	Liver, gallbladder and biliary tract., 0,, 141-150.		0
2681	Complicaciones neurol \tilde{A}^3 gicas en pacientes adultos sometidos a trasplante hep \tilde{A}_i tico ortot \tilde{A}^3 pico: Experiencia de un centro universitario. Revista Medica De Chile, 2008, 136, .	0.1	0
2682	Pediatric liver transplantation: 10 years of experience at a single center in Brazil. Jornal De Pediatria, 2008, 84, 395-402.	0.9	14
2683	Prevalence of hepatopulmonary syndrome in patients with decompensated chronic liver disease and its impact on short-term survival. Arquivos De Gastroenterologia, 2008, 45, 34-37.	0.3	27
2684	Trasplante hepático en Chile: Aspectos generales, indicaciones y contraindicaciones (Documento de) Tj ETQq1	. 1 0,784314 0.1	1 1 rgBT /Over
2685	Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Brazilian Journal of Infectious Diseases, 2008, 12, 306-309.	0.3	32
2686	Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics: Targets and Therapy, 2008, 2, 779.	3.0	34
2689	Clinical Features and Treatment Outcomes of Upper Gastrointestinal Bleeding in Patients with Cirrhosis. Journal of Korean Medical Science, 2008, 23, 635.	1.1	24
2690	Mortality prediction of cirrhotic patients admitted to the Intensive Care Unit. Annals of Hepatology, 2008, 7, 78-79.	0.6	1
2691	Ablation Therapy Guided by Contrast-Enhanced Sonography with Sonazoid for Hepatocellular Carcinoma Lesions Not Detected by Conventional Sonography. Journal of Ultrasound in Medicine, 2008, 27, 395-406.	0.8	82
2692	Thermal ablation of hepatocellular carcinoma. Cancer Imaging, 2008, 8, 19-26.	1.2	51
2693	Groin Herniorrhaphy in Patients with Cirrhosis and after Liver Transplantation. American Surgeon, 2009, 75, 962-965.	0.4	12
2694	Surgical treatment of hepatocellular carcinoma: resection and transplantation., 0,, 57-65.		0
2695	Department of Biochemistry., 0,, 98-99.		8
2696	Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antiviral Therapy, 2009, 14, 831-837.	0.6	44

#	Article	IF	CITATIONS
2698	Immediate Listing for Liver Transplantation Versus Standard Care for Child–Pugh Stage B Alcoholic Cirrhosis. Annals of Internal Medicine, 2009, 150, 153.	2.0	64
2699	Endocarditis infecciosa en pacientes con daño hepático crónico: Serie de 4 casos clÃnicos. Revista Chilena De Infectologia, 2009, 26, .	0.0	0
2700	Canadian Consensus Guidelines for the Optimal Use of Etravirine in the Treatment of HIV-Infected Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e24-e34.	0.7	1
2701	Laparoscopic Cholecystectomy in Cirrhotic Patients. Journal of the Society of Laparoendoscopic Surgeons, 2009, 13, 592-596.	0.5	27
2703	Platelet count/spleen diameter ratio for non-invasive prediction of high risk esophageal varices in cirrhotic patients. Annals of Hepatology, 2009, 8, 325-330.	0.6	36
2704	Subjective Satisfaction and Quality of Life in Patients Prior to Listing for Liver Transplantation. International Journal of Artificial Organs, 2009, 32, 39-42.	0.7	4
2705	Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment. Journal of Clinical Pharmacology, 2009, 49, 465-476.	1.0	66
2706	Relationship Between Changes in Brain MRI and ¹ H-MRS, Severity of Chronic Liver Damage, and Recovery After Liver Transplantation. Experimental Biology and Medicine, 2009, 234, 1075-1085.	1.1	28
2707	<pre><scp>L</scp>-[1-¹³C]phenylalanine breath test in patients with chronic liver disease of different etiologies. Isotopes in Environmental and Health Studies, 2009, 45, 192-197.</pre>	0.5	6
2708	Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment. Antimicrobial Agents and Chemotherapy, 2009, 53, 5185-5196.	1.4	15
2709	Prognostic Indices for Budd–Chiari Syndrome: Valid for Clinical Studies but Insufficient for Individual Management. American Journal of Gastroenterology, 2009, 104, 1140-1146.	0.2	65
2710	Increased Plasma Carbon Monoxide in Patients With Viral Cirrhosis and Hyperdynamic Circulation. American Journal of Gastroenterology, 2009, 104, 891-897.	0.2	26
2711	Coexisting Gastric Varices Should Not Preclude Prophylactic Ligation of Large Esophageal Varices in Cirrhosis. Digestion, 2009, 80, 165-169.	1.2	5
2712	Survival of patients with skeletal metastases from hepatocellular carcinoma after surgical management. Journal of Bone and Joint Surgery: British Volume, 2009, 91-B, 1505-1512.	3.4	20
2714	Treatment of Hepatocellular Carcinoma. Oncology, 2009, 77, 43-49.	0.9	6
2715	Qualitative and Quantitative Evaluation of Hepatocellular Carcinoma and Cirrhotic Liver Enhancement Using Gd-EOB-DTPA. American Journal of Roentgenology, 2009, 193, 1053-1060.	1.0	135
2716	Independent and Additive Interactive Effects Among Tumor Necrosis Factor-α Polymorphisms, Substance Use Habits, and Chronic Hepatitis B and Hepatitis C Virus Infection on Risk for Hepatocellular Carcinoma. Medicine (United States), 2009, 88, 349-357.	0.4	34
2717	Indication of the Extent of Hepatectomy for Hepatocellular Carcinoma on Cirrhosis by a Simple Algorithm Based on Preoperative Variables. Archives of Surgery, 2009, 144, 57.	2.3	55

#	Article	IF	CITATIONS
2718	Clinical Profile, Etiology and Therapeutic Outcome in 324 Hepatocellular Carcinoma Patients at a Tertiary Care Center in India. Oncology, 2009, 77, 162-171.	0.9	51
2719	Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors, Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after Viral Hepatitis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4844-4850.	1.8	41
2720	Value of Liver Parenchymal Phase Contrast-Enhanced Sonography to Diagnose Premalignant and Borderline Lesions and Overt Hepatocellular Carcinoma. American Journal of Roentgenology, 2009, 192, 698-705.	1.0	28
2721	Effect of Signal Intensity from the Accumulated Microbubbles in the Liver for Differentiation of Idiopathic Portal Hypertension from Liver Cirrhosis. Radiology, 2009, 252, 587-594.	3.6	37
2722	Therapeutic effect of balloon-occluded retrograde transvenous obliteration for gastric varices in relation to haemodynamics in the short gastric vein. British Journal of Radiology, 2009, 82, 930-935.	1.0	7
2723	Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy. American Journal of Physiology - Renal Physiology, 2009, 296, G330-G338.	1.6	72
2724	Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 2009, 53, 1747-1752.	1.4	42
2726	Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. Journal of Antimicrobial Chemotherapy, 2009, 63, 992-997.	1.3	3
2727	Cytochrome P450 3A Inhibition by Atazanavir and Ritonavir, but Not Demography or Drug Formulation, Influences Saquinavir Population Pharmacokinetics in Human Immunodeficiency Virus Type 1-Infected Adults. Antimicrobial Agents and Chemotherapy, 2009, 53, 3524-3527.	1.4	7
2728	Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301. Journal of Clinical Oncology, 2009, 27, 1800-1805.	0.8	195
2729	Prefilter Bivalirudin for Preventing Hemofilter Occlusion in Continuous Renal Replacement Therapy. Annals of Pharmacotherapy, 2009, 43, 1360-1365.	0.9	7
2730	N-glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing. Mechanisms of Ageing and Development, 2009, 130, 92-97.	2.2	44
2731	Outcome of patients with liver cirrhosis admitted to a specialty liver intensive care unit in India. Journal of Critical Care, 2009, 24, 387-393.	1.0	22
2732	Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer, 2009, 9, 33.	1.1	79
2733	Injection Sclerotherapy of Bleeding Oesophageal and Gastric Varices Using a Flexible Endoscope. Acta Medica Scandinavica, 1982, 211, 125-129.	0.0	37
2734	Chronic Liver Disease Impairs Bacterial Clearance in a Human Model of Induced Bacteremia. Clinical and Translational Science, 2009, 2, 199-205.	1.5	39
2735	Survival Benefit-Based Deceased-Donor Liver Allocation. American Journal of Transplantation, 2009, 9, 970-981.	2.6	291
2736	Transarterial Chemoinfusion for Hepatocellular Carcinoma as Downstaging Therapy and a Bridge toward Liver Transplantation. American Journal of Transplantation, 2009, 9, 1158-1168.	2.6	128

#	Article	IF	CITATIONS
2737	Erectile Dysfunction in End-Stage Liver Disease Men. Journal of Sexual Medicine, 2009, 6, 1395-1401.	0.3	38
2738	Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study. Clinical Therapeutics, 2009, 31, 2459-2469.	1.1	31
2739	Chemoprevention Indication Score: A user-friendly tool for prevention of breast cancer – Pilot analysis. Breast, 2009, 18, 289-293.	0.9	9
2740	Operative risks of digestive surgery in cirrhotic patients. Gastroenterologie Clinique Et Biologique, 2009, 33, 555-564.	0.9	36
2741	Nationwide Volume and Mortality after Elective Surgery in Cirrhotic Patients. Journal of the American College of Surgeons, 2009, 208, 96-103.	0.2	149
2743	Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology, 2009, 49, 97-105.	3.6	241
2744	Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology, 2009, 50, 555-564.	3.6	208
2745	Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology, 2009, 50, 791-798.	3.6	253
2746	A novel Global Assessment Scale for Wilson's Disease (GAS for WD). Movement Disorders, 2009, 24, 509-518.	2.2	103
2747	Intraoperative renal support during liver transplantation. Liver Transplantation, 2009, 15, 73-78.	1.3	97
2748	A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: Validation using prognostic markers for pre-liver transplant status. Liver Transplantation, 2009, 15, 790-797.	1.3	50
2749	Prediction of posthepatectomy hepatic functional reserve by serum hyaluronate. British Journal of Surgery, 2009, 96, 501-508.	0.1	22
2750	Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. British Journal of Surgery, 2009, 96, 1049-1057.	0.1	74
2751	Laparoscopic liver resections for hepatocellular carcinoma. Is it a feasible option for patients with liver cirrhosis?. Langenbeck's Archives of Surgery, 2009, 394, 255-264.	0.8	39
2752	Amphiphilic perfluoroalkyl carbohydrates as new tools for liver imaging. International Journal of Pharmaceutics, 2009, 379, 301-308.	2.6	13
2753	Sleep and circadian abnormalities in patients with cirrhosis: features of delayed sleep phase syndrome?. Metabolic Brain Disease, 2009, 24, 427-439.	1.4	58
2754	Brain metastases from hepatocellular carcinoma: prognostic factors and outcome. Journal of Neuro-Oncology, 2009, 91, 307-313.	1.4	103
2755	External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis. Digestive Diseases and Sciences, 2009, 54, 654-660.	1.1	55

#	Article	IF	CITATIONS
2756	Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application. Hepatology International, 2009, 3, 283-293.	1.9	34
2757	Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clinical and Translational Oncology, 2009, 11, 276-283.	1.2	15
2758	Prediction of postoperative hepatic dysfunction after cardiac surgery in patients with chronic congestive heart failure. General Thoracic and Cardiovascular Surgery, 2009, 57, 357-362.	0.4	17
2760	Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. Japanese Journal of Radiology, 2009, 27, 185-193.	1.0	32
2761	Surgical Strategy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Based on Prognostic Factors. Journal of Gastrointestinal Surgery, 2009, 13, 1078-1083.	0.9	60
2762	Perioperative Risk Assessment for Hepatocellular Carcinoma by Using the MELD Score. Journal of Gastrointestinal Surgery, 2009, 13, 2268-2275.	0.9	30
2763	Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Advances in Therapy, 2009, 26, 249-262.	1.3	81
2764	Proton-Beam Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis*. Strahlentherapie Und Onkologie, 2009, 185, 782-788.	1.0	109
2765	Risk Factors of Surgical Site Infection After Hepatectomy for Liver Cancers. World Journal of Surgery, 2009, 33, 312-317.	0.8	54
2766	Value of MELD and MELDâ€Based Indices in Surgical Risk Evaluation of Cirrhotic Patients: Retrospective Analysis of 190 Cases. World Journal of Surgery, 2009, 33, 1711-1719.	0.8	38
2767	Partial Splenic Embolization Versus Splenectomy for the Management of Hypersplenism in Cirrhotic Patients. World Journal of Surgery, 2009, 33, 1702-1710.	0.8	90
2768	An Update on Longâ€Term Outcome of Curative Hepatic Resection for Hepatocholangiocarcinoma. World Journal of Surgery, 2009, 33, 1916-1921.	0.8	20
2769	Predictive Factors for Rebleeding and Death in Alcoholic Cirrhotic Patients with Acute Variceal Bleeding: A Multivariate Analysis. World Journal of Surgery, 2009, 33, 2127-2135.	0.8	42
2770	Prediction of Survival After Liver Transplantation for Chronic Severe Hepatitis B Based on Preoperative Prognostic Scores: A Single Center's Experience in China. World Journal of Surgery, 2009, 33, 2420-2426.	0.8	13
2771	Predicting Morbidity and Mortality After Hepatic Resection in Patients with Hepatocellular Carcinoma: The Role of Model for Endâ€Stage Liver Disease Score. World Journal of Surgery, 2009, 33, 2412-2419.	0.8	68
2772	Intermittent Pringle Maneuver and Hepatic Function: Perioperative Monitoring by Noninvasive ICGâ€Clearance. World Journal of Surgery, 2009, 33, 2627-2634.	0.8	11
2773	Chronic Schistosomiasis Japonica is an Independent Adverse Prognostic Factor for Survival in Hepatocellular Carcinoma Patients Who Have Undergone Hepatic Resection: Clinicopathological and Prognostic Analysis of 198 Consecutive Patients. World Journal of Surgery, 2009, 33, 2644-2650.	0.8	6
2774	Predictors of esophageal varices in patients with HBV-related cirrhosis: a retrospective study. BMC Gastroenterology, 2009, 9, 11.	0.8	60

#	Article	IF	Citations
2775	Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterology, 2009, 9, 72.	0.8	57
2776	Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis. Alimentary Pharmacology and Therapeutics, 2009, 29, 801-810.	1.9	17
2777	Ascites improves upon plus serum sodium model for endâ€stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Alimentary Pharmacology and Therapeutics, 2009, 30, 741-748.	1.9	25
2778	Rotterdam score predicts early mortality in Buddâ€Chiari syndrome, and surgical shunting prolongs transplantâ€free survival. Alimentary Pharmacology and Therapeutics, 2009, 30, 1060-1069.	1.9	36
2779	Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clinical and Experimental Immunology, 2009, 158, 219-229.	1.1	54
2780	Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of Endâ€stage Liver Disease score. European Journal of Clinical Investigation, 2009, 39, 65-71.	1.7	15
2781	Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease. Journal of Clinical Pharmacy and Therapeutics, 2009, 34, 575-583.	0.7	20
2782	Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. Journal of Viral Hepatitis, 2009, 17, 668-74.	1.0	16
2783	An observational cohort study of triage for critical care provision during pandemic influenza: â€~clipboard physicians' or â€~evidenced based medicine'?. Anaesthesia, 2009, 64, 1199-1206.	1.8	78
2784	Reduced Duodenal Cytochrome P450 3A Protein Expression and Catalytic Activity in Patients With Cirrhosis. Clinical Pharmacology and Therapeutics, 2009, 85, 387-393.	2.3	31
2785	Quality of life is not related with liver disease severity but with anemia, malnutrition, and depression in HCVâ€infected hemodialysis patients. Hemodialysis International, 2009, 13, 62-71.	0.4	10
2786	Effect of Extracorporeal Liver Support by Molecular Adsorbents Recirculating System and Prometheus on Redox State of Albumin in Acuteâ€onâ€Chronic Liver Failure. Therapeutic Apheresis and Dialysis, 2009, 13, 431-436.	0.4	38
2787	Underlying mechanism of portal hypertensive gastropathy in cirrhosis: A hemodynamic and morphological approach. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1541-1546.	1.4	30
2788	Validation of model for endâ€stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1547-1553.	1.4	21
2789	Quantitation of tissue polypeptide antigen (TPA) in hepatic and systemic circulation in patients with chronic liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1847-1851.	1.4	1
2790	Dermatological signs in Wilson's disease. Pediatrics International, 2009, 51, 395-398.	0.2	28
2791	Liver transplantations with donors aged 60â€∫years and above: the low liver damage strategy. Transplant International, 2009, 22, 423-433.	0.8	48
2792	MELD and other predictors of survival after liver transplantation. Clinical Transplantation, 2009, 23, 220-227.	0.8	41

#	Article	IF	CITATIONS
2793	Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma. Hpb, 2009, 11, 351-357.	0.1	66
2794	Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. Hpb, 2009, 11, 398-404.	0.1	59
2795	Model for endâ€stage liver disease, model for endâ€stage liver diseaseâ€sodium and Child–Turcotte–Pugh scores over time for the prediction of complications of liver cirrhosis. Liver International, 2009, 29, 221-226.	1.9	21
2796	Identification of bacterial DNA in neutrocytic and nonâ€neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver International, 2009, 29, 1206-1214.	1.9	48
2797	Nightâ€time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. Liver International, 2009, 29, 1372-1382.	1.9	80
2798	Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver International, 2009, 29, 1521-1527.	1.9	39
2799	Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver International, 2010, 30, 816-825.	1.9	69
2800	G-308A TNF-α polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study. Cancer Epidemiology, 2009, 33, 261-264.	0.8	54
2801	The Comprehensive Geriatric Assessment and the multidimensional approach. A new look at the older patient with gastroenterological disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 829-837.	1.0	41
2802	Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population. Annals of Surgical Oncology, 2009, 16, 413-422.	0.7	178
2803	Management of Early Hepatocellular Carcinoma in Patients with Well-Compensated Cirrhosis. Annals of Surgical Oncology, 2009, 16, 1820-1831.	0.7	48
2804	Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opinion on Pharmacotherapy, 2009, 10, 333-343.	0.9	165
2805	Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Critical Care, 2009, 13, R8.	2.5	40
2807	The transjugular intrahepatic portosystemic shunt (TIPS). Clinical Radiology, 2009, 64, 664-674.	0.5	41
2808	Î ² 2-glycoprotein-I plasma levels in liver cirrhosis. Clinica Chimica Acta, 2009, 403, 257-258.	0.5	2
2809	The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thrombosis Research, 2009, 124, 132-136.	0.8	155
2810	Correlation Between Selected Prognostic Factors and Postoperative Course in Liver Transplant Recipients. Transplantation Proceedings, 2009, 41, 3091-3102.	0.3	21
2812	Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?. Journal of Hepatology, 2009, 50, 17-35.	1.8	177

#	Article	IF	CITATIONS
2813	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. Journal of Hepatology, 2009, 50, 916-922.	1.8	69
2814	Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. Journal of Hepatology, 2009, 50, 906-915.	1.8	56
2815	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. Journal of Hepatology, 2009, 51, 288-295.	1.8	26
2816	The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome. Journal of Hepatology, 2009, 51, 475-482.	1.8	205
2817	Sleep–wake patterns in patients with cirrhosis: All you need to know on a single sheet. Journal of Hepatology, 2009, 51, 690-695.	1.8	30
2818	Electroencephalographic analysis for the assessment of hepatic encephalopathy: Comparison of non-parametric and parametric spectral estimation techniques. Neurophysiologie Clinique, 2009, 39, 107-115.	1.0	22
2819	Model for End-Stage Liver Disease Predicts Mortality for Tricuspid Valve Surgery. Annals of Thoracic Surgery, 2009, 87, 1460-1468.	0.7	93
2820	Prediction of oesophageal varices in patients with compensated cirrhosis: A novel scoring system. Arab Journal of Gastroenterology, 2009, 10, 129-134.	0.4	4
2821	Transarterial embolization with microspheres in the treatment of monofocal HCC. Digestive and Liver Disease, 2009, 41, 143-149.	0.4	6
2822	A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Digestive and Liver Disease, 2009, 41, 431-441.	0.4	36
2823	Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Digestive and Liver Disease, 2009, 41, 740-748.	0.4	36
2824	Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems. Digestive and Liver Disease, 2009, 41, 700-706.	0.4	6
2825	Changing trends in acute upper-GI bleeding: a population-based study. Gastrointestinal Endoscopy, 2009, 70, 212-224.	0.5	171
2826	Role of sorafenib in HCC patients with compromised liver function. Nature Reviews Clinical Oncology, 2009, 6, 505-506.	12.5	31
2827	Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clinical Chemistry and Laboratory Medicine, 2009, 47, 305-10.	1.4	31
2828	Low Cerebral Oxygen Consumption and Blood Flow in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy. Gastroenterology, 2009, 136, 863-871.	0.6	102
2829	A 28-Year Study of the Course of Hepatitis Î" Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. Gastroenterology, 2009, 136, 1629-1638.	0.6	285
2830	An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis. Gastroenterology, 2009, 137, 2105-2111.	0.6	472

#	ARTICLE	IF	CITATIONS
2831	Scoring systems for postoperative mortality in left colonic peritonitis. CirugÃa Española (English) Tj ETQq0 0 0	gBT/Over	logk 10 Tf 50
2832	Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut, 2009, 58, 833-838.	6.1	37
2833	Pharmacokinetic Changes of Psychotropic Drugs in Patients with Liver Disease. Drug Safety, 2009, 32, 561-578.	1.4	29
2834	Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin. Clinical Pharmacokinetics, 2009, 48, 281-302.	1.6	54
2835	Combination of Sorafenib andÂlntensity Modulated RadiotherapyÂforÂUnresectable Hepatocellular Carcinoma. Clinical Drug Investigation, 2009, 29, 65-71.	1.1	37
2836	Acute-on-Chronic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction. , 2009, , 658-671.		O
2837	Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites. American Journal of Gastroenterology, 2009, 104, 1130-1134.	0.2	188
2838	Predicting Early Mortality After Acute Variceal Hemorrhage Based on Classification and Regression Tree Analysis. Clinical Gastroenterology and Hepatology, 2009, 7, 1347-1354.	2.4	137
2839	Extrahepatic Collateral Artery Supply to the Tumor Thrombi of Hepatocellular Carcinoma Invading Inferior Vena Cava: The Prevalence and Determinant Factors. Journal of Vascular and Interventional Radiology, 2009, 20, 22-29.	0.2	64
2840	Perioperative risk assessment for patients with cirrhosis and liver disease. Expert Review of Gastroenterology and Hepatology, 2009, 3, 65-75.	1.4	22
2841	Molecular profiling to predict hepatocellular carcinoma outcome. Expert Review of Gastroenterology and Hepatology, 2009, 3, 101-103.	1.4	37
2842	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2009, 10, 25-34.	5.1	5,104
2843	Aeromonas Spontaneous Bacterial Peritonitis: A Highly Fatal Infectious Disease in Patients with Advanced Liver Cirrhosis. Journal of the Formosan Medical Association, 2009, 108, 293-300.	0.8	19
2844	Assessment of liver function for safe hepatic resection. Hepatology Research, 2009, 39, 107-116.	1.8	180
2845	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Is the addition of subcutaneous interferonâ€Î±â€⊋b beneficial?. Hepatology Research, 2009, 39, 223-230.	1.8	18
2846	Urinary bile acid sulfate levels in patients with hepatitis C virusâ€related chronic liver diseases. Hepatology Research, 2009, 39, 760-765.	1.8	4
2847	Value of the extracellular water ratio for assessment of cirrhotic patients with and without ascites. Hepatology Research, 2009, 39, 1072-1079.	1.8	25
2848	Tests of Coagulation in Liver Disease. Clinics in Liver Disease, 2009, 13, 55-61.	1.0	47

#	Article	IF	CITATIONS
2849	Hepatocellular Carcinoma in Patients With Cryptogenic Cirrhosis. Clinical Gastroenterology and Hepatology, 2009, 7, 580-585.	2.4	48
2850	Levels and Initial Course of Serum Alanine Aminotransferase Can Predict Outcome of Patients With Budd–Chiari Syndrome. Clinical Gastroenterology and Hepatology, 2009, 7, 1230-1235.	2.4	39
2851	Liver Transplantation: From Child to MELD. Medical Clinics of North America, 2009, 93, 931-950.	1.1	26
2852	Preoperative Risk Assessment for Patients with Liver Disease. Medical Clinics of North America, 2009, 93, 917-929.	1.1	11
2853	Nodules Less Than 20 mm and Vascular Invasion are Predictors of Survival in Small Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2009, 43, 191-195.	1.1	37
2854	Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. European Journal of Gastroenterology and Hepatology, 2009, 21, 1383-1394.	0.8	31
2855	Detection of Hepatocellular Carcinoma. Journal of Computer Assisted Tomography, 2009, 33, 844-850.	0.5	61
2856	Are Acquired Hepatocerebral Degeneration and Hepatic Myelopathy Reversible?. Journal of Clinical Gastroenterology, 2009, 43, 176-181.	1.1	56
2857	A Modified Percutaneous Transhepatic Varices Embolization With 2-Octyl Cyanoacrylate in the Treatment of Bleeding Esophageal Varices. Journal of Clinical Gastroenterology, 2009, 43, 463-469.	1.1	22
2858	Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 350-391.	2.3	719
2860	Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon- $\hat{l}\pm 2b$. Annals of Internal Medicine, 2009, 150, 528.	2.0	162
2861	Role of Hepatitis B Virus Infection in the Prognosis After Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis. Archives of Surgery, 2009, 144, 906.	2.3	29
2862	QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clinical Science, 2009, 116, 851-859.	1.8	86
2863	Surgical treatment for hepatocellular carcinoma in elderly patients. Aging Health, 2009, 5, 333-343.	0.3	1
2864	Nitric oxide and carbon monoxide lung transfer in patients with advanced liver cirrhosis. Journal of Applied Physiology, 2009, 107, 139-143.	1.2	37
2865	Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?. European Journal of Gastroenterology and Hepatology, 2009, 21, 1212-1218.	0.8	51
2866	Solitary Large Hepatocellular Carcinoma. Annals of Surgery, 2009, 249, 118-123.	2.1	174
2867	Trends in Perioperative Outcome After Hepatic Resection. Annals of Surgery, 2009, 249, 995-1002.	2.1	206

#	Article	IF	CITATIONS
2868	Is Portal Hypertension a Contraindication to Hepatic Resection?. Annals of Surgery, 2009, 250, 922-928.	2.1	202
2869	MELD Score and Blood Product Requirements During Liver Transplantation: No Link. Transplantation, 2009, 87, 1689-1694.	0.5	74
2870	Cirrhotic patients in the medical intensive care unit: Early prognosis and long-term survival*. Critical Care Medicine, 2010, 38, 2108-2116.	0.4	216
2871	Predictions and outcomes for the critically ill patient with cirrhosis: Is it time to settle on the SOFA and let jaundiced views on outcome MELD away?*. Critical Care Medicine, 2010, 38, 2259-2260.	0.4	20
2872	Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Advanced Hepatocellular Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 43-46.	0.6	18
2873	Detection of Small Hepatocellular Carcinoma. Investigative Radiology, 2010, 45, 740-746.	3.5	49
2874	Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2010, 22, 199-206.	0.8	101
2875	Abnormal brain processing in hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2010, 22, 1323-1330.	0.8	13
2876	Serum Sodium Predicts Prognosis in Critically Ill Cirrhotic Patients. Journal of Clinical Gastroenterology, 2010, 44, 220-226.	1.1	77
2877	Do Chronic Liver Disease Scoring Systems Predict Outcomes in Trauma Patients With Liver Disease? A Comparison of MELD and CTP. Journal of Trauma, 2010, 69, 568-573.	2.3	10
2878	Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests. European Journal of Gastroenterology and Hepatology, 2010, 22, 532-540.	0.8	45
2879	Long Term Follow-up and Outcome of Liver Transplantation for Alcoholic Liver Disease. Journal of Clinical Gastroenterology, 2010, 44, 52-57.	1.1	21
2880	Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes?. Current Opinion in HIV and AIDS, 2010, 5, 517-523.	1.5	12
2881	Nutritional status and quality of life at varying degrees of clinical severity of chronic liver disease. Nutrition and Food Science, 2010, 40, 581-590.	0.4	2
2882	Transient ultrasound elastography and magnetic resonance elastography for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2010, , .	1.5	4
2883	Magnetic resonance imaging, computer tomography scan, and oesophagography for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2010, , .	1.5	4
2886	Non-invasive test of liver fibrosis for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2010 , , .	1.5	4
2887	An Autopsy Case of Disseminated Cryptococcosis Manifesting as Acute Diarrhea in a Patient with Primary Biliary Cirrhosis. Internal Medicine, 2010, 49, 1793-1796.	0.3	6

#	Article	IF	CITATIONS
2888	Indirect Calorimetry and Anthropometry to Estimate Energy Metabolism in Patients with Liver Cirrhosis. Journal of Nutritional Science and Vitaminology, 2010, 56, 372-379.	0.2	24
2890	Nonsurgical Options for Hepatocellular Carcinoma: Evolving Role of External Beam Radiotherapy. Cancer Control, 2010, 17, 100-110.	0.7	28
2891	Characteristic expression pattern of oxidative stress in livers with cryptogenic hepatocellular carcinoma. Experimental and Therapeutic Medicine, 2010, 1, 809-816.	0.8	2
2892	PWE-058â€The utility of scoring systems in predicting early and late mortality in alcoholic hepatitis: whose score is it anyway?: Abstract PWE-058. Gut, 2010, 59, A108.1-A108.	6.1	0
2893	Postoperative Morbidity and Mortality of Head and Neck Cancers in Patients With Liver Cirrhosis Undergoing Surgical Resection Followed by Microsurgical Free Tissue Transfer. Annals of Surgical Oncology, 2010, 17, 536-543.	0.7	27
2894	Is MARS system enough for A.phalloides-induced liver failure treatment?. Human and Experimental Toxicology, 2010, 29, 823-832.	1.1	27
2895	An assessment of surgery for portal hypertensive patients performed at a single community hospital. Surgery Today, 2010, 40, 620-625.	0.7	10
2896	Long-term effect of endoscopic injection therapy with combined cyanoacrylate and ethanol for gastric fundal varices in relation to portal hemodynamics. Abdominal Imaging, 2010, 35, 8-14.	2.0	2
2897	Expression of Hepatocyte Growth Factor Activator Inhibitor Type 1Âin Human Hepatocellular Carcinoma and Postoperative Outcomes. World Journal of Surgery, 2010, 34, 1563-1571.	0.8	7
2898	Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemotherapy and Pharmacology, 2010, 66, 699-707.	1.1	39
2899	Diagnosis of liver disease by using CMAC neural network approach. Expert Systems With Applications, 2010, 37, 6157-6164.	4.4	25
2900	MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiology, 2010, 34, 448-452.	0.8	24
2902	Infectious endocarditis in patients with cirrhosis of the liver: a model of infection in the frail patient. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 1271-1275.	1.3	32
2903	Laparoscopic cholecystectomy in cirrhotic patients: the value of MELD score and Child–Pugh classification in predicting outcome. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 407-412.	1.3	82
2904	Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma. Journal of Gastroenterology, 2010, 45, 60-67.	2.3	23
2905	Disturbances of parathyroid hormone–vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatology International, 2010, 4, 634-640.	1.9	65
2906	Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clinical and Translational Oncology, 2010, 12, 218-225.	1.2	273
2908	Split-brain syndrome after hepatic transplantation: a tacrolimus-related vasculitis?. Metabolic Brain Disease, 2010, 25, 155-159.	1.4	4

#	Article	IF	CITATIONS
2909	Doppler Ultrasound of Hepatic and System Hemodynamics in Patients with Alcoholic Liver Cirrhosis. Digestive Diseases and Sciences, 2010, 55, 458-466.	1.1	19
2910	Frequency and Factors Associated with Small Intestinal Bacterial Overgrowth in Patients with Cirrhosis of the Liver and Extra Hepatic Portal Venous Obstruction. Digestive Diseases and Sciences, 2010, 55, 1142-1148.	1.1	33
2911	The patient with gastrointestinal disease. Surgery, 2010, 28, 437-440.	0.1	0
2912	Elevated serum tumor necrosis factor-α and soluble tumor necrosis factor receptors correlate with aberrant energy metabolism in liver cirrhosis. Nutrition, 2010, 26, 269-275.	1.1	21
2914	Outcome of repeat hepatectomy in patients with hepatocellular carcinoma aged 75 years and older. Surgery, 2010, 147, 696-703.	1.0	52
2915	Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin. Pharmacotherapy, 2010, 30, 35-42.	1.2	20
2916	Clinical Significance of Plasma Osteopontin Level in Egyptian Patients with Hepatitis C Virus-related Hepatocellular Carcinoma. Archives of Medical Research, 2010, 41, 541-547.	1.5	30
2917	Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: An open-label, multiple-dose, controlled Phase I study in adults. Clinical Therapeutics, 2010, 32, 328-337.	1.1	19
2918	Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding. Hepatology, 2010, 52, 230-237.	3.6	39
2919	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology, 2010, 52, 249-255.	3.6	123
2920	Quantification of superparamagnetic iron oxideâ€mediated signal intensity change in patients with liver cirrhosis using T2 and T2* mapping: A preliminary report. Journal of Magnetic Resonance Imaging, 2010, 31, 1379-1386.	1.9	7
2921	Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner?. Liver Transplantation, 2010, 16, 964-973.	1.3	50
2922	Religiosity associated with prolonged survival in liver transplant recipients. Liver Transplantation, 2010, 16, 1158-1163.	1.3	15
2923	Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. Journal of Infection, 2010, 61, 323-329.	1.7	32
2924	Alcohol consumption among patients with hepatitis B infection in northern Portugal considering gender and hepatitis B virus genotype differences. Alcohol, 2010, 44, 149-156.	0.8	20
2925	Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case–control study. Cancer Epidemiology, 2010, 34, 298-302.	0.8	31
2926	Pitfalls in measuring highâ€density lipoprotein cholesterol concentrations in HIVâ€infected patients. HIV Medicine, 2010, 11, 260-265.	1.0	0
2927	Evaluation of Quantitative Portal Venous, Hepatic Arterial, and Total Hepatic Tissue Blood Flow Using Xenon CT in Alcoholic Liver Cirrhosis— Comparison With Liver Cirrhosis Related to Hepatitis C Virus and Nonalcoholic Steatohepatitis. Alcoholism: Clinical and Experimental Research, 2010, 34, S7-S13.	1.4	18

#	Article	IF	CITATIONS
2928	Liver Disease and HPLC Quantification of Disialotransferrin for Heavy Alcohol Use: A Case Series. Alcoholism: Clinical and Experimental Research, 2010, 34, 1956-1960.	1.4	18
2929	A study of muscle tissue oxygenation and peripheral microcirculatory dysfunction in cirrhosis using near infrared spectroscopy. Liver International, 2010, 30, 463-471.	1.9	21
2930	Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease. Liver International, 2010, 30, 1003-1011.	1.9	22
2931	Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver International, 2010, 30, 1033-1042.	1.9	36
2932	Effects of terlipressin and somatostatin on liver and thorax blood volumes in patients with cirrhosis. Liver International, 2010, 30, 1371-1378.	1.9	5
2933	How to manage medications in the setting of liver disease with the application of six questions. International Journal of Clinical Practice, 2010, 64, 858-867.	0.8	7
2934	Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease. British Journal of Clinical Pharmacology, 2010, 70, 400-408.	1.1	11
2935	Influence of hepatic impairment on pharmacokinetics of the human GLPâ€1 analogue, liraglutide. British Journal of Clinical Pharmacology, 2010, 70, 807-814.	1.1	58
2936	Impact of evidenceâ€based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2010, 31, 493-501.	1.9	30
2937	Changes in quality of life and sexual health are associated with lowâ€dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2010, 31, 719-734.	1.9	22
2938	Outcomes of critically ill patients with cirrhosis admitted to intensive care: an important perspective from the nonâ€transplant setting. Alimentary Pharmacology and Therapeutics, 2010, 32, 233-243.	1.9	46
2939	The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Alimentary Pharmacology and Therapeutics, 2010, 32, 1343-1350.	1.9	103
2940	The effectiveness of relative dose response to retinol intake as an evaluation of vitamin A status of cirrhotic patients. Journal of Human Nutrition and Dietetics, 2010, 23, 583-589.	1.3	16
2941	ORIGINAL ARTICLE: Dysregulation of plasma ghrelin in alcoholic cirrhosis. Clinical Endocrinology, 2010, 73, 323-329.	1.2	12
2942	Blood–Brain Barrier Permeability for Ammonia in Patients with Different Grades of Liver Fibrosis is Not Different from Healthy Controls. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1384-1393.	2.4	26
2943	Variant in PNPLA3 is associated with alcoholic liver disease. Nature Genetics, 2010, 42, 21-23.	9.4	388
2944	Intrahepatic Transit Time Predicts Liver Fibrosis in Patients with Chronic Hepatitis B: Quantitative Assessment with Contrast-Enhanced Ultrasonography. Ultrasound in Medicine and Biology, 2010, 36, 1066-1075.	0.7	25
2945	High prevalence of diabetes mellitus in patients with liver cirrhosis. Diabetic Medicine, 2010, 27, 1308-1311.	1.2	38

#	Article	IF	CITATIONS
2946	Protein C and Dâ€dimer are related to portal vein thrombosis in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 116-121.	1.4	65
2947	High incidence of zinc deficiency among Filipino children with compensated and decompensated liver disease. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 387-390.	1.4	9
2948	Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 403-407.	1.4	57
2949	Longâ€term results of balloonâ€occluded retrograde transvenous obliteration for gastric fundal varices: Hepatic deterioration links to portosystemic shunt syndrome. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1129-1135.	1.4	117
2950	Increasing liver transplantation waiting list mortality: a report from the Australian National Liver Transplantation Unit, Sydney. Internal Medicine Journal, 2010, 40, 619-625.	0.5	14
2951	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transplant International, 2010, 23, 712-722.	0.8	45
2952	Article Commentary: Fundamentals of Liver Surgery for the Practicing General Surgeon. American Surgeon, 2010, 76, 461-469.	0.4	1
2953	Transarterial Radioembolization with Yttrium-90 for Regional Management of Hepatocellular Cancer: The Early Results of a Nontransplant Center. American Surgeon, 2010, 76, 1079-1083.	0.4	1
2954	Does Surgical Resection Have a Role in the Treatment of Large or Multinodular Hepatocellular Carcinoma?. American Surgeon, 2010, 76, 1189-1197.	0.4	18
2955	Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepatic Medicine: Evidence and Research, 2010, 2, 147.	0.9	3
2956	Evaluation of Portal Hypertensive Enteropathy by Scoring with Capsule Endoscopy: Is Transient Elastography of Clinical Impact?. Journal of Clinical Biochemistry and Nutrition, 2010, 47, 37-44.	0.6	35
2957	The use of whey protein concentrate in management of chronic hepatitis C virus – a pilot study. Archives of Medical Science, 2010, 5, 748-755.	0.4	7
2958	Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, 159-172.	0.7	2
2959	Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. Oncology Letters, 2010, 1, 57-61.	0.8	33
2960	Comparative study of coagulation and thrombin generation in the portal and jugular plasma of patients with cirrhosis. Thrombosis and Haemostasis, 2010, 104, 741-749.	1.8	38
2961	Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: Is it necessary?. World Journal of Gastroenterology, 2010, 16, 2146.	1.4	36
2962	Cognitive performance and mood in patients on the waiting list for liver transplantation and their relation to the model for end-stage liver disease. Arquivos De Neuro-Psiquiatria, 2010, 68, 62-66.	0.3	10
2963	Perfil epidemiológico e genotÃpico da infecção pelo vÃrus da hepatite B no Norte de Portugal. Revista De Saude Publica, 2010, 44, 1087-1093.	0.7	4

#	Article	IF	CITATIONS
2965	Planejamento pr \tilde{A} ©-operat \tilde{A}^3 rio em hepatectomias. Revista Do Colegio Brasileiro De Cirurgioes, 2010, 37, 370-375.	0.3	10
2966	Platelet Function and Other Indices of Hemostasis in Chronic Liver Disease. Gastroenterology Research, 2010, 3, 167-170.	0.4	0
2967	Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma. Oncology Letters, 2010, 1, 905-911.	0.8	3
2968	Mammary Duct Ectasia in a Man with Liver Disease, End Stage Renal Failure, and Adjacent Arteriovenous Fistula. Journal of Radiology Case Reports, 2010, 4, 36-41.	0.2	2
2969	Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study. Oncologist, 2010, 15, 1198-1204.	1.9	87
2970	Bacteremia, Acute Physiology and Chronic Health Evaluation II and Modified End Stage Liver Disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Critical Care Medicine, 2010, 38, 121-126.	0.4	611
2971	Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. Current Medical Research and Opinion, 2010, 26, 1-7.	0.9	31
2972	Human herpesvirus type 8 in patients with cirrhosis independent of thrombocytopenia. Journal of Clinical Pathology, 2010, 63, 254-258.	1.0	10
2973	Percutaneous radiofrequency ablation for the treatment of early stage hepatocellular carcinoma: A health technology assessment. International Journal of Technology Assessment in Health Care, 2010, 26, 390-397.	0.2	8
2974	Comparison of Decompensated Cirrhosis With and Without Patent Paraumbilical Vein. Journal of Diagnostic Medical Sonography, 2010, 26, 143-146.	0.1	0
2975	Predictors of minimal hepatic encephalopathy in patients with cirrhosis. Saudi Journal of Gastroenterology, 2010, 16, 181.	0.5	29
2976	Value of duplex doppler ultrasonography in non-invasive assessment of children with chronic liver disease. World Journal of Gastroenterology, 2010, 16, 6139.	1.4	12
2977	Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut, 2010, 59, 387-396.	6.1	145
2978	Abdominal wall hernia repair in cirrhotic patients: outcomes seen at a tertiary care hospital in a developing country. Tropical Doctor, 2010, 40, 5-8.	0.2	0
2979	Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06). Oncologist, 2010, 15, 285-292.	1.9	93
2980	A Confusing Relationship Between Child–Turcotte–Pugh Class A and Compensated Cirrhosis. American Journal of Gastroenterology, 2010, 105, 470-472.	0.2	5
2981	Peripheral and Splanchnic Indole and Oxindole Levels in Cirrhotic Patients: A Study on the Pathophysiology of Hepatic Encephalopathy. American Journal of Gastroenterology, 2010, 105, 1374-1381.	0.2	49
2982	On the Origin and the Consequences of Circadian Abnormalities in Patients With Cirrhosis. American Journal of Gastroenterology, 2010, 105, 1773-1781.	0.2	7 3

#	Article	IF	Citations
2983	Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver disease. Blood, 2010, 116, 335-342.	0.6	112
2984	Laparoscopic Versus Open Cholecystectomy in Patients with Liver Cirrhosis: A Prospective, Randomized Study. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2010, 20, 405-409.	0.5	33
2985	Is portal hypertensive enteropathy an important additional cause of blood loss in portal hypertensive patients?. Scandinavian Journal of Gastroenterology, 2010, 45, 1497-1502.	0.6	28
2986	The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2010, 13, 173-177.	2.0	22
2987	Bone Mineral Density, Bone Turnover Markers and Cytokines in Alcohol-Induced Cirrhosis. Alcohol and Alcoholism, 2010, 45, 427-430.	0.9	29
2988	Clinical Experience with Linezolid at a Large Academic Medical Center: A Case Series and Review of the Literature. Hospital Pharmacy, 2010, 45, 916-926.	0.4	3
2989	Challenges for Biomarker Discovery in Body Fluids Using SELDI-TOF-MS. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-15.	3.0	71
2990	Anaesthesia for patients with liver disease. Continuing Education in Anaesthesia, Critical Care & Pain, 2010, 10, 15-19.	0.6	65
2991	MR Findings of the Brain in Children and Adolescents with Portal Hypertension and the Relationship with Blood Manganese Levels. Neuropediatrics, 2010, 41, 12-17.	0.3	5
2992	Obesity and Microvascular Invasion in Hepatocellular Carcinoma. Cancer Investigation, 2010, 28, 1063-1069.	0.6	25
2993	Liver Transplant Considerations for Evaluation, CTP, and MELD. Critical Care Nursing Clinics of North America, 2010, 22, 403-411.	0.4	0
2994	Ambulatory Surgery: How Much Testing Do We Need?. Anesthesiology Clinics, 2010, 28, 185-197.	0.6	35
2995	Transarterial Chemoembolization with Epirubicin-eluting Beads versus Transarterial Embolization before Liver Transplantation for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2010, 21, 327-332.	0.2	132
2997	Prioritization for liver transplantation. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 659-668.	8.2	60
2998	Drug Dosing Considerations for the Critically Ill Patient with Liver Disease. Critical Care Nursing Clinics of North America, 2010, 22, 335-340.	0.4	11
2999	Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. Digestive and Liver Disease, 2010, 42, 200-204.	0.4	76
3000	The safety and probable therapeutic effect of routine use of antibiotics and simultaneously treating bleeding gastric varices by using endoscopic cyanoacrylate injection and concomitant esophageal varices with banding ligation: a pilot study. Gastrointestinal Endoscopy, 2010, 71, 1141-1149.	0.5	11
3001	Brain edema dynamics in patients with overt hepatic encephalopathyA magnetic resonance imaging study. Neurolmage, 2010, 52, 481-487.	2.1	61

#	Article	IF	Citations
3002	The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1215-1230.	1.5	11
3003	A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance. Clinical Pharmacokinetics, 2010, 49, 189-206.	1.6	178
3004	Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment. Clinical Pharmacokinetics, 2010, 49, 343-350.	1.6	19
3005	Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment. Clinical Pharmacokinetics, 2010, 49, 607-618.	1.6	30
3006	Lactic Acidosis Induced by Metformin. Drug Safety, 2010, 33, 727-740.	1.4	180
3007	Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel. Clinical Pharmacokinetics, 2010, 49, 777-798.	1.6	54
3008	Treatment of early hepatocellular carcinoma: Towards personalized therapy. Digestive and Liver Disease, 2010, 42, S242-S248.	0.4	31
3009	Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental and Clinical Medicine, 2010, 2, 93-103.	0.2	21
3010	Hepatocellular Carcinoma: Diagnosis, staging, and treatment strategy. Radiologia, 2010, 52, 385-398.	0.3	7
3011	Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C. Gastroenterology, 2010, 138, 136-146.	0.6	82
3012	Myeloperoxidase and carbonyl proteins: Promising markers for non-invasive monitoring of graft rejection after heart transplantation. Journal of Heart and Lung Transplantation, 2010, 29, 1352-1357.	0.3	17
3013	Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Human Immunology, 2010, 71, 621-626.	1.2	118
3014	Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. Journal of Hepatology, 2010, 52, 45-53.	1.8	26
3015	Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. Journal of Hepatology, 2010, 52, 199-205.	1.8	23
3016	Efficacy of entecavir in treatment-na \tilde{A} -ve patients with hepatitis B virus-related decompensated cirrhosis. Journal of Hepatology, 2010, 52, 176-182.	1.8	244
3017	The evaluation of renal function and disease in patients with cirrhosis. Journal of Hepatology, 2010, 52, 605-613.	1.8	218
3018	Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: Results of a randomized controlled trial. Journal of Hepatology, 2010, 53, 267-272.	1.8	129
3019	Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease. Journal of Hepatology, 2010, 53, 551-557.	1.8	63

#	Article	IF	CITATIONS
3021	Comparison of gadoxetic acid-enhanced MRI and superparamagnetic iron oxide-enhanced MRI for the detection of hepatocellular carcinoma. Clinical Radiology, 2010, 65, 358-365.	0.5	36
3022	CT and MRI findings of cirrhosis-related benign nodules with ischaemia or infarction after variceal bleeding. Clinical Radiology, 2010, 65, 801-808.	0.5	3
3023	Oxidized albumin is associated with water retention and severity of disease in patients with chronic liver diseases. European E-journal of Clinical Nutrition and Metabolism, 2010, 5, e247-e253.	0.4	8
3024	Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation. European Journal of Radiology, 2010, 74, e6-e11.	1.2	21
3025	Serum selenium levels in cirrhotic patients are not influenced by the disease severity index. Nutrition Research, 2010, 30, 574-578.	1.3	17
3026	Combined use of D-dimer and P-selectin for the diagnosis of splenic or portal vein thrombosis following splenectomy. Thrombosis Research, 2010, 125, e206-e209.	0.8	22
3027	The Effect of Recipient Hepatitis C Virus Infection on Outcomes Following Heart Transplantation. Transplantation Proceedings, 2010, 42, 1784-1787.	0.3	7
3028	Survival Before and After Model for End-stage Liver Disease Score Introduction on the Brazilian Liver Transplant Waiting List. Transplantation Proceedings, 2010, 42, 412-416.	0.3	8
3029	The model of end-stage liver disease (MELD) score in predicting postoperative liver failure after hepatic resection of hepatocellular carcinoma in cirrhotic patients: The Tunisian experience. Arab Journal of Gastroenterology, 2010, 11, 35-38.	0.4	0
3030	Association of MnSOD Ala16Val genotype and activity with hepatocellular carcinoma risk in HCV-infected Egyptian patients. Arab Journal of Gastroenterology, 2010, 11, 19-23.	0.4	2
3031	Leptin, osteocalcin, and bone mineral density in post-hepatitic liver cirrhosis. Arab Journal of Gastroenterology, 2010, 11, 130-135.	0.4	3
3032	Transmission of varicella-zoster virus originating from a patient with localized herpes zoster: Implications for infection control?. American Journal of Infection Control, 2010, 38, 669-670.	1.1	8
3033	Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma. Hepatology Research, 2010, 40, 550-554.	1.8	17
3034	Portal vein thrombosis in Egyptian patients with liver cirrhosis: Role of methylenetetrahydrofolate reductase <i>C677T</i> gene mutation. Hepatology Research, 2010, 40, 486-493.	1.8	21
3035	Effect of a late evening snack using branchedâ€chain amino acidâ€enriched nutrients in patients undergoing hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatology Research, 2010, 40, 574-584.	1.8	34
3036	Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatology Research, 2010, 40, 911-922.	1.8	14
3037	Scintigraphic evaluation of intrapulmonary shunt in normoxemic cirrhotic patients and effects of terlipressin. Hepatology Research, 2010, 40, 1015-1021.	1.8	6
3038	Prosthetic hip infection in patients with liver cirrhosis: an outcome analysis. International Journal of Infectious Diseases, 2010, 14, e1054-e1059.	1.5	15

#	Article	IF	CITATIONS
3039	Cirrhotic Patients Are at Risk for Health Care–Associated Bacterial Infections. Clinical Gastroenterology and Hepatology, 2010, 8, 979-985.e1.	2.4	274
3040	Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia. Scandinavian Journal of Gastroenterology, 2010, 45, 1509-1515.	0.6	10
3041	Spectral and dynamic electroencephalogram abnormalities are correlated to psychometric test performance in hepatic encephalopathy. Scandinavian Journal of Gastroenterology, 2011, 46, 988-996.	0.6	13
3042	Retrospective analysis of risk factors for development of liver dysfunction in transient leukemia of Down syndrome. Leukemia and Lymphoma, 2011, 52, 1523-1527.	0.6	8
3043	Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scandinavian Journal of Gastroenterology, 2011, 46, 750-759.	0.6	69
3044	Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2011, 46, 201-210.	0.6	6
3045	Usefulness of the Mini Nutritional Assessment in Predicting the Nutritional Status of Patients With Liver Cancer in Taiwan. Nutrition and Cancer, 2011, 63, 334-341.	0.9	15
3046	The effects of liver impairment on opioids used to relieve pain in cancer patients. Palliative Medicine, 2011, 25, 604-605.	1.3	18
3047	Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment. Journal of Clinical Pharmacology, 2011, 51, 978-987.	1.0	39
3048	C-reactive protein level as a predictor of mortality in liver disease patients with bacteremia. Scandinavian Journal of Gastroenterology, 2011, 46, 1478-1483.	0.6	9
3049	Metabolomic Approach by ¹ H NMR Spectroscopy of Serum for the Assessment of Chronic Liver Failure in Patients with Cirrhosis. Journal of Proteome Research, 2011, 10, 3239-3245.	1.8	56
3050	Modified Percutaneous Transhepatic Variceal Embolization With 2-Octylcyanoacrylate for Bleeding Gastric Varices: Long-Term Follow-Up Outcomes. American Journal of Roentgenology, 2011, 197, 502-509.	1.0	14
3051	A Model to Determine 3-Month Mortality Risk in Patients With Acute-on-Chronic Hepatitis B Liver Failure. Clinical Gastroenterology and Hepatology, 2011, 9, 351-356.e3.	2.4	64
3052	A Clinical Prediction Rule and Platelet Count Predict Esophageal Varices in Children. Gastroenterology, 2011, 141, 2009-2016.	0.6	75
3053	Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 111-116.	0.7	17
3054	Evaluation of nitrite/nitrate levels in relation to oxidative stress parameters in liver cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 303-308.	0.7	15
3055	Study of serum ghrelin changes and its correlation with malnutrition in liver cirrhosis in Egypt. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 638-643.	0.7	8
3056	Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension. Digestive and Liver Disease, 2011, 43, 48-53.	0.4	19

#	ARTICLE	IF	CITATIONS
3057	Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis. Digestive and Liver Disease, 2011, 43, 314-318.	0.4	5
3058	Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 319-324.	0.4	21
3059	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Digestive and Liver Disease, 2011, 43, 875-80.	0.4	23
3060	Influence of aquaporin-1 gene polymorphism on water retention in liver cirrhosis. Scandinavian Journal of Gastroenterology, 2011, 46, 1267-1274.	0.6	16
3061	Asenapine Pharmacokinetics in Hepatic and Renal Impairment. Clinical Pharmacokinetics, 2011, 50, 471-481.	1.6	27
3062	Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C. Gastroenterology, 2011, 140, 1970-1979.e3.	0.6	351
3063	Acquired bleeding disorders., 2011,, 565-582.		1
3064	No Impact of Hepatitis C Virus Infection on Mortality Among Drug Users During the First Decade After Seroconversion. Clinical Gastroenterology and Hepatology, 2011, 9, 786-792.e1.	2.4	10
3065	Serum interleukin-18: Does it have a role in the diagnosis of hepatitis C virus related hepatocellular carcinoma?. Arab Journal of Gastroenterology, 2011, 12, 29-33.	0.4	12
3066	Can serum fibrosis markers predict medium/large oesophageal varices in patients with liver cirrhosis?. Arab Journal of Gastroenterology, 2011, 12, 62-67.	0.4	8
3067	Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome. Arab Journal of Gastroenterology, 2011, 12, 131-135.	0.4	6
3068	Systemic inflammatory response syndrome in patients with liver cirrhosis. Arab Journal of Gastroenterology, 2011, 12, 173-177.	0.4	39
3069	Evaluation of nitric oxide as a novel diagnostic marker for hepatocellular carcinoma. Alexandria Journal of Medicine, 2011, 47, 31-35.	0.4	7
3071	No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinoma development in Turkish population: A case-control study. Gene, 2011, 486, 104-109.	1.0	71
3072	The association between the survivin â^31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiology, 2011, 35, 555-559.	0.8	22
3073	Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation. European E-journal of Clinical Nutrition and Metabolism, 2011, 6, e142-e147.	0.4	24
3074	Development of a new predictive model for polypathological patients. The PROFUND index. European Journal of Internal Medicine, 2011, 22, 311-317.	1.0	146
3075	Iron deficiency increases blood manganese level in the Korean general population according to KNHANES 2008. NeuroToxicology, 2011, 32, 247-254.	1.4	63

#	Article	IF	CITATIONS
3076	Predicting the Prognosis of Hepatocellular Carcinoma Using Gene Expression. Journal of Surgical Research, 2011, 171, 524-531.	0.8	6
3077	Assessment of adrenocortical reserve in stable patients with cirrhosis. Journal of Hepatology, 2011, 54, 243-250.	1.8	75
3078	Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. Journal of Hepatology, 2011, 54, 640-649.	1.8	224
3079	Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia. Journal of Hepatology, 2011, 54, 1154-1160.	1.8	50
3080	The MELD score in patients awaiting liver transplant: Strengths and weaknesses. Journal of Hepatology, 2011, 54, 1297-1306.	1.8	140
3081	Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. Journal of Hepatology, 2011, 55, 574-581.	1.8	154
3082	Resumption of ambulatory status after surgery for nonambulatory patients with epidural spinal metastasis. Spine Journal, 2011, 11, 1015-1023.	0.6	47
3083	Laparoscopic liver resection for benign and malignant liver tumors. Hepatobiliary and Pancreatic Diseases International, 2011, 10, 38-42.	0.6	9
3084	Hemoperitoneum in cirrhotic patients without abdominal trauma or tumor. Hepatobiliary and Pancreatic Diseases International, 2011, 10, 644-648.	0.6	8
3085	Antiâ€hypoalbuminemic effect of branchedâ€chain amino acid granules in patients with liver cirrhosis is independent of dietary energy and protein intake. Hepatology Research, 2011, 41, 1027-1035.	1.8	19
3086	Potential peripheral biological predictors of suicidal behavior in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 842-847.	2.5	77
3087	957 THE CLINICAL SIGNIFICANCE OF PLASMA OSTEOPONTIN LEVEL IN EGYPTIAN PATIENTS WITH HEPATITIS C VIRUS-RELATED HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2011, 54, S382-S383.	1.8	0
3088	Tolemerase Reverse Transcriptase Gene Expression as a Tumor Marker for Hepatocellular Carcinoma. American Journal of Biochemistry and Biotechnology, 2011, 7, 55-62.	0.1	1
3089	Correlation of Kupffer cell function and hepatocyte function in chronic viral hepatitis evaluated with superparamagnetic iron oxide-enhanced magnetic resonance imaging and scintigraphy using technetium-99m-labelled galactosyl human serum albumin. Experimental and Therapeutic Medicine, 2011. 2. 607-613.	0.8	6
3090	Integrating Palliative Care with Chronic Liver Disease Care. Journal of Palliative Care, 2011, 27, 20-27.	0.4	25
3091	<i>Inconsistency in the Management of Patients with Hepatocellular Carcinoma: The Need for a Strict Protocol</i> <ir> American Surgeon, 2011, 77, 207-214. </ir>	0.4	3
3092	The effects of magnesium pretreatment on reperfusion injury during living donor liver transplantation. Korean Journal of Anesthesiology, 2011, 60, 408.	0.9	14
3093	Minor Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients: Kelly Clamp Crushing Resection Versus Heat Coagulative Necrosis with Bipolar Radiofrequency Device. American Surgeon, 2011, 77, 1490-1495.	0.4	3

#	Article	IF	CITATIONS
3094	Gastrointestinal Pharmacology. , 2011, , 1234-1247.		1
3095	Uso de octreotida na hemorragia digestiva alta secundária à hipertensão portal em pacientes pediátricos: experiência de um serviço terciário. Revista Paulista De Pediatria, 2011, 29, 606-611.	0.4	0
3096	Serum MicroRNAs as Biomarkers for Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection. PLoS ONE, 2011, 6, e28486.	1.1	262
3097	Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib. PLoS ONE, 2011, 6, e16978.	1.1	60
3098	Efficacy and Safety of Gamma-Hydroxybutyrate in Treating Alcohol Withdrawal Syndrome in an Alcohol-Dependent Inpatient With Decompensated Liver Cirrhosis. Journal of Clinical Psychopharmacology, 2011, 31, 140-141.	0.7	10
3099	Acute-on-chronic liver failure: extracorporeal liver assist devices. Current Opinion in Critical Care, 2011, 17, 195-203.	1.6	54
3100	Acute-on-chronic liver failure: concept, natural history, and prognosis. Current Opinion in Critical Care, 2011, 17, 165-169.	1.6	147
3101	Relation of Serum Levels of Thrombopoietin to Thrombocytopenia in Extrahepatic Portal Vein Obstruction Versus Cirrhotic Children. Journal of Pediatric Hematology/Oncology, 2011, 33, e267-e270.	0.3	5
3102	Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 420-427.	0.9	30
3103	Community-Acquired Pneumonia in Patients With Liver Cirrhosis. Medicine (United States), 2011, 90, 110-118.	0.4	78
3104	Detection of Small Hepatocellular Carcinoma. Investigative Radiology, 2011, 46, 383-389.	3.5	35
3105	Personalized medicine in hepatocellular carcinoma: rationale and clinical data. Clinical Investigation, 2011, 1, 1403-1411.	0.0	1
3106	Amino Acid Substitutions in the Hepatitis C Virus Core Region Are Associated With Postoperative Recurrence and Survival of Patients With HCV Genotype 1b-Associated Hepatocellular Carcinoma. Annals of Surgery, 2011, 254, 326-332.	2.1	12
3107	Liver Dysfunction by Model for End-Stage Liver Disease Score Improves Mortality Prediction in Injured Patients With Cirrhosis. Journal of Trauma, 2011, 71, 6-11.	2.3	12
3108	Perioperative Transfusion Risk Assessment With Elective Hepatectomy. Annals of Surgery, 2011, 253, 629-630.	2.1	0
3109	Outcome Scoring Systems for Short-term Prognosis in Critically Ill Cirrhotic Patients. Shock, 2011, 36, 445-450.	1.0	44
3110	Triple Positive Tumor Markers for Hepatocellular Carcinoma Are Useful Predictors of Poor Survival. Annals of Surgery, 2011, 254, 984-991.	2.1	48
3111	High-Intensity Focused Ultrasound for Hepatocellular Carcinoma. Annals of Surgery, 2011, 253, 981-987.	2.1	108

#	Article	IF	CITATIONS
3112	Is Model for End-Stage Liver Disease Score Associated with Quality of Life after Liver Transplantation?. Progress in Transplantation, 2011, 21, 207-214.	0.4	13
3114	Surgical Outcome of Spinal Hepatocellular Carcinoma Metastases. Neurosurgery, 2011, 68, 888-896.	0.6	23
3115	Assessment of nutritional status of patients waiting for liver transplantation. Clinical Transplantation, 2011, 25, 248-254.	0.8	63
3116	Could metabolic liver function tests predict mortality on waiting list for liver transplantation? A study on 560 patients. Clinical Transplantation, 2011, 25, 755-765.	0.8	14
3117	LabMELDâ€based organ allocation increases total costs of liver transplantation: a singleâ€center experience. Clinical Transplantation, 2011, 25, E558-65.	0.8	16
3118	<i>Lens culinaris</i> agglutininâ€reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 731-738.	1.4	31
3119	Validation of an extension of the international nonâ€invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 669-677.	1.4	22
3120	Repeated liver resection for recurrent hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1189-1194.	1.4	40
3121	Relationships between blood levels of fat soluble vitamins and disease etiology and severity in adults awaiting liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1402-1410.	1.4	25
3122	Nonâ€invasive estimation of liver fibrosis in nonâ€alcoholic fatty liver disease using the ¹³ Câ€caffeine breath test. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1411-1416.	1.4	21
3123	Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, no-no.	1.4	23
3124	Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1765-1771.	1.4	10
3125	Silymarin use and liver disease progression in the Hepatitis C Antiviral Longâ€Term Treatment against Cirrhosis trial. Alimentary Pharmacology and Therapeutics, 2011, 33, 127-137.	1.9	67
3126	A functional polymorphism in preâ€microRNAâ€196aâ€2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case–control study. Journal of Viral Hepatitis, 2011, 18, e399-407.	1.0	95
3127	Evaluation of antiretroviral-related errors and interventions by the clinical pharmacist in hospitalized HIV-infected patients. HIV Medicine, 2011, 12, 494-499.	1.0	47
3128	Liver resection in obese patients: results of a case–control study. Hpb, 2011, 13, 103-111.	0.1	38
3129	Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. Liver International, 2011, 31, 192-196.	1.9	8
3130	Validation of a Mayo post-operative mortality risk prediction model in Korean cirrhotic patients. Liver International, 2011, 31, 222-228.	1.9	28

#	Article	IF	CITATIONS
3131	Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study. Liver International, 2011, 31, 391-400.	1.9	53
3132	Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver International, 2011, 31, 417-424.	1.9	67
3133	Minimal hepatic encephalopathy does not impair health-related quality of life in patients with cirrhosis: a prospective study. Liver International, 2011, 31, 980-984.	1.9	30
3134	Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver International, 2011, 31, 534-540.	1.9	100
3135	Distinct clinical courses according to presenting phenotypes and their correlations to ATP7B mutations in a large Wilson's disease cohort. Liver International, 2011, 31, 831-839.	1.9	49
3136	THIS ARTICLE HAS BEEN RETRACTED: Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation. Liver International, 2011, 31, 850-858.	1.9	15
3137	<scp>NADPH</scp> oxidaseâ€mediated platelet isoprostane overâ€production in cirrhotic patients: implication for platelet activation. Liver International, 2011, 31, 1533-1540.	1.9	37
3138	S-adenosyl-L-methionine Treatment for Alcoholic Liver Disease: A Double-Blinded, Randomized, Placebo-Controlled Trial. Alcoholism: Clinical and Experimental Research, 2011, 35, 1960-1965.	1.4	63
3139	Hepatocellular Carcinoma in Older Adults: Clinical Features, Treatments, and Survival. Journal of the American Geriatrics Society, 2011, 59, 241-250.	1.3	40
3140	Stage of hepatocellular carcinoma is associated with periodontitis. Journal of Clinical Periodontology, 2011, 38, 1015-1020.	2.3	37
3141	Patients' Willingness to Accept Expanded Criteria Donor Liver Transplantation. American Journal of Transplantation, 2011, 11, 1705-1711.	2.6	12
3142	Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery, 2011, 149, 713-724.	1.0	1,703
3143	Comparison of Acute Physiology and Chronic Health Evaluation II Death Risk, Child-Pugh, Charlson, and Model for End-stage Liver Disease Indexes to Predict Early Mortality After Liver Transplantation. Transplantation Proceedings, 2011, 43, 1660-1664.	0.3	23
3144	Etomidate and mortality in cirrhotic patients with septic shock. BMC Clinical Pharmacology, 2011, 11, 22.	2.5	19
3145	No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. Journal of Affective Disorders, 2011, 129, 205-212.	2.0	4
3146	Importance of Low Preoperative Platelet Count in Selecting Patients for Resection of Hepatocellular Carcinoma: A Multi-Institutional Analysis. Journal of the American College of Surgeons, 2011, 212, 638-648.	0.2	105
3147	Segment IV Preserving Middle Hepatic Vein Retrieval in Right Lobe Living Donor Liver Transplantation. Journal of the American College of Surgeons, 2011, 213, e5-e16.	0.2	15
3148	Orally Formulated Artemisinin in Healthy Fasting Vietnamese Male Subjects: A Randomized, Four-Sequence, Open-Label, Pharmacokinetic Crossover Study. Clinical Therapeutics, 2011, 33, 644-654.	1.1	17

#	Article	IF	CITATIONS
3149	Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009). Critical Reviews in Oncology/Hematology, 2011, 80, 393-410.	2.0	33
3150	A multi-institutional, hospital-based assessment of clinical, functional, sociofamilial and health-care characteristics of polypathological patients (PP). Archives of Gerontology and Geriatrics, 2011, 53, 284-291.	1.4	45
3151	Diagnostic difficulties and treatment strategy of hepatic angiomyolipoma. Asian Journal of Surgery, 2011, 34, 158-162.	0.2	17
3152	Coronary Revascularization in Patients With Liver Cirrhosis. Annals of Thoracic Surgery, 2011, 91, 1393-1399.	0.7	40
3153	Improved Diagnostic Imaging and Interventional Therapies Prolong Survival After Resection for Hepatocellular Carcinoma in Cirrhosis: The University of Bologna Experience Over 10ÂYears. Annals of Surgical Oncology, 2011, 18, 1630-1637.	0.7	43
3154	Adherence and Adequacy of Therapy for Esophageal Varices Prophylaxis. Digestive Diseases and Sciences, 2011, 56, 3129-3136.	1.1	8
3155	Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Investigational New Drugs, 2011, 29, 1370-1380.	1.2	51
3156	Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2011, 347, 201-208.	1.4	32
3157	Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metabolic Brain Disease, 2011, 26, 281-289.	1.4	49
3158	The effects of cefazolin on cirrhotic patients with acute variceal hemorrhage after endoscopic interventions. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2911-2918.	1.3	25
3159	Surgical treatment of lymph node metastases from hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 559-566.	1.4	41
3160	Tumorâ€related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 689-699.	1.4	16
3161	Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. Journal of Gastroenterology, 2011, 46, 687-695.	2.3	70
3162	The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1723-1731.	3.3	35
3163	Selection Criteria for Hepatectomy in Patients with Hepatocellular Carcinoma Classified as Childâ€Pugh Class B. World Journal of Surgery, 2011, 35, 834-841.	0.8	24
3164	Impact of the Thoracoabdominal Approach on Peri―and Postoperative Outcomes of Hepatectomy for Hepatocellular Carcinoma. World Journal of Surgery, 2011, 35, 1042-1049.	0.8	7
3165	The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology, 2011, 68, 1485-1495.	1.1	28
3166	Hepatic vein waveforms in liver cirrhosis re-evaluated. Hepatology International, 2011, 5, 581-585.	1.9	14

#	Article	IF	CITATIONS
3167	Study of Predictive Value of Pediatric Risk of Mortality (PRISM) Score in Children with End Stage Liver Disease and Fulminant Hepatic Failure. Indian Journal of Pediatrics, 2011, 78, 301-306.	0.3	4
3168	MELD-Based Indices as Predictors of Mortality in Chronic Liver Disease Patients Who Undergo Emergency Surgery with General Anesthesia. Journal of Gastrointestinal Surgery, 2011, 15, 2029-2035.	0.9	15
3169	Assessment of intrahepatic blood flow by Doppler ultrasonography: Relationship between the hepatic vein, portal vein, hepatic artery and portal pressure measured intraoperatively in patients with portal hypertension. BMC Gastroenterology, 2011, 11, 84.	0.8	21
3170	Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. BMC Clinical Pharmacology, 2011, 11, 3.	2.5	24
3171	Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transplantation, 2011, 17, 129-136.	1.3	70
3172	Patients' expectations and success criteria for liver transplantation. Liver Transplantation, 2011, 17, 1309-1317.	1.3	22
3173	Usefulness of a modified inflammationâ€based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. Journal of Surgical Oncology, 2011, 103, 801-806.	0.8	41
3174	Prognostic significance of postoperative complications after hepatectomy for hepatocellular carcinoma. Journal of Surgical Oncology, 2011, 104, 814-821.	0.8	50
3175	Underweight patients show an increased rate of postoperative death after surgery for hepatocellular carcinoma. Journal of Surgical Oncology, 2011, 104, 809-813.	0.8	7
3176	Portal hypertension correlates with splenic stiffness as measured with MR elastography. Journal of Magnetic Resonance Imaging, 2011, 34, 79-87.	1.9	100
3177	Chronic liver disease and cirrhosis among patients with hepatitis B virus infection in northern Portugal with reference to the viral genotypes. Journal of Medical Virology, 2011, 83, 71-77.	2.5	11
3178	Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: A long-term cohort study. Hepatology, 2011, 53, 136-147.	3.6	159
3179	Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis. Hepatology, 2011, 53, 558-566.	3.6	69
3180	Carbon monoxide enhances early liver regeneration in mice after hepatectomy. Hepatology, 2011, 53, 2016-2026.	3.6	33
3181	A key role for Pre-B cell colony-enhancing factor in experimental hepatitis. Hepatology, 2011, 54, 675-686.	3.6	20
3182	Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology, 2011, 54, 562-572.	3.6	883
3183	Intensive care of the patient with cirrhosis. Hepatology, 2011, 54, 1864-1872.	3.6	215
3184	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology, 2011, 54, 2055-2063.	3.6	321

#	Article	IF	CITATIONS
3185	Vâ€CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer, 2011, 117, 2478-2488.	2.0	39
3186	Anxiety and depression in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 621-632.	0.9	129
3187	Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. International Journal of Cancer, 2011, 129, 1923-1931.	2.3	77
3188	Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease. British Journal of Nutrition, 2011, 106, 1724-1731.	1.2	47
3189	Quantitative Color Mapping of the Arterial Enhancement Fraction in Patients With Diffuse Liver Disease. American Journal of Roentgenology, 2011, 197, 876-883.	1.0	42
3190	Pharmacokinetics of Laropiprant, a Selective Prostaglandin D ₂ Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment. Journal of Clinical Pharmacology, 2011, 51, 406-412.	1.0	1
3191	Pharmacokinetics and Safety of a Single Intravenous Dose of the Antibiotic Tigecycline in Patients With Cirrhosis. Journal of Clinical Pharmacology, 2011, 51, 93-101.	1.0	28
3192	Effects of Hepatic Dysfunction on the Single-Dose Pharmacokinetics of Fesoterodine. Journal of Clinical Pharmacology, 2011, 51, 397-405.	1.0	10
3193	Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics. Journal of Clinical Pharmacology, 2011, 51, 739-750.	1.0	31
3194	Dark adaptation in vitamin A-deficient adults awaiting liver transplantation: improvement with intramuscular vitamin A treatment. British Journal of Ophthalmology, 2011, 95, 544-548.	2.1	25
3195	Assessing Glomerular Filtration Rate in Hospitalized Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2411-2420.	2.2	48
3196	Clinical Spectrum of Renal Disorders in Patients with Cirrhosis of Liver. Renal Failure, 2011, 33, 40-46.	0.8	29
3197	Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian Journal of Radiology and Imaging, 2011, 21, 113-120.	0.3	31
3198	Association Between Portal Vein Color Doppler Findings and the Severity of Disease in Cirrhotic Patients With Portal Hypertension. Iranian Journal of Radiology, 2011, 8, 211-217.	0.1	27
3199	Comparison of Cystatin C and Creatinine-based Glomerular Filtration Rate Formulas with 51Cr-EDTA Clearance in Patients with Cirrhosis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 84-92.	2.2	59
3200	Oral acetyl-l-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. American Journal of Clinical Nutrition, 2011, 93, 799-808.	2.2	75
3201	Clinical Characteristics of Non-B Non-C Hepatocellular Carcinoma: A Single-Center Retrospective Study. Digestion, 2011, 84, 43-49.	1.2	22
3202	Staging Hepatic Fibrosis: Comparison of Gadoxetate Disodium–enhanced and Diffusion-weighted MR Imaging—Preliminary Observations. Radiology, 2011, 259, 142-150.	3.6	172

#	Article	IF	Citations
3203	Kidney Function: Glomerular Filtration Rate Measurement with MR Renography in Patients with Cirrhosis. Radiology, 2011, 259, 462-470.	3.6	55
3204	Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Review of Anticancer Therapy, 2011, 11, 1807-1816.	1.1	22
3205	Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. American Journal of Physiology - Renal Physiology, 2011, 301, G269-G277.	1.6	49
3206	Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89–IgA and IgG–IgA complexes: common mechanisms for distinct diseases. Kidney International, 2011, 80, 1352-1363.	2.6	69
3207	Potential Precipitating Factors of Esophageal Variceal Bleeding: A Case–Control Study. American Journal of Gastroenterology, 2011, 106, 96-103.	0.2	25
3208	Diagnostic Value of the < sup > 13 < / sup > C Methacetin Breath Test in Various Stages of Chronic Liver Disease. Gastroenterology Research and Practice, 2011, 2011, 1-6.	0.7	15
3209	The role of glucocorticoids in sodium retention in cirrhotic patients: A double blind, randomized, crossover study. Scandinavian Journal of Gastroenterology, 2012, 47, 1030-1036.	0.6	0
3210	Relevance of Serum Levels of Interleukin-6 and Syndecan-1 in Patients with Hepatocellular Carcinoma. Scientia Pharmaceutica, 2012, 80, 179-188.	0.7	34
3211	Heme Oxygenase-1 mRNA Expression in Egyptian Patients With Chronic Liver Disease. Hepatitis Monthly, 2012, 12, 278-285.	0.1	19
3212	Motor Deficits Associated With Mild, Chronic Hyponatremia: A Factor Analytic Study. Journal of Motor Behavior, 2012, 44, 255-259.	0.5	2
3213	Clinical Relevance and Discriminatory Value of Elevated Liver Aminotransferase Levels for Dengue Severity. PLoS Neglected Tropical Diseases, 2012, 6, e1676.	1.3	97
3214	CLINICAL OUTCOMES AND ORTHOPEDIC SURGERY FOR BONE METASTASES FROM HEPATOCELLULAR CARCINOMA. Journal of Musculoskeletal Research, 2012, 15, 1250022.	0.1	0
3215	Efficacy and Safety of Levetiracetam for the Prevention of Alcohol Relapse in Recently Detoxified Alcohol-Dependent Patients. Journal of Clinical Psychopharmacology, 2012, 32, 558-562.	0.7	24
3216	Acute kidney injury and in-hospital mortality in critically ill patients with cirrhosis: a cohort study. Gut, 2012, 61, 955-956.	6.1	12
3217	Use of Hepatotoxic Drugs in Chronic Liver Disease. Journal of Patient Safety, 2012, 8, 45-50.	0.7	2
3218	Clinically Important Differences in the Pharmacokinetics of the Ten Newer "Atypical―Antipsychotics. Journal of Psychiatric Practice, 2012, 18, 430-437.	0.3	12
3219	Three-dimensional Doppler ultrasonographic evaluation of hemodynamic changes in the left gastric vein and hepatic artery resistive index before and after variceal band ligation. Egyptian Liver Journal, 2012, 2, 88-95.	0.3	0
3220	Differential Clinical and Virologic Impact of Hepatitis B Virus Genotypes B and C on HIV-Coinfected Patients Receiving Lamivudine-Containing Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2012, 54, 548-555.	2.9	12

#	Article	IF	CITATIONS
3221	Altered Resting-State Brain Activity at Functional MR Imaging during the Progression of Hepatic Encephalopathy. Radiology, 2012, 264, 187-195.	3.6	94
3222	Altered Brain Functional Connectivity in Patients with Cirrhosis and Minimal Hepatic Encephalopathy: A Functional MR Imaging Study. Radiology, 2012, 265, 528-536.	3.6	66
3223	Local-Regional Treatment of Hepatocellular Carcinoma. Radiology, 2012, 262, 43-58.	3.6	331
3224	Normal and Altered Three-dimensional Portal Venous Hemodynamics in Patients with Liver Cirrhosis. Radiology, 2012, 262, 862-873.	3.6	75
3225	Significant Volume Reduction and Shape Abnormalities of the Basal Ganglia in Cases of Chronic Liver Cirrhosis. American Journal of Neuroradiology, 2012, 33, 239-245.	1.2	14
3226	Pharmacokinetics of Oral Tonapofylline and Its Acylâ€Glucuronide Metabolite in Patients With Mild and Moderate Hepatic Impairment. Journal of Clinical Pharmacology, 2012, 52, 543-551.	1.0	1
3227	Pharmacokinetics of the Soluble Guanylate Cyclase Activator Cinaciguat in Individuals With Hepatic Impairment. Journal of Clinical Pharmacology, 2012, 52, 1714-1724.	1.0	5
3228	Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate. Journal of Clinical Pharmacology, 2012, 52, 738-746.	1.0	2
3229	Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study. Journal of Clinical Pharmacology, 2012, 52, 552-558.	1.0	9
3230	Psychomotor Deficits Associated With Hyponatremia: A Retrospective Analysis. Clinical Neuropsychologist, 2012, 26, 74-87.	1.5	10
3231	The Pharmacokinetics and Pharmacodynamics of Tolvaptan in Patients with Liver Cirrhosis with Insufficient Response to Conventional Diuretics: a Multicentre, Double-blind, Parallel-group, Phase III Study. Journal of International Medical Research, 2012, 40, 2381-2393.	0.4	32
3232	Assessment of hepatic function. , 2012, , 58-64.e2.		0
3233	Intrarenal Resistance Index as a Prognostic Parameter in Patients with Liver Cirrhosis Compared with Other Hepatic Scoring Systems. Digestion, 2012, 86, 349-354.	1.2	6
3234	Body Composition in Liver Cirrhosis. , 2012, , 2187-2199.		0
3235	Prediction of Newly Developed Acute Renal Failure using Serum Phosphorus Concentrations after Living-donor Liver Transplantation. Journal of International Medical Research, 2012, 40, 2199-2212.	0.4	3
3236	Profile and Outcome of Patients With Liver Cirrhosis Requiring Mechanical Ventilation. Journal of Intensive Care Medicine, 2012, 27, 373-378.	1.3	23
3237	Perioperative Assessment of Terlipressin Infusion during Living Donor Liver Transplantation. Journal of International Medical Research, 2012, 40, 225-236.	0.4	18
3238	Symptom Clusters in Chinese Patients With Primary Liver Cancer. Oncology Nursing Forum, 2012, 39, E468-E479.	0.5	16

#	Article	IF	CITATIONS
3239	Small Intestinal Edema Had the Strongest Correlation with Portal Venous Pressure amongst Capsule Endoscopy Findings. Digestion, 2012, 86, 48-54.	1.2	14
3240	Thyroid and Hepatic Haemodynamic Alterations among Egyptian Children with Liver Cirrhosis. ISRN Gastroenterology, 2012, 2012, 1-7.	1.5	13
3241	Nutritional Status Assessment in Cirrhotic Patients after Protein Supplementation. ISRN Gastroenterology, 2012, 2012, 1-4.	1.5	16
3242	The Utility of Scoring Systems in Predicting Early and Late Mortality in Alcoholic Hepatitis: Whose Score Is It Anyway?. International Journal of Hepatology, 2012, 2012, 1-5.	0.4	24
3243	Health-Related Quality of Life in Chinese Patients with Chronic Liver Disease. Gastroenterology Research and Practice, 2012, 2012, 1-7.	0.7	19
3244	Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients. Clinical Cancer Research, 2012, 18, 4397-4405.	3.2	87
3245	Pharmacokinetics of Amphotericin B Colloidal Dispersion in Critically III Patients with Cholestatic Liver Disease. Antimicrobial Agents and Chemotherapy, 2012, 56, 5414-5418.	1.4	10
3246	Decreased CD27 on B Lymphocytes in Patients with Primary Hepatocellular Carcinoma. Journal of International Medical Research, 2012, 40, 307-316.	0.4	18
3247	Adult Liver Transplantation in the United States. American Journal of the Medical Sciences, 2012, 343, 462-469.	0.4	30
3248	Primary Liver Cancer. Medical Radiology, 2012, , 163-182.	0.0	1
3248 3249	Primary Liver Cancer. Medical Radiology, 2012, , 163-182. Adding variceal status to Child–Turcotte–Pugh score improves its performance in predicting early mortality in cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 1348-1349.	0.0	5
	Adding variceal status to Child–Turcotte–Pugh score improves its performance in predicting early		
3249	Adding variceal status to Child–Turcotte–Pugh score improves its performance in predicting early mortality in cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 1348-1349. Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic	0.8	5
3249 3250	Adding variceal status to Child–Turcotte–Pugh score improves its performance in predicting early mortality in cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 1348-1349. Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Annals of Surgery, 2012, 256, 706-713. Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective	0.8	5
3249 3250 3251	Adding variceal status to Child–Turcotte–Pugh score improves its performance in predicting early mortality in cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 1348-1349. Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Annals of Surgery, 2012, 256, 706-713. Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective study. European Journal of Gastroenterology and Hepatology, 2012, 24, 897-904. Liver transplantation for hepatocellular carcinoma in clinical practice. European Journal of	0.8 2.1 0.8	5 142 38
3249 3250 3251 3252	Adding variceal status to Child–Turcotte–Pugh score improves its performance in predicting early mortality in cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 1348-1349. Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Annals of Surgery, 2012, 256, 706-713. Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective study. European Journal of Gastroenterology and Hepatology, 2012, 24, 897-904. Liver transplantation for hepatocellular carcinoma in clinical practice. European Journal of Gastroenterology and Hepatology, 2012, 24, 195-202. An Elevated Arterial Enhancement Fraction Is Associated With Clinical and Imaging Indices of Liver	0.8 2.1 0.8	5 142 38
3249 3250 3251 3252 3253	Adding variceal status to Child–Turcotte–Pugh score improves its performance in predicting early mortality in cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 1348-1349. Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Annals of Surgery, 2012, 256, 706-713. Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective study. European Journal of Gastroenterology and Hepatology, 2012, 24, 897-904. Liver transplantation for hepatocellular carcinoma in clinical practice. European Journal of Gastroenterology and Hepatology, 2012, 24, 195-202. An Elevated Arterial Enhancement Fraction Is Associated With Clinical and Imaging Indices of Liver Fibrosis and Cirrhosis. Journal of Computer Assisted Tomography, 2012, 36, 681-689. What is the role of radiation therapy in treating liver tumors?. Clinical Practice (London, England),	0.8 2.1 0.8 0.8	5 142 38 15

#	Article	IF	CITATIONS
3257	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. European Journal of Gastroenterology and Hepatology, 2012, 24, 849-856.	0.8	35
3258	Waders Sign on Bone Scan. Clinical Nuclear Medicine, 2012, 37, 385-386.	0.7	1
3262	Interpretación diagnóstica y pronóstica de las pruebas de función hepática. Medicine, 2012, 11, 733-739.	0.0	0
3263	Hepatocellular carcinoma. Lancet, The, 2012, 379, 1245-1255.	6.3	3,897
3264	Introduction to Drug Pharmacokinetics in the Critically III Patient. Chest, 2012, 141, 1327-1336.	0.4	199
3265	Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. Journal of Thrombosis and Haemostasis, 2012, 10, 2116-2122.	1.9	76
3266	Effect of Liver Disease on Pharmacokinetics. , 2012, , 81-96.		3
3267	Drug Metabolism in Liver Failure. , 2012, , 43-50.		1
3268	Psychometric Hepatic Encephalopathy Score for the detection of minimal hepatic encephalopathy in Korean patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1695-1704.	1.4	34
3269	Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1681-1687.	1.4	61
3270	Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Critical Care, 2012, 16, R227.	2.5	105
3271	Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child–Pugh grade A cirrhosis. British Journal of Surgery, 2012, 99, 1701-1710.	0.1	71
3272	Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. Clinical Pharmacokinetics, 2012, 51, 619-628.	1.6	34
3273	Serum lactate level predict mortality in elderly patients with cirrhosis. Wiener Klinische Wochenschrift, 2012, 124, 520-525.	1.0	20
3274	Effects of antiviral therapy on longâ€ŧerm outcome after liver resection for hepatitis B virusâ€ŧelated hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 685-696.	1.4	41
3275	A high value of serum des- \hat{l}^3 -carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment. Journal of Gastroenterology, 2012, 47, 1134-1142.	2.3	9
3276	Enumeration, isolation, and electron microscopic study of hematopoietic stem cells in Egyptian patients with chronic liver diseases. Comparative Clinical Pathology, 2012, 21, 1349-1359.	0.3	0
3277	A patients' and caregivers' perspective on hepatic encephalopathy. Metabolic Brain Disease, 2012, 27, 567-572.	1.4	39

#	Article	IF	CITATIONS
3278	Phase II Study of Concomitant Thalidomide During Radiotherapy for Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 817-825.	0.4	15
3279	Child-Turcotte score versus MELD for prognosis in a randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis. Journal of Surgical Research, 2012, 178, 139-146.	0.8	15
3280	Hepatic resection for huge (>15 cm) multinodular HCC with macrovascular invasion. Journal of Surgical Research, 2012, 178, 743-750.	0.8	21
3281	Transarterial Chemoembolization for Hepatitis B Virus–associated Hepatocellular Carcinoma: Improved Survival after Concomitant Treatment with Nucleoside Analogues. Journal of Vascular and Interventional Radiology, 2012, 23, 317-322.e1.	0.2	26
3282	Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. Journal of Hepatology, 2012, 57, 1251-1257.	1.8	55
3283	Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2012, 10, 291-296.	2.4	19
3284	Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2012, 10, 166-173.e1.	2.4	659
3285	Cirrhosis as a Risk for Surgery. Hospital Medicine Clinics, 2012, 1, e488-e497.	0.2	0
3286	810 Improved Long-Term Survival After Major Resection for Hepatocellular Carcinoma: A Multicenter Analysis Based on a New Definition of Major Hepatectomy. Gastroenterology, 2012, 142, S-1041.	0.6	0
3287	Diagnostic Criteria, Clinical Features, and Incidence of Thyroid Storm Based on Nationwide Surveys. Thyroid, 2012, 22, 661-679.	2.4	315
3288	Mini-Nutritional Assessment Predicts Functional Status and Quality of Life of Patients With Hepatocellular Carcinoma in Taiwan. Nutrition and Cancer, 2012, 64, 543-549.	0.9	22
3289	Levercirrose. Bijblijven (Amsterdam, Netherlands), 2012, 28, 43-52.	0.0	O
3290	Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 35-40.	1,2	9
3291	Care of the Cirrhotic Patient. Infectious Disease Clinics of North America, 2012, 26, 979-994.	1.9	5
3292	Is the Patient a Candidate for Liver Transplantation?. Clinics in Liver Disease, 2012, 16, 435-448.	1.0	23
3293	Urinary Metabolite Variation Is Associated with Pathological Progression of the Post-Hepatitis B Cirrhosis Patients. Journal of Proteome Research, 2012, 11, 3838-3847.	1.8	28
3294	Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. Pathology Research and Practice, 2012, 208, 15-21.	1.0	11
3295	Laparoscopic or open cholecystectomy in cirrhosis: a systematic review of outcomes and meta-analysis of randomized trials. Hpb, 2012, 14, 153-161.	0.1	70

#	Article	IF	CITATIONS
3296	Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virusâ€related decompensated cirrhosis. Liver International, 2012, 32, 656-664.	1.9	32
3297	Association of 25â€hydroxyvitamin <scp>D</scp> levels with liver dysfunction and mortality in chronic liver disease. Liver International, 2012, 32, 845-851.	1.9	97
3298	Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis. Clinical Microbiology and Infection, 2012, 18, 246-252.	2.8	21
3299	Systematic Review of Noncancer Presentations with a Median Survival of 6 Months or Less. American Journal of Medicine, 2012, 125, 512.e1-512.e16.	0.6	52
3300	Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. American Journal of Surgery, 2012, 203, 101-106.	0.9	83
3301	Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. American Journal of Surgery, 2012, 203, 741-750.	0.9	39
3302	An assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery. American Journal of Surgery, 2012, 203, 589-593.	0.9	36
3303	Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an Intensive Care Unit. Journal of Hepatology, 2012, 56, 95-102.	1.8	172
3304	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology, 2012, 56, 1080-1088.	1.8	109
3305	The impact of organ dysfunction in cirrhosis: Survival at a cost?. Journal of Hepatology, 2012, 56, 1054-1062.	1.8	522
3306	Efficacy of non-selective \hat{l}^2 -blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: A randomized controlled trial. Journal of Hepatology, 2012, 56, 1025-1032.	1.8	150
3307	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. Journal of Hepatology, 2012, 56, 1330-1335.	1.8	436
3308	Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. Journal of Hepatology, 2012, 57, 442-450.	1.8	176
3309	Hepatocellular carcinoma in patients with chronic liver disease: A comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clinical Radiology, 2012, 67, 148-156.	0.5	60
3310	Effects of renin–angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients. European Journal of Internal Medicine, 2012, 23, 179-184.	1.0	20
3311	Can we consider the right hepatic lobe size/albumin ratio a noninvasive predictor of oesophageal varices in hepatitis C virus-related liver cirrhotic Egyptian patients?. European Journal of Internal Medicine, 2012, 23, 267-272.	1.0	24
3312	Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma. European Journal of Radiology, 2012, 81, 2290-2297.	1.2	13
3313	RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population. Gene, 2012, 498, 264-269.	1.0	11

#	Article	IF	CITATIONS
3314	Caudate lobe-sparing subtotal hepatectomy for primary hepatolithiasis. British Journal of Surgery, 2012, 99, 1423-1428.	0.1	14
3315	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology, 2012, 56, 1371-1379.	3.6	130
3316	Levels and values of circulating endothelial progenitor cells, soluble angiogenic factors, and mononuclear cell apoptosis in liver cirrhosis patients. Journal of Biomedical Science, 2012, 19, 66.	2.6	19
3317	Standard abdominal wound edge protection with surgical dressings vs coverage with a sterile circular polyethylene drape for prevention of surgical site infections (BaFO): study protocol for a randomized controlled trial. Trials, 2012, 13, 57.	0.7	11
3318	Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study. BMC Research Notes, 2012, 5, 663.	0.6	24
3320	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia. New England Journal of Medicine, 2012, 367, 716-724.	13.9	274
3321	Combined hepatocellular carcinoma and neuroendocrine carcinoma with sarcomatous change of the liver after transarterial chemoembolization. Hepatology Research, 2012, 42, 1141-1145.	1.8	26
3322	Laboratory Testing for Liver Disease. , 2012, , 201-215.		5
3323	Impact of Cognitive Impairment in a Multicentric Cohort of PolypathologicalÂPatients. International Journal of Gerontology, 2012, 6, 84-89.	0.7	6
3324	Functional Decline Over 1-year Follow-up in a Multicenter Cohort of Polypathological Patients: A New Approach to Functional Prognostication. International Journal of Gerontology, 2012, 6, 68-74.	0.7	21
3325	Serum leptin level and its association with fatigue in patients with chronic hepatitis C virus infection. Arab Journal of Gastroenterology, 2012, 13, 54-57.	0.4	7
3326	Influence of Renal and Hepatic Impairment on the Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Fluticasone Furoate and Vilanterol in Combination. Clinical Therapeutics, 2012, 34, 2316-2332.	1.1	18
3327	Simple tools for complex syndromes: A three-level difficulty test for hepatic encephalopathy. Digestive and Liver Disease, 2012, 44, 957-960.	0.4	31
3328	Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. European Journal of Radiology, 2012, 81, 3002-3009.	1.2	47
3330	Lack of an association of programmed cell death-1 PD1.3 polymorphism with risk of hepatocellular carcinoma susceptibility in Turkish population: A case–control study. Gene, 2012, 511, 308-313.	1.0	23
3331	Lowered frequency and impaired modulation of gamma band oscillations in a bimodal attention task are associated with reduced critical flicker frequency. Neurolmage, 2012, 61, 216-227.	2.1	27
3332	Transplantation of the Liver. , 2012, , 853-868.		0
3333	Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatology International, 2012, 6, 735-743.	1.9	31

#	Article	IF	CITATIONS
3334	Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: A cohort study. Journal of Hepatology, 2012, 57, 1207-1213.	1.8	166
3335	Biliary drainage for obstructive jaundice caused by unresectable hepatocellular carcinoma: the endoscopic versus percutaneous approach. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 636-642.	0.6	28
3336	Radiofrequency ablation of metastatic lesions from breast cancer. Journal of Ultrasound, 2012, 15, 199-205.	0.7	10
3337	Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemotherapy and Pharmacology, 2012, 70, 823-832.	1.1	39
3338	Acute-on chronic liver failure. Journal of Hepatology, 2012, 57, 1336-1348.	1.8	545
3339	Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Japanese Journal of Radiology, 2012, 30, 743-751.	1.0	28
3340	The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 3258-3263.	1.3	34
3341	Asynchronous DNA replication and aneuploidy in lymphocytes of hepatocellular carcinoma patients. Cancer Genetics, 2012, 205, 636-643.	0.2	5
3342	Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy, 2012, 14, 483-493.	0.3	62
3343	Prognostic Significance of Antithrombin III Levels for Outcomes in Patients with Hepatocellular Carcinoma After Curative Hepatectomy. Annals of Surgical Oncology, 2012, 19, 2888-2896.	0.7	13
3344	Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. European Journal of Clinical Pharmacology, 2012, 68, 1501-1508.	0.8	23
3345	Liver Resection and Transplantation in Hepatocellular Carcinoma. Liver Cancer, 2012, 1, 71-82.	4.2	113
3346	Connectivity of Default-Mode Network Is Associated with Cerebral Edema in Hepatic Encephalopathy. PLoS ONE, 2012, 7, e36986.	1.1	28
3347	The Effect of Hepatic Encephalopathy, Hepatic Failure, and Portosystemic Shunt on Brain Volume of Cirrhotic Patients: A Voxel-Based Morphometry Study. PLoS ONE, 2012, 7, e42824.	1.1	45
3348	Prognosis of Patients with Hepatocellular Carcinoma. Validation and Ranking of Established Staging-Systems in a Large Western HCC-Cohort. PLoS ONE, 2012, 7, e45066.	1.1	58
3349	Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma within UCSF Criteria after Liver Resection. PLoS ONE, 2012, 7, e48932.	1.1	41
3350	Risk Models and Scoring Systems for Predicting the Prognosis in Critically III Cirrhotic Patients with Acute Kidney Injury: A Prospective Validation Study. PLoS ONE, 2012, 7, e51094.	1.1	24
3351	Drug dosage recommendations in patients with chronic liver disease. Revista Espanola De Enfermedades Digestivas, 2012, 104, 165-184.	0.1	27

#	Article	IF	CITATIONS
3352	Prognostic Factors for Survival in Patients with Liver Cirrhosis., 0,,.		2
3353	Quantifying Liver Cirrhosis by Extracting Significant Features from MRI T2 Image. Scientific World Journal, The, 2012, 2012, 1-5.	0.8	7
3354	The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Annals of Hepatology, 2012, 11, 240-248.	0.6	54
3355	Splenectomy in cirrhosis with hypersplenism: improvement in cytopenias, child's status and institution of specific treatment for hepatitis C with success. Annals of Hepatology, 2012, 11, 921-929.	0.6	26
3356	Prognostic markers in cirrhotic patients requiring intensive care: a comparative prospective study. Annals of Hepatology, 2012, 11, 513-518.	0.6	13
3357	Different models in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Annals of Hepatology, 2012, 11, 311-319.	0.6	15
3358	Decreased serum total T3 level in hepatitis B and C related cirrhosis by severity of liver damage. Annals of Hepatology, 2012, 11, 667-671.	0.6	34
3359	Prognostic factors associated with in-hospital mortality in patients with spontaneous bacterial peritonitis. Annals of Hepatology, 2012, 11, 915-920.	0.6	21
3360	Impaired Small-World Network Efficiency and Dynamic Functional Distribution in Patients with Cirrhosis. PLoS ONE, 2012, 7, e35266.	1.1	43
3361	Hepatocellular Carcinoma in the Elderly: Clinical Characteristics, Treatment, Survival Analysis in Korean Patients Older than 70 Years. Journal of Korean Medical Science, 2012, 27, 1147.	1.1	21
3362	Poor Prognostic Factors after Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma in the Modern Era. American Surgeon, 2012, 78, 419-425.	0.4	17
3363	Factors related to survival in hepatocellular carcinoma in the geographic area of Sabadell (Catalonia, Spain). Revista Espanola De Enfermedades Digestivas, 2012, 104, 242-247.	0.1	5
3364	Ischemia-Modifi ed Albumin Levels in Children with Chronic Liver Disease. Gut and Liver, 2012, 6, 92-97.	1.4	27
3365	A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials, 2012, , 39.	1.5	2
3366	Evaluation of Biliary Secretory Immunoglobulin-A in Recipients of Living-Donor Liver Transplantation. Journal of Liver, 2012, 01, .	0.3	0
3367	Risk factors for nonalcoholic steatohepatitis in cryptogenic cirrhosis. Arquivos De Gastroenterologia, 2012, 49, 245-249.	0.3	2
3368	Sorafenib in hepatocellular carcinoma – a post marketing evaluation. Immunopharmacology and Immunotoxicology, 2012, 34, 419-422.	1.1	4
3369	Hepatic Resection for "BCLC Stage A―Hepatocellular Carcinoma. The Prognostic Role of Alpha-Fetoprotein. Annals of Surgical Oncology, 2012, 19, 426-434.	0.7	35

#	Article	IF	CITATIONS
3370	Brain defaultâ€mode network abnormalities in hepatic encephalopathy: A restingâ€state functional MRI study. Human Brain Mapping, 2012, 33, 1384-1392.	1.9	62
3371	Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 2012, 55, 1019-1029.	3.6	51
3372	Type 2 diabetes and hepatocellular carcinoma: A case–control study in patients with chronic hepatitis B. International Journal of Cancer, 2012, 131, 1197-1202.	2.3	39
3373	Clinical outcomes of oncologic gastrointestinal resections in patients with cirrhosis. Cancer, 2012, 118, 3494-3500.	2.0	17
3375	Hepatic resection for benign disease and for liver and biliary tumors., 2012,, 1461-1511.e3.		2
3376	Equivalent Outcomes After Anatomical and Non-anatomical Resection of Small Hepatocellular Carcinoma in Patients with Preserved Liver Function. Digestive Diseases and Sciences, 2012, 57, 1942-1948.	1.1	52
3377	The significance of Exonuclease 1 K589E polymorphism on hepatocellular carcinoma susceptibility in the Turkish population: a case–control study. Molecular Biology Reports, 2012, 39, 5943-5951.	1.0	31
3378	Resection Margin with Anatomic or Nonanatomic Hepatectomy for Liver Metastasis from Colorectal Cancer. Journal of Gastrointestinal Surgery, 2012, 16, 1171-1180.	0.9	52
3379	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Internal and Emergency Medicine, 2012, 7, 139-144.	1.0	96
3380	Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion. Hepatology International, 2012, 6, 646-656.	1.9	30
3381	Prevalence and outcome of cirrhosis patients admitted to UK intensive care: a comparison against dialysis-dependent chronic renal failure patients. Intensive Care Medicine, 2012, 38, 991-1000.	3.9	87
3382	Subcuticular Absorbable Suture with Subcutaneous Drainage System Prevents Incisional SSI after Hepatectomy for Hepatocellular Carcinoma. World Journal of Surgery, 2012, 36, 1651-1656.	0.8	20
3383	Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. European Radiology, 2012, 22, 642-653.	2.3	73
3384	MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. European Radiology, 2012, 22, 1224-1232.	2.3	93
3385	HCC: current surgical treatment concepts. Langenbeck's Archives of Surgery, 2012, 397, 681-695.	0.8	50
3386	Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1121-1129.	1.2	69
3387	Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 449-457.	1.4	28
3388	Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma. Journal of Gastroenterology, 2012, 47, 531-539.	2.3	8

#	Article	IF	Citations
3389	Short-term reductions in non-protein respiratory quotient and prealbumin can be associated with the long-term deterioration of liver function after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Journal of Gastroenterology, 2012, 47, 704-714.	2.3	26
3390	Effect of transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma. Journal of Gastroenterology, 2012, 47, 715-722.	2.3	10
3391	Zero mortality in more than 300 hepatic resections: validity of preoperative volumetric analysis. Surgery Today, 2012, 42, 435-440.	0.7	38
3392	<i>NOD2</i> gene variants are a risk factor for cultureâ€positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver International, 2012, 32, 223-230.	1.9	59
3393	Should cirrhosis change our attitude towards treating nonâ€hepatic cancer?. Liver International, 2012, 32, 21-27.	1.9	21
3394	High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. Liver International, 2012, 32, 128-136.	1.9	46
3395	Monoclonal gammopathy after liver transplantation: a risk factor for long-term medical complications other than malignancies. Transplant International, 2012, 25, 25-33.	0.8	7
3396	Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation. Alimentary Pharmacology and Therapeutics, 2012, 35, 861-862.	1.9	2
3397	Overnight glucose infusion suppresses renal ammoniagenesis and reduces hyperammonaemia induced by a simulated bleed in cirrhotic patients. Alimentary Pharmacology and Therapeutics, 2012, 35, 921-928.	1.9	5
3398	The decrease of serum MMP-2 activity corresponds to alcoholic cirrhosis stage. Alcohol, 2012, 46, 155-157.	0.8	7
3399	ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Childâ€Turcotteâ€Pugh score and the Model for Endâ€Stage Liver Disease score. Hepatology Research, 2012, 42, 459-472.	1.8	43
3400	Evaluation of a novel nonâ€nvasive ¹³ Câ€glucose breath test for the identification of diabetes mellitus in cirrhotic patients. Hepatology Research, 2012, 42, 1196-1201.	1.8	0
3401	Prevalence of restless legs syndrome in Japanese patients with chronic liver disease. Hepatology Research, 2012, 42, 1221-1226.	1.8	25
3402	Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1213-1218.	0.4	18
3403	Thoracic empyema in patients with liver cirrhosis: Clinical characteristics and outcome analysis of thoracoscopic management. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1144-1151.	0.4	10
3404	A Rare Occurrence of Hepatocellular Carcinoma Metastasis to the Mandible: Report of a Case and Review of the Literature. Journal of Oral and Maxillofacial Surgery, 2012, 70, 1219-1223.	0.5	14
3405	Weight gain in long-term survivors of kidney or liver transplantationâ€"Another paradigm of sarcopenic obesity?. Nutrition, 2012, 28, 378-383.	1.1	71
3406	The necessity of hepatic vein reconstruction after resection of cranial part of the liver and major hepatic veins in cirrhotic patients. Surgery, 2012, 151, 223-231.	1.0	13

#	Article	IF	Citations
3407	Effectiveness of Locoregional Therapy Before Living Donor Liver Transplantation in Patients With Hepatocellular Carcinoma Who Meet the Milan Criteria. Transplantation Proceedings, 2012, 44, 403-408.	0.3	18
3408	The Charlson Comorbidity Index as a Predictor of Outcomes in Liver Transplantation: Single-Center Experience. Transplantation Proceedings, 2012, 44, 1298-1302.	0.3	20
3409	Different patterns of decompensation in patients with alcoholic vs. nonâ€alcoholic liver cirrhosis. Alimentary Pharmacology and Therapeutics, 2012, 35, 1443-1450.	1.9	27
3410	Pharmacokinetics of linagliptin in subjects with hepatic impairment. British Journal of Clinical Pharmacology, 2012, 74, 75-85.	1.1	63
3411	Increased Th17 cells contribute to disease progression in patients with HBVâ€associated liver cirrhosis. Journal of Viral Hepatitis, 2012, 19, 396-403.	1.0	103
3412	Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosisâ€associated liver cirrhosis*. Clinical Transplantation, 2012, 26, 34-41.	0.8	34
3413	Living donor liver transplantation in children: A single North American center experience over two decades. Pediatric Transplantation, 2012, 16, 486-495.	0.5	9
3414	The outcome of critical illness in decompensated alcoholic liver cirrhosis. Acta Anaesthesiologica Scandinavica, 2012, 56, 987-994.	0.7	18
3415	Late evening snack: Exploiting a period of anabolic opportunity in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 430-441.	1.4	194
3416	Induced hyperammonemia may compromise the ability to generate restful sleep in patients with cirrhosis. Hepatology, 2012, 55, 869-878.	3. 6	40
3417	Thrombocytopenia, splenomegaly, and portal blood flow in patients who have undergone liver transplantation for cirrhosis. Liver Transplantation, 2012, 18, 340-346.	1.3	20
3418	Emergency transjugular intrahepatic portosystemic shunt (TIPS): results, complications and predictors of mortality in the first month of follow-up. Radiologia Medica, 2012, 117, 46-53.	4.7	24
3419	Basic and Clinical Research on the Therapeutic Effect of Intervention in Primary Liver Cancer by Targeted Intra-Arterial Verapamil Infusion. Cell Biochemistry and Biophysics, 2012, 62, 59-67.	0.9	15
3420	Changes of Fecal Bifidobacterium Species in Adult Patients with Hepatitis B Virus-Induced Chronic Liver Disease. Microbial Ecology, 2012, 63, 304-313.	1.4	111
3421	No Impact of Perioperative Blood Transfusion on Recurrence of Hepatocellular Carcinoma after Hepatectomy. World Journal of Surgery, 2012, 36, 651-658.	0.8	42
3422	An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemotherapy and Pharmacology, 2012, 69, 605-612.	1.1	24
3423	Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. Investigational New Drugs, 2012, 30, 662-671.	1.2	6
3424	p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case–control study. Molecular Biology Reports, 2012, 39, 1639-1647.	1.0	30

#	Article	IF	CITATIONS
3425	Healthâ€related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. Psycho-Oncology, 2013, 22, 1353-1360.	1.0	39
3426	Intestinal permeability and complications in liver cirrhosis: A prospective cohort study. Hepatology Research, 2013, 43, 200-207.	1.8	34
3427	Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & Differences in viral marker negative & Diral-hepatocellular carcinoma. BMC Research Notes, 2013, 6, 137.	0.6	21
3428	Potential role of cholinesterases to predict short-term outcome after hepatic resection for hepatocellular carcinoma. Updates in Surgery, 2013, 65, 11-18.	0.9	16
3429	Large-Scale Survey of Gut Microbiota Associated With MHE Via 16S rRNA-Based Pyrosequencing. American Journal of Gastroenterology, 2013, 108, 1601-1611.	0.2	149
3430	MPO is a potential biomarker of acute graft-versus-host disease. Biomarkers in Medicine, 2013, 7, 391-393.	0.6	0
3431	Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study. BMC Gastroenterology, 2013, 13, 107.	0.8	21
3432	White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers. BMC Gastroenterology, 2013, 13, 55.	0.8	31
3433	Physiologic and laboratory correlates of depression, anxiety, and poor sleep in liver cirrhosis. BMC Gastroenterology, 2013, 13, 18.	0.8	21
3434	Model for End-Stage Liver Disease and liver cirrhosis-related complications. Hepatology International, 2013, 7, 347-355.	1.9	3
3435	Percutaneous transhepatic variceal embolization with cyanoacrylate vs. transjugular intrahepatic portal systematic shunt for esophageal variceal bleeding. Hepatology International, 2013, 7, 636-644.	1.9	10
3436	The effect of systemic antibiotic prophylaxis for cirrhotic patients with peptic ulcer bleeding after endoscopic interventions. Hepatology International, 2013, 7, 257-267.	1.9	8
3437	Assessment of safety in hepatic resection for hepatocellular carcinoma focusing on indirect hyperbilirubinemia. Journal of Hepato-Biliary-Pancreatic Sciences, 2013, 20, 370-374.	1.4	1
3438	Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Journal of Infection and Chemotherapy, 2013, 19, 381-392.	0.8	149
3439	Prognosis and Predictors of Surgical Complications in Hepatocellular Carcinoma Patients With or Without Cirrhosis after Hepatectomy. World Journal of Surgery, 2013, 37, 1379-1387.	0.8	15
3440	Grey and white matter abnormalities in minimal hepatic encephalopathy: a study combining voxel-based morphometry and tract-based spatial statistics. European Radiology, 2013, 23, 3370-3378.	2.3	38
3441	Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment. Clinical Pharmacokinetics, 2013, 52, 243-254.	1.6	106
3442	Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib. Clinical Pharmacokinetics, 2013, 52, 255-265.	1.6	9

#	Article	IF	CITATIONS
3443	Whole blood rotation thromboelastometry (ROTEM®) profiles in subjects with non-neoplastic portal vein thrombosis. Thrombosis Research, 2013, 132, e131-e134.	0.8	39
3444	Results of cardiac surgery in advanced liver cirrhosis. General Thoracic and Cardiovascular Surgery, 2013, 61, 79-83.	0.4	13
3445	Characteristics of alcoholic liver disease and predictive factors for mortality of patients with alcoholic cirrhosis. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 594-601.	0.6	15
3446	Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ⩽3cm. Results of a multicenter Italian survey. Journal of Hepatology, 2013, 59, 89-97.	1.8	241
3447	Regional metabolic liver function measured in patients with cirrhosis by 2-[18F]fluoro-2-deoxy-d-galactose PET/CT. Journal of Hepatology, 2013, 58, 1119-1124.	1.8	28
3448	A revised scope in different prognostic models in cirrhotic patients: Current and future perspectives, an Egyptian experience. Arab Journal of Gastroenterology, 2013, 14, 158-164.	0.4	4
3449	Prognosis and determinants of pregnancy outcome among patients with postâ€hepatitis liver cirrhosis. International Journal of Gynecology and Obstetrics, 2013, 121, 247-251.	1.0	43
3450	Clinical practice guidelines for evidence-based management of sedoanalgesia in critically ill adult patients. Medicina Intensiva (English Edition), 2013, 37, 519-574.	0.1	37
3451	Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 769-779.	1.8	68
3452	Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma. Meta Gene, 2013, 1, 93-101.	0.3	13
3453	<scp>APACHE II</scp> score is superior to <scp>SOFA</scp> , <scp>CTP</scp> and <scp>MELD</scp> in predicting the shortâ€term mortality in patients with acuteâ€onâ€chronic liver failure (<scp>ACLF</scp>). Journal of Digestive Diseases, 2013, 14, 484-490.	0.7	63
3454	Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatology Research, 2013, 43, 1264-1275.	1.8	91
3455	Prognostic Capability of Different Liver Disease Scoring Systems for Prediction of Early Mortality after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology, 2013, 24, 411-420.e4.	0.2	68
3456	Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases. Radiographics, 2013, 33, 1653-1668.	1.4	81
3457	Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	0.6	195
3458	Acute on chronic liver failure: From pathophysiology to clinical management. Trends in Anaesthesia and Critical Care, 2013, 3, 122-129.	0.4	9
3459	Hepatitis B Virus Infection can Cause Hepatocellular Carcinoma in Less Advanced Liver Cirrhosis: A Comparative Study of 142 Patients from North India. Journal of Clinical and Experimental Hepatology, 2013, 3, 288-295.	0.4	9
3460	Liver abnormalities in drug and substance abusers. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 577-596.	1.0	44

#	Article	IF	Citations
3461	External validation of a simplified BCLC staging system for early hepatocellular carcinoma. European Journal of Surgical Oncology, 2013, 39, 850-857.	0.5	21
3462	Cardiohepatic Interactions in Heart Failure. Journal of the American College of Cardiology, 2013, 61, 2397-2405.	1.2	240
3463	Liver PET/CT and Molecular Imaging. , 2013, , 943-954.		0
3464	A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research, 2013, 19, 6614-6623.	3.2	139
3465	Management of Hepatocellular Carcinoma. Surgical Clinics of North America, 2013, 93, 1423-1450.	0.5	34
3466	Negative energy balance secondary to inadequate dietary intake of patients on the waiting list for liver transplantation. Nutrition, 2013, 29, 1252-1258.	1.1	35
3467	Increased survival of cirrhotic patients with septic shock. Critical Care, 2013, 17, R78.	2.5	35
3468	Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver International, 2013, 33, 1601-1606.	1.9	60
3469	Nutrition Assessment and Management in Advanced Liver Disease. Nutrition in Clinical Practice, 2013, 28, 15-29.	1.1	124
3470	Nonâ€invasive tests for fibrosis and liver stiffness predict 5â€year survival of patients chronically infected with hepatitis B virus. Alimentary Pharmacology and Therapeutics, 2013, 37, 979-988.	1.9	96
3471	Monitoring and managing hepatic disease in anaesthesia. British Journal of Anaesthesia, 2013, 111, i50-i61.	1.5	40
3472	Effects of Metallothionein-1 Genetic Polymorphism and Cigarette Smoking on the Development of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2013, 20, 2088-2095.	0.7	20
3473	Liver transplantation in the critically ill: a multicenter Canadian retrospective cohort study. Critical Care, 2013, 17, R28.	2.5	60
3474	The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor. European Journal of Clinical Pharmacology, 2013, 69, 2011-2019.	0.8	3
3475	Scoring system in upper GI bleeding. Gastrointestinal Endoscopy, 2013, 78, 557.	0.5	1
3476	Percutaneous transhepatic variceal embolization combined with endoscopic ligation for the prevention of variceal rebleeding. Journal of Digestive Diseases, 2013, 14, 388-395.	0.7	8
3477	Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis. Scandinavian Journal of Gastroenterology, 2013, 48, 358-365.	0.6	9
3478	Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron. Clinical Drug Investigation, 2013, 33, 11-23.	1.1	25

#	Article	IF	CITATIONS
3479	Occurrence and recurrence of spontaneous chronic subdural haematoma is associated with a factor XIII deficiency. Clinical Neurology and Neurosurgery, 2013, 115, 13-18.	0.6	23
3480	Ghrelin, leptin and insulin in cirrhotic children and adolescents: Relationship with cirrhosis severity and nutritional status. Regulatory Peptides, 2013, 180, 26-32.	1.9	11
3481	Acute kidney injury in decompensated cirrhosis. Gut, 2013, 62, 131-137.	6.1	205
3482	Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct <scp>F</scp> actor <scp>X</scp> a inhibitor. British Journal of Clinical Pharmacology, 2013, 76, 89-98.	1.1	152
3483	Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. International Journal of Laboratory Hematology, 2013, 35, 101-105.	0.7	7
3484	Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C. Influenza and Other Respiratory Viruses, 2013, 7, 456-465.	1.5	11
3485	Acute renal failure in cirrhotic patients with severe sepsis: Value of urinary interleukinâ€18. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 135-141.	1.4	23
3486	Preparation for Percutaneous Ablation Procedures. Techniques in Vascular and Interventional Radiology, 2013, 16, 209-218.	0.4	3
3487	Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 512-519.	0.6	40
3488	Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: An Indian perspective. Antiviral Research, 2013, 100, 300-305.	1.9	19
3489	Prediction of postoperative complications in elderly patients with hepatocellular carcinoma. Journal of Surgical Research, 2013, 185, 614-619.	0.8	33
3490	Survival after surgery for hepatocellular carcinoma inÂrelation to presence or absence of viral infection. American Journal of Surgery, 2013, 206, 187-193.	0.9	4
3491	Treatment of hepatocellular carcinoma in Child-Pugh B patients. Digestive and Liver Disease, 2013, 45, 852-858.	0.4	32
3492	Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 485-490.	0.7	12
3493	Complications associated with instrumented lumbar surgery in patients with liver cirrhosis: a matched cohort analysis. Spine Journal, 2013, 13, 908-913.	0.6	31
3494	The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. Journal of Hepatology, 2013, 58, 509-521.	1.8	60
3495	Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist. European Journal of Pharmaceutical Sciences, 2013, 49, 836-844.	1.9	4
3496	The Investigation of Total PSA, Free PSA, and Free/Total PSA Ratio in Patients With Liver Cirrhosis Patients According to Child-Pugh Score. Urology, 2013, 81, 617-622.	0.5	9

#	Article	IF	CITATIONS
3497	Factors Associated With Outcomes and Response to Therapy in Patients With Infiltrative Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2013, 11, 572-578.	2.4	30
3498	Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis. Journal of Hepatology, 2013, 58, 427-433.	1.8	124
3499	The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis. Annals of Thoracic Surgery, 2013, 96, 1672-1678.	0.7	33
3500	Brivaracetam Disposition in Mild to Severe Hepatic Impairment. Journal of Clinical Pharmacology, 2013, 53, 633-641.	1.0	39
3501	The thalamus in cirrhotic patients with and without hepatic encephalopathy: A volumetric MRI study. European Journal of Radiology, 2013, 82, e715-e720.	1.2	20
3502	Hypocortisolism in Noncomatose Patients during the Acute Phase of Subarachnoid Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, e189-e196.	0.7	25
3503	GuÃa de práctica clÃnica basada en la evidencia para el manejo de la sedoanalgesia en el paciente adulto crÃticamente enfermo. Medicina Intensiva, 2013, 37, 519-574.	0.4	111
3504	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9.	0.6	2,211
3505	Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. European Journal of Cancer, 2013, 49, 3442-3449.	1.3	176
3506	Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. European Journal of Internal Medicine, 2013, 24, 172-176.	1.0	67
3507	Coagulation imbalance may not contribute to the development of portal vein thrombosis in patients with cirrhosis. Thrombosis Research, 2013, 131, 173-177.	0.8	33
3508	Continuous monitoring of central venous oxygen saturation predicts postoperative liver dysfunction after liver resection. Surgery, 2013, 154, 351-362.	1.0	7
3509	Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. Digestive and Liver Disease, 2013, 45, 516-522.	0.4	7
3510	Liver resection versus radiofrequency ablation in the treatment of cirrhotic patients with hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 270-277.	0.6	10
3511	Resection of peritoneal metastases in patients with hepatocellular carcinoma. Surgery, 2013, 153, 727-731.	1.0	21
3512	Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. Journal of Advanced Research, 2013, 4, 539-546.	4.4	27
3513	Prognostic scores for cirrhotic patients admitted to an intensive care unit: Which consequences for liver transplantation?. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 455-466.	0.7	21
3514	Improved Long-Term Survival after Major Resection for Hepatocellular Carcinoma: A Multicenter Analysis Based on a New Definition of Major Hepatectomy. Journal of Gastrointestinal Surgery, 2013, 17, 66-77.	0.9	107

#	Article	IF	CITATIONS
3515	Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Medical Oncology, 2013, 30, 345.	1.2	26
3516	Evaluating Patients Undergoing Colorectal Surgery to Estimate and Minimize Morbidity and Mortality. Surgical Clinics of North America, 2013, 93, 1-20.	0.5	8
3517	Review article: towards a considered and ethical approach to organ support in criticallyâ€ill patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2013, 37, 174-182.	1.9	32
3518	Hepatic resection for hepatocellular carcinoma in patients with Child–Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication?. Hpb, 2013, 15, 78-84.	0.1	118
3519	Sensitivity and Specificity of Urinary Ethyl Glucuronide and Ethyl Sulfate in Liver Disease Patients. Alcoholism: Clinical and Experimental Research, 2013, 37, 150-155.	1.4	57
3520	Characteristics of elderly hepatitis <scp>C</scp> virusâ€associated hepatocellular carcinoma patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 357-364.	1.4	11
3521	Sleepâ€Wake profiles in patients with primary biliary cirrhosis. Liver International, 2013, 33, 203-209.	1.9	36
3522	Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5Âcm: A multicenter, exploratory analysis. European Journal of Surgical Oncology, 2013, 39, 386-395.	0.5	33
3523	Assessment of liver function: what are we measuring?. Hpb, 2013, 15, 325-326.	0.1	2
3524	Clinical Pharmacokinetic Studies. , 2013, , 1139-1210.		2
3525	Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. British Journal of Radiology, 2013, 86, 20120653.	1.0	67
3526	Genetic Polymorphisms of Alcohol Dehydrogenaseâ€1 <scp>B</scp> and Aldehyde Dehydrogenaseâ€2 and Liver Cirrhosis, Chronic Calcific Pancreatitis, Diabetes Mellitus, and Hypertension Among <scp>J</scp> apanese Alcoholic Men. Alcoholism: Clinical and Experimental Research, 2013, 37, 1391-1401.	1.4	63
3527	Alcohol and Nutrition: An Overview. , 2013, , 3-14.		0
3528	Eltrombopag in patients with chronic liver disease. Expert Opinion on Pharmacotherapy, 2013, 14, 669-678.	0.9	13
3529	Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. Journal of Hepatology, 2013, 58, 956-961.	1.8	95
3530	Predictors of early re-bleeding and mortality after acute variceal haemorrhage. Arab Journal of Gastroenterology, 2013, 14, 63-67.	0.4	17
3531	Anesthesia for Liver Transplantation. Seminars in Cardiothoracic and Vascular Anesthesia, 2013, 17, 180-194.	0.4	43
3532	Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology, 2013, 57, 1962-1968.	3.6	237

#	Article	IF	CITATIONS
3533	Intrahepatic periportal high intensity on hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI: imaging findings and prevalence in various hepatobiliary diseases. Japanese Journal of Radiology, 2013, 31, 9-15.	1.0	17
3534	Short duration of antibiotic prophylaxis in open fractures does not enhance risk of subsequent infection. Bone and Joint Journal, 2013, 95-B, 831-837.	1.9	87
3535	Predictive value of Refit <scp>M</scp> odel for <scp>E</scp> ndâ€ <scp>S</scp> tage <scp>Li</scp> ver <scp>D</scp> isease, Refit <scp>M</scp> odel for <scp>E</scp> ndâ€ <scp>S</scp> tage <scp>Li</scp> ver <scp>D</scp> iseaseâ€ <scp>N</scp> a, and preâ€existing scoring system for 3â€month mortality in <scp>K</scp> orean patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1209-1216.	1.4	14
3536	Child-Pugh Score Predicts Survival After Radical Pericardiectomy for Constrictive Pericarditis. Annals of Thoracic Surgery, 2013, 96, 1679-1685.	0.7	28
3537	Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy. Liver Transplantation, 2013, 19, 1343-1353.	1.3	135
3538	Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma. International Journal of Clinical Oncology, 2013, 18, 829-838.	1.0	40
3539	Relationship Between 13C-Aminopyrine Breath Test and the MELD Score and Its Long-Term Prognostic Use in Patients with Cirrhosis. Digestive Diseases and Sciences, 2013, 58, 3024-3028.	1.1	7
3540	Evaluation of Pharmacologic Prophylaxis for Venous Thromboembolism in Patients with Chronic Liver Disease. Pharmacotherapy, 2013, 33, 375-382.	1.2	40
3541	Comparison of Maddrey Discriminant Function, Child–Pugh Score and Glasgow Alcoholic Hepatitis Score in predicting 28-day mortality on admission in patients with acute hepatitis. Irish Journal of Medical Science, 2013, 182, 63-68.	0.8	8
3542	Child-Pugh score is altered by the albumin measurement method. Hepatology, 2013, 57, 2093-2094.	3.6	6
3543	Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open, 2013, 3, e003370.	0.8	6
3544	Acute kidney injury is independently associated with death in patients with cirrhosis. Frontline Gastroenterology, 2013, 4, 191-197.	0.9	38
3545	Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-NaÃve Patients with Chronic Hepatitis B. Antimicrobial Agents and Chemotherapy, 2013, 57, 1790-1796.	1.4	37
3547	Biologic Factors Affecting HCC Conspicuity in Hepatobiliary Phase Imaging With Liver-Specific Contrast Agents. American Journal of Roentgenology, 2013, 201, 322-331.	1.0	32
3548	Multidisciplinary Management of Hepatocellular Carcinoma: Where Are We Today?. Seminars in Liver Disease, 2013, 33, S3-S10.	1.8	32
3549	Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease. Mediators of Inflammation, 2013, 2013, 1-12.	1.4	20
3550	Nitric Oxide is a Potential Diagnostic Marker for Hepatocellular Carcinoma. Scientia Pharmaceutica, 2013, 81, 763-775.	0.7	11
3551	Value of D-dimer and protein S for diagnosis of portal vein thrombosis in patients with liver cirrhosis. Journal of International Medical Research, 2013, 41, 664-672.	0.4	24

#	Article	IF	Citations
3552	A cross-sectional study on occurrence of type 2 diabetes among patients admitted with chronic liver diseases in a medical college in Kolkata. International Journal of Medicine and Public Health, 2013, 3, 44.	0.3	4
3553	Introducing an Optimal Liver Allocation System for Liver Cirrhosis Patients. Hepatitis Monthly, 2013, 13, e10479.	0.1	3
3554	Modulation of neural activation following treatment of hepatic encephalopathy. Neurology, 2013, 80, 1041-1047.	1.5	22
3555	Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion. Annals of Clinical Biochemistry, 2013, 50, 122-126.	0.8	7
3556	An MLP Classifier for Prediction of HBV-Induced Liver Cirrhosis Using Routinely Available Clinical Parameters. Disease Markers, 2013, 35, 653-660.	0.6	23
3557	A Survey of Correlation Between Insulin-Like Growth Factor-I (IGF-I) Levels and Severity of Liver Cirrhosis. Hepatitis Monthly, 2013, 13, e6181.	0.1	15
3558	Diabetes mellitus at the time of diagnosis ofcirrhosis is associated with higher incidence ofÂspontaneous bacterial peritonitis, but not withÂincreased mortality. Clinical Science, 2013, 125, 341-348.	1.8	25
3559	Assessment of the Relative Dose-Response Test as Indicators of Hepatic Vitamin A Stores in Various Stages of Chronic Liver Disease. Nutrition in Clinical Practice, 2013, 28, 95-100.	1.1	13
3560	Evaluation of transarterial chemoembolization in treating hepatocellular carcinoma. Egyptian Liver Journal, 2013, 3, 41-46.	0.3	0
3561	Assessment of coagulation and fibrinolysis in children with chronic liver disease. Blood Coagulation and Fibrinolysis, 2013, 24, 113-117.	0.5	8
3562	Ultrasonographic Predictors of Esophageal Varices. Journal of Pediatric Gastroenterology and Nutrition, 2013, 57, 700-703.	0.9	13
3563	Risk Models for Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PEP). Pancreas, 2013, 42, 996-1003.	0.5	30
3564	Laparoscopic Ultrasound for Hepatocellular Carcinoma and Colorectal Liver Metastasis. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2013, 23, 135-144.	0.4	19
3565	Does Gallbladder Wall Thickening of Cirrhotic Patients Increase the Risk of Formation of Gallstones?. Journal of Diagnostic Medical Sonography, 2013, 29, 55-57.	0.1	0
3566	Evaluation of the Hepatitis C Virus-Infected Patient: The Initial Encounter. Clinical Infectious Diseases, 2013, 56, 853-860.	2.9	6
3567	Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?. World Journal of Gastroenterology, 2013, 19, 8808.	1.4	72
3568	Selective accumulation of platinum and formation of platinum– <scp>DNA</scp> adducts in hepatocellular carcinoma after transarterial chemoembolization with miriplatin. Hepatology Research, 2013, 43, 1093-1099.	1.8	5
3569	Relationship between urinary fractional excretion of sodium and life prognosis in liver cirrhosis patients. Hepatology Research, 2013, 43, 1156-1162.	1.8	12

#	Article	IF	CITATIONS
3570	Significance of hepatitis <scp>B</scp> virus coreâ€related antigen and covalently closed circular <scp>DNA</scp> levels as markers of hepatitis <scp>B</scp> virus reâ€infection after liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1217-1222.	1.4	37
3571	Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepatic Medicine: Evidence and Research, 2013, 5, 1.	0.9	17
3572	Splenic Vein Embolization Using Coil Anchors and Prophylactic Occlusion of a Hepatofugal Collateral for Hepatic Encephalopathy due to Splenorenal Shunt: Technical Note and Literature Review. Case Reports in Radiology, 2013, 2013, 1-5.	0.5	5
3573	Severe Cardiotoxicity Associated with Ixabepilone use in Metastatic Breast Cancer. Annals of Pharmacotherapy, 2013, 47, e17-e17.	0.9	4
3574	Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy. World Journal of Gastroenterology, 2013, 19, 4464.	1.4	19
3575	Increased Nâ€terminal cleavage of alphaâ€2â€antiplasmin in patients with liver cirrhosis. Journal of Thrombosis and Haemostasis, 2013, 11, 2029-2036.	1.9	38
3576	The liver to abdominal area ratio (LAAR): a novel imaging score for prognostication in cirrhosis. Alimentary Pharmacology and Therapeutics, 2013, 38, 1385-1394.	1.9	6
3577	Postoperative adverse outcomes after non-hepatic surgery in patients with liver cirrhosis. British Journal of Surgery, 2013, 100, 1784-1790.	0.1	31
3578	The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome?. Transplant International, 2013, 26, 1070-1079.	0.8	11
3579	Partial hepatectomy for ruptured hepatocellular carcinoma. British Journal of Surgery, 2013, 100, 1071-1079.	0.1	68
3580	Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria. Journal of Digestive Diseases, 2013, 14, 552-558.	0.7	12
3581	Palliative Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice Using Biliary Drainage with Subsequent Transarterial Chemoembolization. Journal of Palliative Medicine, 2013, 16, 1026-1033.	0.6	12
3582	Pharmacokinetics of Singleâ€Dose Dolutegravir in HIVâ€Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls. Clinical Pharmacology in Drug Development, 2013, 2, 342-348.	0.8	31
3583	An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 518-523.	0.7	16
3584	Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrastâ€enhanced ⟨scp⟩US⟨/scp⟩. Liver International, 2013, 33, 605-615.	1.9	56
3585	Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007–2011. Hepatology Research, 2013, 43, 106-112.	1.8	63
3586	Importance of screening for synchronous malignant neoplasms in patients with hepatocellular carcinoma: impact of <scp>FDG PET</scp> / <scp>CT</scp> . Liver International, 2013, 33, 1085-1091.	1.9	16
3587	Predicting the development of acute kidney injury in liver cirrhosis – an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers. Alimentary Pharmacology and Therapeutics, 2013, 37, 989-997.	1.9	34

#	Article	IF	CITATIONS
3588	Regorafenib. Annals of Pharmacotherapy, 2013, 47, 1685-1696.	0.9	45
3589	Effect of <i><scp>H</scp>elicobacter pylori</i> infection on esophagogastric variceal bleeding in patients with liver cirrhosis and portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1444-1449.	1.4	16
3590	Mortality Risk According to Different Clinical Characteristics of First Episode of Liver Decompensation in Cirrhotic Patients: A Nationwide, Prospective, 3-Year Follow-Up Study in Italy. American Journal of Gastroenterology, 2013, 108, 1112-1122.	0.2	43
3591	HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. British Journal of Cancer, 2013, 109, 1657-1665.	2.9	27
3592	¹³ C-aminopyrine demethylation is decreased in cirrhotic patients with normal biochemical markers. Isotopes in Environmental and Health Studies, 2013, 49, 346-356.	0.5	2
3593	What Special Considerations Are Needed for Treating Patients With Chronic Liver Disease?. , 2013, , 308-311.		0
3594	Development of the Post Cardiac Surgery (POCAS) prognostic score. Critical Care, 2013, 17, R209.	2.5	24
3596	A feasibility study to evaluate splanchnic arterial and venous hemodynamics by flow-sensitive 4D MRI compared with Doppler ultrasound in patients with cirrhosis and controls. European Journal of Gastroenterology and Hepatology, 2013, 25, 669-675.	0.8	42
3597	Colorectal Cancer Surgery in Portal Hypertensive Patients. Diseases of the Colon and Rectum, 2013, 56, 577-585.	0.7	7
3598	A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers. Annals of Surgery, 2013, 257, 929-937.	2.1	431
3599	Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome. Transplantation, 2013, 95, 1528-1534.	0.5	17
3600	Comparison of modified percutaneous transhepatic variceal embolization and endoscopic cyanoacrylate injection for gastric variceal rebleeding. World Journal of Gastroenterology, 2013, 19, 706.	1.4	18
3601	The Influence of the Severity of Chronic Virus-Related Liver Disease on Propofol Requirements during Propofol-Remifentanil Anesthesia. Yonsei Medical Journal, 2013, 54, 231.	0.9	13
3602	Preoperative evaluation of hepatic reserve function by phenacetin metabolism test for the prevention of postoperative liver dysfunction. African Journal of Pharmacy and Pharmacology, 2013, 7, 2591-2595.	0.2	0
3603	Hepatocellular Carcinoma in Child-Pugh C Cirrhosis: Prognostic Factors and Survival Benefit of Nontransplant Treatments. Digestive Diseases, 2013, 31, 490-498.	0.8	25
3604	Determination of Serum Carbohydrate-Deficient Transferrin (CDT) by the Nephelometric N Latex CDT Assay in Japanese Habitual Drinkers and Patients with Non-Alcoholic Liver Diseases. Journal of Alcoholism and Drug Dependence, 2013, 01, .	0.2	0
3605	A Study of Plasma D-Dimer Levels in Various Stages of Liver Disease. Journal of Liver, 2013, 02, .	0.3	2
3606	Validation of the chronic liver disease questionnaire in Serbian patients. World Journal of Gastroenterology, 2013, 19, 4950.	1.4	16

#	Article	IF	CITATIONS
3607	Evaluation of nutritional indicators and body composition in patients with advanced liver disease enrolled for liver transplantation. Acta Cirurgica Brasileira, 2013, 28, 733-739.	0.3	17
3608	Altered Effective Connectivity Network of the Basal Ganglia in Low-Grade Hepatic Encephalopathy: A Resting-State fMRI Study with Granger Causality Analysis. PLoS ONE, 2013, 8, e53677.	1.1	24
3609	Reduction in Non-Protein Respiratory Quotient Is Related to Overall Survival after Hepatocellular Carcinoma Treatment. PLoS ONE, 2013, 8, e55441.	1.1	5
3610	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. PLoS ONE, 2013, 8, e64283.	1.1	25
3611	Changes in Risk of Immediate Adverse Reactions to Iodinated Contrast Media by Repeated Administrations in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e76018.	1.1	15
3612	Comparison of Immunogenicity and Safety of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: A Randomized, Controlled Trial. PLoS ONE, 2013, 8, e80409.	1.1	49
3613	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, 6, 187.	1.1	75
3614	Liver and Gastrointestinal Physiology. , 2013, , 475-486.		3
3615	Liver Transplantation for Alcoholic Liver Disease among Canadian Transplant Centres: A National Study. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 643-646.	1.8	20
3616	Anesthetic Considerations for Patients with Liver Disease. , 2013, , .		7
3617	IGF-I and IGFBP-3 serum levels in patients hospitalized for complications of liver cirrhosis. Annals of Hepatology, 2013, 12, 456-463.	0.6	13
3618	Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. Annals of Hepatology, 2013, 12, 413-419.	0.6	31
3619	Dyspnea and respiratory muscle strength in end-stage liver disease. World Journal of Hepatology, 2013, 5, 56.	0.8	29
3620	Abnormalities in the serum phospholipids fatty acid profile in patients with alcoholic liver cirrhosis - a pilot study. Journal of Clinical Biochemistry and Nutrition, 2013, 53, 49-54.	0.6	30
3621	Banding ligation versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children. The Cochrane Library, 0, , .	1.5	7
3622	Predictive Factors for Child-Pugh Score Elevation in Hepatocellular Carcinoma Patients Treated with Conformal Radiation Therapy: Dose-Volume Histogram Analysis. Tumori, 2013, 99, 164-171.	0.6	10
3623	Short-term Results of Laparoscopic versus Open Liver Resection for Liver Metastasis from Colorectal Cancer: A Comparative Study. American Surgeon, 2013, 79, 495-501.	0.4	49
3624	Management of hepatocellular carcinoma: international guidelines. Italian Journal of Medicine, 2013, , 136-147.	0.2	0

#	Article	IF	CITATIONS
3625	Assessment of hepatic function and investigation of jaundice. , 2014, , 231-249.		3
3626	The Analysis of Prognostic Factors Affecting Survival in Liver Transplantation: A Single Institution Experience. The Journal of the Korean Society for Transplantation, 2014, 28, 211.	0.2	0
3627	BIOCHEMICAL NUTRITIONAL PROFILE OF LIVER CIRRHOSIS PATIENTS WITH HEPATOCELLULAR CARCINOMA. Arquivos De Gastroenterologia, 2014, 51, 10-15.	0.3	9
3628	Sarcopenia as a Useful Predictor for Long-Term Mortality in Cirrhotic Patients with Ascites. Journal of Korean Medical Science, 2014, 29, 1253.	1.1	62
3629	Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vascular Health and Risk Management, 2014, 10, 101.	1.0	21
3630	Oral health and liver function in children and adolescents with cirrhosis of the liver. Przeglad Gastroenterologiczny, 2014, 1, 24-31.	0.3	5
3631	Quantitative Assessment of the Presence and Severity of Cirrhosis in Patients with Hepatitis B Using Right Liver Lobe Volume and Spleen Size Measured at Magnetic Resonance Imaging. PLoS ONE, 2014, 9, e89973.	1.1	17
3632	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. PLoS ONE, 2014, 9, e99115.	1.1	8
3633	Longitudinal Brain White Matter Alterations in Minimal Hepatic Encephalopathy before and after Liver Transplantation. PLoS ONE, 2014, 9, e105887.	1.1	27
3634	Assessment of Serum Acylated Ghrelin in Children and Adolescents with Chronic Liver Diseases: Relation to Nutritional Status. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	3
3635	Recent Advances in Liver Resection for Hepatocellular Carcinoma. Frontiers in Surgery, 2014, 1, 21.	0.6	35
3636	Child-Pugh Score Is an Independent Risk Factor for Immediate Bleeding after Colonoscopic Polypectomy in Liver Cirrhosis. Yonsei Medical Journal, 2014, 55, 1281.	0.9	14
3637	ANALYSIS OF THE SURVIVAL OF CIRRHOTIC PATIENTS ENLISTED FOR LIVER TRANSPLANTATION IN THE PREAND POST-MELD ERA IN SOUTHERN BRAZIL. Arquivos De Gastroenterologia, 2014, 51, 46-52.	0.3	10
3638	Clinical relevance of sarcopenia in patients with cirrhosis. World Journal of Gastroenterology, 2014, 20, 8061.	1.4	193
3639	Can the model for end-stage liver disease score replace the indocyanine green clearance test in the selection of right hemihepatectomy in Child-Pugh class A?. Annals of Surgical Treatment and Research, 2014, 86, 122.	0.4	8
3640	Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 7011.	1.4	26
3641	Liver transplantation: Fifty years of experience. World Journal of Gastroenterology, 2014, 20, 5363.	1.4	81
3642	Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. World Journal of Hepatology, 2014, 7, 261.	0.8	14

#	Article	IF	CITATIONS
3643	Predicting outcome in primary biliary cirrhosis. Annals of Hepatology, 2014, 13, 316-326.	0.6	41
3644	Plasma cytokine levels imbalance in cirrhotic patients with impaired glucose tolerance and diabetes mellitus. A prospective study. Annals of Hepatology, 2014, 13, 403-410.	0.6	5
3645	Band ligation vs. N-Butyl-2-cyanoacrylate injection in acute gastric variceal bleeding: a prospective follow-up study. Annals of Hepatology, 2014, 13, 75-83.	0.6	37
3646	The Impact of Serum Interleukin-17 on Chronic Hepatitis C and Its Sequelae. Journal of Liver, 2014, 03, .	0.3	0
3647	Antiviral agents for hepatitis B virus-related cirrhosis. The Cochrane Library, 2014, , .	1.5	0
3648	Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World Journal of Gastroenterology, 2014, 20, 16996.	1.4	53
3649	The role of Interleukin 28B gene polymorphism in Turkish patients with hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 788-795.	0.6	14
3650	Balloon-Occluded Retrograde Transvenous Obliteration versus Endoscopic Injection Sclerotherapy for Isolated Gastric Varices: A Comparative Study. Kurume Medical Journal, 2014, 60, 105-113.	0.0	14
3651	Minimal hepatic encephalopathy in patients with liver cirrhosis: Magnetic resonance spectroscopic brain findings versus neuropsychological changes. Arab Journal of Gastroenterology, 2014, 15, 108-113.	0.4	13
3653	Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology, 2014, 60, 1851-1860.	3.6	135
3654	Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. Journal of Clinical Pharmacology, 2014, 54, 291-300.	1.0	30
3655	Factors Predicting Surgical Resection in Patients with Intrahepatic Cholangiocarcinoma and Cirrhosis. Journal of Investigative Surgery, 2014, 27, 219-225.	0.6	8
3656	Postoperative morphine concentration in infants with or without biliary atresia and its association with hepatic blood flow. Anaesthesia, 2014, 69, 583-590.	1.8	6
3657	Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. Future Virology, 2014, 9, 9-20.	0.9	0
3658	Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. British Journal of Cancer, 2014, 110, 2090-2098.	2.9	46
3659	Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis. Nature Medicine, 2014, 20, 467-469.	15.2	13
3660	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemotherapy and Pharmacology, 2014, 74, 1089-1098.	1.1	38
3661	Ivacaftor for patients with cystic fibrosis. Expert Review of Respiratory Medicine, 2014, 8, 533-538.	1.0	20

#	Article	IF	Citations
3662	Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2014, 106, .	3.0	28
3663	Angiogenesis-Related Biomarkers in Patients with Alcoholic Liver Disease: Their Association with Liver Disease Complications and Outcome. Mediators of Inflammation, 2014, 2014, 1-11.	1.4	14
3664	Nutrition assessment in patients undergoing liver transplant. Indian Journal of Critical Care Medicine, 2014, 18, 672-681.	0.3	18
3665	Cryptosporidiosis in patients with diarrhea and chronic liver diseases. Journal of Infection in Developing Countries, 2014, 8, 1584-1590.	0.5	13
3666	Impact of Serum Chemerin Levels on Liver Functional Reserves and Platelet Counts in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2014, 15, 11294-11306.	1.8	26
3667	Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model. Oncology, 2014, 86, 295-302.	0.9	11
3668	Value of renal resistive index in hepatitis C virus related liver cirrhosis and its response to midodrine. Egyptian Journal of Radiology and Nuclear Medicine, 2014, 45, 1079-1087.	0.3	2
3669	Cognitive Function in Patients With Alcoholic and Nonalcoholic Chronic Liver Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2014, 26, 241-248.	0.9	10
3670	Activity of eribulin mesylate in heavily pretreated breast cancer granted accessvia the Cancer Drugs Fund. Future Oncology, 2014, 10, 363-376.	1.1	16
3671	Pharmacokinetics of Antidepressants in Patients with Hepatic Impairment. Clinical Pharmacokinetics, 2014, 53, 1069-1081.	1.6	7
3672	Evaluation of Fibrotic Liver Disease with Whole-Liver T1ϕMR Imaging: A Feasibility Study at 1.5 T. Radiology, 2014, 271, 408-415.	3.6	105
3673	Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Clinical Pharmacology in Drug Development, 2014, 3, 34-42.	0.8	30
3674	Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESSâ€HCC risk model. Cancer, 2014, 120, 3485-3493.	2.0	125
3675	Predictors of inâ€hospital mortality after acute variceal bleeding in patients with hepatocellular carcinoma and concurrent main portal vein thrombosis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 344-351.	1.4	14
3676	Comparison of scoring systems and outcome of patients admitted to a liver intensive care unit of a tertiary referral centre with severe variceal bleeding. Alimentary Pharmacology and Therapeutics, 2014, 39, 1286-1300.	1.9	25
3677	Ratios of regulatory T cells/Tâ€helper 17 cells and transforming growth factorâ€Î²1/interleukinâ€Ĩ7 to be associated with the development of hepatitis <scp>B</scp> virusâ€associated liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1065-1072.	1.4	41
3678	Interleukinâ€21 mediates hepatitis <scp>B</scp> virusâ€associated liver cirrhosis by activating hepatic stellate cells. Hepatology Research, 2014, 44, E198-205.	1.8	14
3679	The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. Journal of Clinical Pharmacology, 2014, 54, 1368-1374.	1.0	27

#	Article	IF	CITATIONS
3680	Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. Hpb, 2014, 16, 758-767.	0.1	23
3681	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	0.6	365
3682	Glomerular filtration rate is an independent factor of mortality in patients with decompensated cirrhosis. Hepatology Research, 2014, 44, E145-55.	1.8	13
3683	Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood, 2014, 124, 1020-1028.	0.6	114
3684	Risk factors for 1â€year mortality in patients with intermediateâ€stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization. Advances in Digestive Medicine, 2014, 1, 126-131.	0.1	3
3685	Postâ€therapeutic needle biopsy in patients with hepatocellular carcinoma is a useful tool to evaluate response to proton irradiation. Hepatology Research, 2014, 44, 403-409.	1.8	3
3686	New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Medicine, 2014, 3, 1359-1367.	1.3	282
3687	Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. Hepatology Research, 2014, 44, 481-490.	1.8	5
3688	Comparison of inflammationâ€based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 682-688.	1.4	72
3689	Post-hepatectomy haemorrhage: a single-centre experience. Hpb, 2014, 16, 965-971.	0.1	2
3690	Severe 25â€hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma – a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2014, 39, 1204-1212.	1.9	70
3691	<scp>CYP3A</scp> activity in severe liver cirrhosis correlates with <scp>C</scp> hild– <scp>P</scp> ugh and model for endâ€stage liver disease (<scp>MELD</scp>) scores. British Journal of Clinical Pharmacology, 2014, 77, 160-169.	1.1	53
3692	Transjugular intrahepatic portosystemic shunt for Budd–Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver International, 2014, 34, 1164-1175.	1.9	69
3693	Influenza A(H1N1)pdm09 vaccine effectiveness and other characteristics associated with hospitalization in chronic liver disease patients. Liver International, 2014, 34, 700-706.	1.9	6
3694	Model for End-Stage Liver Disease (MELD) Score Does Not Predict Outcomes of Hepatitis B–Induced Acute-on-Chronic Liver Failure in Transplant Recipients. Transplantation Proceedings, 2014, 46, 3502-3506.	0.3	9
3695	Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?. Internal Medicine Journal, 2014, 44, 865-872.	0.5	47
3696	Diagnostic and prognostic role of <scp>SCCA</scp> â€ <scp>lgM</scp> serum levels in hepatocellular carcinoma (<scp>HCC</scp>). Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1637-1644.	1.4	44
3697	The singleâ€dose pharmacokinetics of alitretinoin and its metabolites are not significantly altered in patients with cirrhosis. British Journal of Dermatology, 2014, 170, 408-414.	1.4	4

#	Article	IF	CITATIONS
3698	Etiology and mortality of spontaneous bacterial peritonitis in liver transplant recipients: A cohort study. Liver Transplantation, 2014, 20, 856-863.	1.3	5
3699	Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1397-1408.	1.5	15
3700	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 144-153.	1.1	217
3701	Anatomic Versus Nonanatomic Hepatectomy for a Solitary Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2014, 18, 1994-2002.	0.9	77
3702	Scoring systems predict the prognosis of acute-on-chronic hepatitis B liver failure: an evidence-based review. Expert Review of Gastroenterology and Hepatology, 2014, 8, 623-632.	1.4	14
3703	Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy. JAMA Internal Medicine, 2014, 174, 1727.	2.6	167
3704	Symptoms and Distress Among Patients With Liver Cirrhosis but Without Hepatocellular Carcinoma in Taiwan. Gastroenterology Nursing, 2014, 37, 49-59.	0.2	10
3705	MELD-Na. Journal of Clinical Gastroenterology, 2014, 48, 870-877.	1.1	14
3706	Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments. Therapeutic Advances in Infectious Disease, 2014, 2, 17-42.	1.1	21
3707	Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. European Journal of Gastroenterology and Hepatology, 2014, 26, 396-403.	0.8	5
3708	Prognostic Impact of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma. Annals of Surgery, 2014, 259, 532-542.	2.1	145
3709	Advances in management and prognostication in critically ill cirrhotic patients. Current Opinion in Critical Care, 2014, 20, 210-217.	1.6	51
3710	Addition of â€~serum sodium' as a variable in the â€~model for end-stage liver disease' scoring system. Egyptian Liver Journal, 2014, 4, 29-35.	0.3	0
3711	Stratifying the Risks of Oral Anticoagulation in Patients With Liver Disease. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 461-467.	0.9	48
3712	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. Seminars in Liver Disease, 2014, 34, 444-455.	1.8	112
3713	Treatment of Hepatocellular Carcinoma. Digestive Diseases, 2014, 32, 554-563.	0.8	33
3714	Role of Pentoxifylline and Sparfloxacin in Prophylaxis of Spontaneous Bacterial Peritonitis in Cirrhotic Patients. ISRN Gastroenterology, 2014, 2014, 1-9.	1.5	1
3715	Preoperative Gadoxetic Acid-Enhanced MRI and Simultaneous Treatment of Early Hepatocellular Carcinoma Prolonged Recurrence-Free Survival of Progressed Hepatocellular Carcinoma Patients after Hepatic Resection. HPB Surgery, 2014, 2014, 1-8.	2.2	21

#	Article	IF	Citations
3716	Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Molecular and Clinical Oncology, 2014, 2, 1047-1054.	0.4	18
3717	HIV/Hepatitis C Virus-Coinfected Patients and Cirrhosis: How to Diagnose It and What to Do Next?. Clinical Infectious Diseases, 2014, 58, 840-847.	2.9	6
3718	Red cell distribution width as a potential index to assess the severity of hepatitis <scp>B</scp> virusâ€related liver diseases. Hepatology Research, 2014, 44, E464-70.	1.8	30
3719	Threshold Doses for Focal Liver Reaction After Stereotactic Ablative Body Radiation Therapy for Small Hepatocellular Carcinoma Depend on Liver Function: Evaluation onÂMagnetic Resonance Imaging With Gd-EOB-DTPA. International Journal of Radiation Oncology Biology Physics, 2014, 88, 306-311.	0.4	64
3720	Directly observed therapy for chronic hepatitis C: A randomized clinical trial in the prison setting. GastroenterologÃa Y HepatologÃa, 2014, 37, 443-451.	0.2	14
3721	Lipopolysaccharide binding protein in cirrhotic patients with severe sepsis. Journal of the Chinese Medical Association, 2014, 77, 68-74.	0.6	14
3722	High preâ€operative serum aminotransferase levels predict local recurrence after curative resection of hepatocellular carcinoma. Advances in Digestive Medicine, 2014, 1, 14-20.	0.1	0
3723	Prediction of Early Mortality After Variceal Bleeding: Score One More for MELD. Gastroenterology, 2014, 146, 337-339.	0.6	8
3724	A comparison of liver surface and hepatic vein wall ultrasound as markers for fibrosis or cirrhosis of the liver. Radiography, 2014, 20, 8-14.	1.1	1
3725	Development of a Six-Month Prognostic Index in Patients With Advanced Chronic Medical Conditions: The PALIAR Score. Journal of Pain and Symptom Management, 2014, 47, 551-565.	0.6	48
3726	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. Digestive and Liver Disease, 2014, 46, 632-638.	0.4	11
3727	Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?. Internal and Emergency Medicine, 2014, 9, 397-403.	1.0	15
3728	Treatment selection for gastric cancer with portal hypertension: clinical management. Gastric Cancer, 2014, 17, 302-309.	2.7	3
3729	Remnant liver volume-based predictors of postoperative liver dysfunction after hepatectomy: analysis of 625 consecutive patients from a single institution. International Journal of Clinical Oncology, 2014, 19, 614-621.	1.0	21
3730	Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system. Journal of Gastroenterology, 2014, 49, 324-331.	2.3	35
3731	Tissue factor expression on blood monocytes in patients with hepatitis C virus-induced chronic liver disease. Comparative Clinical Pathology, 2014, 23, 1159-1166.	0.3	1
3732	Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Budd–Chiari Syndrome Patients: Results From a Single Center. CardioVascular and Interventional Radiology, 2014, 37, 691-697.	0.9	36
3733	Clinical Presentation and Survival of Asian and Non-Asian Patients with HCV-Related Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2014, 59, 192-200.	1.1	27

#	Article	IF	CITATIONS
3734	Major Hepatectomy Is a Safe Modality for the Treatment of Intrahepatic Cholangiocarcinoma in Selected Patients Complicated with Cirrhosis. Journal of Gastrointestinal Surgery, 2014, 18, 194-199.	0.9	7
3735	CEACAM1 Long Cytoplasmic Domain Isoform is Associated with Invasion and Recurrence of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2014, 21, 505-514.	0.7	28
3736	Factors Associated with Aggravation of Esophageal Varices after B-RTO for Gastric Varices. CardioVascular and Interventional Radiology, 2014, 37, 1243-1250.	0.9	17
3737	Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, 63, 844-855.	6.1	1,180
3738	Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. British Journal of Cancer, 2014, 110, 2277-2282.	2.9	9
3739	Singleâ€dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. Journal of Clinical Pharmacology, 2014, 54, 732-741.	1.0	26
3740	Clinical Analysis of Anatomical Resection for the Treatment of Hepatocellular Carcinoma Based on the Stratification of Liver Function. World Journal of Surgery, 2014, 38, 1154-1163.	0.8	29
3741	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. Journal of Translational Medicine, 2014, 12, 21.	1.8	14
3742	Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment. Clinical Drug Investigation, 2014, 34, 127-133.	1.1	28
3743	Competing risks and prognostic stages of cirrhosis: a 25â€year inception cohort study of 494 patients. Alimentary Pharmacology and Therapeutics, 2014, 39, 1180-1193.	1.9	389
3744	Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis. European Radiology, 2014, 24, 1394-402.	2.3	103
3745	Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. Journal of Hepatology, 2014, 60, 570-578.	1.8	129
3746	Randomized controlled trial of monthly versus biweekly endoscopic variceal ligation for the prevention of esophageal variceal rebleeding. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1229-1236.	1.4	18
3747	Early mortality and long-term survival after abdominal surgery in patients with liver cirrhosis. Surgery, 2014, 155, 623-632.	1.0	42
3748	Determinants of alpha $\hat{a} \in \hat{f}$ etoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. Cancer, 2014, 120, 2150-2157.	2.0	56
3749	Hepatic encephalopathy is associated with slowed and delayed stimulus-associated somatosensory alpha activity. Clinical Neurophysiology, 2014, 125, 2427-2435.	0.7	19
3750	Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2014, 23, 289-311.	0.6	58
3751	Fungal infection in patients with end-stage liver disease: low frequency or low index of suspicion. International Journal of Infectious Diseases, 2014, 23, 69-74.	1.5	76

#	Article	IF	CITATIONS
3752	Surgery in Patients with Portal Hypertension. Clinics in Liver Disease, 2014, 18, 477-505.	1.0	28
3753	Insight into the relationship between brain/behavioral speed and variability in patients with minimal hepatic encephalopathy. Clinical Neurophysiology, 2014, 125, 287-297.	0.7	18
3754	A novel mortality model for acute alcoholic hepatitis including variables recorded after admission to hospital. Computers in Biology and Medicine, 2014, 44, 132-135.	3.9	1
3755	Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatology Research, 2014, 44, 1329-1338.	1.8	33
3756	A Comparison of Measured and Calculated Free 25(OH) Vitamin D Levels in Clinical Populations. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1631-1637.	1.8	164
3757	The Role of Organic Anion Transporters in Diagnosing Liver Diseases by Magnetic Resonance Imaging. Drug Metabolism and Disposition, 2014, 42, 675-684.	1.7	33
3758	Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology, 2014, 60, 954-963.	3.6	169
3759	Branched-chain amino acid supplementation in adults with cirrhosis and porto-systemic encephalopathy: Systematic review. Clinical Nutrition, 2014, 33, 958-965.	2.3	25
3760	Inferior Right Hepatic Veinâ€preserving Major Right Hepatectomy for Hepatocellular Carcinoma in Patients with Significant Fibrosis or Cirrhosis. World Journal of Surgery, 2014, 38, 159-167.	0.8	10
3761	Application of an isocratic methanol-based HPLC method for the determination of iohexol concentrations and glomerular filtration rate in patients with cirrhosis. Annals of Clinical Biochemistry, 2014, 51, 80-88.	0.8	8
3762	Measuring hepatic functional reserve using low temporal resolution Gd-EOB-DTPA dynamic contrast-enhanced MRI: a preliminary study comparing galactosyl human serum albumin scintigraphy with indocyanine green retention. European Radiology, 2014, 24, 112-119.	2.3	39
3763	Hepatectomy and liver regeneration: from experimental research to clinical application. ANZ Journal of Surgery, 2014, 84, 665-671.	0.3	16
3764	Surgical Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. World Journal of Surgery, 2014, 38, 490-496.	0.8	86
3765	Pharmacokinetic of Antiepileptic Drugs in Patients with Hepatic or Renal Impairment. Clinical Pharmacokinetics, 2014, 53, 29-49.	1.6	26
3766	A historical review of classic articles in surgery field. American Journal of Surgery, 2014, 208, 841-849.	0.9	55
3767	Antibiotic dosing in cirrhosis. American Journal of Health-System Pharmacy, 2014, 71, 1621-1634.	0.5	22
3768	Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. British Journal of Clinical Pharmacology, 2014, 77, 998-1010.	1.1	24
3769	Free fatty acid as a marker of energy malnutrition in liver cirrhosis. Hepatology Research, 2014, 44, 218-228.	1.8	28

#	Article	IF	Citations
3770	Tryptophan Supplementation and Postoperative Deliriumâ€"A Randomized Controlled Trial. Journal of the American Geriatrics Society, 2014, 62, 1764-1771.	1.3	32
3771	Changes in highly sensitive alphaâ€fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy. Cancer Medicine, 2014, 3, 643-651.	1.3	13
3772	Highest intraoperative lactate level could predict postoperative infectious complications after hepatectomy, reflecting the Pringle maneuver especially in chronic liver disease. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 489-498.	1.4	19
3773	Clinical but not histological factors predict longâ€term prognosis in patients with histologically advanced nonâ€decompensated alcoholic liver disease. Liver International, 2014, 34, 235-242.	1.9	32
3774	Prognostic value of serum cystatin C levels in cirrhotic patients with normal serum creatinine. Open Medicine (Poland), 2014, 9, 625-631.	0.6	1
3775	Increased DNA Damage in Hepatitis C Virus-Related Hepatocellular Carcinoma. DNA and Cell Biology, 2014, 33, 884-890.	0.9	15
3776	High early cardiovascular mortality after liver transplantation. Liver Transplantation, 2014, 20, 1306-1316.	1.3	154
3777	Prognostic factors in patients with refractory ascites treated by transjugular intrahepatic porto-systemic shunt: From the liver to the kidney. Digestive and Liver Disease, 2014, 46, 1001-1007.	0.4	10
3778	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. British Journal of Clinical Pharmacology, 2014, 77, 929-938.	1.1	65
3779	Epidemiology, Diagnosis and Early Patient Management of Esophagogastric Hemorrhage. Gastroenterology Clinics of North America, 2014, 43, 765-782.	1.0	15
3780	Hepatic Perfusion Parameters of Contrast-Enhanced Ultrasonography Correlate With the Severity of Chronic Liver Disease. Ultrasound in Medicine and Biology, 2014, 40, 2556-2563.	0.7	11
3781	Systemic treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 921-935.	1.0	9
3782	The utility of scoring systems in critically ill cirrhotic patients admitted to a general intensive care unit. Journal of Critical Care, 2014, 29, 1131.e1-1131.e6.	1.0	17
3783	Acute-On-Chronic Liver Failure. Clinics in Liver Disease, 2014, 18, 561-574.	1.0	24
3784	Evolving Trends in Liver Transplantation. Clinics in Liver Disease, 2014, 18, 519-527.	1.0	6
3785	Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and metaâ€analysis. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 639-647.	1.4	36
3786	Treatment of intermediate-stage hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2014, 11, 525-535.	12.5	377
3787	Advances in preoperative assessment of liver function. Hepatobiliary and Pancreatic Diseases International, 2014, 13, 361-370.	0.6	60

#	Article	IF	CITATIONS
3788	How grim is hepatocellular carcinoma?. Annals of Medicine and Surgery, 2014, 3, 71-76.	0.5	17
3789	Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C). Journal of Antimicrobial Chemotherapy, 2014, 69, 471-475.	1.3	22
3790	Prognosis prediction and staging. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 855-865.	1.0	20
3791	Liver resection for HCC: Patient's selection and controversial scenarios. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 881-896.	1.0	36
3792	Necrotizing fasciitis in liver cirrhosis. Formosan Journal of Surgery, 2014, 47, 132-137.	0.1	2
3793	Increased Complication Rates After Hip and Knee Arthroplasty in Patients With Cirrhosis of the Liver. Clinical Orthopaedics and Related Research, 2014, 472, 2774-2778.	0.7	51
3794	Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas. European Radiology, 2014, 24, 2157-2166.	2.3	18
3795	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. Journal of Hepatology, 2014, 61, 1038-1047.	1.8	741
3796	Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Medicine, 2014, 40, 988-997.	3.9	48
3797	Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemotherapy and Pharmacology, 2014, 74, 267-275.	1.1	36
3798	Effect of liver dysfunction on circulating sclerostin. Journal of Bone and Mineral Metabolism, 2014, 32, 545-549.	1.3	31
3799	Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2014, 21, 2700-2707.	0.7	22
3800	Hepatocellular carcinoma: A comprehensive overview of surgical therapy. Journal of Surgical Oncology, 2014, 110, 712-719.	0.8	43
3801	Enzymatic Liver Function Capacity Correlates with Disease Severity of Patients with Liver Cirrhosis: A Study with the LiMAx Test. Digestive Diseases and Sciences, 2014, 59, 2983-2991.	1.1	36
3802	Prediction of spontaneous bacterial peritonitis in cirrhotic ascites by a simple scoring system. Scandinavian Journal of Gastroenterology, 2014, 49, 595-603.	0.6	25
3803	Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma. Tumor Biology, 2014, 35, 3689-3698.	0.8	4
3804	Effect of Hepatic Impairment on the Pharmacokinetics of Levomilnacipran Following a Single Oral Dose of a Levomilnacipran Extended-Release Capsule in Human Participants. Clinical Drug Investigation, 2014, 34, 351-359.	1.1	11
3805	Consumption of Cisatracurium in different age groups, using a closed loop computer controlled system. BMC Anesthesiology, 2014, 14, 29.	0.7	2

#	Article	IF	CITATIONS
3806	Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life― cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterology, 2014, 14, 87.	0.8	21
3807	HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial. Trials, 2014, 15, 91.	0.7	25
3808	Current Treatment for Small (<5Âcm) Hepatocellular Carcinoma. Advances in Surgery, 2014, 48, 97-114.	0.6	3
3809	Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology, 2014, 60, 65-76.	3.6	118
3810	Laparoscopic sleeve gastrectomy in patients with NASH-related cirrhosis: A case-matched study. Surgery for Obesity and Related Diseases, 2014, 10, 405-410.	1.0	53
3811	Systematic review: the effects of autologous stem cell therapy for patients with liver disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 673-685.	1.9	56
3812	When to Consider Liver Transplant During the Management of Chronic Liver Disease. Medical Clinics of North America, 2014, 98, 153-168.	1.1	20
3813	Admission factors associated with prolonged (>14 days) intensive care unit stay. Journal of Critical Care, 2014, 29, 60-65.	1.0	26
3814	Association of Abnormal Plasma Bilirubin With Aggressive Hepatocellular Carcinoma Phenotype. Seminars in Oncology, 2014, 41, 252-258.	0.8	40
3815	Hypoglycemia is associated with increased mortality in patients with acute decompensated liver cirrhosis. Journal of Critical Care, 2014, 29, 316.e7-316.e12.	1.0	39
3816	Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. Journal of Hepatology, 2014, 61, 51-58.	1.8	104
3817	Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization. Clinical Biochemistry, 2014, 47, 184-190.	0.8	22
3818	Brain regional homogeneity changes following transjugular intrahepatic portosystemic shunt in cirrhotic patients support cerebral adaptability theoryâ€"A resting-state functional MRI study. European Journal of Radiology, 2014, 83, 578-583.	1.2	14
3819	Preoperative variables associated with transfusion requirements in orthotopic liver transplantation. Transfusion and Apheresis Science, 2014, 50, 99-105.	0.5	15
3820	Early markers of neural dysfunction and compensation: A model from minimal hepatic encephalopathy. Clinical Neurophysiology, 2014, 125, 1138-1144.	0.7	6
3821	Recumbent deoxygenation in mild/moderate liver cirrhosis: the "Clinodeoxia― The ortho-clino paradigm. Respiratory Medicine, 2014, 108, 1040-1048.	1.3	2
3822	The impact and effect of liver insufficiency of HCV infection on patients with chronic obstructive pulmonary diseases. The Egyptian Journal of Chest Diseases and Tuberculosis, 2014, 63, 81-85.	0.1	4
3823	Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology, 2014, 146, 442-452.e1.	0.6	123

#	Article	IF	CITATIONS
3824	Erectile dysfunction in patients with chronic hepatitis C virus infection. Arab Journal of Gastroenterology, 2014, 15, 16-20.	0.4	15
3825	Covert Hepatic Encephalopathy: Does the Mini-Mental State Examination Help?. Journal of Clinical and Experimental Hepatology, 2014, 4, 89-93.	0.4	12
3826	Variability in free 25(OH) vitamin D levels in clinical populations. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 156-158.	1.2	52
3827	Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases. Japanese Journal of Radiology, 2014, 32, 405-413.	1.0	21
3828	Toward an Improved Definition of Acute-on-Chronic Liver Failure. Gastroenterology, 2014, 147, 4-10.	0.6	255
3829	Abnormal functional connectivity within the default mode network in patients with HBV-related cirrhosis without hepatic encephalopathy revealed by resting-state functional MRI. Brain Research, 2014, 1576, 73-80.	1.1	18
3830	Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment. Epilepsy Research, 2014, 108, 891-901.	0.8	17
3831	A multicenter prospective study of infections related morbidity and mortality in cirrhosis of liver. Indian Journal of Gastroenterology, 2014, 33, 336-342.	0.7	27
3832	Alcoholic liver disease in the intensive care unit: Outcomes and predictors of prognosis. Journal of Critical Care, 2014, 29, 1131.e7-1131.e13.	1.0	10
3833	Model for End-Stage Liver Disease score predicts mortality in critically ill cirrhotic patients. Journal of Critical Care, 2014, 29, 881.e7-881.e13.	1.0	26
3834	Hilar cholangiocarcinoma in cirrhotic liver: A case–control study. International Journal of Surgery, 2014, 12, 762-767.	1.1	8
3835	Treatment Algorithms for Managing Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology, 2014, 4, S80-S89.	0.4	54
3836	Management of End-stage Liver Disease. Medical Clinics of North America, 2014, 98, 119-152.	1.1	36
3837	The feasibility of endoscopic submucosal dissection for superficial esophageal cancer in patients with cirrhosis (with video). Gastrointestinal Endoscopy, 2014, 79, 681-685.	0.5	24
3838	Hypoalbuminemia in Acute Heart Failure Patients: Causes and Its Impact on Hospital and Long-Term Mortality. Journal of Cardiac Failure, 2014, 20, 350-358.	0.7	113
3839	ThymosinÎ ² 4: A novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient?. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 310-317.	0.7	9
3840	Tollâ€ike receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatology Research, 2014, 44, 769-778.	1.8	65
3841	Preoperative liver function assessments to estimate the prognosis and safety of liver resections. Surgery Today, 2014, 44, 1-10.	0.7	50

#	Article	IF	CITATIONS
3842	Branched-chain Amino Acid Granules Improve the Non-protein Respiratory Quotient after Radiofrequency Ablation. Internal Medicine, 2014, 53, 1469-1475.	0.3	8
3843	Liver Intensive Care. Introductory Series in Medicine, 2014, , 625-646.	0.0	0
3845	Capsule endoscopy for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2014, 2014, CD008760.	1.5	23
3846	Good Clinical Practice., 2014, , 756-787.		0
3847	Default Mode Network Functional Connectivity. Medicine (United States), 2014, 93, e227.	0.4	18
3848	Diagnosing Dying. Anesthesia and Analgesia, 2014, 118, 879-882.	1.1	4
3849	The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor. Clinical Pharmacology in Drug Development, 2014, 3, 421-427.	0.8	14
3850	Alcoholic Ketosis: Prevalence, Determinants, and Ketohepatitis in Japanese Alcoholic Men. Alcohol and Alcoholism, 2014, 49, 618-625.	0.9	16
3851	Complications of Chronic Alcoholism That Affect Critical Illness. , 2015, , 1-18.		0
3852	Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma. Ultrasound in Medicine and Biology, 2015, 41, 3070-3078.	0.7	16
3853	Hepatocellular carcinoma: management of a complex and challenging condition. Gastrointestinal Nursing, 2015, 13, S20-S26.	0.0	1
3854	A Comprehensive Method for Predicting Fatal Liver Failure of Patients With Liver Cancer Resection. Medicine (United States), 2015, 94, e784.	0.4	5
3855	An openâ€label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. Journal of Clinical Pharmacology, 2015, 55, 1395-1405.	1.0	47
3856	Sarcopenia, obesity and sarcopenic obesity: effects on liver function and volume in patients scheduled for major liver resection. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 155-163.	2.9	22
3857	Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis Bâ€positive patients with hepatocellular carcinoma. Journal of Surgical Oncology, 2015, 111, 862-867.	0.8	27
3858	Editorial: dynamic changes of the inflammationâ€based index predict mortality following chemoembolisation for hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2015, 41, 1216-1217.	1.9	2
3859	S-adenosyl-L-methionine for people with alcoholic liver disease. The Cochrane Library, 2015, , .	1.5	1
3860	An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. International Journal of Oncology, 2015, 46, 944-952.	1.4	8

#	Article	IF	CITATIONS
3861	Role of local and distant functional connectivity density in the development of minimal hepatic encephalopathy. Scientific Reports, 2015, 5, 13720.	1.6	16
3863	Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal varices in children. The Cochrane Library, 0, , .	1.5	8
3864	Outcomes of resection of giant hepatocellular carcinoma in a tertiary institution: does size matter?. Hpb, 2015, 17, 988-993.	0.1	14
3865	Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report. Oncology Letters, 2015, 9, 2495-2498.	0.8	3
3866	Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B. Molecular Medicine Reports, 2015, 11, 2644-2652.	1.1	16
3867	Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure. Scientific Reports, 2015, 5, 14240.	1.6	22
3868	Function of interleukin-17 and \hat{a} in the blood of patients with hepatitis B-related liver cirrhosis. Molecular Medicine Reports, 2015, 11, 121-126.	1.1	37
3869	Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Oncology Research and Treatment, 2015, 38, 596-603.	0.8	20
3870	Sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children. The Cochrane Library, 2015, , .	1.5	5
3871	Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies. Clinical Therapeutics, 2015, 37, 2823-2836.	1.1	11
3872	Key New Studies in Gastric and Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 475-481.	0.4	1
3873	Impact of liver cirrhosis due to chronic hepatitis C viral infection on the outcome of ovarian cancer: a prospective study. BMC Cancer, 2015, 15, 754.	1.1	4
3874	Impaired Motor Competence in Children With Transplanted Liver. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 723-728.	0.9	21
3875	Impact of anticoagulation on upperâ€gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology, 2015, 62, 575-583.	3.6	105
3876	Tumors With Intrahepatic Bile Duct Differentiation in Cirrhosis. Transplantation, 2015, 99, 151-157.	0.5	69
3877	Validation of the "Metroticket―model in a cohort of patients transplanted for hepatocellular carcinoma in southern Brazil. Clinical Transplantation, 2015, 29, 806-812.	0.8	1
3878	Ischaemiaâ€modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. Liver International, 2015, 35, 2425-2432.	1.9	20
3879	microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. Diagnostic Pathology, 2015, 10, 129.	0.9	45

#	Article	IF	CITATIONS
3880	Validation and analysis of prognostic scoring systems for critically ill patients with cirrhosis admitted to ICU. Critical Care, 2015, 19, 364.	2.5	22
3881	Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. Journal of Medical Virology, 2015, 87, 1368-1376.	2.5	2
3882	The short―and longâ€ŧerm outcomes of pancreaticoduodenectomy for cancer in child a patients are acceptable: A patient ontrol study from the Surgical French Association report for pancreatic surgery. Journal of Surgical Oncology, 2015, 111, 776-783.	0.8	27
3883	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatology Research, 2015, 45, 656-662.	1.8	42
3884	Patients with manifest hepatic encephalopathy can reveal impaired thermal perception. Acta Neurologica Scandinavica, 2015, 132, 156-163.	1.0	10
3885	Acuteâ€onâ€chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology, 2015, 62, 232-242.	3.6	248
3886	Impact of the branchedâ€chain amino acid to tyrosine ratio and branchedâ€chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1412-1419.	1.4	24
3887	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1522-1528.	1.4	15
3888	The risk of perioperative adverse events in patients with chronic liver disease. Liver International, 2015, 35, 713-723.	1.9	11
3889	Predictive Scores in Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2015, 49, 438-447.	1.1	12
3890	Pharmacokinetics and Safety of Vilazodone in Hepatic Impairment. American Journal of Therapeutics, 2015, 22, 269-277.	0.5	7
3891	Transarterial chemoembolization with drugâ€eluting beads is effective for the maintenance of the Milanâ€in status in patients with a small hepatocellular carcinoma. Liver Transplantation, 2015, 21, 1259-1269.	1.3	35
3892	Symptom Distress in Patients With End-Stage Liver Disease Toward the End of Life. Gastroenterology Nursing, 2015, 38, 201-210.	0.2	24
3893	Chronic Liver Disease Questionnaire would be a primary screening tool of neuropsychiatric test detecting minimal hepatic encephalopathy of cirrhotic patients. Hepatology Research, 2015, 45, 994-1003.	1.8	13
3894	Urotensin II as a novel marker for portal hypertension and bleeding varices. Egyptian Liver Journal, 2015, 5, 54-59.	0.3	0
3895	Impact of serum glycosylated <i>Wisteria floribunda</i> agglutinin positive Macâ€2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatology Research, 2015, 45, 1083-1090.	1.8	35
3896	Gut dysbiosis in acuteâ€onâ€chronic liver failure and its predictive value for mortality. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1429-1437.	1.4	131
3897	Tenofovir disoproxil fumarate has a substantial efficacy against multidrugâ€resistant strains of hepatitis B virus. Liver International, 2015, 35, 2265-2274.	1.9	2

#	Article	IF	CITATIONS
3898	A novel objective method for deceased donor and recipient size matching in liver transplantation. Liver Transplantation, 2015, 21, 1471-1477.	1.3	18
3899	Aldehyde dehydrogenase 2 polymorphism for development to hepatocellular carcinoma in <scp>E</scp> ast <scp>A</scp> sian alcoholic liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1376-1383.	1.4	17
3900	The Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Ospemifene, a Tissue-Selective Estrogen Agonist/Antagonist. American Journal of Therapeutics, 2015, 22, 171-181.	0.5	2
3901	A Clinical Decision Rule Based on the AST-to-Platelet Ratio Index Improves Adherence to Published Guidelines on the Management of Acute Variceal Bleeding. Journal of Clinical Gastroenterology, 2015, 49, 599-606.	1.1	1
3902	Elevated Preoperative Serum Hs-CRP Level as a Prognostic Factor in Patients Who Underwent Resection for Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e2209.	0.4	12
3903	Management of cancer of the liver, gallbladder and biliary tract., 0, , 196-211.		O
3905	2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2015, 16, 465.	1.5	168
3906	Adjuvant Iodine < sup > 131 < /b> < /sup > Lipiodol after Resection of Hepatocellular Carcinoma. Journal of Oncology, 2015, 2015, 1-7.	0.6	7
3907	Does SEN virus (SENV) infection affect the progression of chronic hepatitis C or B among Egyptian patients?. African Journal of Microbiology Research, 2015, 9, 1504-1512.	0.4	2
3908	Model for End-Stage Liver Disease, Model for Liver Transplantation Survival and Donor Risk Index as predictive models of survival after liver transplantation in 1,006 patients. Clinics, 2015, 70, 413-418.	0.6	12
3909	Real-time two-dimensional shear wave ultrasound elastography of the liver is a reliable predictor of clinical outcomes and the presence of esophageal varices in patients with compensated liver cirrhosis. Croatian Medical Journal, 2015, 56, 470-481.	0.2	50
3910	Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience. OncoTargets and Therapy, 2015, 8, 3775.	1.0	5
3911	Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields. Journal of Hepatocellular Carcinoma, 2015, 2, 49.	1.8	0
3912	Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Oncotarget, 2015, 6, 43090-43098.	0.8	61
3913	Prognostic Models in Cirrhosis: An Anesthetist Perspective. Journal of Clinical Trials, 2015, 04, .	0.1	0
3914	Angiotensin-converting enzyme gene polymorphism (insertion/deletion) and liver fibrosis in Turkish patients from the western Black Sea region, Turkey. Genetics and Molecular Research, 2015, 14, 17079-17090.	0.3	4
3915	Hyponatremia in Patients with Cirrhosis of the Liver. Journal of Clinical Medicine, 2015, 4, 85-101.	1.0	23
3916	Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World Journal of Gastroenterology, 2015, 21, 1207.	1.4	83

#	Article	IF	CITATIONS
3917	Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World Journal of Hepatology, 2015, 7, 1041.	0.8	42
3918	Combining Serum Cystatin C with Total Bilirubin Improves Short-Term Mortality Prediction in Patients with HBV-Related Acute-On-Chronic Liver Failure. PLoS ONE, 2015, 10, e0116968.	1.1	19
3919	Comparison of the Prevalence of Latent Tuberculosis Infection among Non-Dialysis Patients with Severe Chronic Kidney Disease, Patients Receiving Dialysis, and the Dialysis-Unit Staff: A Cross-Sectional Study. PLoS ONE, 2015, 10, e0124104.	1,1	22
3920	Successful Splenectomy for Hypersplenism in Wilson's Disease: A Single Center Experience from China. PLoS ONE, 2015, 10, e0124569.	1.1	10
3921	Prognostic Significance of the Systemic Inflammatory and Immune Balance in Alcoholic Liver Disease with a Focus on Gender-Related Differences. PLoS ONE, 2015, 10, e0128347.	1.1	24
3922	Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. PLoS ONE, 2015, 10, e0129000.	1.1	15
3923	Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis. PLoS ONE, 2015, 10, e0130021.	1.1	36
3924	Transcriptional Up-Regulation of APE1/Ref-1 in Hepatic Tumor: Role in Hepatocytes Resistance to Oxidative Stress and Apoptosis. PLoS ONE, 2015, 10, e0143289.	1.1	30
3925	Surgical portosystemic shunts versus devascularisation procedures for variceal bleeding due to hepatosplenic schistosomiasis. The Cochrane Library, 2015, , .	1.5	1
3926	Evaluation of Serum Cystatin C as a Marker of Early Renal Impairment in Patients with Liver Cirrhosis. International Journal of Hepatology, 2015, 2015, 1-8.	0.4	20
3927	Urinary Metabolite Profiling Offers Potential for Differentiation of Liver-Kidney Yin Deficiency and Dampness-Heat Internal Smoldering Syndromes in Posthepatitis B Cirrhosis Patients. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-11.	0.5	12
3928	MR Prediction of Liver Function and Pathology Using Gd-EOB-DTPA: Effect of Liver Volume Consideration. BioMed Research International, 2015, 2015, 1-5.	0.9	8
3929	Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Advances in Hematology, 2015, 2015, 1-19.	0.6	11
3930	Psychometrics of the Greek Chronic Liver Disease Questionnaire for Measuring HRQL. Gastroenterology Research and Practice, 2015, 2015, 1-6.	0.7	3
3931	Plasma betatrophin levels in patients with liver cirrhosis. World Journal of Gastroenterology, 2015, 21, 10662.	1.4	17
3932	The performance of prognostic models as predictors of mortality in patients with acute decompensation of cirrhosis. Annals of Hepatology, 2015, 14, 83-92.	0.6	10
3933	DEPARTMENT OF HEALTH & HUMAN SERVICES. Pharmacy Today, 2015, 21, 20-21.	0.0	134
3934	Factors associated with 25-hydroxyvitamin D levels in patients with liver cirrhosis. Annals of Hepatology, 2015, 14, 99-107.	0.6	7

#	Article	IF	CITATIONS
3935	Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage. The Cochrane Library, 0 , , .	1.5	0
3936	Banding ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children. The Cochrane Library, 2015, , .	1.5	9
3937	Banding ligation versus sclerotherapy for primary prophylaxis of oesophageal varices in children. The Cochrane Library, $2015, , .$	1.5	7
3938	Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget, 2015, 6, 9551-9563.	0.8	48
3939	Current and future treatments for hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 8478.	1.4	140
3940	Nutritional care in hospitalized patients with chronic liver disease. World Journal of Gastroenterology, 2015, 21, 12835.	1.4	37
3941	Molecular prognostic prediction in liver cirrhosis. World Journal of Gastroenterology, 2015, 21, 10262.	1.4	12
3942	Budd-Chiari syndrome and liver transplantation. Intractable and Rare Diseases Research, 2015, 4, 24-32.	0.3	39
3943	Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World Journal of Hepatology, 2015, 7, 2292.	0.8	13
3944	Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B. World Journal of Gastroenterology, 2015, 21, 8373.	1.4	16
3945	Admission des patients cirrhotiques en réanimation : le score de Child-Pugh est-il un outil pertinent ?. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2015, 24, 389-397.	0.1	1
3946	Outcomes of ESD for patients with early gastric cancer and comorbid liver cirrhosis: a propensity score analysis. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 1560-1566.	1.3	31
3947	Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer, 2015, 15, 465.	1.1	105
3948	Evaluation of Liver Biomarkers as Prognostic Factors for Outcomes to Yttrium-90 Radioembolization of Primary and Secondary Liver Malignancies. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 305-309.	0.7	5
3949	Establishment and Validation of ALPH-Q Score to Predict Mortality Risk in Patients With Acute-on-Chronic Hepatitis B Liver Failure. Medicine (United States), 2015, 94, e403.	0.4	19
3950	Abdominal wall hernia in cirrhotic patients: emergency surgery results in higher morbidity and mortality. BMC Surgery, 2015, 15, 65.	0.6	49
3951	The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Journal of Radiation Research, 2015, 56, 325-331.	0.8	21
3952	Mortality after cardiac surgery in patients with liver cirrhosis classified by the Child-Pugh score. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 520-530.	0.5	55

#	Article	IF	Citations
3953	Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e2133.	0.4	56
3955	Clinical comparison of laparoscopic and open liver resection after propensity matching selection. Surgery, 2015, 158, 573-587.	1.0	26
3956	Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2015, 33, 1257-1262.	1.2	75
3957	Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis. Digestive Diseases, 2015, 33, 118-124.	0.8	4
3958	Prognosis of untreated hepatocellular carcinoma. Hepatology, 2015, 61, 184-190.	3.6	188
3959	Safe Hepatectomy Selection Criteria for Hepatocellular Carcinoma Patients: A Validation of 336 Consecutive Hepatectomies. The BILCHE Score. World Journal of Surgery, 2015, 39, 237-243.	0.8	40
3960	Exploration of skin perfusion in cirrhotic patients with septic shock. Journal of Hepatology, 2015, 62, 549-555.	1.8	38
3961	Multifrequency Time-Harmonic Elastography for the Measurement of Liver Viscoelasticity in Large Tissue Windows. Ultrasound in Medicine and Biology, 2015, 41, 724-733.	0.7	40
3962	Optimizing signal intensity correction during evaluation of hepatic parenchymal enhancement on gadoxetate disodium-enhanced MRI: Comparison of three methods. European Journal of Radiology, 2015, 84, 339-345.	1.2	13
3963	Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2015, 41, 459-466.	1.9	93
3964	High seroprevalence of human herpesvirus type 8 in patients with hepatocellular carcinoma. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 55-62.	1.3	2
3966	Risk factors of recurrence among 471 Chinese patients with Budd-Chiari syndrome. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 620-626.	0.7	14
3967	No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. Thrombosis Research, 2015, 135, 292-297.	0.8	23
3968	Creatinine modified <scp>C</scp> hild– <scp>T</scp> urcotte– <scp>P</scp> ugh and integrated model of endâ€stage liver disease scores as predictors of spontaneous bacterial peritonitisâ€related inâ€hospital mortality: Applicable or not. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1205-1210.	1.4	9
3969	Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. Journal of Hepatology, 2015, 63, 50-59.	1.8	76
3970	Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma. Journal of Oncology Pharmacy Practice, 2015, 21, 323-330.	0.5	18
3971	Longâ€term outcomes after hospitalization with spontaneous bacterial peritonitis. Journal of Digestive Diseases, 2015, 16, 228-240.	0.7	19
3972	Prognostic Benefit of the Addition of a Quantitative Index of Hepatic Encephalopathy to the MELD score: the MELDâ€EEG. Liver International, 2015, 35, 58-64.	1.9	40

#	Article	IF	CITATIONS
3973	A novel integrated <scp>M</scp> odel for <scp>E</scp> ndâ€ <scp>S</scp> tage <scp>L</scp> iver <scp>D</scp> isease model predicts shortâ€term prognosis of hepatitis <scp>B</scp> virusâ€related acuteâ€onâ€chronic liver failure patients. Hepatology Research, 2015, 45, 405-414.	1.8	23
3974	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approachâ€"The ALBI Grade. Journal of Clinical Oncology, 2015, 33, 550-558.	0.8	1,810
3975	Analyses of a Cirrhotic Patient's Evolution Using Self Organizing Mapping and Child-Pugh Scoring. Journal of Medical Systems, 2015, 39, 17.	2.2	1
3976	The Transforming Growth Factor \hat{l}^2 1/Interleukin-31 Pathway Is Upregulated in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure and Is Associated with Disease Severity and Survival. Vaccine Journal, 2015, 22, 484-492.	3.2	29
3978	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015, 62, 831-840.	1.8	289
3979	Blood Transfusion is Associated with Recurrence of Hepatocellular Carcinoma After Hepatectomy in Child–Pugh Class A Patients. World Journal of Surgery, 2015, 39, 1044-1051.	0.8	50
3980	Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure–Sequential Organ Failure Scoring System. Clinical Gastroenterology and Hepatology, 2015, 13, 1353-1360.e8.	2.4	91
3981	Impact of Severe Oesophagogastric Varices on Liver Resection for Hepatocellular Carcinoma in Cirrhotic Patients. World Journal of Surgery, 2015, 39, 461-468.	0.8	12
3982	Presentation and complications associated with cirrhosis of the liver. Current Medical Research and Opinion, 2015, 31, 925-937.	0.9	56
3983	A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. Liver International, 2015, 35, 184-191.	1.9	17
3984	A new approach to the use of \hat{l} ±-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. British Journal of Cancer, 2015, 112, 69-76.	2.9	66
3985	Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. European Journal of Pharmacology, 2015, 746, 353-362.	1.7	17
3986	Modeling and Simulation Support Eltrombopag Dosing in Thrombocytopenic Patients with Chronic HCV Infection. Pharmaceutical Research, 2015, 32, 2015-2028.	1.7	5
3987	Unroofing hepatectomy: A facilitating approach for resection of deepâ€seated hepatocellular carcinoma adjacent to major intrahepatic vessels in cirrhotic patients. Journal of Surgical Oncology, 2015, 111, 396-403.	0.8	5
3988	FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1311-1319.	1.2	11
3989	Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clinical Pharmacokinetics, 2015, 54, 837-849.	1.6	31
3990	Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. Gastroenterology, 2015, 149, 660-668.e1.	0.6	196
3991	A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child–Pugh Classification. Clinical Pharmacokinetics, 2015, 54, 1245-1258.	1.6	14

#	Article	IF	CITATIONS
3992	Clinical and prognostic role of ammonia in advanced decompensated heart failure. The cardio-abdominal syndrome?. International Journal of Cardiology, 2015, 195, 53-60.	0.8	15
3993	The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase. Magnetic Resonance Imaging, 2015, 33, 768-773.	1.0	17
3995	Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis. Thrombosis Research, 2015, 135, 1124-1130.	0.8	16
3996	Comparison of Different Scoring Systems in Predicting Short-Term Mortality After Liver Transplantation. Transplantation Proceedings, 2015, 47, 1207-1210.	0.3	19
3997	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. Journal of Hepatology, 2015, 63, 1118-1125.	1.8	74
3998	The Mucosa-associated Microbiota of PSC Patients is Characterized by Low Diversity and Low Abundance of Uncultured Clostridiales II. Journal of Crohn's and Colitis, 2015, 9, 342-348.	0.6	106
3999	Individualized care for portal hypertension: Not quite yet. Journal of Hepatology, 2015, 63, 543-545.	1.8	32
4000	Understanding the Complexities of Cirrhosis. Clinical Therapeutics, 2015, 37, 1822-1836.	1.1	37
4001	Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC. Journal of Hepatology, 2015, 63, 93-101.	1.8	89
4002	Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. Journal of Hepatology, 2015, 63, 805-812.	1.8	43
4003	Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer, 2015, 4, 126-136.	4.2	125
4004	Liver cancer: Approaching a personalized care. Journal of Hepatology, 2015, 62, S144-S156.	1.8	239
4005	Administration of Antithrombin III Attenuates Posthepatectomy Liver Failure in Hepatocellular Carcinoma. Digestive Surgery, 2015, 32, 173-180.	0.6	11
4006	Surgical Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices. World Journal of Surgery, 2015, 39, 2510-2518.	0.8	6
4007	Transient Respiratory Motion Artifact During Arterial Phase MRI With Gadoxetate Disodium: Risk Factor Analyses. American Journal of Roentgenology, 2015, 204, 1220-1227.	1.0	55
4008	Cytotoxic T lymphocytes and natural killer cells display impaired cytotoxic functions and reduced activation in patients with alcoholic hepatitis. American Journal of Physiology - Renal Physiology, 2015, 308, G269-G276.	1.6	25
4009	The degree of spleen stiffness measured on acoustic radiation force impulse elastography predicts the severity of portal hypertension in patients with biliary atresia after portoenterostomy. Journal of Pediatric Surgery, 2015, 50, 559-564.	0.8	18
4011	Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. Journal of Hepatology, 2015, 62, S131-S143.	1.8	358

#	Article	IF	Citations
4012	Survival and prognostic indicators of Budd–Chiari syndrome: a systematic review of 79 studies. Expert Review of Gastroenterology and Hepatology, 2015, 9, 865-875.	1.4	34
4013	Diffusion Kurtosis Imaging to Assess Response to Treatment in Hypervascular Hepatocellular Carcinoma. American Journal of Roentgenology, 2015, 204, W543-W549.	1.0	75
4014	Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor. Clinical Therapeutics, 2015, 37, 610-628.e4.	1.1	38
4015	Current Indications, Contraindications, Delisting Criteria, and Timing For Transplantation. , 2015, , 94-104.		1
4016	Preoperative Neutrophil to Lymphocyte Ratio and Prognostic Nutritional Index Predict Overall Survival After Hepatectomy for Hepatocellular Carcinoma. World Journal of Surgery, 2015, 39, 1501-1509.	0.8	107
4017	Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Langenbeck's Archives of Surgery, 2015, 400, 471-476.	0.8	8
4018	Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. Hepatology International, 2015, 9, 84-92.	1.9	29
4019	Assessment of nutritional status and health-related quality of life before and after liver transplantation. BMC Gastroenterology, 2015, 15, 6.	0.8	12
4021	Acute Kidney Injury in Schistosomiasis: A Retrospective Cohort of 60 Patients in Brazil. Journal of Parasitology, 2015, 101, 244-247.	0.3	15
4022	Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C. Clinical Immunology, 2015, 158, 77-87.	1.4	49
4023	2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut and Liver, 2015, 9, 267-317.	1.4	167
4024	Addressing the Interplay of Liver Disease and Hepatocellular Carcinoma on Patient Survival: The ALBI Scoring Model. Journal of Clinical Oncology, 2015, 33, 529-531.	0.8	21
4025	Long-and short-range functional connectivity density alteration in non-alcoholic cirrhotic patients one month after liver transplantation: A resting-state fMRI study. Brain Research, 2015, 1620, 177-187.	1,1	16
4026	MELD Scores and Child–Pugh Classifications Predict the Outcomes of ERCP in Cirrhotic Patients With Choledocholithiasis. Medicine (United States), 2015, 94, e433.	0.4	26
4027	Prediction of esophageal varices in cirrhotic patients with apparent diffusion coefficient of the spleen. Abdominal Imaging, 2015, 40, 1465-1469.	2.0	37
4028	A laboratory marker, FIB-4 index, asÂaÂpredictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. Surgery, 2015, 157, 699-707.	1.0	44
4029	Hepatic Resection for Hepatocellular Carcinoma in Patients With Portal Hypertension. Medicine (United States), 2015, 94, e495.	0.4	16
4030	Nutrition Status and Intestinal Permeability in Patients Eligible for Liver Transplantation. Journal of Parenteral and Enteral Nutrition, 2015, 39, 163-170.	1.3	14

#	Article	IF	CITATIONS
4031	Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clinical Gastroenterology and Hepatology, 2015, 13, 2333-2341.e6.	2.4	98
4032	Acute-on-chronic liver failure. Lancet, The, 2015, 386, 1576-1587.	6.3	270
4033	Is toxoplasmosis a potential risk factor for liver cirrhosis?. Asian Pacific Journal of Tropical Medicine, 2015, 8, 784-791.	0.4	17
4034	Selenium deficiency occurs in some patients with moderate-to-severe cirrhosis and can be corrected by administration of selenate but not selenomethionine: a randomized controlled trial. American Journal of Clinical Nutrition, 2015, 102, 1126-1133.	2.2	37
4035	Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution. Bioanalysis, 2015, 7, 2713-2724.	0.6	32
4036	The Model for End-stage Liver Disease score is potentially a useful predictor of hyperkalemia occurrence among hospitalized angiotensin receptor blocker users. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 48-54.	0.7	4
4037	Which riskâ€adjustment index performs better in predicting 30â€day mortality? A systematic review and metaâ€analysis. Journal of Evaluation in Clinical Practice, 2015, 21, 292-299.	0.9	10
4038	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	0.6	330
4039	Phenotypic and functional characterization of macrophages with therapeutic potential generated from human cirrhotic monocytes in a cohort study. Cytotherapy, 2015, 17, 1604-1616.	0.3	50
4040	Simple organ failure count <i>versus</i> à€ <scp>CANONIC</scp> grading system for predicting mortality in acuteâ€onâ€chronic liver failure. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 575-581.	1.4	34
4041	Left-sided infective endocarditis in patients with liver cirrhosis. Journal of Infection, 2015, 71, 627-641.	1.7	14
4042	Plasma levels of matrix metalloproteinase-2 and -9 in male and female patients with cirrhosis of different aetiologies. Journal of Clinical Pathology, 2015, 68, 917-922.	1.0	5
4043	Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests. Journal of Antimicrobial Chemotherapy, 2015, 70, 3100-3106.	1.3	13
4044	Validation of the Conventional Resection Criteria in Patients with Hepatocellular Carcinoma in Terms of the Incidence of Posthepatectomy Liver Failure and Long-Term Prognosis. Digestive Surgery, 2015, 32, 344-351.	0.6	33
4045	Gadoxetate Disodium–Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology. American Journal of Roentgenology, 2015, 205, 546-553.	1.0	9
4046	Clinical usefulness of international normalized ratio calibration of prothrombin time in patients with chronic liver disease. International Journal of Hematology, 2015, 102, 163-169.	0.7	12
4047	Button hole hernioplasty: A new technique for treatment of umblical hernia in cirrhotic patients. A prospective follow up study. International Journal of Surgery, 2015, 24, 64-69.	1.1	1
4048	A controlled trial of early versus delayed feeding following ligation in the control of acute esophageal variceal bleeding. Journal of the Chinese Medical Association, 2015, 78, 642-647.	0.6	14

#	Article	IF	Citations
4049	Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biology of Blood and Marrow Transplantation, 2015, 21, 2052-2060.	2.0	48
4050	Patterns of portosystemic collaterals and diameters of portal venous system in cirrhotic patients with hepatitis B on magnetic resonance imaging: Association with Child-Pugh classifications. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 351-358.	0.7	12
4051	Comparison of Survival Outcomes Between Right Posterior Sectionectomy and Right Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Liver: A Singleâ€Centre Experience. World Journal of Surgery, 2015, 39, 2764-2770.	0.8	14
4052	Prognostic models for alcoholic hepatitis. Biomarker Research, 2015, 3, 20.	2.8	20
4053	Vitamin A and retinol-binding protein deficiency among chronic liver disease patients. Nutrition, 2015, 31, 664-668.	1.1	41
4054	The Utility of Galectin-3 for Predicting Cause-Specific Death in Hospitalized Patients With Heart Failure. Journal of Cardiac Failure, 2015, 21, 51-59.	0.7	21
4055	A score model for the continuous grading of early allograft dysfunction severity. Liver Transplantation, 2015, 21, 38-46.	1.3	139
4056	Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. Platelets, 2015, 26, 577-582.	1.1	14
4057	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut, 2015, 64, 322-331.	6.1	30
4058	Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography. Journal of Gastroenterology, 2015, 50, 85-94.	2.3	19
4059	Nutrition Status of Patients With Chronic Hepatitis B or C. Nutrition in Clinical Practice, 2015, 30, 290-296.	1.1	10
4060	Sleep and Circadian Rhythms in Hospitalized Patients with Decompensated Cirrhosis: Effect of Light Therapy. Neurochemical Research, 2015, 40, 284-292.	1.6	39
4061	Prognostication Systems as Applied to Primary and Metastatic Hepatic Malignancies. Surgical Oncology Clinics of North America, 2015, 24, 41-56.	0.6	2
4062	Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition, 2015, 31, 193-199.	1.1	321
4063	Day–night variations in thyroid stimulating hormone and its relation with clinical status and metabolic parameters in patients with cirrhosis of the liver. Endocrine, 2015, 48, 942-948.	1.1	9
4064	Monitoring Coagulation Proteins During Progression of Liver Disease. Indian Journal of Clinical Biochemistry, 2015, 30, 210-216.	0.9	6
4065	Management of Complications of End-Stage Liver Disease in the Intensive Care Unit. Journal of Intensive Care Medicine, 2016, 31, 94-103.	1.3	8
4066	Image-guided ablation of hepatocellular carcinoma. , 0, , 91-99.		3

#	Article	IF	CITATIONS
4067	Evaluation of Results in Liver Transplantation with Ultrafast Technic Harvesting in Non-Heart-Beating Donors (Maastricht II and III): An Analysis of a Large Single-Center Experience. , 2016, 06, .		O
4068	IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2016, 58, 37.	0.5	1
4069	Body mass index and cholesterol level predict surgical outcome in patients with hepatocellular carcinoma in Taiwan - a cohort study. Oncotarget, 2016, 7, 22948-22959.	0.8	35
4070	Scoring Systems and Risk Stratification in Cirrhotic Patients with Acute Variceal Bleeding "Scoring in Variceal Bleeding". Journal of Liver, 2016, 5, .	0.3	2
4071	Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients. Journal of Hepatocellular Carcinoma, 2016, 3, 19.	1.8	12
4072	Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function. International Journal of COPD, 2016, 11, 585.	0.9	7
4073	Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis. Archives of Medical Science, 2016, 2, 365-371.	0.4	13
4074	Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 1-9.	1.8	26
4075	Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. World Journal of Gastroenterology, 2016, 22, 10064.	1.4	28
4076	Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery?. World Journal of Hepatology, 2016, 8, 355.	0.8	129
4077	Splenectomy Causes 10-Fold Increased Risk of Portal Venous System Thrombosis in Liver Cirrhosis Patients. Medical Science Monitor, 2016, 22, 2528-2550.	0.5	34
4078	Handgrip dynamometry: a surrogate marker of malnutrition to predict the prognosis in alcoholic liver disease. Annals of Gastroenterology, 2016, 29, 509-514.	0.4	16
4079	IS RESECTION OF HEPATOCELLULAR CARCINOMA IN THE ERA OF LIVER TRANSPLANTATION WORTHWILE? A single center experience. Arquivos De Gastroenterologia, 2016, 53, 169-174.	0.3	8
4080	Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis. European Journal of Gastroenterology and Hepatology, 2016, 28, 444-448.	0.8	25
4081	Serum Liver Fibrosis Markers in the Prognosis of Liver Cirrhosis: A Prospective Observational Study. Medical Science Monitor, 2016, 22, 2720-2730.	0.5	7
4082	Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surgery and Nutrition, 2016, 5, 209-216.	0.7	14
4083	Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma?. Translational Gastroenterology and Hepatology, 2016, 1, 51-51.	1.5	1
4084	High serum ferritin is associated with worse outcome of patients with decompensated cirrhosis. Annals of Gastroenterology, 2016, 30, 217-224.	0.4	14

#	Article	IF	CITATIONS
4085	Changes in Cardiac Varices and Their Clinical Significance after Eradication of Esophageal Varices by Band Ligation. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-9.	0.8	8
4086	Association between Pre-Transplant Serum Malondialdehyde Levels and Survival One Year after Liver Transplantation for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2016, 17, 500.	1.8	23
4087	Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2016, 17, 1524.	1.8	16
4088	Effects of Vitamin D Supplementation on Serum 25-Hydroxyvitamin D Concentrations in Cirrhotic Patients: A Randomized Controlled Trial. Nutrients, 2016, 8, 278.	1.7	19
4090	Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. PLoS ONE, 2016, 11, e0146076.	1.1	50
4091	Serum Leptin Is a Biomarker of Malnutrition in Decompensated Cirrhosis. PLoS ONE, 2016, 11, e0159142.	1.1	23
4092	Assessment of Preoperative Liver Function in Patients with Hepatocellular Carcinoma – The Albumin-Indocyanine Green Evaluation (ALICE) Grade. PLoS ONE, 2016, 11, e0159530.	1.1	60
4093	Epidemiology, Risk Factors, and In-Hospital Mortality of Venous Thromboembolism in Liver Cirrhosis: A Single-Center Retrospective Observational Study. Medical Science Monitor, 2016, 22, 969-976.	0.5	14
4094	Challenges of advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 7645.	1.4	135
4095	Serum Interleukin (IL)-9 and IL-10, but not T-Helper 9 (Th9) Cells, are Associated With Survival of Patients With Acute-on-Chronic Hepatitis B Liver Failure. Medicine (United States), 2016, 95, e3405.	0.4	18
4096	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology, 2016, 63, 827-838.	3.6	467
4097	Effect of living donor liver transplantation on depressive symptoms in hepatitis C virus patients. Middle East Current Psychiatry, 2016, 23, 39-43.	0.5	O
4098	Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus–related Cirrhosis Patients Receiving Antivirals. Journal of Clinical Gastroenterology, 2016, 50, 676-685.	1.1	1
4099	Epidemiology, Evolution, and Longâ€Term Survival of Alcoholic Cirrhosis Patients Submitted to Liver Transplantation in Southeastern <scp>S</scp> pain. Alcoholism: Clinical and Experimental Research, 2016, 40, 794-805.	1.4	26
4100	Characteristics and outcomes of neutropenia after orthotopic liver transplantation. Liver Transplantation, 2016, 22, 217-225.	1.3	22
4101	Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatology Research, 2016, 46, 743-751.	1.8	138
4102	How to manage patients on rivaroxaban in the emergency department. European Journal of Emergency Medicine, 2016, 23, 320-329.	0.5	2
4103	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 467-474.	1.4	47

#	Article	IF	CITATIONS
4104	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. Oncology, 2016, 91, 153-161.	0.9	36
4105	<i>TNFâ€Î±</i> and <i>ILâ€10</i> polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals. Journal of Medical Virology, 2016, 88, 1587-1595.	2.5	25
4106	Surgery for hepatocellular carcinoma presenting with variceal bleeding: The eastern experience. Journal of Surgical Oncology, 2016, 113, 165-174.	0.8	7
4107	FIB-4 Index is a Predictor of Background Liver Fibrosis and Long-Term Outcomes After Curative Resection of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2016, 23, 467-474.	0.7	23
4108	Role of Procalcitonin and Câ€Reactive Protein As Biomarkers of Infection in Children With Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 406-411.	0.9	15
4109	Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. British Journal of Surgery, 2016, 103, 871-880.	0.1	130
4110	A lowâ€cost, userâ€friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. Hepatology, 2016, 63, 1651-1659.	3.6	29
4111	Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. Alimentary Pharmacology and Therapeutics, 2016, 43, 1154-1167.	1.9	37
4112	Clinical characteristics and prognosis of nonâ€B nonâ€C hepatocellular carcinoma patients with modest alcohol consumption. Hepatology Research, 2016, 46, 434-442.	1.8	11
4113	Liver regeneration after splenectomy in patients with liver cirrhosis. Hepatology Research, 2016, 46, 443-449.	1.8	20
4114	Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. Hepatology Research, 2016, 46, 521-528.	1.8	7
4115	Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from <scp>Japan</scp> . Hepatology Research, 2016, 46, 734-742.	1.8	23
4116	New predictive model of rebleeding during followâ€up of patents with obscure gastrointestinal bleeding: A multicenter cohort study. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 752-760.	1.4	26
4117	Acuteâ€onâ€chronic liver failure in India: The Indian National Association for Study of the Liver consortium experience. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1742-1749.	1.4	40
4118	Low air temperature increases the risk of oesophageal variceal bleeding: a population and hospitalâ€based caseâ€crossover study in Taiwan. Liver International, 2016, 36, 856-864.	1.9	4
4119	The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?. Liver International, 2016, 36, 445-453.	1.9	22
4120	A multicentre comparison between Child Pugh and Albuminâ€Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver International, 2016, 36, 1821-1828.	1.9	85
4121	Comparison between alcohol―and hepatitis C virus―elated hepatocellular carcinoma: clinical presentation, treatment and outcome. Alimentary Pharmacology and Therapeutics, 2016, 43, 385-399.	1.9	59

#	Article	IF	Citations
4122	Endovascular treatment of symptomatic Budd–Chiari syndrome – in favour of early transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2016, 28, 656-660.	0.8	35
4123	Albumin–bilirubin <i>versus</i> Child–Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. British Journal of Surgery, 2016, 103, 725-734.	0.1	242
4124	Costâ€effectiveness of wholeâ€body bone scans in the preâ€liver transplant assessment of patients with hepatocellular carcinoma in Southern Brazil. Clinical Transplantation, 2016, 30, 399-406.	0.8	5
4125	Utility of combined grayâ€scale and perflubutane contrastâ€enhanced ultrasound for diagnosing early hepatocellular carcinomas: Comparison of well differentiated and distinctly nodular types. Hepatology Research, 2016, 46, 1214-1225.	1.8	3
4126	Acute on chronic liver failure because of acute hepatic insults: Etiologies, course, extrahepatic organ failure and predictors of mortality. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 856-864.	1.4	53
4127	The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximinâ€Î±. Liver International, 2016, 36, 1295-1303.	1.9	46
4128	Polymorphisms of $\hat{l}\pm 1$ -antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection. Balkan Journal of Medical Genetics, 2016, 19, 35-44.	0.5	7
4129	Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open, 2016, 6, e009889.	0.8	42
4130	Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness. BMJ Open, 2016, 6, e013177.	0.8	7
4131	ATXN7 Gene Variants and Expression Predict Post-Operative Clinical Outcomes in Hepatitis B Virus-Related Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2016, 39, 2427-2438.	1.1	12
4132	Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open, 2016, 6, e012991.	0.8	30
4134	Predicting mortality of patients with cirrhosis admitted to medical intensive care unit: An experience of a single tertiary center. Arab Journal of Gastroenterology, 2016, 17, 159-163.	0.4	13
4135	A comprehensive validation of HBV-related acute-on-chronic liver failure models to assist decision-making in targeted therapeutics. Scientific Reports, 2016, 6, 33389.	1.6	3
4136	Single-center study on transplantation of livers donated after cardiac death: A report of 6 cases. Experimental and Therapeutic Medicine, 2016, 11, 988-992.	0.8	5
4137	Risk of Tuberculosis Among Patients on Dialysis. Medicine (United States), 2016, 95, e3813.	0.4	15
4139	Role of Nutrition and Muscle in Cirrhosis. Current Treatment Options in Gastroenterology, 2016, 14, 257-273.	0.3	40
4140	Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. Internal and Emergency Medicine, 2016, 11, 1059-1066.	1.0	90
4141	Laparoscopic hepatectomy in cirrhotics: safe if you adjust technique. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 4307-4314.	1.3	29

#	Article	IF	CITATIONS
4142	The Impact of Liver and Renal Dysfunction on the Pharmacokinetics and Pharmacodynamics of Sedative and Analgesic Drugs in Critically Ill Adult Patients. Critical Care Nursing Clinics of North America, 2016, 28, 183-194.	0.4	4
4143	Endocarditis infecciosa en pacientes diagnosticados de cirrosis hepática. ¿Está indicado el tratamiento quirúrgico?. Cirugia Cardiovascular, 2016, 23, 113-118.	0.1	0
4144	Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Internal and Emergency Medicine, 2016, 11, 959-967.	1.0	40
4145	Geriatric assessment as a predictor of postoperative complications in elderly patients with hepatocellular carcinoma. Langenbeck's Archives of Surgery, 2016, 401, 205-214.	0.8	34
4146	New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy. Clinical Neurophysiology, 2016, 127, 2933-2941.	0.7	22
4147	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Clinical and Experimental Hepatology, 2016, 6, 186-194.	0.4	13
4148	Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy. Journal of Hepatology, 2016, 65, 517-523.	1.8	20
4149	Comparison of the Outcomes of Patients with Hepatocellular Carcinoma and Portal Hypertension After Liver Resection Versus Radiofrequency Ablation. World Journal of Surgery, 2016, 40, 1709-1719.	0.8	19
4150	Determination of Resectability. Surgical Clinics of North America, 2016, 96, 163-181.	0.5	10
4151	Child-Pugh, MELD, and ALBI scores for predicting the in-hospital mortality in cirrhotic patients with acute-on-chronic liver failure. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-10.	1.4	50
4152	Prognosis research and risk of bias. Internal and Emergency Medicine, 2016, 11, 251-260.	1.0	11
4153	Quantitative evaluation of human's hepatic functional reserve by indicator pharmacokinetics method. Optik, 2016, 127, 5390-5395.	1.4	1
4154	Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma. Molecular Diagnosis and Therapy, 2016, 20, 265-277.	1.6	37
4155	Vitamin D deficiency in chronic liver disease, clinical-epidemiological analysis and report after vitamin d supplementation. GastroenterologÃa Y HepatologÃa (English Edition), 2016, 39, 305-310.	0.0	6
4156	How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood, 2016, 128, 488-496.	0.6	45
4157	Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: Preliminary result. Oncology Letters, 2016, 12, 579-584.	0.8	16
4158	Accuracy of rule extraction using a recursive-rule extraction algorithm with continuous attributes combined with a sampling selection technique for the diagnosis of liver disease. Informatics in Medicine Unlocked, 2016, 5, 26-38.	1.9	13
4159	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Medicina ClÃnica (English Edition), 2016, 146, 511.e1-511.e22.	0.1	2

#	Article	IF	CITATIONS
4160	Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. Digestive Diseases and Sciences, 2016, 61, 3309-3320.	1.1	19
4161	Hepatitis B Virus Infection and Liver Decompensation. Clinics in Liver Disease, 2016, 20, 681-692.	1.0	7
4162	Contemporary Perioperative Anesthetic Management of Hepatic Resection. Advances in Anesthesia, 2016, 34, 85-103.	0.5	1
4163	Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. Journal of Hepatology, 2016, 65, 1140-1147.	1.8	296
4164	Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry. Alimentary Pharmacology and Therapeutics, 2016, 44, 704-714.	1.9	41
4165	Reversionâ€Inducingâ€Cysteineâ€Rich Protein With Kazal Motifs (RECK) Gene Single Nucleotide Polymorphism With Hepatocellular Carcinoma: A Case–Control Study. Journal of Clinical Laboratory Analysis, 2016, 30, 36-40.	0.9	6
4166	A phaseâ€1, openâ€label, singleâ€dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. Journal of Clinical Pharmacology, 2016, 56, 316-323.	1.0	4
4167	Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30â€positive haematologic malignancies and hepatic or renal impairment. British Journal of Clinical Pharmacology, 2016, 82, 696-705.	1.1	49
4168	Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol. Systematic Reviews, 2016, 5, 100.	2.5	17
4169	Protein Biomarkers in the Management of Hepatocellular Carcinoma: Novel Combinatory Approaches. , 2016, , 331-338.		0
4170	A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study. Digestive and Liver Disease, 2016, 48, 1180-1186.	0.4	18
4171	Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clinica Chimica Acta, 2016, 462, 15-22.	0.5	47
4172	Glucocorticosteroids for people with alcoholic hepatitis. The Cochrane Library, 0, , .	1.5	3
4173	Prognostic significance of Dicer expression in hepatocellular carcinoma. Oncology Letters, 2016, 11, 3961-3966.	0.8	10
4174	Obesity paradox in cirrhosis: is it real or just an illusion?. Liver International, 2016, 36, 1412-1414.	1.9	6
4175	Brain-Derived Neurotrophic Factor in Children and Adolescents with Cirrhosis Due to Biliary Atresia. Annals of Nutrition and Metabolism, 2016, 69, 1-8.	1.0	11
4176	Management of gastrointestinal bleeding in patients with cirrhosis. Current Problems in Surgery, 2016, 53, 366-395.	0.6	7
4177	Population Pharmacokinetics of Single-Dose Riociguat in Patients with Renal or Hepatic Impairment. Pulmonary Circulation, 2016, 6, S75-S85.	0.8	12

#	Article	IF	CITATIONS
4178	Resection of hepatocellular carcinoma in elderly patients and the role of energy balance. International Journal of Surgery, 2016, 33, S119-S125.	1.1	6
4179	Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63â€2521). Pulmonary Circulation, 2016, 6, S5-S14.	0.8	22
4180	Mannose-binding lectin 2 rs 11003123 polymorphism is associated with the development of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis in the Chinese population. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 282-288.	0.6	4
4181	Spontaneous remission of hepatocellular carcinoma without any treatment. Journal of Cancer Research and Practice, 2016, 3, 128-131.	0.2	1
4182	EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma. Scientific Reports, 2016, 6, 31237.	1.6	17
4183	Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open, 2016, 1, e000042.	2.0	194
4184	Prognosis for recipients with hepatocellular carcinoma of salvage liver transplantation versus those of primary liver transplantation: a retrospective single-center study. SpringerPlus, 2016, 5, 1809.	1.2	7
4185	Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule. Scientific Reports, 2016, 6, 35987.	1.6	35
4186	Inflammatory markers and clinical characteristics for predicting persistent positivity of interferon gamma release assay in dialysis population. Scientific Reports, 2016, 6, 34577.	1.6	6
4187	Reviewing the diagnostic criteria for acute-on-chronic liver failure. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1385-1395.	1.4	11
4188	Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Scientific Reports, 2016, 6, 34055.	1.6	165
4189	Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thrombosis Journal, 2016, 14, 42.	0.9	130
4190	The Child–Turcotte Classification: From Gestalt to Sophisticated Statistics and Back. Digestive Diseases and Sciences, 2016, 61, 3102-3104.	1.1	13
4191	Prevalence, Risk Factors and In-hospital Outcomes of QTc Interval Prolongation in Liver Cirrhosis. American Journal of the Medical Sciences, 2016, 352, 285-295.	0.4	22
4192	Interaction between periodontitis and liver diseases. Biomedical Reports, 2016, 5, 267-276.	0.9	57
4193	Association of umbilical hernia with volume of ascites in liver cirrhosis: a retrospective observational study. Journal of Evidence-Based Medicine, 2016, 9, 170-180.	0.7	13
4194	Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients. EJNMMI Research, 2016, 6, 57.	1.1	25
4195	The ratio of glycated albumin to glycated hemoglobin increase with decreasing residual hepatic function. Acta Hepatologica Japonica, 2016, 57, 161-170.	0.0	1

#	ARTICLE	IF	CITATIONS
4196	Prognostic Scoring System for radiofrequency ablation: Usefulness of Albumin-bilirubin (ALBI)-grade. Acta Hepatologica Japonica, 2016, 57, 312-319.	0.0	4
4197	Thyroid dysfunction in chronic viral hepatitis [B and C]; An Egyptian pilot study. Egyptian Liver Journal, 2016, 6, 70-76.	0.3	0
4198	Fish oil-based lipid emulsions versus standard lipid emulsions for treatment of parenteral nutrition-associated liver disease in children. The Cochrane Library, 2016, , .	1.5	0
4199	Fish oil-based lipid emulsions versus standard lipid emulsions for prevention of parenteral nutrition-associated liver disease in children. The Cochrane Library, 2016, , .	1.5	0
4200	Physiological and prescribing tips for managing liver impairment. NursePrescribing, 2016, 14, 507-509.	0.1	0
4201	Effect of the severity of liver dysfunction on the minimum alveolar concentration of sevoflurane responding to an electronic stimulation in cirrhotic patients. BMC Anesthesiology, 2016, 16, 98.	0.7	3
4202	Optimal 2-[18F]fluoro-2-deoxy-d-galactose PET/CT protocol for detection of hepatocellular carcinoma. EJNMMI Research, 2016, 6, 56.	1.1	11
4203	The impact of alcohol care teams on emergency secondary care use following a diagnosis of alcoholic liver disease - a national cohort study. BMC Public Health, 2016, 16, 685.	1.2	4
4204	Development and validation of method for defining conditions using Chinese electronic medical record. BMC Medical Informatics and Decision Making, 2016, 16, 110.	1.5	13
4205	Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma. Medicine (United States), 2016, 95, e4717.	0.4	6
4206	CLIF–SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis. Medicine (United States), 2016, 95, e3935.	0.4	19
4207	Does adding variceal status to the Child–Turcotte–Pugh score improve its performance in predicting mortality in cirrhosis?. Medicine (United States), 2016, 95, e4884.	0.4	2
4208	Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. British Journal of Surgery, 2016, 103, 891-898.	0.1	66
4209	Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance. Cancer, 2016, 122, 1974-1986.	2.0	76
4210	Liver cancer arterial perfusion modelling and CFD boundary conditions methodology: a case study of the haemodynamics of a patientâ€specific hepatic artery in literatureâ€based healthy and tumourâ€bearing liver scenarios. International Journal for Numerical Methods in Biomedical Engineering, 2016, 32, e02764.	1.0	26
4211	Clinical characteristics and survival outcomes of superâ€elderly hepatocellular carcinoma patients not indicated for surgical resection. Hepatology Research, 2016, 46, E5-E14.	1.8	5
4212	A modified prognostic score for critically ill patients with cirrhosis: An observational study. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 450-458.	1.4	9
4213	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1336-1341.	1.4	25

#	Article	IF	CITATIONS
4214	Serum WFA ⁺ â€M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver International, 2016, 36, 293-301.	1.9	33
4215	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. European Journal of Cancer, 2016, 63, 25-33.	1.3	40
4216	Homocysteine, Liver Function Derangement and Brain Atrophy in Alcoholics. Alcohol and Alcoholism, 2016, 51, 691-697.	0.9	6
4217	Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterology Journal, 2016, 4, 363-370.	1.6	16
4218	Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. Annals of Oncology, 2016, 27, 1782-1787.	0.6	32
4219	Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib. European Journal of Clinical Pharmacology, 2016, 72, 563-572.	0.8	0
4221	Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects. European Journal of Pharmaceutical Sciences, 2016, 89, 83-93.	1.9	3
4222	Comparison of surgical resection and transarterial chemoembolization for patients with intermediate stage hepatocellular carcinoma. Journal of Cancer Research and Practice, 2016, 3, 34-38.	0.2	4
4223	Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2016, 10, 869-877.	1.4	30
4224	Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2016, 27, 795-802.	0.2	64
4225	Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterology, 2016, 16, 50.	0.8	12
4226	Antifungal agents and liver toxicity: a complex interaction. Expert Review of Anti-Infective Therapy, 2016, 14, 765-776.	2.0	66
4227	Clinical Characteristics and Prognosis in Children and Adolescents With Autoimmune Hepatitis and Overlap Syndrome. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 76-81.	0.9	38
4228	Sectional Localization of a Small Hepatocellular Carcinoma in the Right Hepatic Lobe by Computed Tomography: Comparison between the Conventional and Portal Vein Tracing Methods. European Radiology, 2016, 26, 4524-4530.	2.3	1
4229	Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1300-1306.	1.4	103
4230	Genetic variation in <i><scp>PTX</scp>3</i> and plasma levels associated with hepatocellular carcinoma in patients with <scp>HCV</scp> . Journal of Viral Hepatitis, 2016, 23, 116-122.	1.0	45
4231	Liver regeneration â€" mechanisms and models to clinical application. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 473-485.	8.2	278
4232	Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. British Journal of Clinical Pharmacology, 2016, 82, 369-379.	1.1	25

#	ARTICLE	IF	CITATIONS
4233	Predictors of progression into acuteâ€onâ€chronic liver failure from acute deterioration of preâ€existing chronic liver disease. Hepatology Research, 2016, 46, 320-328.	1.8	10
4234	Spontaneous ruptured hepatocellular carcinoma. Hepatology Research, 2016, 46, 13-21.	1.8	94
4236	Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis. CNS Drugs, 2016, 30, 41-51.	2.7	29
4237	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology, 2016, 150, 835-853.	0.6	1,365
4238	The Role of Psychological Distress in Relapse Prevention of Alcohol Addiction. Can High Scores on the SCL-90-R Predict Alcohol Relapse?. Alcohol and Alcoholism, 2016, 51, 27-31.	0.9	20
4239	Evaluating the current surgical strategies for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2016, 10, 341-357.	1.4	7
4240	Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. Journal of Infectious Diseases, 2016, 213, 966-974.	1.9	60
4241	Child–Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis. Medicine (United) Tj ETQq1 I	1 8:78431	4 rgBT /Ove
4242	Quantitative Assessment of the Portal Pressure for the Liver Surgery Using Serological Tests. Annals of Surgery, 2016, 264, 330-338.	2.1	12
4243	From Child-Pugh to Model for End-Stage Liver Disease. Medical Clinics of North America, 2016, 100, 449-464.	1.1	20
4244	Hepatocellular carcinoma: From diagnosis to treatment. Surgical Oncology, 2016, 25, 74-85.	0.8	369
4245	Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. Cancer Science, 2016, 107, 173-180.	1.7	6
4246	Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1031-1036.	1.4	198
4247	Management of Postoperative Hepatic Failure. Journal of the American College of Surgeons, 2016, 222, 195-208.	0.2	38
4248	Bioavailability of paracetamol with/without caffeine in Egyptian patients with hepatitis C virus. European Journal of Clinical Pharmacology, 2016, 72, 573-582.	0.8	2
4249	Extracorporeal support for patients with acute and acute on chronic liver failure. Expert Review of Medical Devices, 2016, 13, 367-380.	1.4	11
4250	Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. Journal of Hepatology, 2016, 64, 1058-1067.	1.8	77
4251	Evaluation of abnormal liver function tests. Postgraduate Medical Journal, 2016, 92, 223-234.	0.9	218

#	Article	IF	CITATIONS
4252	Nonselective \hat{l}^2 -Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 1096-1104.e9.	2.4	66
4253	Monomicrobial Aeromonas and Vibrio bacteremia in cirrhotic adults in southern Taiwan: Similarities and differences. Journal of Microbiology, Immunology and Infection, 2016, 49, 509-515.	1.5	13
4254	Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 113, 179-186.	1.1	7
4255	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. Clinical Pharmacokinetics, 2016, 55, 723-733.	1.6	35
4256	Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent. Abdominal Radiology, 2016, 41, 1522-1531.	1.0	9
4258	Risk Assessment and Perioperative Care for Patients with Renal or Liver Disease. Hospital Medicine Clinics, 2016, 5, 205-223.	0.2	1
4259	Minimally Required Iodine Dose for the Detection of Hypervascular Hepatocellular Carcinoma on 80-kVp CT. American Journal of Roentgenology, 2016, 206, 518-525.	1.0	14
4260	The FIB-4 index is a significant prognostic factor in patients with non-B non-C hepatocellular carcinoma after curative surgery. Langenbeck's Archives of Surgery, 2016, 401, 195-203.	0.8	11
4262	Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. Scandinavian Journal of Gastroenterology, 2016, 51, 618-624.	0.6	14
4263	An Easy and Useful Noninvasive Score Based on α-1-acid Glycoprotein and C-Reactive Protein for Diagnosis of Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection. Journal of Immunoassay and Immunochemistry, 2016, 37, 273-288.	0.5	12
4264	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. American Journal of Gastroenterology, 2016, 111, 70-77.	0.2	59
4265	Prognostic role of mean platelet volume in patients with cirrhosis. Digestive and Liver Disease, 2016, 48, 409-413.	0.4	16
4266	Preoperative hepatic dysfunction could predict postoperative mortality and morbidity in patients undergoing cardiac surgery: Utilization of the MELD scoring system. International Journal of Cardiology, 2016, 203, 682-689.	0.8	33
4267	Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 64-73.	0.6	29
4268	Endovascular treatment of acute and chronic portal vein thrombosis in patients with cirrhotic and non-cirrhotic liver. Acta Radiologica, 2016, 57, 572-579.	0.5	45
4269	Quantitative magnetic resonance imaging in patients with cirrhosis: a cross-sectional study. Metabolic Brain Disease, 2016, 31, 1315-1325.	1.4	10
4270	Liver Resection for De Novo Hepatocellular Carcinoma Complicated by Pyogenic Liver Abscess: A Clinical Challenge. World Journal of Surgery, 2016, 40, 412-418.	0.8	5
4271	Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. Translational Research, 2016, 168, 134-145.	2.2	110

#	Article	IF	CITATIONS
4272	Cross-Cultural Adaptation and Psychometric Assessment of the Liver Disease Symptom Index 2.0 to Measure Health-Related Quality of Life Among Iranian Patients With Chronic Hepatitis B. Journal of Transcultural Nursing, 2016, 27, 496-508.	0.6	6
4273	Higher Grades and Repeated Recurrence of Hepatic Encephalopathy May Be Related to High Serum Manganese Levels. Biological Trace Element Research, 2016, 169, 153-158.	1.9	12
4274	Preoperative thrombocytopenia and outcomes of hepatectomy for hepatocellular carcinoma. Journal of Surgical Research, 2016, 201, 498-505.	0.8	21
4275	Wilson's disease with and without rapid eye movement sleep behavior disorder compared to healthy matched controls. Sleep Medicine, 2016, 17, 179-185.	0.8	28
4276	Serum level of taurine would be associated with the amelioration of minimal hepatic encephalopathy in cirrhotic patients. Hepatology Research, 2016, 46, 215-224.	1.8	4
4277	Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis. Journal of Proteome Research, 2016, 15, 1126-1134.	1.8	78
4278	Malnutrition and sarcopenia predict postâ€liver transplantation outcomes independently of the Model for Endâ€stage Liver Disease score. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 113-121.	2.9	236
4279	Electrocardiographic findings in hepatic cirrhosis and their association with the severity of disease. Cor Et Vasa, 2017, 59, e105-e113.	0.1	4
4280	Tpâ€e Interval, Tpâ€e/QTc Ratio, and Fragmented QRS Are Correlated with the Severity of Liver Cirrhosis. Annals of Noninvasive Electrocardiology, 2017, 22, .	0.5	8
4281	Comparison of creatinine and cystatin formulae with ⁵¹ Chromiumâ€ethylenediaminetetraacetic acid glomerular filtration rate in patients with decompensated cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 191-198.	1.4	18
4282	Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 383-396.	0.6	27
4283	Abnormalities of voxel-based whole-brain functional connectivity patterns predict the progression of hepatic encephalopathy. Brain Imaging and Behavior, 2017, 11, 784-796.	1.1	24
4284	Telbivudine versus lamivudine and entecavir for treatment-naÃ-ve decompensated hepatitis B virus-related cirrhosis. Clinical and Experimental Medicine, 2017, 17, 233-241.	1.9	16
4285	Effects of inâ€hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease. Hepatology Research, 2017, 47, E22-E34.	1.8	54
4286	Incorporating albumin–bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 221-228.	1.4	47
4287	Risk stratification of decompensated cirrhosis patients by Chronic Liver Failure Consortium scores: Classification and regression tree analysis. Hepatology Research, 2017, 47, 328-337.	1.8	26
4288	Budd–Chiari syndrome: Focus on surgical treatment. Hepatology Research, 2017, 47, 142-148.	1.8	16
4289	Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis. Journal of Gastroenterology, 2017, 52, 229-236.	2.3	18

#	Article	IF	CITATIONS
4290	Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics. Journal of Clinical Pharmacology, 2017, 57, 777-783.	1.0	18
4291	Outcome analysis of hip or knee arthroplasty in patients with cirrhotic liver disease. Journal of Orthopaedics, 2017, 14, 171-175.	0.6	13
4292	Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Practical Radiation Oncology, 2017, 7, 173-182.	1.1	42
4293	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncology, The, 2017, 18, e101-e112.	5.1	123
4294	Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 939-946.	0.4	94
4295	D-dimer level for predicting the in-hospital mortality in liver cirrhosis: A retrospective study. Experimental and Therapeutic Medicine, 2017, 13, 285-289.	0.8	41
4296	Effect of Age (over 75ÂYears) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2017, 21, 657-665.	0.9	15
4297	Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. Journal of the American College of Surgeons, 2017, 224, 610-621.	0.2	52
4298	Hepatic vein transit time of second-generation ultrasound contrast agent: new tool in the assessment of portal hypertension. Journal of Ultrasound, 2017, 20, 43-52.	0.7	6
4299	Effects of low-dose tolvaptan on electrolyte abnormality and hemodynamic parameters in a liver cirrhosis-associated portopulmonary hypertension patient: A case report. Experimental and Therapeutic Medicine, 2017, 13, 269-272.	0.8	3
4300	Percutaneous transhepatic obliteration and percutaneous transhepatic sclerotherapy for intractable hepatic encephalopathy and gastric varices improves the hepatic function reserve. Biomedical Reports, 2017, 6, 99-102.	0.9	17
4301	Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 1017-1025.	0.9	17
4302	Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. Journal of Gastroenterology, 2017, 52, 1112-1121.	2.3	27
4303	Comparison of the prognostic value of Chronic Liver Failure Consortium scores and traditional models for predicting mortality in patients with cirrhosis. GastroenterologÃa Y HepatologÃa, 2017, 40, 276-285.	0.2	11
4304	Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatology Research, 2017, 47, 1359-1367.	1.8	78
4305	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 65-71.	1.8	83
4306	Acute Care Management of the <scp>HIV</scp> â€Infected Patient: A Report from the <scp>HIV</scp> Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy, 2017, 37, 611-629.	1.2	10
4307	Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics. European Journal of Clinical Pharmacology, 2017, 73, 633-641.	0.8	1

#	Article	IF	CITATIONS
4308	Impact of transjugular intrahepatic portosystemic shunt implantation on liver perfusion measured by volume perfusion CT. Acta Radiologica, 2017, 58, 1167-1173.	0.5	17
4309	Hepatitis C virus infection. Nature Reviews Disease Primers, 2017, 3, 17006.	18.1	354
4310	Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. American Journal of Kidney Diseases, 2017, 70, 297-300.	2.1	14
4311	Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions. Drug Metabolism and Disposition, 2017, 45, 390-398.	1.7	31
4312	Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Scientific Reports, 2017, 7, 42563.	1.6	29
4313	Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. Molecular and Clinical Oncology, 2017, 6, 389-396.	0.4	7
4314	Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. Digestive Diseases and Sciences, 2017, 62, 1363-1372.	1.1	4
4315	The impact of liver disorders on perioperative management of reoperative cardiac surgery: a retrospective study in adult congenital heart disease patients. Journal of Anesthesia, 2017, 31, 170-177.	0.7	9
4316	Improving the Diagnostic Criteria for Primary Liver Graft Nonfunction in Adults Utilizing Standard and Transportable Laboratory Parameters: An Outcome-Based Analysis. American Journal of Transplantation, 2017, 17, 1255-1266.	2.6	23
4317	Management of Abdominal Drainage after Hepatic Resection. Digestive Surgery, 2017, 34, 400-410.	0.6	12
4318	T 1ϕmapping improvement using stretched-type adiabatic locking pulses for assessment of human liver function at 3 T. Magnetic Resonance Imaging, 2017, 40, 17-23.	1.0	17
4319	Pro–Brain Natriuretic Peptide and Troponin T-Hypersensitivity Levels Correlate With the Severity of Liver Dysfunction in Liver Cirrhosis. American Journal of the Medical Sciences, 2017, 354, 131-139.	0.4	10
4320	Periprocedural management of acute variceal bleeding. Techniques in Gastrointestinal Endoscopy, 2017, 19, 69-73.	0.3	0
4321	Hand grip strength: A reliable, reproducible, cost-effective tool to assess the nutritional status and outcomes of cirrhotics awaiting liver transplant. Clinical Nutrition ESPEN, 2017, 19, 49-53.	0.5	26
4322	Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation. Molecular and Clinical Oncology, 2017, 6, 455-461.	0.4	5
4323	Severity and Outcome of Acute-on-Chronic Liver Failure is Dependent on the Etiology of Acute Hepatic Insults. Journal of Clinical Gastroenterology, 2017, 51, 734-741.	1.1	36
4324	Internal dysregulation of the renin system in patients with stable liver cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 298-309.	0.6	6
4325	Liver-to-abdominal area ratio for predicting the in-hospital mortality in advanced liver cirrhosis. Postgraduate Medicine, 2017, 129, 756-761.	0.9	4

#	Article	IF	CITATIONS
4327	High <scp>MELD</scp> score does not adversely affect outcome of living donor liver transplantation: Experience in 1000 recipients. Clinical Transplantation, 2017, 31, e13006.	0.8	34
4328	Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. Journal of Clinical Gastroenterology, 2017, 51, 650-655.	1.1	35
4329	Comparison of the prognostic value of Chronic Liver Failure Consortium scores and traditional models for predicting mortality in patients with cirrhosis. GastroenterologÃa Y HepatologÃa (English) Tj ETQq0 0	Oog®T/O	verlock 10 T
4330	Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine. Journal of Pharmaceutical Sciences, 2017, 106, 2380-2391.	1.6	56
4331	Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2017, 4, CD008759.	1.5	36
4332	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer, 2017, 6, 204-215.	4.2	159
4333	N-Terminal pro-B-Type Natriuretic Peptide Levels are Linked with Modified Child-Pugh Classification in Patients with Nonalcoholic Cirrhosis [NT-ProBNP and Liver Cirrhosis]. Cell Biochemistry and Biophysics, 2017, 75, 111-117.	0.9	4
4334	Budd-Chiari syndrome: outcomes of endovascular interventionâ€"A single-center experience. Indian Journal of Gastroenterology, 2017, 36, 209-216.	0.7	9
4335	Variceal Haemorrhage., 0,, 84-90.		0
4336	Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (United States), 2017, 96, e7142.	0.4	49
4337	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. Journal of Hepatology, 2017, 67, 700-707.	1.8	11
4338	Relationship of Abnormal Chromatographic Pattern for Carbohydrate-Deficient Transferrin with Severe Liver Disease. Alcohol and Alcoholism, 2017, 52, 24-28.	0.9	16
4339	The utility of 5-aminolevulinic acid-mediated photodynamic diagnosis in the detection of intraoperative bile leakage. American Journal of Surgery, 2017, 213, 1077-1082.	0.9	19
4340	Mortalidad hospitalaria en pacientes cirróticos en un centro de tercer nivel de Latinoamérica. Revista De GastroenterologÃa De México, 2017, 82, 201-202.	0.4	0
4341	Predictors of seropositivity for human herpesvirus type 8 in patients with mild cirrhosis. Emerging Microbes and Infections, 2017, 6, 1-6.	3.0	2
4342	Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test. Journal of the Endocrine Society, 2017, 1, 886-896.	0.1	35
4343	Integration of Child-Pugh score with future liver remnant yields improved prediction of liver dysfunction risk for HBV-related hepatocellular carcinoma following hepatic resection. Oncology Letters, 2017, 13, 3631-3637.	0.8	15
4344	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient metaâ€analysis. Hepatology, 2017, 66, 1219-1231.	3.6	80

#	Article	IF	CITATIONS
4345	Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2017, 29, 946-950.	0.8	4
4346	Concordance among methods of nutritional assessment in patients included on the waiting list for liver transplantation. Journal of Epidemiology, 2017, 27, 469-475.	1.1	7
4347	Role of hepatic resection in patients with intermediateâ€stage hepatocellular carcinoma: A multicenter study from Japan. Cancer Science, 2017, 108, 1414-1420.	1.7	40
4348	Prognostic value of Notch receptors in postsurgical patients with hepatitis B virusâ€related hepatocellular carcinoma. Cancer Medicine, 2017, 6, 1587-1600.	1.3	20
4349	A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis. Digestive Diseases and Sciences, 2017, 62, 2166-2173.	1.1	36
4350	Development and validation of a prognostic model for acute-on-chronic hepatitis B liver failure. European Journal of Gastroenterology and Hepatology, 2017, 29, 669-678.	0.8	14
4351	Laparoscopic hepatectomy in a morbidly obese patient with liver cirrhosis: A case report. Molecular and Clinical Oncology, 2017, 6, 233-234.	0.4	3
4353	Hepatic resection for benign disease and for liver and biliary tumors. , 2017, , 1522-1571.e4.		0
4354	Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma. Cytokine, 2017, 96, 75-86.	1.4	37
4355	The consensus on liver autotransplantation from an international panel of experts. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 10-16.	0.6	4
4356	Comparison of risk adjustment methods in patients with liver disease using electronic medical record data. BMC Gastroenterology, 2017, 17, 5.	0.8	13
4357	Resection of T4 hepatocellular carcinomas with adjacent structures, is it justified?. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 52-57.	0.6	1
4358	Lifetime drinking history in patients with alcoholic liver disease and patients with alcohol use disorder without liver disease. Scandinavian Journal of Gastroenterology, 2017, 52, 762-767.	0.6	20
4359	Anaesthesia in patients with liver disease. Current Opinion in Anaesthesiology, 2017, 30, 392-398.	0.9	32
4360	Usefulness of the Glasgow–Blatchford score to predict 1-week mortality in patients with esophageal variceal bleeding. European Journal of Gastroenterology and Hepatology, 2017, 29, 547-551.	0.8	9
4361	C-reactive protein-to-albumin ratio is a predictor of hepatitis B virus related decompensated cirrhosis. European Journal of Gastroenterology and Hepatology, 2017, 29, 472-480.	0.8	18
4362	A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 268-275.	0.7	7
4363	Long-term outcome of patients with liver cirrhosis admitted to a general intensive care unit. Annals of Intensive Care, 2017, 7, 37.	2.2	16

#	Article	IF	CITATIONS
4364	Interleukin-10 and Interferon Gamma Gene Polymorphisms and Hepatitis C Virus–Related Liver Cirrhosis Risk. Journal of Interferon and Cytokine Research, 2017, 37, 175-180.	0.5	10
4365	A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acuteâ€onâ€chronic liver failure. Alimentary Pharmacology and Therapeutics, 2017, 45, 1413-1426.	1.9	61
4366	Model for End-Stage Liver Disease–Sodium Score. Clinics in Liver Disease, 2017, 21, 275-287.	1.0	27
4367	Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment. Clinical Pharmacology in Drug Development, 2017, 6, 206-212.	0.8	29
4368	Role of Serum Soluble CD163 in the Diagnosis, Risk of Bleeding, and Prognosis of Gastro-Esophageal Varices in Cirrhotic Patients. Journal of Interferon and Cytokine Research, 2017, 37, 112-118.	0.5	5
4369	Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. International Journal of Clinical Oncology, 2017, 22, 715-725.	1.0	12
4370	Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A. Journal of Gastrointestinal Surgery, 2017, 21, 957-966.	0.9	20
4371	The optimal cut-off value of the preoperative prognostic nutritional index for the survival differs according to the TNM stage in hepatocellular carcinoma. Surgery Today, 2017, 47, 986-993.	0.7	16
4372	Oral branched-chain amino acid granules improve structure and function of human serum albumin in cirrhotic patients. Journal of Gastroenterology, 2017, 52, 754-765.	2.3	34
4373	The short-term effect of liver transplantation on the low-frequency fluctuation of brain activity in cirrhotic patients with and without overt hepatic encephalopathy. Brain Imaging and Behavior, 2017, 11, 1849-1861.	1.1	14
4374	Technical Failure of MR Elastography Examinations of the Liver: Experience from a Large Single-Center Study. Radiology, 2017, 284, 401-412.	3.6	124
4375	Platelet Counts and Genetic Polymorphisms of Alcohol Dehydrogenaseâ€1B and Aldehyde Dehydrogenaseâ€2 in Japanese Alcoholic Men. Alcoholism: Clinical and Experimental Research, 2017, 41, 171-178.	1.4	8
4376	Survival in patients with Child–Pugh class C cirrhosis: Analysis of the liver transplant registry in Japan. Hepatology Research, 2017, 47, 1155-1164.	1.8	16
4377	Nutrition and the transplant candidate. Liver Transplantation, 2017, 23, 1451-1464.	1.3	46
4378	Development and Validation of a Chronic Pancreatitis PrognosisÂScore in 2 Independent Cohorts. Gastroenterology, 2017, 153, 1544-1554.e2.	0.6	43
4379	Chronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation. Pancreatology, 2017, 17, 898-904.	0.5	3
4380	Glucocorticosteroids for people with alcoholic hepatitis. The Cochrane Library, 2017, 11, CD001511.	1.5	20
4381	Randomized clinical trial of hepatic resection <i>versus</i> radiofrequency ablation for early-stage hepatocellular carcinoma. British Journal of Surgery, 2017, 104, 1775-1784.	0.1	229

#	Article	IF	CITATIONS
4382	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control, 2017, 24, 107327481772925.	0.7	9
4383	Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2017, 29, 1416-1423.	0.8	113
4384	A sonographic Doppler study of the hepatic vein, portal vein and hepatic artery in liver cirrhosis: Correlation of hepatic hemodynamics with clinical Child Pugh score in Singapore. Ultrasound, 2017, 25, 213-221.	0.3	14
4385	Proton beam therapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2017, 17, 911-924.	1.1	23
4386	Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control, 2017, 24, 107327481772923.	0.7	24
4387	Comparison of APACHE IV with APACHE II, SAPS 3, MELD, MELD-Na, and CTP scores in predicting mortality after liver transplantation. Scientific Reports, 2017, 7, 10884.	1.6	13
4388	A review of drug-drug interactions in older HIV-infected patients. Expert Review of Clinical Pharmacology, 2017, 10, 1329-1352.	1.3	17
4389	An educational tool for the prophylaxis of hepatic encephalopathy. BMJ Open Gastroenterology, 2017, 4, e000161.	1.1	17
4390	Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. Scientific Reports, 2017, 7, 10289.	1.6	4
4391	Clinical significance of miRNA-autophagy transcript expression in patients with hepatocellular carcinoma. Biomarkers in Medicine, 2017, 11, 641-656.	0.6	2
4392	Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. Therapeutic Apheresis and Dialysis, 2017, 21, 465-472.	0.4	12
4393	The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 797-811.	1.4	24
4394	Improved prediction of survival by a risk factor-integrated inflammatory score in Sorafenib treated hepatocellular carcinoma. Journal of Hepatology, 2017, 66, S452-S453.	1.8	5
4395	Abnormalities in the 24â€hour rhythm of skin temperature in cirrhosis: Sleepâ€wake and general clinical implications. Liver International, 2017, 37, 1833-1842.	1.9	39
4396	Predictors of Mortality in Living Donor Liver Transplantation. Transplantation Proceedings, 2017, 49, 1376-1382.	0.3	4
4398	Patients with early recurrence of hepatocellular carcinoma have poor prognosis. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 279-288.	0.6	45
4399	Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. Journal of Hepatology, 2017, 67, 950-956.	1.8	94
4400	Radiation Therapy for Liver Tumors: Future Directions. , 2017, , 269-281.		0

#	Article	IF	CITATIONS
4401	Individualized risk estimation for postoperative morbidity after hepatectomy: the Humanitas score. Hpb, 2017, 19, 910-918.	0.1	22
4402	Survival outcomes of hepatocellular carcinoma resection with postoperative complications – a propensity-score-matched analysis. Medicine (United States), 2017, 96, e6430.	0.4	19
4403	Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients. Medicine (United States), 2017, 96, e6949.	0.4	17
4404	FIB-4 and imaging for measuring fibrosis in hepatitis C virus. European Journal of Gastroenterology and Hepatology, 2017, 29, 192-198.	0.8	9
4405	Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study. Clinical Pharmacology in Drug Development, 2017, 6, 439-447.	0.8	11
4406	Primary sclerosing cholangitis – a comprehensive review. Journal of Hepatology, 2017, 67, 1298-1323.	1.8	538
4407	Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm. Liver Cancer, 2017, 6, 185-188.	4.2	11
4408	A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir. Case Reports in Gastroenterology, 2017, 11, 369-376.	0.3	2
4409	Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics. Journal of Clinical Pharmacology, 2017, 57, 1454-1459.	1.0	7
4410	Nomogram for cirrhosis in patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis. Scientific Reports, 2017, 7, 17493.	1.6	3
4411	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer, 2017, 6, 325-336.	4.2	202
4412	Perioperative Care of Patients With Liver Cirrhosis: A Review. Health Services Insights, 2017, 10, 117863291769127.	0.6	46
4413	The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies. Advances in Therapy, 2017, 34, 2612-2624.	1.3	9
4414	Drug updates and approvals. Nurse Practitioner, 2017, 42, 8-16.	0.2	2
4416	Aggressive nutrition intervention reduces ascites and frequency of paracentesis in malnourished patients with cirrhosis and ascites. JGH Open, 2017, 1, 92-97.	0.7	14
4417	Management of Advanced and Terminal Hepatocellular Carcinoma: When and How to Treat, and When not to Treat?. Digestive Disease Interventions, 2017, 01, 138-144.	0.3	0
4418	Nutrition and Muscle in Cirrhosis. Journal of Clinical and Experimental Hepatology, 2017, 7, 340-357.	0.4	113
4419	Differences in the impact of prognostic factors for hepatocellular carcinoma over time. Cancer Science, 2017, 108, 2438-2444.	1.7	35

#	Article	IF	CITATIONS
4420	Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hospital Pharmacy, 2017, 52, 294-301.	0.4	4
4423	Dysfunctional neutrophil effector organelle mobilization and microbicidal protein release in alcohol-related cirrhosis. American Journal of Physiology - Renal Physiology, 2017, 313, G203-G211.	1.6	12
4424	Gadoxetic acid-enhanced high temporal-resolution hepatic arterial-phase imaging with view-sharing technique: Impact on the LI-RADS category. European Journal of Radiology, 2017, 94, 167-173.	1,2	7
4425	Progressive hypofractionated carbonâ€ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer, 2017, 123, 3955-3965.	2.0	66
4426	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. Journal of Vascular and Interventional Radiology, 2017, 28, 1210-1223.e3.	0.2	103
4427	High burden of coronary atherosclerosis in patients with cirrhosis. European Journal of Clinical Investigation, 2017, 47, 565-573.	1.7	14
4428	Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?. Investigational New Drugs, 2017, 35, 386-391.	1.2	4
4429	Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?. Journal of Hepatology, 2017, 66, 442-450.	1.8	72
4430	Diagnostic accuracy of contrastâ€enhanced computed tomography for esophageal varices in liver cirrhosis: a retrospective observational study. Journal of Evidence-Based Medicine, 2017, 10, 46-52.	2.4	24
4431	Preoperative Liver Recipient Evaluation and Preparation. , 2017, , 333-344.		0
4432	Changing Concepts of Cirrhotic Coagulopathy. American Journal of Gastroenterology, 2017, 112, 274-281.	0.2	149
4433	Comparison of clinical characteristics and outcomes of spontaneous bacterial peritonitis and culture negative neutrocytic ascites. Scandinavian Journal of Gastroenterology, 2017, 52, 199-203.	0.6	19
4434	Usefulness of albuminâ€bilirubin grade for evaluation of longâ€term prognosis for hepatitis Bâ€related cirrhosis. Journal of Viral Hepatitis, 2017, 24, 238-245.	1.0	68
4435	Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment. Journal of Clinical Pharmacology, 2017, 57, 328-335.	1.0	32
4436	Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, doubleâ€blind trial. Hepatology Research, 2017, 47, 972-982.	1.8	82
4437	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. Alimentary Pharmacology and Therapeutics, 2017, 45, 160-168.	1.9	70
4438	Long-term Outcome and Analysis of Dysfunction of Transjugular Intrahepatic Portosystemic Shunt Placement in Chronic Primary Budd-Chiari Syndrome. Radiology, 2017, 283, 280-292.	3.6	54
4439	A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 651-658.	1.4	3

#	ARTICLE	IF	CITATIONS
4440	Breathâ€print analysis by eâ€nose may refine risk stratification for adverse outcomes in cirrhotic patients. Liver International, 2017, 37, 242-250.	1.9	11
4441	Oral anticoagulation in patients with atrial fibrillation and medical non-neoplastic disease in a terminal stage. Internal and Emergency Medicine, 2017, 12, 53-61.	1.0	9
4442	Anesthetic and operative considerations for laparoscopic liver resection. Surgery, 2017, 161, 1191-1202.	1.0	28
4443	Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, 94-102.	0.2	34
4444	Urine albumin-to-creatinine ratio is associated with the severity of liver disease, renal function and survival in patients with decompensated cirrhosis. Hepatology International, 2017, 11, 306-314.	1.9	9
4445	n-3 fatty acid-based parenteral nutrition improves postoperative recovery for cirrhotic patients with liver cancer: A randomized controlled clinical trial. Clinical Nutrition, 2017, 36, 1239-1244.	2.3	39
4446	Association of daptomycin use with resistance development in Enterococcus faecium bacteraemiaâ€"a 7-year individual and population-based analysis. Clinical Microbiology and Infection, 2017, 23, 118.e1-118.e7.	2.8	14
4447	Clinical Outcomes of Peritoneal Dialysis in End-Stage Renal Disease Patients with Liver Cirrhosis: A Propensity Score Matching Study. Peritoneal Dialysis International, 2017, 37, 314-320.	1.1	12
4448	ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 879-886.	1.4	126
4449	Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort. European Radiology, 2017, 27, 1227-1237.	2.3	17
4450	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 2017, 15, 421-430.e6.	2.4	72
4451	Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. Journal of Hepatology, 2017, 66, 610-618.	1.8	195
4452	Liver stiffness measurement predicts highâ€grade postâ€hepatectomy liver failure: A prospective cohort study. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 506-514.	1.4	39
4453	Lowâ€grade endotoxemia and platelet activation in cirrhosis. Hepatology, 2017, 65, 571-581.	3.6	107
4454	Rotational thromboelastometry can detect factor <scp>XIII</scp> deficiency and bleeding diathesis in patients with cirrhosis. Liver International, 2017, 37, 562-568.	1.9	39
4455	Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies. Clinical Pharmacokinetics, 2017, 56, 395-408.	1.6	9
4457	Predictors of Mortality in Long-Term Follow-Up of Patients with Terminal Alcoholic Cirrhosis: Is It Time to Accept Remodeled Scores?. Medical Principles and Practice, 2017, 26, 169-175.	1.1	10
4458	Expression of cluster of differentiation 151 prior to and following transcatheter arterial chemoembolization therapy in patients with hepatocellular carcinoma and its association with clinicopathological characteristics. Oncology Letters, 2018, 15, 1133-1142.	0.8	0

#	Article	IF	CITATIONS
4459	Impact of alcohol & smoking on the surgical management of gastrointestinal patients. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 589-595.	1.0	3
4460	Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. Genes and Diseases, 2017, 4, 215-221.	1.5	68
4461	Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncology Letters, 2017, 15, 315-323.	0.8	22
4462	Quantification of ascites based on abdominoâ€'pelvic computed tomography scans for predicting the inâ€'hospital mortality of liver cirrhosis. Experimental and Therapeutic Medicine, 2017, 14, 5733-5742.	0.8	7
4463	ICG Clearance Test and 99mTc-GSA SPECT/CT Fusion Images. Visceral Medicine, 2017, 33, 449-454.	0.5	18
4464	Magnetic resonance imaging performed with gadoxetate disodium for the diagnosis of hepatocellular carcinoma in cirrhotic and non-cirrhotic patients. The Cochrane Library, 0, , .	1.5	3
4465	Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis. Biomedical Reports, 2017, 7, 558-562.	0.9	10
4466	Usefulness of ALBI grade in prediction of outcomes in patients with hepatitis B related hepatocellular carcinoma. Acta Hepatologica Japonica, 2017, 58, 379-385.	0.0	2
4467	Early Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement in Patients with Cirrhosis and Variceal Bleeding. Digestive Disease Interventions, 2017, 01, 272-276.	0.3	3
4468	Reassessment of different criteria for diagnosing post-hepatectomy liver failure: a single-center study of 1683 hepatectomy. Oncotarget, 2017, 8, 89269-89277.	0.8	14
4469	Beta-blockers for prevention of oesophageal variceal rebleeding in cirrhotic patients. The Cochrane Library, 0, , .	1.5	0
4470	What is the Optimal Timing for Liver Surgery of Resectable Synchronous Liver Metastases from Colorectal Cancer?. American Surgeon, 2017, 83, 45-53.	0.4	9
4471	Chronic hepatitis B and D: prognosis according to Child-Pugh score. Revista Brasileira De Enfermagem, 2017, 70, 1048-1053.	0.2	4
4472	Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World Journal of Hepatology, 2017, 9, 270.	0.8	16
4473	Advances in systemic therapy for hepatocellular carcinoma. , 2017, , 1502-1513.e4.		0
4474	Prognostic factors of the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure. Clinics, 2017, 72, 686-692.	0.6	9
4475	Association between Serum Selenium Concentrations and Levels of Proinflammatory and Profibrotic Cytokinesâe"Interleukin-6 and Growth Differentiation Factor-15, in Patients with Alcoholic Liver Cirrhosis. International Journal of Environmental Research and Public Health, 2017, 14, 437.	1.2	33
4476	Adipokines in Liver Cirrhosis. International Journal of Molecular Sciences, 2017, 18, 1392.	1.8	63

#	Article	IF	CITATIONS
4477	Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients. Frontiers in Microbiology, 2017, 8, 2222.	1.5	172
4478	Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. BioMed Research International, 2017, 2017, 1-8.	0.9	13
4479	Child-Pugh Parameters and Platelet Count as an Alternative to ICG Test for Assessing Liver Function for Major Hepatectomy. HPB Surgery, 2017, 2017, 1-8.	2.2	15
4480	Thromboelastographic Evaluation of Coagulation in Patients With Liver Disease. Annals of Laboratory Medicine, 2017, 37, 204-212.	1.2	35
4481	Nutritional Status in Liver Cirrhosis., 2017,,.		1
4482	Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis. Nutrients, 2017, 9, 1114.	1.7	15
4483	Liver resection in cirrhosis., 2017, , 1578-1586.e3.		0
4484	The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients. PLoS ONE, 2017, 12, e0189345.	1.1	32
4485	Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection. BMC Cancer, 2017, 17, 464.	1.1	44
4486	Liver resection for hepatocellular carcinoma in patients with hematological malignancies. World Journal of Surgical Oncology, 2017, 15, 194.	0.8	1
4487	Metabolic liver function in humans measured by 2-18F-fluoro-2-deoxy-D-galactose PET/CT–reproducibility and clinical potential. EJNMMI Research, 2017, 7, 71.	1.1	12
4488	Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry. Endocrine Journal, 2017, 64, 867-880.	0.7	25
4489	Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) ― Digest Version ―. Circulation Journal, 2017, 81, 581-612.	0.7	33
4490	Single port access for laparoscopic lateral segmentectomy. Wideochirurgia I Inne Techniki Maloinwazyjne, 2017, 4, 357-365.	0.3	3
4491	MicroRNAs and clinical implications in hepatocellular carcinoma. World Journal of Hepatology, 2017, 9, 1001.	0.8	40
4492	CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on Chronic Liver Failure admitted to the ward. Revista Espanola De Enfermedades Digestivas, 2017, 109, 399-405.	0.1	36
4493	A pilot evaluation of a computer-based psychometric test battery designed to detect impairment in patients with cirrhosis. International Journal of General Medicine, 2017, Volume 10, 281-289.	0.8	6
4494	Partial hepatectomy for spontaneous tumor rupture in patients with hepatocellular carcinoma: a retrospective cohort study. Cancer Management and Research, 2017, Volume 9, 525-537.	0.9	13

#	Article	IF	CITATIONS
4495	Anti-Nuclear Cytoplasmic Antibody–Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hospital Pharmacy, 2017, 52, 294-301.	0.4	2
4496	Non-neoplastic Portal Vein Thrombosis in HCV Cirrhosis Patients: is it an Immuno-Inflammatory Disorder?. Annals of Hepatology, 2017, 16, 574-583.	0.6	3
4497	Symptoms of Daytime Sleepiness and Sleep Apnea in Liver Cirrhosis Patients. Annals of Hepatology, 2017, 16, 591-598.	0.6	19
4498	Algorithm for Screening of Adrenal Function in Stable Patients with Cirrhosis. Annals of Hepatology, 2017, 16, 788-796.	0.6	4
4499	Clinical characteristics of nonB nonC hepatocellular carcinoma compared to HBV―and HCV―elated hepatocellular carcinoma. Advances in Digestive Medicine, 2017, 4, 43-49.	0.1	0
4500	Chronic liver failure-consortium acute-on-chronic liver failure and acute decompensation scores predict mortality in Brazilian cirrhotic patients. World Journal of Gastroenterology, 2017, 23, 5237.	1.4	25
4501	Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis. Oncotarget, 2017, 8, 79480-79490.	0.8	14
4502	Operative microwave ablation for hepatocellular carcinoma: a single center retrospective review of 219 patients. Journal of Gastrointestinal Oncology, 2017, 8, 337-346.	0.6	26
4503	Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis. Translational Gastroenterology and Hepatology, 2017, 2, 88-88.	1.5	14
4504	Acute-on-chronic liver failure: recent update. Journal of Biomedical Research, 2017, 31, 283.	0.7	20
4505	How can we improve the performance of Model for Endâ€Stage Liver Disease sodium score in patients with hepatitis B virusâ€related decompensated liver cirrhosis commencing antiviral treatment?. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1641-1648.	1.4	7
4506	Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. Arab Journal of Gastroenterology, 2018, 19, 26-32.	0.4	9
4507	Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal of Vascular and Interventional Radiology, 2018, 29, 540-549.e4.	0.2	7
4508	Does Transjugular Intrahepatic Portosystemic Shunt Stent Differentially Improve Survival in a Subset of Cirrhotic Patients?. Seminars in Liver Disease, 2018, 38, 087-096.	1.8	37
4509	Investigating miRNA-661 and <i>ATG4-B</i> mRNA expression as potential biomarkers for hepatocellular carcinoma. Biomarkers in Medicine, 2018, 12, 245-256.	0.6	9
4510	Alcohol-related acute-on-chronic liver failureâ€"Comparison of various prognostic scores in predicting outcome. Indian Journal of Gastroenterology, 2018, 37, 50-57.	0.7	16
4511	Neurocognitive impairment with hepatitis C and HIV co-infection in Southern Brazil. Journal of NeuroVirology, 2018, 24, 339-349.	1.0	17
4512	Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2018, 17, 1114-1122.	1.9	47

#	Article	IF	Citations
4513	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist, 2018, 23, 586-593.	1.9	75
4514	A Comparative Study of Albumin-Bilirubin Score with Child-Pugh Score, Model for End-Stage Liver Disease Score and Indocyanine Green R15 in Predicting Posthepatectomy Liver Failure for Hepatocellular Carcinoma Patients. Digestive Diseases, 2018, 36, 236-243.	0.8	72
4515	Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncology Letters, 2018, 15, 7175-7181.	0.8	5
4516	Safe use of proton pump inhibitors in patients with cirrhosis. British Journal of Clinical Pharmacology, 2018, 84, 1806-1820.	1.1	32
4517	Nomogram and Validity of a Model for Predicting Malnutrition in Patients on Liver Transplant Lists. Digestive Diseases and Sciences, 2018, 63, 1952-1961.	1.1	5
4518	Biochemical and molecular characterisation of neurological Wilson disease. Journal of Medical Genetics, 2018, 55, 587-593.	1.5	7
4519	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	1.8	6,153
4520	Preoperative Serum Insulin-Like Growth Factor 1 Level as a Prognostic Factor in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. Journal of Interferon and Cytokine Research, 2018, 38, 153-160.	0.5	2
4521	Evaluation of Lung Function in Liver Transplant Candidates. Transplantation Proceedings, 2018, 50, 762-765.	0.3	2
4522	Relationship of muscle cramps to quality of life and sleep disturbance in patients with chronic liver diseases: A nationwide study. Liver International, 2018, 38, 2309-2316.	1.9	27
4524	Pharmacokinetics and Safety of Bazedoxifene in Hepatically Impaired and Healthy Postmenopausal Women. Clinical Pharmacology in Drug Development, 2018, 7, 365-372.	0.8	5
4525	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	0.6	162
4526	Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. Thrombosis Research, 2018, 163, 71-76.	0.8	47
4527	Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine (United States), 2018, 97, e9757.	0.4	2
4528	Prolonged Catheter Use and Infection in Regional Anesthesia. Anesthesiology, 2018, 128, 764-773.	1.3	58
4529	42,573 cases of hepatectomy in China: a multicenter retrospective investigation. Science China Life Sciences, 2018, 61, 660-670.	2.3	51
4530	Prognostic Models in Acute Liver Failure. Clinics in Liver Disease, 2018, 22, 375-388.	1.0	10
4532	A dedicated paracentesis clinic decreases healthcare utilization for serial paracenteses in decompensated cirrhosis. Abdominal Radiology, 2018, 43, 2190-2197.	1.0	8

#	Article	IF	CITATIONS
4533	Benefits of Laparoscopic Approach for Resection of Liver Tumors in Cirrhotic Patients. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2018, 28, 553-561.	0.5	8
4534	Indocyanine Green Retention Rates at 15Âmin Predicted Hepatic Decompensation in a Western Population. World Journal of Surgery, 2018, 42, 2570-2578.	0.8	12
4535	National Early Warning Score Accurately Discriminates the Risk of Serious Adverse Events in Patients With Liver Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1657-1666.e10.	2.4	14
4536	Operative outcome of liver resections for hepatocellular carcinoma: Retrospective case control study of a twelve-years pioneer experience in the Sudan. International Journal of Surgery Open, 2018, 10, 37-42.	0.2	2
4537	Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpoints. Practical Radiation Oncology, 2018, 8, 157-166.	1.1	22
4538	Comprehensive Geriatric Assessment in Patients with Organ Failure. Practical Issues in Geriatrics, 2018, , 133-147.	0.3	0
4539	Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis. JAMA - Journal of the American Medical Association, 2018, 319, 27.	3.8	135
4540	The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2018, 194, 403-413.	1.0	20
4541	Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Safety, 2018, 41, 603-613.	1.4	36
4542	Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control, 2018, 25, 107327481774462.	0.7	182
4543	Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment. Journal of Clinical Pharmacology, 2018, 58, 522-532.	1.0	7
4544	Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis. Hepatology, 2018, 68, 224-233.	3.6	37
4545	Oral mucosa lesions and gingival bleeding can indicate the progression ofÂliver disease in children and adolescents aged two to 18Âyears. Acta Paediatrica, International Journal of Paediatrics, 2018, 107, 886-892.	0.7	3
4546	Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation. Thrombosis Research, 2018, 167, 119-124.	0.8	4
4547	Serum BTP concentrations are not affected by hepatic dysfunction. BMC Nephrology, 2018, 19, 87.	0.8	6
4548	A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology, 2018, 94, 329-339.	0.9	36
4549	2D shear wave elastography combined with MELD improved prognostic accuracy in patients with acute-on-chronic hepatitis B liver failure. European Radiology, 2018, 28, 4465-4474.	2.3	11
4550	Sublingual microcirculatory alterations in cirrhotic patients. Microcirculation, 2018, 25, e12448.	1.0	9

#	Article	IF	CITATIONS
4551	A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncology Letters, 2018, 15, 4411-4422.	0.8	24
4552	Preoperative Chemotherapy May Not Influence the Remnant Liver Regenerations and Outcomes After Hepatectomy for Colorectal Liver Metastasis. World Journal of Surgery, 2018, 42, 3316-3330.	0.8	13
4553	Microvascular invasion and positive HB e antigen are associated with poorer survival after hepatectomy of early hepatocellular carcinoma: A retrospective cohort study. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 330-338.	0.7	20
4554	End-Stage Liver Disease in Patients with Intracranial Hemorrhage Is Associated with Increased Mortality: A Cohort Study. World Neurosurgery, 2018, 113, e320-e327.	0.7	3
4555	Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults. Clinical Therapeutics, 2018, 40, 512-525.	1.1	36
4556	Clinical Outcomes and Prognosis Markers of Patients With Liver Disease Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e005727.	1.4	36
4557	Evaluation of vitamin D status bone mineral density and dental health in children with cholestasis. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 368-377.	0.7	15
4558	Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. American Journal of Gastroenterology, 2018, 113, 1475-1483.	0.2	82
4559	Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 861-866.	0.6	57
4560	Interlobar Artery Resistive Index predicts Acute-on-Chronic Liver Failure Syndrome in Cirrhotic Patients withÂAcute Decompensation. Ultraschall in Der Medizin, 2018, 39, 39-47.	0.8	2
4561	Selecting antithrombotic therapy for stroke prevention in atrial fibrillation: Health professionals' feedback on a decision support tool. Health Informatics Journal, 2018, 24, 309-322.	1.1	7
4562	Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study. Clinical Pharmacokinetics, 2018, 57, 345-354.	1.6	16
4563	A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. Hepatology Research, 2018, 48, E61-E67.	1.8	19
4564	Role of Indocyanine Green in Predicting Post-Transarterial Chemoembolization Liver Failure in Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology, 2018, 8, 28-34.	0.4	9
4565	New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatology International, 2018, 12, 34-43.	1.9	79
4566	Mesoatrial Shunt for Budd-Chiari Syndrome. Annals of Vascular Surgery, 2018, 47, 62-68.	0.4	0
4567	Modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 704-709.	1.4	25
4568	Intraoperative ultrasound for prediction of hepatocellular carcinoma biological behaviour: Prospective comparison with pathology. Liver International, 2018, 38, 312-320.	1.9	11

#	Article	IF	Citations
4569	Robotic left lateral sectionectomy as stepwise approach for cirrhotic liver. Journal of Robotic Surgery, 2018, 12, 549-552.	1.0	2
4570	Combining albuminâ€bilirubin score with future liver remnant predicts postâ€hepatectomy liver failure in <scp>HBV</scp> â€associated <scp>HCC</scp> patients. Liver International, 2018, 38, 494-502.	1.9	57
4571	Health care-associated infections in pre-transplant liver intensive care unit: Perspectives and challenges. Journal of Infection and Public Health, 2018, 11, 398-404.	1.9	10
4572	T 2 â^— -weighted imaging of the liver versus the spleen to assess hepatitis B-related cirrhosis and its Child–Pugh class. Radiology of Infectious Diseases, 2018, 5, 33-40.	2.4	0
4573	Pediatric CLIF-SOFA score is the best predictor of 28-day mortality in children with decompensated chronic liver disease. Journal of Hepatology, 2018, 68, 449-455.	1.8	27
4574	The albuminâ€bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in <scp>HIV</scp> â€associated hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2018, 47, 95-103.	1.9	20
4575	Clinical significance of smallâ€bowel villous edema in patients with liver cirrhosis: A capsule endoscopy study. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 825-830.	1.4	4
4576	Prevalence and Impact of Bacterial Infections in Children With Liver Diseaseâ€"A Prospective Study. Journal of Clinical and Experimental Hepatology, 2018, 8, 35-41.	0.4	11
4577	Prognostic value of lectin pathway molecules and complement proteins in ascitic fluid and blood in patients with liver cirrhosis. Scandinavian Journal of Gastroenterology, 2018, 53, 64-69.	0.6	14
4578	Image-guided treatment of Budd-Chiari syndrome: a giant leap from the past, a small step towards the future. Abdominal Radiology, 2018, 43, 1908-1919.	1.0	6
4579	Transjugular intrahepatic portosystemic shunt treatment of variceal bleeding in an unselected patient population. Scandinavian Journal of Gastroenterology, 2018, 53, 70-75.	0.6	2
4580	Comparison of Regeneration of Remnant Liver After Hemihepatectomy with or Without the Middle Hepatic Vein. World Journal of Surgery, 2018, 42, 1100-1110.	0.8	7
4581	Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 910-917.	1.4	19
4582	Validation of prognostic scores to predict shortâ€term mortality in patients with acuteâ€onâ€chronic liver failure. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 900-909.	1.4	23
4583	Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut, 2018, 67, 2181-2191.	6.1	255
4584	High serum soluble CD40L levels previously to liver transplantation in patients with hepatocellular carcinoma are associated with mortality at one year. Journal of Critical Care, 2018, 43, 316-320.	1.0	7
4585	Smallâ€forâ€size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria. Liver Transplantation, 2018, 24, 35-43.	1.3	14
4586	Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis. Platelets, 2018, 29, 520-527.	1.1	34

#	Article	IF	Citations
4587	Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Digestive and Liver Disease, 2018, 50, 68-75.	0.4	28
4588	External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. Hepatology, 2018, 67, 2215-2225.	3. 6	40
4589	Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. CardioVascular and Interventional Radiology, 2018, 41, 587-593.	0.9	40
4590	Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Investigational New Drugs, 2018, 36, 476-486.	1.2	5
4591	Spontaneous bacteremia and spontaneous bacterial peritonitis share similar prognosis in patients with cirrhosis: a cohort study. Hepatology International, 2018, 12, 181-190.	1.9	15
4592	Development of a simple indocyanine green measurement method using an automated biochemical analyser. Annals of Clinical Biochemistry, 2018, 55, 491-495.	0.8	1
4593	Ischemic stroke in liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2018, 30, 233-240.	0.8	22
4594	Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis. Scandinavian Journal of Gastroenterology, 2018, 53, 200-205.	0.6	5
4595	Preoperative maximal removal rate of technetium-99m-galactosyl-human serum albumin of the remnant liver is associated with postoperative tumor relapse in hepatitis C virus-related hepatocellular carcinoma. Nuclear Medicine Communications, 2018, 39, 28-34.	0.5	1
4596	Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment. Journal of Clinical Pharmacology, 2018, 58, 357-363.	1.0	21
4597	The Patient with End-Stage Liver Disease. , 2018, , 165-182.		0
4598	Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. European Journal of Gastroenterology and Hepatology, 2018, 30, 44-53.	0.8	10
4599	Palliative care in decompensated cirrhosis: A review. Liver International, 2018, 38, 768-775.	1.9	33
4600	Quantitative assessment of liver function with whole-liver T1rho mapping at 3.0 T. Magnetic Resonance Imaging, 2018, 46, 75-80.	1.0	18
4601	Loss of skeletal muscle mass in patients with chronic liver disease is related to decrease in bone mineral density and exercise tolerance. Hepatology Research, 2018, 48, 345-354.	1.8	9
4602	Comparison of Hepatectomy for Patients with Metabolic Syndrome-Related HCC and HBV-Related HCC. Journal of Gastrointestinal Surgery, 2018, 22, 615-623.	0.9	18
4603	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67, 1784-1796.	3.6	93
4604	Renal vein dilation predicts poor outcome in patients with refractory cirrhotic ascites. Hepatology Research, 2018, 48, E117-E125.	1.8	4

#	Article	IF	CITATIONS
4605	Hypoalbuminemia is a predictor of mortality and rebleeding in peptic ulcer bleeding under proton pump inhibitor use. Journal of the Formosan Medical Association, 2018, 117, 316-325.	0.8	12
4606	The Impact of Serosal Invasion on Prognosis after Curative Hepatectomy for Hepatocellular Carcinoma: Invasion to Adjacent Organs and Rupture of Tumor Were Crucial Tumor-Related Prognostic Factors Needed for Survival. Digestive Surgery, 2018, 35, 155-163.	0.6	6
4607	Laparoscopic liver resections for hepatocellular carcinoma. Can we extend the surgical indication in cirrhotic patients?. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 617-626.	1.3	59
4608	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology, 2018, 17, 110-118.	0.6	20
4609	Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Therapeutic Drug Monitoring, 2018, 40, 663-674.	1.0	63
4610	Serum sodium, model for end-stage liver disease, and a recent invasive procedure are risk factors for severe acute-on-chronic liver failure and death in cirrhotic patients hospitalized with bacterial infection. European Journal of Gastroenterology and Hepatology, 2018, 30, 1055-1059.	0.8	11
4611	Clinical Significance of Serum Adiponectin and Resistin Levels in Liver Cirrhosis. Annals of Hepatology, 2018, 17, 286-299.	0.6	28
4612	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. Annals of Hepatology, 2018, 17, 830-835.	0.6	25
4613	Oesophageal varices in patients with liver cirrhosis attending a major tertiary hospital in Ghana. Pan African Medical Journal, 2018, 31, 230.	0.3	11
4614	99mTc-Phy portal perfusion index imaging helps predict the severity of hepatitis B virus cirrhosis. Nuclear Medicine Communications, 2018, 39, 818-824.	0.5	2
4615	Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 840-840.	0.6	23
4616	Effect of Admission Time on the Outcomes of Liver Cirrhosis with Acute Upper Gastrointestinal Bleeding: Regular Hours versus Off-Hours Admission. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-14.	0.8	14
4617	The Diagnostic and Prognostic Values of C-Reactive Protein and Procalcitonin during Bacterial Infections in Decompensated Cirrhosis. Gastroenterology Research and Practice, 2018, 2018, 1-7.	0.7	8
4618	Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?. Journal of Gastrointestinal Oncology, 2018, 9, 750-761.	0.6	15
4619	Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 741-749.	0.6	12
4620	Managing portal hypertension in patients with liver cirrhosis. F1000Research, 2018, 7, 533.	0.8	36
4621	Heterogeneous liver uptake of Tc-99m-GSA as quantified through SPECT/CT helps to evaluate the degree of liver fibrosis. Medicine (United States), 2018, 97, e11765.	0.4	5
4622	Evaluation of prognostic values of inflammation-based makers in patients with HBV-related acute-on-chronic liver failure. Medicine (United States), 2018, 97, e13324.	0.4	32

#	Article	IF	CITATIONS
4623	Model for end-stage liver disease score and hemodynamic instability as a predictor of poor outcome in early transjugular intrahepatic portosystemic shunt treatment for acute variceal hemorrhage. European Journal of Gastroenterology and Hepatology, 2018, 30, 1441-1446.	0.8	11
4624	Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. Journal of Cardiovascular Pharmacology, 2018, 72, 296-302.	0.8	12
4625	<i>Short- and Long-Term Results of Laparoscopic Parenchyma-Sparing Hepatectomy for Small-Sized Hepatocellular Carcinoma: A Comparative Study Using Propensity Score Matching Analysis</i> American Surgeon, 2018, 84, 230-237.	0.4	14
4626	Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis. The Cochrane Library, 2018, 2018, CD001023.	1.5	13
4627	Presence of Sarcopenia and Its Rate of Change Are Independently Associated with Long-term Mortality in Patients with Liver Cirrhosis. Journal of Korean Medical Science, 2018, 33, e299.	1.1	24
4628	Validation of a Symptoms Distress Scale in a Cirrhotic Population Using Item Response Theory. Nursing Research, 2018, 67, 359-368.	0.8	0
4629	Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease. Translational Gastroenterology and Hepatology, 2018, 3, 41-41.	1.5	13
4630	Potential Role of Microfibrillar-Associated Protein 4, Fibrotic Indices and Oxidative Stress in Hepatocellular Carcinoma. Scientia Pharmaceutica, 2018, 86, 44.	0.7	5
4631	ALBI Score as a Predictor of Survival in Patients with Compensated Cirrhosis Resected for Hepatocellular Carcinoma: Exploratory Evaluation in Relationship to PALBI and MELD Liver Function Scores. Acta Clinica Croatica, 2018, 57, 292-300.	0.1	5
4632	Human cytomegalovirus and Epstein-Barr virus infections, risk factors, and their influence on the liver function of patients with acute-on-chronic liver failure. BMC Infectious Diseases, 2018, 18, 577.	1.3	16
4633	Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opinion on Drug Safety, 2018, 17, 1225-1232.	1.0	46
4634	Presepsin levels in cirrhotic patients with bacterial infections and/or portal hypertension-related bleeding, presenting with or without acute kidney injury. Annals of Gastroenterology, 2018, 31, 604-612.	0.4	6
4635	The utility of the subcuticular suture in hepatic resection. Wspolczesna Onkologia, 2018, 22, 184-190.	0.7	1
4636	Postoperative survival analysis and prognostic nomogram model for patients with portal hypertension. World Journal of Gastroenterology, 2018, 24, 4499-4509.	1.4	5
4637	Effect of baseline renal and hepatic function on the incidence of adverse drug events: the Japan Adverse Drug Events study. Drug Metabolism and Personalized Therapy, 2018, 33, 165-173.	0.3	3
4638	Predictive power of Model for End-Stage Liver Disease and Child-Turcotte-Pugh score for mortality in cirrhotic patients. Clinical and Experimental Hepatology, 2018, 4, 240-246.	0.6	9
4639	Clinical evaluation of the M-ANNHEIM classification: Development ofÂthe M-ANNHEIM-Surgery-Score as a new tool to monitor patients with chronic pancreatitis. Zeitschrift Fur Gastroenterologie, 2018, 56, 1481-1490.	0.2	5
4640	Staging systems of hepatocellular carcinoma: A review. Indian Journal of Gastroenterology, 2018, 37, 481-491.	0.7	88

#	Article	IF	CITATIONS
4641	The Short- and Long-Term Outcomes in Elderly Patients with Hepatocellular Carcinoma after Curative Surgery: A Case-Controlled Study with Propensity Score Matching. European Surgical Research, 2018, 59, 380-390.	0.6	12
4642	Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality. Clinical and Experimental Gastroenterology, 2018, Volume 11, 431-438.	1.0	10
4643	Development and external validation of a prognostic nomogram for acute decompensation of chronic hepatitis B cirrhosis. BMC Gastroenterology, 2018, 18, 179.	0.8	12
4644	Morning Bright Light Treatment for Sleep-Wake Disturbances in Primary Biliary Cholangitis: A Pilot Study. Frontiers in Physiology, 2018, 9, 1530.	1.3	18
4645	Validation of the albuminâ€indocyanine green evaluation model in patients with resected hepatocellular carcinoma and comparison with the albumin–bilirubin score. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 26, 51-57.	1.4	18
4646	Albumin-Bilirubin Score: An Accurate Predictor of Hepatic Decompensation in High-Risk Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2018, 29, 1527-1534.e1.	0.2	14
4647	Usefulness of aspartate aminotransferase to platelet ratio index as a prognostic factor following hepatic resection for hepatocellular carcinoma. Molecular and Clinical Oncology, 2018, 9, 369-376.	0.4	6
4648	Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients. Canadian Respiratory Journal, 2018, 2018, 1-6.	0.8	21
4649	Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology, 2018, 155, 1816-1827.e9.	0.6	113
4650	Nurse-led clinic for patients with liver cirrhosisâ€"effects on health-related quality of life: study protocol of a pragmatic multicentre randomised controlled trial. BMJ Open, 2018, 8, e023064.	0.8	7
4651	Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World Journal of Surgical Oncology, 2018, 16, 208.	0.8	45
4652	What Is the Optimal Sedative Regimen in Severe Traumatic Brain Injury Patients?., 2018,, 47-60.		0
4653	Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 860-870.	2.9	101
4654	Cirrhosis and Portal Hypertension in the Pediatric Population. Clinics in Liver Disease, 2018, 22, 735-752.	1.0	25
4655	Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment. Clinical Therapeutics, 2018, 40, 1701-1710.	1.1	17
4656	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United European Gastroenterology Journal, 2018, 6, 1039-1048.	1.6	54
4657	Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis. Infectious Agents and Cancer, 2018, 13, 30.	1.2	3
4658	Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin. Clinical Drug Investigation, 2018, 38, 1001-1009.	1.1	10

#	Article	IF	CITATIONS
4659	Dynamic Prognostication in Critically Ill Cirrhotic Patients With Multiorgan Failure in ICUs in Europe and North America: A Multicenter Analysis*. Critical Care Medicine, 2018, 46, 1783-1791.	0.4	45
4660	First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 146-154.	0.4	2
4661	Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities. Expert Opinion on Drug Safety, 2018, 17, 553-572.	1.0	9
4662	Outcomes of abdominal surgeries in cirrhotic patients performed by liver transplant surgeons: Are these safe?. American Journal of Surgery, 2018, 216, 518-523.	0.9	4
4663	Hepatic Encephalopathy Diagnosis Conundrums. , 2018, , 117-128.		0
4664	Risk stratification using a novel liver functional reserve score of combination prothrombin time–international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma. Surgery, 2018, 164, 404-410.	1.0	24
4665	Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study. Internal Medicine, 2018, 57, 1533-1542.	0.3	1
4666	Autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection. Clinical and Translational Gastroenterology, 2018, 9, e166.	1.3	20
4667	Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 906-909.	0.7	3
4668	Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Investigational New Drugs, 2018, 36, 911-918.	1.2	18
4669	MicroRNA profiles in serum samples from patients with stable cirrhosis and miRNA-21 as a predictor of transplant-free survival. Pharmacological Research, 2018, 134, 179-192.	3.1	19
4670	Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study. Advances in Therapy, 2018, 35, 1239-1250.	1.3	1
4671	Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients. Digestive and Liver Disease, 2018, 50, 1225-1231.	0.4	37
4672	Two sides of a coin: GG genotype of C7 provides protection against fibrosis severity while showing a higher risk for hepatocellular carcinoma in patients with hepatitis C. Human Immunology, 2018, 79, 702-707.	1.2	5
4673	Psychiatric and functional neuroimaging abnormalities in chronic hepatitis C virus patients: Is vasculitis a contributing factor?. Arab Journal of Gastroenterology, 2018, 19, 71-75.	0.4	4
4674	Severe Coagulopathy Secondary to Fulminant Herpes Simplex Virus Hepatitis in a Severely Burned Patient: A Case Report and Review of the Literature. Journal of Burn Care and Research, 2018, 39, 1071-1076.	0.2	3
4676	Prediction of acute kidney injury in cirrhotic patients: a new score combining renal, liver and inflammatory markers. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 149-154.	0.8	16
4677	Homocysteine, insulin-like growth factor one and oestrogen levels in patients with erectile dysfunction-associated chronic hepatitis C virus infection. Andrologia, 2018, 50, e13116.	1.0	7

#	Article	IF	CITATIONS
4678	Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study. Infectious Agents and Cancer, 2018, 13, 17.	1.2	1
4679	Albumin mass balance and kinetics in liver transplantation. Critical Care, 2018, 22, 152.	2.5	12
4680	Propensity scoreâ€matched comparison of nonâ€anatomical resection and radiofrequency ablation for hepatocellular carcinoma in patients with up to three tumours, each measuring up to 3 cm in diameter. BJS Open, 2018, 2, 213-219.	0.7	3
4681	The abdominal wall hernia in cirrhotic patients: a historical challenge. World Journal of Emergency Surgery, 2018, 13, 35.	2.1	28
4682	Small Bowel Transit and Altered Gut Microbiota in Patients With Liver Cirrhosis. Frontiers in Physiology, 2018, 9, 470.	1.3	26
4683	Brain Regional Homogeneity Changes in Cirrhotic Patients with or without Hepatic Encephalopathy Revealed by Multi-Frequency Bands Analysis Based on Resting-State Functional MRI. Korean Journal of Radiology, 2018, 19, 452.	1.5	8
4684	Splenectomy Leads to Amelioration of Altered Gut Microbiota and Metabolome in Liver Cirrhosis Patients. Frontiers in Microbiology, 2018, 9, 963.	1.5	38
4685	Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis: study protocol for a feasibility randomised controlled trial. Trials, 2018, 19, 401.	0.7	10
4686	Acute care and emergency general surgery in patients with chronic liver disease: how can we optimize perioperative care? A review of the literature. World Journal of Emergency Surgery, 2018, 13, 32.	2.1	18
4687	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology, 2018, 68, 1232-1244.	3.6	26
4688	Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month. PLoS ONE, 2018, 13, e0200364.	1.1	7
4689	Cirrhosis and End-Stage Liver Disease. , 2018, , 501-511.		0
4690	Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of leadâ€time bias. Liver International, 2018, 38, 2260-2268.	1.9	8
4691	IL-28B <i>rs12979860</i> polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. British Journal of Biomedical Science, 2018, 75, 157-162.	1.2	13
4692	Possible Synergistic Effects of Glutathione and C-Reactive Protein in the Progression of Liver Cirrhosis. Nutrients, 2018, 10, 678.	1.7	6
4693	Role of T-Helper 9 Cells in Chronic Hepatitis C-Infected Patients. Viruses, 2018, 10, 341.	1.5	10
4694	Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma. Journal of Cellular Biochemistry, 2018, 119, 8600-8610.	1.2	50
4695	All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response. PLoS ONE, 2018, 13, e0199941.	1.1	17

#	Article	IF	CITATIONS
4696	Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization. British Journal of Biomedical Science, 2018, 75, 187-191.	1.2	17
4697	Monocyte human leukocyte antigen – Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure. PLoS ONE, 2018, 13, e0200644.	1.1	8
4698	Competing endogenous RNA network crosstalk reveals novel molecular markers in colorectal cancer. Journal of Cellular Biochemistry, 2018, 119, 6869-6881.	1.2	11
4699	The efficacy of serum brain natriuretic peptide for the early detection of portopulmonary hypertension in biliary atresia patients before liver transplantation. Pediatric Transplantation, 2018, 22, e13203.	0.5	9
4700	Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. Surgery, 2018, 164, 1014-1022.	1.0	11
4701	Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nature Communications, 2018, 9, 2146.	5.8	152
4702	Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. Alimentary Pharmacology and Therapeutics, 2018, 48, 313-321.	1.9	73
4703	The Predictors of Microscopic Vessel Invasion Differ Between Primary Hepatocellular Carcinoma and Hepatocellular Carcinoma with a Treatment History. World Journal of Surgery, 2018, 42, 3694-3704.	0.8	14
4704	Intention-to-treat analysis of liver transplantation, resection and thermal ablation for hepatocellular carcinoma in a single centre. Hpb, 2018, 20, 966-976.	0.1	4
4706	Low expression of <scp>WW</scp> domainâ€containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Cancer Medicine, 2018, 7, 3031-3043.	1.3	16
4707	Serum total antioxidant capacity prior to liver transplantation for hepatocellular carcinoma is associated with 1-year liver transplantation survival. Journal of International Medical Research, 2018, 46, 2641-2649.	0.4	3
4708	Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Clinical Pharmacology in Drug Development, 2018, 7, 880-888.	0.8	6
4709	Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis. Scientific Reports, 2018, 8, 9242.	1.6	19
4710	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer, 2019, 8, 121-129.	4.2	159
4711	External validation of the PALIAR index for patients with advanced, nononcologic chronic diseases. Aging Clinical and Experimental Research, 2019, 31, 393-402.	1.4	8
4712	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. Digestive and Liver Disease, 2019, 51, 95-103.	0.4	12
4713	Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine $N\hat{a}\in C$ actyl $\hat{a}\in \hat{D}$ action \hat{C} and \hat{C} and \hat{C} and \hat{C} and \hat{C} and \hat{C} action \hat{C} and \hat{C} action \hat{C} action \hat{C} action \hat{C} and \hat{C} action \hat{C} and \hat{C} action \hat{C} and \hat{C} action \hat{C} and \hat{C} action \hat{C} action \hat{C} and \hat{C} action \hat{C} action \hat{C} action \hat{C} action \hat{C} action \hat{C} action \hat{C} and \hat{C} action \hat{C} and \hat{C} action \hat{C} action \hat{C} action \hat{C} and \hat{C} action \hat{C} and \hat{C} action	1.4	17
4714	The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. European Radiology, 2019, 29, 1048-1058.	2.3	18

#	Article	IF	CITATIONS
4715	Survival Outcomes After Intracranial Hemorrhage in Liver Disease. Operative Neurosurgery, 2019, 16, 138-146.	0.4	2
4716	Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFPâ€Score. World Journal of Surgery, 2019, 43, 221-229.	0.8	5
4717	Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2Âcm based on propensity score matching analysis. Hepatology Research, 2019, 49, 344-354.	1.8	44
4718	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatology Research, 2019, 49, 111-117.	1.8	81
4719	Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 76-83.	0.9	16
4721	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. JHEP Reports, 2019, 1, 270-277.	2.6	12
4722	Prevalence and predictors for spontaneous bacterial peritonitis in cirrhotic patients with ascites admitted at medical block in Korle-Bu Teaching Hospital, Ghana. Pan African Medical Journal, 2019, 33, 35.	0.3	12
4723	Non-endoscopic predictors of esophageal varices in children with chronic liver disease and their utility in resource-constrained countries. Indian Journal of Gastroenterology, 2019, 38, 310-316.	0.7	1
4724	Role of extracellular LncRNA-SNHG14/miRNA-3940-5p/NAP12 mRNA in colorectal cancer. Archives of Physiology and Biochemistry, 2021, 127, 479-485.	1.0	15
4725	ALBI/ST ratio versus FIB-4 and APRI as a predictor of posthepatectomy liver failure in hepatocellular carcinoma patients. Medicine (United States), 2019, 98, e15168.	0.4	6
4726	Admission plasma uromodulin and the risk of acute kidney injury in hospitalized patients with cirrhosis: a pilot study. American Journal of Physiology - Renal Physiology, 2019, 317, G447-G452.	1.6	10
4727	Impact of Liver Cirrhosis on Early and Midterm Results After Transcatheter Aortic Valve Replacement: A Retrospective, Observational Study. Structural Heart, 2019, 3, 236-243.	0.2	1
4728	Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study). Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2641-2646.	1.8	7
4729	Health literacy and liver cirrhosis: testing three screening tools for face validity. British Journal of Nursing, 2019, 28, 441-445.	0.3	5
4730	Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study. Scientific Reports, 2019, 9, 10195.	1.6	10
4731	Soluble CD25 as a predictor of hepatocellular carcinoma compared with alpha-fetoprotein. Clinical and Experimental Hepatology, 2019, 5, 140-146.	0.6	2
4732	Muscle performance and fatigue in compensated chronic liver disease. Scandinavian Journal of Gastroenterology, 2019, 54, 925-933.	0.6	6
4733	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology, 2019, 97, 277-285.	0.9	66

#	Article	IF	CITATIONS
4734	Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam. Cancer Control, 2019, 26, 107327481986279.	0.7	11
4735	Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutrition Journal, 2019, 18, 34.	1.5	33
4736	Utility of MELD scoring system for assessing the prognosis of acute fatty liver of pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 240, 161-166.	0.5	7
4737	Scoring Systems and Postoperative Outcomes in Pediatric LiverÂTransplantation. Transplantation Proceedings, 2019, 51, 2430-2433.	0.3	5
4738	The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985825.	1.4	9
4739	Oral Anticoagulants in Liver Disease. Journal of the American College of Cardiology, 2019, 73, 3309-3311.	1.2	4
4740	Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus–Infected Cells and Liver to Identify Pathways Associated With Disease Development. Gastroenterology, 2019, 157, 537-551.e9.	0.6	71
4741	Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score. BMJ Open Gastroenterology, 2019, 6, e000286.	1.1	1
4742	Specialized care improves outcomes for patients with cirrhosis who require general surgical operations. PLoS ONE, 2019, 14, e0223454.	1.1	1
4743	Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis. Nutrients, 2019, 11, 2379.	1.7	5
4744	The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma. Annals of Surgical Oncology, 2019, 26, 4566-4575.	0.7	16
4745	Level and Value of T Cell-derived Circulating Microparticles in Liver Cirrhosis Patients. In Vivo, 2019, 33, 2265-2272.	0.6	1
4746	Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 cases. Journal of Cancer, 2019, 10, 5007-5014.	1.2	3
4747	Transplantation with GXHPC1 for Liver Cirrhosis: Phase 1 Trial. Cell Transplantation, 2019, 28, 100S-111S.	1.2	20
4748	Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients. Clinics in Liver Disease, 2019, 23, 589-605.	1.0	18
4749	Surgery in Patients with Portal Hypertension. Clinics in Liver Disease, 2019, 23, 755-780.	1.0	12
4750	Band ligation versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2019, 9, CD010546.	1.5	6
4751	The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. Journal of Hepatology, 2019, 70, 648-657.	1.8	13

#	Article	IF	CITATIONS
4752	THE COST OF ADULT LIVER TRANSPLANTATION IN A REFERRAL CENTER IN SOUTHERN BRAZIL. Arquivos De Gastroenterologia, 2019, 56, 165-171.	0.3	5
4753	Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. Oncology, 2019, 97, 334-340.	0.9	39
4754	High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis. Annals of Gastroenterology, 2019, 32, 451-456.	0.4	8
4755	Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis. World Journal of Gastroenterology, 2019, 25, 378-387.	1.4	16
4757	Nutrition Risk Assessment Using the Modified NUTRIC Score in Cirrhotic Patients with Acute Gastroesophageal Variceal Bleeding: Prevalence of High Nutrition Risk and its Independent Prognostic Value. Nutrients, 2019, 11, 2152.	1.7	18
4758	Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy. Oncology Letters, 2019, 18, 3903-3913.	0.8	4
4759	Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key?. Journal of Clinical Pathology, 2019, 72, 669-676.	1.0	9
4760	Evaluation of the effectiveness of eight screening tools in detecting risk of malnutrition in cirrhotic patients: the KIRRHOS study. British Journal of Nutrition, 2019, 122, 1368-1376.	1.2	33
4761	Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: A single-center experience in China. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 532-537.	0.6	26
4762	Non-invasive markers as predictors of oesophageal varices in cirrhotic patient in a teaching hospital in Ghana. Ghana Medical Journal, 2019, 53, 142.	0.1	5
4763	Health-related quality of life in patients with compensated and decompensated liver cirrhosis. European Journal of Internal Medicine, 2019, 70, 54-59.	1.0	35
4764	Exacerbation of Portal Hypertensive Enteropathy after Endoscopic Injection Sclerotherapy for Esophageal Varices. Digestion, 2021, 102, 188-196.	1.2	4
4765	Plasma diamine oxidase level predicts 6-month readmission for patients with hepatitis B virus-related decompensated cirrhosis. Virology Journal, 2019, 16, 115.	1.4	5
4766	The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatology International, 2019, 13, 199-204.	1.9	33
4767	Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. Internal and Emergency Medicine, 2019, 14, 753-761.	1.0	14
4768	Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma. JAMA Network Open, 2019, 2, e187142.	2.8	21
4769	ALBI and PALBI Grades Are Associated with the Outcome of Patients with Stable Decompensated Cirrhosis. Annals of Hepatology, 2019, 18, 126-136.	0.6	32
4770	Treatment of AECHB and Severe Hepatitis (Liver Failure). , 2019, , 273-370.		0

#	Article	IF	CITATIONS
4771	Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement. PLoS ONE, 2019, 14, e0217442.	1.1	23
4772	Evaluation and Management of Cirrhotic Patients Undergoing Elective Surgery. Current Gastroenterology Reports, 2019, 21, 32.	1.1	7
4773	Six-minute walk test before and after large-volume paracentesis in cirrhotic patients with refractory ascites: A pilot study. Arab Journal of Gastroenterology, 2019, 20, 81-85.	0.4	7
4774	Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis. Digestive and Liver Disease, 2019, 51, 1692-1697.	0.4	7
4775	Epstein-Barr virus infection is associated with a higher Child-Pugh score and may predict poor prognoses for patients with liver cirrhosis. BMC Gastroenterology, 2019, 19, 94.	0.8	10
4776	Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and allâ€cause admissions in patients on the liver transplant waiting list. Alimentary Pharmacology and Therapeutics, 2019, 50, 435-441.	1.9	43
4777	Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis. Journal of Clinical Medicine, 2019, 8, 782.	1.0	12
4778	A simplified prediction model for early intrahepatic recurrence after hepatectomy for patients with unilobar hepatocellular carcinoma without macroscopic vascular invasion: An implication for adjuvant therapy and postoperative surveillance. Surgical Oncology, 2019, 30, 6-12.	0.8	15
4779	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver International, 2019, 39, 1478-1489.	1.9	41
4780	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in realâ€world conditionsâ€"Multicenter analysis. Cancer Medicine, 2019, 8, 3719-3728.	1.3	131
4781	Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI. Digestive and Liver Disease, 2019, 51, 1438-1445.	0.4	8
4782	Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Frontiers in Oncology, 2019, 9, 370.	1.3	42
4783	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	1.0	335
4784	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
4785	Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open″abel, singleâ€dose, parallelâ€group study. British Journal of Clinical Pharmacology, 2019, 85, 2011-2021.	1.1	8
4786	Laparoscopic liver resection for patients with cardiac disease. Wspolczesna Onkologia, 2019, 23, 37-42.	0.7	2
4787	Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 301-318.e2.	2.3	76
4788	Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions Annals of Hepatology, 2019, 18, 325-330.	0.6	8

#	ARTICLE	IF	CITATIONS
4789	TACE, DEE-TACE, and Its Evolution in Metastatic Disease. Digestive Disease Interventions, 2019, 03, 052-062.	0.3	O
4790	High serum caspase-3 levels in hepatocellular carcinoma prior to liver transplantation and high mortality risk during the first year after liver transplantation. Expert Review of Molecular Diagnostics, 2019, 19, 635-640.	1.5	2
4791	Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 353-359.	1.2	6
4792	Impact of Sarcopenia and Frailty in a Multicenter Cohort of Polypathological Patients. Journal of Clinical Medicine, 2019, 8, 535.	1.0	26
4793	Longâ€'term results of liver transplantation for polycystic liver disease: Singleâ€'center experience in China. Experimental and Therapeutic Medicine, 2019, 17, 4183-4189.	0.8	1
4794	Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clinical Pharmacokinetics, 2019, 58, 1131-1147.	1.6	95
4795	Inter- and intra-reader agreement for gadoxetic acid–enhanced MRI parameter readings in patients with chronic liver diseases. European Radiology, 2019, 29, 6600-6610.	2.3	19
4796	Potential role of IncRNA-TSIX, miR-548-a-3p, and SOGA1 mRNA in the diagnosis of hepatocellular carcinoma. Molecular Biology Reports, 2019, 46, 4581-4590.	1.0	23
4797	LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10–19 mm With Arterial Phase Hyperenhancement. American Journal of Roentgenology, 2019, 213, W57-W65.	1.0	28
4798	Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Clinical Pharmacokinetics, 2019, 58, 1469-1482.	1.6	9
4799	Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS ONE, 2019, 14, e0216173.	1.1	37
4800	Physical Assessment for Pharmacists. , 2019, , 31-53.		O
4801	Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 1453-1465.	1.2	7
4802	High-density lipoprotein cholesterol for the prediction of mortality in cirrhosis with portal vein thrombosis: a retrospective study. Lipids in Health and Disease, 2019, 18, 79.	1.2	6
4803	Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis. Archives of Medical Science, 2019, 15, 434-448.	0.4	12
4804	Prevalence of diabetes in liver cirrhosis: A systematic review and metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2019, 35, e3157.	1.7	42
4805	In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival. PLoS ONE, 2019, 14, e0212770.	1.1	10
4806	Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. Journal of Clinical Gastroenterology, 2019, 53, e303-e307.	1.1	17

#	Article	IF	CITATIONS
4807	Impact of Helicobacter pylori Infection on Gastric Variceal Bleeding among Patients with Liver Cirrhosis. Gastroenterology Research and Practice, 2019, 2019, 1-6.	0.7	8
4808	Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation. Oncology, 2019, 96, 242-251.	0.9	8
4809	Endoscopic Ultrasound for the Diagnosis and Staging of Liver Tumors. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 339-350.	0.6	11
4810	Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2019, 30, 330-338.	0.2	24
4811	Dissecting the multinodular hepatocellular carcinoma subset: is there a survival benefit after hepatectomy?. Updates in Surgery, 2019, 71, 57-66.	0.9	7
4812	Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY) Tj ETQq1 1 Metabolism and Pharmacokinetics, 2019, 44, 619-628.	0.784314 0.6	rgBT /Over 18
4813	Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population. American Journal of Surgery, 2019, 217, 899-905.	0.9	10
4814	Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Postâ€therapeutic outcome and prognostic indicators. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1604-1610.	1.4	17
4815	Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	22
4816	Impact of MELD Score–Based Organ Allocation on Mortality, Bleeding, and Transfusion in Liver Transplantation: A Before-and-After Observational Cohort Study. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 2719-2725.	0.6	16
4817	Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios. Nutrition and Cancer, 2019, 71, 1132-1141.	0.9	11
4818	Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics. Journal of Clinical Pharmacology, 2019, 59, 1188-1194.	1.0	16
4819	Low Serum Melatonin Levels Prior to Liver Transplantation in Patients with Hepatocellular Carcinoma are Associated with Lower Survival after Liver Transplantation. International Journal of Molecular Sciences, 2019, 20, 1696.	1.8	3
4820	Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncology, The, 2019, 20, e200-e207.	5.1	68
4821	Shortâ€term outcomes of <i>en bloc</i> combined heart and liver transplantation in the failing Fontan. Clinical Transplantation, 2019, 33, e13540.	0.8	46
4822	Serum folate concentrations at diagnosis are associated with hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort study. British Journal of Nutrition, 2019, 121, 1376-1388.	1.2	7
4823	Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2019, 17, 1388-1397.e1.	2.4	16
4824	Treatment strategies for locally advanced hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2019, 4, 12-12.	1.5	14

#	Article	IF	CITATIONS
4825	Comparison between dynamic gadoxetate-enhanced MRI and 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT for quantitative assessment of liver function. European Radiology, 2019, 29, 5063-5072.	2.3	25
4826	Endoscopic injection sclerotherapy versus N-Butyl-2 Cyanoacrylate injection in the management of actively bleeding esophageal varices: a randomized controlled trial. BMC Gastroenterology, 2019, 19, 23.	0.8	20
4827	Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. Digestive Diseases and Sciences, 2019, 64, 632-642.	1.1	20
4828	Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis. Digestive and Liver Disease, 2019, 51, 1172-1178.	0.4	44
4829	Diagnostic Operation of the Liver and Techniques of Hepatic Resection., 2019, , 1456-1471.		1
4830	Outcomes in patients with portal hypertension undergoing gastrointestinal surgery: A propensity score matched analysis from the NSQIP dataset. American Journal of Surgery, 2019, 217, 664-669.	0.9	3
4831	<p>Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia</p> . Therapeutics and Clinical Risk Management, 2019, Volume 15, 269-274.	0.9	3
4832	Minimally Invasive Liver Surgery in Elderly Patientsâ€"A Single-Center Experience. Journal of Surgical Research, 2019, 239, 92-97.	0.8	13
4833	Prediction of risk of falls based on handgrip strength in chronic liver disease patients living independently. Hepatology Research, 2019, 49, 823-829.	1.8	16
4834	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer, 2019, 8, 312-325.	4.2	88
4835	Predicting Future Complications of Cirrhosis. Current Hepatology Reports, 2019, 18, 9-19.	0.4	1
4836	Comparative liver function models for ruptured hepatocellular carcinoma: AÂ10-year single center experience. Asian Journal of Surgery, 2019, 42, 874-882.	0.2	12
4837	Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity scoreâ€matching analysis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1809-1816.	1.4	17
4838	Clinical Usefulness of Bioavailable Vitamin D and Impact of GC Genotyping on the Determination of Bioavailable Vitamin D in a Korean Population. International Journal of Endocrinology, 2019, 2019, 1-9.	0.6	8
4839	Longâ€term outcomes of patients with hepatitis B virusâ€related acute on chronic liver failure: An observational cohort study. Liver International, 2019, 39, 854-860.	1.9	17
4840	Real-time navigation during hepatectomy using fusion indocyanine green-fluorescence imaging: protocol for a prospective cohort study. BMJ Open, 2019, 9, e030233.	0.8	6
4841	External validation of Liaoning score for predicting esophageal varices in liver cirrhosis: a Chinese multicenter cross-sectional study. Annals of Translational Medicine, 2019, 7, 755-755.	0.7	11
4842	Reduced Serum Sphingolipids Constitute a Molecular Signature of Malnutrition in Hospitalized Patients With Decompensated Cirrhosis. Clinical and Translational Gastroenterology, 2019, 10, e00013.	1.3	10

#	Article	IF	CITATIONS
4843	Selective versus non-selective shunts for the prevention of variceal rebleeding. The Cochrane Library, 0, , .	1.5	1
4844	Role of Radioembolization for Biliary Tract and Primary Liver Cancer. Surgical Oncology Clinics of North America, 2019, 28, 731-743.	0.6	11
4845	Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Transplantation Proceedings, 2019, 51, 3338-3346.	0.3	16
4846	Glucocorticosteroids for people with alcoholic hepatitis. The Cochrane Library, 2019, 2019, CD001511.	1.5	11
4847	C-Reactive Protein in the Prediction of Localization of Gastrointestinal Perforation. European Surgical Research, 2019, 60, 179-185.	0.6	3
4848	Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. The Cochrane Library, 0, , .	1.5	O
4849	Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity. Therapeutic Drug Monitoring, 2019, 41, 732-739.	1.0	17
4850	The external validation of a difficulty scoring system for predicting the risk of intraoperative complications during laparoscopic liver resection. BMC Surgery, 2019, 19, 179.	0.6	9
4851	Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis. Journal of Clinical Medicine, 2019, 8, 2057.	1.0	10
4852	Novel patient risk factors and validation of a difficulty scoring system in laparoscopic repeat hepatectomy. Scientific Reports, 2019, 9, 17653.	1.6	9
4853	Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Medicine (United States), 2019, 98, e13929.	0.4	4
4854	Sarcopenia impairs health-related quality of life in cirrhotic patients. European Journal of Gastroenterology and Hepatology, 2019, 31, 1550-1556.	0.8	21
4855	Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis. Medicine (United States), 2019, 98, e18366.	0.4	4
4856	Clinical features of liver cirrhosis patients with muscle cramping: a multicenter study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1557-1562.	0.8	12
4857	Clinical effectiveness of MARS treatment – multidirectional analysis of positive clinical response to treatment. Clinical and Experimental Hepatology, 2019, 5, 271-278.	0.6	1
4858	Anthropometric, biochemical and clinical assessment of malnutrition among Egyptian children with chronic liver diseases: a single institutional cross-sectional study. BMC Gastroenterology, 2019, 19, 223.	0.8	7
4859	Sorafenib for Treatment of Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2019, 53, 464-469.	1.1	19
4860	Predictive value of the Chinese group on the study of severe hepatitis B-acute-on-chronic liver failure score in the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Chinese Medical Journal, 2019, 132, 1541-1549.	0.9	5

#	Article	IF	CITATIONS
4861	Contrast-Enhanced CT May Be a Diagnostic Alternative for Gastroesophageal Varices in Cirrhosis with and without Previous Endoscopic Variceal Therapy. Gastroenterology Research and Practice, 2019, 2019, 1-15.	0.7	9
4862	Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 447-456.	4.2	42
4863	Development and Validation of a Model to Predict Acute Kidney Injury in Hospitalized Patients With Cirrhosis. Clinical and Translational Gastroenterology, 2019, 10, e00075.	1.3	14
4864	Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis. European Journal of Gastroenterology and Hepatology. 2019. 31. 1256-1263.	0.8	8
4865	Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. Arab Journal of Gastroenterology, 2019, 20, 198-204.	0.4	12
4866	Can l-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation?. European Journal of Gastroenterology and Hepatology, 2019, 31, 878-884.	0.8	23
4867	Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. European Journal of Gastroenterology and Hepatology, 2019, 31, 1148-1156.	0.8	30
4868	Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. The Cochrane Library, 2019, 6, CD004039.	1.5	13
4869	Critical flickering frequency test: a diagnostic tool for minimal hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2019, 31, 1030-1034.	0.8	9
4870	ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma. Acta Radiologica, 2019, 60, 702-709.	0.5	13
4871	Safety and Effectiveness of Suture-mediated Arterial Closure Device in Hepatocellular Carcinoma Patients Who Underwent Drug-Eluting Beads Transarterial Chemoembolization. Annals of Vascular Surgery, 2019, 55, 203-209.	0.4	1
4872	The Relationship Between Postoperative Chemotherapy and Remnant Liver Regeneration and Outcomes After Hepatectomy for Colorectal Liver Metastasis. Journal of Gastrointestinal Surgery, 2019, 23, 1973-1983.	0.9	4
4873	Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection. Breast Cancer, 2019, 26, 154-163.	1.3	11
4874	Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 387-402.	4.2	18
4875	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in realâ€world conditions: Multicenter analysis. Cancer Medicine, 2019, 8, 137-146.	1.3	112
4876	Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. European Radiology, 2019, 29, 2679-2689.	2.3	58
4877	Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using timeâ€dependent receiver operating characteristic. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1066-1073.	1.4	40
4878	Outcomes of pancreatoduodenectomy in the cirrhotic patient: risk stratification and meta-analysis. Hpb, 2019, 21, 301-309.	0.1	6

#	Article	IF	CITATIONS
4879	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Vâ€"Special Situations. Thrombosis and Haemostasis, 2019, 119, 014-038.	1.8	28
4880	Prediction of the varices needing treatment with nonâ€invasive tests in patients with compensated advanced chronic liver disease. Liver International, 2019, 39, 1071-1079.	1.9	33
4881	Cirrhosis., 2019,, 495-504.		0
4882	Efficacy and safety of partial splenic embolization for hypersplenism in pre- and post-liver transplant patients: A 16-year comparative analysis. Clinical Imaging, 2019, 54, 71-77.	0.8	9
4883	Conditional survival in patients with spontaneous tumor rupture of hepatocellular carcinoma after partial hepatectomy: a propensity score matching analysis. Hpb, 2019, 21, 722-730.	0.1	9
4884	Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy. British Journal of Biomedical Science, 2019, 76, 24-28.	1.2	16
4885	Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 576-584.	1.1	9
4886	Assessing liver function: diagnostic efficacy of parenchymal enhancement and liver volume ratio of Gd-EOB-DTPA-enhanced MRI study during interstitial and hepatobiliary phase. Abdominal Radiology, 2019, 44, 1340-1349.	1.0	9
4887	Treg/Th17 imbalance is associated with poor autoimmune hepatitis prognosis. Clinical Immunology, 2019, 198, 79-88.	1.4	10
4888	Hernia Management in Cirrhosis: Risk Assessment, Operative Approach, and Perioperative Care. Journal of Surgical Research, 2019, 235, 1-7.	0.8	3
4889	Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort. International Journal of Cancer, 2019, 144, 2823-2832.	2.3	61
4891	Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy. Metabolic Brain Disease, 2019, 34, 213-221.	1.4	5
4892	Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery. European Journal of Clinical Pharmacology, 2019, 75, 561-568.	0.8	6
4893	Liver and Gastrointestinal Physiology. , 2019, , 630-644.		0
4894	Development and validation of an imaging and clinical scoring system to predict early mortality in spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization. Abdominal Radiology, 2019, 44, 903-911.	1.0	7
4895	Child–Pugh Classification: Time to Abandon?. Seminars in Liver Disease, 2019, 39, 096-103.	1.8	49
4896	Symptom prevalence and quality of life of patients with end-stage liver disease: A systematic review and meta-analysis. Palliative Medicine, 2019, 33, 24-36.	1.3	157
4897	Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. European Journal of Clinical Pharmacology, 2019, 75, 217-226.	0.8	8

#	Article	IF	CITATIONS
4898	AGA Clinical Practice Update on Surgical Risk AssessmentÂand Perioperative Management in Cirrhosis: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 595-606.	2.4	79
4899	Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study. Drug Safety, 2019, 42, 539-546.	1.4	23
4900	Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlentherapie Und Onkologie, 2019, 195, 246-253.	1.0	17
4901	Recent advances in medical management of hepatocellular carcinoma. Hepatology Research, 2019, 49, 14-32.	1.8	53
4902	Prognosis of cirrhotic patients admitted to Emergency Departments: A multicenter study. American Journal of Emergency Medicine, 2019, 37, 1317-1321.	0.7	4
4903	Hernia repair in patients with chronic liver disease - A 15-year single-center experience. American Journal of Surgery, 2019, 217, 59-65.	0.9	11
4904	A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. Journal of Gastroenterology, 2019, 54, 367-376.	2.3	156
4905	Cortical networks are disturbed in people with cirrhosis even in the absence of neuropsychometric impairment. Clinical Neurophysiology, 2019, 130, 419-427.	0.7	2
4906	Volumetric and Functional Regeneration of Remnant Liver after Hepatectomy. Journal of Gastrointestinal Surgery, 2019, 23, 914-921.	0.9	20
4907	Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis. Liver International, 2019, 39, 371-381.	1.9	51
4908	Large Balloon Dilatation Versus Mechanical Lithotripsy After Endoscopic Sphincterotomy in the Management of Large Common Bile Duct Stones in Cirrhotic Patients. Journal of Clinical Gastroenterology, 2019, 53, e150-e156.	1.1	6
4909	Albumin-Indocyanine Green Evaluation Grading System Predicts Post-Hepatectomy Liver Failure for Biliary Tract Cancer. Digestive Surgery, 2019, 36, 13-19.	0.6	10
4910	Vitamin D non-sufficiency is prevalent in children with chronic liver disease in a tropical country. Pediatrics and Neonatology, 2019, 60, 12-18.	0.3	14
4911	Prognostic Factors and Survival Outcomes of Surgical Resection of Huge Hepatocellular Carcinomas. Journal of Gastrointestinal Cancer, 2020, 51, 250-253.	0.6	4
4912	Comparison of FIB-4 Index and Child-Pugh Score in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 823-831.	0.9	22
4913	The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. Clinical Pharmacology in Drug Development, 2020, 9, 162-174.	0.8	9
4914	Aortic valve replacement in patients with preexisting liver disease: Transfemoral approach with favorable survival. Catheterization and Cardiovascular Interventions, 2020, 95, 54-64.	0.7	6
4915	The tumor diameter cut-off for predicting microscopic intrahepatic metastasis of hepatocellular carcinoma patients without treatment history differs from that of hepatocellular carcinoma patients with a treatment history. Clinical and Translational Oncology, 2020, 22, 319-329.	1.2	3

#	Article	IF	Citations
4916	Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. Nephrology Dialysis Transplantation, 2020, 35, 1554-1561.	0.4	22
4917	Self-Management Behaviors Among Patients With Liver Cirrhosis in Shanghai, China: A Cross-Sectional Study. Clinical Nursing Research, 2020, 29, 448-459.	0.7	11
4918	Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. Journal of Hepatology, 2020, 72, 75-84.	1.8	105
4919	Management of liver failure in general intensive care unit. Anaesthesia, Critical Care & Damp; Pain Medicine, 2020, 39, 143-161.	0.6	26
4920	Impact of MELD score and cardiopulmonary bypass duration on post-operative hypoxic hepatitis in patients with liver cirrhosis undergoing open heart surgery. Journal of the Formosan Medical Association, 2020, 119, 838-844.	0.8	6
4921	A New Recalibrated Fourâ€Category Child–Pugh Score Performs Better than the Original Child–Pugh and MELD Scores in Predicting Inâ€Hospital Mortality in Decompensated Alcoholic Cirrhotic Patients with Acute Variceal Bleeding: a Realâ€World Cohort Analysis. World Journal of Surgery, 2020, 44, 241-246.	0.8	14
4922	Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series. Modern Rheumatology, 2020, 30, 1009-1015.	0.9	4
4923	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology, 2020, 72, 88-102.	3.6	76
4924	A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma. Surgery Today, 2020, 50, 369-378.	0.7	8
4925	Clinical application of Albumin-Bilirubin (ALBI) score: The current status. Journal of the Royal College of Surgeons of Edinburgh, 2020, 18, 178-186.	0.8	29
4926	The Management of Recurrence within Six Months after Hepatic Resection for Colorectal Liver Metastasis. Digestive Surgery, 2020, 37, 282-291.	0.6	8
4927	Evolution of diagnostic criteria for acute kidney injury in patients with decompensated cirrhosis: A prospective study in a tertiary university hospital. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 551-563.	0.7	8
4928	Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. Internal and Emergency Medicine, 2020, 15, 263-271.	1.0	23
4929	Circulating Resistin Is Associated with Plasma Glucagon-Like Peptide-1 in Cirrhotic Patients with Hepatitis C Virus Genotype-4 Infection. Endocrine Research, 2020, 45, 17-23.	0.6	4
4930	The Difficult Patient. , 2020, , 287-308.		0
4931	Diagnostic value of serum cytokeratinâ€18 in children with chronic liver disease. Journal of Paediatrics and Child Health, 2020, 56, 41-46.	0.4	2
4932	A Standardized Multimodal Analgesia Protocol Reduces Perioperative Opioid Use in Minimally Invasive Colorectal Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 2286-2294.	0.9	24
4933	Perioperative Evaluation and Management of Patients With Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions. Clinical Gastroenterology and Hepatology, 2020, 18, 2398-2414.e3.	2.4	53

#	Article	IF	CITATIONS
4934	Does Preoperative MELD Score Predict Adverse Outcomes Following Pancreatic Resection: an ACS NSQIP Analysis. Journal of Gastrointestinal Surgery, 2020, 24, 2259-2268.	0.9	12
4935	The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine. Clinical Pharmacology in Drug Development, 2020, 9, 639-650.	0.8	17
4936	Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment. Current Medical Research and Opinion, 2020, 36, 245-249.	0.9	13
4937	[18 F]â€Fluoroâ€2â€deoxy―D â€galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma. Liver International, 2020, 40, 447-455.	1.9	5
4938	Serum Bioavailable, Rather Than Total, 25â€hydroxyvitamin D Levels Are Associated With Hepatocellular Carcinoma Survival. Hepatology, 2020, 72, 169-182.	3.6	25
4939	Liver and Bile Duct Cancer. , 2020, , 1314-1341.e11.		8
4940	Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Nonâ€6mall Cell Lung Cancer. Clinical and Translational Science, 2020, 13, 41-46.	1.5	2
4941	Dietary total antioxidant capacity is positively associated with muscular strength in cirrhotic outpatients: a crossâ€sectional study. Journal of Human Nutrition and Dietetics, 2020, 33, 78-85.	1.3	3
4942	Aminopyrine breath test predicts liverâ€related events and death in HCVâ€related cirrhosis on SVR after DAA therapy. Liver International, 2020, 40, 530-538.	1.9	1
4943	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer, 2020, 9, 73-83.	4.2	37
4944	Sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2020, 1, CD011659.	1.5	9
4945	Child-Turcotte-Pugh Score, MELD Score and MELD-Na Score as Predictors of Short-Term Mortality among Patients with End-Stage Liver Disease in Northern India. Inflammatory Intestinal Diseases, 2020, 5, 1-10.	0.8	27
4946	The clinical significance of serum chitinase 3â€like 1 in hepatitis B–related chronic liver diseases. Journal of Clinical Laboratory Analysis, 2020, 34, e23200.	0.9	14
4947	Infection as a predictor of mortality in decompensated liver cirrhosis: exploring the relationship to severity of liver failure. European Journal of Gastroenterology and Hepatology, 2020, 32, 1458-1465.	0.8	5
4948	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematology,the, 2020, 7, e61-e72.	2.2	56
4949	Nutritional assessment, handgrip strength and adductor pollicis muscle thickness in patients with chronic viral hepatitis. Clinical Nutrition Experimental, 2020, 29, 49-61.	2.0	0
4950	The Relationship Between the Number of Ports and Surgical Outcomes in Laparoscopic Hepatectomy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2020, 30, 85-90.	0.4	1
4951	Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus. Hepatology Research, 2020, 50, 92-100.	1.8	13

#	ARTICLE	IF	CITATIONS
4952	Pre- and Peri-Operative Factors Associated with Chronic Critical Illness in Liver Transplant Recipients. Surgical Infections, 2020, 21, 246-254.	0.7	6
4953	Risk factors and prognostic analysis of acute-on-chronic liver failure of chronic hepatitis B after cessation of nucleos(t)ide analogs. European Journal of Gastroenterology and Hepatology, 2020, 32, 265-275.	0.8	4
4954	Apa1 (rs7975232) SNP in the vitamin D receptor is linked to hepatocellular carcinoma in hepatitis C virus cirrhosis. British Journal of Biomedical Science, 2020, 77, 53-57.	1.2	10
4955	Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 524-531.	0.7	5
4956	Prognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2020, 32, 769-778.	0.8	10
4957	A Comprehensive Review of Outcome Predictors in Low MELD Patients. Transplantation, 2020, 104, 242-250.	0.5	19
4958	Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 45-57.	1.5	24
4959	Assessing nutritional status in a cohort of liver cirrhosis outpatients: A prospective cross-sectional study. Nutrition and Health, 2020, 26, 19-25.	0.6	9
4960	Liver stiffness measurement predicts longâ€ŧerm survival and complications in nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 581-589.	1.9	75
4961	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2020, 38, 193-202.	0.8	1,255
4962	Crosstalk between miRâ€215 and epithelialâ€mesenchymal transition specific markers (Eâ€cadherin and) Tj ETQq 1231-1238.	0 0 0 rgBT 2.5	
4963	Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients. British Journal of Clinical Pharmacology, 2020, 86, 763-770.	1.1	2
4964	Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma. JAMA Oncology, 2020, 6, 255.	3.4	120
4965	Safety of variceal band ligation in patients with cirrhosis and portal vein thrombosis treated with anticoagulant therapy: A retrospective study. European Journal of Gastroenterology and Hepatology, 2020, 32, 395-400.	0.8	10
4966	Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 748-753.	0.8	19
4967	Acute-on-Chronic Liver Failure in Budd–Chiari Syndrome: Profile and Predictors of Outcome. Digestive Diseases and Sciences, 2020, 65, 2719-2729.	1.1	14
4968	Infection deteriorating hepatitis B virus related acute-on-chronic liver failure: a retrospective cohort study. BMC Gastroenterology, 2020, 20, 320.	0.8	8
4969	<p>Serum Lactate Level Predicts Short-Term and Long-Term Mortality of HBV-ACLF Patients: A Prospective Study</p> . Therapeutics and Clinical Risk Management, 2020, Volume 16, 849-860.	0.9	7

#	Article	IF	CITATIONS
4970	Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study. BMJ Open, 2020, 10, e038194.	0.8	10
4971	Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres. Journal of Gastrointestinal Oncology, 2020, 11, 715-723.	0.6	3
4972	The Impact of Hypoxic Hepatitis on Clinical Outcomes after Extracorporeal Cardiopulmonary Resuscitation. Journal of Clinical Medicine, 2020, 9, 2994.	1.0	5
4973	Phase Angle Is an Independent Predictor of 6â€Month Mortality in Patients With Decompensated Cirrhosis: A Prospective Cohort Study. Nutrition in Clinical Practice, 2020, 35, 1061-1069.	1.1	16
4974	Lights off, camera on! Laparoscopic cholecystectomy improves outcomes in cirrhotic patients with acute cholecystitis. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, , .	1.4	4
4975	Prognostic value of DCTA scoring system in heart failure. Herz, 2021, 46, 243-252.	0.4	2
4976	A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101534.	0.7	19
4977	Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. European Journal of Gastroenterology and Hepatology, 2020, 32, 1046-1053.	0.8	0
4978	Correlation of Serum Cardiac Markers with Acute Decompensating Events in Liver Cirrhosis. Gastroenterology Research and Practice, 2020, 2020, 1-15.	0.7	3
4979	QT interval abnormalities and heart rate variability in patients with cirrhosis. Arab Journal of Gastroenterology, 2020, 21, 246-252.	0.4	2
4980	Clinical implications of thoracic duct dilatation in patients with chronic liver disease. Medicine (United States), 2020, 99, e19889.	0.4	4
4981	Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. Archives of Physiology and Biochemistry, 2023, 129, 373-378.	1.0	4
4982	Diverticulitis: An update from the age old Paradigm. Current Problems in Surgery, 2020, 57, 100863.	0.6	20
4983	Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study. Scientific Reports, 2020, 10, 16093.	1.6	30
4984	Comparison of conventional scoring systems versus MAGIC score to predict short-term mortality in patients hospitalized for alcoholic hepatitis. Scandinavian Journal of Gastroenterology, 2020, 55, 1318-1323.	0.6	0
4985	Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acuteâ€onâ€chronic liver failure. Alimentary Pharmacology and Therapeutics, 2020, 52, 855-865.	1.9	28
4986	Diverticulitis: An Update From the Age Old Paradigm. Current Problems in Surgery, 2020, 57, 100862.	0.6	56
4987	Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. Journal of Viral Hepatitis, 2020, 27, 671-679.	1.0	41

#	Article	IF	CITATIONS
4988	Mean Platelet Volume/Lymphocyte Ratio as a Prognostic Indicator for HBV-Related Decompensated Cirrhosis. Gastroenterology Research and Practice, 2020, 2020, 1-7.	0.7	7
4989	Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. Journal of the Formosan Medical Association, 2020, 119, 1483-1489.	0.8	7
4990	Liver resection in Cirrhotic liver: Are there any limits?. International Journal of Surgery, 2020, 82, 109-114.	1.1	17
4991	Selfâ€management programmes for cirrhosis: A systematic review. Journal of Clinical Nursing, 2020, 29, 3625-3637.	1.4	6
4992	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	1.7	47
4993	Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis. Clinical and Translational Gastroenterology, 2020, 11, e00189.	1.3	5
4994	Pituitary adenylate cyclaseâ€activating peptide: Potential roles in the pathophysiology and complications of cirrhosis. Liver International, 2020, 40, 2578-2589.	1.9	2
4995	A prediction model for outcome in patients with HBV-ACLF based on predisposition, injury, response and organ failure. Scientific Reports, 2020, 10, 20176.	1.6	7
4996	Clinical Characterization of Ulcerative Colitis in Patients with Primary Sclerosing Cholangitis. Gastroenterology Research and Practice, 2020, 2020, 1-8.	0.7	5
4997	Role of EEG in Predicting Outcome of Hepatic Encephalopathy Patients. Neurodiagnostic Journal,the, 2020, 60, 272-288.	0.1	7
4998	Clinical significance of serum human epididymis protein 4 in liver fibrosis. Medicine (United States), 2020, 99, e23428.	0.4	3
4999	Pharmacokinetics and safety of evogliptin in hepatically impaired patients. British Journal of Clinical Pharmacology, 2020, 87, 2757-2766.	1.1	2
5000	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1812-1819.	1.4	28
5001	Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphereâ,,¢). Hpb, 2020, 22, 1330-1338.	0.1	5
5002	The technique of 3D reconstruction combining with biochemistry to build an equivalent formula of indocyanine green (ICG) clearance test to assess the liver reserve function. BMC Surgery, 2020, 20, 283.	0.6	13
5003	Gadoxetate disodium-enhanced MRI: Assessment of arterial phase artifacts and hepatobiliary uptake in a large series. European Journal of Radiology, 2020, 132, 109313.	1.2	6
5004	High-density lipoprotein cholesterol is a predictor of survival in cirrhotic patients with acute gastrointestinal bleeding: a retrospective study. BMC Gastroenterology, 2020, 20, 381.	0.8	8
5005	Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. Cancers, 2020, 12, 2146.	1.7	23

#	ARTICLE	IF	Citations
5006	Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment. Journal of Chemotherapy, 2020, 32, 420-428.	0.7	5
5007	Value of Liver Regeneration in Predicting Short-Term Prognosis for Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure. BioMed Research International, 2020, 2020, 1-7.	0.9	8
5008	Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis. Clinical and Translational Gastroenterology, 2020, 11, e00211.	1.3	15
5009	Artificial neural network model for preoperative prediction of severeÂliver failure after hemihepatectomy in patients with hepatocellular carcinoma. Surgery, 2020, 168, 643-652.	1.0	30
5010	Impact of Glutathione and Vitamin B-6 in Cirrhosis Patients: A Randomized Controlled Trial and Follow-Up Study. Nutrients, 2020, 12, 1978.	1.7	5
5011	Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites?. Scandinavian Journal of Gastroenterology, 2020, 55, 951-957.	0.6	15
5012	Clinical significance of serum miR-768-3p in HBV-related hepatocellular carcinoma and its potential mechanism. Clinical and Experimental Medicine, 2020, 20, 569-576.	1.9	7
5013	Prevalence of RLS among subjects with chronic liver disease and its effect on sleep and mood. Sleep Medicine, 2020, 73, 144-152.	0.8	8
5014	Laparoscopic Liver Surgery: What Are the Advantages in Patients with Cirrhosis and Portal Hypertension? Systematic Review and Meta-Analysis with Personal Experience. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 1054-1065.	0.5	16
5015	The trials and tribulations of liver allocation. Transplant International, 2020, 33, 1343-1352.	0.8	11
5016	Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Reports, 2020, 2, 100151.	2.6	26
5017	LIRER score – a valuable tool to predict medium-long-term outcomes in hepatic cirrhosis decompensation. Scandinavian Journal of Gastroenterology, 2020, 55, 1079-1086.	0.6	1
5018	Validation of a new prognostic model to predict short and medium-term survival in patients with liver cirrhosis. BMC Gastroenterology, 2020, 20, 265.	0.8	4
5019	Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma. Applied Sciences (Switzerland), 2020, 10, 7178.	1.3	2
5020	Plateletâ€toâ€white blood cell ratio: A novel and promising prognostic marker for HBVâ€associated decompensated cirrhosis. Journal of Clinical Laboratory Analysis, 2020, 34, e23556.	0.9	11
5021	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	0.8	313
5022	The albumin–bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. Scientific Reports, 2020, 10, 17812.	1.6	10
5023	Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis. The Cochrane Library, 2020, 2020, CD000553.	1.5	3

#	Article	IF	CITATIONS
5024	Predicting mortality for hepatorenal syndrome with liverâ€specific scores. GastroHep, 2020, 2, 336-343.	0.3	7
5025	Mapping nursing interventions using the Therapeutic Intervention Scoring System in bloodless liver transplantations. Intensive and Critical Care Nursing, 2020, 61, 102917.	1.4	1
5026	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. Open Forum Infectious Diseases, 2020, 7, ofaa453.	0.4	7
5027	Liverâ€specific scores as predictors of mortality in spontaneous bacterial peritonitis. GastroHep, 2020, 2, 224-231.	0.3	8
5028	Short―and mediumâ€ŧerm prognosis of HIVâ€infected patients receiving intensive care: a Brazilian multicentre prospective cohort study. HIV Medicine, 2020, 21, 650-658.	1.0	3
5029	The Prognosis Analysis of Liver Cirrhosis with Acute Variceal Bleeding and Validation of Current Prognostic Models: A Large Scale Retrospective Cohort Study. BioMed Research International, 2020, 2020, 1-7.	0.9	8
5030	Health related quality of life in chronic liver diseases. Liver International, 2020, 40, 2630-2642.	1.9	15
5031	Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound—Toward Improved Detection of Liver Impairment. Clinical and Translational Gastroenterology, 2020, 11, e00239.	1.3	34
5032	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatology Research, 2020, 50, 1375-1385.	1.8	22
5033	Small intestinal dysmotility in cirrhotic patients: correlation with severity of liver disease and cirrhosis-associated complications. Zeitschrift Fur Gastroenterologie, 2021, 59, 540-550.	0.2	1
5034	HepatoScoreâ€14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology, 2021, 73, 2278-2292.	3.6	10
5035	Novel Calculators for Risk Stratification in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2020, 54, 789-794.	1.1	1
5036	Acquired hepatocerebral degeneration and hepatic encephalopathy: one or two entities?. European Journal of Neurology, 2020, 27, 2396-2404.	1.7	6
5037	An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	7
5038	Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization. Hepatology Research, 2020, 50, 1244-1254.	1.8	18
5039	A novel predictive score for citrate accumulation among patients receiving artificial liver support system therapy with regional citrate anticoagulation. Scientific Reports, 2020, 10, 12861.	1.6	7
5040	Hospital-Acquired Versus Community-Acquired Acute Kidney Injury in Patients With Cirrhosis: A Prospective Study. American Journal of Gastroenterology, 2020, 115, 1505-1512.	0.2	12
5041	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infectious Diseases and Therapy, 2020, 9, 851-866.	1.8	16

#	Article	IF	CITATIONS
5042	Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (United States), 2020, 99, e21387.	0.4	3
5043	Developing a selection-aided model to screen Cirrhotic Intrahepatic Cholangiocarcinoma for Hepatectomy. Journal of Cancer, 2020, 11, 5623-5634.	1.2	3
5044	Organ System Network Disruption Is Associated With Poor Prognosis in Patients With Chronic Liver Failure. Frontiers in Physiology, 2020, 11, 983.	1.3	10
5045	<p>Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes</p> . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 107-116.	1.8	10
5046	Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor. Drug Research, 2020, 70, 401-409.	0.7	2
5047	Super-Resolution Microscopy Reveals an Altered Fibrin Network in Cirrhosis: The Key Role of Oxidative Stress in Fibrinogen Structural Modifications. Antioxidants, 2020, 9, 737.	2.2	9
5048	The Spectrum of Disease Severity in Cirrhosis and Its Implications for Hemostasis. Seminars in Thrombosis and Hemostasis, 2020, 46, 716-723.	1.5	9
5049	Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?. BMJ Open Gastroenterology, 2020, 7, e000533.	1.1	3
5050	Prognostic Performance of Albumin–Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Frontiers in Oncology, 2020, 10, 525461.	1.3	15
5051	Efficacy and safety of laparoscopic hepatectomy for hepatocellular carcinoma comorbid with cirrhosis. Przeglad Gastroenterologiczny, 2020, 15, 225-233.	0.3	5
5052	Band ligation versus sclerotherapy for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2021, 2021, CD011803.	1.5	7
5053	Temporal bone carcinoma: testing the prognostic value of a novel clinical and histological scoring system. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4179-4186.	0.8	5
5054	Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma. Liver Research, 2020, 4, 199-205.	0.5	7
5055	Socioeconomic and marital status among liver cirrhosis patients and associations with mortality: a population-based cohort study in Sweden. BMC Public Health, 2020, 20, 1820.	1.2	12
5056	<p>Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients</p> . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 219-232.	1.8	23
5057	Can We Add the History of the Nonoperative Therapy of Varices to Other Success Chapters of Modern Medicine?. Clinical Liver Disease, 2020, 16, 73-82.	1.0	2
5058	Laparoscopic versus open right posterior sectionectomy: an international, multicenter, propensity score-matched evaluation. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 6139-6149.	1.3	16
5059	Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer, 2020, 9, 518-528.	4.2	22

#	Article	IF	CITATIONS
5060	Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 756-770.	4.2	50
5061	Potential role ofÂintestinal microfloraÂin disease progression among patients with different stages of Hepatitis B. Gut Pathogens, 2020, 12, 50.	1.6	23
5063	Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 537-537.	0.7	11
5064	<p>Indocyanine Green Clearance Test for the Preoperative Assessment of Chemotherapy-Related Hepatic Injury in Patients with Colorectal Liver Metastasis</p> . Cancer Management and Research, 2020, Volume 12, 3237-3245.	0.9	5
5065	Usefulness of Circulating Methylated p16 as a Noninvasive Molecular Biomarker for Hepatitis C-Related Hepatocellular Carcinoma with Normal Serum Alpha-Fetoprotein Levels. International Journal of General Medicine, 2020, Volume 13, 147-155.	0.8	2
5066	Acute upper gastrointestinal bleeding: A review. Surgery in Practice and Science, 2020, 1, 100004.	0.2	4
5067	Robotic Liver Resections: Application of Difficulty Score Systems to an Initial Experience. Is a Specific Robotic Difficulty Score Necessary?. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 1177-1182.	0.5	3
5068	Basic principles of liver allocation and development over the years. Current Opinion in Organ Transplantation, 2020, 25, 99-103.	0.8	4
5069	Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy. Infectious Agents and Cancer, 2020, 15, 35.	1.2	5
5070	Predictive value of gadoxetic acid enhanced magnetic resonance imaging for posthepatectomy liver failure after a major hepatectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 531-540.	1.4	11
5071	Liver fibrosis is a major risk factor for liver regeneration. Medicine (United States), 2020, 99, e20003.	0.4	12
5072	Changes in thyroid function in patients with liver failure and their clinical significance: A clinical study of non-thyroidal illness syndrome in patients with liver failure. Hepatobiliary and Pancreatic Diseases International, 2020, 19, 561-566.	0.6	6
5073	Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Annals of Translational Medicine, 2020, 8, 553-553.	0.7	37
5074	Features of Blood Clotting on Thromboelastography in Hospitalized Patients With Cirrhosis. American Journal of Medicine, 2020, 133, 1479-1487.e2.	0.6	11
5076	Realâ€world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitorâ€based therapies. Journal of Viral Hepatitis, 2020, 27, 1190-1201.	1.0	2
5077	A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer, 2020, 20, 504.	1.1	17
5078	Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. Journal of Clinical Gastroenterology, 2020, 54, 503-511.	1.1	10
5079	Realâ€world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Alimentary Pharmacology and Therapeutics, 2020, 52, 351-358.	1.9	30

#	Article	IF	CITATIONS
5080	Revisiting the indications for liver transplantation in cirrhotic patients considering the longâ€term outcomes of cirrhotic patients. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 655-662.	1.4	4
5081	Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life. Anti-Cancer Drugs, 2020, 31, 523-527.	0.7	6
5082	The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Review of Gastroenterology and Hepatology, 2020, 14, 619-629.	1.4	7
5083	Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices. Medicine (United States), 2020, 99, e20721.	0.4	4
5084	Risk Stratification Strategies for Colorectal Cancer Screening. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 423-440.	0.6	2
5085	The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center. BioMed Research International, 2020, 2020, 1-9.	0.9	15
5086	Assessing the Prognostic Performance of the Child-Pugh, Model for End-Stage Liver Disease, and Albumin-Bilirubin Scores in Patients with Decompensated Cirrhosis: A Large Asian Cohort from Gastroenterology Department. Disease Markers, 2020, 2020, 1-9.	0.6	26
5087	Influence of Preformed Antibodies in Liver Transplantation. Journal of Clinical Medicine, 2020, 9, 708.	1.0	19
5088	Non-Alcoholic Cirrhosis and Heart Rate Variability: A Systematic Mini-Review. Medicina (Lithuania), 2020, 56, 116.	0.8	5
5089	Recommendations for Preoperative Assessment and Shared Decision-Making in Cardiac Surgery. Current Anesthesiology Reports, 2020, 10, 185-195.	0.9	23
5090	Natural Language Processing for Mimicking Clinical Trial Recruitment in Critical Care: AÂSemi-Automated Simulation Based on the LeoPARDS Trial. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 2950-2959.	3.9	28
5091	The Surgical Treatment of Portal Hypertension. Clinical Liver Disease, 2020, 15, S52-S63.	1.0	5
5092	Prognosis of Hepatic Encephalopathy. Clinics in Liver Disease, 2020, 24, 219-229.	1.0	12
5093	Effectiveness Analysis of the Immunization Against Hepatitis B in Liver Transplantation Patients. Transplantation Proceedings, 2020, 52, 1365-1369.	0.3	0
5094	Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway. PLoS ONE, 2020, 15, e0230263.	1.1	11
5095	Lymphocyte-To-Monocyte Ratio as the Best Simple Predictor of Bacterial Infection in Patients with Liver Cirrhosis. International Journal of Environmental Research and Public Health, 2020, 17, 1727.	1.2	33
5096	Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes. Cancer Immunology, Immunotherapy, 2020, 69, 1253-1263.	2.0	11
5097	Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis. Journal of Clinical Medicine, 2020, 9, 643.	1.0	2

#	Article	IF	CITATIONS
5098	Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2020, 3, CD011573.	1.5	8
5099	Acute gastroinstinal bleeding: a review. International Journal of Surgery Global Health, 2020, 3, e18-e18.	0.2	2
5100	Hepatic uptake index in the hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine penta acetic acid–enhanced magnetic resonance imaging estimates functional liver reserve and predicts post-hepatectomy liver failure. Surgery, 2020, 168, 419-425.	1.0	10
5101	Significance of Amylase Monitoring in Peritoneal Drainage Fluid after Splenectomy: A Clinical Analysis of Splenectomy in 167 Patients with Hepatolenticular Degeneration. American Surgeon, 2020, 86, 334-340.	0.4	4
5102	Palliative Care and Hospice Referrals in Patients with Decompensated Cirrhosis: What Factors Are Important?. Journal of Palliative Medicine, 2020, 23, 1066-1075.	0.6	21
5103	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. Oncology, 2020, 98, 295-302.	0.9	24
5104	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1033-1050.	1.2	14
5105	Calculated body muscle mass as a useful screening marker for low skeletal muscle mass and sarcopenia in chronic liver disease. Hepatology Research, 2020, 50, 704-714.	1.8	8
5106	Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Critical Care, 2020, 24, 55.	2.5	34
5107	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. Journal of Hepatology, 2020, 73, 113-120.	1.8	58
5108	Model for Endâ€Stage Liver Diseaseâ€Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. Hepatology, 2020, 72, 1747-1757.	3.6	42
5109	Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Drugs - Real World Outcomes, 2020, 7, 141-149.	0.7	33
5110	C C motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells. Hepatobiliary and Pancreatic Diseases International, 2020, 19, 440-448.	0.6	9
5112	Lower Gastrointestinal Bleeding in Patients With Cirrhosis—Etiology and Outcomes. American Journal of the Medical Sciences, 2020, 359, 206-211.	0.4	5
5113	Precision medicine in variceal bleeding: Are we there yet?. Journal of Hepatology, 2020, 72, 774-784.	1.8	47
5114	Red blood cell distribution width: A promising index for evaluating the severity and long-term prognosis of hepatitis B virus–related diseases. Digestive and Liver Disease, 2020, 52, 440-446.	0.4	17
5115	A population-based cohort study of mortality of intensive care unit patients with liver cirrhosis. BMC Gastroenterology, 2020, 20, 15.	0.8	11
5116	Changes in hepatic fibrosis stages after achieving SVR following directâ€acting antiâ€viral treatment: a prospective study. GastroHep, 2020, 2, 39-48.	0.3	8

#	Article	IF	CITATIONS
5117	Gadobenate dimeglumineâ€enhanced magnetic resonance imaging can accurately predict the severity of esophageal varices and portal vein pressure in patients with hepatitis B cirrhosis. Journal of Digestive Diseases, 2020, 21, 104-111.	0.7	4
5118	Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial. Phytotherapy Research, 2020, 34, 1446-1454.	2.8	32
5119	Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents. Gastrointestinal Tumors, 2020, 7, 50-60.	0.3	12
5120	A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. Journal of Hepatology, 2020, 73, 855-862.	1.8	67
5121	ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. Expert Review of Gastroenterology and Hepatology, 2020, 14, 383-400.	1.4	29
5122	Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer, 2020, 9, 275-292.	4.2	34
5123	The association between vitamin D-related gene polymorphisms and hepatitis B virus-related liver cirrhosis. Journal of International Medical Research, 2020, 48, 030006052091090.	0.4	3
5124	Combination with portosystemic shunt occlusion and antiviral therapy improves prognosis of decompensated cirrhosis. JGH Open, 2020, 4, 670-676.	0.7	1
5125	Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma. Journal of International Medical Research, 2020, 48, 030006052090876.	0.4	3
5126	Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Advances in Therapy, 2020, 37, 1910-1932.	1.3	40
5127	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients With Child-Pugh B or C Cirrhosis. Advances in Radiation Oncology, 2020, 5, 889-896.	0.6	11
5128	Histological changes, lipid metabolism, and oxidative and endoplasmic reticulum stress in the liver of laying hens exposed to cadmium concentrations. Poultry Science, 2020, 99, 3215-3228.	1.5	32
5129	Severe hyperbilirubinemia is associated with higher risk of contrast-related acute kidney injury following contrast-enhanced computed tomography. PLoS ONE, 2020, 15, e0231264.	1.1	15
5130	The risk of vancomycin toxicity in patients with liver impairment. Annals of Clinical Microbiology and Antimicrobials, 2020, 19, 13.	1.7	8
5131	Influence of gastroesophageal flap valve on esophageal variceal bleeding in patients with liver cirrhosis. Digestive Endoscopy, 2021, 33, 100-109.	1.3	4
5132	Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 688-697.	0.9	10
5133	Laparoscopic repeat hepatectomy is a more favorable treatment than open repeat hepatectomy for contralateral recurrent hepatocellular carcinoma cases. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 2896-2906.	1.3	14
5134	Surgical resection of early stage hepatocellular carcinoma: balancing tumor biology with the host liver. Chinese Clinical Oncology, 2021, 10, 5-5.	0.4	4

#	Article	IF	CITATIONS
5135	CLIF-OF >9 predicts poor outcome in patients with Amanita phalloides poisoning. American Journal of Emergency Medicine, 2021, 39, 96-101.	0.7	4
5136	A novel model for predicting posthepatectomy liver failure based on liver function and degree of liver resection in patients with hepatocellular carcinoma. Hpb, 2021, 23, 134-143.	0.1	10
5137	Alcohol use disorder and the liver. Addiction, 2021, 116, 1270-1278.	1.7	35
5138	Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease. International Journal of Radiation Oncology Biology Physics, 2021, 109, 212-219.	0.4	20
5139	Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 167-180.	8.2	97
5140	Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy. Hepatology Research, 2021, 51, 662-673.	1.8	21
5141	Preoperative Remnant Liver Function Evaluation Using a Routine Clinical Dynamic Gd-EOB-DTPA-Enhanced MRI Protocol in Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 3672-3682.	0.7	15
5142	Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Advances in Cancer Research, 2021, 149, 1-61.	1.9	330
5143	Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment. Journal of Clinical Pharmacology, 2021, 61, 493-505.	1.0	6
5144	Selection of Patients With Cirrhosis For Surgery: As Much An Art As Science. Hepatology, 2021, 73, 7-9.	3.6	2
5145	New anthropometric and biochemical models for estimating appendicular skeletal muscle mass in male patients with cirrhosis. Nutrition, 2021, 84, 111083.	1.1	4
5146	Utility of viscoelastic coagulation testing in liver surgery: a systematic review. Hpb, 2021, 23, 331-343.	0.1	14
5147	Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study. Annals of Hepatology, 2021, 22, 100294.	0.6	6
5148	Characterization of the Gastric Mucosal Microbiota in Patients with Liver Cirrhosis and Its Associations with Gastrointestinal Symptoms. Engineering, 2021, 7, 507-514.	3.2	0
5149	Electronic Medication Management System Introduction and Deprescribing Practice in Post-Acute Care. Journal of the American Medical Directors Association, 2021, 22, 90-95.	1.2	4
5150	Paraphenylenediamine and related chemicals as allergens responsible for allergic contact dermatitis. Archives of Medical Science, 2021, 17, 714-723.	0.4	11
5151	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. Gastroenterology Report, 2021, 9, 133-138.	0.6	21
5152	Calf and arm circumference as simple markers for screening sarcopenia in patients with chronic liver disease. Hepatology Research, 2021, 51, 176-189.	1.8	21

#	Article	IF	CITATIONS
5153	The Effects of Allogeneic Blood Transfusion in Hepatic Resection. American Surgeon, 2021, 87, 228-234.	0.4	7
5154	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	1.8	38
5155	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. Journal of Hepatology, 2021, 74, 200-219.	1.8	16
5156	Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. Journal of the National Cancer Institute, 2021, 113, 123-136.	3.0	28
5157	Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). European Radiology, 2021, 31, 1630-1641.	2.3	8
5158	Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease. Digestive Diseases, 2021, 39, 247-257.	0.8	11
5159	Pretransplant ascites or encephalopathy and their influence on survival and liver graft rejection in alcoholic cirrhosis disease. Archives of Medical Science, 2021, 17, 682-693.	0.4	6
5160	New prognostic score based on galectin-3 has similar performance to model for end-stage liver disease and sodium score in patients with stable decompensated cirrhosis. Annals of Gastroenterology, 2021, 34, 728-735.	0.4	1
5161	Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2021, 2021, CD011561.	1.5	7
5162	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. Oncology, 2021, 99, 518-527.	0.9	5
5163	Hematological alterations in hepatic cirrhosis – a challenge in clinical practice. Oncolog-Hematolog Ro, 2021, 1, 36.	0.0	0
5164	Predictive factors of failure to control bleeding and 6-week mortality after variceal hemorrhage in liver cirrhosis – a tertiary referral center experience. Archives of Medical Science, 2021, 18, 52-61.	0.4	0
5165	Postoperative Mortality in Patients With Cirrhosis: Reconsidering Expectations. American Surgeon, 2022, 88, 181-186.	0.4	1
5166	Autoimmune Sclerosing Cholangitis in Children: A Prospective Case-Control Study. Pediatric Gastroenterology, Hepatology and Nutrition, 2021, 24, 154.	0.4	3
5167	TNFR1 and the TNF $\hat{l}\pm$ axis as a targetable mediator of liver injury from stereotactic body radiation therapy. Translational Oncology, 2021, 14, 100950.	1.7	14
5168	Assessment and Research Progress of Liver Reserve Function before Hepatectomy. Advances in Clinical Medicine, 2021, 11, 4127-4134.	0.0	0
5169	Model for end stage liver disease for prediction of mortality in people with cirrhosis. The Cochrane Library, 0, , .	1.5	0
5170	A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system. Scientific Reports, 2021, 11, 1469.	1.6	8

#	Article	IF	CITATIONS
5171	The correlation between the autotaxin enzyme and pruritus in Egyptian patients suffering from chronic liver disease. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2021, 20, 302-307.	1.1	0
5172	Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis. Hepatology International, 2021, 15, 93-104.	1.9	28
5173	Fibrosis and hepatic regeneration mechanism. Translational Gastroenterology and Hepatology, 2022, 7, 9-9.	1.5	8
5174	The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction. Global Heart, 2021, 16, 3.	0.9	1
5175	Surgical resection of early stage hepatocellular carcinoma improves patient survival at safety net hospitals. Journal of Surgical Oncology, 2021, 123, 963-969.	0.8	6
5176	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. Liver Cancer, 2021, 10, 115-125.	4.2	12
5177	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. Journal of Gastroenterology, 2021, 56, 261-273.	2.3	28
5178	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer, 2021, 10, 126-136.	4.2	6
5179	Association of Circulatory Long Non-Coding RNA AFAP1-AS1 with Risk and Progression of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection. The Egyptian Journal of Hospital Medicine, 2021, 82, 416-425.	0.0	0
5180	Identifying Mild Hepatic Encephalopathy Based on Multi-Layer Modular Algorithm and Machine Learning. Frontiers in Neuroscience, 2020, 14, 627062.	1.4	9
5181	An Ensemble Learning Approach for Enhanced Classification of Patients With Hepatitis and Cirrhosis. IEEE Access, 2021, 9, 24485-24498.	2.6	28
5182	A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators. Scientific Reports, 2021, 11, 1810.	1.6	16
5183	Does gallbladder wall thickness measurement predict esophageal varices in cirrhotic patients with portal hypertension?. European Journal of Gastroenterology and Hepatology, 2021, 33, 917-925.	0.8	9
5184	Gut–liver–brain axis in chronic liver disease with a focus on hepatic encephalopathy. , 2021, , 159-185.		1
5185	Clinical Microbiology: An Overview., 2021,, 91-93.		0
5186	Vitamin D receptor gene polymorphisms and risk of hepatocellular carcinoma in hepatitis C-related liver cirrhosis. Egyptian Liver Journal, 2021, 11 , .	0.3	3
5187	Physiotherapy in palliative medicine: patient and caregiver wellness. BMJ Supportive and Palliative Care, 2023, 13, e197-e204.	0.8	3
5188	Renal arterial resistance index among subjects with liver cirrhosis in a Nigerian population. Journal of Clinical Ultrasound, 2021, 49, 538-545.	0.4	2

#	Article	IF	Citations
5189	Perspective: A Framework to Screen Pediatric and Adolescent Hematopoietic Cellular Therapy Patients for Organ Dysfunction: Time for a Multi-Disciplinary and Longitudinal Approach. Frontiers in Oncology, 2021, 11, 622630.	1.3	2
5190	Dynamically remodeled hepatic extracellular matrix predicts prognosis of early-stage cirrhosis. Cell Death and Disease, 2021, 12, 163.	2.7	22
5191	Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C. Sovremennye Tehnologii V Medicine, 2021, 13, 27.	0.4	7
5192	Utility of Abdominal Drain in Gastrectomy (ADiGe) Trial: study protocol for a multicenter non-inferiority randomized trial. Trials, 2021, 22, 152.	0.7	5
5193	Changes in patient background and prognosis after hepatectomy for hepatocellular carcinoma by hepatitis virus infection status: New trends in Japan. Annals of Gastroenterological Surgery, 2021, 5, 553-566.	1.2	6
5194	Child-Turcotte-Pugh and Model for End-Stage Liver Disease Scores: Accuracy of Predictability for Mortality in Acute Variceal Hemorrhage. Life and Science, 2021, 2, 8.	0.1	0
5195	Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience. Journal of Clinical Medicine, 2021, 10, 785.	1.0	6
5196	Malnutrition in Patients with Liver Cirrhosis. Nutrients, 2021, 13, 540.	1.7	57
5197	Hospice care for end stage liver disease in the United States. Expert Review of Gastroenterology and Hepatology, 2021, 15, 797-809.	1.4	4
5198	A closer look at quality of life in the hepatocellular carcinoma literature. Quality of Life Research, 2021, 30, 1525-1535.	1.5	7
5199	Anatomical resection is useful for the treatment of primary solitary hepatocellular carcinoma with predicted microscopic vessel invasion and/or intrahepatic metastasis. Surgery Today, 2021, 51, 1429-1439.	0.7	7
5200	Multimodal treatment strategies for colorectal liver metastases. Swiss Medical Weekly, 2021, 151, w20390.	0.8	9
5201	Exaggerated Microvascular Vasodilating Responses in Cirrhotic Patients With Septic Shock*. Critical Care Medicine, 2021, 49, e404-e411.	0.4	4
5202	Performance of albumin-bilirubin score in prediction of hepatic encephalopathy in cirrhotic patients with acute variceal bleeding. Egyptian Liver Journal, $2021,11,1$	0.3	2
5203	The prognostic value of P-wave dispersion and left atrial functions assessed with three-dimensional echocardiography in patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 1441-1450.	0.8	3
5204	Quality of life in primary sclerosing cholangitis: a systematic review. Health and Quality of Life Outcomes, 2021, 19, 100.	1.0	3
5205	Evaluating the Correlation of Hemostatic and Endocrine Parameters with Child-Turcotte-Pugh Scoring in Patients with Non-Alcoholic Liver Cirrhosis. Disease and Diagnosis, 2021, 10, 29-35.	0.1	0
5206	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	1.7	18

#	Article	IF	CITATIONS
5207	Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. GastroenterologÃa Y HepatologÃa, 2022, 45, 25-39.	0.2	10
5208	Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. Breast Cancer Research, 2021, 23, 33.	2.2	3
5209	Evaluation Transplantation of Bone-Derived Mesenchymal Stem Cell in the Patients with Hepatitis C-Related Liver Cirrhosis (Pi lot Study). Russian Archives of Internal Medicine, 2021, 11, 132-145.	0.0	0
5210	Prediction of Post-hepatectomy Liver Failure in Patients With Hepatocellular Carcinoma Based on Radiomics Using Gd-EOB-DTPA-Enhanced MRI: The Liver Failure Model. Frontiers in Oncology, 2021, 11, 605296.	1.3	17
5211	Patterns of dendritic cell and monocyte subsets are associated with disease severity and mortality in liver cirrhosis patients. Scientific Reports, 2021, 11, 5923.	1.6	19
5212	Effectiveness of Albumin-bilirubin Score as a Predictor of Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 77, 115-122.	0.2	6
5213	Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging. Abdominal Radiology, 2021, 46, 3995-4001.	1.0	2
5214	A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir. Case Reports in Gastroenterology, 2021, 15, 436-442.	0.3	0
5215	Prevalence and risk factors of endoscopically confirmed gastroesophageal reflux disease (GERD) in patients with liver cirrhosis. Egyptian Liver Journal, $2021,11,1$	0.3	0
5216	Clinical characteristics and surgical treatments of primary hepatic angiosarcoma. BMC Gastroenterology, 2021, 21, 156.	0.8	8
5217	Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure. European Journal of Gastroenterology and Hepatology, 2021, 33, 1023-1028.	0.8	2
5218	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers, 2021, 13, 1673.	1.7	21
5219	Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Cancer Chemotherapy and Pharmacology, 2021, 88, 259-270.	1.1	11
5220	Direct-acting Antiviral Therapy Improves the Outcome of Chronic Hepatitis C/intermediate-stage B Hepatocellular Carcinoma Patients. Anticancer Research, 2021, 41, 2007-2016.	0.5	4
5221	Pancreaticoduodenectomy combined with splenectomy for a patient with pancreatic cancer and pancytopenia due to liver cirrhosis: Case report. International Journal of Surgery Case Reports, 2021, 81, 105715.	0.2	1
5222	A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 241-251.	1.8	12
5223	Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacology Research and Perspectives, 2021, 9, e00758.	1.1	3
5224	The Combination of Shear Wave Elastography and Platelet Counts Can Effectively Predict High-Risk Varices in Patients with Hepatitis B-Related Cirrhosis. BioMed Research International, 2021, 2021, 1-9.	0.9	3

#	Article	IF	CITATIONS
5225	Follow-Up of Liver Stiffness with Shear Wave Elastography in Chronic Hepatitis C Patients in Sustained Virological Response Augments Clinical Risk Assessment. Processes, 2021, 9, 753.	1.3	2
5226	Utility of Serum Neuropilin-1 and Angiopoietin-2 as Markers of Hepatocellular Carcinoma. Journal of Investigative Medicine, 2021, 69, 1222-1229.	0.7	22
5227	A Physiologically Based Pharmacokinetic Analysis To Predict the Pharmacokinetics of Intravenous Isavuconazole in Patients with or without Hepatic Impairment. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3
5228	Diffusion tensor imaging of the spleen in prediction and grading of esophageal varices in cirrhotic children with portal hypertension. Japanese Journal of Radiology, 2021, 39, 907-913.	1.0	1
5229	Comparison of combined heartâ€'liver vs heart-only transplantation in pediatric and young adult Fontan recipients. Journal of Heart and Lung Transplantation, 2021, 40, 298-306.	0.3	22
5230	Impact of tricuspid regurgitation severity and repair on aortic valve replacement. Annals of Thoracic Surgery, 2021, , .	0.7	3
5231	Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1863-1871.	1.3	4
5232	Micronvasive behaviour of single small hepatocellular carcinoma: which treatment?. Updates in Surgery, 2021, 73, 1359-1369.	0.9	9
5233	Development and Validation of a Nomogram Based on Noninvasive Liver Reserve and Fibrosis (PALBI and) Tj ETQqQ Carcinoma. Journal of Oncology, 2021, 2021, 1-10.	0 0 0 rgBT 0.6	/Overlock : 7
5234	Predicting Operative Outcomes in Patients with Liver Disease: Albumin-Bilirubin Score vs Model for End-Stage Liver Disease-Sodium Score. Journal of the American College of Surgeons, 2021, 232, 470-480e2.	0.2	11
5235	The Role of MicroRNAs (miRNA 155, miRNA-146b) and Procalcitonin as Novel Markers for the Diagnosis of Spontaneous Bacterial Peritonitis. Open Biomarkers Journal, 2021, 11, 28-38.	0.1	0
5236	Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget, 2021, 12, 756-766.	0.8	2
5237	Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database. Drugs - Real World Outcomes, 2021, 8, 301-314.	0.7	9
5238	Predictive and Prognostic Value of Ascitic Fluid Mannose Binding Lectin in Patients with Spontaneous Bacterial Peritonitis. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2021, 20, 196-200.	1.1	1
5239	Usefulness of International Normalized Ratio to Albumin Ratio for Evaluation of Mortality in Hepatitis B Virus-Associated Decompensated Cirrhosis. BioMed Research International, 2021, 2021, 1-6.	0.9	7
5241	Risk Stratification Score to Predict Readmission of Patients With Acute Decompensated Cirrhosis Within 90 Days. Frontiers in Medicine, 2021, 8, 646875.	1.2	2
5242	Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker. Cancer Medicine, 2021, 10, 3584-3592.	1.3	7
5243	A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery, 2021, 169, 1044-1051.	1.0	18

#	Article	IF	CITATIONS
5244	Polymorphism of mixed cryoglobulinemia manifestations in hepatitis C virus chronic infection. Problemy Zdorov $\hat{E}^1\tilde{A}$ ¢ I \tilde{A} "kologii, 2021, , 160-169.	0.0	0
5245	Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterology, 2021, 21, 220.	0.8	10
5246	The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone. Seminars in Liver Disease, 2021, 41, 213-224.	1.8	13
5247	Longâ€term evolution of Llâ€RADS observations in HCVâ€related cirrhosis treated with directâ€acting antivirals. Liver International, 2021, 41, 2179-2188.	1.9	3
5248	Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders. Infection and Drug Resistance, 2021, Volume 14, 1921-1930.	1.1	1
5249	Predictive Role of AURKA rs 1047972 Gene Polymorphism and the Risk of Development of Hepatocellular Carcinoma. Immunological Investigations, 2022, 51, 1211-1221.	1.0	3
5250	Elevated serum tyrosine concentration is associated with a poor prognosis among patients with liver cirrhosis. Hepatology Research, 2021, 51, 786-795.	1.8	2
5251	Arm lean mass determined by dual-energy X-ray absorptiometry is superior to characterize skeletal muscle and predict sarcopenia-related mortality in cirrhosis. American Journal of Physiology - Renal Physiology, 2021, 320, G729-G740.	1.6	10
5252	Clinical Prediction Models for Hepatitis B Virus-related Acute-on-chronic Liver Failure: A Technical Report. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	3
5253	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. Hepatology Research, 2021, 51, 796-802.	1.8	4
5254	Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clinical Pharmacokinetics, 2021, 60, 1349-1360.	1.6	12
5255	Assessment of clinical factors affecting outcome of myasthenia gravis. Muscle and Nerve, 2021, 64, 90-94.	1.0	4
5256	Physiologicallyâ€based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. Biopharmaceutics and Drug Disposition, 2021, 42, 263-284.	1.1	14
5257	Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	12
5258	Evaluation of Muscle Cramp Associated with Liver Cirrhosis with a Focus on the Liver Function and Nutritional Status. Internal Medicine, 2021, 60, 1343-1348.	0.3	2
5259	Therapeutic efficacy of lenvatinib as thirdâ€ine treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research, 2021, 51, 880-889.	1.8	15
5260	Predictors of complications after liver surgery: a systematic review of the literature. Hpb, 2021, 23, 645-655.	0.1	10
5261	Predicting mortality for cirrhotic patients with acute oesophageal variceal haemorrhage using liverâ€specific scores. GastroHep, 2021, 3, 236-246.	0.3	5

#	Article	IF	Citations
5262	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina ClÃnica (English Edition), 2021, 156, 463.e1-463.e30.	0.1	16
5263	Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis. World Journal of Hepatology, 2021, 13, 557-570.	0.8	24
5264	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 2021, 13, 2608.	1.7	34
5265	Two-stage exchange Arthroplasty for knee Periprosthetic joint infection exhibit high infection recurrence rate in patients with chronic viral hepatitis. BMC Musculoskeletal Disorders, 2021, 22, 538.	0.8	3
5266	Correlation of Native Liver Parenchyma T1 and T2 Relaxation Times and Liver Synthetic Function Tests: A Pilot Study. Diagnostics, 2021, 11, 1125.	1.3	2
5267	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. Digestive Diseases, 2022, 40, 322-334.	0.8	3
5268	Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients. Antibiotics, 2021, 10, 666.	1.5	1
5269	A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients with cancer and liver impairment. ESMO Open, 2021, 6, 100162.	2.0	4
5270	The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis. United European Gastroenterology Journal, 2021, 9, 672-680.	1.6	6
5271	Prognostic Factors Related to the Mortality Rate of Acute-on-Chronic Liver Failure Patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 2573-2580.	1.1	2
5272	Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10, 2662.	1.0	13
5273	Machine Learning Prediction of Biomarkers from SNPs and of Disease Risk from Biomarkers in the UK Biobank. Genes, 2021, 12, 991.	1.0	12
5274	Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP Reports, 2021, 3, 100287.	2.6	2
5276	Association between Insulin-Like Growth Factor-‎―â€ã€Ž1 and Severity ‎of Liver Disease in Patients with Li Cirrhosis ‎. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2021, 11, 208-215.	ver 8.1	О
5277	Assessing Patient Proficiency with Internet-Connected Technology and Their Preferences for E-Health in Cirrhosis. Journal of Medical Systems, 2021, 45, 72.	2.2	5
5278	Surgical treatment of hepatocellular carcinoma. BioScience Trends, 2021, 15, 138-141.	1.1	63
5279	Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatology International, 2021, 15, 531-567.	1.9	41
5280	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Cancer Reports, 2022, 5, e1464.	0.6	43

#	Article	IF	Citations
5281	Assessment of dietary habits and the adequacy of dietary intake of patients with cirrhosis-the KIRRHOS study. Clinical Nutrition, 2021, 40, 3992-3998.	2.3	4
5282	Survival of Patients with Lung Cancer in the Setting of Liver Cirrhosis: A Multicenter Propensity Score Matching Study. Cancer Management and Research, 2021, Volume 13, 4373-4381.	0.9	0
5283	Artificial Intelligence to Predict Esophageal Varices in Patients with Cirrhosis. Acibadem Universitesi Saglik Bilimleri Dergisi, 0, , .	0.0	1
5284	Towards a new definition of decompensated cirrhosis. Journal of Hepatology, 2022, 76, 202-207.	1.8	66
5285	Gadoxetic Acid-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging of Histologically Defined Early Hepatocellular Carcinoma. Korean Journal of Abdominal Radiology, 2021, 5, 17-31.	0.0	0
5286	Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial. Oncologist, 2021, 26, e1919-e1930.	1.9	14
5287	Non-invasive diagnosis and follow-up in liver transplantation. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101774.	0.7	2
5288	Safety and efficacy of endoscopic cyanoacrylate injection in the management of gastric varices: A systematic review and metaâ€analysis. JGH Open, 2021, 5, 1047-1055.	0.7	9
5289	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clinical Gastroenterology and Hepatology, 2022, 20, 1636-1662.e36.	2.4	95
5290	Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization. Bulletin Du Cancer, 2021, 108, 931-939.	0.6	5
5291	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. Journal of Hepatology, 2021, 75, 1355-1366.	1.8	15
5292	Peripheral neuropathy after viral eradication with directâ€ecting antivirals in chronic HCV hepatitis: A prospective study. Liver International, 2021, 41, 2611-2621.	1.9	7
5293	Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis. Frontiers in Medicine, 2021, 8, 698502.	1.2	5
5294	Characterization of Medication Errors in a Medical Intensive Care Unit of a University Teaching Hospital in South Korea. Journal of Patient Safety, 2021, Publish Ahead of Print, 1-8.	0.7	6
5295	Vasoactive drugs for adults with cirrhosis and large ascites treated with paracentesis. The Cochrane Library, 2021, 2021, .	1.5	0
5296	ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers, 2021, 13, 3794.	1.7	16
5297	B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101698.	0.7	7
5298	Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	6

#	Article	IF	CITATIONS
5299	Hepatic blood volume is decreased in patients with cirrhosis and does not decrease further after a meal like in healthy persons. Scandinavian Journal of Gastroenterology, 2021, 56, 1205-1209.	0.6	2
5300	Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2989.	1.4	0
5301	Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. International Journal of Molecular Sciences, 2021, 22, 7702.	1.8	18
5303	Development of a simple dynamic algorithm for individualized hepatocellular carcinoma riskâ€based surveillance using pre―and postâ€treatment general evaluation score. Liver International, 2021, 41, 2768-2776.	1.9	8
5304	Appraisal of multivariable prognostic models for post-operative liver decompensation following partial hepatectomy: a systematic review. Hpb, 2021, 23, 1773-1788.	0.1	2
5305	Gastrointestinal endoscopy in cirrhotic patient: Issues on the table. World Journal of Gastrointestinal Endoscopy, 2021, 13, 210-220.	0.4	0
5306	Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib. Scientific Reports, 2021, 11, 14474.	1.6	13
5307	A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment. International Journal of Drug Policy, 2021, 96, 103359.	1.6	9
5308	Patient-Reported Outcome Measures Modestly Enhance Prediction of Readmission in Patients with Cirrhosis. Clinical Gastroenterology and Hepatology, 2022, 20, e1426-e1437.	2.4	8
5309	Single-Centre Retrospective Training Cohort Using Artificial Intelligence for Prognostic Prediction of Encephalopathy, Mortality, and Liver Dysfunction after Early TIPS Creation. CardioVascular and Interventional Radiology, 2021, 44, 1597-1608.	0.9	9
5310	The Putative Role of Natural Killer Cells in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2559-2567.	0.5	5
5311	Prediction of high-risk esophageal varices in patients with compensated cirrhosis using albumin-bilirubin-platelet score. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	3
5312	Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function. Journal of Clinical Pharmacology, 2022, 62, 171-181.	1.0	3
5313	Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers, 2021, 13, 3961.	1.7	7
5314	Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment. Molecular Pharmaceutics, 2021, 18, 3563-3577.	2.3	33
5315	Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. Journal of Gastrointestinal Oncology, 2021, 12, 1743-1752.	0.6	6
5316	Low Serum-Free Testosterone Concentration in Chinese Male Patients with Uncomplicated Acute Type B Aortic Dissection. Annals of Vascular Surgery, 2021, 75, 324-331.	0.4	0
5317	Evaluation of liver fibrosis and cirrhosis on the basis of quantitative T1 mapping: Are acute inflammation, age and liver volume confounding factors?. European Journal of Radiology, 2021, 141, 109789.	1.2	9

#	Article	IF	CITATIONS
5318	Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. Drugs in R and D, 2021, 21, 375-384.	1.1	6
5319	Transmediastinal, intrapericardial inferior vena cava approach based on anatomical landmarks for hepatectomy using total hepatic vascular exclusion. Langenbeck's Archives of Surgery, 2021, , 1.	0.8	0
5320	Hepatic Hydrothoraxâ€"An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis. Journal of Clinical Medicine, 2021, 10, 3688.	1.0	11
5321	Artificial intelligence for proteomics and biomarker discovery. Cell Systems, 2021, 12, 759-770.	2.9	106
5322	Applying arterial enhancement fraction (AEF) texture features to predict the tumor response in hepatocellular carcinoma (HCC) treated with Transarterial chemoembolization (TACE). Cancer Imaging, 2021, 21, 49.	1,2	5
5323	To Compare Serum Vitamin D Levels with Severity of Liver Cirrhosis According to Child-Pugh Score in Amritsar, Punjab. Journal of Evidence Based Medicine and Healthcare, 2021, 8, 3090-3096.	0.0	0
5325	Baseline Neutrophil-to-Lymphocyte Ratio Is Independently Associated With 90-Day Transplant-Free Mortality in Patients With Cirrhosis. Frontiers in Medicine, 2021, 8, 726950.	1.2	8
5326	Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis. Journal of Parenteral and Enteral Nutrition, 2022, 46, 858-866.	1.3	20
5327	Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 327-336.	0.7	7
5328	Are Pattern Recognition Receptors Associated with Hepatocellular Carcinoma?. Turkish Journal of Gastroenterology, 2021, 32, 593-599.	0.4	0
5329	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Scientific Reports, 2021, 11, 16663.	1.6	30
5330	Evolution of liver transplant organ allocation policy: Current limitations and future directions. World Journal of Hepatology, 2021, 13, 830-839.	0.8	19
5331	Computed Tomography–Determined Body Composition Abnormalities Usefully Predict Long-term Mortality in Patients With Liver Cirrhosis. Journal of Computer Assisted Tomography, 2021, 45, 684-690.	0.5	3
5332	Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepatic Oncology, 2022, 9, HEP41.	4.2	2
5333	The learning curve of laparoscopic liver resection utilising a difficulty score. Radiology and Oncology, $2021, \dots$	0.6	4
5334	From Child-Pugh to MELD score and beyond: Taking a walk down memory lane. Annals of Hepatology, 2022, 27, 100535.	0.6	26
5335	Role of bile acids in the prediction of hepatocellular carcinoma in HCV-induced liver cirrhosis. Egyptian Liver Journal, $2021,11,$	0.3	1
5336	Liver cirrhosis. Lancet, The, 2021, 398, 1359-1376.	6.3	515

#	Article	IF	CITATIONS
5337	Gut microbiome in cirrhotic hepatitis C virus patients with and without hepatocellular carcinoma. Egyptian Liver Journal, $2021,11,$	0.3	2
5338	Alteration of prognostic efficacy of albuminâ€bilirubin grade and Childâ€Pugh score according to liver fibrosis in hepatocellular carcinoma patients with Childâ€Pugh A following hepatectomy. Annals of Gastroenterological Surgery, 2022, 6, 127-134.	1.2	6
5339	Comparison of General and Liver-Specific Prognostic Scores in Their Ability to Predict Mortality in Cirrhotic Patients Admitted to the Intensive Care Unit. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-13.	0.8	6
5340	Nomogram to Predict the Survival of Chinese Patients with Alcohol-Related Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-8.	0.8	4
5341	Prospective Multicenter Interventional Study of Surgical Resection for Liver Metastasis from Gastric Cancer: RO Resection Rate, and Operative Morbidity and Mortality. Annals of Surgical Oncology, 2022, 29, 924-932.	0.7	7
5342	Effects of different remifentanil target concentrations on MAC _{BAR} of sevoflurane in patients with liver dysfunction under carbon dioxide pneumoperitoneum stimulus: A randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1776-1783.	0.7	1
5343	Animal naming test for the assessment of minimal hepatic encephalopathy in Asian cirrhotic populations. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101729.	0.7	4
5344	Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transplantation, 2021, 27, 1758-1766.	1.3	15
5345	Low sodium to potassium ratio in spot urine sample is associated with progression to acute kidney injury and mortality in hospitalized patients with cirrhosis. Digestive and Liver Disease, 2021, 53, 1159-1166.	0.4	2
5346	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma., 2021, 9, e002794.		43
5347	Predictors of Voriconazole Trough Concentrations in Patients with Child–Pugh Class C Cirrhosis: A Prospective Study. Antibiotics, 2021, 10, 1130.	1.5	10
5348	Anatomic versus non-anatomic resection of hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. Asian Journal of Surgery, 2021, 44, 1143-1150.	0.2	20
5349	The "Hub and Spoke" model has no effect on mortality in acute upper gastrointestinal bleeding: A prospective multicenter cohort study. Digestive and Liver Disease, 2021, 53, 1178-1184.	0.4	1
5350	Prognosis of patients with liver cirrhosis: A multiâ€center retrospective observational study. Hepatology Research, 2021, 51, 1196-1206.	1.8	8
5351	Comparison of Scores for Child-Pugh Criteria and Standard and Modified Models for End-Stage Liver Disease to Assess Cardiac Hepatopathy in Heart Transplant Recipients. Experimental and Clinical Transplantation, 2021, 19, 963-969.	0.2	0
5352	Inverse relationship between the level of miRNA 148a-3p and both TGF- \hat{l}^21 and FIB-4 in hepatocellular carcinoma. Biochemistry and Biophysics Reports, 2021, 27, 101082.	0.7	2
5353	Profound decrease of liver maximum function capacity test of isoflurane sedated patients: A report of three cases. Clinical Case Reports (discontinued), 2021, 9, e04862.	0.2	2
5354	Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification. Journal of Hepatology, 2021, 75, 747-749.	1.8	13

#	Article	IF	CITATIONS
5355	Safety of Tacrolimus in Autoimmune Disease: Results From Post-marketing Surveillance in South Korea. Journal of Rheumatic Diseases, 2021, 28, 202-215.	0.4	1
5356	A multicenter randomized controlled trial comparing administration of antithrombin III after liver resection (HiSCO-05 trial). Surgery, 2021, 170, 1140-1150.	1.0	4
5357	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Reports, 2021, 3, 100347.	2.6	57
5358	Impact of body mass index on hepatocellular carcinoma recurrence after liver transplantation through long-term follow-up. Hepatobiliary Surgery and Nutrition, 2021, 10, 598-609.	0.7	4
5359	Association between the albumin–bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A dataâ€mining analysis. Hepatology Research, 2021, 51, 1207-1218.	1.8	15
5360	Evaluation of Threshold Dose of Damaged Hepatic Tissue After Carbon-Ion Radiation Therapy Using Gd-EOB-DTPA–Enhanced Magnetic Resonance Imaging. Advances in Radiation Oncology, 2021, 6, 100775.	0.6	0
5361	Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. Regenerative Therapy, 2021, 18, 97-101.	1.4	12
5362	Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment. Internal Medicine, 2022, , .	0.3	0
5363	Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. The Cochrane Library, 2021, 2021, CD011973.	1.5	6
5365	Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. Journal of Comparative Effectiveness Research, 2021, 10, 343-352.	0.6	13
5366	Artificial intelligence to predict overall survivals of patients with cirrhosis and outcomes of variceal bleeding. Hepatology Forum, 2021, , .	0.3	1
5367	Functional Assessment of Liver for Radiation Oncologist. , 2021, , 51-57.		0
5369	Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children. The Cochrane Library, 0, , .	1.5	6
5370	Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis. The Cochrane Library, 2018, 2018, CD011717.	1.5	5
5373	Prognosis of Patients with Cirrhosis and Ascites. , 0, , 260-270.		36
5375	A Realâ€World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGETâ€HCC. Hepatology Communications, 2021, 5, 538-547.	2.0	6
5377	Alcohol Effects in Postmenopausal Women. , 1994, , 195-214.		1
5378	Causes of death in patients undergoing liver surgery. Cancer Treatment and Research, 1994, 69, 241-257.	0.2	23

#	ARTICLE	IF	CITATIONS
5379	Is Oxygen Consumption Measurement during Anesthesia for Liver Transplantation Valuable for a Rapid Assessment of Adequate Function of the Graft?. Advances in Experimental Medicine and Biology, 1992, 317, 835-840.	0.8	1
5380	Tryptophan Metabolism and Hepatic Encephalopathy. Advances in Experimental Medicine and Biology, 1999, , 155-167.	0.8	9
5381	Liver (Including Intrahepatic Bile Ducts)., 2002,, 131-138.		13
5382	Autonomic Neuropathy in Liver Cirrhosis: Prevalence and Association with Clinical and Laboratory Features. Advances in Experimental Medicine and Biology, 1991, 298, 295-300.	0.8	6
5383	Natural History and Stages of Cirrhosis. , 2014, , 15-28.		5
5384	Preoperative and Postoperative Care of the Liver Patient. , 2017, , 99-118.		2
5386	Rationale for Non-surgical Interventional Treatment of Hepatocellular Carcinoma. Medical Radiology, 1999, , 245-253.	0.0	1
5387	Risikoerfassung und optimierende Therapie bei intrahepatisehen Erkrankungen der Leber. , 1988, , 79-83.		1
5388	Treatment of Refractory Ascites by Concentrated Ascitic Fluid Reinfusion., 1987,, 303-307.		1
5389	Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome. , 2004, , 209-218.		1
5390	Esophageal varices: from appearance to rupture; natural history and prognostic indicators. , 2004, , 147-154.		25
5391	A survival-based scoring-system for initial graft function following orthotopic liver transplantation. Transplant International, 2003, 16, 794-800.	0.8	11
5392	Patent ductus venosus associated with a hyperintense globus pallidum on T1-weighted magnetic resonance imaging and pulmonary hypertension. European Journal of Pediatrics, 1995, 154, 526-529.	1.3	4
5393	Prediction of variceal hemorrhage in cirrhosis: A prospective follow-up study. Gastroenterology, 1991, 100, 1332-1337.	0.6	32
5394	Assessment of the risk of bleeding from esophageal varices by continuous monitoring of portal pressure. Gastroenterology, 1991, 100, 1403-1410.	0.6	19
5395	Prognostic significance of diabetes in patients with cirrhosis*1. Hepatology, 1994, 20, 119-125.	3.6	175
5396	Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter Italian study. Hepatology, 1994, 20, 1225-1230.	3.6	44
5397	Neuropathies Associated with Renal Failure, Hepatic Disorders, Chronic Respiratory Disease, and Critical Illness., 2005,, 2017-2037.		4

#	Article	IF	CITATIONS
5398	Portal Hypertension and Portacaval Shunt**Supported by NIH Grants A3048, A5919, AM07315, AM07511, AM1228, AM19875, AM12280, AM17103, and DK41920, 2001, , 637-701.		11
5399	Liver Resection for Benign Disease and for Liver and Biliary Tumors. , 2007, , 1341-1416.		13
5400	HEPATIC CIRRHOSIS., 2009, , 505-525.		2
5404	WHY DO VARICES BLEED?. Gastroenterology Clinics of North America, 1992, 21, 85-101.	1.0	79
5405	MR IMAGING IN HEPATIC TRANSPLANTATION. Magnetic Resonance Imaging Clinics of North America, 2001, 9, 821-839.	0.6	10
5406	Measurement of the expiratory ammonia concentration and its clinical significance., 1997, 12, 161.		4
5407	Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism. , 0, .		1
5408	Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. Hepatology, 1996, 23, 1003-1011.	3.6	33
5409	Does malnutrition affect survival in cirrhosis?. Hepatology, 1996, 23, 1041-1046.	3.6	47
5410	Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology, 1996, 23, 1084-1092.	3.6	89
5411	Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology, 1996, 24, 1047-1052.	3.6	38
5412	Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis. Hepatology, 1997, 25, 63-70.	3.6	105
5413	Hepatic tocopherol content in primary hepatocellular carcinoma and liver metastases. Hepatology, 1997, 26, 67-72.	3.6	9
5414	Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology, 1997, 26, 1410-1414.	3.6	65
5415	Quantitation of Plasma Levels of Tetranectin - Effects of Oral Contraceptives, Pregnancy, Treatment with L-Asparaginase and Liver Cirrhosis. Thrombosis and Haemostasis, 1989, 62, 792-796.	1.8	12
5416	Liver Cancer. , 2006, , 763-786.		63
5417	Influence of the metabolic sequelae of liver cirrhosis on nutritional intake. American Journal of Clinical Nutrition, 1999, 69, 331-337.	2.2	35
5418	Hepatocellular Carcinoma and Cirrhosis. Annals of Surgery, 1996, 223, 297-302.	2.1	210

#	Article	IF	CITATIONS
5419	Laparoscopy and Laparoscopic Ultrasonography Avoid Exploratory Laparotomy in Patients With Hepatocellular Carcinoma. Annals of Surgery, 1998, 227, 527-532.	2.1	127
5420	Hepatectomy for Hepatocellular Carcinoma: Toward Zero Hospital Deaths. Annals of Surgery, 1999, 229, 322-330.	2.1	668
5421	Superselective Intra-Arterial Radiometabolic Therapy With I-131 Lipiodol in Hepatocellular Carcinoma. Clinical Nuclear Medicine, 1996, 21, 221-226.	0.7	21
5422	How to use a review article. Critical Care Medicine, 1998, 26, 692-700.	0.4	7
5423	Gallbladder Varices: Diagnosis in Children with Portal Hypertension on Duplex Sonography. Journal of Clinical Gastroenterology, 1996, 23, 228-231.	1.1	12
5424	Gastric Secretion in Chinese Patients with Cirrhosis. Journal of Clinical Gastroenterology, 1996, 23, 256-260.	1.1	7
5425	Tamoxifen Does Not Improve Survival of Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 1998, 26, 200-203.	1.1	57
5426	Serum Uric Acid Levels in Patients With Cirrhosis: A Reevaluation. Journal of Clinical Gastroenterology, 1999, 29, 261-265.	1.1	4
5427	Adenosine Deaminase Isoenzymes and Neopterin in Liver Cirrhosis. Journal of Clinical Gastroenterology, 2000, 30, 181-186.	1.1	24
5428	Use of Octreotide for the Treatment of Severe Gastrointestinal Bleeding in Children. Journal of Pediatric Gastroenterology and Nutrition, 1998, 26, 356-359.	0.9	42
5429	Propranolol in Prevention of Portal Hypertensive Hemorrhage in Children: A Pilot Study. Journal of Pediatric Gastroenterology and Nutrition, 1999, 29, 12-17.	0.9	94
5430	Clinical Relevance of Transforming Growth Factor-beta 1 in the Urine of Patients with Hepatocellular Carcinoma. Medicine (United States), 1997, 76, 213-226.	0.4	37
5431	Prognostic Value of the Monoethylglycinexylidide Test in Pediatric Liver Transplant Candidates. Therapeutic Drug Monitoring, 1996, 18, 378-382.	1.0	21
5432	Amikacin Bayesian Forecasting in Critically Ill Patients With Sepsis and Cirrhosis. Therapeutic Drug Monitoring, 1997, 19, 271-276.	1.0	15
5433	Evaluation of Pharmacokinetic Methods Used to Estimate Caffeine Clearance and Comparison With a Bayesian Forecasting Method. Therapeutic Drug Monitoring, 1998, 20, 78-87.	1.0	10
5434	POOR OUTCOME IN PATIENTS WITH DIABETES MELLITUS UNDERGOING LIVER TRANSPLANTATION Transplantation, 1999, 68, 530-535.	0.5	78
5435	SUCCESSFUL COMBINED LIVER-HEART TRANSPLANTATION IN ADULTS: REPORT OF THREE PATIENTS AND REVIEW OF THE LITERATURE. Transplantation, 1999, 68, 1423-1427.	0.5	28
5436	ACCURACY AND SIGNIFICANCE OF COMPUTED TOMOGRAPHIC SCAN ASSESSMENT OF HEPATIC VOLUME IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. Transplantation, 2000, 69, 545-550.	0.5	109

#	Article	IF	CITATIONS
5437	Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective?. European Journal of Cancer Prevention, 2001, 10, 111-115.	0.6	14
5438	Title is missing!. , 2000, 10, 360-363.		31
5439	Title is missing!. , 2001, 11, 165-169.		21
5440	Impact of organ shortage on liver transplantation. Current Opinion in Organ Transplantation, 2001, 6, 103-106.	0.8	2
5441	Modern Outcomes Following Treatment of Hepatocellular Carcinoma in Hereditary Hemochromatosis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 918-923.	0.6	4
5442	Thyroid Hormone Levels Predict Mortality in Intensive Care Patients With Cirrhosis. American Journal of the Medical Sciences, 2012, 344, 175-179.	0.4	27
5443	Bone Mineral Density of Children With Wilson Disease. Journal of Clinical Gastroenterology, 2008, 42, 194-198.	1.1	30
5444	Platelet–lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. European Journal of Gastroenterology and Hepatology, 2021, 32, 261-268.	0.8	9
5445	Performance of artificial intelligence for prognostic prediction with the albumin-bilirubin and platelet-albumin-bilirubin for cirrhotic patients with acute variceal bleeding undergoing early transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2021, 33, e153-e160.	0.8	5
5446	Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. Nuclear Medicine Communications, 2021, 42, 43-50.	0.5	4
5447	Cirrhotic Patients Admitted to the ICU With Septic Shock: Factors Predicting Short and Long-Term Outcome. Shock, 2019, 52, 408-413.	1.0	12
5448	Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma. Annals of Surgery, 2021, 274, e1209-e1217.	2.1	45
5449	Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes, Obesity and Metabolism, 2018, 20, 998-1005.	2.2	43
5450	Scaling Factors for Clearance in Adult Liver Cirrhosis. Drug Metabolism and Disposition, 2020, 48, 1271-1282.	1.7	16
5451	Selection of Patients for Liver Resection. , 2008, , 303-315.		2
5452	Patterns of Improvement in Resection of Hepatocellular Carcinoma in Cirrhotic Patients: Results of a Non Drainage Policy. HPB Surgery, 1989, 1, 141-147.	2.2	11
5453	EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer, 2020, 9, 734-743.	4.2	35
5454	Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism Journal of Clinical Investigation, 1993, 91, 1897-1902.	3.9	98

#	Article	IF	CITATIONS
5455	Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE Journal of Clinical Investigation, 1997, 100, 1264-1270.	3.9	69
5456	Multiphase CT-based prediction of Child-Pugh classification: a machine learning approach. European Radiology Experimental, 2020, 4, 20.	1.7	10
5457	Effect of direct-acting antivirals on corrected QT interval and cardiac functions in patients with chronic hepatitis C virus infection. Egyptian Heart Journal, 2020, 72, 7.	0.4	7
5458	Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence. Egyptian Liver Journal, 2020, 10, .	0.3	4
5459	Biomarkers Of Malnutrition In Liver Cirrhosis. , 2009, , 203-215.		2
5460	Fibrosing Cholestatic Hepatitis in a Complicated Case of an Adult Recipient After Liver Transplantation: Diagnostic Findings and Therapeutic Dilemma. American Journal of Case Reports, 2016, 17, 597-604.	0.3	2
5461	Long-Term Outcomes of Ante-Situm Resection and Auto-Transplantation in Conventionally Unresectable Hepatocellular Carcinoma: A Single-Center Experience. Annals of Transplantation, 2018, 23, 81-88.	0.5	6
5462	Diagnostic Accuracy of APRI, AAR, FIB-4, FI, and King Scores for Diagnosis of Esophageal Varices in Liver Cirrhosis: A Retrospective Study. Medical Science Monitor, 2015, 21, 3961-3977.	0.5	42
5463	Association Between Hepatocellular Carcinoma and Type 2 Diabetes Mellitus in Chinese Hepatitis B Virus Cirrhosis Patients: A Case-Control Study. Medical Science Monitor, 2017, 23, 3324-3334.	0.5	16
5464	Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy. Medical Science Monitor, 2020, 26, e924040.	0.5	5
5465	Using Lamin B1 mRNA for the early diagnosis of hepatocellular carcinoma: a cross-sectional diagnostic accuracy study. F1000Research, 2018, 7, 1339.	0.8	8
5466	Dosing Accuracy of Direct Oral Anticoagulants in an Academic Medical Center. Journal of Hospital Medicine, 2017, 12, 544-550.	0.7	10
5467	Scoring systems for prediction of mortality in decompensated liver cirrhosis: A meta-analysis of test accuracy. World Journal of Clinical Cases, 2018, 6, 995-1006.	0.3	16
5469	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	3.9	113
5470	An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load. PLoS ONE, 2008, 3, e2573.	1.1	64
5471	ABO Blood Group and the Risk of Hepatocellular Carcinoma: A Case-Control Study in Patients with Chronic Hepatitis B. PLoS ONE, 2012, 7, e29928.	1.1	36
5472	Structural and Functional Abnormalities of Default Mode Network in Minimal Hepatic Encephalopathy: A Study Combining DTI and fMRI. PLoS ONE, 2012, 7, e41376.	1.1	54
5473	Altered Regional Homogeneity in the Development of Minimal Hepatic Encephalopathy: A Resting-State Functional MRI Study. PLoS ONE, 2012, 7, e42016.	1.1	45

#	Article	IF	Citations
5474	Predictors and Prevalence of Latent Tuberculosis Infection in Patients Receiving Long-Term Hemodialysis and Peritoneal Dialysis. PLoS ONE, 2012, 7, e42592.	1.1	42
5475	Dynamic Changes of Intrinsic Brain Activity in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt: A Resting-State fMRI Study. PLoS ONE, 2012, 7, e46681.	1.1	10
5476	Disrupted Functional Connectivity of the Anterior Cingulate Cortex in Cirrhotic Patients without Overt Hepatic Encephalopathy: A Resting State fMRI Study. PLoS ONE, 2013, 8, e53206.	1.1	35
5477	The Outcome of Prophylactic Intravenous Cefazolin and Ceftriaxone in Cirrhotic Patients at Different Clinical Stages of Disease after Endoscopic Interventions for Acute Variceal Hemorrhage. PLoS ONE, 2013, 8, e61666.	1.1	17
5478	A Modified MELD Model for Chinese Pre-ACLF and ACLF Patients and It Reveals Poor Prognosis in Pre-ACLF Patients. PLoS ONE, 2013, 8, e64379.	1.1	42
5479	Quantifying Memory in Complex Physiological Time-Series. PLoS ONE, 2013, 8, e72854.	1.1	26
5480	The Autophagy-Related Marker LC3 Can Predict Prognosis in Human Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e81540.	1.1	73
5481	A New Model to Estimate Prognosis in Patients with Hepatocellular Carcinoma after Yttrium-90 Radioembolization. PLoS ONE, 2013, 8, e82225.	1.1	19
5482	Serum 1H-NMR Metabolomic Fingerprints of Acute-On-Chronic Liver Failure in Intensive Care Unit Patients with Alcoholic Cirrhosis. PLoS ONE, 2014, 9, e89230.	1.1	45
5483	High Serum Levels of HDV RNA Are Predictors of Cirrhosis and Liver Cancer in Patients with Chronic Hepatitis Delta. PLoS ONE, 2014, 9, e92062.	1.1	77
5484	The Influential Roles of Antibiotics Prophylaxis in Cirrhotic Patients with Peptic Ulcer Bleeding after Initial Endoscopic Treatments. PLoS ONE, 2014, 9, e96394.	1.1	5
5485	A Study of the Relationship between Serum Bile Acids and Propranolol Pharmacokinetics and Pharmacodynamics in Patients with Liver Cirrhosis and in Healthy Controls. PLoS ONE, 2014, 9, e97885.	1.1	20
5486	Renal Function in Hepatosplenic Schistosomiasis – An Assessment of Renal Tubular Disorders. PLoS ONE, 2014, 9, e115197.	1.1	18
5487	Comparison of Current Diagnostic Criteria for Acute-On-Chronic Liver Failure. PLoS ONE, 2015, 10, e0122158.	1.1	46
5488	Resting State-fMRI with ReHo Analysis as a Non-Invasive Modality for the Prognosis of Cirrhotic Patients with Overt Hepatic Encephalopathy. PLoS ONE, 2015, 10, e0126834.	1.1	18
5489	Prospective Randomized Trial Comparing Hepatic Venous Outflow and Renal Function after Conventional versus Piggyback Liver Transplantation. PLoS ONE, 2015, 10, e0129923.	1.1	17
5490	Chronological Profiling of Plasma Native Peptides after Hepatectomy in Pigs: Toward the Discovery of Human Biomarkers for Liver Regeneration. PLoS ONE, 2017, 12, e0167647.	1.1	5
5491	Application of chronic liver failure-sequential organ failure assessment score for the predication of mortality after esophageal variceal hemorrhage post endoscopic ligation. PLoS ONE, 2017, 12, e0182529.	1.1	5

#	Article	IF	CITATIONS
5492	Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis. PLoS ONE, 2017, 12, e0185997.	1.1	17
5493	Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0186990.	1.1	237
5494	Integration of Prealbumin into Child-Pugh Classification Improves Prognosis Predicting Accuracy in HCC Patients Considering Curative Surgery. Journal of Clinical and Translational Hepatology, 2018, 6, 1-8.	0.7	9
5495	Patients with Cirrhosis of Liver Operated for Non-transplant Surgery: A Retrospective Analysis. Journal of Clinical and Translational Hepatology, 2019, 7, 1-6.	0.7	5
5496	Related Factors of Quality of Life in Middle-male with Chronic Liver Disease. Journal of Digital Convergence, 2015, 13, 267-277.	0.1	2
5497	Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis. Electronic Physician, 2015, 7, 1349-58.	0.2	10
5498	High Pallidal T1 Signal is Rarely Observed in Obstructive Jaundice, but is Frequently Observed in Liver Cirrhosis. Journal of Occupational Health, 2007, 49, 268-272.	1.0	6
5499	The Significance of Vitamin D Receptor Gene Polymorphisms for Susceptibility to Hepatocellular Carcinoma in Subjects Infected with Hepatitis C Virus. Gastroenterology & Hepatology (Bartlesville,) Tj ETQq1 1 (0. 7&#314</td><td>rg&T Overlo</td></tr><tr><td>5500</td><td>The effect of liver disease on lactate normalization in severe sepsis and septic shock: a cohort study. Clinical and Experimental Emergency Medicine, 2015, 2, 197-202.</td><td>0.5</td><td>55</td></tr><tr><td>5506</td><td>Poor outcomes with treatment of hepatorenal syndrome type 1 with splancnic vasoconstrictors and albumin: report of seven cases and review of the literature. Arquivos De Gastroenterologia, 2009, 46, 214-218.</td><td>0.3</td><td>3</td></tr><tr><td>5507</td><td>Distúrbios trombofÃlicos em crianças e adolescentes com trombose da veia porta. Jornal De Pediatria,
2003, 79, .</td><td>0.9</td><td>1</td></tr><tr><td>5508</td><td>Caracter<math> ilde{A}</math>sticas epidemiol<math> ilde{A}^3</math>gicas de la cirrosis hep<math> ilde{A}</math>¡tica en el Hospital Civil de Guadalajara. Salud Publica De Mexico, 1997, 39, .</td><td>0.1</td><td>12</td></tr><tr><td>5509</td><td>Predictive factors for response to Lamivudine in chronic hepatitis B. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2000, 42, 189-196.</td><td>0.5</td><td>19</td></tr><tr><td>5510</td><td>Prediction of large esophageal varices in cirrhotic patients using classification and regression tree analysis. Clinics, 2011, 66, 119-124.</td><td>0.6</td><td>19</td></tr><tr><td>5511</td><td>Predictive factors for Child-Pugh score elevation in hepatocellular carcinoma patients treated with conformal radiation therapy: dose-volume histogram analysis. Tumori, 2013, 99, 164-71.</td><td>0.6</td><td>8</td></tr><tr><td>5512</td><td>Prognostic factors of liver cirrhosis mortality after a first episode of spontaneous bacterial peritonitis. A multicenter study. Revista Espanola De Enfermedades Digestivas, 2017, 110, 94-101.</td><td>0.1</td><td>2</td></tr><tr><td>5513</td><td>The General Rules for the Study of Primary Liver Cancer. Journal of Liver Cancer, 2017, 17, 19-44.</td><td>0.3</td><td>28</td></tr><tr><td>5514</td><td>Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis. Aging, 2019, 11, 8502-8525.</td><td>1.4</td><td>26</td></tr></tbody></table>	

#	Article	IF	CITATIONS
5515	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget, 2016, 7, 72343-72355.	0.8	57
5516	Contrast-enhanced computed tomography plus gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging for gross classification of hepatocellular carcinoma. Oncotarget, 2017, 8, 29741-29750.	0.8	4
5517	The autophagy marker LC3 strongly predicts immediate mortality after surgical resection for hepatocellular carcinoma. Oncotarget, 2017, 8, 91902-91913.	0.8	14
5518	A novel dynamic model for predicting outcome in patients with hepatitis B virus related acute-on-chronic liver failure. Oncotarget, 2017, 8, 108970-108980.	0.8	13
5519	Bloodstream infection due to <i>Escherichia coli</i> in liver cirrhosis patients: clinical features and outcomes. Oncotarget, 2018, 9, 35780-35789.	0.8	6
5520	The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation. Oncotarget, 2018, 9, 2236-2248.	0.8	6
5521	Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality. Oncotarget, 2018, 9, 21552-21559.	0.8	3
5522	Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT). Oncotarget, 2018, 9, 28818-28829.	0.8	29
5523	Thioredoxin reductase: A novel, independent prognostic marker in patients with hepatocellular carcinoma. Oncotarget, 2015, 6, 17792-17804.	0.8	22
5524	Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma. Oncotarget, 2015, 6, 21193-21207.	0.8	9
5525	Conditional survival estimate of acute-on-chronic hepatitis B liver failure: A dynamic prediction based on a multicenter cohort. Oncotarget, 2015, 6, 23261-23271.	0.8	12
5526	Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study. Oncotarget, 2016, 7, 35071-35083.	0.8	12
5527	Prescribing in liver disease. Australian Prescriber, 2009, 32, 32-35.	0.5	16
5528	Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Medica Okayama, 2005, 59, 217-24.	0.1	34
5529	Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. Hepatoma Research, 2019, 2019, .	0.6	2
5530	Comparative evaluation of ALBI, MELD, and Child-Pugh scores in prognosis of cirrhosis: is ALBI the new alternative?. Annals of Gastroenterology, 2019, 32, 626-632.	0.4	19
5531	A novel online calculator based on albumin-bilirubin and aspartate transaminase-to-platelet ratio index for predicting postoperative morbidity following hepatectomy for hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1591-1591.	0.7	4
5532	Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus. Journal of Gastrointestinal Oncology, 2020, 11, 1333-1349.	0.6	8

#	Article	IF	CITATIONS
5533	Total Knee Arthroplasty in Patients with Liver Cirrhosis. Journal of Bone and Joint Surgery - Series A, 2004, 86, 335-341.	1.4	71
5534	Risk prediction models for hepatocellular carcinoma in different populations. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 150-160.	0.7	10
5535	Living Donor Liver Transplantation. Chirurgia (Romania), 2017, 112, 217.	0.2	17
5536	Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. Clinical Pharmacokinetics, 2012, 51, 619-628.	1.6	3
5537	Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough?. Current Pharmaceutical Design, 2020, 26, 300-309.	0.9	17
5538	Heart Function and Myocardial Tissue Characterization in Patients with HCV Related Cirrhosis: Diastolic Dysfunction and Cardiac Hypertrophy. The Open Gastroenterology Journal, 2007, 1, 1-8.	0.1	2
5539	Talin-1 Gene Expression as a Tumor Marker in Hepatocellular Carcinoma Patients: A Pilot Study. Open Biomarkers Journal, 2020, 10, 15-22.	0.1	6
5540	Non-invasive predictors of esophageous varices in children and adolescents with chronic liver disease or extrahepatic portal venous obstruction. Jornal De Pediatria, 2012, 88, 341-6.	0.9	9
5541	The model for the end-stage liver disease and Child-Pugh score in predicting prognosis in patients with liver cirrhosis and esophageal variceal bleeding. Vojnosanitetski Pregled, 2009, 66, 724-728.	0.1	26
5543	日本血æ"æ¢è¡€å┤ä⅓šDIC è™æ–基準暫定æ;ˆ. Japanese Journal of Thrombosis and Hemostasis, 201∙	4, @5 , 629	-6 \$ 6.
5544	Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis. Terapevticheskii Arkhiv, 2019, 91, 21-27.	0.2	3
5545	Clinical Relevance of Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for the Cirrhotic without Overt Hepatic Encephalopathy Acta Hepatologica Japonica, 1999, 40, 235-242.	0.0	2
5546	A case of decompensated hepatitis B virus-related cirrhosis successfully treated with lamivudine and adefovir allowing repeated treatments for hepatocellular carcinomas. Acta Hepatologica Japonica, 2005, 46, 262-269.	0.0	1
5547	Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: analysis of 114 cases. Acta Hepatologica Japonica, 2011, 52, 449-460.	0.0	5
5548	DNA Methyltransferases as Potential Biomarkers for HCV Related Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3357-3363.	0.5	5
5549	Matrix Metalloproteinase-11 Gene Polymorphisms as a Risk for Hepatocellular Carcinoma Development in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3725-3734.	0.5	3
5550	Phase angle as a nutritional evaluation tool in all stages of chronic liver disease. Nutricion Hospitalaria, 2012, 27, 2072-8.	0.2	35
5552	Nutritional assessment in hepatic cirrhosis; clinical, anthropometric, biochemical and hematological parameters. Nutricion Hospitalaria, 2013, 28, 1615-21.	0.2	25

#	Article	IF	CITATIONS
5554	Beta-Agonist Lung injury Trial-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome. Health Technology Assessment, 2013, 17, v-vi, 1-87.	1.3	39
5555	The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. Health Technology Assessment, 2015, 19, 1	-104 ^{1.3}	34
5556	Study of Correlation of Severity of Hepatic Cirrhosis with Severity of Bone Changes Measured by BMD (Bone Mineral Density). Bangladesh Journal of Medicine, 2013, 22, 41-46.	0.0	2
5557	Little Response of Cerebral Metastasis from Hepatocellular Carcinoma to Any Treatments. Journal of Korean Neurosurgical Society, 2010, 47, 325.	0.5	24
5558	Survival-Related Factors of Spinal Metastasis with Hepatocellular Carcinoma in Current Surgical Treatment Modalities: A Single Institute Experience. Journal of Korean Neurosurgical Society, 2015, 58, 448.	0.5	17
5559	2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2019, 20, 1042.	1.5	189
5560	Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clinical and Molecular Hepatology, 2012, 18, 219.	4.5	24
5561	Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data. Clinical and Molecular Hepatology, 2013, 19, 36.	4.5	22
5562	Important predictor of mortality in patients with end-stage liver disease. Clinical and Molecular Hepatology, 2013, 19, 105.	4.5	85
5563	The secondary prophylactic efficacy of beta-blocker after endoscopic gastric variceal obturation for first acute episode of gastric variceal bleeding. Clinical and Molecular Hepatology, 2013, 19, 280.	4.5	5
5564	Cyanoacrylate injection versus band ligation for bleeding from cardiac varices along the lesser curvature of the stomach. Clinical and Molecular Hepatology, 2016, 22, 487-494.	4.5	10
5565	Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis. Clinical and Molecular Hepatology, 2018, 24, 409-416.	4.5	19
5566	Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?. Clinical and Molecular Hepatology, 2019, 25, 317-325.	4.5	2
5567	Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. Clinical and Molecular Hepatology, 2019, 25, 381-389.	4.5	11
5570	Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels. The Korean Journal of Hepatology, 2011, 17, 130.	1.5	28
5571	Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment. Frontiers in Pharmacology, 2019, 10, 1031.	1.6	12
5572	Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals, 2021, 14, 28.	1.7	17
5573	Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. World Journal of Gastroenterology, 2008, 14, 286.	1.4	39

#	Article	IF	CITATIONS
5574	Hepatocellular carcinoma: Defining the place of surgery in an era of organ shortage. World Journal of Gastroenterology, 2008, 14, 4445.	1.4	17
5575	Accuracy of the automated cell counters for management of spontaneous bacterial peritonitis. World Journal of Gastroenterology, 2008, 14, 5689.	1.4	19
5576	Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score. World Journal of Gastroenterology, 2008, 14, 58.	1.4	7
5577	Does an association exist between chronic pancreatitis and liver cirrhosis in alcoholic subjects?. World Journal of Gastroenterology, 2008, 14, 6171.	1.4	26
5578	Identification and characterization of genotype A and D recombinant hepatitis B virus from Indian chronic HBV isolates. World Journal of Gastroenterology, 2008, 14, 6228.	1.4	23
5579	Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients. World Journal of Gastroenterology, 2008, 14, 6824.	1.4	24
5580	Serum neopterin levels in children with hepatitis-B-related chronic liver disease and its relationship to disease severity. World Journal of Gastroenterology, 2008, 14, 6840.	1.4	19
5581	Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C. World Journal of Gastroenterology, 2008, 14, 701.	1.4	6
5582	Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. World Journal of Gastroenterology, 2008, 14, 7214.	1.4	17
5583	Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease. World Journal of Gastroenterology, 2009, 15, 2768.	1.4	10
5584	Survival predictors in patients treated with a molecular adsorbent recirculating system. World Journal of Gastroenterology, 2009, 15, 3015.	1.4	23
5585	Voxel-based analyses of magnetization transfer imaging ofthe brain in hepatic encephalopathy. World Journal of Gastroenterology, 2009, 15, 5157.	1.4	18
5586	Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2004, 10, 505.	1.4	29
5587	Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World Journal of Gastroenterology, 2004, 10, 1137.	1.4	145
5588	Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases. World Journal of Gastroenterology, 2004, 10, 1353.	1.4	24
5589	Risk-adjustment in hepatobiliarypancreatic surgery. World Journal of Gastroenterology, 2005, 11, 2450.	1.4	21
5590	Blood platelet and monocyte activations and relation to stages of liver cirrhosis. World Journal of Gastroenterology, 2005, 11, 2754.	1.4	35
5591	Natural history of major complications in hepatitis C virus-related cirrhosis evaluated by per-rectal portal scintigraphy. World Journal of Gastroenterology, 2005, 11, 3882.	1.4	4

#	Article	IF	CITATIONS
5592	Circulating adhesion molecules in patients with virus-related chronic diseases of the liver. World Journal of Gastroenterology, 2005, 11, 4566.	1.4	24
5593	Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area. World Journal of Gastroenterology, 2005, 11, 5289.	1.4	18
5594	Low preoperative platelet counts predict a high mortality after partial hepatectomy in patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 5888.	1.4	47
5595	Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 6920.	1.4	19
5596	Bleeding gastric varices: Results of endoscopic injection with cyanoacrylate at King Chulalongkorn Memorial Hospital. World Journal of Gastroenterology, 2005, 11, 7531.	1.4	32
5597	Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. World Journal of Gastroenterology, 2005, 11, 7661.	1.4	49
5598	Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2006, 12, 3275.	1.4	99
5599	Efficacy of balloon-occluded retrograde transvenous obliteration, percutaneous transhepatic obliteration and combined techniques for the management of gastric fundal varices. World Journal of Gastroenterology, 2006, 12, 3866.	1.4	60
5600	Predicting utility of a model for end stage liver disease in alcoholic liver disease. World Journal of Gastroenterology, 2006, 12, 4020.	1.4	31
5601	Doppler study of hepatic vein in cirrhotic patients: Correlation with liver dysfunction and hepatic hemodynamics. World Journal of Gastroenterology, 2006, 12, 5853.	1.4	24
5602	Expression of \hat{l}^2 2-integrin on leukocytes in liver cirrhosis. World Journal of Gastroenterology, 2006, 12, 6193.	1.4	8
5603	Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: A lesson from the past. World Journal of Gastroenterology, 2006, 12, 6331.	1.4	21
5604	Current concepts and controversies in the treatment of alcoholic hepatitis. World Journal of Gastroenterology, 2006, 12, 6909.	1.4	34
5605	Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World Journal of Gastroenterology, 2006, 12, 7319.	1.4	70
5606	Management of digestive bleeding related to portal hypertension in cirrhotic patients: A French multicenter cross-sectional practice survey. World Journal of Gastroenterology, 2006, 12, 7810.	1.4	8
5607	Prognostic value of 13C-phenylalanine breath test on predicting survival in patients with chronic liver failure. World Journal of Gastroenterology, 2007, 13, 4579.	1.4	7
5608	Prevalence of gastric varices and results of sclerotherapy with N-butyl 2 cyanoacrylate for controlling acute gastric variceal bleeding. World Journal of Gastroenterology, 2007, 13, 1247.	1.4	47
5609	Translation and validation of the Greek chronic liver disease questionnaire. World Journal of Gastroenterology, 2010, 16, 5838.	1.4	12

#	Article	IF	CITATIONS
5610	Surgical treatment for liver cancer. World Journal of Gastroenterology, 2010, 16, 927.	1.4	46
5611	Gastroesophageal reflux in cirrhotic patients without esophageal varices. World Journal of Gastroenterology, 2011, 17, 1753.	1.4	12
5612	Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World Journal of Gastroenterology, 2011, 17, 3126-32.	1.4	5
5613	<i>De novo</i> combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients. World Journal of Gastroenterology, 2011, 17, 4804.	1.4	8
5614	Outcome of non surgical hepatic decompression procedures in Egyptian patients with Budd-Chiari. World Journal of Gastroenterology, 2011, 17, 906.	1.4	8
5615	Branched-chain amino acids to tyrosine ratio value as a potential prognostic factor for hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 2005.	1.4	41
5616	Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World Journal of Gastroenterology, 2012, 18, 5211-8.	1.4	34
5617	Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 78.	1.4	12
5618	Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World Journal of Gastroenterology, 2013, 19, 3207.	1.4	16
5619	Impact of cirrhosis on surgical outcome after pancreaticoduodenectomy. World Journal of Gastroenterology, 2013, 19, 7129.	1.4	43
5620	Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: Serum sodium predicts survival. World Journal of Gastroenterology, 2014, 20, 8158.	1.4	17
5621	Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World Journal of Gastroenterology, 2014, 20, 786.	1.4	24
5622	Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 10960.	1.4	4
5623	Cardiac surgery in patients with liver cirrhosis: Risk factors for predicting mortality. World Journal of Gastroenterology, 2014, 20, 12608.	1.4	33
5624	Recent advances in the surgical treatment of hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 14381.	1.4	81
5625	Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. World Journal of Gastroenterology, 2014, 20, 14934.	1.4	67
5626	Covert hepatic encephalopathy: Agreement and predictive validity of different indices. World Journal of Gastroenterology, 2014, 20, 15756.	1.4	50
5627	Therapy for alcoholic liver disease. World Journal of Gastroenterology, 2014, 20, 2143.	1.4	63

#	Article	IF	Citations
5628	Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. World Journal of Gastroenterology, 2015, 21, 246.	1.4	40
5629	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. World Journal of Gastroenterology, 2015, 21, 3013.	1.4	12
5630	High neutrophil-lymphocyte ratio indicates poor prognosis for acute-on-chronic liver failure after liver transplantation. World Journal of Gastroenterology, 2015, 21, 3317-3324.	1.4	23
5631	Prognostic roles of preoperative \hat{l} ±-fetoprotein and des- \hat{l} 3-carboxy prothrombin in hepatocellular carcinoma patients. World Journal of Gastroenterology, 2015, 21, 4933.	1.4	47
5632	Proportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patients. World Journal of Gastroenterology, 2015, 21, 6665.	1.4	9
5633	Impact of muscle wasting on survival in patients with liver cirrhosis. World Journal of Gastroenterology, 2015, 21, 7357.	1.4	48
5634	Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World Journal of Gastroenterology, 2015, 21, 7637.	1.4	96
5635	Serum proinflammatory cytokines and nutritional status in pediatric chronic liver disease. World Journal of Gastroenterology, 2015, 21, 8927.	1.4	17
5636	Allocation of patients with liver cirrhosis and organ failure to intensive care: Systematic review and a proposal for clinical practice. World Journal of Gastroenterology, 2015, 21, 8964.	1.4	13
5637	Endozepine-4 levels are increased in hepatic coma. World Journal of Gastroenterology, 2015, 21, 9103.	1.4	11
5638	Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. World Journal of Gastroenterology, 2015, 21, 9466.	1.4	13
5639	Platelet count combined with right liver volume and spleen volume measured by magnetic resonance imaging for identifying cirrhosis and esophageal varices. World Journal of Gastroenterology, 2015, 21, 10184-10191.	1.4	15
5640	Hepatosplanchnic circulation in cirrhosis and sepsis. World Journal of Gastroenterology, 2015, 21, 2582.	1.4	28
5641	Advances in liver transplantation allocation systems. World Journal of Gastroenterology, 2016, 22, 2922.	1.4	41
5642	Pharmacokinetic drug interactions in liver disease: An update. World Journal of Gastroenterology, 2016, 22, 1260.	1.4	62
5643	Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. World Journal of Gastroenterology, 2016, 22, 10219.	1.4	18
5644	Liver surgery in cirrhosis and portal hypertension. World Journal of Gastroenterology, 2016, 22, 2725.	1.4	82
5645	Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. World Journal of Gastroenterology, 2017, 23, 3122.	1.4	22

#	Article	IF	Citations
5646	Prognostic factors associated with mortality in patients with gastric fundal variceal bleeding. World Journal of Gastroenterology, 2017, 23, 496.	1.4	13
5647	Presence of columnar-lined esophagus is negatively associated with the presence of esophageal varices in Japanese alcoholic men. World Journal of Gastroenterology, 2017, 23, 7150-7159.	1.4	3
5648	Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: A single-center study. World Journal of Gastroenterology, 2017, 23, 629.	1.4	10
5649	Laparoscopic resection (i>vs / i>laparoscopic radiofrequency ablation for the treatment of small hepatocellular carcinomas: A single-center analysis. World Journal of Gastroenterology, 2017, 23, 653.	1.4	20
5650	Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. World Journal of Gastroenterology, 2020, 26, 5022-5049.	1.4	13
5651	Nutritional status in non-alcoholic sub-clinical porto-systemic encephalopathy. World Journal of Gastroenterology, 1998, 4, 380.	1.4	2
5652	Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. World Journal of Gastroenterology, 2000, 5, 296.	1.4	32
5653	Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World Journal of Gastroenterology, 1999, 5, 391.	1.4	48
5654	Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World Journal of Gastroenterology, 2000, 6, 339.	1.4	46
5655	Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World Journal of Gastroenterology, 2002, 8, 237.	1.4	64
5656	Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein. World Journal of Gastroenterology, 2003, 9, 2666.	1.4	48
5657	Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 742-746.	0.1	4
5658	Retrospective analysis of transcatheter arterial chemoembolization treatment for spontaneously ruptured hepatocellular carcinoma. Oncology Letters, 2019, 18, 6423-6430.	0.8	12
5659	Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma. Oncology Letters, 2020, 19, 691-699.	0.8	11
5660	A New Method of Endoscopic Variceal Ligation-Injection SclerotherapyEVLIS for Gastric Varices. Korean Journal of Internal Medicine, 1995, 10, 108-119.	0.7	14
5661	Liver cirrhosis leads to poorer survival in patients with end-stage renal disease. Korean Journal of Internal Medicine, 2016, 31, 730-738.	0.7	11
5662	Vitamin D Receptor Gene Polymorphisms as a Predictive Risk Factor for Hepatocellular Carcinoma Development and Severity in Chronic Hepatitis B. International Journal of Cancer Research, 2016, 13, 26-35.	0.2	7
5663	Patient selection for hepatic resection for metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2012, 3, 3-10.	0.6	131

#	Article	IF	CITATIONS
5664	Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. Journal of Gastrointestinal Oncology, 2015, 6, 259-67.	0.6	25
5665	A review of hepatocellular carcinoma (HCC) staging systems. Chinese Clinical Oncology, 2013, 2, 33.	0.4	70
5666	Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease. Gastroenterology Research, 2009, 2, 344-349.	0.4	8
5667	Modelflow method versus continuous thermodilution technique for cardiac output measurement in liver transplant patients. Daehan Macwi'gwa Haghoeji, 2008, 55, 57.	0.2	1
5668	The procedure outcome of laparoscopic resection for $\hat{a}\in^2$ small $\hat{a}\in^2$ hepatocellular carcinoma is comparable to vlaparoscopic radiofrequency ablation. Journal of Minimal Access Surgery, 2015, 11, 231.	0.4	6
5669	Noninvasive predictors of large esophageal varices: is there an emerging role of aspartate aminotransferase-to-platelet ratio index in hepatocellular carcinoma?. The Egyptian Journal of Internal Medicine, 2015, 27, 139-146.	0.3	4
5670	Chronic liver disease and hepatic encephalopathy: Clinical profile and outcomes. Nigerian Journal of Clinical Practice, 2011, 14, 181.	0.2	14
5671	Effectiveness of intravenous infusion of N-acetylcysteine in cirrhotic patients undergoing major abdominal surgeries. Saudi Journal of Anaesthesia, 2015, 9, 272.	0.2	8
5672	Delayed-onset chest infections in liver transplant recipients: a prospective study. Egyptian Journal of Bronchology, 2016, 10, 147-154.	0.3	1
5673	The Role of Hepatitis C virus and Possible Risk factors in development of Hepatocellular carcinoma: 400 Patients based study. The Egyptian Journal of Internal Medicine, 2019, 31, 64-72.	0.3	7
5674	Impact of CYP2C19 polymorphisms on serum concentration of voriconazole in iranian hematological patients. Journal of Research in Pharmacy Practice, 2017, 6, 151.	0.2	4
5675	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. Cancer Research and Treatment, 2019, 51, 1347-1356.	1.3	8
5676	Non-Invasive Parameters of Oesophageal Varices Diagnosis: Which Sensitive and Applicable; A Pilot Study. Journal of Liver, 2015, 04, .	0.3	6
5677	Hepatocellular Carcinoma: Risk Factors, Diagnosis, Staging and Treatment in a Referral Centre. Journal of Cancer Therapy, 2013, 04, 384-393.	0.1	2
5678	Role of Tyro3, Axl, and Mer Receptors and Their Ligands (Gas6, and Protein S) in Patients with Hepatocellular Carcinoma. Journal of Cancer Therapy, 2017, 08, 112-130.	0.1	10
5679	Predictors of Intra-Hospital Mortality in Patients with Cirrhosis. Open Journal of Gastroenterology, 2014, 04, 141-148.	0.1	6
5680	Liver Transient Elastography Combined to Platelet Count (Baveno VI) Predict High Esophageal Varices in Black African Patient with Compensated Hepatitis B Related Cirrhosis. Open Journal of Gastroenterology, 2018, 08, 192-200.	0.1	8
5681	The Effect of Loop Diuretics on Sarcopenia and Long-Term Prognosis in Patients with Refractory Hepatic Ascites Treated with Tolvaptan. Open Journal of Gastroenterology, 2018, 08, 201-208.	0.1	1

#	ARTICLE	IF	CITATIONS
5682	Gastric cancer surgery for patients with liver cirrhosis. World Journal of Gastrointestinal Surgery, 2009, 1, 49.	0.8	18
5683	Effect of Daikenchuto (TJ-100) on abdominal bloating in hepatectomized patients. World Journal of Gastrointestinal Surgery, 2013, 5, 115.	0.8	6
5684	Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors. World Journal of Gastrointestinal Surgery, 2016, 8, 436.	0.8	15
5685	N-butyl-2-cyanoacrylate, iso-amyl-2-cyanoacrylate and hypertonic glucose with 72% chromated glycerin in gastric varices. World Journal of Gastrointestinal Endoscopy, 2015, 7, 411.	0.4	2
5686	Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World Journal of Hepatology, 2018, 10, 51-61.	0.8	7
5687	Hepatectomy for gallbladder-cancer with unclassified anomaly of right-sided ligamentum teres: A case report and review of the literature. World Journal of Hepatology, 2018, 10, 523-529.	0.8	3
5688	Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. World Journal of Hepatology, 2020, 12, 1031-1045.	0.8	8
5689	Soluble membrane attack complex in ascites in patients with liver cirrhosis without infections. World Journal of Hepatology, 2010, 2, 221.	0.8	2
5690	Surgical management of hepatocellular carcinoma. World Journal of Hepatology, 2014, 7, 245.	0.8	70
5691	Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion. World Journal of Hepatology, 2016, 8, 345.	0.8	43
5692	Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World Journal of Hepatology, 2017, 9, 544.	0.8	9
5693	Association between Severity of Liver Disease, Frequency of Helicobacter pylori Infection, and Degree of Gastric Lesion in Egyptian Patients with Hepatitis B Virus Infection. American Journal of Tropical Medicine and Hygiene, 2018, 98, 221-226.	0.6	9
5694	ATOVAQUONE-PROGUANIL: REPORT FROM THE CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS (II). American Journal of Tropical Medicine and Hygiene, 2007, 76, 208-223.	0.6	82
5695	â€~Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2012, 3, 21.	0.6	2
5696	Liver transplantation in adults: Choosing the appropriate timing. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2012, 3, 49.	0.6	8
5697	Serum selenium concentrations in cirrhotic children. Turkish Journal of Gastroenterology, 2010, 21, 153-155.	0.4	8
5698	Serum iron parameters in cirrhosis and chronic hepatitis: Detailed description. Turkish Journal of Gastroenterology, 2011, 22, 606-611.	0.4	27
5701	Prognostic scores in cirrhotic patients admitted to a gastroenterology intensive care unit. Revista Espanola De Enfermedades Digestivas, 2011, 103, 177-183.	0.1	11

#	Article	IF	Citations
5702	Locoregional treatment for hepatocellular carcinoma: The best is yet to come. World Journal of Radiology, 2015, 7, 306.	0.5	24
5703	Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography. Gut and Liver, 2020, 14, 117-124.	1.4	5
5704	2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut and Liver, 2019, 13, 227-299.	1.4	255
5705	Comparative assessment of prognostic value for revised-mayo risk model and child-pugh score in patients with primary sclerosing cholangitis. Turkish Journal of Gastroenterology, 2015, 26, 31-35.	0.4	4
5706	The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients. Turkish Journal of Gastroenterology, 2015, 26, 163-169.	0.4	31
5707	Cerebral hemodynamics in patients with cirrhosis. Turkish Journal of Gastroenterology, 2016, 27, 264-267.	0.4	3
5708	Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?. Turkish Journal of Gastroenterology, 2019, 30, 964-975.	0.4	16
5709	Prevalence of Insomnia and Sleep Patterns among Liver Cirrhosis Patients. Journal of Circadian Rhythms, 2014, 12, .	2.9	8
5710	Surgery for early stage hepatocellular carcinoma. International Journal of Hepatobiliary and Pancreatic Diseases, 2015, 5, 47.	0.2	1
5711	Evaluation of biomarkers for the detection of hepatocellular carcinoma in patients with hepatitis C virus. Journal of Experimental and Integrative Medicine, 2012, 2, 321.	0.1	4
5712	Study of Hepatoprotective Effect of Silymarin and Ursodeoxycholic Acid in Chronic Hepatitis C Patients. Medicine Science, 2014, 3, 1655.	0.0	1
5713	Gene Regulations in HBV-Related Liver Cirrhosis Closely Correlate with Disease Severity. BMB Reports, 2007, 40, 814-824.	1.1	7
5714	A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma. Annals of Hepatology, 2015, 14, 869-880.	0.6	21
5715	The management of acutely bleeding varices by injection sclerotherapy. Medical Journal of Australia, 1986, 145, 130-133.	0.8	8
5716	Clinical, Research and Treatment Approaches to Affective Disorders. , 2012, , .		2
5717	Biological Prediction of Suicidal Behavior in Patients with Major Depressive Disorder. , 0, , .		2
5718	Serum Thrombopoietin Levels and Its Relationship WithThrombocytopenia in Patients With Cirrhosis. Hepatitis Monthly, 2014, 14, e18556.	0.1	17
5719	Heme Oxygenase-1 mRNA Expression in Egyptian Patients With Chronic Liver Disease. Hepatitis Monthly, 2012, 12, 278-285.	0.1	2

#	Article	IF	CITATIONS
5720	Impact of Severity of Chronic Liver Disease on Health-Related Economics. Hepatitis Monthly, 2020, 20, .	0.1	2
5721	Acute-on-chronic liver failure syndrome - clinical results from an intensive care unit in a liver transplant center. Revista Brasileira De Terapia Intensiva, 2020, 32, 49-57.	0.1	2
5723	Case Series of 10 Patients with Cirrhosis Undergoing Emergent Repair of Ruptured Umbilical Hernias: Natural History and Predictors of Outcomes. Experimental and Clinical Transplantation, 2019, 17, 210-213.	0.2	9
5724	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565.	2.3	477
5725	Comparison of measured and predicted energy expenditure in patients with liver cirrhosis. Asia Pacific Journal of Clinical Nutrition, 2014, 23, 197-204.	0.3	13
5726	Is Model for End-Stage Liver Disease score associated with quality of life after liver transplantation?. Progress in Transplantation, 2011, 21, 207-214.	0.4	12
5727	Comparison of Viral Hepatitis-Associated Hepatocellular Carcinoma Due to HBV and HCV - Cohort from Liver Clinics in Pakistan. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7563-7567.	0.5	18
5728	Using Transjugular Intrahepatic Portosystemic Shunts to Control Variceal Bleeding before Liver Transplantation. Annals of Internal Medicine, 1992, 116, 304-309.	2.0	208
5729	Assessing the prognostic scores for the prediction of the mortality of patients with acute-on-chronic liver failure: a retrospective study. PeerJ, 2020, 8, e9857.	0.9	8
5730	Hepatic Venous Waveform, Splenoportal and Damping Index in Liver Cirrhosis: Correlation with Child Pugh's Score and Oesophageal Varices. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, TC01-5.	0.8	5
5731	Nutritional status and prognosis in cirrhotic patients. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2012, 33, 257-264.	0.0	18
5732	Tissue Biomarkers in the Early Detection of Hepatocellular Carcinoma among Egyptian Patients with Chronic Hepatitis C: A Possible Genetic Profile. British Journal of Medicine and Medical Research, 2013, 3, 1858-1870.	0.2	4
5733	Child-Turcotte-Pugh Score as a Predictive Factor for Long-Term Survival After Repeat Hepatectomy for Recurrent Liver Metastases of Colorectal Cancer. International Surgery, 2021, 105, 611-618.	0.0	0
5734	Sarcomatoid hepatocellular carcinoma in a young African female. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110524.	0.2	1
5736	The Concentration of 25-Hydroxy Vitamin D in Chronic Liver Disease and its' Correlation with Severity. Bangladesh Medical Journal, 2021, 49, 35-42.	0.1	0
5737	Gastrointestinal Cancers and Liver Cirrhosis: Implications on Treatments and Prognosis. Frontiers in Oncology, 2021, 11, 766069.	1.3	5
5738	Determination of the segmental hepatic clearance rate of 99mTc-mebrofenin and its application in the functional assessment of future liver remnant after liver resection. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 385-396.	0.1	1
5739	Risk factors for community-onset pneumonia caused by drug-resistant pathogens: A prospective cohort study. European Journal of Internal Medicine, 2022, 96, 66-73.	1.0	4

#	Article	IF	CITATIONS
5740	Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease. Internal Medicine, 2021, 60, 3195-3203.	0.3	1
5741	Transient elastography and platelet count as noninvasive predictors of gastroesophageal varices in patients with compensated hepatitis C virus–related liver cirrhosis. Medical Journal Armed Forces India, 2021, , .	0.3	O
5742	Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation. Scientific Reports, 2021, 11, 20479.	1.6	5
5743	Assessing the prognosis of cirrhotic patients in the intensive care unit: What we know and what we need to know better. World Journal of Hepatology, 2021, 13, 1341-1350.	0.8	2
5744	Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterology, 2021, 21, 386.	0.8	6
5745	Distinguishing between the complications of Wilson disease-related cirrhosis and HBV-related cirrhosis. Current Medical Research and Opinion, 2022, 38, 75-81.	0.9	1
5746	Determinación de la tasa de aclaramiento hepático segmentario de 99mTc-mebrofenina y su aplicación en la evaluación funcional del remanente hepático futuro tras resección hepática. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 385-396.	0.0	0
5747	TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. Journal of Personalized Medicine, 2021, 11, 1041.	1.1	48
5748	Liver Transplantation for Biliary Atresia in Adulthood: Single-Centre Surgical Experience. Journal of Clinical Medicine, 2021, 10, 4969.	1.0	5
5749	Amino Acid Profile in Malnourished Patients with Liver Cirrhosis and Its Modification with Oral Nutritional Supplements: Implications on Minimal Hepatic Encephalopathy. Nutrients, 2021, 13, 3764.	1.7	8
5750	Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. Scientific Reports, 2021, 11, 20506.	1.6	4
5751	Prevalence, risk factors, and short-term outcomes of postparacentesis acute kidney injury using revised criteria of the international club of ascites. Medicine (United States), 2021, 100, e27431.	0.4	2
5752	Predictors of Short-Term Mortality Following First Episode of Spontaneous Bacterial Peritonitis in Hospitalized Cirrhotic Patients. Cureus, 2021, 13, e18999.	0.2	1
5753	Clinical characteristics and risk factors for mortality upon admission in patients with heart failure hospitalized due to COVID-19 in Spain. Revista Clínica Espanõla, 2021, , .	0.3	7
5754	Prediction and Risk Factors for Prognosis of Cirrhotic Patients with Hepatic Encephalopathy. Gastroenterology Research and Practice, 2021, 2021, 1-14.	0.7	7
5755	Identifying early indicators of secondary peritonitis in critically ill patients with cirrhosis. Scientific Reports, 2021, 11, 21076.	1.6	1
5756	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers, 2021, 13, 5018.	1.7	16
5757	Leberzirrhose und ihre Komplikationen. , 2000, , 489-518.		0

#	Article	IF	CITATIONS
5758	Feature Subset Selection Using Probabilistic Tree Structures. A Case Study in the Survival of Cirrhotic Patients Treated with TIPS. Lecture Notes in Computer Science, 2000, , 97-110.	1.0	2
5760	Utilização das hepatectomias centrais nas cirurgias hepatobiliares. Revista Do Colegio Brasileiro De Cirurgioes, 2000, 27, 413-421.	0.3	1
5761	Trans-thoracic microwave coagulo-necrotic therapy for hepatic tumors without chest tube insertion. Journal of Microwave Surgery, 2001, 19, 67-70.	0.3	0
5762	A Variant of Des-??-Carboxy Prothrombin Was Increased in Alcoholic Liver Disease Without Hepatocellular Carcinoma. Alcoholism: Clinical and Experimental Research, 2001, 25, 46S-50S.	1.4	6
5763	Portale Hypertension., 2002,, 745-797.		0
5764	Cancers of the large bowel and hepatobiliary tract. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 509-534.	0.5	0
5765	Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the Gastrointestinal Tract., 2003, , 461-487.		0
5767	Alcohol and Nutrition. , 2003, , 3-17.		0
5768	Alcohol-induced Liver Disease., 2004,, 205-217.		0
5769	Assessing the Effect of Disease State on the Pharmacokinetics of the Drug. Drugs and the Pharmaceutical Sciences, 2004, , 345-372.	0.1	0
5770	Staging system for hepatocellular carcinoma. Acta Hepatologica Japonica, 2005, 46, 53-63.	0.0	1
5771	Cancers of the large bowel and hepatobiliary tract. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 443-469.	0.5	0
5772	Health Status Assessment and Economic Analyses in Cirrhosis and Portal Hypertension. , 2005, , 469-484.		0
5773	Evaluation of Hepatic Function. , 2005, , 129-137.		0
5776	Pretransplant Evaluation and Care., 2006,, 933-945.		3
5777	Clinical Studies –ÂTypical Designs. , 2006, , 659-720.		0
5778	Pharmacokinetics â€" Pharmacodynamics in New Drug Development. , 2006, , 335-375.		0
5779	Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. European Journal of Haematology, 2006, .	1.1	0

#	Article	IF	CITATIONS
5780	The Erythrocyte 2,3-diphosphoglycerate Concentration and Its Related Factors in Patients with End-stage Liver Disease. Daehan Macwi'gwa Haghoeji, 2007, 52, 430.	0.2	0
5781	Chemotherapy of Liver Tumors., 2007,, 1298-1311.		O
5783	De patiënt met een leverfunctiestoornis. , 2007, , 259-267.		0
5784	Assessment of Liver Function in the Surgical Patient. , 2007, , 30-36.		0
5787	Dose Adjustment- An Important Issue in Critical Care. Internet Journal of Medical Update, 2007, 1, .	0.2	0
5788	Problems Associated with Liver Resection in Cirrhotic Patients. , 2008, , 317-335.		0
5789	Changing role of laparoscopy in the management of patients with cirrhosis. Journal of Minimal Access Surgery, 2008, 4, 63.	0.4	4
5791	The role and perspective of transplant hepatologists in Japan. Acta Hepatologica Japonica, 2008, 49, 28-38.	0.0	3
5792	Laboratory aspects of important organic disorders with psychiatric sequelae., 2008,, 233-274.		0
5794	Living Donor Liver Transplantation in Japan. Nihon Ika Daigaku Igakkai Zasshi, 2009, 5, 13-21.	0.0	O
5795	Acute-on-Chrenic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction. , 2009, , 658-671.		2
5797	Supraumbilical skin rash after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: Two case report. Acta Hepatologica Japonica, 2009, 50, 390-396.	0.0	0
5798	5 Onderzoeksmethoden in de hepatologie. , 2009, , 35-47.		2
5799	Low plasma zinc concentrations in pediatric patients with cirrhosis. Jornal De Pediatria, 2009, 85, 359-364.	0.9	2
5801	Infections in Cirrhosis in Critical Care. Infectious Disease and Therapy, 2009, , 341-349.	0.0	0
5802	Infections in Cirrhosis in Critical Care. Infectious Disease and Therapy, 2009, , 341-349.	0.0	0
5803	Scoring systems to evaluate severity-of-illness and organ dysfunction in patients admitted to the intensive care unit and emergency room. Nihon Kyukyu Igakukai Zasshi, 2010, 21, 327-342.	0.0	0
5804	Crità res d'admission d'un malade cirrhotique en rà © animation. , 2010, , 117-126.		0

#	Article	IF	CITATIONS
5805	Principles of anti-infective therapy. , 2010, , 1275-1287.		О
5806	Anesthesia and the Hepatobiliary System. , 2010, , 2135-2153.		8
5807	Clinical Scoring Systems. , 2010, , 289-293.		0
5808	Chronic Liver Failure. , 2010, , 371-380.		0
5811	Liver Resection for Hepatocellular Carcinoma., 2011,, 109-134.		0
5812	The Hemostasis System During MARS Therapy and Plasma Sorption in Patients with Liver Cell Failure. Obshchaya Reanimatologiya, 2010, 6, 35.	0.2	2
5813	Chronic Liver Disease in the Intensive Care. , 2011, , 541-559.		0
5814	Hepatic Fibrosis and Cirrhosis. Molecular Pathology Library, 2011, , 449-466.	0.1	0
5815	Prognostic Factors, Incidence and Management for Acute Variceal Bleeding in the Liver Transplantation Era. Surgical Science, 2011, 02, 198-203.	0.1	0
5816	A case of untreated poorly differentiated hepatocellular carcinoma of 1.9 cm in diameter. Acta Hepatologica Japonica, 2011, 52, 184-192.	0.0	1
5817	Portale Hypertension., 2011,, 749-782.		0
5818	Long-term results of small-diameter proximal splenorenal venous shunt: A retrospective study. World Journal of Gastroenterology, 2011, 17, 3453.	1.4	0
5819	Hepatologische Labordiagnostik., 2011,, 91-132.		0
5821	Experimental study of scoring model for liver cirrhosis diseases. Academic Journal of Second Military Medical University, 2011, 31, 485-489.	0.0	O
5822	Hyponatremia As A Predictor of Death in End Stage Liver Disease Patients. Indian Journal of Applied Research, 2011, 4, 410-415.	0.0	0
5823	Nonradiological Treatment for Liver Tumors. , 2012, , 89-94.		O
5824	Multiorgan Dysfunction: the State-of-the-Art and Current Approaches to Its Treatment Using Low Flow-Rate Membrane Technologies. Obshchaya Reanimatologiya, 2011, 7, 66.	0.2	4
5825	Patient Selection according to General Condition and Associated Disease. Updates in Surgery Series, 2012, , 77-85.	0.0	0

#	ARTICLE	IF	Citations
5826	Advances in systemic therapy for hepatocellular carcinoma. , 2012, , 1444-1452.e3.		O
5827	Portal Hypertension and Esophageal Varices. , 2012, , 2065-2073.		0
5828	Features of Hormonal Disturbances in Cirrhotic Patients with Hepatic Encephalopathy. Euroasian Journal of Hepato-gastroenterology, 2012, 2, 84-89.	0.1	1
5829	Impact of infection in hospitalized cirrhotic patients in a university hospital. Open Journal of Gastroenterology, 2012, 02, 124-130.	0.1	1
5830	Pulmonary Resection for Lung Cancer in Patients with Liver Cirrhosis., 0, , .		0
5831	Disease Targeted Measures of Health Related Quality of Life (HRQOL) in Patients with Advanced Liver Disease Before and After Liver Transplantation. , 0, , .		0
5832	The Bacterial Endotoxins Levels in the Blood of Cirrhotic Patients as Predictor of the Risk of Esophageal Varices Bleeding. , 0 , , .		0
5833	Gastric Variceal Obliteration By Cyanoacrylate Glue Injection. Journal of Armed Forces Medical College Bangladesh, 2012, 7, 44-46.	0.1	0
5835	Pallidal Signal Intensities on T1-weighted MRI are Highly Observed in Advanced Liver Cirrhosis. Korean Journal of Environmental Health Sciences, 2012, 38, 380-385.	0.1	0
5836	Perioperative Management., 2013,, 221-232.		0
5837	HepatobiliÃ r e Tumoren und Lebermetastasen. , 2013, , 639-662.		0
5838	Diagnostic Operations of the Liver and Techniques of Hepatic Resection., 2013, , 1491-1506.		0
5839	Anesthesia for Patients with Hilar Chlolangiocarcinoma. , 2013, , 155-166.		0
5840	The Proper Scan Delay of the Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging to Evaluate Small-Sized (â‰\$ cm) Hepatocellular Carcinoma in Cirrhotic Liver. Journal of the Korean Society of Radiology, 2013, 68, 319.	0.1	0
5841	Macrophage Inflammatory Protein-1 \hat{l} ± (MIP-1 \hat{l} ±) in Hepatitis C Virus- Related Hepatocellular Carcinoma: Relation to Clinical Staging and Tumour Angiogenesis., 2013, 02,.		0
5843	Multidisciplinary Approach to the Management of Portal Hypertension. , 2013, , 1593-1609.		0
5844	Assessment of Liver Function. , 2013, , 75-89.		0
5845	De patiënt met een leverfunctiestoornis. , 2013, , 345-353.		0

#	Article	IF	CITATIONS
5849	Treatment of the Liver Cirrhosis: Modern Principles, Considering Syntropic Co- and Multimorbid Lesions of Other Organs and Systems of Organs. Lviv Clinical Bulletin, 2013, 2, 37-45.	0.1	5
5852	Hepatic clearance measured with ^{99m} Tc-GSA single-photon emission computed tomography to estimate liver fibrosis. World Journal of Gastroenterology, 2014, 20, 16714.	1.4	15
5853	Thrombocytopenia in Egyptian Patients with Hepatitis C Virus Treated with Standard of Care Therapy: A Cohort Study. International Journal of Tropical Disease & Health, 2014, 4, 1254-1267.	0.1	0
5854	Alocação de fÃgados para transplante em adultos: vantagens e desvantagens do escore MELD. Clinical and Biomedical Research, 2014, 34, 342-346.	0.1	O
5855	Liver and Bile Duct Cancer., 2014, , 1373-1396.e8.		5
5856	Considerations in Organ Failure. , 2014, , 225-246.		O
5857	Assessment of the Nutritional Status of the Egyptian Patient with End Stage Liver Disease Prior to Liver Transplantation. Open Journal of Gastroenterology, 2014, 04, 159-169.	0.1	2
5858	Efficacy of Ursodeoxycholic Acid in Chinese Patients with End-Stage Primary Biliary Cirrhosis. Journal of Gastroenterology and Hepatology Research, 2014, 3, 1248-1251.	0.2	0
5860	Severity of illness and likely outcome from critical illness. , 2014, , 16-26.e3.		1
5861	Liver Transplantation for Primary Biliary Cirrhosis. , 2014, , 287-300.		3
5862	Liver disease and anaesthesia., 0,, 101-101.		0
5863	Relationship of Geriatric Nutritional Risk Index (GNRI) with length of hospitalization and mortality rate in elderly patients. Berkala Ilmu Kedokteran, 2014, 46, 32-40.	0.1	0
5864	Risikofaktoren und prÃ g perative Maßnahmen aus internistischer Sicht. , 1981, , 113-121.		0
5865	Hepatologie. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1981, , 877-958.	0.0	0
5866	Postersession VI. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1984, , 1804-1834.	0.0	0
5867	Symposium B. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1984, , 269-295.	0.0	0
5868	Child and Turcotte's classification of hepatic functional reserve and its modifications by Campbell and by Pugh in predicting blood loss during liver transplantation. , 1985, , 208-220.		0
5869	Prevention of Recurrent Variceal Bleeding: Non-surgical Procedures. Clinics in Gastroenterology, 1985, 14, 209-232.	0.6	8

#	Article	IF	CITATIONS
5870	The Value of Quantitation of Liver Function. , 1987, , 187-188.		O
5871	Prophylactic Treatment of First Variceal Bleeding in Cirrhotics with Nadolol or Ranitidine: A Prospective Randomized Study., 1987,, 417-421.		O
5872	Scoring systems and computer-aided prognosis in patients with bleeding oesophageal or gastric varices. Lecture Notes in Medical Informatics, 1988, , 175-181.	0.1	0
5874	Selective and total shunts in portal hypertension: facts and myths., 1988,, 333-347.		О
5875	The usefulness of Pugh's score to estimate the prognosis of patients with liver cirrhosis Acta Hepatologica Japonica, 1990, 31, 1176-1180.	0.0	0
5876	Selection of the patient for liver transplantation and timing of surgery. Juntendol,, Igaku, 1991, 37, 469-477.	0.1	2
5877	The Present Day Usage of Nonselective Shunts. , 1991, , 519-531.		0
5878	Risk factors in adult liver transplant recipients. , 1991, , 289-294.		0
5879	Prevention of Recurrent Bleeding: Nonshunt Surgery., 1991,, 533-547.		0
5880	Varizensklerosierung., 1991,, 277-296.		0
5881	Ã-sophagusvarizenblutung. , 1992, , 141-154.		0
5882	A Pugh score of 8 adequately selects patients with parenchymal cirrhosis for liver transplantation. , 1992, 5 Suppl 1, 175-178.		O
5883	An Estimation of the Function of Hepatic Microsome (Cytochrome P4501A2) in Liver Cirrhosis using Caffeine Japanese Journal of Gastroenterological Surgery, 1993, 26, 2584-2588.	0.0	0
5884	Surgical Treatment of Malignant Liver Lesions. , 1993, , 44-61.		1
5885	Sklerosierungstherapie von Ã-sophagusvarizen bei der Behandlung der Ã-sophagusvarizenblutung. , 1993, , 345-351.		0
5886	Overview of Endoscopic Injection Sclerotherapy in 1200 Patients with Esophageal Varices. , 1993 , , $262\text{-}266$.		0
5887	Donor Rating and Assessment of Pretransplant Prognosis by Use of the MEGX Test. Medical Science Symposia Series, 1993, , 19-24.	0.0	0
5888	Indication and Timing of Liver Transplantation for Clinicians. The Journal of the Japanese Practical Surgeon Society, 1994, 55, 1350-1357.	0.0	0

#	ARTICLE	IF	Citations
5889	Effect of Liver Disease on Drug Metabolism and Pharmacokinetics. Handbook of Experimental Pharmacology, 1996, , 367-394.	0.9	1
5890	Special Focus on cerebral Myo-Inositol in Patients with Hepatic Encephalopathy: Proton MR Spectroscopic Evaluation. Journal of the Korean Radiological Society, 1996, 35, 159.	0.0	O
5891	Costs of transplantation. , 1997, , 233-240.		2
5892	The liver in kidney disease., 1998,, 941-947.		0
5893	Comparison of Trimethadione Tolerance Test and Child-Pugh Score in Patients with Liver Cirrhosis Japanese Journal of Gastroenterological Surgery, 1998, 31, 36-39.	0.0	0
5894	Assessments of pugh's modification of childturcotte classification as prognostic indicator in liver cirrhotics: a cohort study. Qatar Medical Journal, 1998, 1998, .	0.2	0
5895	Wertigkeit biologischer Marker bei Hepatopathien aus internistischer Sicht., 1999,, 110-117.		0
5896	Use of Interferon-α for Prevention of Hepatocellular Carcinoma in Patients with Chronic Active Hepatitis C with Cirrhosis., 1999,, 93-102.		1
5897	Varizensklerosierung von Ösophagus- und Fundusvarizen und Gummibandligatur. , 1999, , 240-255.		0
5898	Oral Cephalosporins. , 0, , 222-268.		0
5899	Medication prescribing in liver dysfunction. Mental Health Clinician, 2014, 4, 131-137.	0.5	1
5900	Risks and benefits of phase I liver dysfunction studies: Should patients with severe liver dysfunction be included in these trials?. Journal of Clinical Oncology, 2014, 32, 2536-2536.	0.8	0
5901	25-Hydroxyvitamin D3 Level in Patients with Chronic Viral Hepatitis B. Journal of Medical Sciences (Faisalabad, Pakistan), 2014, 14, 192-200.	0.0	1
5902	Predictors of Emergency Blood Transfusion in Esophageal Variceal Bleeding. Journal of Academic Emergency Medicine, 2014, 13, 45-48.	0.1	0
5904	Acute and Chronic Liver Disease., 2015,, 523-550.		0
5906	Pain Management in Patients with Hepatic Impairment. , 2015, , 227-234.		1
5907	Visceral Fat Accumulation Is Associated with Increased Mortality Rate after Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma. Journal of Cancer Therapy, 2015, 06, 1124-1136.	0.1	1
5908	Role of Serum Zinc Level and P300 Event Related Potential in Detection of Minimal Hepatic Encephalopathy. Open Journal of Gastroenterology, 2015, 05, 58-65.	0.1	O

#	Article	IF	Citations
5909	Nutrition profile of a liver transplant recipient. Hepatoma Research, 2015, .	0.6	0
5910	Options and Problems of Drug Application in Patients with Advanced Cancer. , 2015, , 137-156.		O
5911	Preventive measures for recurrent hepatic encephalopathy in a hemodialysis patient. Nihon Toseki lgakkai Zasshi, 2015, 48, 199-205.	0.2	1
5912	Current advances made in the surgical treatment of hepatocellular carcinoma. International Surgery Journal, 2015, 2, 147.	0.0	0
5913	Clinical Use of Indocyanine Green (ICG) Kinetics in Liver Anaesthesia and ICU., 2015, , 177-199.		0
5914	Isolation and Detection of Serum Lp-X by Immunoaffinity Separation Method. Journal of Clinical and Laboratory Investigation Updates, 2015, 3, 1-6.	0.4	0
5916	Model for End-Stage Liver Disease (Meld) Score, As a Prognostic Factor for Cirrhotic Patients, Undergoing Hepatectomy for Hepatocellular Carcinoma. Gastroenterology & Hepatology (Bartlesville,) Tj ETQq0 () TBgn o	Oværlock 10
5917	USEFULNESS OF MELD SCORE IN PREDICTING IN - HOSPITAL MORTALITY IN PAT I ENTS WITH END STAGE LIVER DISEASE: AN OBSERVATIONAL STUDY. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 7734-7740.	0.1	O
5918	Diverse Utility of Endogenous Thrombin Potential and Thromboelastometry in the Assessment of Patients with Alcoholic Cirrhosis. Hematology & Transfusion International Journal, 2015, 1, .	0.1	0
5920	Radiofrequency Thermal Ablation versus Microwave Ablation for Small Hepatocellular Carcinoma. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2015, 5, 171-176.	0.1	0
5924	Sclerotherapy Using Aluminum Potassium Sulfate and Tannic Acid (ALTA) for Haemorrhoids in Patients With Liver Cirrhosis. Annals of Colorectal Research, 2015, 3, .	0.1	0
5925	SLC11A1 : Gene Polymorphism and Progression of Fibrosis in Hepatitis C. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2015, 5, 305-310.	0.1	0
5926	Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival. Journal of Cancer Therapy, 2016, 07, 275-284.	0.1	1
5927	Management of Choledocholithiasis in the Cirrhotic Patient. , 2016, , 151-159.		O
5928	Which Is the Better Predictor of Hepatic Reserve Prior to Liver Resection: MELD or the Child-Pugh Score?. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 189-199.	0.0	0
5929	Effects of Preoperative Platelet Count on Blood Loss for Splenectomy with Esophagogastric Devascularization. Journal of Blood Disorders & Transfusion, 2016, 7, .	0.1	O
5930	What Is the Best Way to Assess Hepatic Reserve Prior to Liver Resection in the Cirrhotic Patient?. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 165-177.	0.0	0
5931	Cirrhotics Treated In Intensive Care Unit Have High Short Term Survival in the Absence of Extrahepatic Organ Dysfunction. Journal of Gastroenterology and Hepatology Research, 2016, 5, 1984-1988.	0.2	O

#	Article	IF	CITATIONS
5932	Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC. AIMS Medical Science, 2016, 3, 162-178.	0.2	0
5933	Changes in Serum Lipid Profile among Patients Suffering from Chronic Liver Disease Secondary to Hepatitis C. Open Journal of Gastroenterology, 2016, 06, 333-342.	0.1	1
5934	Hepatic Hydrothorax in Patients with Decompensated Cirrhosis in Zagazig University Hospitals: A Cross-sectional and Single Center Study. International Journal of Tropical Disease & Health, 2016, 15, 1-8.	0.1	0
5935	Model for End-Stage Liver Disease (MELD) Score as a Biomarker. Exposure and Health, 2016, , 1-24.	2.8	0
5936	Value of Protein C and D-Dimer in Predicting Non Hepatocellular Carcinoma Portal Vein Thrombosis in Patients with Liver Cirrhosis. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2016, 6, 68-74.	0.1	0
5937	Comparative Study of MELD Score and Glasgow Coma Scale in Patients with Hepatic Encephalopathy. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2016, 6, 82-93.	0.1	0
5938	Liver Tumors. Pediatric Oncology, 2017, , 453-476.	0.5	0
5939	Is the Model for End-Stage Liver Disease (MELD) Score the Best Way to Evaluate Liver Transplant Patients Preoperatively?., 2017,, 229-231.		O
5940	Liver Resection., 2017,, 583-597.		0
5941	Arterial blood pressure circadian rhythm in normotensive decompensated cirrhotic patients before and after single paracentesis. Annales Academiae Medicae Silesiensis, 2016, 70, 265-273.	0.1	0
5942	General Care of the Liver Patient., 2017, , 17-25.		0
5943	Colorectal Surgery in Cirrhotics. , 2017, , 201-214.		0
5945	Primary Liver Cancer: Background and Clinical Evidence., 2017,, 103-117.		0
5946	Microbiological study of spontaneous bacterial peritonitis in Tanta University Hospitals. Egyptian Liver Journal, 2017, 7, 5-8.	0.3	1
5947	Child-Turcotte-Pugh-Score., 2017,, 1-1.		0
5948	Complications of Chronic Alcoholism That Affect Critical Illness. , 2017, , 249-266.		0
5949	Resection of Large Hepatocellular Carcinoma: Hanging Technique. , 2017, , 3-16.		0
5950	Model for End-Stage Liver Disease (MELD) Score as a Biomarker. Biomarkers in Disease, 2017, , 47-70.	0.0	0

#	Article	IF	CITATIONS
5951	Performance of Disease-Specific Scoring Models in Intensive Care Patients with Severe Liver Diseases. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, OC12-OC16.	0.8	3
5952	The Impact of Liver Disease on Drug Metabolism. , 2017, , 29-39.		0
5954	EARLY DETECTION OF RENAL BLOOD FLOW IMPEDANCE BY COLOUR DOPPLER IN CHRONIC LIVER DISEASE WITH NORMAL RENAL PARAMETERS. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 1924-1927.	0.1	0
5955	Preoperative Phenacetin Metabolism Test in the Prediction of Postoperative Liver Dysfunction of Patients with Hepatocellular Carcinoma. Medical Science Monitor, 2017, 23, 2607-2611.	0.5	4
5956	Evaluation of INR Elevation in Cirrhotic Patients as a Risk Factor for Esophageal Variceal Bleeding. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2017, 7, 146-154.	0.1	0
5957	Early-Onset Pneumonia After Liver Transplant: Microbial Causes, Risk Factors, and Outcomes, Mansoura University, Egypt, Experience. Experimental and Clinical Transplantation, 2017, 15, 547-553.	0.2	2
5958	Annual Change in FIB-4, but not in APRI, was a Strong Predictor for Liver Disease Progression in Chinese Patients with Chronic Hepatitis C. Hepatitis Monthly, 2017, 18, .	0.1	0
5959	Transplantation of the Liver. , 2018, , 753-768.e3.		0
5960	The Evaluation of Tolvaptan Therapy and Long-Term Prognosis in Hepatocellular Carcinoma with Refractory Ascites. Open Journal of Gastroenterology, 2018, 08, 39-44.	0.1	0
5962	Does Rifaximin Improve EEG and VEP in Egyptian Cirrhotic Patients with Minimal Hepatic Encephalopathy?. Open Journal of Gastroenterology, 2018, 08, 362-376.	0.1	0
5963	Role of Nerve Growth Factor (NGF) and Its Receptor Tyrosine Kinase A (TrK A) in Egyptian Cirrhotic Patients with Pruritus. Open Journal of Gastroenterology, 2018, 08, 317-326.	0.1	0
5964	Ultrasonoscopic description of the structure and function of the heart in patients with syntropic cirrhotic cardiomyopathy and their features depending on the main liver disease severity. Acta Medica Leopoliensia, 2018, 24, 24-36.	0.0	0
5966	Prise en charge des complications de la cirrhose. , 2018, , 263-279.e1.		0
5967	Medical Therapy Options for Advanced Disease in Hepatocellular Carcinoma. , 2018, , 91-97.		0
5968	Approach to Jaundice and Abnormal Liver Function Test Results. , 2018, , 99-116.e6.		2
5969	Patient Selection and Technical Considerations. , 2018, , 3-13.		0
5971	Sofosbuvir/simeprevir versus sofosbuvir/ribavirin regimen in Egyptian patients with hepatitis C virus. Egyptian Liver Journal, 2018, 8, 6-11.	0.3	0
5972	Partial Splenic Artery Embolization in Cirrhosis Is a Safe and Useful Procedure. Open Journal of Gastroenterology, 2018, 08, 327-336.	0.1	1

#	Article	IF	CITATIONS
5973	Drug Metabolism in Liver Failure. , 2018, , 69-78.		0
5974	Cholecystectomy in Cirrhosis. , 2018, , 279-289.		1
5975	Hepatic encephalopathy in patients in Lviv (Ukraine). Journal of Translational Internal Medicine, 2018, 6, 146-151.	1.0	5
5977	Preoperative Preparations for Patients with Hepatocellular Carcinoma. , 2019, , 7-26.		O
5978	Severity Degrees of Syntropic Stable Arterial Hypotension in the Cirrhotic Patients and Their Dependence on the Daily Blood Pressure Monitoring and Liver Damage Class by C.G Child - R.N. Pugh. Lviv Clinical Bulletin, 2018, 3, 43-51.	0.1	1
5979	Types of Segment-Oriented Hepatic Resection by the Glissonean Pedicle Approach. , 2019, , 49-260.		O
5980	Evaluation of pharmaceutical intervention in patients with hepatic insufficiency in a hospital setting. Gastroenterology & Hepatology (Bartlesville, Okla), 2018, 9, .	0.0	1
5981	The role of red cell distribution width as a noninvasive index for predicting liver cell failure and portal hypertension in cirrhotic patients. The Egyptian Journal of Internal Medicine, 2018, 30, 255-263.	0.3	O
5982	Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2018, 19, 3545-3550.	0.5	18
5983	Impact of sepsis and non-communicable diseases on prognostic models to predict the outcome of hospitalized chronic liver disease patients. World Journal of Hepatology, 2018, 10, 944-955.	0.8	1
5984	Coagulopathy in Cirrhotic Patients: Evaluation and Management. , 2019, , 229-244.		0
5985	Correla \tilde{A} § \tilde{A} £o entre a am \tilde{A} ´nia e o potencial evocado relacionado a eventos (P300) em pacientes cirr \tilde{A} ³ticos. Revista Neurociencias, 2009, 17, 122-127.	0.0	3
5986	Early Phase Metabolic Research with Reference to Special Populations., 2019,, 517-538.		0
5987	Prediction of Liver Function Based on DCE-CT. Informatik Aktuell, 2019, , 8-13.	0.4	0
5988	Correlation between nutritional assessment and oxidative stress in candidates for liver transplant. Einstein (Sao Paulo, Brazil), 2019, 18, eAO4039.	0.3	2
5989	Child-Turcotte-Pugh-Score. Springer Reference Medizin, 2019, , 564-564.	0.0	0
5990	Regional gray matter abnormality in hepatic myelopathy patients after transjugular intrahepatic portosystemic shunt: a voxel-based morphometry study. Neural Regeneration Research, 2019, 14, 850.	1.6	3
5991	Relationship between Lp-PLA2 and Child-Pugh classification in patients with hepatitis B cirrhosis. World Chinese Journal of Digestology, 2019, 27, 160-166.	0.0	0

#	Article	IF	CITATIONS
5992	Patterns of nail changes in chronic liver diseases. Sohag Medical Journal (SMJ), 2019, 23, 166-170.	0.1	0
5993	Scoring criteria for determining the safety of liver resection for malignant liver tumors. World Journal of Meta-analysis, 2019, 7, 234-248.	0.1	1
5994	Child-Pugh Classification using Magnetic Resonance Imaging using Gadoxetic Acid-based Contrast Agent Compared with Indocyanine Green and ^{99m} Tc-galactosyl-human Serum Albumin Liver Scintigraphy. Kitakanto Medical Journal, 2019, 69, 183-189.	0.0	0
5995	Acute on Chronic Liver Failure. , 2020, , 193-217.		O
5996	Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease. Egyptian Heart Journal, 2019, 71, 15.	0.4	3
5997	Diagnostic Value of Serum Heat Shock Protein 70 in Hepatocellular Carcinoma Patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2019, 9, 216-223.	0.1	0
5998	TO EVALUATE PROGNOSTIC VALUE OF MELD AND CHILD-TURCOTTE PUGH SCORES IN PATIENTS WITH LIVER CIRRHOSIS AND VARICEAL BLEEDING. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 2586-2590.	0.0	0
5999	Dual Effects of Large Spleen Volume After Splenectomy for the Patients With Chronic Liver Disease. International Surgery, 2019, 104, 412-422.	0.0	0
6000	Prescription Selection and Dosing. , 2020, , 169-175.		0
6001	Is rectus abdominis thickness associated with survival among patients with liver cirrhosis? A prospective cohort study. Sao Paulo Medical Journal, 2019, 137, 401-406.	0.4	3
6002	Prognostic Assessment of Budd–Chiari Syndrome. , 2020, , 189-205.		0
6004	Should Frailty Include Multidimensional and Dynamic Factors?. , 2020, , 233-246.		0
6005	Surgery for Budd–Chiari Syndrome. , 2020, , 171-179.		0
6006	To study adrenal insufficiency and to determine relationship between BMI and serum cortisol levels in cirrhotic patients. International Journal of Clinical Biochemistry and Research, 2019, 6, 518-521.	0.0	0
6007	Acute-on-chronic liver failure. , 2019, , 161-178.		0
6009	Application of acoustic radiation force impulse elastography combined with serum markers in Child-Pugh grading. Clinics, 2020, 75, e1670.	0.6	2
6010	OPTIMUM DURATION OF PERCUTANEOUS TRANSHEPATIC CHOLANGIODRAINAGE IN COMMON BILE DUCT DISEASES COMPLICATED BY OBSTRUCTIVE JAUNDICE. WiadomoÅci Lekarskie, 2020, 73, 1915-1925.	0.1	2
6011	Practical issues in measuring the anticoagulant effect of direct oral anticoagulants. Arhiv Za Farmaciju, 2020, 70, 297-309.	0.2	O

#	Article	IF	CITATIONS
6012	Serum Urea Predicts Long-term Mortality in Hospitalized Patients with Decompensated Cirrhosis. Hepatitis Monthly, 2020, 20, .	0.1	0
6013	The Relationship between Trace Elements and Depression among Older Patients with Chronic Liver Disease. Electronic Journal of General Medicine, 2020, 17, em224.	0.3	0
6014	Efficacy and Pattern of Antibiotic Usage Among Patients with Cirrhosis and/or Chronic Liver Disease in Telangana, India. Exploratory Research and Hypothesis in Medicine, 2020, 000, 1-6.	0.1	0
6015	PREDICTING DEATH IN PATIENTS WITH END-STAGE LIVER DISEASE: A NEW MODEL FOR ASSESSING DISEASE SEVERITY. Innovative Medicine of Kuban, 2020, , 21-27.	0.0	1
6016	Complex treatment of hepatocellular carcinoma at early (BCLC-A) and intermediate (BCLC-B) stages. Annals of HPB Surgery, 2020, 25, 55-66.	0.1	2
6017	Pharmacokinetic Analysis, Analgesic Effects, and Adverse Effects of Tapentadol in Cancer Patients with Pain. Biological and Pharmaceutical Bulletin, 2020, 43, 1000-1006.	0.6	3
6018	LIV-4: A novel model for predicting transplant-free survival in critically ill cirrhotics. World Journal of Hepatology, 2020, 12, 298-311.	0.8	2
6019	Elevated neopterin levels are associated with acute-on-chronic liver failure and mortality in patients with liver cirrhosis. Digestive and Liver Disease, 2020, 52, 753-760.	0.4	1
6020	Correlation of serum betatrophin levels with disease severity and the emergence of insulin resistance in cirrhotic patients. Egyptian Liver Journal, 2020, 10 , .	0.3	2
6021	Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models. European Journal of Gastroenterology and Hepatology, 2021, 33, 1547-1555.	0.8	5
6022	Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis. World Journal of Gastroenterology, 2020, 26, 4316-4326.	1.4	5
6023	Peritoneal Dialysis in a Patient with Acute Kidney Injury, Thrombocytopenia, Urosepsis, and Liver Cirrhosis: A Case Report. American Journal of Case Reports, 2020, 21, e926226.	0.3	0
6024	Adult liver transplantation using pediatric donor livers after cardiac or brain death: A report of three cases. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	4
6025	The Profile and Role of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: An Immunohistochemical Study. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 188-200.	0.6	3
6027	The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis. Egyptian Rheumatology and Rehabilitation, 2020, 47, .	0.2	2
6028	Histologic Changes in Core-Needle Liver Biopsies From Patients With Acute-on-Chronic Liver Failure and Independent Histologic Predictors of 28-Day Mortality. Archives of Pathology and Laboratory Medicine, 2022, 146, 846-854.	1,2	4
6029	A History of the Assessment of Liver Performance. Clinical Liver Disease, 2021, 18, 28-48.	1.0	4
6030	Bioelectrical impedance vector analysis in patients on the waiting list for liver transplant: Associated factors and prognostic effects. Nutrition, 2022, 94, 111528.	1.1	2

#	Article	IF	Citations
6031	A Prospective Multicenter Study of the Chinese Scoring System for Hepatitis B Liver Failure. Frontiers in Medicine, 2021, 8, 751807.	1.2	1
6032	The effect of branched-chain amino acids on body protein breakdown and synthesis in patients with chronic liver disease., 1983,, 103-109.		1
6033	The Epidemiological, Clinical, Biological and Morphological Characteristics of Primitive Liver Cancers in Bangui. Open Journal of Gastroenterology, 2020, 10, 97-105.	0.1	1
6034	Clinical and laboratory parameters as predictors of long-term outcome according to the etiology of underlying chronic liver disease in patients who underwent liver transplantation for hepatocellular carcinoma treatment. Clinics, 2020, 75, e1529.	0.6	O
6035	Prognostic Models in Acute and Acute on Chronic Liver Failure. , 2020, , 91-107.		0
6036	MALNUTRITION IN CIRRHOSIS: ASSOCIATION WITH ETIOLOGY AND HEPATOCELLULAR DYSFUNCTION. Arquivos De Gastroenterologia, 2020, 57, 375-380.	0.3	4
6037	Neutrophil-to-Lymphocyte Ratio and Albumin: New Serum Biomarkers to Predict the Prognosis of Male Alcoholic Cirrhosis Patients. BioMed Research International, 2020, 2020, 1-7.	0.9	6
6038	Bleeding After Elective Interventional Endoscopic Procedures in a Large Cohort of Patients With Cirrhosis. Clinical and Translational Gastroenterology, 2020, 11, e00288.	1.3	9
6039	Altered von Willebrand Factor (vWF) and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension. Journal of Pediatric Hematology/Oncology, 2020, Publish Ahead of Print, e951-e956.	0.3	1
6040	Effect of liver disease on pharmacokinetics. , 2022, , 91-112.		0
6041	The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis. Annals of Gastroenterology, 2020, 33, 667-674.	0.4	4
6042	Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development. , 2020, , 313-342.		0
6043	Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores. Journal of Korean Medical Science, 2020, 35, e129.	1.1	4
6044	Systematic review and meta-analysis of risk scores in prediction for the clinical outcomes in patients with acute variceal bleeding. Annals of Medicine, 2021, 53, 1806-1815.	1.5	9
6045	ERKRANKUNGEN DER VERDAUUNGSORGANE. , 2020, , pA-1-pA7.8-14.		0
6046	Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. Biomedical Reports, 2020, 12, 89-98.	0.9	12
6047	Serum cystatin C unmasks renal dysfunction in cirrhosis and performs better in estimation of glomerular filtration rate. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2020, 31, 1320.	0.4	6
6049	Special Considerations in Organ Failure. , 2020, , 285-313.		0

#	Article	IF	Citations
6050	Perioperative Risk Models., 2020, , 11-30.		О
6051	Hepatocellular Carcinoma (HCC), Where do we stand? Current situation. Pakistan Journal of Medical Sciences, 2020, 36, 344-348.	0.3	3
6052	The Association of Serum Estradiol Level with the Susceptibility and Clinicopathological Features of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Medical Journal of the University of Cairo Faculty of Medicine, 2020, 88, 173-180.	0.0	0
6053	Muscle depletion in cirrhotic patients assessed using computed tomography: a cross-sectional study. Sao Paulo Medical Journal, 2020, 138, 152-157.	0.4	1
6054	Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis. World Journal of Hepatology, 2020, 12, 99-107.	0.8	15
6055	Hyaluronic Acid, Spleen Size and Prothrombin Time Predict the Existence of High-Risk Esophageal Varices in Non-Viral Cirrhosis in Real Life. Medicina Interna (Bucharest, Romania: 1991), 2020, 17, 7-19.	0.1	0
6056	Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib. Revista Da Associação Médica Brasileira, 2020, 66, 275-283.	0.3	0
6057	Association between Portal Vein Colored Doppler Ultrasound Findings and Severity of Liver Disease in Cirrhotic Patients with Portal Hypertension. Al-Azhar International Medical Journal, 2020, .	0.0	1
6059	ACUTE-ON-CHRONIC LIVER FAILURE IS INDEPENDENTLY ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS. Arquivos De Gastroenterologia, 2021, 58, 344-352.	0.3	5
6060	Observational study of the relative efficacy of insulin-glucose treatment for hyperkalaemia in patients with liver cirrhosis. BMJ Open, 2021, 11, e051201.	0.8	0
6061	Presence of ascites at presentation is associated with absence of long term response amongst patients with Budd-Chiari syndrome when treated with medical therapy alone: A single centre real life experience. Journal of Clinical and Experimental Hepatology, 2021, , .	0.4	1
6062	Clinical significance of the latency period of abnormal ammonia metabolism in chronic liver disease: Proposal of a new concept. Hepatology Research, 2022, 52, 75-80.	1.8	1
6063	Role of Eltrompobag in treatment of thrombocytopenia associated with chronic Hepatitis C Virus. SVU - International Journal of Medical Sciences, 2020, 3, 55-60.	0.0	0
6064	Differential diagnosis of human hepatitis. , 2008, , 21-46.		O
6065	Clinical Characteristics of Portal Hemodynamics in Alcoholic Liver Cirrhosis. Alcoholism: Clinical and Experimental Research, 2004, 28, 148S-152S.	1.4	4
6066	Hepatic Disease. , 2004, , 463-490.		0
6068	The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. Journal of Thrombosis and Haemostasis, 2008, 6, 243-248.	1.9	9
6071	Immunomodulation Therapy for Alcoholic Hepatitis. , 2007, , 323-336.		0

#	Article	IF	CITATIONS
6072	Operative Therapie der portalen Hypertension. , 2006, , 654-661.		0
6073	Liver Tumors. , 2007, , 311-330.		O
6075	Association between vitamin D status and depression in children with chronic liver disease. Egyptian Liver Journal, 2020, 10, .	0.3	0
6076	Liver fibrosis assessment by transient elastography in patients with liver cirrhosis after hepatitis C virus eradication. SeÄenovskij Vestnik, 2020, 11, 26-37.	0.3	0
6077	The miR-21 potential of serving as a biomarker for liver diseases in clinical practice. Biochemical Society Transactions, 2020, 48, 2295-2305.	1.6	10
6078	Right ventricular dysfunction in cirrhosis: A speckle-tracking echocardiography study. Journal of Surgery and Medicine, 2020, 4, 1036-1040.	0.0	4
6080	Prognostic Assessment of Variceal Bleeding in Liver Cirrhosis. , 2021, , 161-169.		0
6081	Inpatient Anaesthesia. Clinics in Anaesthesiology, 1986, 4, 445-457.	0.2	0
6082	The Patient with Liver Disease. Clinics in Anaesthesiology, 1986, 4, 747-760.	0.2	0
6084	Liver (Including Intrahepatic Bile Ducts). , 2006, , 127-132.		10
6085	Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Medica Okayama, 2006, 60, 77-84.	0.1	41
6089	Surgical management of portal hypertension. Western Journal of Medicine, 1995, 162, 527-35.	0.3	18
6090	Medical evaluation before operation. Western Journal of Medicine, 1982, 137, 351-8.	0.3	6
6091	Anesthesia in 1984: how safe is it?. Cmaj, 1984, 131, 437-41.	0.1	8
6092	Liver disease and anaesthesia. The BMJ, 1978, 1, 1374-5.	0.0	0
6093	Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. MedGenMed: Medscape General Medicine, 2005, 7, 7.	0.2	13
6094	Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut, 1999, 45 Suppl 6, VII-VI22.	6.1	12
6095	Cross reactivity due to positive canrenone interference. Gut, 2004, 53, 772-3.	6.1	0

#	ARTICLE	IF	CITATIONS
6096	Anaesthesia for injection of bleeding oesophageal varices. Annals of the Royal College of Surgeons of England, 1976, 58, 315-7.	0.3	3
6097	Oesophageal varices: evaluation of injection sclerotherapy without general anesthesia using the flexible fibreoptic gastroscope. Annals of the Royal College of Surgeons of England, 1982, 64, 401-5.	0.3	10
6098	Prospective study of a planned approach to the surgical management of bleeding oesophageal varices. Annals of the Royal College of Surgeons of England, 1986, 68, 256-9.	0.3	0
6099	Upper gastrointestinal bleeding in patients with liver cirrhosis. Journal of the National Medical Association, 2002, 94, 712-5.	0.6	17
6100	Current management of advanced hepatocellular carcinoma. Gastrointestinal Cancer Research: GCR, 2008, 2, 64-70.	0.8	18
6101	Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology. Gastrointestinal Cancer Research: GCR, 2007, 1, S85-9.	0.8	O
6102	Spontaneous bacterial peritonitis: a review of treatment options. P and T, 2009, 34, 204-10.	1.0	25
6105	Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointestinal Cancer Research: GCR, 2011, 4, 40-4.	0.8	40
6106	Platelet count/bipolar spleen diameter ratio for the prediction of esophageal varices: The special Egyptian situation: Noninvasive prediction of esophageal varices. Hepatitis Monthly, 2011, 11, 278-84.	0.1	17
6107	Use of artificial neural network to predict esophageal varices in patients with HBV related cirrhosis. Hepatitis Monthly, 2011, 11, 544-7.	0.1	11
6108	Radio frequency ablation for primary liver cancer: an evidence-based analysis. Ontario Health Technology Assessment Series, 2004, 4, 1-50.	3.0	48
6109	Unresectable hepatocellular carcinoma treated with transarterial chemoembolization: clinical data from a single teaching hospital. International Journal of Clinical and Experimental Medicine, 2013, 6, 367-71.	1.3	2
6110	The evolution in the prioritization for liver transplantation. Annals of Gastroenterology, 2012, 25, 6-13.	0.4	30
6111	Significance of the C-caffeine breath test for patients with cirrhosis. Annals of Gastroenterology, 2014, 27, 53-59.	0.4	3
6112	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterology and Hepatology, 2013, 9, 1-24.	0.2	5
6113	Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences, 2014, 19, 703-8.	0.4	15
6114	Effects of cirrhosis on bone mineral density and bone metabolism. Eurasian Journal of Medicine, 2008, 40, 18-24.	0.2	3
6115	The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Annals of Gastroenterology, 2015, 28, 109-117.	0.4	15

#	Article	IF	CITATIONS
6116	Child-Pugh versus MELD score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis. International Journal of Clinical and Experimental Medicine, 2015, 8, 751-7.	1.3	48
6117	Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. International Journal of Clinical and Experimental Medicine, 2015, 8, 1205-12.	1.3	14
6119	Perineural invasion: a potential reason of hepatocellular carcinoma bone metastasis. International Journal of Clinical and Experimental Medicine, 2015, 8, 5839-46.	1.3	4
6120	Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement: a systematic meta-analytic review. International Journal of Clinical and Experimental Medicine, 2015, 8, 13464-72.	1.3	18
6121	FRZB up-regulated in hepatocellular carcinoma bone metastasis. International Journal of Clinical and Experimental Pathology, 2015, 8, 13353-9.	0.5	4
6122	Medical Care of the Patient With Compensated Cirrhosis. Gastroenterology and Hepatology, 2006, 2, 124-133.	0.2	1
6123	Falsely Elevated Serum Vitamin B Levels Were Associated with the Severity and Prognosis of Chronic Viral Liver Disease. Yonago Acta Medica, 2017, 60, 31-39.	0.3	11
6124	Bleeding oesophageal varices: referral bias and survival. Journal of the Royal College of Physicians of London, 1985, 19, 189-91.	0.2	2
6125	Simplified fibre endoscopic sclerotherapy for oesophageal varices. Journal of the Royal College of Physicians of London, 1982, 16, 236-8.	0.2	6
6126	The effect of intravenous infusion of N-acetyl cysteine in cirrhotic patients undergoing liver resection: A randomized controlled trial. Journal of Anaesthesiology Clinical Pharmacology, 2017, 33, 450-456.	0.2	3
6127	Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing. International Journal of Clinical and Experimental Pathology, 2017, 10, 10495-10504.	0.5	1
6128	Magnetization transfer contrast of various regions of the brain in liver cirrhosis. American Journal of Neuroradiology, 1999, 20, 652-4.	1.2	33
6129	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2021, 21, 30.	0.8	0
6130	A Single-Center Report on Liver Transplantation: First Experiences from Shahid Beheshti University of Medical Sciences. Middle East Journal of Digestive Diseases, 2020, 12, 252-256.	0.2	1
6131	1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy. American Journal of Neuroradiology, 2006, 27, 1019-26.	1,2	79
6132	MR imaging of CNS involvement in children affected by chronic liver disease. American Journal of Neuroradiology, 2000, 21, 845-51.	1.2	14
6133	MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. American Journal of Neuroradiology, 2006, 27, 1373-8.	1.2	101
6134	Different combinations of the GLIM criteria for patients awaiting a liver transplant: Poor performance for malnutrition diagnosis but a potentially useful prognostic tool. Clinical Nutrition, 2022, 41, 97-104.	2.3	16

#	Article	IF	CITATIONS
6135	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma. Clinical Radiology, 2021, , .	0.5	1
6136	Predictive potential of the MELD and Child-Turcotte-Pugh II scores for SBP in patients with cirrhosis and ascites. Arhivi Na Javnoto Zdravje, 2021, 13, 101-109.	0.1	1
6137	Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 747-757.	1.4	4
6138	The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways. Canadian Pharmacists Journal, 2022, 155, 171516352110581.	0.4	1
6139	Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease. World Journal of Cardiology, 2021, 13, 599-607.	0.5	5
6140	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 2022, 76, 681-693.	1.8	1,495
6141	Impacts of body composition parameters and liver cirrhosis on the severity of alcoholic acute pancreatitis. PLoS ONE, 2021, 16, e0260309.	1.1	4
6142	The Outcome after Hospital Discharge in Cirrhosis is Not Worsened with COVID-19 Infection: A Propensity Score-matched Analysis. Journal of Clinical and Experimental Hepatology, 2021, , .	0.4	2
6143	The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. Langenbeck's Archives of Surgery, 2021, , 1.	0.8	1
6144	Role of early transjugular intrahepatic portosystemic stent-shunt in acute variceal bleeding: An update of the evidence and future directions. World Journal of Gastroenterology, 2021, 27, 7612-7624.	1.4	6
6145	Circulating MicroRNA-21 As A Novel Noninvasive Biomarker for Hepatocellular Carcinoma Compared with Alpha Fetoprotein Gold Test. Journal of Pure and Applied Microbiology, 2021, 15, 2473-2485.	0.3	0
6147	Albumin for people with liver cirrhosis and bacterial infections. The Cochrane Library, 2021, 2021, .	1.5	0
6148	Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transplant International, 2002, 15, 34-38.	0.8	7
6149	Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. Transplant International, 2002, 15, 188-195.	0.8	12
6150	Potential of PALBIâ€₹ score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease. JGH Open, 2022, 6, 36-43.	0.7	3
6151	Assessment of Plasma Vitronectin as Diagnostic and Prognostic Marker of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Cirrhosis. Gastroenterology Insights, 2022, 13, 9-19.	0.7	5
6152	Diagnostic potential of T1i-and T2 relaxations in assessing the severity of liver fibrosis and necro-inflammation. Magnetic Resonance Imaging, 2022, 87, 104-112.	1.0	8
6153	Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. Journal of Clinical Lipidology, 2022, 16, 208-219.	0.6	32

#	Article	IF	CITATIONS
6154	Presepsin and Resistin as Diagnostic Markers for Bacterial Infection in Patients with Decompensated Cirrhosis. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2020, .	0.1	0
6155	Effect of delta α-fetoprotein on the detection of liver cancer recurrence. Translational Cancer Research, 2020, 9, 6263-6274.	0.4	5
6156	QN-S3VM Method for Evaluation of Liver Functional Reserve. , 2020, , .		1
6157	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2020, 21, 1-1.	0.8	2
6158	Prognostic value of AlMS65 score in cirrhotic patients with variceal bleeding. Y Hoc Thanh Pho Ho Chi Minh, 2021, 6, 22-26.	0.1	0
6159	Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. Digestive and Liver Disease, 2021, , .	0.4	0
6160	Applicability of the Chronic Liver Failure-Consortium score in patients with cirrhosis and bacterial infections: a single-clinic experience. Gastroenterologia, 2021, 55, 239-245.	0.0	0
6161	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. Cancers, 2022, 14, 385.	1.7	6
6162	Cognitive impairment in recipients of liver transplantation and relation to hepatic encephalopathy. Middle East Current Psychiatry, 2022, 29, .	0.5	0
6163	Development of a Widely Applicable and Simple Prognostic Score for Patients with Acute-on-chronic Liver Failure. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	0
6164	Practical treatment guidance for cancer-associated thrombosis – Managing the challenging patient: A consensus statement. Critical Reviews in Oncology/Hematology, 2022, 171, 103599.	2.0	6
6165	Relationship between the Level of Serum Golgi Protein 73 and the Risk of Short-term Death in Patients with ALD-ACLF. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	2
6166	A painful mass in the jaw. Cleveland Clinic Journal of Medicine, 2022, 89, 27-35.	0.6	0
6167	Preoperative MELD score predicts adverse outcomes following gastrectomy: An ACS NSQIP analysis. American Journal of Surgery, 2022, 224, 501-505.	0.9	2
6168	Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis. Journal of Hepatology, 2022, 77, 98-107.	1.8	3
6169	Mortality Following Appendicectomy in Patients with Liver Cirrhosis: A Systematic Review and Metaâ€Analysis. World Journal of Surgery, 2022, 46, 531-541.	0.8	5
6171	Liver transplant allocation policies and outcomes in United States: A comprehensive review. World Journal of Methodology, 2022, 12, 32-42.	1.1	21
6172	Risk Factors for Esophageal Collateral Veins in Cirrhosis with and without Previous Endoscopic Esophageal Variceal Therapy. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-13.	0.8	2

#	Article	IF	CITATIONS
6173	Early prediction of decompensation (<scp>EPOD</scp>) score: Nonâ€invasive determination of cirrhosis decompensation risk. Liver International, 2022, 42, 640-650.	1.9	6
6174	Evaluation of staging systems to predict prognosis in hepatocellular carcinoma patients treated with radioembolization. Heliyon, 2022, 8, e08770.	1.4	1
6175	Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma. Cancer Medicine, 2022, 11, 1535-1541.	1.3	9
6176	Prognostic impact of albumin-bilirubin score on the prediction of in-hospital mortality in patients with heart failure: a retrospective cohort study. BMJ Open, 2022, 12, e049325.	0.8	10
6177	From LI-RADS Classification to HCC Pathology: A Retrospective Single-Institution Analysis of Clinico-Pathological Features Affecting Oncological Outcomes after Curative Surgery. Diagnostics, 2022, 12, 160.	1.3	19
6178	Liver volume based prediction model for patients with hepatitis B virusâ€related acuteâ€onâ€chronic liver failure. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 1253-1263.	1.4	4
6179	Plasma angiopoietin 2 as a novel prognostic biomarker in alcohol-related cirrhosis and hepatitis. Liver Research, 2022, , .	0.5	0
6180	Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study. Journal of Oncology Pharmacy Practice, 2023, 29, 626-636.	0.5	1
6181	Feeding Vessel Ablation: A Novel Subsegmental Devascularization Technique for the Treatment of Hepatocellular Carcinoma Located at the Liver Marginal Angle. Ultrasound in Medicine and Biology, 2022, 48, 546-553.	0.7	0
6182	Effect of Ayurveda Management on Liver Cirrhosis with Ascites-A Retrospective Cohort Study. Journal of Ayurveda and Integrative Medicine, 2022, 13, 100508.	0.9	3
6183	Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. GastroenterologÃa Y HepatologÃa (English Edition), 2022, 45, 25-39.	0.0	0
6184	OUP accepted manuscript. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, , .	0.7	0
6185	Value of Bile Acids in Diagnosing Hepatitis C Virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma. , 0, 79, .		3
6186	QT Interval Prolongation Among Patients with Chronic Liver Disease Attending Jimma Medical Center Gastroenterology Clinic, Southwest Ethiopia. Research Reports in Clinical Cardiology, 0, Volume 13, 9-18.	0.2	1
6187	Food Intake Visual Scaleâ€"A practical tool for assessing the dietary intake of hospitalized patients with decompensated cirrhosis. Nutrition in Clinical Practice, 2023, 38, 187-198.	1.1	5
6188	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease, 2022, 54, 452-460.	0.4	38
6189	Survival Analysis Using Albumin-Bilirubin (ALBI) Grade for Patients Treated with Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2022, 33, 510-517.e1.	0.2	7
6190	Hip Fractures in Patients With Liver Cirrhosis: Worsening Liver Function Is Associated with Increased Mortality. Clinical Orthopaedics and Related Research, 2022, 480, 1077-1088.	0.7	12

#	Article	IF	CITATIONS
6191	Prediction of Survival After Partial Hepatectomy Using a Physiologically Based Pharmacokinetic Model of Indocyanine Green Liver Function Tests. Frontiers in Physiology, 2021, 12, 730418.	1.3	7
6192	Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study. Annals of Translational Medicine, 2022, 10, 411-411.	0.7	5
6193	The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma. In Vivo, 2022, 36, 865-873.	0.6	9
6195	Prediction of Posthepatectomy Liver Failure with a Combination of Albumin-Bilirubin Score and Liver Resection Percentage. Journal of the American College of Surgeons, 2022, 234, 155-165.	0.2	2
6196	Nuclear Medicine Therapy in primary liver cancers. , 2022, , .		0
6197	Severe Vitamin D Deficiency Is Strongly Associated with Liver Dysfunction and Disease Severity in Hepatitis B Virus Related Cirrhosis and Liver Failure Patients. Journal of Nutritional Science and Vitaminology, 2022, 68, 16-22.	0.2	5
6198	Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. Frontiers in Oncology, 2022, 12, 850454.	1.3	7
6199	Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Review of Anticancer Therapy, 2022, 22, 297-306.	1.1	3
6200	Profoundly Disturbed Lipoproteins in Cirrhotic Patients: Role of Lipoprotein-Z, a Hepatotoxic LDL-like Lipoprotein. Journal of Clinical Medicine, 2022, 11, 1223.	1.0	3
6201	Significance of promoter methylation of multiple tumor suppressor genes in hepatocellular carcinoma. Egyptian Journal of Medical Human Genetics, 2022, 23, .	0.5	4
6202	Liver Disease Outcomes after Sustained Virological Response in Patients with Chronic Hepatitis C Infection Treated with Generic Direct-Acting Antivirals. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	0
6203	Palliative Care, Patient-Reported Measures, and Outcomes in Hospitalized Patients With Cirrhosis. Journal of Pain and Symptom Management, 2022, , .	0.6	2
6204	Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clinical Pharmacokinetics, 2022, 61, 857-867.	1.6	16
6205	Risk factors of unplanned intraoperative conversion to hand-assisted laparoscopic surgery or open surgery in laparoscopic liver resection. Langenbeck's Archives of Surgery, 2022, 407, 1961-1969.	0.8	5
6206	The useful predictors of zinc deficiency for the management of chronic liver disease. Journal of Gastroenterology, 2022, 57, 322-332.	2.3	5
6207	Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. Journal of Clinical Oncology, 2022, 40, 2078-2082.	0.8	11
6208	The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAKâ€954). Journal of Clinical Pharmacology, 2022, , .	1.0	0
6209	Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. PLoS ONE, 2022, 17, e0265668.	1.1	9

#	Article	IF	CITATIONS
6210	Predicting Complications following Surgical Resection of Hepatocellular Carcinoma Using Newly Developed Neo-Glasgow Prognostic Score with ALBI Grade: Comparison of Open and Laparoscopic Surgery Cases. Cancers, 2022, 14, 1402.	1.7	7
6211	Portal Hypertensive Gastropathy in Liver Cirrhosis: Prevalence, Natural History, and Risk Factors. Internal Medicine, 2022, 61, 605-613.	0.3	2
6212	Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study. Liver Cancer, 2022, 11, 368-382.	4.2	10
6213	Pretreatment Positron Emission Tomography with ¹⁸ F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma. Oncology, 2022, 100, 320-330.	0.9	5
6214	COVID-19 in Cirrhotic Patients: Is Portal Vein Thrombosis a Potential Complication?. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-4.	0.8	4
6216	Differences in the Intestinal Microbiome Associated with Diarrhea during Lenvatinib Treatment for Hepatocellular Carcinoma. Digestive Diseases, 2023, 41, 138-147.	0.8	4
6217	Prognostic Role of Albumin-Bilirubin Grade in Hepatocellular Carcinoma After Ultrasound-guided Percutaneous Radiofrequency Ablation. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2022, Publish Ahead of Print, .	0.4	1
6218	Highly Increased Levels of Inter-î±-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases. Journal of Clinical and Translational Hepatology, 2022, 10, 796-802.	0.7	3
6219	T1 reduction rate with Gd-EOB-DTPA determines liver function on both 1.5ÂT and 3ÂT MRI. Scientific Reports, 2022, 12, 4716.	1.6	5
6220	Utility of prognostic scores in predicting short-term mortality in patients with acute-on-chronic liver failure. Egyptian Liver Journal, 2022, 12, .	0.3	0
6221	Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation. Acta Pharmacologica Sinica, 2022, 43, 2723-2734.	2.8	6
6222	Noninvasive assessment of liver function reserve with fluorescent dosimetry of indocyanine green. Biomedical Optics Express, 2022, 13, 1995.	1.5	2
6223	Role of albumin in the treatment of decompensated liver cirrhosis. Current Opinion in Gastroenterology, 2022, 38, 200-205.	1.0	6
6224	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.4	3
6225	Serum Folate deficiency in HCV related Hepatocellular Carcinoma. Scientific Reports, 2022, 12, 5025.	1.6	3
6226	Assessment of Liver Function With MRI: Where Do We Stand?. Frontiers in Medicine, 2022, 9, 839919.	1.2	8
6227	Effect of liver cirrhosis on theophylline trough concentrations: A comparative analysis of organ impairment using Child–Pugh and MELD scores. British Journal of Clinical Pharmacology, 2022, , .	1,1	0
6228	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 396-404.	0.9	1

#	Article	IF	CITATIONS
6229	Anticoagulation Considerations in Liver Disease. Critical Care Nursing Quarterly, 2022, 45, 156-166.	0.4	1
6230	Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy. Journal of Clinical Medicine, 2022, 11, 2057.	1.0	1
6231	Comparison of Liver Fibrosis and Function Indices with Extracellular Volume using Dual-Energy CT: A Retrospective Study. Current Medical Imaging, 2022, 18, .	0.4	1
6232	Exaggerated inflammatory response to bacterial products in decompensated cirrhotic patients is orchestrated by interferons IL-6 and IL-8. American Journal of Physiology - Renal Physiology, 2022, 322, G489-G499.	1.6	5
6233	Platelet-albumin (PAL) score as a predictor of perioperative outcomes and survival in patients with hepatocellular carcinoma undergoing liver resection in a Western center. Surgical Oncology, 2022, 42, 101752.	0.8	4
6234	Inflammatory Biomarkers in Addictive Disorders. Biomolecules, 2021, 11, 1824.	1.8	14
6235	Hepatic impairment as a risk factor of adverse drug reactions. Consilium Medicum, 2021, 23, 939-948.	0.1	1
6236	Preoperative nutritional score predicts underlying liver status and surgical risk of hepatocellular carcinoma. Scandinavian Journal of Surgery, 2022, 111, 145749692110619.	1.3	2
6237	Comparative study between sorafenib and lenvatinib as the firstâ€line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a realâ€world setting. JGH Open, 2022, 6, 29-35.	0.7	6
6238	Nomograms including the controlling nutritional status score in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation for prediction survival: a retrospective analysis. British Journal of Nutrition, 2022, 128, 1966-1974.	1.2	2
6239	Red cell distribution width as a predictor of outcome in hospitalized cirrhotic patients. European Journal of Gastroenterology and Hepatology, 2021, 33, e978-e985.	0.8	3
6240	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLCâ€B stage patients classified as beyond up to seven criteria – Multicenter analysis. Hepatology Research, 2022, 52, 308-316.	1.8	25
6241	Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 2161.	3.8	163
6242	The role of vasoactive drugs in the treatment of oesophageal varices. Expert Opinion on Pharmacotherapy, 2004, 5, 349-60.	0.9	9
6244	The effect of intravenous infusion of N-acetyl cysteine in cirrhotic patients undergoing liver resection: A randomized controlled trial. Journal of Anaesthesiology Clinical Pharmacology, 2017, 33, 450.	0.2	6
6245	The Pharmacogenetics of Opiates and Its Impact on Delirium in Mechanically Ventilated Adults: A Pilot Study. Journal of Pharmacy Technology, 0, , 875512252210851.	0.5	0
6246	Development and External Validation of the Munich Sorafenib Evaluation Score for Hepatocellular Carcinoma. Digestive Diseases, 2023, 41, 268-281.	0.8	0
6247	Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 ν m Drug-Eluting Bead Transcatheter Arterial Chemoembolization. Cureus, 2022, 14, e24047.	0.2	1

#	Article	IF	CITATIONS
6248	Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan. Scientific Reports, 2022, 12, 6479.	1.6	8
6249	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Medicine, 2022, 11, 3796-3808.	1.3	21
6250	Development of a risk score model for 1â€year graft loss after adult deceased donor liver transplantation in Japan based on a 20â€year nationwide cohort. Annals of Gastroenterological Surgery, 0, , .	1,2	3
6252	Plates section., 0,, 357-364.		0
6282	Models in Clinical Hepatology. , 0, , 2053-2064.		0
6283	Management of Portal Hypertension and Biliary Problems Prior to Transplantation. , 0, , 43-65.		0
6284	Pharmacologic Basis for High-Dose Chemotherapy. , 0, , 130-157.		0
6285	Hyperintense lesions of the globus pallidus on MRI in children with chronic liver disease. European Journal of Pediatrics, 1994, 153, 802-806.	1.3	1
6286	Coagulation profiles and intraoperative substitution requirements during elective piggyback liver transplantation with prophylactic antifibrinolytic therapy. Transplant International, 2002, 15, 310-6.	0.8	1
6287	Hepatic amino-acid metabolism in liver cirrhosis and in the long-term course after liver transplantation. Transplant International, 2003, 16, 1-8.	0.8	6
6288	Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology, 1995, 22, 1132-1135.	3.6	10
6289	Obstructions of portal veins and tumor numbers are associated with humped hepatocellular carcinoma. Acta Medica Okayama, 2010, 64, 299-305.	0.1	0
6291	The effect of Saccharomyces boulardii in patients eligible for liver transplantation. Nutricion Hospitalaria, 2014, 31, 778-84.	0.2	4
6292	EFFECT OF ANTIOXIDANT POTENTIAL ON SEVERITY OF CIRRHOSIS IN HUMANS. Nutricion Hospitalaria, 2015, 32, 2294-300.	0.2	1
6295	Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data. Clinical and Experimental Hepatology, 2022, 8, 7-13.	0.6	0
6296	Prophylactic cyanoacrylate injection for gastric extension of esophageal varices: a randomized controlled trial. Clinical and Experimental Hepatology, 2022, 8, 84-91.	0.6	1
6297	ÂExternal validation and comparison of six prognostic models in a prospective cohort of HBV-ACLF in China. Annals of Hepatology, 2016, 15, 236-45.	0.6	12
6298	ÂClinical characteristics of liver failure from a systemic cause: A report from an advanced critical care center. Annals of Hepatology, 2016, 15, 254-9.	0.6	0

#	Article	IF	CITATIONS
6299	Diastolic dysfunction is associated with low urinary sodium excretion in patients with decompensated cirrhosis. Annals of Hepatology, 2016, 15, 545-751.	0.6	8
6300	Prevalence and correlates of poor sleep quality in chronic liver disease patients Sleep Science, 2021, 14, 266-272.	0.4	0
6301	Decreased diversity of salivary microbiome in patients with stable decompensated cirrhosis Hippokratia, 2020, 24, 157-165.	0.3	0
6302	Comparison of the New Neo-Glasgow Prognostic Score Based on the Albumin-Bilirubin Grade with Currently Used Nutritional Indices for Prognostic Prediction following Surgical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study in Japan. Cancers, 2022, 14, 2091.	1.7	2
6303	Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. Diagnostics, 2022, 12, 1069.	1.3	5
6304	Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis. Journal of Clinical Medicine, 2022, 11, 2479.	1.0	2
6305	Child–Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib. Journal of Clinical Medicine, 2022, 11, 2550.	1.0	3
6306	Survival benefit of Lâ \in carnitine supplementation in patients with cirrhosis. Journal of Parenteral and Enteral Nutrition, 2022, , .	1.3	2
6307	Chronic liver disease questionnaire to manage patients with chronic liver diseases. Hepatology Research, 2022, , .	1.8	0
6308	Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. Diagnostics, 2022, 12, 1187.	1.3	0
6309	Inadequate social support decreases survival in decompensated liver cirrhosis patients. GastroenterologÃa Y HepatologÃa, 2023, 46, 28-38.	0.2	2
6310	Natural History of Compensated and Decompensated HCV-Related Cirrhosis in HIV-Infected Patients: A Prospective Multicentre Study. Antiviral Therapy, 2007, 12, 899-908.	0.6	25
6311	Organ Allocation in Pediatric Abdominal Transplant. Seminars in Pediatric Surgery, 2022, , 151180.	0.5	0
6312	"Beyond MELD―– Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation. Journal of Hepatology, 2022, 76, 1318-1329.	1.8	24
6313	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Scientific Reports, 2022, 12, 8421.	1.6	4
6314	Diagnosis and predicted outcomes of patients with cystic fibrosis related liver disease considered for lung transplantation. Clinical Transplantation, 2022, , e14713.	0.8	0
6315	Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the <scp>P2Y12</scp> receptor antagonist selatogrel. Clinical and Translational Science, 2022, 15, 1906-1915.	1.5	3
6316	High plasma levels of betaine, a trimethylamine <scp>Nâ€Oxide</scp> â€related metabolite, are associated with the severity of cirrhosis. Liver International, 2022, , .	1.9	2

#	Article	IF	CITATIONS
6317	Splenic vein embolization as a feasible treatment for patients with hepatic encephalopathy related to large spontaneous splenorenal shunts. Annals of Hepatology, 2022, , 100725.	0.6	4
6318	Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List?. Transplantation, 2022, 106, 2122-2136.	0.5	4
6320	Necrotizing Soft-Tissue Infections: A Retrospective Review of Predictive Factors for Limb Loss. Clinics in Orthopedic Surgery, 2022, 14, 297.	0.8	2
6321	Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated Cirrhosis. Disease Markers, 2022, 2022, 1-10.	0.6	1
6322	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Childâ€Pugh class A or B liver function in realâ€world clinical practice. Hepatology Research, 2022, 52, 773-783.	1.8	34
6323	Clinical Profile, Patterns of Care & Description and Patients with Hepatocellular Carcinoma: Prospective multi-center Study. Journal of Clinical and Experimental Hepatology, 2022, 12, 1463-1473.	0.4	4
6324	Tomoelastography based on multifrequency MR elastography predicts liver function reserve in patients with hepatocellular carcinoma: a prospective study. Insights Into Imaging, 2022, 13, .	1.6	3
6325	Randomized Clinical Trial: Effects of \hat{l}^2 -Hydroxy- \hat{l}^2 -Methylbutyrate (HMB)-Enriched vs. HMB-Free Oral Nutritional Supplementation in Malnourished Cirrhotic Patients. Nutrients, 2022, 14, 2344.	1.7	8
6326	Does firstâ€line treatment have prognostic impact for unresectable <scp>HCC</scp> ?â€"Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	1.3	25
6334	Investigation of the influential factors for hepatic osteodystrophy in chronic liver disease: A case–control survey among the patients attending a tertiary care hospital in a rural region of Northern India. Tzu Chi Medical Journal, 2022, .	0.4	0
6335	Epidemiology, clinical features, and mortality rate of Wilson disease in Moroccan children: A pediatric case series. Archives De Pediatrie, 2022, , .	0.4	2
6336	Correlation between dynamic changes in free triiodothyronine levels and 90-day prognosis in patients with HBV-related acute-on-chronic liver failure. European Journal of Medical Research, 2022, 27, .	0.9	3
6337	Suitability of Laparoscopic Liver Resection of Segment VII: a Retrospective Two-Center Study. Journal of Gastrointestinal Surgery, 2022, 26, 2274-2281.	0.9	2
6338	DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation. World Journal of Hepatology, 2022, 14, 1182-1189.	0.8	1
6339	An mALBI-Child–Pugh-based nomogram for predicting post-hepatectomy liver failure grade B–C in patients with huge hepatocellular carcinoma: a multi-institutional study. World Journal of Surgical Oncology, 2022, 20, .	0.8	5
6340	Minimally invasive ways to treat and prevent gastroesophageal portal bleeding. Annals of HPB Surgery, 2022, 27, 48-57.	0.1	2
6341	The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer. Annals of Surgical Oncology, 2022, 29, 7063-7073.	0.7	2
6342	Analysis of the albuminâ€bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after directâ€acting antiviral therapy. JGH Open, 2022, 6, 496-502.	0.7	4

#	Article	IF	CITATIONS
6343	Sclerostin in Excessive Drinkers: Relationships with Liver Function and Body Composition. Nutrients, 2022, 14, 2574.	1.7	5
6344	EASL International Recognition Award Recipient 2022: Prof. Patrick S. Kamath. Journal of Hepatology, 2022, , .	1.8	0
6345	Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside. Vascular Pharmacology, 2022, 145, 107022.	1.0	3
6346	Tools and scores for perioperative pulmonary, renal, hepatobiliary, hematological, and surgical site infection risk assessment: an update. Revista Do Colegio Brasileiro De Cirurgioes, 0, 49, .	0.3	0
6347	Ferramentas e escores para avaliação de risco perioperatório pulmonar, renal, hepatobiliar, hematológico e de infecção do sÃŧio cirúrgico: uma atualização. Revista Do Colegio Brasileiro De Cirurgioes, 0, 49, .	0.3	0
6348	Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin–bilirubin score (ALBS grade). Journal of Gastroenterology, 2022, 57, 581-586.	2.3	6
6349	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 857-864.	0.8	3
6350	Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project. Microbiology Spectrum, 2022, 10, .	1.2	3
6351	Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases. Mayo Clinic Proceedings, 2022, 97, 1380-1395.	1.4	0
6352	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. Antibiotics, 2022, 11, 898.	1.5	4
6353	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). Journal of Gastroenterology, 2022, 57, 587-597.	2.3	5
6354	Measurement of midâ€arm circumference as a starting point for nutritional assessment of patients with decompensated cirrhosis: A prospective cohort study. Journal of Human Nutrition and Dietetics, 2023, 36, 116-125.	1.3	1
6355	Noninvasively Assessed Portal Hypertension Grade Predicts Post-Hepatectomy Liver Failure in Patients With HepatocellCarcinoma: A Multicenter Study. Frontiers in Oncology, 0, 12, .	1.3	1
6356	ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization. Frontiers in Nuclear Medicine, 0, 2, .	0.7	O
6357	Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality inÂpatients with chronic liver disease. Hepatology Research, 2022, 52, 928-936.	1.8	16
6358	Short-term prognostic factors for hepatitis B virus-related acute-on-chronic liver failure. World Journal of Clinical Cases, 2022, 10, 8186-8195.	0.3	1
6359	Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. Journal of Hepatology, 2022, 77, 1554-1563.	1.8	52
6360	A Novel Nomogram for Prediction of Post-Hepatectomy Liver Failure in Patients with Resectable Hepatocellular Carcinoma: A Multicenter Study. Journal of Hepatocellular Carcinoma, 0, Volume 9, 901-912.	1.8	3

#	ARTICLE	IF	CITATIONS
6361	Use of endoscopic band ligation alone and in combination with nonselective beta blockers for prevention of variceal bleeding in ascites patients on the liver transplant waiting list. Vestnik Transplantologii I Iskusstvennykh Organov, 2022, 24, 42-50.	0.1	3
6362	At the heart of the problem: congestive cardiac failure as a cause of ascites: A narrative review. Medicine (United States), 2022, 101, e29951.	0.4	1
6363	Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart. Cureus, 2022, , .	0.2	1
6364	Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians. World Journal of Hepatology, 2022, 14, 1562-1575.	0.8	2
6365	Development and validation of a nomogram for predicting overall survival in cirrhotic patients with acute kidney injury. World Journal of Gastroenterology, 2022, 28, 4133-4151.	1.4	3
6366	Handgrip strength: A simple and effective tool to predict mortality after liver transplantation. Clinical Nutrition ESPEN, 2022, 51, 323-335.	0.5	2
6367	Outcome and prognostic markers of cirrhotic and non-cirrhotic patients admitted to a hepatology ICU in a tertiary care university hospital. African Health Sciences, 2022, 22, 377-383.	0.3	0
6368	Volumetric imaging reveals VEGF-C-dependent formation of hepatic lymph vessels in mice. Frontiers in Cell and Developmental Biology, 0, 10 , .	1.8	6
6369	Machine learning predicts portal vein thrombosis after splenectomy in patients with portal hypertension: Comparative analysis of three practical models. World Journal of Gastroenterology, 2022, 28, 4681-4697.	1.4	8
6370	Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review. Cureus, 2022, , .	0.2	6
6371	Development and validation of the Cirrhotic Ascites Severity modelâ€"A patientâ€reported outcomeâ€based model to predict 1â€year mortality. Hepatology Communications, 2022, 6, 3175-3185.	2.0	1
6372	Risk factors for acute kidney injury after liver transplantation in intensive care unit: a retrospective cohort study. Sao Paulo Medical Journal, 0, , .	0.4	0
6373	The Effect of Diet and Exercise Interventions on Body Composition in Liver Cirrhosis: A Systematic Review. Nutrients, 2022, 14, 3365.	1.7	11
6374	Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes. Scientific Reports, 2022, 12, .	1.6	0
6375	Liver Transplant Recipient Characteristics Associated With Worse Post-Transplant Outcomes in Using Elderly Donors. Transplant International, 0, 35, .	0.8	3
6376	Radiological and pathological assessment with EOB-MRI after Y90 radiation lobectomy prior to liver resection for hepatocellular carcinoma. Hpb, 2022, , .	0.1	1
6377	Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma. Hepatology International, 2022, 16, 1330-1338.	1.9	5
6378	The gut microbiota $\hat{a} \in A$ vehicle for the prevention and treatment of hepatocellular carcinoma. Biochemical Pharmacology, 2022, 204, 115225.	2.0	4

#	Article	IF	Citations
6379	Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2373-2382.	2.9	4
6381	The Indications and Implications of Liver Transplantation. Journal of the Royal College of Physicians of Edinburgh, The, 1999, 29, 144-152.	0.2	3
6382	Indications for open hepatectomy in the era of laparoscopic liver resection: a high volume single institutional study. Journal of Liver Cancer, 2022, 22, 146-157.	0.3	2
6383	Development and validation of a prognostic nomogram for decompensated liver cirrhosis. World Journal of Clinical Cases, 0, 10, 10467-10477.	0.3	0
6384	Total Joint Arthroplasty Should Not Be Delayed in Hepatitis C Patients After Successful Treatment Achieving a Sustained Viral Load. Arthroplasty Today, 2022, 17, 107-113.	0.8	4
6385	Association of Sat-a and Alu methylation status with HCV-induced chronic liver disease and hepatocellular carcinoma. Virus Research, 2022, 321, 198928.	1.1	1
6386	Development of the AAST Disease Severity Stratification System. , 2022, , 29-41.		0
6387	Comparison of outcomes between variceal and non variceal gastrointestinal bleeding in patients with cirrhosis: Insights from a Nationwide Inpatient Sample. Annals of Gastroenterology, 2022, , .	0.4	1
6388	Surgical Approach to Cirrhotic Patients. , 2022, , 487-504.		0
6389	Clinical Significance of MiR-130b and MiR-125b as Biomarkers in Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2687-2693.	0.5	0
6390	Clinical observation and risk assessment after splenectomy in hepatolenticular degeneration patients associated with hypersplenism. Frontiers in Surgery, 0, 9, .	0.6	2
6391	The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis. Oncology, 2023, 101, 134-144.	0.9	4
6392	Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test. Hepatology Research, 0, , .	1.8	0
6393	Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. Critical Care, 2022, 26, .	2.5	19
6395	Comparison of survival prediction values of different scoring models for patients undergoing transjugular intrahepatic portal shunt: A multicenter retrospective study., 2022, 1, 107-115.		1
6396	The Effect of Stereotactic Body Radiation Therapy for Hepatocellular Cancer on Regional Hepatic Liver Function. International Journal of Radiation Oncology Biology Physics, 2023, 115, 794-802.	0.4	6
6397	Systemic exposure to propranolol in patients with chronic liver disease and its correlation with portal blood flow. Frontiers in Medicine, 0, 9, .	1.2	0
6398	Design and conduct considerations for studies in patients with hepatic impairment. Clinical and Translational Science, 2023, 16, 50-61.	1.5	6

#	ARTICLE	IF	CITATIONS
6399	Shortness of breath due to portopulmonary hypertension and hepatopulmonary syndrome: diagnostic challenges and complex management approach in frail patients. Clinical Medicine, 2022, 22, 485-489.	0.8	0
6400	Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials. Hepatology International, 2022, 16, 1468-1483.	1.9	7
6401	Measurement of skeletal muscle volume is useful for predicting prognosis in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2022, 34, 1151-1157.	0.8	1
6402	A comprehensive review of prognostic scoring systems to predict survival after transjugular intrahepatic portosystemic shunt placement., 2022, 1, 133-144.		1
6403	Liver resection of hepatocellular carcinoma in HIV-HCV co-infected patients: a retrospective case series. Egyptian Liver Journal, 2022, 12, .	0.3	0
6404	Retrospective Study of the Efficacy and Safety of Chemoembolization with Drug-Eluting Microspheres Combined with Intra-Arterial Infusion of Bevacizumab for Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 973-985.	1.8	1
6405	AIMS65 and PALBI Scores as Predictors of Six Months' Mortality in Cirrhotic Patients with Acute Variceal Bleeding. Open Biomarkers Journal, 2022, 12, .	0.1	0
6406	The Prognostic Value of Serum HBV-RNA during Hepatitis B Virus Infection is Related to Acute-on-Chronic Liver Failure. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-8.	0.8	1
6407	Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort. Medicine (United States), 2022, 101, e30097.	0.4	0
6408	A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitisÂC virusâ€related decompensated cirrhosis. Hepatology Research, 2023, 53, 26-34.	1.8	4
6409	Human stem cells for decompensated cirrhosis in adults. The Cochrane Library, 2022, 2022, .	1.5	0
6410	The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment. Cancers, 2022, 14, 5323.	1.7	3
6411	Efficacy predictors of third-generation cephalosporins in treating spontaneous bacterial peritonitis. Medicine (United States), 2022, 101, e30164.	0.4	1
6412	The Elevated De Ritis Ratio on Admission Is Independently Associated with Mortality in COVID-19 Patients. Viruses, 2022, 14, 2360.	1.5	3
6413	Branched-chain amino acids supplementation has beneficial effects on the progression of liver cirrhosis: A meta-analysis. World Journal of Clinical Cases, 0, 10, 10984-10996.	0.3	1
6415	Clinical significance of neutrophil extracellular traps biomarkers in thrombosis. Thrombosis Journal, 2022, 20, .	0.9	9
6416	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 583-705.	4.5	102
6418	Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after Hepatectomy. Cancers, 2022, 14, 5292.	1.7	3

#	Article	IF	CITATIONS
6419	Near-zero open conversion rate of laparoscopic liver resection: a high-volume single-center experience of the past 5Âyears. Surgical Endoscopy and Other Interventional Techniques, 0, , .	1.3	2
6420	The effect of sarcopenia and serum myokines on prognosis and survival in cirrhotic patients: a multicenter cross-sectional study. European Journal of Gastroenterology and Hepatology, 2022, 34, 1261-1268.	0.8	2
6421	Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease. Medicine (United States), 2022, 101, e31145.	0.4	1
6422	Polyarthritis presented in a patient with untreated chronic hepatitis B infection. Modern Rheumatology Case Reports, 2023, 7, 320-323.	0.3	1
6423	New indexes derived from routine blood tests and their clinical application in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 102043.	0.7	2
6424	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study. Medicine (United) Tj ETQq $1\ 1\ C$.7 84 314 r	gB& Overloc
6425	Splenic Artery Ligation: An Ontable Bail-Out Strategy for Small-for-Size Remnants after Major Hepatectomy: A Retrospective Study. Journal of Personalized Medicine, 2022, 12, 1687.	1.1	0
6426	Interspecies differences in clinical characteristics and risk factors for third-generation cephalosporin resistance between Escherichia coli and Klebsiella pneumoniae bloodstream infection in patients with liver cirrhosis. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 1459-1465.	1.3	1
6428	Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma. Internal Medicine, 2022, 61, 3157-3164.	0.3	1
6429	Treatment patterns for hepatocellular carcinoma in patients with <scp>Child–Pugh</scp> class B and their impact on survival: A Korean nationwide registry study. Liver International, 2022, 42, 2830-2842.	1.9	6
6430	Analysis of ESPEN and GLIM algorithms reveals specific drivers for the diagnosis of malnutrition in patients with chronic gastrointestinal diseases. Nutrition, 2023, 106, 111887.	1.1	6
6431	A Pilot Study of High-Definition Transcranial Direct Current Stimulation in Refractory Status Epilepticus: The SURESTEP Trial. Neurotherapeutics, 2023, 20, 181-194.	2.1	3
6432	Low serum total thyroxine and free triiodothyronine in patients with hepatic encephalopathy due to non-alcoholic cirrhosis. Swiss Medical Weekly, 0 , , .	0.8	15
6433	Mortality and drug exposure in a 5-year cohort of patients with chronic liver disease. Swiss Medical Weekly, 0, , .	0.8	14
6434	The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study. Acta Gastro-Enterologica Belgica, 2022, 85, 433-437.	0.4	2
6435	Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study. Anticancer Research, 2022, 42, 5465-5473.	0.5	2
6436	Preoperative predictive nomogram based on alanine aminotransferase, prothrombin time activity, and remnant liver proportion (APART score) to predict post-hepatectomy liver failure after major hepatectomy. European Surgical Research, 0, , .	0.6	0
6437	Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor. PLoS ONE, 2022, 17, e0277266.	1.1	4

#	Article	IF	CITATIONS
6438	Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment. Cancers, 2022, 14, 5524.	1.7	3
6439	High-risk liver patients are not associated with adverse events following pancreaticoduodenectomy. American Journal of Surgery, 2022, , .	0.9	0
6440	Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Scientific Reports, 2022, 12, .	1.6	8
6441	Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis. Current Treatment Options in Oncology, 2022, 23, 1761-1774.	1.3	1
6442	Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. JHEP Reports, 2023, 5, 100627.	2.6	11
6443	Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2023, 16, 1-12.	0.4	2
6444	Risk stratification system for skin and soft tissue infections after allogeneic hematopoietic stem cell transplantation: PAH risk score. Frontiers of Medicine, 2022, 16, 957-968.	1.5	1
6445	Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C. PLoS ONE, 2022, 17, e0276592.	1.1	2
6446	Red blood cell transfusion is associated with an increased risk of splanchnic vein thrombosis in patients with cirrhosis. Transfusion Medicine, 0, , .	0.5	0
6447	Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease. Scientific Reports, 2022, 12, .	1.6	5
6450	Detecting liver cirrhosis in computed tomography scans using clinically-inspired and radiomic features. Computers in Biology and Medicine, 2023, 152, 106378.	3.9	6
6451	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2022, 23, 1126.	1.5	44
6452	Covered Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Portal Hypertension: Looking for the Right Patient and the Right Time. European Medical Journal Hepatology, 0, , 2-11.	1.0	0
6453	Low high-density lipoprotein cholesterol levels predicting poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure. Frontiers in Medicine, 0, 9, .	1.2	2
6454	Impact of COVID-19 on endoscopic follow-up of gastroesophageal varices. Egyptian Liver Journal, 2022, 12, .	0.3	0
6455	A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis. PLoS ONE, 2022, 17, e0277829.	1.1	1
6456	Therapeutic plasmaâ€exchange improves shortâ€term, but not longâ€term, outcomes in patients with acuteâ€onâ€chronic liver failure: A propensity scoreâ€matched analysis. Journal of Clinical Apheresis, 2023, 38, 376-389.	0.7	4
6457	Systematic review: the role of frailty in advanced chronic liver disease. Alimentary Pharmacology and Therapeutics, 2023, 57, 280-289.	1.9	3

#	Article	IF	CITATIONS
6458	Elevated calprotectin levels are associated with mortality in patients with acute decompensation of liver cirrhosis. World Journal of Hepatology, 0, 14, 1964-1976.	0.8	4
6459	Noninvasive Prediction of Kiâ€67 Expression in Hepatocellular Carcinoma Using Machine Learningâ€Based Ultrasomics. Journal of Ultrasound in Medicine, 2023, 42, 1113-1122.	0.8	4
6460	Automated Machine Learning in Predicting 30-Day Mortality in Patients with Non-Cholestatic Cirrhosis. Journal of Personalized Medicine, 2022, 12, 1930.	1.1	2
6461	Effect of albumin measurement methods on the albumin–bilirubin grade. Annals of Clinical Biochemistry, 0, , 000456322211436.	0.8	0
6462	Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022, 58, .	0.4	5
6463	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Journal of Liver Cancer, 2023, 23, 1-120.	0.3	24
6464	Preoperative Transient Elastography in Patients with Esophageal Cancer. Diagnostics, 2022, 12, 3194.	1.3	0
6465	Effects of Short-Term Human Albumin Infusion for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis. Journal of Clinical Medicine, 2023, 12, 107.	1.0	2
6466	Survival prediction using the Freiburg index of post-TIPS survival (FIPS) in critically ill patients with acute- on chronic liver failure: A retrospective observational study. Frontiers in Medicine, 0, 9, .	1.2	0
6467	Does etiological investigation have an impact on the outcomes of community-acquired pneumonia? – A prospective cohort study. European Journal of Internal Medicine, 2023, 108, 85-92.	1.0	1
6468	Baseline <scp>ALBI</scp> score and early variation of serum <scp>AFP</scp> predicts outcomes in patients with <scp>HCC</scp> treated by atezolizumab–bevacizumab. Liver International, 2023, 43, 708-717.	1.9	18
6469	Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. PLoS ONE, 2022, 17, e0279416.	1.1	0
6470	Easy to say, hard to do. To the anniversary of two fundamental discoveries. Part 2. Transplantologi \tilde{A}^{c} , 2022, 14, 500-518.	0.1	0
6471	Predicting changes in the pharmacokinetics of CYP3Aâ€metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 261-273.	1.3	5
6472	Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study. Journal of Clinical Medicine, 2022, 11, 7318.	1.0	4
6473	New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. Cancer Medicine, 2023, 12, 6980-6993.	1.3	8
6474	Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study. Anticancer Research, 2022, 42, 6007-6018.	0.5	1
6475	Evaluation of the Prognostic Value of Existing Scoring Systems for Nosocomial Infection in Patients with Decompensated Liver Cirrhosis. Turkish Journal of Gastroenterology, 2023, 34, 43-52.	0.4	0

#	Article	IF	CITATIONS
6477	External validation of Chronic Liver Failure-Consortium Acute Decompensation score in the risk stratification of cirrhotic patients hospitalized with acute variceal bleeding. European Journal of Gastroenterology and Hepatology, 2023, 35, 302-312.	0.8	2
6478	Establishment and validation of a prediction model for the first recurrence of Budd–Chiari syndrome after endovascular treatment: a large sample size, single-center retrospective study. Hepatology International, 2023, 17, 159-169.	1.9	0
6479	Prognosis prediction performs better in patients with non-cirrhosis hepatitis B virus-related acute-on-chronic liver failure than those with cirrhosis. Frontiers in Microbiology, 0, 13, .	1.5	1
6480	CLIF-SOFA and CLIF-C scores for the prognostication of acute-on-chronic liver failure and acute decompensation of cirrhosis: A systematic review. World Journal of Hepatology, 0, 14, 2025-2043.	0.8	7
6482	Plasma human neutrophil peptides as biomarkers of disease severity and mortality in patients with decompensated cirrhosis. Liver International, 2023, 43, 1096-1106.	1.9	1
6483	Assessment and prediction of malnutrition and sarcopenia in liver cirrhosis patients. Nutrire, 2023, 48, .	0.3	1
6484	Circadian rhythms and the liver. Liver International, 0, , .	1.9	1
6485	Disease Severity Scoring System in Chronic Liver Disease. , 2023, , 105-113.		0
6487	Value of Preoperative Systemic Immune-Inflammation Index and Albumin-Bilirubin Grade in Patients with Hepatocellular Carcinoma Undergoing Transarterial Embolization., 2023, 34, 413-420.		2
6488	Predicting dry weight in patients with cirrhotic ascites undergoing large-volume paracentesis. Clinical Nutrition ESPEN, 2023, 54, 34-40.	0.5	0
6489	Seven centimeters as an optimal cutoff value for prognosis stratification in large monofocal hepatocellular carcinoma. Langenbeck's Archives of Surgery, 2023, 408, .	0.8	1
6490	A novel prognostic model for predicting the risk of first variceal hemorrhage in patients with HBV-related cirrhosis. Frontiers in Cellular and Infection Microbiology, $0,13,.$	1.8	1
6491	Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence. Cancers, 2023, 15, 508.	1.7	3
6492	Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia. Medicina (Lithuania), 2023, 59, 146.	0.8	0
6493	Cirrhosis and non-hepatic surgery in 2023 $\hat{a} \in \hat{a}$ a precision medicine approach. Expert Review of Gastroenterology and Hepatology, 2023, 17, 155-173.	1.4	2
6495	Uâ€shaped relationship between subcutaneous adipose tissue index and mortality in liver cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 0, , .	2.9	3
6496	Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma. Cancers, 2023, 15, 236.	1.7	0
6497	Effectiveness of COVID-19 Vaccination with mRNA Vaccines for Patients with Cirrhosis in Hungary: Multicentre Matched Cohort Study. Vaccines, 2023, 11, 50.	2.1	2

#	Article	IF	CITATIONS
6498	Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?. Frontiers in Medicine, 0, 9, .	1.2	2
6499	Noninvasive assessment of the presence and size of esophageal varices. Vojnosanitetski Pregled, 2023, , 8-8.	0.1	0
6500	Mortality scoring systems for liver transplant recipients: before and after model for end-stage liver disease score. Anesthesia and Pain Medicine, 2023, 18, 21-28.	0.5	1
6501	Lenvatinib <i>Versus</i> Sorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis. Anticancer Research, 2023, 43, 755-763.	0.5	2
6502	Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial. Internal and Emergency Medicine, 2023, 18, 513-521.	1.0	7
6503	Recipient Survival after Orthotopic Liver Transplantation: Interpretable Machine Learning Survival Tree Algorithm for Patient-Specific Outcomes. Journal of the American College of Surgeons, 2023, 236, 563-572.	0.2	1
6504	Acute kidney injury development and impact on clinical and economic outcomes in patients with cirrhosis: an observational cohort study over a 10-year period. European Journal of Gastroenterology and Hepatology, 2023, 35, 497-504.	0.8	0
6505	Improvement of sarcopenia is beneficial for prognosis in cirrhotic patients after TIPS placement. Digestive and Liver Disease, 2023, , .	0.4	4
6506	Satellite liver transplant centres significantly improve transplant assessment outcomes for patients with chronic liver disease but not hepatocellular carcinoma: a retrospective cohort study. Frontline Gastroenterology, 2023, 14, 334-342.	0.9	1
6507	A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet, The, 2023, 401, 347-356.	6.3	136
6508	Cirrhosis: Reviewing the Literature and Future Perspectives. European Medical Journal Hepatology, 0, , $111-117$.	1.0	0
6509	Inadequate social support decreases survival in decompensated liver cirrhosis patients. GastroenterologÃa Y HepatologÃa (English Edition), 2023, 46, 28-38.	0.0	0
6510	Serum Myostatin among Excessive Drinkers. International Journal of Molecular Sciences, 2023, 24, 2981.	1.8	1
6511	Anemia Is Associated with Disease Severity, Hepatic Complications, and Progression of Wilson Disease: A Retrospective Cohort Study. Digestive Diseases, 2023, 41, 632-640.	0.8	1
6512	Nonselective beta-blockers in primary prophylaxis of esophageal variceal bleeding in patients with ascites waitlisted for liver transplantation. Vestnik Transplantologii I Iskusstvennykh Organov, 2023, 25, 68-76.	0.1	0
6513	Prognostic significance of sarcopenia and severe vitamin D deficiency in patients with cirrhosis. JGH Open, 2023, 7, 351-357.	0.7	2
6514	Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease. Journal of Clinical Medicine, 2023, 12, 2869.	1.0	1
6515	Low haemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation. JHEP Reports, 2023, 5, 100698.	2.6	3

#	Article	IF	CITATIONS
6516	Echinocandin use in an Australian tertiary hospital: implications for antifungal stewardship. Journal of Pharmacy Practice and Research, 0, , .	0.5	0
6517	Characteristics and predictors of short-term mortality in decompensated cirrhotic patients with acute-on-chronic liver failure. Clinical and Experimental Hepatology, 2022, 8, 300-308.	0.6	0
6518	Liver Transplantation for Budd-Chiari Syndrome in the MELD Era. Transplantation Direct, 2022, 8, e1407.	0.8	2
6519	Development and validation of the Adult cirrhosiS Knowledge Questionnaire. European Journal of Gastroenterology and Hepatology, 2023, 35, 333-341.	0.8	0
6520	Usefulness of the Albumin–Bilirubin Score in Determining the Initial Dose of Voriconazole for Patients with Liver Cirrhosis. Biological and Pharmaceutical Bulletin, 2023, 46, 230-236.	0.6	0
6521	Immune checkpoint molecule Tim-3 promotes NKT cell apoptosis and predicts poorer prognosis in Sepsis. Clinical Immunology, 2023, 254, 109249.	1.4	3
6522	Liver and spleen stiffness for the diagnosis of oesophageal varices in adults with chronic liver disease. The Cochrane Library, 2023, 2023, .	1.5	0
6524	Treatment of recurrent hepatocellular carcinoma following liver resection, ablation or liver transplantation. World Journal of Meta-analysis, 0, 11, 47-54.	0.1	0
6525	Breath Biopsy ^{\hat{A}^{\otimes}} to Identify Exhaled Volatile Organic Compounds Biomarkers for Liver Cirrhosis Detection. Journal of Clinical and Translational Hepatology, 2023, 000, 000-000.	0.7	4
6526	Impact of COVID-19 on Patients with Decompensated Liver Cirrhosis. Diagnostics, 2023, 13, 600.	1.3	1
6527	Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of â‰型 cm. PLoS ONE, 2023, 18, e0281154.	1.1	0
6528	Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review. PLoS ONE, 2023, 18, e0278545.	1.1	3
6529	Validation of the diagnostic accuracy of neutrophil to lymphocyte ratio (NLR) and mean platelet volume (MPV) in cirrhotic patients with spontaneous bacterial peritonitis. Egyptian Liver Journal, 2023, 13, .	0.3	0
6530	Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients. Cancers, 2023, 15, 1222.	1.7	2
6531	Management of Hepatocellular Carcinoma. JAMA Surgery, 2023, 158, 410.	2.2	72
6532	Association of polycythemia vera with nonâ€'cirrhotic portal hypertension in five patients: A case series. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	2
6533	Evaluation of Pretreatment Albumin–Bilirubin Grade as a Better Prognostic Factor Compared to Child–Pugh Classification in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization Combined with Radiotherapy. Journal of Personalized Medicine, 2023, 13, 354.	1,1	0
6534	Sclerostin, vascular risk factors, and brain atrophy in excessive drinkers. Frontiers in Human Neuroscience, 0, 17, .	1.0	3

#	Article	IF	CITATIONS
6535	Machine learning-based model for predicting the esophagogastric variceal bleeding risk in liver cirrhosis patients. Diagnostic Pathology, 2023, 18 , .	0.9	3
6536	Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. Frontiers in Oncology, $0,13,.$	1.3	1
6537	The Association of Albumin-Bilirubin (ALBI) Grade with Mortality Risk in Trauma Patients with Liver Injuries. Risk Management and Healthcare Policy, 0, Volume 16, 279-286.	1.2	3
6538	Factors predicting mortality in patients with alcoholic liver cirrhosis visiting the emergency department. Medicine (United States), 2023, 102, e33074.	0.4	0
6539	Conversion of Minimally Invasive Liver Resection for HCC in Advanced Cirrhosis: Clinical Impact and Role of Difficulty Scoring Systems. Cancers, 2023, 15, 1432.	1.7	2
6540	Monitoring the hepatobiliary function using image techniques and labeled cholephilic compounds. , 0, , $18\text{-}33$.		0
6541	Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series. CardioVascular and Interventional Radiology, 2023, 46, 460-469.	0.9	3
6543	Delimiting Low Level of Difficulty Scoring System Based on the Extent of Resection Difficulty Scoring System for Laparoscopic Liver Resection. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, O, , .	0.5	0
6544	CHIBA score: a novel model for predicting 3-month mortality in a cohort of Decompensated Liver Disease (DCLD). Egyptian Liver Journal, 2023, 13, .	0.3	0
6545	Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations. World Journal of Clinical Cases, 0, 11, 1753-1760.	0.3	0
6546	Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn trial. The Lancet Regional Health Americas, 2023, 20, 100466.	1.5	1
6547	Safety and efficacy of double plasma molecular adsorption system with sequential lowâ€volume plasma exchange in intermediateâ€stage hepatitis B virusâ€related acuteâ€onâ€chronic liver failure. Journal of Medical Virology, 2023, 95, .	2.5	0
6548	Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology. Cancers, 2023, 15, 1687.	1.7	1
6549	Comparison of Child-Pugh, MELD, MELD-Na, and ALBI Scores in Predicting In-Hospital Mortality in Patients with HCC. International Journal of Clinical Medicine, 2023, 14, 148-162.	0.1	0
6550	Low Prealbumin Levels Were Associated with Increased Frequency of Hepatic Encephalopathy in Hepatitis B Virus (HBV)-Related Decompensated Cirrhosis. Medical Science Monitor, 0, 29, .	0.5	1
6551	Assessment of clinico-epidemiological profile of Hepatocellular carcinoma in the last two decades. The Egyptian Journal of Internal Medicine, 2023, 35, .	0.3	0
6552	Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Multicenter Study. American Journal of Gastroenterology, 2023, 118, 2191-2200.	0.2	9
6553	Novel CABIN score outperforms other prognostic models in predicting in-hospital mortality after salvage transjugular intrahepatic portosystemic shunting. World Journal of Gastrointestinal Pathophysiology, 0, 14, 34-45.	0.5	O

#	Article	IF	Citations
6554	Serum copeptin is associated with major complications of liver cirrhosis and spontaneous bacterial peritonitis. Clinical and Experimental Hepatology, 2023, 9, 71-78.	0.6	2
6555	Child-Pugh Class B or C Liver Disease Increases the Risk of Early Mortality in Patients With Hepatitis C Undergoing Elective Total Joint Arthroplasty Regardless of Treatment Status. Clinical Orthopaedics and Related Research, 2023, Publish Ahead of Print, .	0.7	0
6556	Evolution of risk prediction models for post-operative mortality in patients with cirrhosis. Hepatology International, 2023, 17, 542-545.	1.9	1
6557	Predicting Post-hepatectomy Liver Failure Preoperatively for Child-Pugh A5 Hepatocellular Carcinoma Patients by Liver Stiffness. Journal of Gastrointestinal Surgery, 2023, 27, 1177-1187.	0.9	2
6558	Prevalence of portal vein and splanchnic venous thrombosis in dogs with chronic hepatitis. Journal of Small Animal Practice, 2023, 64, 375-383.	0.5	0
6559	Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics. AAPS Journal, 2023, 25, .	2.2	2
6560	Value of Some Scoring Systems for the Prognosis of Rebleeding and In-Hospital Mortality in Liver Cirrhosis with Acute Variceal Bleeding. Gastroenterology Insights, 2023, 14, 144-155.	0.7	0
6561	Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations. Cancers, 2023, 15, 2001.	1.7	5
6562	Effect of splenectomy based on inverse probability weighting of the propensity score on Wilson's disease with hypersplenism: A retrospective cohort study. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	0
6563	Transcatheter Arterial Chemoembolization for Treatment-Naive Hepatocellular Carcinoma Has Different Treatment Effects Depending on Central or Peripheral Tumor Location. Liver Cancer, 2023, 12, 576-589.	4.2	0
6564	The Added Value of Sarcopenia on Existing Risk Scores to Predict Mortality after TIPS Placement: A Multicenter Study. Academic Radiology, 2023, 30, S246-S256.	1.3	3
6566	Small Intestinal Bacterial Overgrowth Is Associated with Poor Prognosis in Cirrhosis. Microorganisms, 2023, 11, 1017.	1.6	4
6592	Cirrhotic Patients., 2023,, 389-400.		0
6667	Postoperative Liver Failure: Definitions, Risk factors, Prediction Models and Prevention Strategies. Journal of Gastrointestinal Surgery, 2023, 27, 2640-2649.	0.9	1
6687	Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents. Clinical Pharmacokinetics, 2023, 62, 1365-1392.	1.6	0
6739	Nonmechanical preservation and allocation of liver grafts. , 2024, , 101-137.		0
6749	Hepatic functional deterioration in chronic liver disease. , 2024, , 11-17.		0
6763	Stem Cells and Extracellular Vesicles for Prevention and Treatment of Liver Fibrosis. , 2024, , .		0

ARTICLE IF CITATIONS

Clinical Pharmacokinetic Studies. , 2024, , 1-87.